"Rank","Title","Status","Study Results","Conditions","Interventions","Locations","URL"
1,"A Systems Approach to Predict the Outcome of SARS-CoV-2 in the Population of a City; COVID-19","Recruiting","No Results Available","SARS Coronavirus (SARS-CoV-2) Infection","Other: Study A|Other: Study B|Other: Study C","Viollier AG, Allschwil, Switzerland|University Hospital Basel, Basel, Switzerland|Biozentrum University of Basel, Basel, Switzerland|sciCore University of Basel, Basel, Switzerland|Department of Biosystems Science and Engineering ETH Zurich, Basel, Switzerland|Swiss Institute of Bioinformatics, Geneva, Switzerland","https://ClinicalTrials.gov/show/NCT04351503"
2,"Investigating Severe Acute Respiratory Syndrome (SARS)","Completed","No Results Available","SARS Virus",,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00066209"
3,"Phase I Dose Escalation SARS-CoV Recombinant S Protein, With and Without Adjuvant, Vaccine Study","Withdrawn","No Results Available","SARS","Drug: Aluminum hydroxide adjuvant (Alhydrogel®)|Other: Phosphate buffered saline Placebo|Biological: Recombinant S protein SARS vaccine","University of Iowa - Infectious Disease Clinic, Iowa City, Iowa, United States|Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States|Cincinnati Children's Hospital Medical Center - Infectious Diseases, Cincinnati, Ohio, United States","https://ClinicalTrials.gov/show/NCT01376765"
4,"Collection of Convalescent SARS Plasma by Apheresis","Completed","No Results Available","Severe Acute Respiratory Syndrome|SARS",,"The Chinese University of Hong Kong, Hong Kong, China","https://ClinicalTrials.gov/show/NCT00342524"
5,"SARS Survivor Evaluations","Withdrawn","No Results Available","Coronavirus (SARS-CoV)",,"Beijing Ditan Hospital, Beijing, Beijing, China|Beijing You'An Hospital, Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT00523276"
6,"Norwegian SARS-CoV-2 Study - Virological, Clinical and Immunological Characterisation of COVID-19","Recruiting","No Results Available","SARS Virus|Severe Acute Respiratory Syndrome","Diagnostic Test: SARS-CoV-2 PCR","Vestre Viken Drammen Hospital, Drammen, Viken, Norway|Haukeland University Hospital, Bergen, Norway|Østfold Hospital Trust, Fredrikstad, Norway|Akershus University Hospital, Lørenskog, Norway|Oslo University Hospital, Oslo, Norway|University Hospital North Norway, Tromsø, Norway|St Olavs Hospital, Trondheim, Norway","https://ClinicalTrials.gov/show/NCT04381819"
7,"Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis","Active, not recruiting","No Results Available","SARS Pneumonia","Drug: Tocilizumab","Università Politecnica delle Marche, Ancona, AN, Italy","https://ClinicalTrials.gov/show/NCT04315480"
8,"SARS Coronavirus Vaccine (SARS-CoV)","Withdrawn","No Results Available","Coronavirus (SARS-CoV)","Drug: Aluminum hydroxide|Drug: Placebo|Biological: SARS-CoV","Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT00533741"
9,"Immune Response and Risk of Serious Infection to SARS-Cov2","Recruiting","No Results Available","SARS Cov2, Immune Response","Biological: Blood sample collection","Chu Dijon Bourogne, Dijon, France","https://ClinicalTrials.gov/show/NCT04410432"
10,"Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2","Recruiting","No Results Available","SARS-CoV Infection|Severe Acute Respiratory Syndrome (SARS) Pneumonia","Drug: Chloroquine diphosphate","Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz, Manaus, Amazonas, Brazil","https://ClinicalTrials.gov/show/NCT04323527"
11,"Study of Viral Load and Maternal-fetal Serology in the Interpretation of the Vertical Transmission of SARS Cov-2 (COVID-19) During Pregnancy","Recruiting","No Results Available","Sars-CoV2","Diagnostic Test: biological samples day of delivery","Chu Besancon, Besancon, France","https://ClinicalTrials.gov/show/NCT04402918"
12,"WGS ANALYSIS OF SARS-COV-2 POSITIVE PATIENTS","Enrolling by invitation","No Results Available","Coronavirus Infection|SARS-CoV-2",,"Vanda Pharmaceuticals, Inc., Washington, District of Columbia, United States","https://ClinicalTrials.gov/show/NCT04353401"
13,"Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection","Recruiting","No Results Available","SARS-CoV Infection","Drug: Losartan","Sharp Grossmont Hospital, La Mesa, California, United States|Sharp Chula Vista Medical Center, San Diego, California, United States|Sharp Coronado Hospital, San Diego, California, United States|Sharp Memorial Hospital, San Diego, California, United States","https://ClinicalTrials.gov/show/NCT04340557"
14,"Hydroxychloroquine to Prevent SARS-CoV-2 Infection","Not yet recruiting","No Results Available","SARS-CoV-2","Drug: Hydroxychloroquine","Centro Médico Naval ""Cirujano Mayor Santiago Távara"", Callao, Peru|Hospital Nacional Hipólito Unanue, Lima, Peru|Hospital Nacional Arzobispo Loayza, Lima, Peru|Hospital Cayetano Heredia, Lima, Peru","https://ClinicalTrials.gov/show/NCT04414241"
15,"Sero-epidemiological Study of the SARS-CoV-2 Virus Responsible for COVID-19 in France","Recruiting","No Results Available","SARS (Severe Acute Respiratory Syndrome)|COVID-19","Other: Human Biological samples","CHU Amiens-Picardie, Amiens, France|CHU François Mitterand, Dijon, France|Centre Hospitalier Départemental de Vendée, La Roche-sur-Yon, France|CHU Limoges, Limoges, France|Hôpital de la Croix Rousse, Lyon, France|CHRU de Nancy, Nancy, France|Hôpitaux de Brabois, Nancy, France|CHR Orléans, Orléans, France|Institut Pasteur, Paris, France|Hôpital la Pitié Salpetrière, Paris, France|CHU Poitiers, Poitiers, France|Hôpital Pontchaillou, Rennes, France|CHU Saint-Etienne, Saint-Étienne, France|CHRU de Strasbourg, Strasbourg, France|CH de Tourcoing, Tourcoing, France|Hôpital Bretonneau, Tours, France","https://ClinicalTrials.gov/show/NCT04325646"
16,"Long Term Physical Functional Limitations in Daily Living in SARS-CoV2 Infected Patients Hospitalized in the Acute Phase Then Requiring Rehabilitation","Not yet recruiting","No Results Available","Infection With Coronavirus SARS-CoV2","Other: Data record","Damien JOLLY, Reims, France","https://ClinicalTrials.gov/show/NCT04356378"
17,"Increased Risk of SARS-CoronaVirus-2 (SARS-CoV-2) Infection Associated With Endoscopy (DECORE Study)","Recruiting","No Results Available","SARS-CoV 2|COVID","Behavioral: Telephonic medical visit|Procedure: Gastrointestinal endoscopy|Procedure: Abdominal ultrasound","Hospital Rio Hortega, Valladolid, Spain","https://ClinicalTrials.gov/show/NCT04401033"
18,"Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection","Recruiting","No Results Available","Sars-CoV2","Drug: Peginterferon lambda alfa-1a subcutaneous injection|Other: Saline","Johns Hopkins Hospital, Baltimore, Maryland, United States","https://ClinicalTrials.gov/show/NCT04344600"
19,"Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19","Recruiting","No Results Available","SARS-CoV Infection|Severe Acute Respiratory Syndrome (SARS) Pneumonia","Drug: Methylprednisolone Sodium Succinate|Drug: Placebo solution","Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz, Manaus, Amazonas, Brazil","https://ClinicalTrials.gov/show/NCT04343729"
20,"COVID-19: Human Epidemiology and Response to SARS-CoV-2","Enrolling by invitation","No Results Available","Coronavirus Disease 2019 (COVID-19)|SARS-CoV-2","Procedure: Collection of Biological Samples|Procedure: Symptom and Exposure Surveys","Children's Hospital Colorado: Inner City Asthma Consortium (ICAC) Site, Aurora, Colorado, United States|Children's Hospital Colorado: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages (OMEGA) Site, Aurora, Colorado, United States|Children's National Medical Center: Inner City Asthma Consortium (ICAC) Site, Washington, District of Columbia, United States|Ann & Robert H. Lurie Children's Hospital of Chicago: Food Allergy Outcomes Related to White and African American Racial Differences (FORWARD) and Improving Technology-Assisted Recording of Asthma Control in Children (iTRACC) Site, Chicago, Illinois, United States|Massachusetts General Hospital:Childhood Microbiome (CHIME) and Wheezing Index (WIND) Site, Boston, Massachusetts, United States|Boston Children's Hospital: School Inner-City Asthma Study (SICAS-2), Environmental Assessment of Sleep in Youth (EASY), Severe Asthma Research Program (SARP) and Preventing Asthma in High Risk Kids (PARK) Site, Boston, Massachusetts, United States|Boston Medical Center: Inner City Asthma Consortium (ICAC) Site, Boston, Massachusetts, United States|Henry Ford Health System: Inner City Asthma Consortium (ICAC) Site, Detroit, Michigan, United States|Henry Ford Health System: Microbes, Asthma, Allergy and Pets (MAAP) and Wayne County Health, Environment, Allergy, and Asthma Longitudinal Study (WHEALS) Site, Detroit, Michigan, United States|St. Louis Children's Hospital: Inner City Asthma Consortium (ICAC) Site, Saint Louis, Missouri, United States|Columbia University Medical Center: Inner City Asthma Consortium (ICAC) Site, New York, New York, United States|Cincinnati Children's Hospital Medical Center: Greater Cincinnati Pediatric Clinic Repository (GCPCR) and Mechanisms of Progression of Atopic Dermatitis to Asthma in Children (MPAACH) Site, Cincinnati, Ohio, United States|Cincinnati Children's Hospital Medical Center: Inner City Asthma Consortium (ICAC) Site, Cincinnati, Ohio, United States|Cincinnati Children's Hospital Medical Center: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages (OMEGA) Site, Cincinnati, Ohio, United States|Cincinnati Children's Hospital Medical Center:Cincinnati Childhood Allergy & Air Pollution Study (CCAAPS) Site, Cincinnati, Ohio, United States|Vanderbilt University Medical Center: Infant Susceptibility to Pulmonary Infections and Asthma Following RSV Exposure Study (INSPIRE) Site, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center: Inner City Asthma Consortium (ICAC) Site, Dallas, Texas, United States|University of Wisconsin Hospital and Clinics: Childhood Origins of Asthma (COAST) Site, Madison, Wisconsin, United States|University of Wisconsin Hospital and Clinics: Wisconsin Infant Study Cohort (WISC) Site, Madison, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT04375761"
21,"Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel","Recruiting","No Results Available","Coronavirus Infection","Drug: Emtricitabine/tenofovir disoproxil|Drug: Hydroxychloroquine|Drug: Placebo: Emtricitabine/tenofovir disoproxil Placebo|Drug: Placebo: Hydroxychloroquine","Hospital Universitario de Ferrol, Ferrol, A Coruña, Spain|Hospital Clínico Universitario de Santiago, Santiago De Compostela, A Coruña, Spain|Hospital General de Elche, Elche, Alicante, Spain|Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain|Hospital Sant Joan de Deu de Esplugues, Esplugues De Llobregat, Barcelona, Spain|Parc Sanitari Sant Joan de Déu de Sant Boi, Sant Boi De Llobregat, Barcelona, Spain|Hospital Infanta Margarita, Cabra, Córdoba, Spain|Hospital Insular de Las Palmas, Las Palmas De Gran Canaria, Gran Canaria, Spain|Hospital Universitario de Canarias, Las Palmas De Gran Canaria, Gran Canaria, Spain|Hospital de Donostia, San Sebastián, Guipuzcoa, Spain|Hospital San Pedro, Logroño, La Rioja, Spain|Hospital Principe de Asturias, Alcalá De Henares, Madrid, Spain|Hospital Fundación de Alcorcón, Alcorcón, Madrid, Spain|Hospital Colllado Villalba, Collado-Villalba, Madrid, Spain|Hospital Severo Ochoa, Leganés, Madrid, Spain|Hospital Rey Juan Carlos, Móstoles, Madrid, Spain|Hospital Quirón Pozuelo, Pozuelo De Alarcón, Madrid, Spain|Hospital de Torrejón, Torrejón De Ardoz, Madrid, Spain|Hospital Infanta Elena, Valdemoro, Madrid, Spain|Hospital Virgen del Castillo, Yecla, Murcia, Spain|Hospital Costa del Sol, Marbella, Málaga, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|Hospital Arnau de Vilanova, Llíria, Valencia, Spain|Hospital de Araba, Alava, Vitoria, Spain|Hospital General Universitario de Albacete, Albacete, Spain|Centro Médico Teknon, Barcelona, Spain|Hospital Clinic, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Dexeus, Barcelona, Spain|Hospital Quirón Barcelona, Barcelona, Spain|Hospital Sant Pau, Barcelona, Spain|Hospital Universitario Sagrat Cor, Barcelona, Spain|Hospital Universitario de Burgos, Burgos, Spain|Hospital Virgen de la Luz, Cuenca, Spain|Hospital Clínico San Cecilio, Granada, Spain|Hospital Universitario de León, León, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Fundación Jiménez Díaz, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Infanta Leonor, Madrid, Spain|Hospital La Princesa, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Gregorio Marañon, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Puerta de Hierro, Madrid, Spain|Hospital Reina Sofía, Murcia, Spain|Hospital Universitario Virgen de la Arrixaca, Murcia, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Complejo Asistencial de Palencia, Palencia, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital General de Segovia, Segovia, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Virgen Macarena, Sevilla, Spain|Hospital Clinico Universitario, Valencia, Spain|Hospital Dr. Peset, Valencia, Spain|Hospital General de Valencia, Valencia, Spain|Hospital La Fe, Valencia, Spain|Hospital de Valladolid, Valladolid, Spain|Hospital Rio Hortega, Valladolid, Spain|Hospital Lozano Blesa, Zaragoza, Spain|Hospital Miguel Servet, Zaragoza, Spain|Hospital Nuestra Señora de Sonsoles, Ávila, Spain","https://ClinicalTrials.gov/show/NCT04334928"
22,"Testing for Dysautonomia in Patients Hospitalized for SARS-CoV-2 Infection (COVID-19) : COVIDANS Study","Recruiting","No Results Available","SARS-CoV 2","Other: ECG-Holter","CHU Hopital nord, Saint-Étienne, France","https://ClinicalTrials.gov/show/NCT04374045"
23,"SARS Cov-2 in Conjunctival Secretion","Completed","No Results Available","Sars-CoV2|Tear","Diagnostic Test: Tears swab","ASST Sette Laghi, Varese, Italy","https://ClinicalTrials.gov/show/NCT04402853"
24,"Treatments to Decrease the Risk of Hospitalization or Death in Elderly Outpatients With Symptomatic SARS-CoV-2 Infection (COVID-19)","Not yet recruiting","No Results Available","Corona Virus Infection|Sars-CoV2","Dietary Supplement: Vitamins|Drug: Hydroxychloroquine|Drug: Imatinib|Drug: Favipiravir|Drug: Telmisartan","Bordeaux university Hospital, Bordeaux, France","https://ClinicalTrials.gov/show/NCT04356495"
25,"Assessment of the Presence of the SARS-COV-2 Virus in the Peritoneum of COVID-19 Patients","Recruiting","No Results Available","Coronavirus Infection","Other: Collection of samples","Department of General and Digestive Surgery, Hospital René Dubos, Pontoise, France|Department of Gynecology-Obstetrics, Hospital René Dubos, Pontoise, France","https://ClinicalTrials.gov/show/NCT04361396"
26,"SARS-CoV-2 Disguise Study","Recruiting","No Results Available","Sars-CoV2","Diagnostic Test: SARS-CoV-2-test|Other: SARS-CoV-2 questionnaire survey","Meshalkin National Medical Research Center, Novosibirsk, Russian Federation","https://ClinicalTrials.gov/show/NCT04395794"
27,"Long-term Assessment of Organ Functions Among Survivors of Severe Acute Respiratory Syndrome","Unknown status","No Results Available","SARS Virus|Long-Term Survivors",,"Peking University People's Hospital, Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT03443102"
28,"Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection","Suspended","No Results Available","Coronavirus Infection","Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin|Drug: Chloroquine Sulfate","Washington University School of Medicine Infectious Disease Clinical Research Unit, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States","https://ClinicalTrials.gov/show/NCT04341727"
29,"Solid Organ Transplant Recipients With SARS-CoV-2 French Registry","Recruiting","No Results Available","SARS-CoV-2",,"Service de Néphrologie et Transplantation, Strasbourg, France","https://ClinicalTrials.gov/show/NCT04360707"
30,"Evaluation and Treatment of Severe Acute Respiratory Syndrome (SARS)","Withdrawn","No Results Available","Severe Acute Respiratory Syndrome",,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00073086"
31,"Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)","Recruiting","No Results Available","Corona Virus Infection","Drug: Colchicine|Drug: Placebo oral tablet","University of California, San Francisco - San Francisco General Hospital, San Francisco, California, United States|New York University School of Medecine, New York, New York, United States|Montreal Heart Institute, Montreal, Quebec, Canada|Hospital Universitario La Paz, IdiPaz, La Paz, Madrid, Spain","https://ClinicalTrials.gov/show/NCT04322682"
32,"NOsocomial Dissemination Risk of SARS-Cov2","Not yet recruiting","No Results Available","Sars-CoV2",,,"https://ClinicalTrials.gov/show/NCT04339881"
33,"Convalescent Plasma Compared to the Best Available Therapy for the Treatment of SARS-CoV-2 Pneumonia","Recruiting","No Results Available","Coronavirus Infection","Biological: Plasma|Other: Best Available Therapy","Hospital Universitario José E. Gonzalez, Monterrey, Nuevo Leon, Mexico","https://ClinicalTrials.gov/show/NCT04358783"
34,"Clinical, Biological and Genetic Prognostic Factors for SARS-CoV-2 Infection in Patients Hospitalized in Strasbourg","Recruiting","No Results Available","SARS-CoV-2",,"Service de Virologie - Hôpital Civil, Strasbourg, France","https://ClinicalTrials.gov/show/NCT04405726"
35,"Rapid SARS-CoV-2 IgG Antibody Testing in High Risk Healthcare Workers","Not yet recruiting","No Results Available","SARS-CoV-2","Diagnostic Test: SARS-CoV-2 IgG Antibody Testing Kit",,"https://ClinicalTrials.gov/show/NCT04334876"
36,"SARS-COV2 Pandemic Serosurvey and Blood Sampling","Recruiting","No Results Available","SARS-COV2 Virus",,"University of Alabama, Birmingham, Alabama, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT04334954"
37,"Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus","Recruiting","No Results Available","SARS-CoV-2 Infection","Drug: hydroxychloroquine|Drug: azithromycin|Drug: hydroxychloroquine placebo","Hopial Avicenne, Bobigny, France|Hôpital GHU Paris Saclay, Le Kremlin-Bicêtre, France|Hôpital Saint Antoine, Paris, France|Hôpital Broca, Paris, France|Hôpital La Pitié-Salpétrière, Paris, France|Hôpital Cochin, Paris, France|Hôpital européen Georges Pompidou, Paris, France|Hôpital Necker, Paris, France","https://ClinicalTrials.gov/show/NCT04344379"
38,"Rapid Salivary Test to Detect SARS-CoV-2 (COVID-19)","Recruiting","No Results Available","COVID-19|SARS-CoV 2|Corona Virus Infection","Diagnostic Test: rapid salivary test","ASST dei Sette Laghi, Varese, VA, Italy","https://ClinicalTrials.gov/show/NCT04357327"
39,"Seroprevalence of SARS CoV 2 Antibodies in Previously Undiagnosed Healthcare Workers","Enrolling by invitation","No Results Available","SARS-CoV 2|COVID-19","Other: Serologic testing","Mayo Clinic in Florida, Jacksonville, Florida, United States","https://ClinicalTrials.gov/show/NCT04383587"
40,"Study of SARS-CoV2 Virus (COVID-19) Seroprevalence in the Population of Creil Air Force Base (BA110)","Recruiting","No Results Available","Sars-CoV2","Diagnostic Test: Anti-SARS-CoV2 Serology|Behavioral: Questionnaire|Diagnostic Test: Anti-SARS-CoV2 serological controls and serum neutralization","24e antenne médicale de Creil, Creil, France","https://ClinicalTrials.gov/show/NCT04404270"
41,"Study of the SARS-COV-2 (COVID-19) Serological Profile of an Army Training Hospital Staff","Recruiting","No Results Available","Sars-CoV2","Diagnostic Test: Anti-SARS-CoV2 Serology|Other: Questionnaire","Hôpital d'Instuction des Armées Sainte-Anne, Toulon, France|Hôpital d'Instruction des Armées Robert Picqué, Villenave-d'Ornon, France","https://ClinicalTrials.gov/show/NCT04387838"
42,"Evaluation of Quickly Diagnostic Saliva Tests for SARS-CoV-2","Recruiting","No Results Available","SARS-CoV-2","Diagnostic Test: Sampling salivary","UCH Montpellier, Montpellier, France","https://ClinicalTrials.gov/show/NCT04337424"
43,"Prevalence of Long-term Respiratory Complications of Severe SARS-CoV-2 Pneumonia","Not yet recruiting","No Results Available","Severe SARS-CoV2 Pneumonia","Other: Blood sample and data record","Damien JOLLY, Reims, France","https://ClinicalTrials.gov/show/NCT04376840"
44,"Current and Past SARS-CoV-2 Infection and COVID-19 in Healthcare","Recruiting","No Results Available","SARS-CoV 2","Diagnostic Test: Throat swab sample for measuring current infection with SARS-CoV-2|Diagnostic Test: Blood sample for serology to measure past infection with SARS-CoV-2","Karolinska University Hospital, Stockholm, Sweden","https://ClinicalTrials.gov/show/NCT04411576"
45,"Screening for SARS-CoV-2-Infections and Monitoring of Serological Responses to SARS-CoV-2 in Healthcare Workers","Recruiting","No Results Available","SARS-Cov-2","Diagnostic Test: Nasal swab|Diagnostic Test: Serum testing","Greifswald University Medicine, Greifswald, Germany","https://ClinicalTrials.gov/show/NCT04370119"
46,"Serological Study of the Exposure of Personnel to Sars-cov-2","Not yet recruiting","No Results Available","Sars-CoV2","Diagnostic Test: Sars-Cov-2 serology",,"https://ClinicalTrials.gov/show/NCT04422977"
47,"IC14 (Anti-CD14) Treatment in Patients With SARS-CoV-2 (COVID-19)","Not yet recruiting","No Results Available","Sars-CoV2","Biological: IC14|Other: Placebo","University of Washington, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT04391309"
48,"Convalescent Plasma for the Treatment of Severe SARS-CoV-2 (COVID-19)","Not yet recruiting","No Results Available","SARS-Cov-2","Drug: Convalescent plasma","Hospital San Vicente Fundacion, Medellín, Antioquia, Colombia","https://ClinicalTrials.gov/show/NCT04391101"
49,"Convalescent Plasma to Limit SARS-CoV-2 Associated Complications","Not yet recruiting","No Results Available","SARS-CoV 2","Biological: SARS-CoV-2 convalescent plasma|Biological: Plasma from a volunteer donor",,"https://ClinicalTrials.gov/show/NCT04373460"
50,"EPA-FFA to Treat Hospitalised Patients With COVID-19 (SARS-CoV-2)","Not yet recruiting","No Results Available","SARS-CoV-2","Drug: Eicosapentaenoic acid gastro-resistant capsules",,"https://ClinicalTrials.gov/show/NCT04335032"
51,"The Effect of EIDD-2801 on Viral Shedding of SARS-CoV-2 (COVID-19)","Not yet recruiting","No Results Available","SARS-CoV 2","Drug: 200 mg EIDD-2801|Drug: 300 mg EIDD-2801|Drug: Placebo (PBO)","Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States|John Hopkins Hospital, Baltimore, Maryland, United States|Suburban Hospital, Bethesda, Maryland, United States|Howard County General Hospital, Columbia, Maryland, United States","https://ClinicalTrials.gov/show/NCT04405739"
52,"Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19)","Recruiting","No Results Available","Corona Virus Infection","Biological: Anti-SARS-CoV-2 Human Convalescent Plasma","Johns Hopkins Hospitals, Baltimore, Maryland, United States","https://ClinicalTrials.gov/show/NCT04377672"
53,"Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) Infection","Recruiting","No Results Available","SARS-CoV-2","Drug: Interferon beta 1a|Drug: Placebo","Belfast City Hospital, Belfast, United Kingdom|Queen Elizabeth Hospital,, Birmingham, United Kingdom|Bradford Royal Infirmary, Bradford, United Kingdom|Hull and East Yorkshire NHS Trust, Castle Hill Hospital,, Hull, United Kingdom|Glenfield Hospital,, Leicester, United Kingdom|Wythenshawe Hospital, Manchester, United Kingdom|City Campus of Nottingham University, Nottingham, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom|University Hospital Southampton Nhs Foundation Trust, Southampton, United Kingdom","https://ClinicalTrials.gov/show/NCT04385095"
54,"Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection","Recruiting","No Results Available","SARS-CoV-2","Other: Standard of care|Drug: Hydroxychloroquine|Drug: Azithromycin","Duke Regional Hospital, Durham, North Carolina, United States|Duke University Hospital, Durham, North Carolina, United States|Durham VA Medical Center, Durham, North Carolina, United States|Duke Raleigh Hospital, Raleigh, North Carolina, United States","https://ClinicalTrials.gov/show/NCT04335552"
55,"Blood Ozonization in Patients With SARS-CoV-2 Respiratory Failure","Recruiting","No Results Available","SARS-CoV-2 Respiratory Failure","Procedure: Medical Ozone procedure","Dott. Amato De Monte, Udine, Italy","https://ClinicalTrials.gov/show/NCT04388514"
56,"Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19","Recruiting","No Results Available","SARS (Severe Acute Respiratory Syndrome)|Coronavirus","Drug: Nitric Oxide Gas","University of Alabama, Birmingham, Alabama, United States|Louisiana State University Health Shreveport, Shreveport, Louisiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT04306393"
57,"The Use of Peripheral Blood Specimens From Patients Suspected of Having SARS-CoV-2 Infections in Research Studies Intended to Support the Development of COVID-19 Detection Methods, Treatments, and/or Vaccines","Not yet recruiting","No Results Available","SARS-CoV-2","Diagnostic Test: nasal pharyngeal (NP) swab samples|Diagnostic Test: peripheral blood draw",,"https://ClinicalTrials.gov/show/NCT04391400"
58,"Predictors of Respiratory Failure in SARS-Cov-2 Infection","Recruiting","No Results Available","SARS-CoV-2 Pneumonia",,"University of Bologna - Department of Medical and Surgical Sciences, Bologna, Italy","https://ClinicalTrials.gov/show/NCT04316949"
59,"Beaumont Quantitative Lung Function Imaging to Characterize Patients With SARS-COV 2","Recruiting","No Results Available","SARS-COV2|Severe Acute Respiratory Syndrome|COVID-19","Device: CT-V","Beaumont Health, Royal Oak, Michigan, United States","https://ClinicalTrials.gov/show/NCT04320511"
60,"Study of Specific Viral Immune Responses Induced by SARS-CoV-2 (COVID-19)","Recruiting","No Results Available","SARS-CoV-2 Infection","Other: Additional biological samples","CHU Jean Minjoz, Besançon, France","https://ClinicalTrials.gov/show/NCT04365322"
61,"Pro-thrombotic Status in Patients With SARS-Cov-2 Infection","Recruiting","No Results Available","Severe Acute Respiratory Syndrome Coronavirus 2","Other: SARS-Cov-2 infection","Azienda Ospedaliera Universitaria di Ferrara, Ferrara, Italy","https://ClinicalTrials.gov/show/NCT04343053"
62,"Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)","Available","No Results Available","SARS-CoV2 Infection","Drug: Remdesivir","University of Alabama- Birmingham, Birmingham, Alabama, United States|Banner- University Medical Center Phoenix, Phoenix, Arizona, United States|Community Regional Medical Centers (CRMC), Fresno, California, United States|St. Jude Medical Center, Fullerton, California, United States|Scripps Memorial Hospital La Jolla, La Jolla, California, United States|Long Beach Memorial Medical Center, Long Beach, California, United States|Huntington Hospital, Pasadena, California, United States|Scripps Mercy Hospital, San Diego, California, United States|California Pacific Medical Center, San Francisco, California, United States|University of California, Medical Center (Parnassus Campus), San Francisco, California, United States|Regional Medical Center, San Jose, California, United States|San Mateo Medical Center, San Mateo, California, United States|Santa Rosa Memorial Hospital, Santa Rosa, California, United States|Los Robles Regional Medical Center, Thousand Oaks, California, United States|PIH Health Whittier Hospital, Whittier, California, United States|The Medical Center Of Aurora, Aurora, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|Swedish Medical Center, Englewood, Colorado, United States|Greenwich Hospital, Greenwich, Connecticut, United States|Middlesex Health, Middletown, Connecticut, United States|The Hospital of Central Connecticut, New Britain, Connecticut, United States|The Stamford Health Medical Group- Pulmonary Associates, Stamford, Connecticut, United States|George Washington University Hospital, Washington, District of Columbia, United States|Aventura Hospital and Medical Center, Aventura, Florida, United States|Lawnwood Regional Medical Center, Fort Pierce, Florida, United States|Memorial Regional Hospital, Hollywood, Florida, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|AdventHealth Orlando, Investigational Drug Services, Orlando, Florida, United States|Sarasota Memorial Hospital, Sarasota, Florida, United States|Piedmont Atlanta Hospital, Atlanta, Georgia, United States|Wellstar Atlanta Medical Center, Atlanta, Georgia, United States|Piedmont Columbus Regional-Midtown Hospital, Columbus, Georgia, United States|Grady Health System- Grady Memorial Hospital, Decatur, Georgia, United States|Piedmont Fayette Hospital, Fayetteville, Georgia, United States|Memorial Health University Medical Center, Savannah, Georgia, United States|John D. Archbold Memorial Hospital, Thomasville, Georgia, United States|Swedish Hospital, Chicago, Illinois, United States|Mercy Hospital & Medical Center, Chicago, Illinois, United States|Northwestern Lake Forest Hospital, Lake Forest, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Northwestern Medicine Central DuPage Hospital, Winfield, Illinois, United States|St. Vincent Hospital and Health Care Center, Inc., Carmel, Indiana, United States|Richard L Roudebush Indianapolis VA, Indianapolis, Indiana, United States|Riverview Health, Noblesville, Indiana, United States|Our Lady of the Lakes Regional Medical Center, Baton Rouge, Louisiana, United States|Touro Infirmary, New Orleans, Louisiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Slidell Memorial Hospital, Slidell, Louisiana, United States|University of Maryland, Baltimore, Maryland, United States|Mercy Medical Center, Baltimore, Maryland, United States|Calvert Health Medical Center, Prince Frederick, Maryland, United States|University of Maryland St. Joseph Medical Center, Towson, Maryland, United States|Steward St. Elizabeth's Medical Center of Boston, Inc., Boston, Massachusetts, United States|Cambridge Health Alliance, Cambridge, Massachusetts, United States|Charlton Memorial Hospital, Fall River, Massachusetts, United States|Lawrence General Hospital, Lawrence, Massachusetts, United States|Lowell General Hospital, Lowell, Massachusetts, United States|South Shore Hospital, South Weymouth, Massachusetts, United States|UMass Memorial Medical Center, Worcester, Massachusetts, United States|St. Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Huron Valley-Sinai Hospital, Commerce, Michigan, United States|Wayne Statue University/ Detroit Receiving Hospital, Detroit, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|McLaren Health Care Corporation, Flint, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|CarePoint Health Bayonne Medical Center, Bayonne, New Jersey, United States|Clara Maass Medical Center, Belleville, New Jersey, United States|Cooper University Hospital, Camden, New Jersey, United States|Hackensack Meridian Health - JFK Medical Center, Edison, New Jersey, United States|Trinitas Regional Medical Center, Elizabeth, New Jersey, United States|Englewood Health, Englewood, New Jersey, United States|Hunterdon Medical Center, Flemington, New Jersey, United States|CentraState Medical Center, Freehold, New Jersey, United States|Robert Wood Johnson University Hospital Hamilton, Hamilton, New Jersey, United States|Jersey City Medical Center, Jersey City, New Jersey, United States|Christ Hospital- Carepoint Health, Jersey City, New Jersey, United States|Monmouth Medical Center, Long Branch, New Jersey, United States|Atlantic Health System/ Morristown Medical Center, Morristown, New Jersey, United States|Jersey Shore University Medical Center, Neptune, New Jersey, United States|Saint Peter's University Hospital, New Brunswick, New Jersey, United States|Saint Michael's Medical Center, Newark, New Jersey, United States|University Hospital, Newark, New Jersey, United States|Ocean Medical Center, Oakhurst, New Jersey, United States|Bayshore Medical Center, Red Bank, New Jersey, United States|The Valley Hospital, Ridgewood, New Jersey, United States|Atlantic Health System/Overlook Medical Center, Summit, New Jersey, United States|Holy Name Medical Center, Teaneck, New Jersey, United States|Capital Health, Trenton, New Jersey, United States|Virtua Health Voorhees Campus, Voorhees, New Jersey, United States|St. Peter's Hospital, Albany, New York, United States|Mount Sinai Queens, Astoria, New York, United States|Good Samaritan Hospital Medical Center, Bay Shore, New York, United States|Southside Hospital, Bay Shore, New York, United States|Lincoln Medical Center, Bronx, New York, United States|St Barnabus Hospital, Bronx, New York, United States|Montefiore Medical Center, Weiler Campus, Bronx, New York, United States|Montefiore Health System Moses Medical Center, Bronx, New York, United States|The Brooklyn Hospital Center, Brooklyn, New York, United States|Kingsbrook Jewish Medical Center, Brooklyn, New York, United States|University Hospital Brooklyn (SUNY Downstate), Brooklyn, New York, United States|Woodhull Medical Center, Brooklyn, New York, United States|Kings County Hospital Center, Brooklyn, New York, United States|New York Harbor VA Medical Center, Brooklyn, New York, United States|Brookdale University Hospital and Medical Center, Brooklyn, New York, United States|Interfaith Medical Center, Brooklyn, New York, United States|NewYork-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States|Maimonides Medical Center, Brooklyn, New York, United States|NYU Langone Hospital - Brooklyn, Brooklyn, New York, United States|Mount Sinai Brooklyn, Brooklyn, New York, United States|New York City Health and Hospitals - Coney Island, Brooklyn, New York, United States|Kaleida Health System, Buffalo, New York, United States|Nassau University Medical Center, East Meadow, New York, United States|New York Presbyterian- Queens, Flushing, New York, United States|Glens Falls Hospital, Glens Falls, New York, United States|Queens Hospital Center, Jamaica, New York, United States|NYU Langone Health, New York, New York, United States|Hospital for Special Surgery, New York, New York, United States|New York City Health and New York City Health and Hospitals - Metropolitan- Metropolitan, New York, New York, United States|NewYork-Presyterian/Columbia University Irving Medical Center- Milstein Hospital, New York, New York, United States|New York City Health + Hospitals / Harlem, New York, New York, United States|New York Presbyterian Lower Manhattan Hospital, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Mount Sinai South Nassau, Oceanside, New York, United States|Vassar Brothers Medical Center, Poughkeepsie, New York, United States|Rochester General Hospital, Rochester, New York, United States|St. Francis Hospital, Roslyn, New York, United States|Ellis Hospital, Schenectady, New York, United States|Staten Island University Hospital- Northwell Health (North Campus), Staten Island, New York, United States|Stony Brook University Hospital/ Stony Brook Children's, Stony Brook, New York, United States|Samaritan Hospital, Troy, New York, United States|UNC Hospitals, Chapel Hill, North Carolina, United States|Atrium Health- Carolinas Medical Center, Charlotte, North Carolina, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|The Ohio State University College of Medicine, Columbus, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Saint Francis Hospital, Tulsa, Oklahoma, United States|St. Luke's Hospital - Bethlehem Campus, Bethlehem, Pennsylvania, United States|Mercy Catholic Medical Center - Fitzgerald Campus, Darby, Pennsylvania, United States|St Mary Medical Center, Langhorne, Pennsylvania, United States|Philadelphia VA Medical Center, Philadelphia, Pennsylvania, United States|Einstein Medical Center Philadelphia, Philadelphia, Pennsylvania, United States|Allegheny Health Network, Pittsburgh, Pennsylvania, United States|UPMC, Pittsburgh, Pennsylvania, United States|Roger Williams Medical Center,, Providence, Rhode Island, United States|Kent Hospital, Warwick, Rhode Island, United States|St. Francis Hospital, Greenville, South Carolina, United States|Lexington Medical Center, West Columbia, South Carolina, United States|TriStar Centennial Medical Center, Nashville, Tennessee, United States|St. David's South Austin Medical Center, Austin, Texas, United States|Texas Health Presbyterian Hospital Dallas, Dallas, Texas, United States|HCA Houston Healthcare West, Houston, Texas, United States|University of Texas Medical Branch Galveston, League City, Texas, United States|Covenant Medical Center, Lubbock, Texas, United States|Methodist Mansfield Medical Center, Mansfield, Texas, United States|Methodist Healthcare System of San Antonio, Ltd. LLP, dha, Methodist Hospital, San Antonio, Texas, United States|Saint Mark's Hospital, Salt Lake City, Utah, United States|Inova Fairfax Medical Campus, Falls Church, Virginia, United States|Henrico Doctors Hospital, Richmond, Virginia, United States|Carilion Medical Center, Roanoke, Virginia, United States|Overlake Hospital Medical Center, Bellevue, Washington, United States|University of Washington Medical Center- Montlake Campus, Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|St. Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|The Royal Melbourne Hospital, Parkville, Victoria, Australia|Universitätsklinik für Innere Medizin II, Innsbruck, Austria|Kepler Universitätsklinikum, Linz, Austria|Sozialmedizinisches Zentrum Süd - Kaiser-Franz-Josef-Spital, Wien, Austria|Centre Hospitalier Universitaire Saint Pierre, Brussels, Belgium|Ghent University Hospital, Ghent, Belgium|Jessa Ziekenhuis, Hasselt, Belgium|AZ Groeninge, Kortrijk, Belgium|Universitair Ziekenhuis Leuven, Leuven, Belgium|Centre Hospitalier Universitaire de Liège, Liège, Belgium|Hôpital Civil Marie Curie, Lodelinsart, Belgium|William Osler Health System, Brampton, Ontario, Canada|The Ottowa Hospital, Ottawa, Ontario, Canada|Nicosia General Hospital, Nicosia, Cyprus|Všeobecná fakultní nemocnice v Praze, Prague, Czechia|Eticka komise pro multicentircke klinicke hodnoceni Fakultni nemocnice v Motole, Praha 5, Czechia|Nemocnice Na Bulovce, Praha 8, Czechia|Rigshospitalet, Copenhagen, Denmark|Põhja-Eesti Regionaalhaigla, Tallinn, Estonia|Vilnius University, Tartu, Estonia|Hopital Avicenne, Bobigny, France|Centre Hospitalier Regional Universitaire Brest Hôpital de la Cavale Blanche à Brest, Brest Cedex, France|Centre Hospitalier Universitaire Gabriel-Montpied, Clermont Ferrand, France|Hôpitaux Civils de Colmar, Colmar, France|Centre Hospitalier Sud Francilien, Corbeil Essonnes, France|Hôpital Raymond Poincaré, Garches, France|Centre Hospitalier Régional d'Orléans, Orléans, France|Centre Hospitalier Universitaire de Poitiers, Poitiers, France|Hôpital Charles-Nicolle, Rouen, France|Saint Josef Hospital Ruhr Universitaet Bochum, Bochum, Germany|Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Germany|Universitatsklinikum, Essen, Germany|Universitätsklinikum Freiburg, Freiburg, Germany|Universitätsmedizin Göttingen, Göttingen, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Heidelberg, Heidelberg, Germany|Universitätsklinikum des Saarlandes, Homburg, Germany|Caritas-Krankenhaus St. Josef, Regensburg, Germany|Klinikum Würzburg Mitte, Würzburg, Germany|University General Hospital of Patras Panagia I Voithia, Patra, Greece|General Hospital of Thessaloniki George Papanikolaou, Thessaloniki, Greece|Kenézy Gyula Kórház És Rendelőintézet, Debrecen, Hungary|Landspítali, Reykjavik, Iceland|Kerry University Hospital, Tralee, Ireland|Shaare Zedek Medical Center, Jerusalem, Israel|Hasharon Hospital, Petah Tikva, Israel|Sheba Medical Center at Tel Hashomer, Ramat Gan, Israel|Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona, Ancona, Italy|Azienda Universitaria Ospedaliera Consorziale - Policlinico di Bari, Bari, Italy|Azienda Ospedaliero Universitaria, Bologna, Italy|Presidio Ospedaliero Garibaldi-Nesima, Catania, Italy|Azienda Ospedaliero - Universitaria Careggi, Florence, Italy|Ospedale Policlinico San Martino, Genova, Italy|Ospedale San Gerardo di Monza, Monza, Italy|Azienda Ospedaliera dei Colli, Napoli, Italy|Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy|Azienda Ospedaliero Universitaria, Turin, Italy|Radboud Universitair Medisch Centrum, Nijmegen, Netherlands|HagaZiekenhuis, The Hague, Netherlands|Szpital Uniwersytecki w Krakowie, Krakow, Poland|Wojewódzki Specjalistyczny Szpital im. dr. Wł. Biegańskiego, Lodz, Poland|Wielospecjalistyczny Szpital Miejski Im Józefa Strusia Zakład Opiekuńczo Leczniczy, Poznan, Poland|Wojewódzki Szpital Specjalistyczny Megrez Sp. z o.o., Tychy, Poland|Centro Hospitalar Universitário de Lisboa Central - Hospital Curry Cabral, Lisboa, Portugal|Centro Hospitalar Universitário do Porto E.P.E., Porto, Portugal|Centro Hospitalar Universitário De São João, Porto, Portugal|Institutul National de Boli Infectioase Prof. Dr. Matei Bals, Bucharest, Romania|Spitalul Clinic de Boli Infecţioase Sfânta Parascheva Iaşi, Iasi, Romania|Clinical hospital for infectious disease, Timisoara, Romania|Univerzitná Nemocnica L. Pasteura Košice - Pracovisko Rastislavova 43, Košice, Slovakia|Univerzitetni Klinicni Center Ljubljana, Ljubljana, Slovenia|Univerzitetni Klinicni Center Maribor, Maribor, Slovenia|Hospital Universitari Germans Trias i Pujol, Badalona, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Hospital Universitario Son Espases, Palma de Mallorca, Spain|Hospital Clinico Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Donostia, San Sebastian, Spain|Hospital Virgen De La Salud, Santa Cruz de Tenerife, Spain|Hospital Virgen De La Salud, Toledo, Spain|Hospital Clinico Universitario de Valladolid, Valladolid, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|Kantonsspital Aarau, Aarau, Switzerland|University Hospital Basel, Basel, Switzerland|Spitalzentrum Biel, Biel, Switzerland|Kantonsspital Graubünden, Chur, Switzerland|Centre Hospitalier Universitaire Vaudois Lausanne, Lausanne, Switzerland|Luzerner Kantonsspital, Luzern, Switzerland|University Hospital of Wales, Cardiff and Vale NHS Trust, Cardiff, United Kingdom|Barts Health NHS Trust, London, United Kingdom|Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom|St. George's Hospital, London, United Kingdom|Southampton University Hospital, Southampton, United Kingdom","https://ClinicalTrials.gov/show/NCT04323761"
63,"Dynamic Profiles of Cytokine/Chemokine in Severe Acute Respiratory Syndrome","Completed","No Results Available","SARS",,,"https://ClinicalTrials.gov/show/NCT00173459"
64,"COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2","Recruiting","No Results Available","SARS-CoV-2 Infection","Drug: lopinavir/ritonavir|Drug: Hydroxychloroquine Sulfate|Drug: Losartan|Drug: Placebos","Bassett Medical Center, Cooperstown, New York, United States","https://ClinicalTrials.gov/show/NCT04328012"
65,"Risk Stratification With Chest CT to Rule-out Suspected SARS-CoV-2 Infections","Active, not recruiting","No Results Available","Severe Acute Respiratory Syndrome Coronavirus 2","Device: CT-imaging","Jena University Hospital, Jena, Thuringia, Germany","https://ClinicalTrials.gov/show/NCT04357938"
66,"Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)","Available","No Results Available","Severe Acute Respiratory Syndrome Coronavirus 2","Other: Anti-Sars-CoV-2 Convalescent Plasma",,"https://ClinicalTrials.gov/show/NCT04360486"
67,"ACE Inhibitors or ARBs Discontinuation in Context of SARS-CoV-2 Pandemic","Recruiting","No Results Available","History of Cardiovascular Disease Treated With RAS Blockers and With SARS-CoV-2 Infection","Drug: 1: discontinuation of RAS blocker therapy|Drug: 2: continuation of RAS blocker therapy","Cardiologie, Groupe Hospitalier Pitié-Salpêtrière, Paris, France","https://ClinicalTrials.gov/show/NCT04329195"
68,"TOFAcitinib in SARS-CoV2 Pneumonia","Not yet recruiting","No Results Available","SARS-COv2 Related Interstitial Pneumonia","Drug: Tofacitinib","Ospedali Riuniti di Ancona, Ancona, Marche, Italy","https://ClinicalTrials.gov/show/NCT04332042"
69,"Stem Cell Educator Therapy Treat the Viral Inflammation in COVID-19","Not yet recruiting","No Results Available","Severe Acute Respiratory Syndrome (SARS) Pneumonia","Combination Product: Stem Cell Educator-Treated Mononuclear Cells Apheresis",,"https://ClinicalTrials.gov/show/NCT04299152"
70,"Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada)","Recruiting","No Results Available","Corona Virus Infection|SARS-CoV Infection|Coronavirus","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","University of Minnesota, Minneapolis, Minnesota, United States|University of Alberta, Edmonton, Alberta, Canada|University of British Columbia, Vancouver, British Columbia, Canada|University of Manitoba, Winnipeg, Manitoba, Canada|Eastern Health, Saint John's, Newfoundland and Labrador, Canada|McMaster University, Hamilton, Ontario, Canada|Lawson Health Research Institute, London, Ontario, Canada|Research Institute of the McGill University Health Centre, Montréal, Quebec, Canada","https://ClinicalTrials.gov/show/NCT04421664"
71,"COVID-19 Study of the Serological Response Against the Severe Acute Respiratory Syndrome (SARS) Coronavirus 2 (CoV-2) Virus in 2 Types of Employees, Hospital and Non-hospital, at Institute Curie","Recruiting","No Results Available","Volunteers From the Institute Curie Staff Who Are Not Showing Active SARS-CoV-2 Infection","Diagnostic Test: Blood samples (collection of 5 mL of blood in a dry tube)","Institut Curie, Paris, France","https://ClinicalTrials.gov/show/NCT04369066"
72,"Severe Acute Respiratory Syndrome-Coronavirus-2 and Loss of Autonomy in the Elderly","Recruiting","No Results Available","SARS-CoV 2",,"University hospital of Rennes, Rennes, France|Va de Lys-Ramsay Gds group Clinic, Tourcoing, France|Hopsital of Valenciennes, Valenciennes, France|University hospital of Guadeloupe, Les Abymes, Guadeloupe|University hospital of Martinique, Fort-de-France, Martinique","https://ClinicalTrials.gov/show/NCT04414319"
73,"Anti-SARS Cov-2 T Cell Infusions for COVID 19","Not yet recruiting","No Results Available","SARS-CoV 2|Viral Infection|COVID 19","Biological: Partially HLA-matched Virus Specific T cells (VSTs)","Houston Methodist Hospital, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT04401410"
74,"Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19","Not yet recruiting","No Results Available","Coronavirus Infections","Drug: Conestat alfa","University Hospital Basel, Division of Internal Medicine, Basel, Switzerland","https://ClinicalTrials.gov/show/NCT04414631"
75,"Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19.","Withdrawn","No Results Available","Coronavirus|SARS (Severe Acute Respiratory Syndrome)","Drug: Nitric Oxide Gas",,"https://ClinicalTrials.gov/show/NCT04290871"
76,"Antibody Seroprevalence and Rate of Asymptomatic Infections With SARS-CoV-2 in Austrian Hospital Personnel.","Recruiting","No Results Available","Severe Acute Respiratory Syndrome Coronavirus 2|SARS-CoV 2|Coronavirus Infection|Covid19","Diagnostic Test: a specifically designed self-administered questionnaire","Allgemeine Unfallversicherungsanstalt, Vienna, Austria","https://ClinicalTrials.gov/show/NCT04354779"
77,"Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19)","Not yet recruiting","No Results Available","Coronavirus Infections|SARS-CoV 2|SARS (Severe Acute Respiratory Syndrome)|Pulmonary Disease","Drug: Hydroxychloroquine Sulfate|Drug: Hydroxychloroquine Sulfate + Azythromycin","Apsen Farmacêutica S.A., São Paulo, Brazil","https://ClinicalTrials.gov/show/NCT04361461"
78,"Seroprevalence of SARS-Cov-2 Antibodies in Children","Recruiting","No Results Available","COVID|Corona Virus Infection","Diagnostic Test: Covid-19 Antibody testing (IgG and IgM)","Royal Belfast Hospital for Sick Children, Belfast, United Kingdom|University Hospital of Wales, Cardiff, United Kingdom|Royal Hospital for Children, Glasgow, United Kingdom|Public Health England, London, United Kingdom|Public Health England, Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT04347408"
79,"Hydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia Trial","Not yet recruiting","No Results Available","SARS-CoV-2 Pneumonia|COVID-19","Drug: Hydroxychloroquine","Kootenai Health, Coeur d'Alene, Idaho, United States","https://ClinicalTrials.gov/show/NCT04382625"
80,"Study of Immune Response During SARS-CoV-2 Infection - (COVID-19)","Not yet recruiting","No Results Available","New Coronavirus Disease (COVID-19), Infection With SARS-CoV-2","Other: blood sampling|Other: additional blood tubes","Antibes Hospital, Antibes, France|Cannes Hospital, Cannes, France|Nice Hospital, Nice, France","https://ClinicalTrials.gov/show/NCT04355351"
81,"Plasma Therapy of COVID-19 in Critically Ill Patients","Recruiting","No Results Available","SARS-CoV Infection","Biological: Convalescent Plasma (anti-SARS-CoV-2 plasma)|Biological: Non-convalescent Plasma (control plasma)","Columbia University Irving Medical Center/NYP, New York, New York, United States","https://ClinicalTrials.gov/show/NCT04359810"
82,"LSALT Peptide vs. Placebo to Prevent ARDS and Other Organ Injuries in Patients Infected With SARS-CoV-2 (COVID-19)","Not yet recruiting","No Results Available","COVID|Severe Acute Respiratory Syndrome|Sars-CoV2","Drug: LSALT peptide|Drug: Placebo",,"https://ClinicalTrials.gov/show/NCT04402957"
83,"HOME-CoV: Hospitalization or Outpatient ManagEment of Patients With a SARS-CoV-2 Infection","Recruiting","No Results Available","Coronavirus Infection","Other: HOME-CoV rule implementation","Clinique Universitaire Saint-Luc, Bruxelles, Belgium|CHU de Liège, Liege, Belgium|Ch Argenteuil, Argenteuil, France|CHU Brest, Brest, France|CH Cholet, Cholet, France|CHU Clermont Ferrand, Clermont Ferrand, France|Ch Colmar, Colmar, France|CH Alpes Lemant, Contamine-sur-Arve, France|CHU Dijon, Dijon, France|CH Le Mans, Le Mans, France|CH Libourne, Libourne, France|CH Limoges, Limoges, France|Ch Longjumeau, Longjumeau, France|Hospices Civils de Lyon (University Hospital of Lyon), Lyon, France|Chu Montpellier, Montpellier, France|Centre Hospitalier Universitaire de Nantes, Nantes, France|CH Niort, Niort, France|Hopital Paris Saint Joseph, Paris, France|Hopital Saint Antoine, Paris, France|Hôpital Bichat, Paris, France|Hôpital Lariboisière, Paris, France|CHU de Poitiers, Poitiers, France|CH Reims, Reims, France|Ch Remiremont, Remiremont, France|Chu Rennes, Rennes, France|CHU de Rouen, Rouen, France|CHU de St Etienne, Saint Etienne, France|CH de Saint-Brieuc, Saint-Brieuc, France|Ch Troyes, Troyes, France|CH VICHY, Vichy, France|CH Princesse Grace, Monaco, Monaco","https://ClinicalTrials.gov/show/NCT04338841"
84,"A Pilot Study to Assess Hydroxychloroquine in Patients With SARS-CoV-2 (COVID-19)","Not yet recruiting","No Results Available","COVID-19|SARS-CoV-2","Drug: Hydroxychloroquine|Drug: Placebo","Oregon Health and Science University, Portland, Oregon, United States","https://ClinicalTrials.gov/show/NCT04363866"
85,"Efficacy of Captopril in Covid-19 Patients With Severe Acute Respiratory Syndrome (SARS) CoV-2 Pneumonia (CAPTOCOVID)","Not yet recruiting","No Results Available","Pneumonia|Coronavirus Infection|COVID-19","Drug: captopril 25mg","CH Victor Dupuy- Argenteuil, Argenteuil, France|Hôpital Avicenne,, Bobigny, France|Hôpital Avicenne, Bobigny, France|Hôpital Avicenne, Bobigny, France|Hôpital Antoine Béclère, Clamart, France|CH de Compiègne-Noyon, Compiègne, France|Groupe hospitalier Sud Ile de France, Melun, France|Hôpital de la Pitié- Salpêtrière, Paris, France|Hôpital Tenon, Paris, France|CHRU de Tours, Hôpital Bretonneau, Tours, France|Hôpital de Tours, Tours, France","https://ClinicalTrials.gov/show/NCT04355429"
86,"Efficacy and Safety of GSP 301 Nasal Spray in Children (Aged 6 to Under 12 Years) With Seasonal Allergic Rhinitis (SAR)","Completed","Has Results","Seasonal Allergic Rhinitis (SAR)","Drug: GSP 301 NS|Drug: GSP 301 Placebo NS","Glenmark Investigational Site 18, Mission Viejo, California, United States|Glenmark Investigational Site 32, Ontario, California, United States|Glenmark Investigational Site 30, Paramount, California, United States|Glenmark Investigational Site 17, San Diego, California, United States|Glenmark Investigational Site 21, Colorado Springs, Colorado, United States|Glenmark Investigational Site 13, Marietta, Georgia, United States|Glenmark Investigational Site 26, Savannah, Georgia, United States|Glenmark Investigational Site 28, Louisville, Kentucky, United States|Glenmark Investigational Site 14, Baltimore, Maryland, United States|Glenmark Investigational Site 19, Bethesda, Maryland, United States|Glenmark Investigational Site 25, Ypsilanti, Michigan, United States|Glenmark Investigational Site 12, Columbia, Missouri, United States|Glenmark Investigational Site 10, Rolla, Missouri, United States|Glenmark Investigational Site 27, Warrensburg, Missouri, United States|Glenmark Investigational Site 15, Omaha, Nebraska, United States|Glenmark Investigational Site 3, High Point, North Carolina, United States|Glenmark Investigational Site 8, Raleigh, North Carolina, United States|Glenmark Investigational Site 11, Cincinnati, Ohio, United States|Glenmark Investigational Site 29, Cincinnati, Ohio, United States|Glenmark Investigational Site 2, Edmond, Oklahoma, United States|Glenmark Investigational Site 33, Tulsa, Oklahoma, United States|Glenmark Investigational Site 4, Medford, Oregon, United States|Glenmark Investigational Site 6, Spartanburg, South Carolina, United States|Glenmark Investigational Site 5, Austin, Texas, United States|Glenmark Investigational Site 24, Kerrville, Texas, United States|Glenmark Investigational Site 1, New Braunfels, Texas, United States|Glenmark Investigational Site 7, San Antonio, Texas, United States|Glenmark Investigational Site 9, San Antonio, Texas, United States|Glenmark Investigational Site 20, Waco, Texas, United States|Glenmark Investigational Site 31, Waco, Texas, United States|Glenmark Investigational Site 22, Draper, Utah, United States|Glenmark Investigational Site 23, Greenfield, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT03463031"
87,"Vienna Versus SARS-CoV-2 Virus Study","Recruiting","No Results Available","SARS-CoV-2|COVID-19","Diagnostic Test: Laboratory Analyses","Medical University of Vienna, Vienna, Austria","https://ClinicalTrials.gov/show/NCT04407429"
88,"Feasibility Study of Anti-SARS-CoV-2 Plasma Transfusions in COVID-19 Patients With SRD","Recruiting","No Results Available","Severe Acute Respiratory Syndrome|COVID","Drug: SARS-CoV-2 plasma","Ascension Providence Hospital, Novi Campus, Novi, Michigan, United States|Ascension Providence Hospital, Southfield Campus, Southfield, Michigan, United States|Ascension Macomb-Oakland Hospital, Warren Campus, Warren, Michigan, United States","https://ClinicalTrials.gov/show/NCT04411602"
89,"Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR)","Completed","Has Results","Seasonal Allergic Rhinitis (SAR)","Drug: GSP 301 NS|Drug: GOM-NS|Drug: GMM-2 NS|Drug: GSP 301 placebo NS","Investigational Site 406, Mission Viejo, California, United States|Investigational Site 414, Orange, California, United States|Investigational Site 435, San Diego, California, United States|Investigational Site 420, Centennial, Colorado, United States|Investigational Site 444, Colorado Springs, Colorado, United States|Investigational Site 428, Aventura, Florida, United States|Investigational Site 412, Miami, Florida, United States|Investigational Site 436, Bethesda, Maryland, United States|Investigational Site 432, South Dartmouth, Massachusetts, United States|Investigational Site 426, Minneapolis, Minnesota, United States|Investigational Site 403, Plymouth, Minnesota, United States|Investigational Site 443, Columbia, Missouri, United States|Investigational Site 441, Rolla, Missouri, United States|Investigational Site 440, Saint Louis, Missouri, United States|Investigational Site 405, Bellevue, Nebraska, United States|Investigational Site 434, Skillman, New Jersey, United States|Investigational Site 408, Rochester, New York, United States|Investigational Site 418, Rockville Centre, New York, United States|Investigational Site 402, High Point, North Carolina, United States|Investigational Site 427, Raleigh, North Carolina, United States|Investigational Site 419, Cincinnati, Ohio, United States|United States 404, Cincinnati, Ohio, United States|United States 407, Edmond, Oklahoma, United States|Investigational Site 410, Oklahoma City, Oklahoma, United States|Investigational Site 424, Tulsa, Oklahoma, United States|Investigational Site 411, Pittsburgh, Pennsylvania, United States|Investigational Site 416, Spartanburg, South Carolina, United States|Investigational Site 415, Austin, Texas, United States|Investigational Site 442, Austin, Texas, United States|Investigational Site 417, Boerne, Texas, United States|Investigational Site 421, Dallas, Texas, United States|Investigational Site 430, Dallas, Texas, United States|Investigational Site 431, El Paso, Texas, United States|Investigational Site 433, Kerrville, Texas, United States|Investigational Site 422, New Braunfels, Texas, United States|Investigational Site 401, San Antonio, Texas, United States|Investigational Site 413, San Antonio, Texas, United States|Investigational Site 425, San Antonio, Texas, United States|Investigational Site 437, San Antonio, Texas, United States|Investigational Site 400, Waco, Texas, United States|Investigational Site 409, Waco, Texas, United States|Investigational Site 423, Draper, Utah, United States|Investigational Site 439, Greenfield, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT02870205"
90,"Detection of SARS-CoV-2 in Semen of COVID-19 Positive Males","Not yet recruiting","No Results Available","COVID-19|Sars-CoV2|Corona Virus Infection|Semen","Diagnostic Test: Ejaculated semen sample",,"https://ClinicalTrials.gov/show/NCT04391829"
91,"Correlative Study on Cancer Patients and Healthcare Professionals Exposed to Infection by Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-Cov-2), COVID-19 Causative Agent.","Recruiting","No Results Available","COVID-19|SARS-CoV-2","Other: serological test|Other: Rapid molecular test|Genetic: Next generation Sequencing (NGS) analysis|Other: serum chemistry analysis","UO Microbiologia,Centro Servizi Pievesestina, AUSL Romagna, Cesena, FC, Italy|Irst Irccs, Meldola, FC, Italy","https://ClinicalTrials.gov/show/NCT04345315"
92,"Treatment of SARS Caused by COVID-19 With Ruxolitinib","Recruiting","No Results Available","COVID-19|Severe Acute Respiratory Syndrome Coronavirus 2","Drug: Ruxolitinib Oral Tablet","Grupo Cooperativo de Hemopatías Malignas, Huixquilucan, Estado De México, Mexico","https://ClinicalTrials.gov/show/NCT04334044"
93,"SARS-CoV-2 Associated Respiratory Failure Recovery (COVID-19 CAir)","Recruiting","No Results Available","SARS-CoV 2|COVID","Other: Questionnaires, spirometry","University Hospital Zurich, Zurich, Switzerland","https://ClinicalTrials.gov/show/NCT04365595"
94,"Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19","Recruiting","No Results Available","SARS-CoV-2|COVID-19","Other: Sample collection","Alabama Vaccine CRS, Birmingham, Alabama, United States|UCLA CARE Center CRS, Los Angeles, California, United States|Bridge HIV CRS, San Francisco, California, United States|George Washington University CRS, Washington, District of Columbia, United States|The Ponce de Leon Center CRS, Atlanta, Georgia, United States|The Hope Clinic of the Emory Vaccine Center CRS, Decatur, Georgia, United States|Adolescent & Young Adult Research at The CORE Center (AYAR at CORE), Chicago, Illinois, United States|New Orleans Adolescent Trials Unit CRS, New Orleans, Louisiana, United States|Johns Hopkins University CRS, Baltimore, Maryland, United States|Brigham and Women's Hospital Vaccine CRS (BWH VCRS), Boston, Massachusetts, United States|Fenway Health Clinical Research Site CRS, Boston, Massachusetts, United States|New Jersey Medical School Clinical Research Center CRS, Newark, New Jersey, United States|Bronx Prevention Research Center CRS, Bronx, New York, United States|Harlem Prevention Center CRS, New York, New York, United States|Columbia P&S CRS, New York, New York, United States|New York Blood Center CRS, New York, New York, United States|University of Rochester Vaccines to Prevent HIV Infection CRS, Rochester, New York, United States|Chapel Hill CRS, Chapel Hill, North Carolina, United States|Case CRS, Cleveland, Ohio, United States|Penn Prevention CRS, Philadelphia, Pennsylvania, United States|Vanderbilt Vaccine CRS, Nashville, Tennessee, United States|Seattle Vaccine and Prevention CRS, Seattle, Washington, United States|CITBM - UNIDEC, Centro de Investigaciones Tecnológicas, Biomédicas y Medioambientales CRS, Bellavista, Callao, Peru|San Miguel CRS, San Miguel, Lima, Peru|Asociacion Civil Selva Amazonica (ACSA) CRS, Iquitos, Maynas, Peru|Via Libra CRS, Lima, Peru|Barranco CRS, Lima, Peru","https://ClinicalTrials.gov/show/NCT04403880"
95,"Quantification of Radiological Pulmonary Involvement in Acute Respiratory Failure","Recruiting","No Results Available","SARS (Severe Acute Respiratory Syndrome)",,"Service d' Anesthésie Réanimation Chirurgicale, Strasbourg, France","https://ClinicalTrials.gov/show/NCT04374734"
96,"Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection","Recruiting","No Results Available","COVID-19|SARS-CoV Infection|Severe Acute Respiratory Syndrome (SARS) Pneumonia|Clinical Trial","Drug: Chloroquine Diphosphate|Drug: Placebo oral tablet","Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz, Manaus, Amazonas, Brazil","https://ClinicalTrials.gov/show/NCT04342650"
97,"Long-term Pulmonary Outcomes After Infection With Sars-CoV-2","Not yet recruiting","No Results Available","Sars-CoV2|Covid19","Diagnostic Test: Imaging of the lungs","Aarhus University Hospital, Aarhus, Denmark","https://ClinicalTrials.gov/show/NCT04401163"
98,"Dornase Alfa for ARDS in Patients With SARS-CoV-2","Recruiting","No Results Available","SARS-CoV 2|ARDS","Drug: Dornase Alfa Inhalation Solution","University of Missouri Hospital and Clinics, Columbia, Missouri, United States","https://ClinicalTrials.gov/show/NCT04402970"
99,"Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome","Completed","Has Results","Severe Acute Respiratory Syndrome (SARS) Pneumonia|Coronavirus Infections|ARDS, Human","Drug: Methylprednisolone|Other: standard care","Marco Confalonieri, Trieste, TS, Italy","https://ClinicalTrials.gov/show/NCT04323592"
100,"Pyridostigmine in Severe SARS-CoV-2 Infection","Recruiting","No Results Available","COVID-19|SARS-CoV-2","Drug: Pyridostigmine Bromide|Drug: Placebo","Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Tlalpan, Mexico","https://ClinicalTrials.gov/show/NCT04343963"
101,"A Cohort of Patients With Possible or Confirmed SARS-CoV-2 (COVID-19)","Recruiting","No Results Available","SARS-CoV-2|COVID-19","Other: blood sample","Uh Montpellier, Montpellier, France","https://ClinicalTrials.gov/show/NCT04347850"
102,"Serological Testing for COVID-19 (SARS-CoV-2) in ESKD","Recruiting","No Results Available","SARS-CoV 2|End Stage Renal Failure on Dialysis","Other: dialysis","Jessa Ziekenhuis, Hasselt, Limburg, Belgium|University Hospitals Leuven, Leuven, Belgium","https://ClinicalTrials.gov/show/NCT04378686"
103,"A Multi-centre, Double-blinded, Randomized, Placebo-controlled Trial on the Efficacy and Safety of Lopinavir / Ritonavir Plus Ribavirin in the Treatment of Severe Acute Respiratory Syndrome","Unknown status","No Results Available","Severe Acute Respiratory Syndrome","Drug: Lopinavir / Ritonavir plus Ribavirin","Department of Health, Hong Kong, China|Kowloon Hospital, Hong Kong, China|Prince of Wales Hospital, Hong Kong, China|Princess Margaret Hospital, Hong Kong, China|Queen Mary Hospital, Hong Kong, China|The Chinese University of Hong Kong, Hong Kong, China|The University of Hong Kong, Hong Kong, China|Tuen Mun Hospital, Hong Kong, China|United Christian Hospital, Hong Kong, China","https://ClinicalTrials.gov/show/NCT00578825"
104,"Seroepidemiological Study of SARS-CoV-2 (COVID-19) Infection in Population Subgroups in the State of São Paulo","Not yet recruiting","No Results Available","COVID|SARS-CoV 2","Diagnostic Test: Serological test|Diagnostic Test: Nasopharyngeal Swab|Diagnostic Test: Oropharyngeal Swab",,"https://ClinicalTrials.gov/show/NCT04408014"
105,"GLS-1200Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19) in Health Care Personnel","Recruiting","No Results Available","SARS-CoV 2|Infection","Drug: GLS-1200|Drug: Placebo","University of Pennsylvania, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT04408183"
106,"Description of Ophthalmologic Injuries in Intensive Care During the SARS-CoV2 Epidemic - COVID19","Recruiting","No Results Available","Covid19|Sars-CoV2","Procedure: Ophthalmologic exam","Fondation Adolphe de Rothschild, Paris, France","https://ClinicalTrials.gov/show/NCT04385810"
107,"Prospective Analysis of Morbi-mortality of Patients With Cancers in Active Phase of Treatment Suspected or Diagnosed of a SARS-CoV-2 Infection","Recruiting","No Results Available","Sars-CoV2|Cancer",,"Institut Bergonié, Bordeaux, France|Centre François Baclesse, Caen, France|Centre Hospitalier Métropole Savoie, Chambéry, France|Centre Jean Perrin, Clermont-Ferrand, France|Centre Georges François Leclerc, Dijon, France|Centre Oscar Lambret, Lille, France|Centre Leon Berard, Lyon, France|CH Annecy-Genevois, Metz-Tessy, France|Institut de Cancérologie de Montpellier, Montpellier, France|Groupement Hospitalier Porte de Provence, Montélimar, France|Centre Antoine Lacassagne, Nice, France|Centre Hospitalier Lyon-Sud, Pierre-Bénite, France|Institut Jean Godinot, Reims, France|Centre Henri Becquerel, Rouen, France|Institut de Cancérologie de l'Ouest, Saint-Herblain, France|Institut de cancérologie Strasbourg Europe (ICANS), Strasbourg, France|Institut Universitaire du Cancer de Toulouse - IUCT Oncopole, Toulouse, France|CH Valence, Valence, France","https://ClinicalTrials.gov/show/NCT04363632"
108,"Host-pathogen Interactions During SARS-CoV-2 Infection","Recruiting","No Results Available","Infection, Coronavirus|Severe Acute Respiratory Syndrome Coronavirus 2","Biological: Blood sample|Biological: Low or upper respiratory tract sample|Biological: Stool collection or fecal swab|Genetic: Blood sample for whole genome sequencing|Other: phone call","Groupement Hospitalier Nord-Daupine, Bourgoin-Jallieu, France|Hôpital femme-mère-enfant, Bron, France|Hôpital Louis Pradel, Bron, France|Hôpital Louis Mourier, Colombes, France|Centre Hospitalo-Universitaire de Grenoble, La Tronche, France|Hopital de la Croix-Rousse, Lyon, France|Hôpital Edouard Herriot, Lyon, France|Hôpital mère - enfant Nantes, Nantes, France|Centre Hospitalier Lyon Sud, Pierre-Bénite, France|Hôpital Nord de Saint Etienne, Saint-Priest-en-Jarez, France|Hôpital Nord-Ouest, Villefranche-sur-Saône, France|Centre Hospitalier D'Annecy-Genevois, Épagny, France","https://ClinicalTrials.gov/show/NCT04376476"
109,"COVID-19: SARS-CoV-2 Specific Memory B and T-CD4+ Cells","Not yet recruiting","No Results Available","COVID-19|SARS-CoV-2 Infection","Other: 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (hospitalized Patients )|Other: 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (cured Patients)",,"https://ClinicalTrials.gov/show/NCT04402892"
110,"Lung Irradiation for COVID-19 Pneumonia","Not yet recruiting","No Results Available","SARS-CoV 2","Radiation: Phase 1|Radiation: Phase 2",,"https://ClinicalTrials.gov/show/NCT04393948"
111,"COVID-19 - Study of the Kinetics of the Immune Response During the Intensive Care Unit Stay in Adult Patients Infected With SARS-CoV-2: Multicentric Non Interventional Study","Recruiting","No Results Available","Intensive Care Unit|SARS-Cov-2","Biological: Collection of blood samples in order to create a biocollection","Hôpital Pierre Wertheimer, Bron, France|Hôpital Gabriel Montpied, Clermont-Ferrand, France|Centre hospitalier universitaire de Grenoble Alpes, Grenoble, France|Hôpital Edouard Herriot, Lyon, France|Hôpital Edouard Herriot, Lyon, France|Hôpial de la Croix Rousse, Lyon, France|Hôpital Lyon Sud, Pierre-Bénite, France|CH de St Etienne, Saint-Étienne, France","https://ClinicalTrials.gov/show/NCT04392401"
112,"Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)","Recruiting","No Results Available","Coronavirus Infections|Pneumonia, Viral","Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine","Hospital de Urgência e Emergência de Rio Branco, Rio Branco, AC, Brazil|Hospital e Clínica São Roque, Ipiaú, BA, Brazil|Hospital da Cidade, Salvador, BA, Brazil|Hospital Maternidade São Vicente de Paulo, Barbalha, CE, Brazil|Hospital de Messejana Dr. Carlos Alberto Studart Gomes, Fortaleza, CE, Brazil|Hospital Unimed Cariri, Juazeiro Do Norte, CE, Brazil|Hospital Brasilia, Brasilia, DF, Brazil|Instituto de Cardiologia do Distrito Federal, Brasília, Distrito Federal, Brazil|Fundação Social Rural de Colatina, Colatina, Espirito Santo, Brazil|Hospital Estadual Jayme dos Santos Neves, Serra, ES, Brazil|Hospital Evangélico de Vila Velha, Vila Velha, ES, Brazil|Secretaria de Estado de Saúde de Goias, Goiânia, GO, Brazil|Santa Casa de Misericórdia de Belo Horizonte Santa Casa de BH, Belo Horizonte, MG, Brazil|Hospital Santa Paula, Passos, MG, Brazil|Santa Casa da Misericordia - UTI (São João Del Rey), São João Del Rei, MG, Brazil|Hospital Maternidade E Pronto Socorro Santa Lucia Ltda, Poços De Caldas, Minas Gerais, Brazil|Universidade Estadual de Londrina, Londrina, Paraná, Brazil|Hospital Adventista de Belém, Belém, Pará, Brazil|Hospital Adventista de Belem, Belem, PA, Brazil|Procape - Pronto S.Cardiologico de Pe.Prof.Luiz Tavares-, Recife, PE, Brazil|Liga Paranaense de Combate ao Câncer, Curitiba, PR, Brazil|Hospital Giselda Trigueiro, Natal, Rio Grande Do Norte, Brazil|Hospital Moinhos de Vento, Porto Alegre, Rio Grande Do Sul, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Naval Marcílio Dias, Rio de Janeiro, RJ, Brazil|Hospital São Lucas, Rio De Janeiro, RJ, Brazil|Hospital Maternidade PROMATER, Natal, RN, Brazil|Associação Dr. Bartholomeu Tacchini, Bento Gonçalves, RS, Brazil|Hospital Geral de Caxias do Sul, Caxias Do Sul, RS, Brazil|Hospital Bruno Born, Lajeado, RS, Brazil|Hospital São Vicente de Paulo, Passo Fundo, RS, Brazil|Maestri E Kormann Consultoria Medico-Cientifica, Blumenau, Santa Catarina, Brazil|Sociedade Literaria e Caritativa Santo Agostinho, Criciúma, Santa Catarina, Brazil|Hospital Nereu Ramos, Florianópolis, SC, Brazil|Hospital Universitário Polydoro Ernani de São Thiago/HU - UFSC, Florianópolis, SC, Brazil|Centro Hospitalar Unimed, Joinville, SC, Brazil|Hospital Dona Helena, Joinville, SC, Brazil|Hospital Municipal Sao Jose, Joinville, SC, Brazil|Hospital Regional Hans Dieter Schmidt, Joinville, SC, Brazil|Faculdade de Medicina de Botucatu, Botucatu, SP, Brazil|nstituto de Pesquisa Clínica de Campinas, Campinas, SP, Brazil|Fundação do ABC (Hospital Estadual Mário Covas), Santo André, SP, Brazil|AC Camargo Cancer Center - Fundação Antonio Prudente, São Paulo, SP, Brazil|Casa de Saude Santa Marcelina, São Paulo, SP, Brazil|Hospital Alemão Oswaldo Cruz, São Paulo, SP, Brazil|Hospital Moriah, São Paulo, SP, Brazil|Hospital Nove de Julho, São Paulo, SP, Brazil|Hospital Santa Paula, São Paulo, SP, Brazil|Hospital São Camilo Pompeia, São Paulo, SP, Brazil|Fundação Pio XII, Barretos, São Paulo, Brazil|Santa Casa de Misericordia de Votuporanga, Votuporanga, São Paulo, Brazil|Hospital Israelita Albert Einstein, São Paulo, Brazil|Associacao Beneficente Siria, São Paulo, Brazil|Hospital Vila Santa Catarina, São Paulo, Brazil|Real e Benemérita Associação Portuguesa de Beneficência/SP, São Paulo, Brazil|Real e Benemérita Associação Portuguesa de Beneficência/SP, São Paulo, Brazil|Secretaria de Saúde do Estado de São Paulo, São Paulo, Brazil|Serv Social da Industria do papel, papelão e cortiça do estado de SP, São Paulo, Brazil|Sociedade Beneficente de Senhoras Hospital Sírio-Libanês, São Paulo, Brazil|Universidade Federal de São Paulo, São Paulo, Brazil","https://ClinicalTrials.gov/show/NCT04321278"
113,"Characterization of Cardiovascular Diseases and Risk Factors in Patients With Suspected SARS-CoV2/Covid-19 Infection","Recruiting","No Results Available","Cardiovascular Diseases|Cardiovascular Risk Factor|SARS","Diagnostic Test: Assessment of cardiovascular diseases and cardiovascular risk factors","University Hospital Essen, Essen, NRW, Germany","https://ClinicalTrials.gov/show/NCT04327479"
114,"The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection","Recruiting","No Results Available","Coronavirus Infections","Drug: Lopinavir and Ritonavir Tablets|Drug: Arbidol","Guangzhou Eighth People's Hospital, Guangzhou, Guangdong, China","https://ClinicalTrials.gov/show/NCT04252885"
115,"Interferon Lambda Therapy for COVID-19","Not yet recruiting","No Results Available","SARS-CoV-2","Drug: Peginterferon Lambda-1A","Icahn School of Medicine at Mount Sinai, New York, New York, United States","https://ClinicalTrials.gov/show/NCT04388709"
116,"Serologic Surveillance for SARS-CoV-2 (COVID-19) in a Prospective Cohort of Health Care Workers","Not yet recruiting","No Results Available","COVID-19|SARS-CoV 2|Health Personnel","Diagnostic Test: Serologic SARS-CoV-2 screening",,"https://ClinicalTrials.gov/show/NCT04387890"
117,"Immune Cells in Inflammatory Arthritis With Coronaviruses, Including COVID-19","Not yet recruiting","No Results Available","SARS Virus","Other: 40ml blood sample","Universit of Manchester, Manchester, Greater Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT04363047"
118,"IMATINIB IN COVID-19 DISEASE IN AGED PATIENTS.","Not yet recruiting","No Results Available","SARS Virus","Drug: Experimental drug","CHU Bordeaux, Bordeaux, France|CH de Versailles, Le Chesnay, France","https://ClinicalTrials.gov/show/NCT04357613"
119,"Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds","Recruiting","No Results Available","SARS-CoV-2|Coronavirus Infection|Asymptomatic Condition|COVID-19","Drug: Hydroxychloroquine Sulfate Regular dose|Drug: Hydroxychloroquine Sulfate Loading Dose|Drug: Chloroquine|Drug: Placebo","Expo Covid Center, Lahore, Punjab, Pakistan|Mayo Hospital, Lahore, Punjab, Pakistan|Pakistan Kidney and Liver Institute, Lahore, Punjab, Pakistan","https://ClinicalTrials.gov/show/NCT04346667"
120,"Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS","Recruiting","No Results Available","Severe Acute Respiratory Syndrome Coronavirus 2|Severe Acute Respiratory Distress Syndrome","Biological: Umbilical cord Wharton's jelly-derived human|Other: NaCl 0.9%","Hôpital Pitié-Salpêtrière - APHP, Paris, France|Hôpital Européen Georges Pompidou - APHP, Paris, France","https://ClinicalTrials.gov/show/NCT04333368"
121,"Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection","Recruiting","No Results Available","SARS-CoV-2 (COVID-19) Infection|Advanced or Metastatic Hematological or Solid Tumor","Drug: Chloroquine analog (GNS651)|Drug: Nivolumab|Drug: Tocilizumab|Other: Standard of care|Drug: Avdoralimab|Drug: Monalizumab","Centre Léon Bérard, Lyon, Rhône, France|CHU Clermont Ferrand, Clermont Ferrand, France|Centre Oscar Lambret, Lille, France|AP-HP Hôpital Saint Antoine, Paris, France|AP-HP La Pitié Salpétrière, Paris, France|Hôpital Saint-Joseph, Paris, France|AP-HP Tenon, Paris, France|AP-HP Hôpital Bichat Claude Bernard, Paris, France|GH Diaconesses Croix Saint Simon, Paris, France|Gustave Roussy, Villejuif, France","https://ClinicalTrials.gov/show/NCT04333914"
122,"Study of Alferon® LDO (Low Dose Oral) in Normal Volunteers","Completed","No Results Available","Severe Acute Respiratory Syndrome","Drug: Alferon LDO","Princess Margaret Hospital, Lai Chi Kok, Kowloon, Hong Kong","https://ClinicalTrials.gov/show/NCT00215826"
123,"Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older","Recruiting","No Results Available","SARS-CoV-2","Biological: Biological: mRNA-1273: 50 mcg|Other: Placebo|Biological: Biological: mRNA-1273: 100 mcg","Meridian Clinical Research, Savannah, Georgia, United States|Heartland Research Associates, Newton, Kansas, United States|Heartland Research Associates, Kansas City, Missouri, United States|Meridian Clinical Research, Norfolk, Nebraska, United States|Meridian Clinical Research, Omaha, Nebraska, United States|Trial Management Associates, Wilmington, North Carolina, United States|Meridian Clinical Research, Dakota Dunes, South Dakota, United States|Benchmark Research, Austin, Texas, United States|Benchmark Research, San Angelo, Texas, United States|Advanced Clinical Research/Velocity, West Jordan, Utah, United States","https://ClinicalTrials.gov/show/NCT04405076"
124,"Efficacy of Chloroquine or Hydroxychloroquine in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19","Suspended","No Results Available","COVID|COVID-19|SARS-CoV 2|Coronavirus|Corona Virus Infection","Drug: Chloroquine|Drug: Hydroxychloroquine|Other: standard care","Centro de Estudos e Pesquisa em Emergencias Clinicas e Terapia Intensiva, Curitiba, Parana, Brazil","https://ClinicalTrials.gov/show/NCT04420247"
125,"PET/CT Imaging in COVID-19 Patients","Enrolling by invitation","No Results Available","COVID-19|SARS-CoV-2 Infection","Drug: 18F-αvβ6-BP","University of California Davis, Sacramento, California, United States","https://ClinicalTrials.gov/show/NCT04376593"
126,"Rutgers COVID-19 Cohort Study","Recruiting","No Results Available","Coronavirus|SARS-CoV-2","Other: Non-Interventional","Clinical Research Center Rutgers-Robert Wood Johnson Medical School RWJUH East Tower -, New Brunswick, New Jersey, United States|Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|Clinical Research Unit Rutgers New Jersey Medical School, Newark, New Jersey, United States|Rutgers School of Dental Medicine, Newark, New Jersey, United States|University Hospital, Newark, New Jersey, United States|Environmental and Occupational Health Sciences Institute, Piscataway, New Jersey, United States|RUCDR Infinite Biologics, Piscataway, New Jersey, United States","https://ClinicalTrials.gov/show/NCT04336215"
127,"Efficacy and Safety of Early COVID-19 Convalescent Plasma in Patients Admitted for COVID-19 Infection","Recruiting","No Results Available","Severe Acute Respiratory Syndrome Coronavirus 2","Biological: COVID-19 convalescent plasma","Hospital Clínico Universidad Católica, Santiago, Chile","https://ClinicalTrials.gov/show/NCT04375098"
128,"Longitudinal Study of Covid-19 Infection Among HCW in a French University Hospital","Not yet recruiting","No Results Available","Sars-CoV2","Other: self-administered questionnaire|Diagnostic Test: SARS-Cov2 testing",,"https://ClinicalTrials.gov/show/NCT04362267"
129,"Prevalence of COVID-19 Infection Among HCW in a French University Hospital","Not yet recruiting","No Results Available","Sars-CoV2","Other: self-administered questionnaire|Diagnostic Test: SARS-Cov2 testing",,"https://ClinicalTrials.gov/show/NCT04371692"
130,"French Multicentre Observational Study on SARS-Cov-2 Infections (COVID-19) ICU Management Study","Recruiting","No Results Available","Pneumonia, Viral|Critically Ill|Corona Virus Infection","Other: No intervention","CHU Nimes, Nîmes, France","https://ClinicalTrials.gov/show/NCT04340466"
131,"Impact of COVID-19 Infection on the Incidence of Ventilator-acquired Infections","Recruiting","No Results Available","SARS-CoV 2",,"Hôpital Roger Salengro, ICU, CHU Lille, Lille, France","https://ClinicalTrials.gov/show/NCT04359693"
132,"Bacterial and Fungal Microbiota of Patients With Severe Viral Pneumonia With COVID-19","Not yet recruiting","No Results Available","Sars-CoV2",,,"https://ClinicalTrials.gov/show/NCT04359706"
133,"In-depth Immunological Investigation of COVID-19.","Recruiting","No Results Available","Coronavirus Infections","Other: Patient sampling","UZ Leuven, Leuven, Belgium","https://ClinicalTrials.gov/show/NCT04327570"
134,"Electrocardiogram Analysis in COVID-19 Patients","Recruiting","No Results Available","SARS-CoV Infection","Diagnostic Test: ECG","Arcispedale S. Anna, Ferrara, Italy","https://ClinicalTrials.gov/show/NCT04367129"
135,"IgG/IgM Antibody Test in Patients Who Have Tested Negative or Positive for COVID-19 With Nasopharyngeal PCR Testing.","Recruiting","No Results Available","SARS-CoV 2","Diagnostic Test: Clungene rapid test cassette","Fadi A. Haddad MD Inc., La Mesa, California, United States|Sharp Grossmont Hospital, La Mesa, California, United States|Sharp Memorial Hosptial, San Diego, California, United States","https://ClinicalTrials.gov/show/NCT04402814"
136,"Association Between BMI and COVID-19","Active, not recruiting","No Results Available","SARS-CoV 2","Other: Patients admitted to Intensive Care Unit with SARS-CoV2","Centre Hospitalier Régional & Universitaire de Lille (CHRU), Lille, France","https://ClinicalTrials.gov/show/NCT04391738"
137,"Hydroxychloroquine or Diltiazem-Niclosamide for the Treatment of COVID-19","Not yet recruiting","No Results Available","Sars-CoV2","Other: Standard of care (SOC)|Drug: Hydroxychloroquine|Drug: Association of diltiazem and niclosamide",,"https://ClinicalTrials.gov/show/NCT04372082"
138,"Mechanisms to Morbidity and Mortality for Covid-19","Not yet recruiting","No Results Available","Coronavirus|SARS",,,"https://ClinicalTrials.gov/show/NCT04314232"
139,"Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers","Recruiting","No Results Available","Coronavirus Infection","Drug: INO-4800|Device: CELLECTRA® 2000","Central Kentucky Research Associates, Lexington, Kentucky, United States|Center for Pharmaceutical Research, Kansas City, Missouri, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT04336410"
140,"Cardiac complicAtions in Patients With SARS Corona vIrus 2 regisTrY","Recruiting","No Results Available","COVID-19; Cardiovascular Diseases",,"University Medical Center Utrecht, Utrecht, Netherlands","https://ClinicalTrials.gov/show/NCT04325412"
141,"Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.","Recruiting","No Results Available","SARS-CoV-2","Biological: Emapalumab|Biological: Anakinra","ASST Spedali Civili di Brescia Dipartimento di Reumatologia e Immunologia Clinica, Brescia, Italy|Ospedale Maggiore Policlinico, Dipartimento di Anestesia-Rianimazione e Medicina di Urgenza, Milano, Italy|Azienda Ospedaliero-Universitaria di Parma, Dipartimento di Malattie infettive ed epatologia, Parma, Italy|Ospedale Lazzaro Spallanzani, Dipartimento di Malattie Infettive ad alta Intensità di cura ed altamente contagiose,Ospedale Lazzaro Spallanzani, Roma, Italy","https://ClinicalTrials.gov/show/NCT04324021"
142,"Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)","Active, not recruiting","No Results Available","Coronavirus Infections","Drug: Hydroxychloroquine Oral Product|Drug: Hydroxychloroquine + azithromycin","Hospital Geral Clériston Andrade, Feira De Santana, BA, Brazil|Hospital Ana Nery - HAN/SESAB, Salvador, BA, Brazil|HHospital SAMUR, Vitória Da Conquista, BA, Brazil|Hospital Geral de Vitória da Conquista, Vitória Da Conquista, BA, Brazil|Hospital de Brasília, Brasilia, DF, Brazil|Instituto de Cardiologia do Distrito Federal, Brasília, DF, Brazil|Hospital Maternidade São José - UNESC - Fundação Social Rural de Colatina, Colatina, ES, Brazil|Hospital Vila da Serra, Nova Lima, MG, Brazil|Santa Casa de Misericórdia de São João Del Rei, São João Del Rei, MG, Brazil|Associação Evangélica Beneficente de Londrina - Hospital Evangélico de Londrina, Londrina, PR, Brazil|Instituto Estadual do Cérebro Paulo Niemeyer, Rio De Janeiro, RJ, Brazil|Hospital Geral de Caxias do Sul, Caxias do Sul, RS, Brazil|Hospital Santa Rita - Irmandade Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil|Hospital São Francisco - Irmandade Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil|Hospital São José, Criciuma, SC, Brazil|Hospital Baía Sul - Baía Sul Medical Center, Florianópolis, SC, Brazil|Hospital Nereu Ramos, Florianópolis, Sc, Brazil|Centro Hospitalar Unimed, Joinville, SC, Brazil|Hospital de Amor - Unidade Barretos (Fundação PIO XII), Barretos, SP, Brazil|Casa de Saúde Santa Marcelina, São Paulo, SP, Brazil|Hospital Albert Einstein, São Paulo, SP, Brazil|Hospital Beneficência Portuguesa - Real e Benemérita Associação Portuguesa de Beneficência, São Paulo, SP, Brazil|Hospital BP Mirante - Real e Benemérita, São Paulo, SP, Brazil|Hospital das Clínicas da FMUSP, São Paulo, SP, Brazil|Hospital do Servidor Público Estadual - HSPE - IAMSPE, São Paulo, SP, Brazil|Hospital São Paulo - UNIFESP, São Paulo, SP, Brazil|Hospital Sírio-Libanês, São Paulo, SP, Brazil|Hospital SEPACO, São Paulo, S, Brazil","https://ClinicalTrials.gov/show/NCT04322123"
143,"A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure","Recruiting","No Results Available","SARS CoV-2 Infection","Biological: Human Amniotic Fluid","University of Utah Health, Salt Lake City, Utah, United States","https://ClinicalTrials.gov/show/NCT04319731"
144,"A New Screening Strategy for 2019 Novel Coronavirus Infection","Not yet recruiting","No Results Available","Novel Coronavirus Infection Pneumonia","Diagnostic Test: Standard screening strategy|Diagnostic Test: New screening strategy","the Fifth Medical Center of Chinese PLA General Hospital, Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT04281693"
145,"Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2","Recruiting","No Results Available","Corona Virus Infection|Acute Respiratory Distress Syndrome|SARS-CoV Infection|Coronavirus|Coronavirus Infections","Drug: Hydroxychloroquine|Other: Placebo","Nationwide Enrollment via Internet, please email: covid19@umn.edu, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|Internet, New York, New York, United States|University of Alberta, Edmonton, Alberta, Canada|University of Manitoba, Winnipeg, Manitoba, Canada|Research Institute of the McGill University Heath Centre, Montréal, Quebec, Canada","https://ClinicalTrials.gov/show/NCT04308668"
146,"COVID-19: Healthcare Worker Bioresource: Immune Protection and Pathogenesis in SARS-CoV-2","Recruiting","No Results Available","Health Care Worker Patient Transmission|Coronavirus|Coronavirus Infections|Immunological Abnormality","Diagnostic Test: COPAN swabbing and blood sample collection","Barts Heart Center, London, United Kingdom|Royal Free London NHS Foundation Trust, London, United Kingdom","https://ClinicalTrials.gov/show/NCT04318314"
147,"Norwegian Coronavirus Disease 2019 Study","Active, not recruiting","No Results Available","Corona Virus Infection","Drug: Hydroxychloroquine Sulfate","Akershus University Hospital, Lørenskog, Norway","https://ClinicalTrials.gov/show/NCT04316377"
148,"Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease)","Not yet recruiting","No Results Available","Sars-CoV2|Acute Respiratory Distress Syndrome|COVID-19","Genetic: Mesenchymal Stromal Cells","Houston Methodist Hospital, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT04345601"
149,"Study to Evaluate the Safety and Efficacy of ATYR1923 In Patients With Severe Pneumonia Related to COVID-19","Recruiting","No Results Available","SARS-CoV-2 (COVID-19) Severe Pneumonia","Drug: ATYR1923 1 mg/kg|Drug: ATYR1923 3 mg/kg|Drug: Placebo","aTyr Investigative Site, Washington, District of Columbia, United States|Inova Fairfax Medical Campus, Falls Church, Virginia, United States","https://ClinicalTrials.gov/show/NCT04412668"
150,"Efficacy of Melatonin in the Prophylaxis of Coronavirus Disease 2019 (COVID-19) Among Healthcare Workers.","Not yet recruiting","No Results Available","Covid19|SARS-CoV 2|Coronavirus Infection","Drug: Melatonin 2mg|Drug: Placebo oral tablet",,"https://ClinicalTrials.gov/show/NCT04353128"
151,"Somerset and South Essex Coronavirus Antigen Testing","Not yet recruiting","No Results Available","COVID|SARS-CoV 2","Diagnostic Test: PCL COV05 - COVID 19 Ag Rapid FIA test (Rapid Antigen Test)","Musgrove Park Hospital, Taunton, Somerset, United Kingdom","https://ClinicalTrials.gov/show/NCT04403906"
152,"COVID-19 Patients Characterization, Biobank, Treatment Response and Outcome Predictor","Recruiting","No Results Available","Coronavirus Infections","Other: Observational Study","Autoimmunity and Vascular Inflammation Unit, Division of Regenerative Medicine, Stem Cells and Gene Therapy - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|AIDS Immunopathogenesis Unit - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Department of Infection Diseases - IRCCS San Raffaele Scientific Institute -, Milan, Lombardy, Italy|Department of Internal Medicine - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Diabetes Research Institute -IRCCS San Raffaele Scientific Istitute, Milan, Lombardy, Italy|Division of Immunology, Transplantation and Infectious Diseases - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Division of Research of Regenerative Medicine, Cell and Gene Therapy - IRCCS San Raffaele Scientific Istitute, Milan, Lombardy, Italy|Laboratory of Microbiology and Virology - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Nephrology Unit - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Strategic Program in Nephrology and Dialysis - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Viral pathogens and biosafety Unit - IRCCS San Raffaele Scietific Institute, Milan, Lombardy, Italy|Unit of Immunology, Rheumatology, Allergy and Rare Diseases - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Università Vita-Salute San Raffaele, Milano, Mi, Italy","https://ClinicalTrials.gov/show/NCT04318366"
153,"A Study of Opaganib in Coronavirus Disease 2019 Pneumonia","Not yet recruiting","No Results Available","Coronavirus Infections","Drug: Opaganib|Drug: Placebo",,"https://ClinicalTrials.gov/show/NCT04414618"
154,"Impact of Confinement and Preventive Measures in Period of SARS-COV2 Infection on Clinical Features, Diagnostic and Therapeutic Management and Prognosis of Patients With Lung Cancer: an Ambispective Study Extended Over 2 Time Periods.","Not yet recruiting","No Results Available","COVID|SARS-CoV 2|Lung Cancer",,,"https://ClinicalTrials.gov/show/NCT04366219"
155,"Clinical Trial of Sarilumab in Adults With COVID-19","Not yet recruiting","No Results Available","SARS-CoV 2|SARS","Drug: Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]|Drug: Sarilumab 400 MG/2.28 ML Subcutaneous Solution [KEVZARA]|Drug: Best available treatment","Hospital Universitario Reina Sofía, Córdoba, Spain","https://ClinicalTrials.gov/show/NCT04357860"
156,"Effects on the Qt Interval of COVID-19 Coronavirus Infection","Recruiting","No Results Available","Coronavirus Infection|Intensive Care Patients",,"Servicio de Anestesia, Hospital General Universitario Gregorio Marañon, Madrid, Spain","https://ClinicalTrials.gov/show/NCT04422535"
157,"HDL Target of CoViD19 ? Analysis on the Caregivers of the Reunion University Hospital","Not yet recruiting","No Results Available","SARS-CoV Infection","Other: research specific blood sample","Centre Hospitalier Universitaire de la Réunion, Saint-Pierre, France","https://ClinicalTrials.gov/show/NCT04384705"
158,"A Longitudinal Study of COVID-19 Positive Patients Testing Nasal Swabs and Collecting Blood Samples for Research","Recruiting","No Results Available","SARS-CoV Infection","Diagnostic Test: Odd/Even birth year intervention groups","Everett Clinic, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT04327804"
159,"Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure","Recruiting","No Results Available","Covid-19|Sars-CoV2","Biological: Multiple Doses of Anti-SARS-CoV-2 convalescent plasma","8700 Beverly Blvd., Los Angeles, California, United States|Johns Hopkins University, Baltimore, Maryland, United States","https://ClinicalTrials.gov/show/NCT04353206"
160,"PREEMPTIVE THERAPY WITH COLCHICINE IN PATIENTS OLDER THAN 70 YEARS WITH HIGH RISK OF SEVERE PNEUMONIAE DUE TO CORONAVIRUS","Active, not recruiting","No Results Available","SARS-CoV-2 Infection (COVID-19)","Drug: Colchicine plus symptomatic treatment (paracetamol)|Drug: Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations)","Atención primaria (Área 2), Laredo, Cantabria, Spain|Gerencia de atención primaria (Área 3), Reinosa, Cantabria, Spain|Atencion primaria (AREA 1), Santander, Cantabria, Spain|Gerencia de atención primaria (área 4), Torrelavega, Cantabria, Spain","https://ClinicalTrials.gov/show/NCT04416334"
161,"Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction","Recruiting","No Results Available","COVID-19|Virus Diseases|Macrophage Activation Syndrome|Corona Virus Infection","Drug: Anakinra|Drug: Tocilizumab","2nd Department of Critical Care Medicine, ATTIKON University Hospital, Athens, Haidari, Greece|Intensive Care Unit, Ioannina University Hospital, Ioánnina, Ioannina, Greece|Department of Internal Medicine, Patras University Hospital, Patras, Rion, Greece|Department of Internal Medicine, I PAMMAKARISTOS Hospital, Athens, Greece|Intensive Care Unit, General Hospital of Athens KORGIALENIO-BENAKIO E.E.S., Athens, Greece|1st Department of Pulmonary Medicine and Intensive Care Unit, Athens, Greece|Intensive Care Unit, General Hospital of Athens IPPOKRATEIO, Athens, Greece|4th Department of Internal Medicine, Attikon University Hospital, Athens, Greece|Intensive Care Unit, General Hospital ASKLEPIEIO Voulas, Athens, Greece|Intensive Care Unit, ""Latsio"", Thriasio Elefsis General Hospital, Elefsína, Greece|Intensive Care Unit, ""Koutlimbaneio & Triantafylleio"" Larissa General Hospital, Larissa, Greece|Department of Internal Medicine, Larissa University Hospital, Larissa, Greece|Intensive Care Unit, AGIOS DIMITRIOS General Hospital of Thessaloniki, Thessaloniki, Greece|Intensive Care Unit, G. GENNIMATAS General Hospital of Thessaloniki, Thessaloniki, Greece|Intensive Care Unit, Theageneio Oncological Hospital of Thessaloniki, Thessaloniki, Greece|Intensive Care Unit, General Hospital of Thessaloniki IPPOKRATEIO, Thessaloniki, Greece|Department of Anesthesiology and Intensive Care Medicine, University General Hospital of Thessaloniki AHEPA, Thessaloniki, Greece","https://ClinicalTrials.gov/show/NCT04339712"
162,"Part 2 on the Study Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children (COVILLE2 )","Not yet recruiting","No Results Available","COVID19","Diagnostic Test: RT-PCR SARS-Cov2|Diagnostic Test: Sars-Cov2 serology",,"https://ClinicalTrials.gov/show/NCT04416893"
163,"Study to Determine the Immunization Status Among Nephrological Health Care Personnel Against SARS-CoV-2 in a Single Center Over the Course of 12 Months During the Worldwide COVID-19 Pandemic.","Recruiting","No Results Available","SARS-CoV 2|Immunization; Infection",,"Medical University of Vienna, Division for Nephrology and Dialysis, Vienna, Austria","https://ClinicalTrials.gov/show/NCT04347694"
164,"Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19)","Not yet recruiting","No Results Available","COVID-19|SARS-CoV 2|Severe Acute Respiratory Syndrome Coronavirus 2|Virus Disease|Coronavirus Infections|Pharyngeal Diseases","Drug: Oral-B Mouth Sore mouthwash|Drug: Crest Pro-Health Multi-Protection mouthwash|Drug: CloSYS mouthwash|Drug: Distilled water","University Of California, San Francisco, San Francisco, California, United States","https://ClinicalTrials.gov/show/NCT04409873"
165,"Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)","Recruiting","No Results Available","SARS-CoV-2 Infection","Drug: Tocilizumab (TCZ)|Drug: Placebo","University Hospital Bern (Inselspital), Bern, Switzerland|Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland|Ospedale Regionale di Lugano (EOC), Viganello, Switzerland|University Hospital Zurich, Zurich, Switzerland","https://ClinicalTrials.gov/show/NCT04335071"
166,"Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study of the Efficacy and Safety of Cetirizine HCl Syrup vs. Loratadine Syrup vs. Placebo in Treatment of Children With Seasonal Allergic Rhinitis (SAR)","Completed","No Results Available","Allergic Rhinitis|Hay Fever|SAR|Rhinitis, Allergic, Seasonal","Drug: Cetirizine|Drug: Loratadine|Other: Placebo",,"https://ClinicalTrials.gov/show/NCT02932774"
167,"Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children","Active, not recruiting","No Results Available","Covid19","Diagnostic Test: Data collection and rhinopharyngeal swab","Cabinet du Dr Belaroussi, Boulogne, France|Cabinet du Dr Derkx, Champigny-sur-Marne, France|Cabinet du Dr Coicadan, Chennevières-sur-Marne, France|14 Av rené Samuel, Clamart, France|Cabinet du Dr Corrard, Combs-la-Ville, France|10 rue Delambre, Lagny-sur-Marne, France|157 Avenue du Général Leclerc, Maisons-Alfort, France|21 Grande Rue Charles de Gaulle, Nogent-sur-Marne, France|Cabinet du Dr Deberdt, Nogent-sur-Marne, France|Cabinet du Dr Wollner, Nogent-sur-Marne, France|4 allée des Norottes, Noisy-le-Grand, France|Cabinet du Dr D'acremont, Paris, France|146 Avenue Ledru Rollin, Paris, France|132 Boulevard du Montparnasse, Paris, France|Cabinet du Dr Romain, Paris, France|Cabinet du Dr Turberg-Romain, Paris, France|15 Quai Louis Blériot, Paris, France|Cabinet du Dr Michot, Paris, France|24 rue Volta, Puteaux, France|Cabinet du Dr Cohen, Saint-Maur-des-Fossés, France|Cabinet de Pédiatrie des Docteurs Ravilly et Bessa, Villejuif, France|13 Villa Beauséjour, Vincennes, France","https://ClinicalTrials.gov/show/NCT04318431"
168,"Honey & Nigella Sativa Trial Against COVID-19","Recruiting","No Results Available","Coronavirus Infection|Sars-CoV2","Drug: Honey|Drug: Nigella Sativa / Black Cumin|Drug: Placebos","Kingedward Medical University, Mayo Hospital, Lahore, Punjab, Pakistan|Federal Post-Graduate Medical Institute, Shaikh Zayed Hospital, Lahore, Punjab, Pakistan|Services Institute of Medical Sciences, Services Hospital, Lahore, Punjab, Pakistan","https://ClinicalTrials.gov/show/NCT04347382"
169,"Frequency and Clinical Evolution of Olfactory and Taste Disorders in COVID-19 Patients","Enrolling by invitation","No Results Available","COVID-19 by SARS-CoV-2 Infection",,"CHU de Nice, Nice, France","https://ClinicalTrials.gov/show/NCT04361565"
170,"Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial","Recruiting","No Results Available","Covid-19|Coronavirus Infection|SARS-CoV-2 Infection","Drug: Ivermectin|Drug: Placebo","Clinica Universidad de Navarra, Pamplona, Navarra, Spain","https://ClinicalTrials.gov/show/NCT04390022"
171,"Pre-exposure Prophylaxis for SARS-Coronavirus-2","Active, not recruiting","No Results Available","COVID-19|Corona Virus Infection|ARDS|Acute Respiratory Distress Syndrome","Drug: Hydroxychloroquine|Other: Placebo","Nationwide Enrollment via Internet, please email: covid19@umn.edu, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States","https://ClinicalTrials.gov/show/NCT04328467"
172,"Use of Dexmedetomidine in Light to Moderate Sedation in the Patient in the Palliative Situation of a Sars-cov-2 / COVID-19 Infection","Not yet recruiting","No Results Available","COVID-19 Infection|Sars-cov-2|Respiratory Failure|Palliative Situation","Drug: Treatment with Dexmedetomidine","University Hospital, Limoges, France","https://ClinicalTrials.gov/show/NCT04350086"
173,"BCG Vaccination for Healthcare Workers in COVID-19 Pandemic","Recruiting","No Results Available","COVID-19|Sars-CoV2","Biological: Bacille Calmette-Guérin (BCG)|Other: Placebo Comparator","TASK Foundation, Cape Town, Western Cape, South Africa","https://ClinicalTrials.gov/show/NCT04379336"
174,"COVID-19: Herd Immunity Study in the Czech Republic","Completed","No Results Available","COVID|SARS-CoV 2","Diagnostic Test: SARS-CoV-2 diagnostic rapid test|Diagnostic Test: Quantitative analysis of SARS-CoV-2 antibodies","Institute of Health Information and Statistics of the Czech Republic, Prague, Czechia","https://ClinicalTrials.gov/show/NCT04401085"
175,"Collection of Anti-SARS-CoV-2 Immune Plasma","Recruiting","No Results Available","Coronavirus Disease 2019 (COVID-19)",,"University of Miami Infectious Diseases Research Unit, Miami, Florida, United States|Bloodworks Northwest, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT04344977"
176,"Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease","Recruiting","No Results Available","Acute Respiratory Distress Syndrome|SARS-CoV-2|COVID|COVID-19|Severe Acute Respiratory Syndrome","Drug: Valsartan (Diovan)|Drug: Placebo oral tablet","Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, Netherlands|Rijnstate, Arnhem, Netherlands|Radboudumc, Nijmegen, Netherlands|Laurentius Ziekenhuis, Roermond, Netherlands|Erasmus MC, Rotterdam, Netherlands|Franciscus Gasthuis, Rotterdam, Netherlands|Ikazia Ziekenhuis, Rotterdam, Netherlands","https://ClinicalTrials.gov/show/NCT04335786"
177,"Long Term Functional Outcomes of COVID-19 Patients Treated by Rehabilitation Services viaTelehealth","Recruiting","No Results Available","SARS-CoV 2|SARS Pneumonia","Behavioral: Therapy Intervention","Missouri Orthopedic Institute, Columbia, Missouri, United States","https://ClinicalTrials.gov/show/NCT04385901"
178,"The Vietnam Chloroquine Treatment on COVID-19","Recruiting","No Results Available","SARS-CoV-2 Infection|COVID-19","Drug: Chloroquine phosphate","National Hospital for Tropical Diseases, Hanoi, Vietnam|Can Gio COVID Hospital, Ho Chi Minh City, Vietnam|Cho Ray Hospital, Ho Chi Minh City, Vietnam|Cu Chi COVID Hospital, Ho Chi Minh City, Vietnam|Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam","https://ClinicalTrials.gov/show/NCT04328493"
179,"Hydroxychloroquine Chemoprophylaxis for COVID-19 Infection in High-risk Healthcare Workers.","Not yet recruiting","No Results Available","SARS-CoV-2|Healthcare Workers","Drug: Hydroxychloroquine|Drug: Placebo oral tablet",,"https://ClinicalTrials.gov/show/NCT04370015"
180,"Magnetic Resonance Imaging to Detect Signs of Viral Pneumonia in Patients With Coronavirus Infection: Multicenter Prospective Study","Recruiting","No Results Available","Coronavirus Infections|Pneumonia","Diagnostic Test: Chest MRI","Olga Panina, Moscow, Russian Federation","https://ClinicalTrials.gov/show/NCT04424355"
181,"International SARS-CoV-2 (COVID-19) Infection Observational Study","Not yet recruiting","No Results Available","COVID|COVID19|SARS-CoV 2|Dyspnea","Other: Data Collection","Denver Public Health, Denver, Colorado, United States|Hospital General de Agudos JM Ramos Mejia Servicio de Inmunocomprometidos, Buenos Aires, Argentina|CHIP Department of Infectious Diseases, Copenhagen, Denmark|University College London Medical School Centre for Sexual Health and HIV Research, London, England, United Kingdom","https://ClinicalTrials.gov/show/NCT04385251"
182,"COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients","Recruiting","No Results Available","COVID-19|SARS-CoV 2","Drug: Povidone-Iodine Nasal Spray and Gargle","University of Kentucky, Lexington, Kentucky, United States","https://ClinicalTrials.gov/show/NCT04364802"
183,"Nigella Sativa in COVID-19","Recruiting","No Results Available","COVID-19|SARS-CoV-2","Dietary Supplement: Nigella sativa","King Abdulaziz University Hospital, Jeddah, Saudi Arabia","https://ClinicalTrials.gov/show/NCT04401202"
184,"The Prone Position in Covid-19 Affected Patients","Active, not recruiting","No Results Available","Sars-CoV2","Procedure: Prone position","ASST Monza, Monza, MB, Italy","https://ClinicalTrials.gov/show/NCT04365959"
185,"Assessment of Covid-19 Infection Rates in Healthcare Workers Using a Desynchronization Strategy","Recruiting","No Results Available","SARS-CoV-2",,"Guido Beldi, Bern, Switzerland","https://ClinicalTrials.gov/show/NCT04333862"
186,"The COVID-19 ICU PRAYER Study","Recruiting","No Results Available","Coronavirus Infection","Behavioral: prayer","Research Medical Center, Kansas City, Missouri, United States","https://ClinicalTrials.gov/show/NCT04361838"
187,"Coronavirus Disease 2019 (COVID-19) Study of Hospitalized Patients in Hong Kong","Recruiting","No Results Available","Coronavirus Infections","Other: No intervention","Prince of Wales Hospital, Sha Tin, Hong Kong","https://ClinicalTrials.gov/show/NCT04325919"
188,"Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19","Not yet recruiting","No Results Available","Coronavirus Infection","Drug: Selinexor",,"https://ClinicalTrials.gov/show/NCT04355676"
189,"COVID-19 Among Healthcare Workers in Belgian Hospitals","Recruiting","No Results Available","SARS-CoV-2|COVID-19",,"Sciensano, Brussels, Belgium","https://ClinicalTrials.gov/show/NCT04373889"
190,"Compassionate Use Open-Label Anti-CD14 Treatment in Patients With SARS-CoV-2 (COVID-19)","Available","No Results Available","COVID|ARDS, Human|Ards|Sars-CoV2","Biological: IC14, a monoclonal antibody against CD14","IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milano, Italy","https://ClinicalTrials.gov/show/NCT04346277"
191,"Low Dose Radiotherapy in COVID-19 Pneumonia","Recruiting","No Results Available","COVID|SARS (Severe Acute Respiratory Syndrome)","Radiation: Low Dose Radiotherapy","Imam Hossein Hospital, Tehran, Iran, Islamic Republic of","https://ClinicalTrials.gov/show/NCT04390412"
192,"Blood Collection Study From COVID-19 Convalescents to Identify Immunogenic Viral Epitopes","Recruiting","No Results Available","Identify the Viral Epitopes of Memory CD8 T Cells From Individuals That Have Recovered From SARS-CoV-2 Infection|Determine Which SARS-CoV-2 Proteins Are Frequently Recognized by T Cells in Patients With Varying HLA Types",,"Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Atlantic Health System, Morristown, New Jersey, United States","https://ClinicalTrials.gov/show/NCT04397900"
193,"Understanding Immunity to SARS-CoV-2, the Coronavirus Causing COVID-19","Recruiting","No Results Available","Coronavirus","Other: There is no intervention","Stanford University, Hospital, and Clinics, Stanford, California, United States","https://ClinicalTrials.gov/show/NCT04373148"
194,"Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury","Recruiting","No Results Available","CoronaVirus Induced Disease-2019 (COVID-19)","Drug: Ibrutinib|Drug: Placebo","Stanford Univ School Medicine /ID# 221954, Stanford, California, United States|Medstar Health Research Institute /ID# 221886, Washington, District of Columbia, United States|GW Medical Faculty Associates /ID# 222023, Washington, District of Columbia, United States|Midway Immunology and Research /ID# 222004, Fort Pierce, Florida, United States|Brigham & Women's Hospital /ID# 221847, Boston, Massachusetts, United States|Intermountain Healthcare /ID# 221955, Salt Lake City, Utah, United States","https://ClinicalTrials.gov/show/NCT04375397"
195,"Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)","Recruiting","No Results Available","COVID-19","Biological: RPH-104 80 mg|Drug: Olokizumab 64 mg|Drug: Placebo","Federal State Budget Institution ""National Medical Surgery Center named after N.I. Pirogov"" of Ministry of Health of Russian Federation, Moscow, Russian Federation|State Budget Healthcare Institution ""City Clinical Hospital № 15 named after O.M. Filatov"" of Moscow City Healthcare Department, Moscow, Russian Federation|Federal State Budgetary Institution ""Federal Center for Cerebrovascular Pathology and Stroke"" of the Ministry of Health of the Russian Federation, Moscow, Russian Federation|Federal State Autonomous Education Insitution of High Education the First Moscow State Medical University named after I.M. Sechenov of Ministry of Healthcare of Russian Federation (Sechenov University), Moscow, Russian Federation|Federal State Budget Institution ""National Medicine Research Center on Cardiology"" By Ministry of Healthcare of Russian Federation, Moscow, Russian Federation|State Budget Institution of Healthcare ""City Clinical Hospital #52"", Moscow City Healthcare Department, Moscow, Russian Federation|Moscow State Budget Institution of Healthcare ""Scientific Research Institute of Emergency Medicine named after N.V. Sklifosovsky of Moscow Department of Healthcare"", Moscow, Russian Federation|State Budget Healthcare Institution ""City Clinical Hospital #40"", Moscow City Healthcare Department, ""Communarca"" Division, Moscow, Russian Federation|АО ""State Company ""Medsi"" based on Clinical Hospital №1"", Moscow, Russian Federation|Saint Petersburg State Budget Institution of Healthcare ""Clinical infectious diseases hospital named after S.P. Botkin"", Saint Petersburg, Russian Federation|Saint-Petersburg State Budget Institution of Healthcare ""City Hospital №40"", Saint Petersburg, Russian Federation","https://ClinicalTrials.gov/show/NCT04380519"
196,"Performance of 3 Sampling Methods for the Detection of SARS-CoV-2 (COVID-19) With Real-time Reverse Transcriptase PCR","Not yet recruiting","No Results Available","Covid-19|SARS-CoV-2|Diagnosis|Polymerase Chain Reaction","Other: samling of oropharynx and nasopharynx","Jessa Hospital, Hasselt, Belgium","https://ClinicalTrials.gov/show/NCT04361448"
197,"Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients","Not yet recruiting","No Results Available","COVID-19|Sars-CoV2","Biological: COVID-19 Convalescent Plasma (CCP)|Biological: Placebo","San Francisco General Hospital, San Francisco, California, United States","https://ClinicalTrials.gov/show/NCT04421404"
198,"Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial)","Not yet recruiting","No Results Available","Corona Virus Infection|COVID-19|SARS-CoV 2|Nitric Oxide|Respiratory Disease|Pneumonia, Viral|Inhaled Nitric Oxide","Device: Nitric Oxide delivered via LungFit™ system","Baptist Health Center for Clinical Research, Little Rock, Arkansas, United States","https://ClinicalTrials.gov/show/NCT04397692"
199,"Whole Blood Collection From Individuals in the Convalescent Phase of SARS-CoV-2 Infection","Not yet recruiting","No Results Available","COVID|Sars-CoV2",,,"https://ClinicalTrials.gov/show/NCT04409184"
200,"Randomised Evaluation of COVID-19 Therapy","Recruiting","No Results Available","Severe Acute Respiratory Syndrome","Drug: Lopinavir-Ritonavir|Drug: Corticosteroid|Drug: Hydroxychloroquine|Drug: Azithromycin|Biological: Convalescent plasma|Drug: Tocilizumab","Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom","https://ClinicalTrials.gov/show/NCT04381936"
201,"Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19","Recruiting","No Results Available","Coronavirus",,"Shanghai Public Health Clinical Center, Shanghai, Shanghai, China","https://ClinicalTrials.gov/show/NCT04292340"
202,"Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia","Recruiting","No Results Available","Corona Virus Infection|SARS-CoV 2|SARS Pneumonia|Pneumonia","Drug: High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma","University of Virginia Medical Center, Charlottesville, Virginia, United States|University of Virginia, Charlottesville, Virginia, United States","https://ClinicalTrials.gov/show/NCT04374565"
203,"Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment","Completed","No Results Available","Novel Coronavirus Infection","Drug: Lopinavir/ritonavir|Drug: Ribavirin|Drug: Interferon Beta-1B","University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong","https://ClinicalTrials.gov/show/NCT04276688"
204,"COVID19-hematological Malignancies: the Italian Hematology Alliance","Recruiting","No Results Available","SARS-CoV-2 Infection|Hematological Malignancies",,"SC Ematologia Ospedale SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy|UOC Ematologia, Ospedali Riuniti, Ancona, Italy|UOC Ematologia e Terapia Cellulare, Ospedale Mazzoni, Ascoli Piceno, Italy|SC Oncologia Medica, CRO, Aviano, Italy|SC Ematologia, Policlinico Bari, Bari, Italy|UOC Ematologia, I.R.C.C.S Istituto Tumori Giovanni Paolo II, Bari, Italy|SSD Ematologia, Ospedale degli Infermi, Biella, Italy|UOC Ematologia, Azienda Ospedaliero-Universitaria Policlinico S.Orsola-Malpighi,, Bologna, Italy|Ematologia e Centro Trapianto Midollo Osseo, Ospedale di Bolzano, Bolzano, Italy|UO Ematologia e CTMO, ASST Spedali Civili, Brescia, Italy|UO Ematologia e CTMO, ASST Spedali Civili, Brescia, Italy|UOC Onco-Ematologia ASST Valle Olona, Busto Arsizio, Italy|SC Ematologia e CTMO AZIENDA OSPEDALIERA ""G. BROTZU"" - OSPEDALE ONCOLOGICO BUSINCO, Cagliari, Italy|UOC Ematologia, AOU Policlinico Vittorio Emanuele, Catania, Italy|Ematologia, Ospedale Valduce, Como, Italy|UOC Ematologia, Azienda Ospedaliera di Cosenza, Cosenza, Italy|UO Ematologia e CTMO, ASST Cremona, Cremona, Italy|SC Ematologia Ospedale S. Croce, Cuneo, Italy|UOC, Ematologia Azienda Ospedaliero Universitaria Arcispedale S. Anna, Ferrara, Italy|S.O.D. Ematologia, Azienda Ospedaliero Universitaria Careggi, Firenze, Italy|UOC Ematologia, Policlinico Ospedali Riuniti, Foggia, Italy|IRST-IRCC di Meldola, Forlì, Italy|UO Ematologia, Ospedale Policlinico S.Martino IRCCS, Genova, Italy|UO Ematologia, Ospedale Policlinico San Martino, Genova, Italy|UOC di Ematologia e Trapianto di Cellule Staminali, P.O. Vito Fazzi, Lecce, Italy|UOC di Ematologia, Ospedale di Legnano, Legnano, Italy|UO Dipartimento di Ematologia, USL 6, Livorno, Italy|UOC Oncologia ASST Lodi, Lodi, Italy|UOC Ematologia Azienda Ospedaliera Universitaria ""G.Martino"", Messina, Italy|UO Ematologia, Ospedale dell'Angelo di Mestre, Mestre, Italy|Ematologia, IEO, Milano, Italy|SC Ematologia, Istituto Nazionale dei Tumori, Milano, Italy|SC Ematologia, Ospedale Niguarda, Milano, Italy|UO Ematologia, IRCCS Ospedale San Raffaele, Milano, Italy|UO Servizio di Ematologia e Medicina Trasfusionale, Ospedale Luigi Sacco, Milano, Italy|UOC Ematologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy|UO Ematologia Policlinico di Modena, Modena, Italy|UOC Ematologia, Ospedale S. Gerardo, Monza, Italy|SC Ematologia Istituto Nazionale Tumori - IRCCS ""Fondazione G. Pascale"",, Napoli, Italy|UOC Ematologia e Trapianti di Midollo, AOU Federico II, Napoli, Italy|UOC Ematologia, Ospedale Antonio Cardarelli, Napoli, Italy|UOC Ematologia, Azienda Ospedaliero-Universitaria Maggiore della Carità, Novara, Italy|Ospedale san Luigi Gonzaga, Orbassano, Italy|Ematologia Azienda Ospedaliera di Padova, Padova, Italy|UO Ematologia, Policlinico Paolo Giaccone, Palermo, Italy|UOC Ematologia e CTMO, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy|SC Ematologia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|SC Ematologia e Trapianto di Midollo Osseo, Azienda Ospedaliera di Perugia, Perugia, Italy|UO Ematologia e CTMO, Azienda Ospedaliera Ospedali Riuniti, Pesaro, Italy|UOC di Ematologia, Ospedale Civile Spirito Santo, Pescara, Italy|UO Ematologia e CTMO, Presidio Ospedaliero di Piacenza, Piacenza, Italy|UO Ematologia, AOU Pisana- Santa Chiara, Pisa, Italy|UO Ematologia dell'Ospedale Santa Maria delle Croci, Ravenna, Italy|UOC Ematologia, Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli, Reggio Calabria, Italy|SC Ematologia, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy|UO Ematologia, Ospedale Infermi, Rimini, Italy|AOU Azienda Ospedaliera Universitaria Sant'Andrea, Roma, Italy|IFO - Ematologia e Trapianto Cellule -Istituto Nazionale del Cancro di Regina Elena, Roma, Italy|SC Ematologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy|UO Ematologia e Trapianti di Cellule Staminali, A.O. S. Camillo-Forlanini, Roma, Italy|UO Ematologia, Policlinico Tor Vergata, Roma, Italy|UOC Ematologia e trapianto di cellule staminali, Policlinico Universitario Campus Bio-Medico, Roma, Italy|UOC Ematologia Policlinico Umberto I, Roma, Italy|UOC Ematologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy|UOC Ematologia- Azienda Ospedaliera San Giovanni Addolorata, Roma, Italy|UO Ematologia, Istituto Clinico Humanitas, Rozzano, Italy|UOC Ematologia e centro trapianti cellule staminali emopoietiche, AOU San Giovanni Di Dio e Ruggi D'aragona, Salerno, Italy|Ematologia ASL Imperiese, Sanremo, Italy|Medicina Interna ed Ematologia, Asl 1, Savona, Italy|UOC Ematologia, Policlinico Santa Maria alle Scotte, Siena, Italy|UOC Ematologia e Trapianto Midollo Osseo, Ospedale S. G. Moscati, Taranto, Italy|SCDU Ematologia e terapie cellulari, Ospedale Mauriziano Umberto I, Torino, Italy|UO Ematologia, Ospedale Universitario Molinette San Giovanni Battista, Torino, Italy|UO Ematologia, Ospedale Universitario Molinette San Giovanni Battista, Torino, Italy|UO Ematologia, Ospedale Civili Ca' Foncello, Treviso, Italy|SC Ematologia, Azienda sanitaria universitaria Giuliano Isontina, Trieste, Italy|Clinica Ematologia, Azienda Ospedaliera-Universitaria Santa Maria della Misericordia, Udine, Italy|UOC Ematologia, ASST Sette Laghi, Osp. Di Circolo e Fondazione Macchi, Varese, Italy|UOC Ematologia, Azienda Ospedaliera Integrata di Verona, Verona, Italy|UOC Ematologia, Azienda Ospedaliera Integrata di Verona, Verona, Italy|UOC Ematologia, Ospedale San Bortolo, Vicenza, Italy","https://ClinicalTrials.gov/show/NCT04352556"
205,"Organicell Flow for Patients With COVID-19","Not yet recruiting","No Results Available","Corona Virus Infection|COVID-19|SARS|Acute Respiratory Distress Syndrome","Biological: Organicell Flow|Other: Placebo","Landmark Hospital, Naples, Florida, United States|Landmark Hospital, Athens, Georgia, United States","https://ClinicalTrials.gov/show/NCT04384445"
206,"Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and Adverse Outcomes in Patients With COVID19","Recruiting","No Results Available","Corona Virus Infection|COVID-19","Other: Suspension or Maintenance of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors","Idor, São Paulo, Brazil","https://ClinicalTrials.gov/show/NCT04364893"
207,"Serology COVID-19 From the Cornwall Hospital Union","Recruiting","No Results Available","Corona Virus Infection","Biological: Serological test|Biological: Serum test","CH de Cornouaille, Quimper, France","https://ClinicalTrials.gov/show/NCT04363593"
208,"Detection Rate of SARS-CoV-2 in Male Genitourinary System and Its Impact on Male Reproductive Health.","Recruiting","No Results Available","Coronavirus Disease 2019","Other: Coronavirus Disease 2019","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China","https://ClinicalTrials.gov/show/NCT04388631"
209,"Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults","Recruiting","No Results Available","SARS-CoV-2 Infection|COVID-19","Biological: BNT162a1|Biological: BNT162b1|Biological: BNT162b2|Biological: BNT162c2|Other: Placebo","University of Maryland, Center for Vaccine Development and Global Health, Baltimore, Maryland, United States|NYU Langone Health, New York, New York, United States|Rochester Regional Health/Rochester General Hospital, Rochester, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States","https://ClinicalTrials.gov/show/NCT04368728"
210,"Multicentric Retrospective Observational Study of Thoracic Scanner Performance in COVID Screening.","Recruiting","No Results Available","The Gold Standard for Current SARS CoV2 Detection is RT-PCR","Diagnostic Test: Thoracic CT Scan","Chu de Poitiers, Poitiers, France","https://ClinicalTrials.gov/show/NCT04339686"
211,"Trial of Alpha One Antitrypsin Inhalation in Treating Patient With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)","Recruiting","No Results Available","Coronavirus","Drug: alpha one antitrypsin inhalation","Ministry of Health, Mecca, Saudi Arabia","https://ClinicalTrials.gov/show/NCT04385836"
212,"Trial of Treatments for COVID-19 in Hospitalized Adults","Recruiting","No Results Available","Corona Virus Infection","Drug: Remdesivir|Drug: Lopinavir/ritonavir|Drug: Interferon Beta-1A|Drug: Hydroxychloroquine|Other: Standard of care","Centre Hospitalier Universitaire Amiens-Picardie, Amiens, France|Centre Hospitalier Regional Metz-Thionville, Ars-Laquenexy, France|Centre Hospitalier Régional Universitaire de Besançon, Besançon, France|Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France|APHP - hôpital Henri-Mondor, Créteil, France|Centre Hospitalier Universitaire Dijon-Bourgogne, Dijon, France|Centre Hospitalier Universitaire de Martinique, Fort De France, France|AP-HP Hôpital Bicêtre, Kremlin-Bicêtre, France|Centre Hospitalo-Universitaire de Grenoble, La Tronche, France|Centre Hospitalier Régional Universitaire de Lille, Lille, France|Hospices Civils de Lyon, Lyon, France|Centre Hospitalier Universitaire de Montpellier, Montpellier, France|Groupe Hospitalier de la Région de Mulhouse Sud Alsace, Mulhouse, France|Centre Hospitalier Régional et Universitaire de Nancy, Nancy, France|Centre Hospitalier Universitaire de Nantes, Nantes, France|Centre Hospitalo-Universitaire de Nice, Nice, France|APHP - Hôpital Saint Antoine, Paris, France|APHP - Hôpital Universitaire Pitié Salpêtrière, Paris, France|APHP - Hôpital Cochin, Paris, France|Hôpital Paris Saint-Joseph et Marie Lannelongue, Paris, France|APHP- Hôpital Européen Georges-Pompidou, Paris, France|APHP - Hôpital Bichat Claude Bernard, Paris, France|Centre Hospitalier Universitaire de Rennes, Rennes, France|Hopital DELAFONTAINE, Saint-Denis, France|Hôpital d'Instruction des Armées BEGIN, Saint-Mandé, France|Centre Hospitalier Universitaire de Saint Etienne, Saint-Étienne, France|Centre Hospitalier Régional Universitaire de Strasbourg, Strasbourg, France|Centre Hospitalier Universitaire de Toulouse, Toulouse, France|Centre Hospitalier Universitaire de Toulouse, Toulouse, France|Centre Hospitalier de Tourcoing, Tourcoing, France|Centre Hospitalier Universitaire de Tours, Tours, France|Centre Hospitalier Annecy Genevois, Épagny, France|Centre Hospitalier Luxembourg, Luxembourg, Luxembourg|Hôpitaux Robert Schuman, Luxembourg, Luxembourg","https://ClinicalTrials.gov/show/NCT04315948"
213,"PATCH 2&3:Prevention & Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine","Recruiting","No Results Available","Coronavirus|Corona Virus Infection","Drug: Group A HCQ|Drug: Group B Control","ProHealth New York, New York, New York, United States","https://ClinicalTrials.gov/show/NCT04353037"
214,"Prevalence of SARS-CoV-2 in Conjunctival Swab Samples Among Patients With Conjunctivitis During the COVID-19 Pandemic","Recruiting","No Results Available","Conjunctivitis|SARS-CoV-2|COVID-19|Ocular Infection, Viral|Ocular Inflammation",,"Wilmer Eye Institute, Baltimore, Maryland, United States","https://ClinicalTrials.gov/show/NCT04374656"
215,"COVID-19 and ICU-acquired MDR Bacteria","Recruiting","No Results Available","Sars-CoV2|Critical Illness",,"Hôpital Roger Salengro, ICU, CHU Lille, Lille, France","https://ClinicalTrials.gov/show/NCT04378842"
216,"Immunophenotyping Assessment in a COVID-19 Cohort","Enrolling by invitation","No Results Available","Coronavirus Disease 2019 (COVID-19)|SARS-CoV-2","Procedure: Biological sample collection|Procedure: Data Collection: Clinical Care Assessments","University of California, Los Angeles: Department of Medicine, Los Angeles, California, United States|University of California San Francisco School of Medicine, San Francisco, California, United States|Stanford Medicine: Sean N. Parker Center for Allergy & Asthma Research, Stanford, California, United States|Yale School of Medicine, New Haven, Connecticut, United States|Emory University School of Medicine, Atlanta, Georgia, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Drexel University College of Medicine, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT04378777"
217,"Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION Trial","Not yet recruiting","No Results Available","Coronavirus Infection","Drug: Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed|Drug: Group 2: control group with enoxaparin 40mg/d",,"https://ClinicalTrials.gov/show/NCT04394377"
218,"Covid-19 Pandemic Triage Score","Active, not recruiting","No Results Available","Sars-CoV2|Covid19","Diagnostic Test: STC-19 score","Groupe Hospitalier de la Rochelle Ré Aunis, La Rochelle, France","https://ClinicalTrials.gov/show/NCT04371471"
219,"Clinical Performance of the VivaDiag ™ COVID-19 lgM / IgG Rapid Test in Early Detecting the Infection of COVID-19","Not yet recruiting","No Results Available","Coronavirus Infections","Device: VivaDiag™ COVID-19 lgM/IgG Rapid Test","Unità' Complesse di cure primarie (UCCP), ASP Catanzaro, Catanzaro, Italy","https://ClinicalTrials.gov/show/NCT04316728"
220,"Registry for Clinical Presentation and Management of Patients With COVID-19 in the Emergency Room","Not yet recruiting","No Results Available","Corona Virus Infection|SARS-CoV 2","Other: Retrospective data collection","University Hospital of Cologne, Cologne, Germany","https://ClinicalTrials.gov/show/NCT04351854"
221,"Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial","Enrolling by invitation","No Results Available","Coronavirus Infections","Biological: Convalescent Plasma","Imam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Mazandaran, Iran, Islamic Republic of","https://ClinicalTrials.gov/show/NCT04327349"
222,"Precision Immunology to Determine the Immune Response in Patients With COVID-19","Recruiting","No Results Available","SARS-CoV 2|COVID","Other: Blood draw","University Hospital Bonn, Bonn, Germany","https://ClinicalTrials.gov/show/NCT04360733"
223,"An Observational Study of the Use of Siltuximab (SYLVANT) in Patients Diagnosed With COVID-19 Infection Who Have Developed Serious Respiratory Complications","Completed","No Results Available","Severe Acute Respiratory Syndrome (ARDS) Secondary to SARS-COV-2 Infection",,"ASST - Papa Giovanni XXIII, Bergamo, Italy","https://ClinicalTrials.gov/show/NCT04322188"
224,"Convalescent Plasma for COVID-19 Close Contacts","Recruiting","No Results Available","SARS-CoV 2|COVID-19","Biological: Convalescent Plasma (anti-SARS-CoV-2 plasma)|Biological: Control (albumin 5%)","Columbia University Irving Medical Center/NYP, New York, New York, United States","https://ClinicalTrials.gov/show/NCT04390503"
225,"Clinical Study of SARS in Children","Completed","No Results Available","Epidemiology",,,"https://ClinicalTrials.gov/show/NCT00173576"
226,"Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome","Not yet recruiting","No Results Available","SARS-CoV 2|COVID19|SARS (Severe Acute Respiratory Syndrome)|Cytokine Release Syndrome|Cytokine Storm","Drug: BAT + Calcifediol|Drug: BAT",,"https://ClinicalTrials.gov/show/NCT04366908"
227,"BCG Vaccine for Health Care Workers as Defense Against COVID 19","Recruiting","No Results Available","Coronavirus|Coronavirus Infection|Coronavirus as the Cause of Diseases Classified Elsewhere","Biological: BCG Vaccine|Biological: Placebo Vaccine","Cedars-Sinai Medical Center, Los Angeles, California, United States|Texas A&M Family Care Clinic, Bryan, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Baylor St. Luke's Medical Center, Houston, Texas, United States|Harris Health System - Ben Taub Hospital, Houston, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT04348370"
228,"Immunomodulatory Profile of Dexmedetomidine Sedation in Patients Recovering After ARDS Covid-19","Recruiting","No Results Available","SARS-CoV 2","Other: Inflammatory cytokines and chemokines profiles of patients with dexmedetomidine administration","Intensive Care Unit and Respiratory division ; Groupe hospitalier Pitie-Salpetriere and Universite Pierre et Marie Curie Paris 6, Paris, France","https://ClinicalTrials.gov/show/NCT04413864"
229,"Treatment for COVID-19 in High-Risk Adult Outpatients","Recruiting","No Results Available","COVID-19|SARS-CoV-2","Drug: Ascorbic Acid|Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin|Drug: Folic Acid","Ruth M. Rothstein CORE Center - Cook County Health, Chicago, Illinois, United States|Tulane University, New Orleans, Louisiana, United States|Boston University, Boston, Massachusetts, United States|NYU Langone Health, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|University of Washington Coordinating Center, Seattle, Washington, United States|UW Virology Research Clinic, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT04354428"
230,"Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)","Recruiting","No Results Available","COVID-19|Corona Virus Infection|SARS (Severe Acute Respiratory Syndrome)|SARS-CoV-2","Drug: Hydroxychloroquine Sulfate|Drug: Ascorbic Acid","University of California Los Angeles, Los Angeles, California, United States|Tulane, New Orleans, Louisiana, United States|University of Maryland, Baltimore, Baltimore, Maryland, United States|Boston University, Boston, Massachusetts, United States|NYU Langone Health, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|University of Washington, Coordinating Center, Seattle, Washington, United States|UW Virology Research Clinic, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT04328961"
231,"Contamination During Removal of Two Different Personal Protective Systems","Completed","No Results Available","Severe Acute Respiratory Syndrome","Procedure: Powered Air purifying respirator","Kingston General Hospital, Kingston, Ontario, Canada","https://ClinicalTrials.gov/show/NCT00150475"
232,"Factors Associated With a Positive SARS-CoV-2 Serology in Contact Subjects at High/Moderate Risk of Coronavirus SARS-CoV-2 Infection. COVID19.","Recruiting","No Results Available","Coronavirus","Diagnostic Test: Serology|Genetic: Sequencing","Service de maladies infectieuses et tropicales Hôpital Jean Minjoz CHRU Besançon, Besançon, France|Service des Maladies infectieuses et tropicales, Pôle Spécialités médicales, CHU Pellegrin, Bordeaux, France|Service des maladies infectieuses Hôpital Gabriel Montpied CHU de Clermont Ferrand, Clermont Ferrand, France|Centre d'investigation clinique 1432 Hôpital François Mitterrand CHU Bourgogne, Dijon, France|Centre d'investigation clinique 1406 CHU Grenoble, Grenoble, France|Centre d'Investigation Clinique 1403 -CHU Lille, Lille, France|Centre d'investigation clinique Infectiologie Hôtel-Dieu CHU Nantes, Nantes, France|Centre d'Investigation Clinique Hôpital Saint Louis, Paris, France|Centre d'investigation Clinique 1425, Hôpital Bichat Claude Bernard, Paris, France|Hôpital Cochin CIC 1417 Bâtiment Lavoisier, Paris, France|Centre d'investigation clinique 1414 Service de Pharmacologie clinique CHU Rennes Hôpital Pontchaillou, Rennes, France|Centre Hospitalier Félix Guyon Ile de la Réunion CHU nord, Saint Denis, France|Département maladie infectieux CHU Saint Etienne, Saint Etienne, France|Centre d'Investigation Clinique Ile de la Réunion CHU sud, Saint-Pierre, France|Centre Investigation Clinique 1415 CHRU Tours - Hôpital Bretonneau, Tours, France|Centre Investigation Clinique 1433 CHRU de NANCY, Vandœuvre-lès-Nancy, France|Service de Maladies infectieuses et tropicales Centre hospitalier, Cayenne, French Guiana","https://ClinicalTrials.gov/show/NCT04322279"
233,"Different Susceptibility to SARS CoV-2 Infection Among Health Care Workers Highly Exposed to COVID-19.","Recruiting","No Results Available","Health Care Worker Patient Transmission|Receptor Site Alteration|Susceptibility, Disease|Immune Response","Diagnostic Test: Susceptibility to infection","Hospital Ramon y Cajal, Madrid, Spain","https://ClinicalTrials.gov/show/NCT04402827"
234,"ARMOR Study: COVID-19 Seroprevalence Among Healthcare Workers","Recruiting","No Results Available","Covid-19|Coronavirus Infection|Coronavirus","Other: COVID-19 Serology|Behavioral: Health Care Worker Survey","NewYork-Presbyterian Hosptial/Columbia University Irving Medical Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT04367857"
235,"STerOids in COVID-19 Study","Not yet recruiting","No Results Available","Coronavirus Infection","Drug: Budesonide dry powder inhaler",,"https://ClinicalTrials.gov/show/NCT04416399"
236,"Extracorporeal Membrane Oxygenation (ECMO) and Coronavirus Disease (COVID) 19","Recruiting","No Results Available","ARDS Related to Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 2|Acute Refractory Heart Failure Related to SARS-CoV 2",,"Angers University Hospital, Angers, France|Besançon Hospital, Besançon, France|Brest university Hospital, Brest, France|Caen University Hospital, Caen, France|Clermont ferrand University hospital, Clermont-Ferrand, France|APHP Henri Mondor Paris University Hospital, Créteil, France|Dijon University Hospital, Dijon, France|Vendée Hospital, La Roche-sur-Yon, France|Grenoble University Hospital, La Tronche, France|APHP Kremli Bicetre Paris University Hospital, Le Kremlin-Bicêtre, France|Marie Lannelongue Hospital, Le Plessis-Robinson, France|Lens Hospital, Lens, France|Lille University Hospital, Lille, France|Limoges University Hospital, Limoges, France|Clinique de la Sauvegarde, Lyon, France|Lyon University Hospital, Lyon, France|Marseille Européen Hospital, Marseille, France|APHM la Timone- Marseille University Hospital, Marseille, France|Metz University Hospital, Metz, France|Montpellier University Hospital, Montpellier, France|Emile Muller Hospital, Mulhouse, France|Nancy University Hospital, Nancy, France|Nantes University Hospital, Nantes, France|Ambroise Paré Hospital, Neuilly-sur-Seine, France|Nimes University Hospital, Nimes, France|Institut Mutualiste Montsouris, Paris, France|APHP Hopital Européen Georges Pompidou - Paris University Hospital, Paris, France|APHP necker Paris University Hospital, Paris, France|APHP Bichat - Paris University Hospital, Paris, France|Bordeaux University Hospital, Pessac, France|Poitiers University hospital, Poitiers, France|Reims University hospital, Reims, France|Rennes University hospital, Rennes, France|Rouen University Hospital, Rouen, France|Saint brieuc Hospital, Saint brieuc, France|La Réunion University Hospital, Saint-Denis, France|Saint Etienne University Hospital, Saint-Étienne, France|Strasbourg University Hospital, Strasbourg, France|Toulouse University Hospital - Rangueil Hospital, Toulouse, France|Tours University Hospital, Tours, France|Bretagne Atlantique Hospital, Vannes, France","https://ClinicalTrials.gov/show/NCT04397588"
237,"Health, Perception, Practices, Relations and Social Inequalities in the General Population During the Covid-19 Crisis","Recruiting","No Results Available","SARS-CoV 2","Biological: Non applicable","Inserm, Paris, France","https://ClinicalTrials.gov/show/NCT04392388"
238,"Modulation of Hyperinflammation in COVID-19","Recruiting","No Results Available","COVID-19|SARS","Device: Control group|Device: SLEDD with a L-MOD","Victoria Hospital - Critical Care Trauma Centre, London, Ontario, Canada","https://ClinicalTrials.gov/show/NCT04353674"
239,"SARS-CoV 2 in Personal Protective Equipment","Not yet recruiting","No Results Available","rt PCR|COVID|Personal Protective Equipment PPE|SARS-CoV 2|Health Personnel Attitude|Virus Diseases",,,"https://ClinicalTrials.gov/show/NCT04398043"
240,"The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients","Recruiting","No Results Available","SARS-CoV Infection|COVID 19|Acute Respiratory Distress Syndrome ARDS","Drug: Hydroxychloroquine|Drug: Remdesivir|Other: (Standard of Care) SoC","Andreas Barratt-Due, Oslo, Norway","https://ClinicalTrials.gov/show/NCT04321616"
241,"Convalescent Plasma of Covid-19 to Treat SARS-COV-2 a Randomized Doble Blind 2 Center Trial","Recruiting","No Results Available","COVID-19","Biological: Convalescent Plasma of patients with COVID-19|Other: placebo (hartmann plus albumine)","Hospital Nava de Alta Especialidad, Mexico City, Mexico|Hospital General de Mexico Dr Eduardo Liceaga, Mexico City, Mexico","https://ClinicalTrials.gov/show/NCT04405310"
242,"COVID-19 Respiratory Distress and Antithrombotic Drugs in Subject's Habits","Recruiting","No Results Available","Sars-CoV2",,"Service Médecine Intensive et Réanimation, Strasbourg, France","https://ClinicalTrials.gov/show/NCT04412473"
243,"Incidence of COVID-19 Test Conversion in Post-surgical Patients","Recruiting","No Results Available","Sars-CoV2","Diagnostic Test: COVID-19 PCR and Serology","North Shore University Hospital, Manhasset, New York, United States|Long Island Jewish Medical Center, New Hyde Park, New York, United States","https://ClinicalTrials.gov/show/NCT04392323"
244,"Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to ""no Treatment"" in SARS CoV 2 Virus","Recruiting","No Results Available","COVID - 19","Drug: hydroxychloroquine in combination with camostat mesylate|Drug: Hydroxychloroquine in combination of Azithromycin","Sheba Medical Center, Ramat Gan, Israel|Sheba Medical Center, Tel HaShomer, Israel","https://ClinicalTrials.gov/show/NCT04355052"
245,"Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19","Recruiting","No Results Available","Covid-19|Sars-CoV2|Diabete Mellitus|Cardiopathy|Pulmonary Disease|Renal Disease|Liver Diseases","Dietary Supplement: Viusid and Asbrip","Hospital de Especialidades Dr. Teodoro Maldonado Carbo, Guayaquil, Ecuador","https://ClinicalTrials.gov/show/NCT04407182"
246,"Endotracheal Tube Obstruction in Covid-19 Patients Requiring Mechanical Ventilation","Recruiting","No Results Available","Sars-CoV2",,"Service d'Anesthésie-Réanimation - Nouvel Hôpital Civil, Strasbourg, France","https://ClinicalTrials.gov/show/NCT04394429"
247,"Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients","Recruiting","No Results Available","COVID-19|Coronavirus|Coronavirus Infection","Biological: Convalescent Plasma|Other: Saline solution","Montefiore Medical Center, Bronx, New York, United States|NYU Langone Health, New York, New York, United States","https://ClinicalTrials.gov/show/NCT04364737"
248,"Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection","Recruiting","No Results Available","Coronavirus Infection","Drug: Selinexor|Other: Placebo","UCLA, Los Angeles, California, United States|Kaiser Permanente Oakland, Oakland, California, United States|UC Davis Health, Sacramento, California, United States|Kaiser Permanente Sacramento, Sacramento, California, United States|Kaiser Permanente San Francisco, San Francisco, California, United States|Miami Cancer Institute at Baptist Health, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Advocate Christ Medical Center, Oak Lawn, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Norton Healthcare, Louisville, Kentucky, United States|Boston Medical Center, Boston, Massachusetts, United States|Karmanos, Detroit, Michigan, United States|Michigan Center of Medical Research, Farmington Hills, Michigan, United States|Michigan Center of Medical Research, Royal Oak, Michigan, United States|Columbia University, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Levine Cancer Institute-Atrium Health University City, Charlotte, North Carolina, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|Baylor Scott & White Dallas, Dallas, Texas, United States|MultiCare Institute for Research & Innovation (Puget Sound), Tacoma, Washington, United States|Hospital Hietzing, 2. Medical department - Center for Diagnosis and Therapy of Rheumatic Diseases, Vienna, Austria|CHU Bordeaux, Bordeaux, France|CHU Lyon, Lyon, France|CHU Nantes, Nantes, France|Hadassah MC, Jerusalem, Israel|Hasharon Medical Center, Petah Tiqva, Israel|Sheba Medical Center, Tel HaShomer, Israel|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Servicio de Medicina Interna, Hospital Universitario de Salamanca, Universidad de Salamanca, Salamanca, Spain|Princess Royal University Hospital, Kent, United Kingdom|Kings College Hospital, London, United Kingdom|The Royal Marsden Hospital, London, United Kingdom|University Hospitals Plymouth NHS Trust, Plymouth, United Kingdom","https://ClinicalTrials.gov/show/NCT04349098"
249,"The Impact of Camostat Mesilate on COVID-19 Infection","Recruiting","No Results Available","Corona Virus Infection","Drug: Camostat Mesilate|Drug: Placebo oral tablet","Department of Infectious Diseases, Aalborg, Denmark|Department for Infectious Diseases, Aarhus University Hospital, Aarhus N, Denmark|Herning Regional Hospital, Herning, Denmark|Northzealands hospital - Hillerød, Hillerød, Denmark|Horsens Regional Hospital, Horsens, Denmark|Bispebjerg hospital, København, Denmark|Dept. of Infectious Diseases, Odense University Hospital, Odense, Denmark|Randers Regional Hospital, Randers, Denmark|Silkeborg Hospital, Silkeborg, Denmark","https://ClinicalTrials.gov/show/NCT04321096"
250,"COVID-19 Infection and Transmission in Exposed, Confined and Community-based Infants","Not yet recruiting","No Results Available","Coronavirus|Coronavirus Infection|Covid19|Sars-CoV2","Diagnostic Test: Rapid detection test|Diagnostic Test: Nasopharyngeal swab|Diagnostic Test: Stool collection",,"https://ClinicalTrials.gov/show/NCT04413968"
251,"COVID-19 Prophylaxis With Hydroxychloroquine Associated With Zinc For High-Risk Healthcare Workers","Not yet recruiting","No Results Available","Coronavirus Infections","Drug: Hydroxychloroquine","Drug Research and Development Center (NPDM), Federal University of Ceará (UFC), Fortaleza, Ceará, Brazil","https://ClinicalTrials.gov/show/NCT04384458"
252,"Convalescent Plasma in the Treatment of COVID 19","Enrolling by invitation","No Results Available","SARS-CoV-2|COVID|Coronavirus","Biological: Convalescent Plasma","Trinity Health Of New England, Hartford, Connecticut, United States","https://ClinicalTrials.gov/show/NCT04343261"
253,"Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19","Recruiting","No Results Available","COVID-19","Other: Blood donation from convalescent donor","National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore","https://ClinicalTrials.gov/show/NCT04351659"
254,"Study of the Pathogenesis of Olfactory Disorders in COVID-19","Recruiting","No Results Available","Coronavirus Infection|Severe Acute Respiratory Syndrome|Sars-CoV2","Other: Nasal swab|Other: Taste and olfactory function evaluation","Hôpital Lariboisière, Policlinique, Paris, France|Hôpital Lariboisière, Service ORL, Paris, France","https://ClinicalTrials.gov/show/NCT04366934"
255,"Phase I Study of a Vaccine for Severe Acute Respiratory Syndrome (SARS)","Completed","No Results Available","Healthy","Procedure: Blood Test|Procedure: Urine Test|Procedure: Physical Exam|Drug: Vaccine|Drug: VRC-SRSDNA015-00-VP","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00099463"
256,"Intensive Care Associated Complications and Outcome of Acute Respiratory Distress Syndrome Due to COVID-19","Recruiting","No Results Available","COVID|Corona Virus Infection|Sars-CoV2","Procedure: Study Arm","Inselspital Bern, Bern, Switzerland","https://ClinicalTrials.gov/show/NCT04397172"
257,"Monocytes and NK Cells Activity in Covid-19 Patients","Recruiting","No Results Available","COVID-19|Severe Acute Respiratory Syndrome Coronavirus 2|Immunomodulation","Diagnostic Test: Study of immune-mediated mechanisms in patients tested positive for SARS-CoV-2","ATS Insubria, Varese, Italy","https://ClinicalTrials.gov/show/NCT04375176"
258,"Lung CT Scan Analysis of SARS-CoV2 Induced Lung Injury","Recruiting","No Results Available","covid19","Other: Lung CT scan analysis in COVID-19 patients","Ospedale Papa Giovanni XXIII, Bergamo, Italy|Policlinico San Marco-San Donato group, Bergamo, Italy|Azienda Ospedaliero-Universitaria di Ferrara, Ferrara, Italy|ASST di Lecco Ospedale Alessandro Manzoni, Lecco, Italy|ASST Melegnano-Martesana, Ospedale Santa Maria delle Stelle, Melzo, Italy|ASST Monza, Monza, Italy|AUSL Romagna-Ospedale Infermi di Rimini, Rimini, Italy|Istituto per la Sicurezza Sociale-Ospedale della Repubblica di San Marino, San Marino, San Marino","https://ClinicalTrials.gov/show/NCT04395482"
259,"EXercise TRAining and Sedentary Lifestyle on Clinical Outcomes in Patients With COVID-19","Not yet recruiting","No Results Available","COVID-19|SARS-CoV 2|Corona Virus Infection|Sedentary Behavior","Other: Electronic questionnaire","Marcelo Rodrigues dos Santos, São Paulo, Sao Paulo, Brazil","https://ClinicalTrials.gov/show/NCT04396353"
260,"Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia","Not yet recruiting","No Results Available","SARS Virus|SARS-CoV-2|COVID-19","Other: Convalescent SARS COVID-19 plasma|Other: Placebo",,"https://ClinicalTrials.gov/show/NCT04383535"
261,"Impact of Auricular Vagus Nerve Neuromodulation on COVID-19 Positive Inpatients Outcome","Recruiting","No Results Available","Covid19|SARS-CoV Infection","Procedure: Auricular neuromodulation|Procedure: Control","Fondation Adolphe de Rothschild, Paris, France","https://ClinicalTrials.gov/show/NCT04341415"
262,"Efficacy and Safety of COVID-19 Convalescent Plasma","Recruiting","No Results Available","Convalescent Plasma|COVID-19|SARS-CoV 2","Biological: anti-SARS-CoV-2 convalescent plasma","Institute for Transfusion Medicine of RNM, Skopje, North Macedonia","https://ClinicalTrials.gov/show/NCT04397523"
263,"Maternal-foetal Transmission of SARS-Cov-2","Recruiting","No Results Available","Maternal Fetal Infection Transmission|COVID-19|SARS-CoV 2","Diagnostic Test: Diagnosis of SARS-Cov2 by RT-PCR and : IgG, Ig M serologies in the amniotoc fluid, the blood cord and the placenta","CHR Orléans, Orléans, France","https://ClinicalTrials.gov/show/NCT04395924"
264,"CoV-ICU Score, Intensive Care Unit, SARS-CoV-2","Not yet recruiting","No Results Available","Coronavirus as the Cause of Diseases Classified Elsewhere","Other: COVICU",,"https://ClinicalTrials.gov/show/NCT04383483"
265,"Hemodynamic Characteristics of Patients With SARS-CoV-2","Not yet recruiting","No Results Available","Coronavirus|SARS-CoV-2|COVID-19|Acute Respiratory Distress Syndrome|Shock|Acute Circulatory Failure|Left Ventricular Dysfunction|Fluid Overload","Device: Transpulmonary thermodilution|Device: Echocardiography","Bicetre Hospital, Paris, Val-de-Marne, France","https://ClinicalTrials.gov/show/NCT04337983"
266,"Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)","Recruiting","No Results Available","Cerebrovascular Accident|Chronic Obstructive Pulmonary Disease|Chronic Renal Failure|Coronary Artery Disease|Diabetes Mellitus|Malignant Neoplasm|SARS Coronavirus 2 Infection","Other: Best Practice|Biological: Tocilizumab","Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States","https://ClinicalTrials.gov/show/NCT04361552"
267,"Study of Standard of Care Plus Intravenous Immunoglobulin (IVIG) Compared to Standard of Care Alone in the Treatment of COVID-19 Infection","Recruiting","No Results Available","Sars-CoV2","Drug: Octagam","Sharp Grossmont Hospital, La Mesa, California, United States|Sharp Memorial Hospital, San Diego, California, United States","https://ClinicalTrials.gov/show/NCT04411667"
268,"Study of Kinetics and Efficacy of the Immune Response Against COVID-19 Among Hospital Staff","Recruiting","No Results Available","Sars-CoV2","Other: Clinical interview|Biological: Blood collection|Biological: Saliva collection","Hôpital d'Instuction des Armées Percy, Clamart, France","https://ClinicalTrials.gov/show/NCT04408001"
269,"NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER, COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE","Recruiting","No Results Available","Sars-CoV2","Drug: IgIV","Centre Hospitalier de Versailles, Le Chesnay, France","https://ClinicalTrials.gov/show/NCT04403269"
270,"Rapid Detection of COVID-19 by Portable and Connected Biosensor","Not yet recruiting","No Results Available","Sars-CoV2","Diagnostic Test: COVID-19 RT-PCR|Diagnostic Test: Biosensor",,"https://ClinicalTrials.gov/show/NCT04367142"
271,"Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19","Recruiting","No Results Available","Sars-CoV2","Drug: ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS","Hospital Universitario de Jerez de la Frontera, Jerez de la Frontera, Cádiz, Spain|Hospital Reina Sofía, Córdoba, Spain|Hospital Universitario Virgen de las Nieves, Granada, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Unversitario Virgen del Rocío, Sevilla, Spain|Hospital Nuestra Señora de Valme, Sevilla, Spain","https://ClinicalTrials.gov/show/NCT04366323"
272,"Tocilizumab Treatment in Patients With COVID-19","Recruiting","No Results Available","Sars-CoV2","Drug: Tocilizumab","National Cancer Institute of Mexico, Mexico city, Distrito Federal, Mexico","https://ClinicalTrials.gov/show/NCT04363853"
273,"Rhu-pGSN for Severe Covid-19 Pneumonia","Not yet recruiting","No Results Available","Sars-CoV2","Drug: Recombinant human plasma gelsolin (Rhu-pGSN)|Other: Placebo",,"https://ClinicalTrials.gov/show/NCT04358406"
274,"Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects","Recruiting","No Results Available","Sars-CoV2","Drug: BLD-2660","Blade Research Site, Irvine, California, United States|Blade Research Site, Los Angeles, California, United States|Blade Reseach Site, San Jose, California, United States|Blade Research Site, Washington, District of Columbia, United States|Blade Research Site, Tampa, Florida, United States|Blade Research Site, Peoria, Illinois, United States|Blade Research Site, Metairie, Louisiana, United States|Blade Research Site, Baltimore, Maryland, United States|Blade Research Site, Detroit, Michigan, United States|Blade Research Site, Saint Louis, Missouri, United States|Blade Research Site, North Las Vegas, Nevada, United States|Blade Research Site, Durham, North Carolina, United States|Blade Research Site, Fayetteville, North Carolina, United States|Blade Research Site, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States","https://ClinicalTrials.gov/show/NCT04334460"
275,"COVID-19 Seroconversion Among Front Line Medical and Paramedical Staff in Emergency, Intensive Care Units and Infectious Disease Departments During the 2020 Epidemic","Recruiting","No Results Available","Sars-CoV2","Other: blood sample","Hopital Pitié Salpetrière, Paris, France","https://ClinicalTrials.gov/show/NCT04304690"
276,"Analysis of the Inflammatory Response and the Development of Humoral and Cellular Immunity in Patients With COVID-19","Recruiting","No Results Available","SARS-CoV-2","Other: Active COVID-19 disease","UMAE Hospital de Especialidades del Centro Médico Nacional Siglo XXI, IMSS., México, Ciudad De México, Mexico","https://ClinicalTrials.gov/show/NCT04423640"
277,"Muscle Mass and Strength as Predictors of Time to Discharge in Patients With COVID-19","Recruiting","No Results Available","SARS-CoV 2",,"Univsersity of Sao Paulo, Sao Paulo, Brazil","https://ClinicalTrials.gov/show/NCT04406233"
278,"Exploring Brain Damages After COVID-19 Infection","Recruiting","No Results Available","SARS-CoV 2","Procedure: Auditory Evoked Potentials (AEP)|Procedure: Blink and Masseter Inhibitory Reflex","CHU de Bordeaux, Bordeaux, France","https://ClinicalTrials.gov/show/NCT04405986"
279,"A Safety, Tolerability and Efficacy of EIDD-2801 to Eliminate Infectious Virus Detection in Persons With COVID-19","Not yet recruiting","No Results Available","SARS-CoV 2","Drug: 200 mg EIDD-2801|Drug: Placebo","University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States","https://ClinicalTrials.gov/show/NCT04405570"
280,"Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection","Recruiting","No Results Available","SARS-CoV 2","Biological: Hyperimmune plasma|Drug: Standard of care for SARS-CoV-2 infection","Hospital U. Jerez de la Frontera, Jerez de la Frontera, Cádiz, Spain|Hospital U. Puerto Real, Puerto Real, Cádiz, Spain|Hospital Costa del Sol, Marbella, Málaga, Spain|Hospital U. Torrecárdenas, Almería, Spain|Hospital U. Puerta del Mar, Cádiz, Spain|Hospital U. Virgen de las Nieves, Granada, Spain|Hospital U. San Cecilio, Granada, Spain|Hospital Juan Ramón Jiménez, Huelva, Spain|Hospital Regional U. de Málaga, Málaga, Spain|Hospital U. Virgen de la Victoria, Málaga, Spain|Hospital Unversitario Virgen Macarena, Sevilla, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital U. Nuestra Señora de Valme, Sevilla, Spain|Hospital San Juan de Dios, Sevilla, Spain","https://ClinicalTrials.gov/show/NCT04366245"
281,"Efficacy of Tocilizumab on Patients With COVID-19","Not yet recruiting","No Results Available","SARS-CoV 2","Drug: Tocilizumab|Drug: Placebos","Massachusetts General Hospital, Boston, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT04356937"
282,"Impact of Zinc and Vitamin D3 Supplementation on the Survival of Aged Patients Infected With COVID-19","Not yet recruiting","No Results Available","SARS-CoV 2","Dietary Supplement: Zinc gluconate|Dietary Supplement: 25-OH cholecalciferol",,"https://ClinicalTrials.gov/show/NCT04351490"
283,"Observational Study of Follow-up of Hospitalized Patients Diagnosed With COVID-19 to Evaluate the Effectiveness of the Drug Treatment Used to Treat This Disease. COVID-19 Registry","Recruiting","No Results Available","SARS-CoV-2","Drug: Patients with the treatment agains COVID19","Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain","https://ClinicalTrials.gov/show/NCT04347278"
284,"Prevention of Coronavirus Disease (COVID-19) Outbreaks With Nitazoxanide","Recruiting","No Results Available","Coronavirus Infection","Drug: Nitazoxanide 500Mg Oral Tablet","Materno-Perinatal Hospital ""Mónica Pretelini"", Toluca, Mexico","https://ClinicalTrials.gov/show/NCT04406246"
285,"Observational Study in Diagnosed Patients COVID-19, Supported on an Outpatient Basis. (COVID-PSL)","Not yet recruiting","No Results Available","Coronavirus Infection",,"Yasmine Dudoit, Paris, France","https://ClinicalTrials.gov/show/NCT04402905"
286,"SINUS WASH Pilot Study in Adults Testing Positive for COVID-19","Recruiting","No Results Available","Coronavirus Infection","Drug: Povidone-Iodine|Drug: Normal saline","Hampshire Hospitals NHS Foundation Trust, Basingstoke, Hampshire, United Kingdom","https://ClinicalTrials.gov/show/NCT04393792"
287,"Serologic Testing of Household Contacts of Confirmed Cases of COVID-19","Recruiting","No Results Available","Coronavirus Infection",,"Hospital Universitario José E. Gonzalez, Monterrey, Nuevo Leon, Mexico","https://ClinicalTrials.gov/show/NCT04393142"
288,"Epidemiological Study of the Covid-19 Presto Test","Not yet recruiting","No Results Available","Coronavirus Infection","Diagnostic Test: Covid-19 presto test","Unité de Recherche PARADICT-O - Service de Médecine - Orléans Métropole, Orléans, France","https://ClinicalTrials.gov/show/NCT04387968"
289,"Efficacy and Tolerability of Hydroxychloroquine in Adult Patients With COVID-19","Recruiting","No Results Available","Coronavirus Infection","Drug: Hydroxychloroquine Sulfate 200 MG [Plaquenil]","Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan City, Taiwan","https://ClinicalTrials.gov/show/NCT04384380"
290,"C-reactive Protein Levels Among Individuals With COVID-19","Not yet recruiting","No Results Available","Coronavirus Infection","Diagnostic Test: C-reactive protein","The Parker Institute, Frederiksberg Hospital, Copenhagen, Denmark","https://ClinicalTrials.gov/show/NCT04373798"
291,"A Randomised Controlled Trial of Early Intervention in COVID-19: Favipiravir Verses HydroxycholorquiNe & Azithromycin & Zinc vErsEs Standard CaRe","Not yet recruiting","No Results Available","Coronavirus Infection","Drug: Favipiravir|Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Zinc Sulfate|Other: Standard of care management","Chelsea and Westminster Hospital, London, United Kingdom|West Middlesex University Hospital, London, United Kingdom","https://ClinicalTrials.gov/show/NCT04373733"
292,"Hungarian COVID-19 Epidemiological Research","Recruiting","No Results Available","Coronavirus Infection",,"Semmelweis University - Heart and Vascular Center, Budapest, Hungary|University of Debrecen, Debrecen, Hungary|University of Pecs, Pecs, Hungary|University of Szeged, Szeged, Hungary","https://ClinicalTrials.gov/show/NCT04370067"
293,"COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19","Recruiting","No Results Available","Coronavirus Infection","Drug: Colchicine|Drug: Usual Care","Maimonides Medical Center, Brooklyn, New York, United States","https://ClinicalTrials.gov/show/NCT04363437"
294,"Sequencing and Tracking of Phylogeny in COVID-19 Study","Recruiting","No Results Available","Coronavirus Infection",,"Portsmouth Hospitals NHS Trust, Queen Alexandra Hospital, Portsmouth, Hampshire, United Kingdom","https://ClinicalTrials.gov/show/NCT04359849"
295,"Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19","Recruiting","No Results Available","Coronavirus Infection","Other: No intervention","Brigham and Women's Hospital, Boston, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT04343898"
296,"Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19","Recruiting","No Results Available","Coronavirus Infection","Drug: Nitazoxanide 500 MG|Drug: Hydroxychloroquine","Materno-Perinatal Hospital ""Mónica Pretelini"", Toluca, Mexico","https://ClinicalTrials.gov/show/NCT04341493"
297,"Gerontological Telemonitoring of Older Adults Living in Nursing Homes With COVID-19 Disease","Not yet recruiting","No Results Available","Coronavirus Infection","Other: telehealth applications",,"https://ClinicalTrials.gov/show/NCT04337788"
298,"Hydroxychloroquine in Outpatient Adults With COVID-19","Suspended","No Results Available","Coronavirus Infection","Drug: Hydroxychloroquine SAR321068|Drug: Placebo","Investigational Site Number 8400001, Boston, Massachusetts, United States|Investigational Site Number 0561001, Bruxelles, Belgium|Investigational Site Number 0561002, Lodelinsart, Belgium|Investigational Site Number 2501001, Bordeaux Cedex, France|Investigational Site Number 2501002, Paris, France|Investigational Site Number 5281001, Groningen, Netherlands|Investigational Site Number 5281002, Harderwijk, Netherlands","https://ClinicalTrials.gov/show/NCT04333654"
299,"Clinical Evaluation of Cordio Application in Adult COVID-19 Virus Positive Patients","Not yet recruiting","No Results Available","Coronavirus Infection","Device: Cordio App",,"https://ClinicalTrials.gov/show/NCT04325048"
300,"sFlt1: a Biomarker of Organ Dysfunction in Critically-ill Patients With COVID-19?","Recruiting","No Results Available","CORONAVIRUS INFECTIONS","Other: measurement of circulating sFlt1 concentration","Chu Reims, Reims, France","https://ClinicalTrials.gov/show/NCT04394195"
301,"Survey of Satisfaction on Traditional Chinese Medicine Jing-Guan-Fang (JGF) for COVID-19 Prevention","Recruiting","No Results Available","Corona Virus Infection",,"Branch of Chinese Medicine, Taipei City Hospital, Taipei, Taiwan|Branch of Linsen Chinese Medicine and Kunming, Taipei City Hospital, Taipei, Taiwan|Taipei City Hospital, Taipei, Taiwan","https://ClinicalTrials.gov/show/NCT04388644"
302,"Demographics and Outcomes of COVID 19 in Pregnancy at a Community Based Hospital","Not yet recruiting","No Results Available","Corona Virus Infection","Other: COVID positive via testing",,"https://ClinicalTrials.gov/show/NCT04385914"
303,"Covid-19 Triage Using Camera-based AI","Not yet recruiting","No Results Available","Coronavirus Infections","Device: RIA-device (Remote Investigation and Assessment)","Östra Sjukhuset, Gothenburg, Sweden","https://ClinicalTrials.gov/show/NCT04383457"
304,"Haemoglobin Concentration on COVID-19","Recruiting","No Results Available","Corona Virus Infection","Other: File scanning","Konya Training and Research Hospital, Konya, Turkey","https://ClinicalTrials.gov/show/NCT04377607"
305,"Hydroxychloroquine to Prevent COVID-19 Disease Amongst Healthcare Workers","Not yet recruiting","No Results Available","Corona Virus Infection","Drug: Apo-Hydroxychloroquine|Drug: Matched Placebo","St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada","https://ClinicalTrials.gov/show/NCT04371523"
306,"Awake Prone Position in Hypoxemic Patients With Coronavirus Disease 19 (COVI-PRONE): A Randomized Clinical Trial","Not yet recruiting","No Results Available","Corona Virus Infection","Procedure: Awake Proning","St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada","https://ClinicalTrials.gov/show/NCT04350723"
307,"CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI)","Active, not recruiting","No Results Available","Corona Virus Infection","Drug: Tocilizumab","APHP- Hopital Tenon, Paris, France|APHP - Beaujon, Paris, France|APHP - Bichat, Paris, France|APHP - Hopital Necker, Paris, France|APHP - Pitié Salpêtrière, Paris, France|APHP - Saint Louis, Paris, France|CHU Strasbourg, Strasbourg, France|Institut Gustave Roussy, Villejuif, France","https://ClinicalTrials.gov/show/NCT04331808"
308,"Sarilumab COVID-19","Recruiting","No Results Available","Corona Virus Infection","Drug: Sarilumab SAR153191|Drug: Placebo","Investigational Site Number 0320001, Caba, Argentina|Investigational Site Number 1240001, Montreal, Canada|Investigational Site Number 1240005, Montreal, Canada|Investigational Site Number 1240004, Toronto, Canada|Investigational Site Number 1240002, Toronto, Canada|Investigational Site Number 1240003, Vancouver, Canada|Investigational Site Number 1520003, Santiago, Chile|Investigational Site Number 1520001, Talca, Chile|Investigational Site Number 2500001, Bordeaux Cedex, France|Investigational Site Number 2500007, Clamart, France|Investigational Site Number 2500006, La Roche Sur Yon Cedex 9, France|Investigational Site Number 2500002, Nantes, France|Investigational Site Number 2500005, Paris Cedex 18, France|Investigational Site Number 2500003, Strasbourg, France|Investigational Site Number 2500004, Suresnes, France|Investigational Site Number 2760003, Bonn, Germany|Investigational Site Number 2760006, Braunschweig, Germany|Investigational Site Number 2760002, Essen, Germany|Investigational Site Number 2760004, Köln, Germany|Investigational Site Number 2760001, Münster, Germany|Investigational Site Number 3760003, Ashdod, Israel|Investigational Site Number 3760002, Jerusalem, Israel|Investigational Site Number 3760001, Ramat Gan, Israel|Investigational Site Number 3800005, Milano, Italy|Investigational Site Number 3800001, Milano, Italy|Investigational Site Number 3800002, Milano, Italy|Investigational Site Number 3800003, Modena, Italy|Investigational Site Number 3800004, Parma, Italy|Investigational Site Number 3800006, Rozzano, Italy|Investigational Site Number 3920002, Fuchu-Shi, Japan|Investigational Site Number 3920003, Iruma-Gun, Japan|Investigational Site Number 3920001, Kamakura-Shi, Japan|Investigational Site Number 6430003, Moscow, Russian Federation|Investigational Site Number 6430002, Moscow, Russian Federation|Investigational Site Number 6430001, Moscow, Russian Federation|Investigational Site Number 7240003, Barcelona, Spain|Investigational Site Number 7240004, Barcelona, Spain|Investigational Site Number 7240002, Madrid, Spain|Investigational Site Number 7240005, Madrid, Spain|Investigational Site Number 7240001, Madrid, Spain","https://ClinicalTrials.gov/show/NCT04327388"
309,"Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI","Active, not recruiting","No Results Available","Corona Virus Infection","Drug: Sarilumab","Kremlin Bicetre hospital APHP, Le Kremlin-Bicêtre, Ile De France, France|Cochin Aphp, Paris, Ile De France, France|HEGP, Paris, Ile De France, France|NECKER Hospital, Paris, France","https://ClinicalTrials.gov/show/NCT04324073"
310,"Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients","Recruiting","No Results Available","Corona Virus Infection",,"Kremlin Bictre APHP, Le Kremlin-Bicêtre, Ile De France, France|Cochin Aphp, Paris, Ile De France, France|Hegp Aphp, Paris, Ile De France, France","https://ClinicalTrials.gov/show/NCT04324047"
311,"Study of Biomarkers in the Long-term Impact of Coronavirus Infection in the Cardiorespiratory System","Not yet recruiting","No Results Available","COVID19|Corona Virus Infection|Myocardial Injury|Pneumonia","Other: BIOMARKERS IN THE LONG TERM IMPACT OF CORONAVIRUS INFECTION IN THE CARDIORRESPIRATORY SYSTEM","Instituto do Coração - Hospital das Clínicas - Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil","https://ClinicalTrials.gov/show/NCT04353245"
312,"Acute Respiratory Failure and COVID-19 in Real Life","Recruiting","No Results Available","Coronavirus Infections|Respiratory Failure|Ventilator Lung","Other: standard operating procedures","Luigi Sacco University Hospital, Milan, Lombardia, Italy","https://ClinicalTrials.gov/show/NCT04307459"
313,"Dissemination of SARS-COV-2 (COVID-19) in the Environment of Infected Patients Admitted to Intensive Care Unit","Recruiting","No Results Available","Covid-19|Viral Infection",,"Service de réanimation Hôpital Avicenne, Bobigny, France|Service de réanimation Hôpital Bichat, Paris, France|Service de réanimation Hôpital Tenon, Paris, France","https://ClinicalTrials.gov/show/NCT04355481"
314,"Diagnostics of COVID-19/DARTS (Development and Assessment of Rapid Testing for SARS-CoV-2 Outbreak)","Not yet recruiting","No Results Available","COVID-19",,"St. Georges Hospital Foundation Trust, London, United Kingdom","https://ClinicalTrials.gov/show/NCT04351646"
315,"A Safety, Tolerability, Pharmacokinetics and Immunogenicity Trial of Co-administered MERS-CoV Antibodies REGN3048 and REGN3051","Completed","No Results Available","Corona Virus Infection","Other: Placebo|Biological: REGN3048|Biological: REGN3051","WCCT Global Cypress Clinical Pharmacology Unit, Cypress, California, United States","https://ClinicalTrials.gov/show/NCT03301090"
316,"French COVID Cohort","Recruiting","No Results Available","Coronavirus Infections",,"CHG Agen, Agen, France|Centre Hospitalier Du Pays D'aix, Aix-en-Provence, France|CHU Amiens, Amiens, France|CHU Angers, Angers, France|CH Annecy Genevois, Annecy, France|Hopital privé d'Antony, Antony, France|Hôpital de Mercy. CHR METZ-THIONVILLE, Ars-Laquenexy, France|Centre Hospitalier Henri Duffaut, Avignon, France|Chu Jean Minjoz, Besançon, France|Hôpital Avicenne AP-HP, Bobigny, France|CHU Pellegrin, Bordeaux, France|CHU Ambroise Paré, Boulogne-Billancourt, France|Ch Fleyriat, Bourg-en-Bresse, France|Chru Hopital Cavale Blanche, Brest, France|CHU Brest, Brest, France|Centre hospitalier de Béziers, Béziers, France|CH Cahors, Cahors, France|Chms Chambery Nh, Chambéry, France|Centre Hospitalier De Cholet, Cholet, France|CHU Gabriel Montpied, Clermont-Ferrand, France|CH Colmar - Hopital Pasteur, Colmar, France|Centre hospitalier Alpes Leman, Contamine-sur-Arve, France|Centre hospitalier Intercommunal de Créteil, Créteil, France|Hôpital Henri Mondor, Créteil, France|Centre Hospitalier Dax, Dax, France|CHU Dijon Bourgogne, Dijon, France|Hopital Raymond Poincare, Garches, France|CHU Grenoble, Grenoble, France|Grand Hopital de l'Est Francilien site Marne-la-Vallée, Jossigny, France|Chd Les Oudairies, La Roche-sur-Yon, France|Hôpital Universitaire Bicêtre, Le Kremlin-Bicêtre, France|Centre Hospitalier Emile Roux, Le Puy-en-Velay, France|Centre Hospitalier Universitaire de Lille, Lille, France|CHRU Lille, Hôpital Salengro, Lille, France|CHU de Lille, Lille, France|Hôpital de la Croix-Rousse, Lyon, France|Hôpital Louis Raffalli, Manosque, France|Assistance publique hopitaux de Marseille, hopital Nord, Marseille, France|Hôpital Conception, Marseille, France|Groupe Hospitalier Sud Ile De France, Melun, France|CH de Mont Marsan, Mont de Marsan, France|CHU Montpellier, Montpellier, France|CHU Nantes, Nantes, France|Hopital Américain de Paris, Neuilly-sur-Seine, France|CHU de Nice, Nice, France|CHU Caremeau, Nîmes, France|APHP Bichat, Paris, France|APHP Tenon, Paris, France|CH Lariboisière, Paris, France|Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, France|Hopital Cochin-CIC1417, Paris, France|Hopital Européen Georges Pompidou, Paris, France|Hopital Saint Antoine, Paris, France|Hopital Saint Louis, Paris, France|La pitié salpetrière, Paris, France|Centre Hospitalier de Pau, Pau, France|CH de Perpignan, Perpignan, France|CHU de Poitiers, Poitiers, France|Centre Hospitalier de Périgueux, Périgueux, France|Ch Cornouaille, Quimper, France|Chu Reims, Reims, France|Hôpital Pontchaillou, Rennes, France|CHU Rouen Normandie, Rouen, France|Hopital d'instruction des armées Begin 69, Saint-Mandé, France|Centre hospitalier Louis Constant Fleming, Saint-Martin, France|CHU de Saint-Etienne, Saint-Étienne, France|CH de Saintonge, Saintes, France|Centre Hospitalier de Soissons, Soissons, France|N.H.C. - Nouvel Hopital Civil, Strasbourg, France|Hopital Foch, Suresnes, France|CHR Metz-Thionville -Hopital Bel Air, Thionville, France|Hopitaux du Leman, Thonon-les-Bains, France|Centre Hospitalier Universitaire de Rangueil, Toulouse, France|CHU de Toulouse, Toulouse, France|CHU Toulouse IUCT Institut Universitaire de Cancer de Toulouse, Toulouse, France|Hôpital Gustave Dron, Tourcoing, France|Centre Hospitalier Régional Universitaire de Tours, Tours, France|CHRU de Tours, Tours, France|CHU Nancy, Vandœuvre-lès-Nancy, France|Centre Hospitalier Intercommunal, Villeneuve Saint Georges, France|CH Annecy Genevois, Épagny, France","https://ClinicalTrials.gov/show/NCT04262921"
317,"Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease","Recruiting","No Results Available","Severe Acute Respiratory Syndrome","Biological: Otilimab|Biological: Placebo|Drug: Standard of care","GSK Investigational Site, Saint Louis Park, Minnesota, United States|GSK Investigational Site, Saint Paul, Minnesota, United States|GSK Investigational Site, Charlotte, North Carolina, United States|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain","https://ClinicalTrials.gov/show/NCT04376684"
318,"Urinary Biomarkers for AKI Diagnosis in Patients With SARS-CoV-2 (COVID-19)","Recruiting","No Results Available","COVID-19|Renal Replacement Therapy|Acute Kidney Injury","Other: [TIMP-2]*[IGFBP-7]","Uhmontpellier, Montpellier, France","https://ClinicalTrials.gov/show/NCT04393428"
319,"Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19","Recruiting","No Results Available","COVID-19 Drug Treatment","Drug: IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care.","Centro de Educación Médica e Investigaciones Clínicas ""Norberto Quirno"" CEMIC, Buenos Aires, Ciudad De Buenos Aires, Argentina","https://ClinicalTrials.gov/show/NCT04381884"
320,"Seroprevalence of MERS-CoV IgG in Healthcare Workers","Completed","No Results Available","Coronavirus Infections",,"Ewha womans university mokdong hospital, Seoul, Korea, Republic of","https://ClinicalTrials.gov/show/NCT02497885"
321,"Investigational COVID-19 Convalescent Plasma Infusion for Severely or Life-threateningly Ill COVID-19 Patients","Available","No Results Available","COVID-19|SARS-CoV 2|SARS-CoV Infection","Biological: COVID-19 Convalescent Plasma","Rutgers New Jersey Medical School, Newark, New Jersey, United States|University Hospital, Newark, New Jersey, United States","https://ClinicalTrials.gov/show/NCT04420988"
322,"Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early","Recruiting","No Results Available","COVID-19|Virus Diseases|Corona Virus Infection","Drug: Clarithromycin","COVID-19 Department, General Hospital of Attica SISMANOGLEIO-AMALIA FLEMING, Marousi, Athens, Greece|2nd Department of Internal Medicine, General Hospital of Nikaia, Piraeus, Attica, Greece|2nd Department of Internal Medicine, University General Hospital of Alexandroupolis, Alexandroupolis, Greece|1st University Department of Internal Medicine, LAIKO General Hospital of Athens, Athens, Greece|2nd University Department of Internal Medicine, IPPOKRATEION General Hospital of Athens, Athens, Greece|3rd University Department of Internal Medicine, General Hospital of Chest Diseases of Athens I SOTIRIA, Athens, Greece|1st Department of Internal Medicine, General University Hospital of Ioannina, Ioánnina, Greece|2nd Department of Internal Medicine, General Hospital of Piraeus ""Tzaneio"", Piraeus, Greece|1st Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki, Thessaloníki, Greece","https://ClinicalTrials.gov/show/NCT04398004"
323,"Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19)","Recruiting","No Results Available","COVID-19","Biological: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Biological: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule|Biological: Two doses of placebo at the emergency vaccination schedule|Biological: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Biological: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule|Biological: Two doses of placebo at the routine vaccination schedule","Suining County Center for Disease Control and Prevention, Xuzhou, Jiangsu, China","https://ClinicalTrials.gov/show/NCT04352608"
324,"Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease","Not yet recruiting","No Results Available","COVID|Sars-CoV2|SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere","Drug: N-acetylcysteine",,"https://ClinicalTrials.gov/show/NCT04419025"
325,"Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19","Not yet recruiting","No Results Available","Covid-19|Corona Virus Infection|SARS-CoV 2","Drug: Oxytocin|Drug: Standard of Care","CNRS, Lyon, France|Azienda Ospedaliero Universitaria di Parma, Parma, PR, Italy|Ospedale San Francesco, Nuoro, Italy","https://ClinicalTrials.gov/show/NCT04386447"
326,"Human Ab Response & immunoMONItoring of COVID-19 Patients","Recruiting","No Results Available","SARS-CoV-2 Coronavirus|Acute Respiratory Distress Syndrome","Biological: Blood samples collection|Other: Saliva collection","CHU Rennes, Rennes, France","https://ClinicalTrials.gov/show/NCT04373200"
327,"The Safety & Efficacy of Imatinib for the Treatment of SARS-COV-2 Induced Pneumonia","Not yet recruiting","No Results Available","COVID-19","Drug: Imatinib Mesylate|Drug: Standard of Care",,"https://ClinicalTrials.gov/show/NCT04422678"
328,"Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial)","Recruiting","No Results Available","COVID-19|Severe Acute Respiratory Syndrome","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Instituto Nacional de Enfermedades Respiratorias, ""Ismael Cosío Villegas"", Mexico, City, Mexico","https://ClinicalTrials.gov/show/NCT04315896"
329,"Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial)","Not yet recruiting","No Results Available","Contact Person From COVID-19 Confirmed Patient","Drug: Hydroxychloroquine as post exposure prophylaxis|Other: Others(No intervention)",,"https://ClinicalTrials.gov/show/NCT04330144"
330,"COVID-19 Staff Testing of Antibody Responses Study (Co-Stars)","Recruiting","No Results Available","SARS-CoV-2 Infection","Other: Blood test|Other: Standardised questionnaires","Great Ormond Street Hospital, London, United Kingdom","https://ClinicalTrials.gov/show/NCT04380896"
331,"Asymptomatic COVID-19 Trial","Not yet recruiting","No Results Available","SARS-CoV-2 Infection","Drug: Hydroxychloroquine sulfate &Azithromycin|Drug: Placebo","Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States","https://ClinicalTrials.gov/show/NCT04374552"
332,"Vagus Nerve Stimulation ARDS Prevention Trial for COVID-19 Hospitalized Patients","Not yet recruiting","No Results Available","Severe Acute Respiratory Syndrome Coronavirus 2","Device: Transcutaneous Auricular Vagus Nerve Stimulation",,"https://ClinicalTrials.gov/show/NCT04379037"
333,"African Covid-19 Critical Care Outcomes Study","Not yet recruiting","No Results Available","Severe Acute Respiratory Syndrome Coronavirus 2",,,"https://ClinicalTrials.gov/show/NCT04367207"
334,"Surveillance of Individuals Following SARS-CoV-2 Exposure","Recruiting","No Results Available","COVID-19",,"National Institutes of Health Clinical Center, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT04383444"
335,"Adipose Mesenchymal Cells for Abatement of SARS-CoV-2 Respiratory Compromise in COVID-19 Disease","Not yet recruiting","No Results Available","Covid-19 Pneumonia|Cyotokine Storm","Biological: Autologous Adipose MSC's",,"https://ClinicalTrials.gov/show/NCT04352803"
336,"Incidence of Deep Vein Thrombosis at Doppler Echo in Covid-19 Patients With SARS-Cov-2 Pneumopathy Hospitalized in ICU","Not yet recruiting","No Results Available","Deep Vein Thrombosis","Other: Doppler Echo","Centre Hospitalier de Versailles, Le Chesnay, France","https://ClinicalTrials.gov/show/NCT04363528"
337,"Experimental Trial of rhIFNα Nasal Drops to Prevent 2019-nCOV in Medical Staff","Recruiting","No Results Available","2019 Novel Coronavirus Infection","Drug: recombinant human interferon Alpha-1b|Drug: thymosin alpha 1","Taihe Hospital, Shiyan, Hubei, China","https://ClinicalTrials.gov/show/NCT04320238"
338,"COVID-19 Related Health and Infection Control Practices Among Dentists","Recruiting","No Results Available","Severe Acute Respiratory Syndrome Coronavirus 2","Other: No intervention","American Dental Association, Chicago, Illinois, United States","https://ClinicalTrials.gov/show/NCT04423770"
339,"Transmissibility and Viral Load of SARS-CoV-2 in Oral Secretions","Recruiting","No Results Available","COVID-19",,"National Institutes of Health Clinical Center, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT04348240"
340,"COVID-19 in Patients With HIV","Recruiting","No Results Available","HIV/AIDS|COVID-19|SARS-CoV-2","Other: No intervention","University of Missouri-Columbia, Columbia, Missouri, United States","https://ClinicalTrials.gov/show/NCT04333953"
341,"Description of Respiratory Mechanics in Patients With SARS-CoV-2 Associated ARDS","Recruiting","No Results Available","Acute Respiratory Distress Syndrome|COVID","Other: PEEP trial","CHU, Angers, France","https://ClinicalTrials.gov/show/NCT04350710"
342,"Performance Evaluation of BCG Vaccination in Healthcare Personnel to Reduce the Severity of SARS-COV-2 Infection","Not yet recruiting","No Results Available","COVID-19","Biological: vaccine BCG|Other: Placebo","Program for Research and Control in Tropical Diseases - PECET, Medellín, Antioquia, Colombia","https://ClinicalTrials.gov/show/NCT04362124"
343,"Household Transmission Investigation Study for COVID-19 in French Guiana","Recruiting","No Results Available","Coronavirus Infections|Severe Acute Respiratory Syndrome|SARS-CoV Infection","Procedure: Human biological samples","Centre Hospitalier Andrée Rosemon, Cayenne, French Guiana|Institut Pasteur de la Guyane, Cayenne, French Guiana","https://ClinicalTrials.gov/show/NCT04328129"
344,"Assessment of Incidence of SARS-CoV-2 Infection and COVID-19 in Brazil (AVISA)","Not yet recruiting","No Results Available","COVID-19",,,"https://ClinicalTrials.gov/show/NCT04355338"
345,"COVID-19 Risk Stratification","Recruiting","No Results Available","Coronavirus|Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere",,"Brigham and Women's Hospital, Boston, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT04339387"
346,"Inhaled Ibuprofen to Treat COVID-19","Recruiting","No Results Available","Coronavirus Infection|Respiratory Disease|SARS (Disease)","Drug: Inhaled Hypertonic ibuprofen","Centro de Excelencia en Productos y Procesos Córdoba, Córdoba, Argentina","https://ClinicalTrials.gov/show/NCT04382768"
347,"Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial","Recruiting","No Results Available","Pneumonia, Viral|Covid-19","Drug: UNIKINON (Chloroquine phosphate) 200mg tablets","Divine Providence Hospital ""Pammakaristos"", Athens, Greece|Athens General Hospital ""Hippokrateio"", Athens, Greece|Athens General Hospital of Thoracic Diseases ""SOTIRIA"", 1st University Pulmonary Clinic, Athens, Greece|Athens General Hospital of Thoracic Diseases ""SOTIRIA"", 3rd University Pathology Clinic, Athens, Greece|Corfu General Hospital Agia Irini, Corfu, Greece|University General Hospital of Ioannina, Ioánnina, Greece|General Hospital of Athens ""Sismanoglio"", Maroúsi, Greece|University General Hospital of Thessaloniki AHEPA, Thessaloníki, Greece","https://ClinicalTrials.gov/show/NCT04344951"
348,"Humoral Immunity Against SARS-CoV-2 in Liver Transplanted Patients After COVID-19 in Comparison With Immunocompetent Patients","Recruiting","No Results Available","Liver Transplant Infection|Covid19|Mortality|Immune Response","Diagnostic Test: CLIA of IgG and IgM against SARS-Cov-2","Victor Fernandez Alonso, Madrid, Spain|Victor Fernández Alonso, Madrid, Spain","https://ClinicalTrials.gov/show/NCT04410471"
349,"Psychological Impact of the Corona Virus Pandemic in Individuals With Psychiatric Disorders","Recruiting","No Results Available","Corona Virus Infection|Psychiatric Disorder|Psychological Distress","Diagnostic Test: Online Survey","Medical University Graz, Department of Psychiatry and Psychotherapeutic Medicine, Graz, Styria, Austria","https://ClinicalTrials.gov/show/NCT04410835"
350,"Corticosteroids During Covid-19 Viral Pneumonia Related to SARS-Cov-2 Infection","Recruiting","No Results Available","Viral Pneumonia Human Coronavirus|COVID-19","Drug: Prednisone|Other: Control group","Hôpital Pneumologique et Cardiovasculaire Louis Pradel, Bron, France|Groupement Hospitalier Nord, Lyon, France|Groupement Hospitalier Nord, Lyon, France|Hôpital Edouard Herriot, Lyon, France|Hôpital St Joseph Saint Luc, Lyon, France|Hôpital St Joseph, Marseille, France|Centre hospitalier Lyon Sud, Pierre-Bénite, France|Centre hospitalier Lyon Sud, Pierre-Bénite, France|CHU St Etienne, Saint-Étienne, France|Clinique Charcot, Sainte-Foy-lès-Lyon, France|CHG Vienne, Vienne, France|Médipôle, Villeurbanne, France|Clinique des Portes du Sud, Vénissieux, France|CH Annecy-Genevois, Épagny, France","https://ClinicalTrials.gov/show/NCT04344288"
351,"Change in the Ratio of Mean Platelet Volume (MPV) to Platellet(PLT) in Covid-19 Pneumonia Patients","Recruiting","No Results Available","Coronavirus Infection","Other: observation of covid 19 pneumonia","Gaziosmanpaşa TREH, Istanbul, Gaziosmanpaşa, Turkey","https://ClinicalTrials.gov/show/NCT04408378"
352,"Inhaled Corticosteroid Treatment of COVID19 Patients With Pneumonia","Recruiting","No Results Available","Coronavirus Infection","Drug: Inhaled budesonide","Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital de Sabadell-Parc Tauli, Sabadell, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic of Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT04355637"
353,"Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.","Recruiting","No Results Available","Coronavirus Infection","Drug: Ruxolitinib plus simvastatin|Other: Standard of Care","Hospital Universitario Madrid Sanchinarro, Madrid, Spain","https://ClinicalTrials.gov/show/NCT04348695"
354,"Baricitinib for coRona Virus pnEumonia (COVID-19): a THerapeutic Trial","Not yet recruiting","No Results Available","Corona Virus Infection","Drug: Baricitinib",,"https://ClinicalTrials.gov/show/NCT04399798"
355,"Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia","Recruiting","No Results Available","Coronavirus Infections","Drug: Bevacizumab Injection","Renmin Hospital of Wuhan University, Wuhan, Hubei, China|Qilu Hospital of Shandong University, Jinan, Shandong, China|Moriggia-Pelascini Gravedona Hospital, Gravedona, Italy","https://ClinicalTrials.gov/show/NCT04275414"
356,"COPLA Study: Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma","Recruiting","No Results Available","COVID-19","Biological: Convalescent plasma","Centro de Hematología y Medicina Interna, Puebla, Mexico","https://ClinicalTrials.gov/show/NCT04357106"
357,"BromhexIne And Spironolactone For CoronаVirUs Infection Requiring HospiTalization","Recruiting","No Results Available","COVID 19","Drug: Bromhexine and Spironolactone|Drug: Base therapy","Lomonosov Moscow State University Medical Research and Educational Center, Moscow, Moscow Region, Russian Federation","https://ClinicalTrials.gov/show/NCT04424134"
358,"Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer","Completed","Has Results","Ovarian Cancer","Drug: Pimasertib once daily|Drug: Pimasertib placebo|Drug: SAR245409 placebo|Drug: SAR245409|Drug: Pimasertib twice daily","Research site, Augusta, Georgia, United States|Research site, Chicago, Illinois, United States|Research site, Indianapolis, Indiana, United States|Research site, Silver Spring, Maryland, United States|Research site, Boston, Massachusetts, United States|Research site, Boston, Massachusetts, United States|Research site, Ann Arbor, Michigan, United States|Research site, Detroit, Michigan, United States|Research site, Kansas City, Missouri, United States|Research site, Saint Louis, Missouri, United States|Research site, Kalispell, Montana, United States|Research site, New York, New York, United States|Research site, Cincinnati, Ohio, United States|Research site, Columbus, Ohio, United States|Research site, Middletown, Ohio, United States|Research site, Nashville, Tennessee, United States|Research site, Houston, Texas, United States|Research site, Northmead, New South Wales, Australia|Research site, Greenslopes, Queensland, Australia|Research site, Subiaco, Western Australia, Australia|Research site, Kortrijk, Belgium|Research site, Leuven, Belgium|Research site, Hamilton, Ontario, Canada|Research site, Toronto, Ontario, Canada|Research site, Montreal, Quebec, Canada|Research site, Montreal, Quebec, Canada|Research site, Quebec, Canada|Research site, Bordeaux Cedex, Gironde, France|Research site, Chorzow, Poland|Research site, Palma Mallorca, Baleares, Spain|Research site, Madrid, Spain|Research site, Madrid, Spain|Research site, Sevilla, Spain|Research site, Valencia, Spain","https://ClinicalTrials.gov/show/NCT01936363"
359,"Role of Ibuprofen and Other Medicines on Severity of Coronavirus Disease 2019","Not yet recruiting","No Results Available","Coronavirus Infection","Other: Questionnaire","HOPITAL PELLEGRIN, Service des maladies infectieuses et tropicales, Bordeaux, France|HOPITAL PELLEGRIN, service des maladies intensives et réanimation, Bordeaux, France|CHU de Dijon, Dijon, France|CHU de Grenoble, Grenoble, France|CHU de Limoges, Limoges, France|Hôpital St Louis, Paris, France|HEGP, Paris, France|Hôpital Robert Debré, Paris, France|CHU de Rouen, Rouen, France","https://ClinicalTrials.gov/show/NCT04383899"
360,"Treating COVID-19 With a Bidirectional Oxygenation Valve","Recruiting","No Results Available","Coronavirus Infection","Device: bidirectional oxygenation mouthpiece","TMC HealthCare, Tucson, Arizona, United States|Stanford University, Stanford, California, United States|Emory Saint Joseph's Hospital, Atlanta, Georgia, United States","https://ClinicalTrials.gov/show/NCT04326452"
361,"Rintatolimod and IFN Alpha-2b for the Treatment of Mild or Moderate COVID-19 Infection in Cancer Patients","Not yet recruiting","No Results Available","Malignant Neoplasm|SARS Coronavirus 2 Infection","Biological: Recombinant Interferon Alfa-2b|Drug: Rintatolimod","Roswell Park Cancer Institute, Buffalo, New York, United States","https://ClinicalTrials.gov/show/NCT04379518"
362,"Dose-ranging Study to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol in Adult and Adolescent Patients 12 Years and Older With Seasonal Allergic Rhinitis (SAR) (BY9010/M1-602)","Completed","No Results Available","Rhinitis, Allergic, Seasonal","Drug: Ciclesonide HFA|Drug: Placebo","Altana/Nycomed, Mission Viejo, California, United States|Altana/Nycomed, Orange, California, United States|Altana/Nycomed, San Diego, California, United States|Altana/Nycomed, Colorado Springs, Colorado, United States|Altana/Nycomed, Denver, Colorado, United States|Altana/Nycomed, Gainsville, Georgia, United States|Altana/Nycomed, Savannah, Georgia, United States|Altana/Nycomed, Stockbridge, Georgia, United States|Altana/Nycomed, Indianapolis, Indiana, United States|Altana/Nycomed, Overland Park, Kansas, United States|Altana/Nycomed, Bethesda, Maryland, United States|Altana/Nycomed, Minneapolis, Minnesota, United States|Altana/Nycomed, St. Louis, Missouri, United States|Altana/Nycomed, Lincoln, Nebraska, United States|Altana/Nycomed, Papillion, Nebraska, United States|Altana/Nycomed, Skillman, New Jersey, United States|Altana/Nycomed, West Brick, New Jersey, United States|Altana/Nycomed, Raleigh, North Carolina, United States|Altana/Nycomed, Ashland, Oregon, United States|Altana/Nycomed, Medford, Oregon, United States|Altana/Nycomed, Portland, Oregon, United States|Altana/Nycomed, Blue Bell, Pennsylvania, United States|Altana/Nycomed, Pittsburgh, Pennsylvania, United States|Altana/Nycomed, Upland, Pennsylvania, United States|Altana/Nycomed, Charleston, South Carolina, United States|Altana/Nycomed, Austin, Texas, United States|Altana/Nycomed, New Braunfels, Texas, United States|Altana/Nycomed, San Antonio, Texas, United States|Altana/Nycomed, Draper, Utah, United States|Altana/Nycomed, Burke, Virginia, United States|Altana/Nycomed, Richmond, Virginia, United States","https://ClinicalTrials.gov/show/NCT00807053"
363,"Escin in Patients With Covid-19 Infection","Recruiting","No Results Available","Coronavirus Infections","Drug: Escin|Drug: standard therapy","Luca Gallelli, Catanzaro, Italy","https://ClinicalTrials.gov/show/NCT04322344"
364,"Clinical Features of Suspected and Confirmed Patients of 2019 Novel Coronavirus Infection","Recruiting","No Results Available","Coronavirus","Other: Comprehensive treatment","The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China","https://ClinicalTrials.gov/show/NCT04279782"
365,"Factors Associated With Clinical Outcomes in Patients Hospitalized for Covid-19 in GHT-93 Est","Recruiting","No Results Available","COVID|SARS-CoV 2",,"Centre Hospitalier Intercommunal Robert Ballanger, Aulnay-sous-Bois, France|Groupe Hospitalier Pitie Salpetriere, Paris, France","https://ClinicalTrials.gov/show/NCT04366206"
366,"Clinical and Immunological Characterisation of COVID-19 in Children, Adolescents and Adults","Not yet recruiting","No Results Available","COVID-19|SARS-CoV-2","Other: this study is non- interventional","University Hospital Cologne, Cologne, NRW, Germany","https://ClinicalTrials.gov/show/NCT04341168"
367,"A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19","Recruiting","No Results Available","COVID-19|COVID19|Sars-CoV2|SARS-Cov-2","Drug: Hydroxychloroquine|Other: Placebo","Memorial Sloan - Kettering Cancer Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT04379492"
368,"Combination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome Coronavirus","Not yet recruiting","No Results Available","COVID-19","Drug: Drug: Isotretinoin plus Tamoxifen|Drug: Aerosolized Isotretinoin plus Tamoxifen",,"https://ClinicalTrials.gov/show/NCT04389580"
369,"Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers","Active, not recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Placebo of Hydroxychloroquine|Drug: Lopinavir and ritonavir|Drug: Placebo of LPV/r Tablets","CHU d'Angers, Angers, France|CHU de Bordeaux, Bordeaux, France|CHU de Clermont-Ferrand, Clermont-ferrand, France|CHU de Montpellier, Montpellier, France|CHU de Nancy, Nancy, France|CHU de Nantes, Nantes, France|AP-HP - Hôpital Bichat, Paris, France|CHU de Rennes, Rennes, France|CHU de Rouen, Rouen, France|CHU de Saint-Etienne, Saint-Étienne, France","https://ClinicalTrials.gov/show/NCT04328285"
370,"Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection","Not yet recruiting","No Results Available","2019-nCoV","Drug: ASC09/ritonavir group|Drug: lopinavir/ritonavir group",,"https://ClinicalTrials.gov/show/NCT04261907"
371,"Risk of Air Contamination During Visceral Surgery in COVID19 Patients","Not yet recruiting","No Results Available","Sars-CoV2|Surgery|COVID","Other: Cartography of air contamination, environment contamination and biological fluid by Sars-Cov2 during visceral surgery in COVID19 patients.",,"https://ClinicalTrials.gov/show/NCT04395599"
372,"Niclosamide for Mild to Moderate COVID-19","Not yet recruiting","No Results Available","COVID (SARS-CoV-2)","Drug: Niclosamide|Drug: Placebo|Other: Telehealth monitoring",,"https://ClinicalTrials.gov/show/NCT04399356"
373,"Assessment of Obstetric, Fetal and Neonatal Risks and Vertical SARS-CoV-2 Transmission During COVID-19 Pandemic","Recruiting","No Results Available","Pregnancy","Diagnostic Test: COVID 19 diagnostic test by PCR","University Hospital of Toulouse, Toulouse, France","https://ClinicalTrials.gov/show/NCT04360811"
374,"Radiation Eliminates Storming Cytokines and Unchecked Edema as a 1-Day Treatment for COVID-19","Recruiting","No Results Available","Pneumonia|Coronavirus Infection in 2019 (COVID-19)|Severe Acute Respiratory Syndrome (SARS) Pneumonia","Radiation: Low Dose Radiation Therapy","Emory University Hospital Midtown/Winship Cancer Institute, Atlanta, Georgia, United States","https://ClinicalTrials.gov/show/NCT04366791"
375,"Point Of Care UltraSonography for Risk-stratification of COVID-19 Patients","Not yet recruiting","No Results Available","COVID|Coronavirus Infection","Procedure: Follow-up at 14 days",,"https://ClinicalTrials.gov/show/NCT04338100"
376,"Management by Hyperbaric Oxygen Therapy of Patients With Hypoxaemic Pneumonia With SARS-CoV-2 (COVID-19)","Recruiting","No Results Available","Covid-19","Combination Product: Hyperbaric oxygen treatment (HBOT) i.e. inhalation of pressurized oxygen delivered by a hyperbaric chamber (drug/device)","Sainte Anne Military Teaching Hospital, Toulon, France","https://ClinicalTrials.gov/show/NCT04344431"
377,"Technical Development of Cardiovascular Magnetic Resonance Imaging (CMR) Using a Low Specific Absorption Rate (SAR) Scanner System","Recruiting","No Results Available","CAD","Device: MRI scan x 1 Healthy Volunteer|Device: MRI scan x 2 Healthy Volunteer|Device: MRI scan x 2 - CAD patients|Device: MRI scan x 2- non CAD patients","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT03331380"
378,"Pharmacokinetics of SAR441236","Active, not recruiting","No Results Available","HIV-1-infection","Biological: SAR441236|Biological: Placebo|Drug: Antiretroviral treatment","Alabama CRS, Birmingham, Alabama, United States|UCLA CARE Center CRS, Los Angeles, California, United States|UCSD Antiviral Research Center CRS, San Diego, California, United States|Ucsf Hiv/Aids Crs, San Francisco, California, United States|Harbor-UCLA CRS, Torrance, California, United States|University of Colorado Hospital CRS, Aurora, Colorado, United States|The Ponce de Leon Center CRS, Atlanta, Georgia, United States|Northwestern University CRS, Chicago, Illinois, United States|Rush University CRS, Chicago, Illinois, United States|Massachusetts General Hospital CRS (MGH CRS), Boston, Massachusetts, United States|Brigham and Women's Hospital Therapeutics Clinical Research Site (BWH TCRS) CRS, Boston, Massachusetts, United States|Washington University Therapeutics (WT) CRS, Saint Louis, Missouri, United States|New Jersey Medical School Clinical Research Center CRS, Newark, New Jersey, United States|Weill Cornell Chelsea CRS, New York, New York, United States|Columbia P&S CRS, New York, New York, United States|Weill Cornell Uptown CRS, New York, New York, United States|University of Rochester Adult HIV Therapeutic Strategies Network CRS, Rochester, New York, United States|Chapel Hill CRS, Chapel Hill, North Carolina, United States|Cincinnati Clinical Research Site, Cincinnati, Ohio, United States|Case Clinical Research Site, Cleveland, Ohio, United States|Ohio State University CRS, Columbus, Ohio, United States|Penn Therapeutics, CRS, Philadelphia, Pennsylvania, United States|University of Pittsburgh CRS, Pittsburgh, Pennsylvania, United States|The Miriam Hospital Clinical Research Site (TMH CRS) CRS, Providence, Rhode Island, United States|Vanderbilt Therapeutics (VT) CRS, Nashville, Tennessee, United States|University of Washington AIDS CRS, Seattle, Washington, United States|Puerto Rico AIDS Clinical Trials Unit CRS, San Juan, Puerto Rico","https://ClinicalTrials.gov/show/NCT03705169"
379,"Baricitinib Compared to Standard Therapy in Patients With COVID-19","Not yet recruiting","No Results Available","Covid-19|SARS-CoV 2|SARS Pneumonia","Drug: Baricitinib Oral Tablet","Azienda Ospedaliero Universitaria Pisana, Pisa, Italy","https://ClinicalTrials.gov/show/NCT04393051"
380,"PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds","Recruiting","No Results Available","Sars-CoV2|Symptomatic Condition|Covid-19","Drug: Hydroxychloroquine Sulfate Regular dose|Drug: Hydroxychloroquine Sulfate Loading Dose|Drug: Chloroquine|Drug: Placebo","Expo Covid Isolation Center / Mayo Hospital Field Hospital, Lahore, Punjab, Pakistan|Mayo Hospital / King Edward Medical University, Lahore, Punjab, Pakistan|Pakistan Kidney and Liver Institute, Lahore, Punjab, Pakistan|Services Hospital, Lahore, Punjab, Pakistan","https://ClinicalTrials.gov/show/NCT04351191"
381,"EVALUATION OF THE EFFICACY OF THE HYDROXYCHLOROQUINE-AZITHROMYCIN COMBINATION IN THE IN THE PREVENTION OF COVID-19 RELATED SDRA","Withdrawn","No Results Available","Sars-CoV-2, Community-Acquired Pneumonia,COVID-19","Drug: Hydroxychloroquine and azithromycin treatment arm.|Drug: Hydroxychloroquine|Drug: Control arm",,"https://ClinicalTrials.gov/show/NCT04347512"
382,"Understanding COVID-19","Recruiting","No Results Available","SARS-CoV-2 Viral Kinetics and Host Immune Responses","Other: NA (no intervention)","University Hospitals of Geneva, Geneva, Switzerland","https://ClinicalTrials.gov/show/NCT04329546"
383,"Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation","Recruiting","No Results Available","COVID-19|Hypoxia","Drug: L-ascorbic acid","Hunter Holmes Mcguire Veteran Affairs Medical Center, Richmond, Virginia, United States","https://ClinicalTrials.gov/show/NCT04357782"
384,"Clinical, Biological and Histological Pulmonary and Renal Damage Associated With the SARS-CoV-2 Syndrome in Patients Admitted in ICU","Recruiting","No Results Available","Acute Respiratory Distress Syndrome",,"Service Reanimation Medicale, Strasbourg, France","https://ClinicalTrials.gov/show/NCT04385004"
385,"Cardiac Imaging in SARS-CoV-2 (COVID-19)","Recruiting","No Results Available","COVID",,"Royal Alexandra Hospital, Paisley, Renfrewshire, United Kingdom|Royal Infirmary, Glasgow, United Kingdom|Queen Elizabeth University Hospital, Glasgow, United Kingdom","https://ClinicalTrials.gov/show/NCT04403607"
386,"PLACE OF VENOVENOUS ECMO IN THE MANAGEMENT OF SEVERE REFRACTORY ARDS ASSOCIATED WITH SARS-COV-2","Recruiting","No Results Available","Respiratory Distress Syndrome",,"Service de Chirurgie Thoracique Nouvel Hôpital Civil Hôpitaux Universitaires de Strasbourg, Strasbourg, France","https://ClinicalTrials.gov/show/NCT04343404"
387,"Immunity Against SARS-CoV2 in Children and Their Parents / COVID-19","Not yet recruiting","No Results Available","COVID-19 Infection","Biological: serology test|Diagnostic Test: NG Biotech|Biological: nasopharyngeal swab|Biological: rectal swab|Biological: saliva sample","Hôpital necker Enfants-Malades, ¨Paris, France","https://ClinicalTrials.gov/show/NCT04355533"
388,"Use of PCR-Sars-CoV-2 in Children","Not yet recruiting","No Results Available","Covid-19",,"ACTIV network, Créteil, France|PARI network, Créteil, France","https://ClinicalTrials.gov/show/NCT04412317"
389,"Antibody Response Against SARS-CoV-2 in Dialysis Patients During COVID-19","Recruiting","No Results Available","COVID|Terminal Renal Insufficiency",,"Godstrup Hospital, Herning, Denmark","https://ClinicalTrials.gov/show/NCT04367714"
390,"Convalescent Plasma for the Treatment of Patients With COVID-19","Available","No Results Available","COVID-19|SARS-CoV 2","Biological: COVID-19 Convalescent Plasma","Children's Hospital Colorado, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|UCHealth Memorial Hospital North, Colorado Springs, Colorado, United States|Denver Health Medical Center, Denver, Colorado, United States|UCHealth Poudre Valley Hospital, Fort Collins, Colorado, United States|UCHealth Highlands Ranch Hospital, Highlands Ranch, Colorado, United States","https://ClinicalTrials.gov/show/NCT04372368"
391,"Role of Inflammasomes in COVID-19 Disease","Recruiting","No Results Available","COVID-19 by SARS-CoV-2 Infection","Other: COVID-19 patients","Ch Cannes, Réanimation, Cannes, Alpes Maritimes, France|CHU de nice, Nice, Alpes-Maritimes, France","https://ClinicalTrials.gov/show/NCT04385017"
392,"Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Chronic Haemodialysis Patients","Recruiting","No Results Available","COVID-19 by SARS-CoV-2 Infection","Other: blood sample","CHU de nice, Nice, Alpes-Maritimes, France","https://ClinicalTrials.gov/show/NCT04371510"
393,"The Interaction Between Severe Acute Respiratory Distress Syndrome Viral Proteins and Monocytes","Withdrawn","No Results Available","Severe Acute Respiratory Syndrome","Procedure: blood sampling","Li-Chieh Wang, MD, Taipei, Taiwan, China","https://ClinicalTrials.gov/show/NCT00172263"
394,"LUNG FIBROTIC CHANGES ASSOCIATED WITH SARS-CoV-2 INFECTION","Recruiting","No Results Available","Pulmonary Fibrosis",,"Pulmonary Department. Hospital Clinico., Valencia, Spain","https://ClinicalTrials.gov/show/NCT04409275"
395,"Tannin Specific Natural Extract for COVID-19 Infection","Not yet recruiting","No Results Available","COVID-19|SARS-CoV 2|Coronavirus Infection","Dietary Supplement: ARBOX|Other: PLACEBO",,"https://ClinicalTrials.gov/show/NCT04403646"
396,"Describing Chinese Herbal Medicine Telehealth Care for Symptoms Related to Infectious Diseases Such as COVID-19","Recruiting","No Results Available","Coronavirus Infection","Dietary Supplement: Chinese Herbal Medicine","Seattle Intstitute of East Asian Medicine, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT04380870"
397,"COVID-19 - Multicenter Study on Nosocomial Transmission of SARS-CoV-2 Virus","Recruiting","No Results Available","Infection Viral","Other: nosocomial infection/hospital acquired infection","Service Hygiène, Epidémiologie et Prévention, Lyon, France|Service Hygiène, Epidémiologie et Prévention, Lyon, France","https://ClinicalTrials.gov/show/NCT04290780"
398,"Effects of DPP4 Inhibition on COVID-19","Not yet recruiting","No Results Available","Coronavirus Infection|Type 2 Diabetes","Drug: Linagliptin|Drug: Insulin regimen","University of Miami, Miami, Florida, United States","https://ClinicalTrials.gov/show/NCT04341935"
399,"ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection","Enrolling by invitation","No Results Available","Coronavirus Infection","Drug: Tradipitant|Drug: Placebo","Lenox Hill Hospital Northwell Health, New York, New York, United States","https://ClinicalTrials.gov/show/NCT04326426"
400,"Active Monitoring And Determinants of Incidence Infection of COVDI-19","Recruiting","No Results Available","Coronavirus Infection",,"Hospital Universitario de la Princesa, Madrid, Spain","https://ClinicalTrials.gov/show/NCT04326400"
401,"Does Hydroxychloroquine Before & During Patient Exposure Protect Healthcare Workers From Coronavirus?","Enrolling by invitation","No Results Available","Pre-Exposure Prophylaxis|Coronavirus|SARS-CoV 2","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","University Health Network, Toronto, Ontario, Canada","https://ClinicalTrials.gov/show/NCT04374942"
402,"Home Usability Study of the SARS-CoV-2 (COVID-19) Test","Active, not recruiting","No Results Available","COVID-19","Diagnostic Test: SARS-CoV-2","Exact Sciences, Madison, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT04395391"
403,"Ozone Therapy in the Prevention of COVID-19 Infection","Completed","No Results Available","Corona Virus Infection",,"Kardelen Gencer Atalay, Istanbul, Turkey","https://ClinicalTrials.gov/show/NCT04400006"
404,"CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection","Not yet recruiting","No Results Available","Corona Virus Infection","Drug: Anakinra",,"https://ClinicalTrials.gov/show/NCT04341584"
405,"Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection","Recruiting","No Results Available","Corona Virus Infection","Drug: NORS (Nitric Oxide Releasing Solution)","BC Diabetes, Vancouver, British Columbia, Canada","https://ClinicalTrials.gov/show/NCT04337918"
406,"Mapping Organ Health Following COVID-19 Disease Due to SARS-CoV-2 Infection","Recruiting","No Results Available","COVID-19","Diagnostic Test: Outpatient MRI","Mayo Clinic Healthcare, London, United Kingdom|Gemini, Oxford, United Kingdom","https://ClinicalTrials.gov/show/NCT04369807"
407,"Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease","Recruiting","No Results Available","Increased Risk of SARS-CoV-2 Infection","Drug: Bromhexine Hydrochloride","Almazov National Medical Research Centre, Saint Petersburg, Russian Federation","https://ClinicalTrials.gov/show/NCT04405999"
408,"Innovative Tool to Limit Spread of SARS-CoV-2 in Residential Aged Care Facilities","Not yet recruiting","No Results Available","COVID|Influenza|Gastroenteritis","Behavioral: Gamification|Behavioral: Newsfeed function",,"https://ClinicalTrials.gov/show/NCT04377165"
409,"PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19)","Not yet recruiting","No Results Available","COVID-19","Drug: Povidone-Iodine 2%|Drug: Povidone-Iodine 0.5%|Drug: Isotonic saline 0.9%","Stanford Health Care, Stanford, California, United States","https://ClinicalTrials.gov/show/NCT04347954"
410,"Cohort of Patients Infected With SARS-CoV2 (COVID-19) or Suspected of Being","Recruiting","No Results Available","COVID-19","Other: blood samples","GH Pitié-Salpêtrière / Service d'Accueil des Urgences, Paris, Ile-de-France, France","https://ClinicalTrials.gov/show/NCT04352348"
411,"Observational Prospective Cohort Study - Registry of Patients With Hematologic Disease and COVID-19 in Russia","Not yet recruiting","No Results Available","Coronavirus Infection and Hematologic Diseases","Other: Non-interventional study","National Research Center for Hematology, Moscow, Russian Federation","https://ClinicalTrials.gov/show/NCT04422470"
412,"Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients","Recruiting","No Results Available","Cancer & COVID 19","Drug: Hydroxychloroquine|Drug: Azithromycin","Gustave Roussy, Villejuif, Val De Marne, France","https://ClinicalTrials.gov/show/NCT04341207"
413,"Resilience Evaluation of Caregivers During the SARS-CoV2 Epidemic Period : Prospective Cohort.","Recruiting","No Results Available","Psychological","Other: Questionnaire","CHU, Angers, France","https://ClinicalTrials.gov/show/NCT04349163"
414,"Assessment of Endothelial and Haemostatic Changes During Severe SARS-CoV-2 Infection","Recruiting","No Results Available","Covid-19|Endothelial Dysfunction|Thrombosis|Critically Ill",,"Rouen University Hospital, Rouen, France","https://ClinicalTrials.gov/show/NCT04357847"
415,"A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SAR438544 in Comparison to Glucagon in Type 1 Diabetes Mellitus Patients Under Induced Hypoglycemia","Withdrawn","No Results Available","Type 1 Diabetes Mellitus","Drug: SAR438544|Drug: r-glucagon|Drug: insulin",,"https://ClinicalTrials.gov/show/NCT02635243"
416,"Clinical and Immunologic Impact of Perinatal SARS-CoV-2 (COVID-19) Infection","Not yet recruiting","No Results Available","Covid19|Pregnancy Related|Neonatal Infection",,,"https://ClinicalTrials.gov/show/NCT04362956"
417,"RT-PCR on Conjunctival Sample for the Detection of SARS-CoV-2 in Patients With Covid-19","Recruiting","No Results Available","Covid 19 , Conjunctivitus","Diagnostic Test: conjunctival RT PCR","Centre Hospitalier de versailles, Le Chesnay, France","https://ClinicalTrials.gov/show/NCT04397666"
418,"Study of Clinical and Immune Severity Profiles of Patients Infected With SARS-Cov2 (COVID-19)","Recruiting","No Results Available","Respiratory Tract Infections|Respiratory Tract Disease",,"Percy Military Teaching Hospital, Clamart, France|Bégin Military Teaching Hospital, Saint-Mandé, France","https://ClinicalTrials.gov/show/NCT04365166"
419,"SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients","Active, not recruiting","No Results Available","Plasma Cell Myeloma","Drug: Isatuximab SAR650984|Drug: Pomalidomide|Drug: Dexamethasone","Investigational Site Number 840001, Scottsdale, Arizona, United States|Investigational Site Number 840006, Duarte, California, United States|Investigational Site Number 840018, New Haven, Connecticut, United States|Investigational Site Number 840011, Decatur, Illinois, United States|Investigational Site Number 840004, Boston, Massachusetts, United States|Investigational Site Number 840104, Boston, Massachusetts, United States|Investigational Site Number 840010, Chapel Hill, North Carolina, United States|Investigational Site Number 840003, Charlotte, North Carolina, United States|Investigational Site Number 840014, Canton, Ohio, United States|Investigational Site Number 840016, Charleston, South Carolina, United States|Investigational Site Number 840015, Salt Lake City, Utah, United States|Investigational Site Number 840005, Seattle, Washington, United States|Investigational Site Number 840017, Milwaukee, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT02283775"
420,"A Study of SAR428926 in Patients With Advanced Solid Tumors","Completed","No Results Available","Neoplasm Malignant","Drug: SAR428926","Investigational Site Number 2080001, København Ø, Denmark|Investigational Site Number 2500001, Villejuif Cedex, France|Investigational Site Number 7240001, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT02575781"
421,"EMPOWER - BAME vs COVID","Not yet recruiting","No Results Available","COVID-19, SARS-CoV 2 Infection|Health Disparities",,"Future Genetics Limited, Birmingham, West Midlands, United Kingdom","https://ClinicalTrials.gov/show/NCT04399733"
422,"Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis","Completed","No Results Available","Relapsing Multiple Sclerosis","Drug: SAR442168|Drug: Placebo|Drug: Locally approved intravenous contrast medium for contrast enhanced MRI","Investigational Site Number 8400005, Cullman, Alabama, United States|Investigational Site Number 8400002, Maitland, Florida, United States|Investigational Site Number 8400004, Sunrise, Florida, United States|Investigational Site Number 8400009, Tampa, Florida, United States|Investigational Site Number 8400007, Savannah, Georgia, United States|Investigational Site Number 8400001, Northbrook, Illinois, United States|Investigational Site Number 8400008, Dayton, Ohio, United States|Investigational Site Number 8400006, Westerville, Ohio, United States|Investigational Site Number 8400003, Knoxville, Tennessee, United States|Investigational Site Number 1240002, Gatineau, Canada|Investigational Site Number 1240001, Greenfield Park, Canada|Investigational Site Number 1240003, Vancouver, Canada|Investigational Site Number 2030007, Brno, Czechia|Investigational Site Number 2030004, Hradec Kralove, Czechia|Investigational Site Number 2030003, Jihlava, Czechia|Investigational Site Number 2030005, Ostrava - Poruba, Czechia|Investigational Site Number 2030006, Pardubice, Czechia|Investigational Site Number 2030001, Praha 2, Czechia|Investigational Site Number 2030002, Praha 5 - Motol, Czechia|Investigational Site Number 2330001, Tallinn, Estonia|Investigational Site Number 2500004, Nancy Cedex, France|Investigational Site Number 2500001, Nantes Cedex 1, France|Investigational Site Number 2500002, Strasbourg Cedex, France|Investigational Site Number 2500003, Toulouse Cedex 9, France|Investigational Site Number 5280001, Amsterdam, Netherlands|Investigational Site Number 5280002, Sittard-Geleen, Netherlands|Investigational Site Number 6430006, Kazan, Russian Federation|Investigational Site Number 6430003, Moscow, Russian Federation|Investigational Site Number 6430002, Moscow, Russian Federation|Investigational Site Number 6430001, Saint-Petersburg, Russian Federation|Investigational Site Number 6430005, St-Petersburg, Russian Federation|Investigational Site Number 6430004, St-Petersburg, Russian Federation|Investigational Site Number 6430007, Tyumen, Russian Federation|Investigational Site Number 7030001, Bratislava, Slovakia|Investigational Site Number 7030002, Martin, Slovakia|Investigational Site Number 7240006, Barakaldo, Spain|Investigational Site Number 7240002, Barcelona, Spain|Investigational Site Number 7240001, Madrid, Spain|Investigational Site Number 7240004, Murcia, Spain|Investigational Site Number 7240005, Salt, Spain|Investigational Site Number 7240003, Sevilla, Spain|Investigational Site Number 8040002, Chernivtsi, Ukraine|Investigational Site Number 8040005, Dnipro, Ukraine|Investigational Site Number 8040001, Lviv, Ukraine|Investigational Site Number 8040006, Lviv, Ukraine|Investigational Site Number 8040009, Odesa, Ukraine|Investigational Site Number 8040003, Vinnytsya, Ukraine|Investigational Site Number 8040007, Zhytomyr, Ukraine","https://ClinicalTrials.gov/show/NCT03889639"
423,"SAR3419 in Acute Lymphoblastic Leukemia","Terminated","No Results Available","Acute Lymphocytic Leukaemia","Drug: SAR3419","Investigational Site Number 840006, Denver, Colorado, United States|Investigational Site Number 840003, Nashville, Tennessee, United States|Investigational Site Number 840001, Houston, Texas, United States|Investigational Site Number 840002, San Antonio, Texas, United States|Investigational Site Number 840004, Milwaukee, Wisconsin, United States|Investigational Site Number 250006, Amiens, France|Investigational Site Number 250001, Paris Cedex 10, France|Investigational Site Number 250002, Pessac, France|Investigational Site Number 250008, Pierre Benite, France|Investigational Site Number 250004, Rennes, France|Investigational Site Number 250005, Strasbourg, France","https://ClinicalTrials.gov/show/NCT01440179"
424,"Influenza Vaccination, ACEI and ARB in the Evolution of SARS-Covid19 Infection","Recruiting","No Results Available","COVID19|Influenza Vaccination|ACE Inhibitors|ARB","Drug: ACE inhibitor|Drug: ARB","Hospital de Terrassa, Terrassa, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT04367883"
425,"Safety Study of SAR442720 in Combination With Pembrolizumab in Patients With Advanced Malignancies","Not yet recruiting","No Results Available","Metastatic Neoplasm","Drug: SAR442720|Drug: Pembrolizumab",,"https://ClinicalTrials.gov/show/NCT04418661"
426,"Development of Interstitial Lung Disease (ILD) in Patients With Severe SARS-CoV-2 Infection (COVID-19)","Recruiting","No Results Available","Covid-19|Pulmonary Fibrosis","Diagnostic Test: Pulmonary function tests|Diagnostic Test: Imaging|Biological: Blood sampling","Medical University of Innsbruck, Innsbruck, Austria","https://ClinicalTrials.gov/show/NCT04416100"
427,"Trial Evaluating Efficacy and Safety of Nivolumab (Optivo®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort.","Not yet recruiting","No Results Available","COVID19- Infection With SARS-CoV-2 Virus","Drug: Nivolumab Injection","Pneumologie hôpital Tenon, Paris, France","https://ClinicalTrials.gov/show/NCT04343144"
428,"Performance Evaluation of RealDetect™ COVID-19 RT-PCR Kit for the Detection of SARS-CoV-2 Virus","Recruiting","No Results Available","High Sensitivity and Specificity (With 95% Confidence Interval) of RealDetect™ COVID-19 RT-PCR Kit","Device: performance evaluation study of RealDetect RT-PCR Kit for COVID-19 detection","Institute of Epidemiology, Disease Control and Research (IEDCR), Mohakhali, Dhaka (For sample collection & sample storage), Institute for Developing Science & Health Initiatives (ideSHi); Mohakhali, Dhaka (For sample analysis, data collection, data analys, Dhaka, Bangladesh","https://ClinicalTrials.gov/show/NCT04403672"
429,"Brain MRI Imaging in Patients With SARS-Cov2 (COVID-19) Infection With or Without Anosmia","Not yet recruiting","No Results Available","Covid-19|Anosmia","Other: Brain MRI scan","CHU de Nimes, Nîmes, France","https://ClinicalTrials.gov/show/NCT04408391"
430,"Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia","Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Lopinavir / Ritonavir Pill|Drug: Azithromycin|Other: Standard treatment","Hospital Universitario de Neiva, Neiva, Huila, Colombia|Clínica Reina Sofía, Bogotá, Colombia|Fundacion Cardio Infantil, Bogotá, Colombia|Hospital Universitario San Ignacio, Bogotá, Colombia|Clinica Universitaria Colombia, Bogotá, Colombia|Hospital Universitario Nacional de Colombia, Bogotá, Colombia","https://ClinicalTrials.gov/show/NCT04359095"
431,"Study of SAR339375 in Patients With Alport Syndrome","Recruiting","No Results Available","Alport's Syndrome","Drug: Lademirsen (SAR339375)|Drug: Placebo","Investigational Site Number 8400001, Cleveland, Ohio, United States|Investigational Site Number 0360003, Herston, Australia|Investigational Site Number 0360001, Parkville, Australia|Investigational Site Number 8260002, Nottingham, United Kingdom","https://ClinicalTrials.gov/show/NCT02855268"
432,"Early Risk Stratification of Patient Hospitalized for SARS-CoV2 Infection: Critical COVID-19 France CCF","Completed","No Results Available","Infection Viral|Infection, Hospital|COVID",,"CHU d'Amiens, Amiens, France|CHU Annecy, Annecy, France|CHU de Bordeaux, Bordeaux, France|CHU de Caen, Caen, France|Cotentin hospital, Cherbourg, France|CHU Dijon, Dijon, France|Elbeuf Louviers Val de Reuil, Elbeuf, France|CHU de Fréjus / Saint-Raphael, Fréjus, France|Lille Catholic Institute Hospital Group, Lille, Lille, France|CHU de Lyon, Lyon, France|APHM, Marseille, France|Jacques Cartier Private Hospital, Massy, Massy, France|CHR d'Orléans, Orléans, France|Bichat (APHP), Paris, France|Georges Pompidou European Hospital (AP-HP), Paris, France|Institut Mutualiste Montsouris, Paris, Paris, France|CHU de Reims, Reims, France|CHU de Rouen, Rouen, France|CHU Saint Etienne, Saint-Étienne, France|CHU de Strasbourg, Strasbourg, France|CHU de Toulouse, Toulouse, France|Saint Gatien hospital, Tours, France|CHU de Nancy, Vandœuvre-lès-Nancy, France","https://ClinicalTrials.gov/show/NCT04344327"
433,"Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors","Recruiting","No Results Available","Neoplasm Malignant","Biological: SAR408701|Drug: dexamethasone|Drug: naphazoline|Drug: diphenhydramine","Investigational Site Number 3920003, Kashiwa-Shi, Japan|Investigational Site Number 3920002, Nagoya-Shi, Japan|Investigational Site Number 3920001, Sunto-Gun, Japan","https://ClinicalTrials.gov/show/NCT03324113"
434,"Study of the Vascular Compartment and Hypercoagulability During Coronavirus Infection COVID-19","Completed","No Results Available","COVID-19","Procedure: blood sampling","Rouen University Hospital, Rouen, France","https://ClinicalTrials.gov/show/NCT04367662"
435,"Convalescent Plasma to Limit Coronavirus Associated Complications","Withdrawn","No Results Available","Coronavirus","Biological: Convalescent Plasma",,"https://ClinicalTrials.gov/show/NCT04325672"
436,"Evaluation of SAR408701 in Patients With Advanced Solid Tumors","Active, not recruiting","No Results Available","Neoplasm Malignant","Drug: SAR408701","Investigational Site Number 840006, Bakersfield, California, United States|Investigational Site Number 840003, Santa Monica, California, United States|Investigational Site Number 840002, New Haven, Connecticut, United States|Investigational Site Number 840105, Boston, Massachusetts, United States|Investigational Site Number 840005, Boston, Massachusetts, United States|Investigational Site Number 840001, Hackensack, New Jersey, United States|Investigational Site Number 840004, Milwaukee, Wisconsin, United States|Investigational Site Number 124001, Toronto, Canada|Investigational Site Number 250003, Bordeaux Cedex, France|Investigational Site Number 250006, Dijon, France|Investigational Site Number 250004, Marseille Cedex 5, France|Investigational Site Number 250007, Rennes, France|Investigational Site Number 250005, Saint Mande, France|Investigational Site Number 250002, Toulouse Cedex 9, France|Investigational Site Number 250001, Villejuif Cedex, France|Investigational Site Number 410002, Seoul, Korea, Republic of|Investigational Site Number 410005, Seoul, Korea, Republic of|Investigational Site Number 410003, Seoul, Korea, Republic of|Investigational Site Number 410004, Seoul, Korea, Republic of|Investigational Site Number 410001, Seoul, Korea, Republic of|Investigational Site Number 724001, Barcelona, Spain|Investigational Site Number 724007, Madrid, Spain|Investigational Site Number 724004, Madrid, Spain|Investigational Site Number 724006, Madrid, Spain|Investigational Site Number 724003, Madrid, Spain|Investigational Site Number 724002, Majadahonda, Spain","https://ClinicalTrials.gov/show/NCT02187848"
437,"Long Term Safety and Efficacy Study of SAR442168 in Participants With Relapsing Multiple Sclerosis","Recruiting","No Results Available","Relapsing Multiple Sclerosis","Drug: SAR442168","Investigational Site Number 8400005, Cullman, Alabama, United States|Investigational Site Number 8400002, Maitland, Florida, United States|Investigational Site Number 8400009, Tampa, Florida, United States|Investigational Site Number 8400007, Savannah, Georgia, United States|Investigational Site Number 8400001, Northbrook, Illinois, United States|Investigational Site Number 8400008, Dayton, Ohio, United States|Investigational Site Number 8400006, Westerville, Ohio, United States|Investigational Site Number 8400003, Knoxville, Tennessee, United States|Investigational Site Number 1240001, Greenfield Park, Canada|Investigational Site Number 1240003, Vancouver, Canada|Investigational Site Number 2030007, Brno, Czechia|Investigational Site Number 2030004, Hradec Kralove, Czechia|Investigational Site Number 2030003, Jihlava, Czechia|Investigational Site Number 2030005, Ostrava - Poruba, Czechia|Investigational Site Number 2030006, Pardubice, Czechia|Investigational Site Number 2030001, Praha 2, Czechia|Investigational Site Number 2030002, Praha 5 - Motol, Czechia|Investigational Site Number 2330001, Tallinn, Estonia|Investigational Site Number 2500004, Nancy Cedex, France|Investigational Site Number 5280001, Amsterdam, Netherlands|Investigational Site Number 6430006, Kazan, Russian Federation|Investigational Site Number 6430003, Moscow, Russian Federation|Investigational Site Number 6430001, Saint-Petersburg, Russian Federation|Investigational Site Number 6430005, St-Petersburg, Russian Federation|Investigational Site Number 6430007, Tyumen, Russian Federation|Investigational Site Number 7240002, Barcelona, Spain|Investigational Site Number 7240001, Madrid, Spain|Investigational Site Number 7240004, Murcia, Spain|Investigational Site Number 7240005, Salt, Spain|Investigational Site Number 7240003, Sevilla, Spain|Investigational Site Number 8040002, Chernivtsi, Ukraine|Investigational Site Number 8040005, Dnipro, Ukraine|Investigational Site Number 8040001, Lviv, Ukraine|Investigational Site Number 8040006, Lviv, Ukraine|Investigational Site Number 8040009, Odesa, Ukraine|Investigational Site Number 8040003, Vinnytsya, Ukraine|Investigational Site Number 8040007, Zhytomyr, Ukraine","https://ClinicalTrials.gov/show/NCT03996291"
438,"Evaluation of the Fluid Response of SARS-CoV-2 (COVID-19) Patients in Intensive Care; Pleth Variability Index","Not yet recruiting","No Results Available","Pleth Variability Index","Diagnostic Test: Pleth variability index","Erzincan University, Erzincan, Turkey","https://ClinicalTrials.gov/show/NCT04373213"
439,"SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients","Recruiting","No Results Available","Non-small Cell Lung Cancer Metastatic","Drug: SAR408701|Drug: Docetaxel","Investigational Site Number 8400007, Bakersfield, California, United States|Investigational Site Number 8400004, Tinley Park, Illinois, United States|Investigational Site Number 8400003, Nashville, Tennessee, United States|Investigational Site Number 8400013, The Woodlands, Texas, United States|Investigational Site Number 0320004, Buenos Aires, Argentina|Investigational Site Number 0320009, Caba, Argentina|Investigational Site Number 0320005, Rosario, Argentina|Investigational Site Number 0320002, Salta, Argentina|Investigational Site Number 0360002, Blacktown, Australia|Investigational Site Number 0360003, Waratah, Australia|Investigational Site Number 0360001, Woolloongabba, Australia|Investigational Site Number 0560005, Brugge, Belgium|Investigational Site Number 0560002, Bruxelles, Belgium|Investigational Site Number 0560001, Leuven, Belgium|Investigational Site Number 0560003, Liège, Belgium|Investigational Site Number 1240003, Greenfield Park, Canada|Investigational Site Number 1240004, Montreal, Canada|Investigational Site Number 1520007, Santiago, Chile|Investigational Site Number 1520002, Santiago, Chile|Investigational Site Number 1520005, Temuco, Chile|Investigational Site Number 1520001, Viña Del Mar, Chile|Investigational Site Number 3480002, Budapest, Hungary|Investigational Site Number 3480003, Budapest, Hungary|Investigational Site Number 3480008, Farkasgyepü, Hungary|Investigational Site Number 3920011, Bunkyo-Ku, Japan|Investigational Site Number 3920012, Fukuoka-Shi, Japan|Investigational Site Number 3920017, Himeji-Shi, Japan|Investigational Site Number 3920001, Hirakata-Shi, Japan|Investigational Site Number 3920008, Kurume-Shi, Japan|Investigational Site Number 3920002, Nagoya-Shi, Japan|Investigational Site Number 3920015, Nagoya-Shi, Japan|Investigational Site Number 3920009, Natori-Shi, Japan|Investigational Site Number 3920013, Osaka Sayama-Shi, Japan|Investigational Site Number 3920003, Osaka-Shi, Japan|Investigational Site Number 3920014, Sakai-Shi, Japan|Investigational Site Number 3920016, Sapporo-Shi, Japan|Investigational Site Number 3920004, Sunto-Gun, Japan|Investigational Site Number 3920010, Ube-Shi, Japan|Investigational Site Number 3920007, Wakayama-Shi, Japan|Investigational Site Number 3920005, Yokohama-Shi, Japan|Investigational Site Number 4100006, Seoul, Korea, Republic of|Investigational Site Number 4100007, Seoul, Korea, Republic of|Investigational Site Number 4100003, Seoul, Korea, Republic of|Investigational Site Number 4100001, Seoul, Korea, Republic of|Investigational Site Number 4100004, Seoul, Korea, Republic of|Investigational Site Number 6160001, Warsaw, Poland|Investigational Site Number 6430001, Moscow, Russian Federation|Investigational Site Number 6430003, Saint -Petersburg, Russian Federation|Investigational Site Number 7920008, Adana, Turkey|Investigational Site Number 7920002, Adana, Turkey|Investigational Site Number 7920004, Ankara, Turkey|Investigational Site Number 7920003, Edirne, Turkey|Investigational Site Number 7920005, Istanbul, Turkey|Investigational Site Number 7920001, Istanbul, Turkey|Investigational Site Number 7920006, Istanbul, Turkey|Investigational Site Number 7920007, Izmir, Turkey|Investigational Site Number 7920009, Malatya, Turkey","https://ClinicalTrials.gov/show/NCT04154956"
440,"Evaluation of Ganovo （Danoprevir ） Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection","Completed","No Results Available","COVID-19","Drug: Ganovo+ritonavir+/-Interferon nebulization","The Ninth Hospital of Nanchang, Nanchang, Jiangxi, China","https://ClinicalTrials.gov/show/NCT04291729"
441,"SAR408701 in Combination With Ramucirumab in Pre-treated Patients With Non Squamous Non-small Cell Lung Cancer (NSQ NSCLC)","Not yet recruiting","No Results Available","Non-small Cell Lung Cancer Metastatic","Drug: SAR408701|Drug: ramucirumab",,"https://ClinicalTrials.gov/show/NCT04394624"
442,"SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients","Active, not recruiting","No Results Available","Plasma Cell Myeloma","Drug: isatuximab SAR650984|Drug: lenalidomide|Drug: dexamethasone","Investigational Site Number 840004, San Francisco, California, United States|Investigational Site Number 840001, Tampa, Florida, United States|Investigational Site Number 840002, Saint Louis, Missouri, United States|Investigational Site Number 840005, New York, New York, United States|Investigational Site Number 840003, Columbus, Ohio, United States","https://ClinicalTrials.gov/show/NCT01749969"
443,"Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection","Completed","No Results Available","COVID-19","Drug: Danoprevir+Ritonavir","Huoshenshan Hostipal, Wuhan, Hubei, China","https://ClinicalTrials.gov/show/NCT04345276"
444,"Development of a Molecular Diagnostic Strategy for SARS-CoV2 Based on Saliva in the Context of the COVID-19 Pandemic","Recruiting","No Results Available","COVID|RT-ddPCR Multiplex","Diagnostic Test: Saliva collection","Rouen University Hospital, Rouen, France","https://ClinicalTrials.gov/show/NCT04367545"
445,"Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19","Recruiting","No Results Available","COVID-19","Biological: Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Biological: Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule|Biological: Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Biological: Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule|Biological: High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule|Biological: High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule|Biological: Placebo on a 0- and 28-day schedule|Biological: Placebo on a 0- and 14-day schedule","West China Second University Hospital, Sichuan University / West China women's and children's Hospital, Chengdu, Sichuan, China","https://ClinicalTrials.gov/show/NCT04412538"
446,"Phase 1 Safety Testing of SAR405838","Completed","No Results Available","Neoplasm Malignant","Drug: SAR405838","Investigational Site Number 840101, Boston, Massachusetts, United States|Investigational Site Number 840001, Boston, Massachusetts, United States|Investigational Site Number 840002, New York, New York, United States|Investigational Site Number 250001, Villejuif, France|Investigational Site Number 528001, Amsterdam, Netherlands|Investigational Site Number 528003, Rotterdam, Netherlands|Investigational Site Number 528002, Utrecht, Netherlands","https://ClinicalTrials.gov/show/NCT01636479"
447,"Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy","Recruiting","No Results Available","Pregnancy Related|COVID|Covid-19","Drug: Hydroxychloroquine|Drug: Placebo","Hospital Sant Creu i Sant Pau, Barcelona, Catalunya, Spain|Hospital Clínic Maternity, Barcelona, Catalunya, Spain|University hospital of Torrejón, Madrid, Spain|HM Puerta del Sur, Madrid, Spain","https://ClinicalTrials.gov/show/NCT04410562"
448,"Effect of Hydroxychloroquine in COVID-19 Positive Pregnant Women","Not yet recruiting","No Results Available","COVID-19|SARS-CoV-2|Pregnant Women|Hydroxychloroquine","Drug: hydroxychloroquine sulfate 200 MG|Drug: Placebo oral tablet",,"https://ClinicalTrials.gov/show/NCT04354441"
449,"A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infection","Recruiting","No Results Available","Novel Coronavirus Pneumonia|Pneumonia|Pirfenidone","Drug: pirfenidone","Tongji hospital affiliated to huazhong university of science and technology, Wuhan, Hubei, China","https://ClinicalTrials.gov/show/NCT04282902"
450,"Study of Excretion Balance and Pharmacokinetics of [14C]-SAR442168 in Healthy Male Subjects","Completed","No Results Available","Multiple Sclerosis","Drug: SAR442168","Investigational Site Number 8260001, Nottingham, United Kingdom","https://ClinicalTrials.gov/show/NCT04171310"
451,"Safety Assessment of SAR341402 and NovoLog® Used in Continuous Subcutaneous Insulin Infusion for Type 1 Diabetes Mellitus Patients","Completed","No Results Available","Type 1 Diabetes Mellitus","Drug: Insulin aspart SAR341402|Drug: Insulin aspart","Investigational Site Number 8400001, Little Rock, Arkansas, United States|Investigational Site Number 8400002, Denver, Colorado, United States|Investigational Site Number 8400003, West Des Moines, Iowa, United States","https://ClinicalTrials.gov/show/NCT03436498"
452,"Effect of SAR302503 on ECG Activity in Patients With Solid Tumors","Completed","No Results Available","Neoplasm Malignant","Drug: SAR302503 (TG101348)|Drug: Placebo SAR302503|Drug: Panolosetron","Investigational Site Number 840003, Los Angeles, California, United States|Investigational Site Number 840007, Augusta, Georgia, United States|Investigational Site Number 840002, Detroit, Michigan, United States|Investigational Site Number 840001, St Louis, Missouri, United States|Investigational Site Number 840004, Cincinnati, Ohio, United States|Investigational Site Number 840005, Philadelphia, Pennsylvania, United States|Investigational Site Number 840006, San Antonio, Texas, United States|Investigational Site Number 840008, San Antonio, Texas, United States|Investigational Site Number 056001, Bruxelles, Belgium|Investigational Site Number 056002, Gent, Belgium","https://ClinicalTrials.gov/show/NCT01836705"
453,"Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis","Completed","No Results Available","Systemic Sclerosis","Drug: SAR156597 (ACT14604)|Drug: Placebo","Investigational Site Number 8400006, San Francisco, California, United States|Investigational Site Number 8400005, Washington, District of Columbia, United States|Investigational Site Number 8400002, Cleveland, Ohio, United States|Investigational Site Number 8400007, Houston, Texas, United States|Investigational Site Number 0320003, Buenos Aires, Argentina|Investigational Site Number 0320002, Caba, Argentina|Investigational Site Number 0320005, Capital Federal, Argentina|Investigational Site Number 0320001, San Miguel De Tucuman, Argentina|Investigational Site Number 0560001, Gent, Belgium|Investigational Site Number 0560002, Leuven, Belgium|Investigational Site Number 2330001, Tallinn, Estonia|Investigational Site Number 2500003, Montpellier, France|Investigational Site Number 2500004, Paris Cedex 14, France|Investigational Site Number 2500002, Strasbourg Cedex, France|Investigational Site Number 2760003, Bad Nauheim, Germany|Investigational Site Number 2760001, Berlin, Germany|Investigational Site Number 2760002, Köln, Germany|Investigational Site Number 2760004, Ulm, Germany|Investigational Site Number 3800004, Genova, Italy|Investigational Site Number 3800001, Milano, Italy|Investigational Site Number 3800005, Milano, Italy|Investigational Site Number 3800006, Orbassano, Italy|Investigational Site Number 4840001, Chihuahua, Mexico|Investigational Site Number 4840005, Guadalajara, Mexico|Investigational Site Number 4840002, Guadalajara, Mexico|Investigational Site Number 4840003, Monterrey, Mexico|Investigational Site Number 6160001, Poznan, Poland|Investigational Site Number 6160002, Warszawa, Poland|Investigational Site Number 6160003, Wroclaw, Poland|Investigational Site Number 6420003, Bucharest, Romania|Investigational Site Number 6420004, Bucharest, Romania|Investigational Site Number 6420005, Bucuresti, Romania|Investigational Site Number 6420001, Cluj Napoca, Romania|Investigational Site Number 6420002, Targu Mures, Romania|Investigational Site Number 6430002, Kemerovo, Russian Federation|Investigational Site Number 6430005, Moscow, Russian Federation|Investigational Site Number 6430001, Moscow, Russian Federation|Investigational Site Number 6430004, Moscow, Russian Federation|Investigational Site Number 6430003, Ufa, Russian Federation|Investigational Site Number 8040001, Kyiv, Ukraine|Investigational Site Number 8040002, Kyiv, Ukraine|Investigational Site Number 8040004, Kyiv, Ukraine|Investigational Site Number 8040003, Kyiv, Ukraine|Investigational Site Number 8260001, London, United Kingdom","https://ClinicalTrials.gov/show/NCT02921971"
454,"Facilitating AcceLerated Clinical Validation Of Novel Diagnostics for COVID-19 (FALCON-C19)","Not yet recruiting","No Results Available","Coronavirus Infection|COVID-19","Diagnostic Test: Point-of-care test for SARS-CoV-2",,"https://ClinicalTrials.gov/show/NCT04408170"
455,"A Study to Assess the Feasibility of Screening for SARS-CoV-2 Among Healthy Workers","Recruiting","No Results Available","COVID-19","Procedure: Blood sampling|Procedure: Throat swab","Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, NRW, Germany","https://ClinicalTrials.gov/show/NCT04405466"
456,"First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL","Not yet recruiting","No Results Available","Neoplasm Malignant","Drug: SAR442257|Drug: Acetaminophen or equivalent (premedication)|Drug: Ranitidine or equivalent (premedication)|Drug: Diphenhydramine or equivalent (premedication)|Drug: Montelukast (premedication)|Drug: Dexamethasone (premedication)",,"https://ClinicalTrials.gov/show/NCT04401020"
457,"Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease","Not yet recruiting","No Results Available","SARS-Cov-2|COVID-19","Drug: Angiotensin Receptor Blockers","Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|Canterbury Hospital, Campsie, New South Wales, Australia|Concord Hospital, Concord, New South Wales, Australia|Royal North Shore Hospital, St Leonards, New South Wales, Australia","https://ClinicalTrials.gov/show/NCT04394117"
458,"Safety And Efficacy Of Hydroxychloroquine For At Risk Population (SHARP) Against COVID-19","Not yet recruiting","No Results Available","Coronavirus Infection|Hydroxychloroquine Adverse Reaction","Drug: Hydroxychloroquine Sulfate 200 milligram (mg) Tab",,"https://ClinicalTrials.gov/show/NCT04342156"
459,"Hospital Registry of Acute Myocarditis: Evolution of the Proportion of Positive SARS-COV-2 (COVID19) Cases","Recruiting","No Results Available","Acute Myocarditis","Diagnostic Test: Performing routine care (clinical and paraclinical tests)|Diagnostic Test: Examinations for the research:","CHU de TOULOUSE, Toulouse, France","https://ClinicalTrials.gov/show/NCT04375748"
460,"Study of the Increase in ICU Beds Capacity During COVID-19 Pandemic in France","Recruiting","No Results Available","Coronavirus Infections|COVID19 Outbreak in France",,"CHU de Nîmes, Hôpital Universitaire Carémeau, Nimes, France","https://ClinicalTrials.gov/show/NCT04420286"
461,"Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor SAR442168","Not yet recruiting","No Results Available","Relapsing Multiple Sclerosis","Drug: SAR442168|Drug: Teriflunomide HMR1726|Drug: Placebo to match SAR442168|Drug: Placebo to match Teriflunomide",,"https://ClinicalTrials.gov/show/NCT04410991"
462,"Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor SAR442168","Not yet recruiting","No Results Available","Relapsing Multiple Sclerosis","Drug: SAR442168|Drug: Teriflunomide HMR1726|Drug: Placebo to match SAR442168|Drug: Placebo to match Teriflunomide",,"https://ClinicalTrials.gov/show/NCT04410978"
463,"COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir","Recruiting","No Results Available","Coronavirus Infections|Post-exposure Prophylaxis","Drug: Lopinavir/ritonavir","St. Paul's Hospital, Vancouver, British Columbia, Canada|Sunnybrook Hospital, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada","https://ClinicalTrials.gov/show/NCT04321174"
464,"Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland","Recruiting","No Results Available","Prevention of COVID-19","Drug: Hydroxychloroquine Sulfate 200 MG [Plaquenil]|Drug: Lopinavir/ritonavir","Universitätsspital Basel and SwissTPH, Basel, Switzerland|Hôpitaux Universitaires de Genève, Geneva, Switzerland","https://ClinicalTrials.gov/show/NCT04364022"
465,"Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine","Active, not recruiting","No Results Available","Type 1 Diabetes Mellitus","Drug: Insulin Aspart SAR341402|Drug: Insulin Aspart|Drug: Insulin glargine U100","Investigational Site Number 8400014, Concord, California, United States|Investigational Site Number 8400001, Temecula, California, United States|Investigational Site Number 8400015, Ventura, California, United States|Investigational Site Number 8400010, Aurora, Colorado, United States|Investigational Site Number 8400029, Waterbury, Connecticut, United States|Investigational Site Number 8400038, Doral, Florida, United States|Investigational Site Number 8400030, Miami, Florida, United States|Investigational Site Number 8400032, New Port Richey, Florida, United States|Investigational Site Number 8400026, Ocoee, Florida, United States|Investigational Site Number 8400033, Palm Harbor, Florida, United States|Investigational Site Number 8400012, Atlanta, Georgia, United States|Investigational Site Number 8400005, Columbus, Georgia, United States|Investigational Site Number 8400009, Roswell, Georgia, United States|Investigational Site Number 8400019, Crystal Lake, Illinois, United States|Investigational Site Number 8400028, Des Moines, Iowa, United States|Investigational Site Number 8400018, Lexington, Kentucky, United States|Investigational Site Number 8400023, Baltimore, Maryland, United States|Investigational Site Number 8400003, Rockville, Maryland, United States|Investigational Site Number 8400013, Waltham, Massachusetts, United States|Investigational Site Number 8400004, Flint, Michigan, United States|Investigational Site Number 8400021, Kansas City, Missouri, United States|Investigational Site Number 8400031, Washington, Missouri, United States|Investigational Site Number 8400036, Omaha, Nebraska, United States|Investigational Site Number 8400017, Las Vegas, Nevada, United States|Investigational Site Number 8400007, New York, New York, United States|Investigational Site Number 8400006, Morehead City, North Carolina, United States|Investigational Site Number 8400035, Rocky Mount, North Carolina, United States|Investigational Site Number 8400034, Jefferson City, Tennessee, United States|Investigational Site Number 8400040, Dallas, Texas, United States|Investigational Site Number 8400042, El Paso, Texas, United States|Investigational Site Number 8400027, Houston, Texas, United States|Investigational Site Number 8400016, Mesquite, Texas, United States|Investigational Site Number 8400041, Waco, Texas, United States","https://ClinicalTrials.gov/show/NCT03874715"
466,"SeroCOVIDial Study: Assessment of SARS-COV2 Seroconversion in Patients on Chronic Hemodialysis Patients and in Their Caregivers, a Cohort Study","Recruiting","No Results Available","Chronic Hemodialysis Patients|Caregivers of Chronic Hemodialysis Patients","Biological: Blood sample|Biological: Serum tube collection","Assistance Publique Hôpitaux de Marseille, Marseille, Paca, France","https://ClinicalTrials.gov/show/NCT04420338"
467,"SAR240550 in Combination With Gemcitabine/Cisplatin in Non-small Cell Lung Cancer","Completed","No Results Available","Non-small Cell Lung Cancer Stage IV","Drug: Iniparib|Drug: gemcitabine|Drug: cisplatin","Sanofi-Aventis Investigational Site Number 250002, Caen Cedex, France|Sanofi-Aventis Investigational Site Number 250003, Marseille Cedex 09, France|Sanofi-Aventis Investigational Site Number 250004, Toulouse, France|Sanofi-Aventis Investigational Site Number 250001, Villejuif, France|Sanofi-Aventis Investigational Site Number 276003, Essen, Germany|Sanofi-Aventis Investigational Site Number 276002, Gauting, Germany|Sanofi-Aventis Investigational Site Number 276001, Großhansdorf, Germany|Sanofi-Aventis Investigational Site Number 380003, Livorno, Italy|Sanofi-Aventis Investigational Site Number 380001, Orbassano, Italy|Sanofi-Aventis Investigational Site Number 380002, Rozzano, Italy|Sanofi-Aventis Investigational Site Number 724001, Badalona, Spain|Sanofi-Aventis Investigational Site Number 724002, Barcelona, Spain|Sanofi-Aventis Investigational Site Number 826001, Newcastle Upon Tyne, United Kingdom|Sanofi-Aventis Investigational Site Number 826002, Wolverhampton, United Kingdom","https://ClinicalTrials.gov/show/NCT01086254"
468,"A Safety and Efficacy Study of SAR405838 and Pimasertib in Cancer Patients","Completed","No Results Available","Neoplasm Malignant","Drug: SAR405838|Drug: Pimasertib","Investigational Site Number 250001, Villejuif Cedex, France|Investigational Site Number 528001, Amsterdam, Netherlands|Investigational Site Number 528003, Rotterdam, Netherlands|Investigational Site Number 528002, Utrecht, Netherlands","https://ClinicalTrials.gov/show/NCT01985191"
469,"A Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection","Recruiting","No Results Available","COVID-19","Biological: anti-SARS-CoV-2 convalescent plasma","Froedtert Hospital, Milwaukee, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT04354831"
470,"Losartan for Patients With COVID-19 Requiring Hospitalization","Recruiting","No Results Available","Corona Virus Infection|Acute Respiratory Distress Syndrome|SARS-CoV Infection","Drug: Losartan|Other: Placebo","University of Florida Gainesviile, Gainesville, Florida, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States","https://ClinicalTrials.gov/show/NCT04312009"
471,"Losartan for Patients With COVID-19 Not Requiring Hospitalization","Recruiting","No Results Available","Corona Virus Infection|Acute Respiratory Distress Syndrome|SARS-CoV Infection","Drug: Losartan|Other: Placebo","Hennepin County Medical Center, Minneapolis, Minnesota, United States|M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic Health System, Rochester, Minnesota, United States","https://ClinicalTrials.gov/show/NCT04311177"
472,"The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2","Recruiting","No Results Available","COVID-19","Drug: PUL-042 Inhalation Solution|Drug: Placebo","Ascension St. John, Tulsa, Oklahoma, United States","https://ClinicalTrials.gov/show/NCT04313023"
473,"COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.","Recruiting","No Results Available","COVID-19","Biological: COVID-19 Convalescent Plasma","Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT04397757"
474,"Extra Vascular Lung Water and Pulmonary Permeability in Critically Ill Patients With SARS-CoV-2 (COVID-19)","Recruiting","No Results Available","COVID-19|Pneumonia|Acute Respiratory Distress Syndrome",,"Uhmontpellier, Montpellier, France","https://ClinicalTrials.gov/show/NCT04376905"
475,"Analysis of Volatile Organic Compounds by Electronic Noses in Hospitalised Patients for an Infection by SARS-CoV-2 (COVID-19)","Recruiting","No Results Available","COVID-19","Device: Volatile Organic Compounds analysis","Hôpital Foch, Suresnes, France","https://ClinicalTrials.gov/show/NCT04379154"
476,"Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine","Completed","Has Results","Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus","Drug: Insulin aspart|Drug: Novolog/Novorapid|Drug: Insulin glargine (HOE901)","Investigational Site Number 8400040, Little Rock, Arkansas, United States|Investigational Site Number 8400012, Concord, California, United States|Investigational Site Number 8400002, Escondido, California, United States|Investigational Site Number 8400030, Fresno, California, United States|Investigational Site Number 8400004, Greenbrae, California, United States|Investigational Site Number 8400014, La Jolla, California, United States|Investigational Site Number 8400043, Los Angeles, California, United States|Investigational Site Number 8400036, Pomona, California, United States|Investigational Site Number 8400011, Santa Barbara, California, United States|Investigational Site Number 8400013, Ventura, California, United States|Investigational Site Number 8400037, Aurora, Colorado, United States|Investigational Site Number 8400018, Englewood, Colorado, United States|Investigational Site Number 8400031, New Port Richey, Florida, United States|Investigational Site Number 8400027, Ocoee, Florida, United States|Investigational Site Number 8400007, Atlanta, Georgia, United States|Investigational Site Number 8400022, Columbus, Georgia, United States|Investigational Site Number 8400032, Roswell, Georgia, United States|Investigational Site Number 8400038, Arlington Heights, Illinois, United States|Investigational Site Number 8400005, Des Moines, Iowa, United States|Investigational Site Number 8400041, Metairie, Louisiana, United States|Investigational Site Number 8400015, Rockville, Maryland, United States|Investigational Site Number 8400042, Waltham, Massachusetts, United States|Investigational Site Number 8400019, Flint, Michigan, United States|Investigational Site Number 8400003, Omaha, Nebraska, United States|Investigational Site Number 8400024, Henderson, Nevada, United States|Investigational Site Number 8400028, New York, New York, United States|Investigational Site Number 8400025, Morehead City, North Carolina, United States|Investigational Site Number 8400010, Wilmington, North Carolina, United States|Investigational Site Number 8400023, Fargo, North Dakota, United States|Investigational Site Number 8400029, Bend, Oregon, United States|Investigational Site Number 8400033, Chattanooga, Tennessee, United States|Investigational Site Number 8400044, Austin, Texas, United States|Investigational Site Number 8400009, Dallas, Texas, United States|Investigational Site Number 8400035, Dallas, Texas, United States|Investigational Site Number 8400021, Dallas, Texas, United States|Investigational Site Number 8400017, Houston, Texas, United States|Investigational Site Number 8400001, Houston, Texas, United States|Investigational Site Number 8400020, Houston, Texas, United States|Investigational Site Number 8400016, Mesquite, Texas, United States|Investigational Site Number 8400034, Salt Lake City, Utah, United States|Investigational Site Number 8400008, Renton, Washington, United States|Investigational Site Number 8400039, Bridgeport, West Virginia, United States|Investigational Site Number 2460006, Jyväskylä, Finland|Investigational Site Number 2460002, Kuopio, Finland|Investigational Site Number 2460004, Pori, Finland|Investigational Site Number 2460003, Seinäjoki, Finland|Investigational Site Number 2760001, Berlin, Germany|Investigational Site Number 2760006, Essen, Germany|Investigational Site Number 2760004, Heidelberg, Germany|Investigational Site Number 2760005, Oldenburg In Holstein, Germany|Investigational Site Number 2760002, Pirna, Germany|Investigational Site Number 3480012, Balatonfüred, Hungary|Investigational Site Number 3480011, Budapest, Hungary|Investigational Site Number 3480008, Budapest, Hungary|Investigational Site Number 3480001, Budapest, Hungary|Investigational Site Number 3480005, Budapest, Hungary|Investigational Site Number 3480004, Budapest, Hungary|Investigational Site Number 3480007, Debrecen, Hungary|Investigational Site Number 3480003, Nagykanizsa, Hungary|Investigational Site Number 3480010, Nyíregyháza, Hungary|Investigational Site Number 3480009, Szentendre, Hungary|Investigational Site Number 3920009, Fukuyama-Shi, Japan|Investigational Site Number 3920008, Higashiosaka-Shi, Japan|Investigational Site Number 3920007, Kashiwara-Shi, Japan|Investigational Site Number 3920001, Koriyama-Shi, Japan|Investigational Site Number 3920005, Kumamoto-Shi, Japan|Investigational Site Number 3920003, Mito-Shi, Japan|Investigational Site Number 3920010, Osaka-Shi, Japan|Investigational Site Number 3920002, Sagamihara-Shi, Japan|Investigational Site Number 3920004, Shinjuku-Ku, Japan|Investigational Site Number 3920006, Ushiku-Shi, Japan|Investigational Site Number 6160004, Bialystok, Poland|Investigational Site Number 6160003, Krakow, Poland|Investigational Site Number 6160005, Krakow, Poland|Investigational Site Number 6160007, Lublin, Poland|Investigational Site Number 6160006, Nowy Sacz, Poland|Investigational Site Number 6160001, Poznan, Poland|Investigational Site Number 6160002, Warszawa, Poland|Investigational Site Number 6430002, Samara, Russian Federation|Investigational Site Number 6430003, Saratov, Russian Federation|Investigational Site Number 6430001, St. Petersburg, Russian Federation|Investigational Site Number 6430004, Tomsk, Russian Federation","https://ClinicalTrials.gov/show/NCT03211858"
477,"Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor SAR442168","Not yet recruiting","No Results Available","Secondary Progressive Multiple Sclerosis","Drug: SAR442168|Drug: Placebo to match SAR442168",,"https://ClinicalTrials.gov/show/NCT04411641"
478,"GZ/SAR402671 in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3","Recruiting","No Results Available","Gaucher Disease Type 1-Gaucher Disease Type 3","Drug: GZ402671","Investigational Site Number 840002, New Haven, Connecticut, United States|Investigational Site Number 840001, Dallas, Texas, United States|Investigational Site Number 276001, Mainz, Germany|Investigational Site Number 392001, Minato-Ku, Japan|Investigational Site Number 826003, Cambridge, United Kingdom|Investigational Site Number 826001, London, United Kingdom|Investigational Site Number 826002, Salford, United Kingdom","https://ClinicalTrials.gov/show/NCT02843035"
479,"Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms","Not yet recruiting","No Results Available","COVID-19","Drug: Ivermectin|Drug: Placebo",,"https://ClinicalTrials.gov/show/NCT04407507"
480,"Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis","Completed","Has Results","Idiopathic Pulmonary Fibrosis","Drug: SAR156597|Drug: placebo","Investigational Site Number 840003, Phoenix, Arizona, United States|Investigational Site Number 840020, Jacksonville, Florida, United States|Investigational Site Number 840022, Loxahatchee Groves, Florida, United States|Investigational Site Number 840017, Atlanta, Georgia, United States|Investigational Site Number 840008, Decatur, Georgia, United States|Investigational Site Number 840010, Louisville, Kentucky, United States|Investigational Site Number 840009, Minneapolis, Minnesota, United States|Investigational Site Number 840006, Rochester, Minnesota, United States|Investigational Site Number 840026, Chesterfield, Missouri, United States|Investigational Site Number 840001, Lebanon, New Hampshire, United States|Investigational Site Number 840002, Summit, New Jersey, United States|Investigational Site Number 840015, Jamaica, New York, United States|Investigational Site Number 840023, Mineola, New York, United States|Investigational Site Number 840012, New York, New York, United States|Investigational Site Number 840013, Stony Brook, New York, United States|Investigational Site Number 840014, Philadelphia, Pennsylvania, United States|Investigational Site Number 840011, Dallas, Texas, United States|Investigational Site Number 840024, Everett, Washington, United States|Investigational Site Number 032009, Caba, Argentina|Investigational Site Number 032005, Caba, Argentina|Investigational Site Number 032001, La Plata, Argentina|Investigational Site Number 032004, Mendoza, Argentina|Investigational Site Number 032002, San Miguel De Tucumán, Argentina|Investigational Site Number 032007, Vicente Lopez, Argentina|Investigational Site Number 036005, Camperdown, Australia|Investigational Site Number 036004, Darlinghurst, Australia|Investigational Site Number 036002, Frankston, Australia|Investigational Site Number 036003, Murdoch, Australia|Investigational Site Number 036001, Nundah, Australia|Investigational Site Number 124003, Toronto, Canada|Investigational Site Number 124002, Vancouver, Canada|Investigational Site Number 152003, Quillota, Chile|Investigational Site Number 152001, Santiago, Chile|Investigational Site Number 152004, Santiago, Chile|Investigational Site Number 152006, Santiago, Chile|Investigational Site Number 152002, Talca, Chile|Investigational Site Number 152007, Viña Del Mar, Chile|Investigational Site Number 170004, Armenia, Colombia|Investigational Site Number 170001, Bogota, Colombia|Investigational Site Number 170005, Cali, Colombia|Investigational Site Number 203002, Hradec Kralove, Czechia|Investigational Site Number 203004, Olomouc, Czechia|Investigational Site Number 203003, Praha 2, Czechia|Investigational Site Number 203001, Praha 4, Czechia|Investigational Site Number 208002, Aarhus C, Denmark|Investigational Site Number 208001, Hellerup, Denmark|Investigational Site Number 250007, Bobigny, France|Investigational Site Number 250002, Lille Cedex, France|Investigational Site Number 250001, Lyon, France|Investigational Site Number 250009, Marseille, France|Investigational Site Number 250005, Montpellier, France|Investigational Site Number 250004, Nice, France|Investigational Site Number 250006, Paris, France|Investigational Site Number 250008, Toulouse, France|Investigational Site Number 250003, Tours, France|Investigational Site Number 276003, Coswig, Germany|Investigational Site Number 276002, Donaustauf, Germany|Investigational Site Number 276004, Gießen, Germany|Investigational Site Number 276005, Hannover, Germany|Investigational Site Number 276001, Heidelberg, Germany|Investigational Site Number 300001, Heraklion, Greece|Investigational Site Number 376001, Haifa, Israel|Investigational Site Number 376004, Kfar Saba, Israel|Investigational Site Number 376002, Petah-Tikva, Israel|Investigational Site Number 376005, Rehovot, Israel|Investigational Site Number 376003, Tel Hashomer, Israel|Investigational Site Number 380003, Catania, Italy|Investigational Site Number 380001, Forlì, Italy|Investigational Site Number 380005, Milano, Italy|Investigational Site Number 380002, Orbassano, Italy|Investigational Site Number 380006, Pisa, Italy|Investigational Site Number 380004, Siena, Italy|Investigational Site Number 410005, Bucheon-Si, Korea, Republic of|Investigational Site Number 410001, Incheon, Korea, Republic of|Investigational Site Number 410006, Seongnam, Korea, Republic of|Investigational Site Number 410002, Seoul, Korea, Republic of|Investigational Site Number 410003, Seoul, Korea, Republic of|Investigational Site Number 410004, Seoul, Korea, Republic of|Investigational Site Number 484002, Mexico City, Mexico|Investigational Site Number 484001, Monterrey, Mexico|Investigational Site Number 484005, Monterrey, Mexico|Investigational Site Number 484003, San Juan Del Rio, Mexico|Investigational Site Number 620003, Porto, Portugal|Investigational Site Number 620004, Vila Nova De Gaia, Portugal|Investigational Site Number 724003, Barcelona, Spain|Investigational Site Number 724002, Barcelona, Spain|Investigational Site Number 724001, Hospitalet De Llobregat, Spain|Investigational Site Number 724004, Lugo, Spain|Investigational Site Number 724006, Majadahonda, Spain|Investigational Site Number 724005, Palma De Mallorca, Spain|Investigational Site Number 724007, Sabadell, Spain|Investigational Site Number 792005, Ankara, Turkey|Investigational Site Number 792006, Istanbul, Turkey|Investigational Site Number 792001, Istanbul, Turkey|Investigational Site Number 792004, Istanbul, Turkey|Investigational Site Number 792003, Istanbul, Turkey|Investigational Site Number 792002, Izmir, Turkey|Investigational Site Number 826002, Cambridge, United Kingdom|Investigational Site Number 826003, Exeter, United Kingdom|Investigational Site Number 826004, Leicester, United Kingdom|Investigational Site Number 826001, London, United Kingdom","https://ClinicalTrials.gov/show/NCT02345070"
481,"The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection","Recruiting","No Results Available","COVID-19","Drug: PUL-042 Inhalation Solution|Drug: Placebo","St. Elizabeth Healthcare, Edgewood, Kentucky, United States|Ascension St. John, Tulsa, Oklahoma, United States","https://ClinicalTrials.gov/show/NCT04312997"
482,"Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19)","Not yet recruiting","No Results Available","COVID-19","Biological: Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|Biological: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|Biological: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28|Other: Two doses of placebo at the schedule of day 0,28","Renqiu City Center for Disease Control and Prevention, Renqiu, Hebei, China","https://ClinicalTrials.gov/show/NCT04383574"
483,"Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe)","Not yet recruiting","No Results Available","COVID-19","Drug: Lopinavir / ritonavir tablets combined with Xiyanping injection|Drug: Lopinavir/ritonavir treatment",,"https://ClinicalTrials.gov/show/NCT04295551"
484,"Study of Subretinally Injected SAR439483 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D","Active, not recruiting","No Results Available","Leber's Congenital Amaurosis","Drug: SAR439483|Drug: SAR439483 Diluent Solution|Drug: Prednisone|Drug: Triamcinalone Acetonide|Drug: 1% Prednisolone|Drug: Trimethoprim/polymyxin B","Investigational Site Number 8400001, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT03920007"
485,"An Open Randomized Study of Dalargin Effectiveness in Patients With Severe and Critical Manifestations of SARS-COVID-19","Active, not recruiting","No Results Available","Acute Respiratory Tract Infection|Acute Respiratory Insufficiency|Pneumonia|Septic Shock|Hypoxemia","Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation.|Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection|Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin inhalation|Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection combined with Dalargin inhalation","Burnasyan Federal Medical Biophysical Center FMBA of Russia, Moscow, Russian Federation","https://ClinicalTrials.gov/show/NCT04346693"
486,"First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma","Recruiting","No Results Available","Plasma Cell Myeloma","Drug: SAR442085","Investigational Site Number 8400002, Duarte, California, United States|Investigational Site Number 8400003, Boston, Massachusetts, United States|Investigational Site Number 8400005, Rochester, Minnesota, United States|Investigational Site Number 8400001, New York, New York, United States|Investigational Site Number 8400004, Milwaukee, Wisconsin, United States|Investigational Site Number 2500001, Toulouse Cedex 9, France|Investigational Site Number 7240002, Hospitalet De Llobregat, Spain|Investigational Site Number 7240001, Salamanca, Spain","https://ClinicalTrials.gov/show/NCT04000282"
487,"SAR 1118 in Human Subjects Undergoing Pars Plana Vitrectomy","Terminated","No Results Available","Diabetic Macular Edema (DME)|Pars Plana Vitrectomy","Drug: SAR 1118 0.1%|Drug: SAR 1118 1.0%|Drug: SAR 1118 5.0%","Johns Hopkins University, Baltimore, Maryland, United States","https://ClinicalTrials.gov/show/NCT00936520"
488,"Efficacay of Chloroquine in COVID-19 Treatment","Not yet recruiting","No Results Available","COVID-19|Coronavirus Infection","Drug: Chloroquine","Tanta University, Tanta, Egypt","https://ClinicalTrials.gov/show/NCT04353336"
489,"Piclidenoson for Treatment of COVID-19","Not yet recruiting","No Results Available","COVID-19|Coronavirus Infection","Drug: Piclidenoson","Rabin Medical Center, Petah tikva, Israel","https://ClinicalTrials.gov/show/NCT04333472"
490,"Convalescent Plasma for Patients With COVID-19: A Randomized, Open Label, Parallel, Controlled Clinical Study","Not yet recruiting","No Results Available","Coronavirus|Coronavirus Infection","Drug: Plasma|Drug: Hydroxychloroquine","Universidad del Rosario, Bogota, Cundinamarca, Colombia","https://ClinicalTrials.gov/show/NCT04332835"
491,"Convalescent Plasma for Patients With COVID-19: A Pilot Study","Not yet recruiting","No Results Available","Coronavirus|Coronavirus Infection","Drug: Plasma","Universidad del Rosario, Bogota, Cundinamarca, Colombia","https://ClinicalTrials.gov/show/NCT04332380"
492,"SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients","Completed","No Results Available","Diffuse Large B-cell Lymphoma","Drug: SAR3419","Investigational Site Number 840001, Denver, Colorado, United States|Investigational Site Number 840003, Augusta, Georgia, United States|Investigational Site Number 840005, Boise, Idaho, United States|Investigational Site Number 056002, Gent, Belgium|Investigational Site Number 056001, Leuven, Belgium|Investigational Site Number 203002, Brno, Czechia|Investigational Site Number 203003, Praha 10, Czechia|Investigational Site Number 203001, Praha 2, Czechia|Investigational Site Number 376003, Jerusalem, Israel|Investigational Site Number 376002, Tel Hashomer, Israel|Investigational Site Number 380002, Bergamo, Italy|Investigational Site Number 380004, Bologna, Italy|Investigational Site Number 380008, Mestre, Italy|Investigational Site Number 380001, Milano, Italy|Investigational Site Number 380007, Modena, Italy|Investigational Site Number 380003, Palermo, Italy|Investigational Site Number 380006, Pavia, Italy|Investigational Site Number 616003, Brzozow, Poland|Investigational Site Number 616002, Kielce, Poland|Investigational Site Number 616001, Warszawa, Poland|Investigational Site Number 724002, Barcelona, Spain|Investigational Site Number 724004, Barcelona, Spain|Investigational Site Number 724001, Madrid, Spain|Investigational Site Number 724003, Valencia, Spain|Investigational Site Number 792003, Izmir, Turkey|Investigational Site Number 792001, Izmir, Turkey|Investigational Site Number 826001, Leicester, United Kingdom|Investigational Site Number 826002, Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT01472887"
493,"Sero-prevalence of Coronavirus Disease 2019 (COVID-19) in Healthcare Workers","Not yet recruiting","No Results Available","COVID|Corona Virus Infection","Biological: Specific anti-SARS-CoV-2 antibodies",,"https://ClinicalTrials.gov/show/NCT04424017"
494,"Awake Proning in COVID-19 Patients With Hypoxemic Respiratory Failure","Active, not recruiting","No Results Available","Oxygen Deficiency|Coronavirus Infection","Other: Awake proning","Columbia University Medical Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT04408222"
495,"Evaluating the Efficacy of Artesunate in Adults With Mild Symptoms of COVID-19","Not yet recruiting","No Results Available","Covid 19 Positive|Corona Virus Infection","Drug: Artemisinin / Artesunate|Other: placebo","Princess Nourah Bint Abdulrahman Univeristy, Riyadh, Central, Saudi Arabia","https://ClinicalTrials.gov/show/NCT04387240"
496,"Novel Regimens in COVID-19 Treatment","Not yet recruiting","No Results Available","COVID|Corona Virus Infection","Drug: Nitazoxanide|Drug: Ivermectin|Drug: Chloroquine|Drug: Azithromycin",,"https://ClinicalTrials.gov/show/NCT04382846"
497,"Phase 2 Window Study of SAR439859 Versus Letrozole in ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer (AMEERA-4)","Recruiting","No Results Available","Breast Cancer","Drug: SAR439859|Drug: letrozole","Investigational Site Number 8400003, Bakersfield, California, United States|Investigational Site Number 8400001, Columbus, Georgia, United States|Investigational Site Number 8400004, Chicago, Illinois, United States|Investigational Site Number 8400018, Fort Wayne, Indiana, United States|Investigational Site Number 8400005, Lincoln, Nebraska, United States|Investigational Site Number 8400006, Fort Worth, Texas, United States|Investigational Site Number 8400008, The Woodlands, Texas, United States|Investigational Site Number 8400012, Tacoma, Washington, United States|Investigational Site Number 3800001, Milano, Italy|Investigational Site Number 3800003, Rozzano, Italy|Investigational Site Number 8400007, Hato Rey, Puerto Rico|Investigational Site Number 6430002, Saint -Petersburg, Russian Federation|Investigational Site Number 6430003, Saint-Petersburg, Russian Federation|Investigational Site Number 7240003, Córdoba, Spain|Investigational Site Number 7240001, Madrid, Spain|Investigational Site Number 7240002, Valencia, Spain","https://ClinicalTrials.gov/show/NCT04191382"
498,"Social Media and Covid19 Pandemic","Enrolling by invitation","No Results Available","Social Media|Corona Virus Infection","Behavioral: survey","Bahar Yuksel, Istanbul, Turkey|Haseki Training and Research Hospital, Istanbul, Turkey","https://ClinicalTrials.gov/show/NCT04378738"
499,"Trial of Hydroxychloroquine In Covid-19 Kinetics","Active, not recruiting","No Results Available","Covid 19|Corona Virus Infection","Drug: Hydroxychloroquine|Other: Placebo","University of South Alabama, Mobile, Alabama, United States","https://ClinicalTrials.gov/show/NCT04353271"
500,"A Clinical Study to Investigate the Effect of SAR425899 on Energy Expenditure in Obese Subjects","Completed","No Results Available","Type 2 Diabetes Mellitus","Drug: SAR425899|Drug: Placebo","Investigational Site Number 8400001, Orlando, Florida, United States|Investigational Site Number 8400002, Baton Rouge, Louisiana, United States","https://ClinicalTrials.gov/show/NCT03376802"
501,"Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19)","Recruiting","No Results Available","COVID-19|Corona Virus Infection","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Columbia University Irving Medical Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT04318444"
502,"A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus","Completed","No Results Available","Type 2 Diabetes Mellitus","Drug: SAR425899|Drug: Placebo|Drug: Liraglutide|Drug: Metformin","Investigational Site Number 8400028, Sheffield, Alabama, United States|Investigational Site Number 8400002, Huntington Park, California, United States|Investigational Site Number 8400024, Los Angeles, California, United States|Investigational Site Number 8400001, Los Angeles, California, United States|Investigational Site Number 8400012, Port Hueneme, California, United States|Investigational Site Number 8400027, Denver, Colorado, United States|Investigational Site Number 8400025, Miami, Florida, United States|Investigational Site Number 8400007, Palm Harbor, Florida, United States|Investigational Site Number 8400013, Chicago, Illinois, United States|Investigational Site Number 8400016, Wichita, Kansas, United States|Investigational Site Number 8400023, Wichita, Kansas, United States|Investigational Site Number 8400018, New Orleans, Louisiana, United States|Investigational Site Number 8400019, Rockville, Maryland, United States|Investigational Site Number 8400014, Flint, Michigan, United States|Investigational Site Number 8400003, Troy, Michigan, United States|Investigational Site Number 8400020, Linden, New Jersey, United States|Investigational Site Number 8400022, New York, New York, United States|Investigational Site Number 8400005, Fargo, North Dakota, United States|Investigational Site Number 8400004, Austin, Texas, United States|Investigational Site Number 8400006, Dallas, Texas, United States|Investigational Site Number 8400021, Houston, Texas, United States|Investigational Site Number 8400026, San Antonio, Texas, United States|Investigational Site Number 8400017, Sugar Land, Texas, United States|Investigational Site Number 1240008, Quebec, Canada|Investigational Site Number 1240005, Sainte-Foy, Canada|Investigational Site Number 1240002, Sherbrooke, Canada|Investigational Site Number 1240001, Toronto, Canada|Investigational Site Number 1240003, Vancouver, Canada|Investigational Site Number 2030003, Ceske Budejovice, Czechia|Investigational Site Number 2030001, Krnov, Czechia|Investigational Site Number 2030004, Praha 10 - Uhrineves, Czechia|Investigational Site Number 2030002, Praha 9 - Klanovice, Czechia|Investigational Site Number 2760003, Berlin, Germany|Investigational Site Number 2760001, Dresden, Germany|Investigational Site Number 2760006, Hohenmölsen, Germany|Investigational Site Number 3480001, Balatonfüred, Hungary|Investigational Site Number 3480002, Budapest, Hungary|Investigational Site Number 3480008, Budapest, Hungary|Investigational Site Number 3480005, Budapest, Hungary|Investigational Site Number 3480006, Budapest, Hungary|Investigational Site Number 3480007, Budapest, Hungary|Investigational Site Number 4840004, Actopan, Mexico|Investigational Site Number 4840001, Guadalajara, Mexico|Investigational Site Number 4840003, Guadalajara, Mexico|Investigational Site Number 4840002, Monterrey, Mexico|Investigational Site Number 4840006, San Juan Del Rio, Mexico|Investigational Site Number 6430003, Saratov, Russian Federation|Investigational Site Number 6430002, St-Petersburg, Russian Federation|Investigational Site Number 6430001, St-Petersburg, Russian Federation|Investigational Site Number 6430004, St. Petersburg, Russian Federation|Investigational Site Number 6430005, Voronezh, Russian Federation|Investigational Site Number 7240005, Barcelona, Spain|Investigational Site Number 7240007, Ferrol, Spain|Investigational Site Number 7240001, La Coruña, Spain|Investigational Site Number 7240006, Las Palmas De Gran Canaria, Spain|Investigational Site Number 7240002, Madrid, Spain|Investigational Site Number 7240003, Málaga, Spain|Investigational Site Number 7240004, Málaga, Spain|Investigational Site Number 7240008, Sevilla, Spain","https://ClinicalTrials.gov/show/NCT02973321"
503,"Transfusion of Convalescent Plasma for the Early Treatment of Patients With COVID-19","Recruiting","No Results Available","COVID|SARS-CoV 2","Biological: CONVALESCENT PLASMA","Azienda Ospedaliero Universitaria Pisana, Pisa, Italy","https://ClinicalTrials.gov/show/NCT04393727"
504,"Assessment of the Safety and Effect of SAR425899 Versus Placebo for the Treatment of Non-alcoholic Fatty Liver Disease","Withdrawn","No Results Available","Non-alcoholic Steatohepatitis|Type 2 Diabetes Mellitus","Drug: SAR425899|Drug: Placebo",,"https://ClinicalTrials.gov/show/NCT03437720"
505,"Oral SAR245408 (XL147) and Oral MSC1936369B in Patients With Locally Advanced or Metastatic Solid Tumors","Completed","No Results Available","Solid Tumors","Drug: SAR245408 (XL147)|Drug: MSC1936369B","Investigational Site Number 840001, Boston, Massachusetts, United States|Investigational Site Number 840002, Boston, Massachusetts, United States|Investigational Site Number 840003, Nashville, Tennessee, United States","https://ClinicalTrials.gov/show/NCT01357330"
506,"COHIVE: Coronavirus (COVID-19) Outcomes in HIV Evaluation in Resource Limited Settings","Not yet recruiting","No Results Available","HIV-infection/Aids|Coronavirus Infection",,,"https://ClinicalTrials.gov/show/NCT04371835"
507,"Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant","Recruiting","No Results Available","COVID-19","Biological: SARS-CoV-2 rS|Other: Matrix-M Adjuvant|Other: NSS Saline Placebo","Investigational Research Site 1, Herston, Queensland, Australia|Investigational Research Site 2, Melbourne, Victoria, Australia","https://ClinicalTrials.gov/show/NCT04368988"
508,"SAR407899 Single-dose in Treatment of Mild to Moderate Erectile Dysfunction","Completed","No Results Available","Erectile Dysfunction","Drug: SAR407899|Drug: Placebo|Drug: Sildenafil","Sanofi-Aventis Administrative Office, Paris, France","https://ClinicalTrials.gov/show/NCT00914277"
509,"Phase 2 Study of SAR439859 Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (AMEERA-3)","Recruiting","No Results Available","Breast Cancer Metastatic","Drug: SAR439859|Drug: Endocrine monotherapy as per physician choice","Investigational Site Number 8400008, Birmingham, Alabama, United States|Investigational Site Number 8400018, Bakersfield, California, United States|Investigational Site Number 8400024, Santa Monica, California, United States|Investigational Site Number 8400019, Woodland, California, United States|Investigational Site Number 8400029, Fort Lauderdale, Florida, United States|Investigational Site Number 8400017, Chicago, Illinois, United States|Investigational Site Number 8400005, Chicago, Illinois, United States|Investigational Site Number 8400012, Tinley Park, Illinois, United States|Investigational Site Number 8400031, Urbana, Illinois, United States|Investigational Site Number 8400027, Fairway, Kansas, United States|Investigational Site Number 8400020, Baton Rouge, Louisiana, United States|Investigational Site Number 8400036, Silver Spring, Maryland, United States|Investigational Site Number 8400015, Boston, Massachusetts, United States|Investigational Site Number 8400032, Kansas City, Missouri, United States|Investigational Site Number 8400003, Billings, Montana, United States|Investigational Site Number 8400013, Lebanon, New Hampshire, United States|Investigational Site Number 8400025, Hackensack, New Jersey, United States|Investigational Site Number 8400009, Jamaica, New York, United States|Investigational Site Number 8400030, Pinehurst, North Carolina, United States|Investigational Site Number 8400006, Canton, Ohio, United States|Investigational Site Number 8400014, Tulsa, Oklahoma, United States|Investigational Site Number 8400001, Philadelphia, Pennsylvania, United States|Investigational Site Number 8400023, Pittsburgh, Pennsylvania, United States|Investigational Site Number 8400022, Fort Worth, Texas, United States|Investigational Site Number 8400026, Burlington, Vermont, United States|Investigational Site Number 8400016, Madison, Wisconsin, United States|Investigational Site Number 0320003, Buenos Aires, Argentina|Investigational Site Number 0320006, Buenos Aires, Argentina|Investigational Site Number 0320004, La Rioja, Argentina|Investigational Site Number 0320005, Rosario, Argentina|Investigational Site Number 0320002, Salta, Argentina|Investigational Site Number 0360001, Nedlands, Australia|Investigational Site Number 0360003, South Brisbane, Australia|Investigational Site Number 0360002, Woolloongabba, Australia|Investigational Site Number 0560002, Charleroi, Belgium|Investigational Site Number 0560001, Leuven, Belgium|Investigational Site Number 0560003, Namur, Belgium|Investigational Site Number 0760005, Goiania, Brazil|Investigational Site Number 0760001, Porto Alegre, Brazil|Investigational Site Number 0760002, Porto Alegre, Brazil|Investigational Site Number 0760006, Sao Paulo, Brazil|Investigational Site Number 0760003, São José Do Rio Preto, Brazil|Investigational Site Number 1240004, Calgary, Canada|Investigational Site Number 1240002, Cambridge, Canada|Investigational Site Number 1240003, London, Canada|Investigational Site Number 1240006, Montreal, Canada|Investigational Site Number 2030002, Brno, Czechia|Investigational Site Number 2030003, Novy Jicin, Czechia|Investigational Site Number 2030004, Praha 4, Czechia|Investigational Site Number 2500008, Angers Cedex 9, France|Investigational Site Number 2500006, Creteil Cedex, France|Investigational Site Number 2500007, Marseille, France|Investigational Site Number 2500005, Paris Cedex 10, France|Investigational Site Number 2500002, Saint-Herblain, France|Investigational Site Number 2500001, Villejuif Cedex, France|Investigational Site Number 3760002, Jerusalem, Israel|Investigational Site Number 3800001, Candiolo, Italy|Investigational Site Number 3800002, Milano, Italy|Investigational Site Number 3800003, Prato, Italy|Investigational Site Number 3920007, Chiba-Shi, Japan|Investigational Site Number 3920004, Chuo-Ku, Japan|Investigational Site Number 3920001, Kashiwa-Shi, Japan|Investigational Site Number 3920008, Koto-Ku, Japan|Investigational Site Number 3920002, Nagoya-Shi, Japan|Investigational Site Number 3920003, Osaka-Shi, Japan|Investigational Site Number 3920006, Yokohama-Shi, Japan|Investigational Site Number 4100001, Seoul, Korea, Republic of|Investigational Site Number 4100004, Seoul, Korea, Republic of|Investigational Site Number 4100003, Seoul, Korea, Republic of|Investigational Site Number 4100002, Seoul, Korea, Republic of|Investigational Site Number 4840005, Mexico, Mexico|Investigational Site Number 4840002, Monterrey, Mexico|Investigational Site Number 4840006, Veracruz, Mexico|Investigational Site Number 6160004, Pila, Poland|Investigational Site Number 6160003, Poznan, Poland|Investigational Site Number 8400028, Ponce De Leon, Puerto Rico|Investigational Site Number 6430001, Moscow, Russian Federation|Investigational Site Number 6430003, Moscow, Russian Federation|Investigational Site Number 6430002, Saint -Petersburg, Russian Federation|Investigational Site Number 6430004, Saint-Petersburg, Russian Federation|Investigational Site Number 7240006, Barcelona, Spain|Investigational Site Number 1580002, Taichung, Taiwan|Investigational Site Number 1580003, Tainan, Taiwan|Investigational Site Number 1580001, Taipei, Taiwan|Investigational Site Number 7920004, Ankara, Turkey|Investigational Site Number 7920002, Edirne, Turkey|Investigational Site Number 7920001, Istanbul, Turkey|Investigational Site Number 7920003, Istanbul, Turkey|Investigational Site Number 8040004, Odesa, Ukraine","https://ClinicalTrials.gov/show/NCT04059484"
510,"Trial to Promote Recovery From COVID-19 With Ivermectin or Endocrine Therapy","Not yet recruiting","No Results Available","COVID-19|SARS-CoV 2","Drug: Bicalutamide 150 Mg Oral Tablet|Drug: Ivermectin 3Mg Tab","Johns Hopkins Hospital, Baltimore, Maryland, United States","https://ClinicalTrials.gov/show/NCT04374279"
511,"Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants","Completed","No Results Available","Asthma","Drug: SAR440340|Drug: Dupilumab|Drug: Fluticasone or Fluticasone/salmeterol combination|Drug: Placebo for SAR440340|Drug: Placebo for dupilumab","Investigational Site Number 8400026, Birmingham, Alabama, United States|Investigational Site Number 8400004, Long Beach, California, United States|Investigational Site Number 8400020, Los Angeles, California, United States|Investigational Site Number 8400001, Rolling Hills Estates, California, United States|Investigational Site Number 8400013, San Jose, California, United States|Investigational Site Number 8400009, Stockton, California, United States|Investigational Site Number 8400016, Colorado Springs, Colorado, United States|Investigational Site Number 8400021, Ann Arbor, Michigan, United States|Investigational Site Number 8400022, Minneapolis, Minnesota, United States|Investigational Site Number 8400007, Papillion, Nebraska, United States|Investigational Site Number 8400025, Edmond, Oklahoma, United States|Investigational Site Number 8400011, Medford, Oregon, United States|Investigational Site Number 8400024, Portland, Oregon, United States|Investigational Site Number 8400010, Dallas, Texas, United States|Investigational Site Number 8400023, Dallas, Texas, United States|Investigational Site Number 8400006, Plano, Texas, United States|Investigational Site Number 8400008, Murray, Utah, United States|Investigational Site Number 8400014, Milwaukee, Wisconsin, United States|Investigational Site Number 0320001, Buenos Aires, Argentina|Investigational Site Number 0320003, Caba, Argentina|Investigational Site Number 0320002, Caba, Argentina|Investigational Site Number 0320004, Caba, Argentina|Investigational Site Number 0320005, Mendoza, Argentina|Investigational Site Number 1520002, Quillota, Chile|Investigational Site Number 1520001, Santiago, Chile|Investigational Site Number 1520009, Santiago, Chile|Investigational Site Number 1520008, Santiago, Chile|Investigational Site Number 1520007, Santiago, Chile|Investigational Site Number 1520004, Santiago, Chile|Investigational Site Number 1520005, Talca, Chile|Investigational Site Number 1520003, Viña Del Mar, Chile|Investigational Site Number 4840005, Chihuahua, Mexico|Investigational Site Number 4840004, Durango, Mexico|Investigational Site Number 4840002, Guadalajara, Mexico|Investigational Site Number 4840006, Monterrey, Mexico|Investigational Site Number 4840001, Monterrey, Mexico|Investigational Site Number 4840003, Veracruz, Mexico|Investigational Site Number 6160001, Bialystok, Poland|Investigational Site Number 6160008, Bialystok, Poland|Investigational Site Number 6160005, Bydgoszcz, Poland|Investigational Site Number 6160007, Krakow, Poland|Investigational Site Number 6160002, Poznan, Poland|Investigational Site Number 6160006, Poznan, Poland|Investigational Site Number 6160003, Znin, Poland|Investigational Site Number 6430003, Moscow, Russian Federation|Investigational Site Number 6430001, Moscow, Russian Federation|Investigational Site Number 6430005, Moscow, Russian Federation|Investigational Site Number 6430008, Ryazan, Russian Federation|Investigational Site Number 6430010, Saint-Petersburg, Russian Federation|Investigational Site Number 6430006, Saint-Petersburg, Russian Federation|Investigational Site Number 6430007, St-Petersburg, Russian Federation|Investigational Site Number 6430009, Stavropol, Russian Federation|Investigational Site Number 6430004, Ulyanovsk, Russian Federation|Investigational Site Number 7920004, Ankara, Turkey|Investigational Site Number 7920003, Bursa, Turkey|Investigational Site Number 7920001, Istanbul, Turkey|Investigational Site Number 7920006, Izmir, Turkey|Investigational Site Number 7920007, Izmir, Turkey|Investigational Site Number 7920008, Kirikkale, Turkey|Investigational Site Number 7920002, Mersin, Turkey|Investigational Site Number 7920009, Rize, Turkey|Investigational Site Number 8040008, Chernivtsi, Ukraine|Investigational Site Number 8040012, Ivano-Frankivsk, Ukraine|Investigational Site Number 8040002, Kharkiv, Ukraine|Investigational Site Number 8040009, Kharkiv, Ukraine|Investigational Site Number 8040011, Kharkiv, Ukraine|Investigational Site Number 8040007, Kyiv, Ukraine|Investigational Site Number 8040001, Kyiv, Ukraine|Investigational Site Number 8040006, Odesa, Ukraine|Investigational Site Number 8040003, Ternopil, Ukraine|Investigational Site Number 8040005, Vinnytsya, Ukraine","https://ClinicalTrials.gov/show/NCT03387852"
512,"Pharmacodynamic Study to Assess the Effects of Repeated Dosing of SAR247799 on Endothelial Function in Patients With Type 2 Diabetes Mellitus","Completed","No Results Available","Microvascular Coronary Artery Disease","Drug: SAR247799|Drug: Placebo|Drug: Sildenafil|Drug: Acetylcholine","Investigational Site Number 2760002, Mainz, Germany|Investigational Site Number 2760001, Neuss, Germany","https://ClinicalTrials.gov/show/NCT03462017"
513,"Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma","Completed","No Results Available","Endometrial Cancer|Endometrial Neoplasms","Drug: XL147 (SAR245408)","Investigational Site Number 1526, Newport Beach, California, United States|Investigational Site Number 1532, Orlando, Florida, United States|Investigational Site Number 1239, Augusta, Georgia, United States|Investigational Site Number 1133, Boston, Massachusetts, United States|Investigational Site Number 1325, Columbus, Ohio, United States|Investigational Site Number 1434, Oklahoma City, Oklahoma, United States|Investigational Site Number 1132, Abington, Pennsylvania, United States|Investigational Site Number 1134, Philadelphia, Pennsylvania, United States|Investigational Site Number 1142, Providence, Rhode Island, United States|Investigational Site Number 1527, Dallas, Texas, United States|Investigational Site Number 3212, Kortrijk, Belgium|Investigational Site Number 3211, Leuven, Belgium|Investigational Site Number 3218, Wilrijk, Belgium","https://ClinicalTrials.gov/show/NCT01013324"
514,"Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer","Completed","No Results Available","Triple Negative Breast Cancer","Drug: SAR566658 (ACT14884)","Investigational Site Number 8400002, El Paso, Texas, United States|Investigational Site Number 0560001, Leuven, Belgium|Investigational Site Number 2030002, Praha 2, Czechia|Investigational Site Number 3800003, Genova, Italy|Investigational Site Number 3800001, Milano, Italy|Investigational Site Number 3800004, Roma, Italy|Investigational Site Number 5280001, Maastricht, Netherlands|Investigational Site Number 5280002, Rotterdam, Netherlands|Investigational Site Number 7240002, Barcelona, Spain|Investigational Site Number 7240005, Lleida, Spain|Investigational Site Number 7240001, Madrid, Spain|Investigational Site Number 7240006, Madrid, Spain|Investigational Site Number 7240003, Sevilla, Spain|Investigational Site Number 7240004, Valencia, Spain","https://ClinicalTrials.gov/show/NCT02984683"
515,"Study of SAR421869 in Participants With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B","Terminated","Has Results","Usher Syndrome|Retinitis Pigmentosa","Drug: SAR421869","Investigational Site Number 840001, Portland, Oregon, United States|Investigational Site Number 250001, Paris, France","https://ClinicalTrials.gov/show/NCT01505062"
516,"Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine","Completed","Has Results","Type 2 Diabetes Mellitus","Drug: SAR342434|Drug: Humalog|Drug: insulin glargine HOE901","Investigational Site Number 840217, Foley, Alabama, United States|Investigational Site Number 840237, Muscle Shoals, Alabama, United States|Investigational Site Number 840245, Chandler, Arizona, United States|Investigational Site Number 840219, Phoenix, Arizona, United States|Investigational Site Number 840227, Phoenix, Arizona, United States|Investigational Site Number 840212, Little Rock, Arkansas, United States|Investigational Site Number 840241, El Cajon, California, United States|Investigational Site Number 840238, Fresno, California, United States|Investigational Site Number 840229, Greenbrae, California, United States|Investigational Site Number 840231, Huntington Beach, California, United States|Investigational Site Number 840247, Long Beach, California, United States|Investigational Site Number 840234, Los Angeles, California, United States|Investigational Site Number 840235, Northridge, California, United States|Investigational Site Number 840251, Palm Springs, California, United States|Investigational Site Number 840249, Santa Ana, California, United States|Investigational Site Number 840223, Temecula, California, United States|Investigational Site Number 840259, Tustin, California, United States|Investigational Site Number 840240, Walnut Creek, California, United States|Investigational Site Number 840214, Boynton Beach, Florida, United States|Investigational Site Number 840246, Miami, Florida, United States|Investigational Site Number 840226, New Port Richey, Florida, United States|Investigational Site Number 840205, Ocoee, Florida, United States|Investigational Site Number 840206, Palm Harbor, Florida, United States|Investigational Site Number 840242, Port Charlotte, Florida, United States|Investigational Site Number 840253, Lawrenceville, Georgia, United States|Investigational Site Number 840207, Stockbridge, Georgia, United States|Investigational Site Number 840248, Arlington Heights, Illinois, United States|Investigational Site Number 840204, Avon, Indiana, United States|Investigational Site Number 840257, Evansville, Indiana, United States|Investigational Site Number 840230, Des Moines, Iowa, United States|Investigational Site Number 840239, Rockville, Maryland, United States|Investigational Site Number 840236, Troy, Michigan, United States|Investigational Site Number 840216, Lincoln, Nebraska, United States|Investigational Site Number 840220, Las Vegas, Nevada, United States|Investigational Site Number 840233, Las Vegas, Nevada, United States|Investigational Site Number 840224, Linden, New Jersey, United States|Investigational Site Number 840232, Greensboro, North Carolina, United States|Investigational Site Number 840211, Morehead City, North Carolina, United States|Investigational Site Number 840228, Morganton, North Carolina, United States|Investigational Site Number 840225, Fargo, North Dakota, United States|Investigational Site Number 840221, Columbus, Ohio, United States|Investigational Site Number 840255, Dayton, Ohio, United States|Investigational Site Number 840250, Tipton, Pennsylvania, United States|Investigational Site Number 840243, Uniontown, Pennsylvania, United States|Investigational Site Number 840208, Chattanooga, Tennessee, United States|Investigational Site Number 840215, Jackson, Tennessee, United States|Investigational Site Number 840203, Austin, Texas, United States|Investigational Site Number 840258, Dallas, Texas, United States|Investigational Site Number 840201, Dallas, Texas, United States|Investigational Site Number 840222, Renton, Washington, United States|Investigational Site Number 840209, Milwaukee, Wisconsin, United States|Investigational Site Number 032201, Caba, Argentina|Investigational Site Number 032206, Capital Federal, Argentina|Investigational Site Number 032202, Capital Federal, Argentina|Investigational Site Number 032205, Ciudad Autonoma De Buenos Aire, Argentina|Investigational Site Number 032203, Salta, Argentina|Investigational Site Number 152202, Santiago, Chile|Investigational Site Number 152204, Santiago, Chile|Investigational Site Number 152201, Santiago, Chile|Investigational Site Number 170203, Armenia, Colombia|Investigational Site Number 276201, Berlin, Germany|Investigational Site Number 276204, Heidelberg, Germany|Investigational Site Number 276202, Neumünster, Germany|Investigational Site Number 276206, Potsdam, Germany|Investigational Site Number 276205, Stuttgart, Germany|Investigational Site Number 276203, Sulzbach-Rosenberg, Germany|Investigational Site Number 348205, Budapest, Hungary|Investigational Site Number 348202, Budapest, Hungary|Investigational Site Number 348204, Debrecen, Hungary|Investigational Site Number 348208, Komárom, Hungary|Investigational Site Number 348210, Nagykanizsa, Hungary|Investigational Site Number 348203, Szolnok, Hungary|Investigational Site Number 348209, Sátoraljaújhely, Hungary|Investigational Site Number 380203, Bologna, Italy|Investigational Site Number 380201, Milano, Italy|Investigational Site Number 380204, Roma, Italy|Investigational Site Number 380202, Sesto San Giovanni, Italy|Investigational Site Number 410202, Seoul, Korea, Republic of|Investigational Site Number 410204, Seoul, Korea, Republic of|Investigational Site Number 410205, Seoul, Korea, Republic of|Investigational Site Number 410201, Wonju, Korea, Republic of|Investigational Site Number 642210, Bacau, Romania|Investigational Site Number 642201, Bucuresti, Romania|Investigational Site Number 642202, Bucuresti, Romania|Investigational Site Number 642206, Cluj Napoca, Romania|Investigational Site Number 642204, Deva, Romania|Investigational Site Number 642205, Oradea, Romania|Investigational Site Number 642209, Sibiu, Romania|Investigational Site Number 642207, Targu Mures, Romania|Investigational Site Number 642208, Targu Mures, Romania|Investigational Site Number 642203, Timisoara, Romania|Investigational Site Number 643201, Saint-Petersburg, Russian Federation|Investigational Site Number 643205, Saratov, Russian Federation|Investigational Site Number 643203, St-Petersburg, Russian Federation|Investigational Site Number 643202, St-Petersburg, Russian Federation|Investigational Site Number 643204, St. Petersburg, Russian Federation|Investigational Site Number 724201, Barcelona, Spain|Investigational Site Number 724203, Málaga, Spain|Investigational Site Number 724202, Palma De Mallorca, Spain|Investigational Site Number 792201, Istanbul, Turkey|Investigational Site Number 792202, Istanbul, Turkey|Investigational Site Number 792204, Izmir, Turkey|Investigational Site Number 792203, Izmir, Turkey","https://ClinicalTrials.gov/show/NCT02294474"
517,"Prospective Registry of Corona Virus Disease 2019 (Covid-19) Patients With Neuromuscular Involvement","Recruiting","No Results Available","COVID|Sars-CoV2|Corona Virus Infection|Myositis|Myocarditis","Diagnostic Test: laboratory biomarkers|Diagnostic Test: muscle ultrasound","University Hospital Tuebingen, Tuebingen, Germany","https://ClinicalTrials.gov/show/NCT04367350"
518,"COVID-19 : Neutralizing Human Monoclonal Antibodies Against SARS-Cov-2","Recruiting","No Results Available","COVID","Other: Blood sample","Hôpital de la Croix-Rousse, Lyon, France","https://ClinicalTrials.gov/show/NCT04354766"
519,"Evaluation of Orally Administered SAR439859 in Japanese Postmenopausal Patients With Advanced Breast Cancer (AMEERA-2)","Recruiting","No Results Available","Breast Cancer","Drug: SAR439859","Investigational Site Number 3920002, Chuo-Ku, Japan|Investigational Site Number 3920001, Kashiwa-Shi, Japan|Investigational Site Number 3920003, Nagoya-Shi, Japan","https://ClinicalTrials.gov/show/NCT03816839"
520,"A Clinical Study to Investigate if SAR425899 Binds to the Liver and Pancreas in Overweight to Obese Type 2 Diabetes Mellitus Patients","Completed","No Results Available","Type 2 Diabetes Mellitus","Drug: SAR425899|Drug: [68Ga] Ga-DO3A-VS-Cys40-Tuna-2 (glucagon receptor tracer)|Drug: [68Ga] Ga-DO3A-VS-Cys40-Exendin-4 (GLP-1 receptor tracer)","Investigational Site Number 7520001, Uppsala, Sweden","https://ClinicalTrials.gov/show/NCT03350191"
521,"Clinical Effect of Dialyzable Leukocyte Extract in Suspected or Confirmed Cases of COVID-19 (FUTURE-T)","Not yet recruiting","No Results Available","COVID-19|SARS-CoV-2 Infection","Drug: Dialyzable Leukocyte Extract|Drug: Placebo oral","Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Mexico City, Mexico","https://ClinicalTrials.gov/show/NCT04379479"
522,"Long Term Safety And Tolerability Of SAR339658 In Patients With Ulcerative Colitis (UC)","Terminated","No Results Available","Ulcerative Colitis","Drug: SAR339658","Investigational Site Number 840059, Mission Hills, California, United States|Investigational Site Number 840008, Miramar,, Florida, United States|Investigational Site Number 840048, Winter Park, Florida, United States|Investigational Site Number 840024, Mexico, Missouri, United States|Investigational Site Number 840088, San Antonio, Texas, United States","https://ClinicalTrials.gov/show/NCT01861249"
523,"Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma","Completed","No Results Available","Diffuse Large B-Cell Lymphoma","Drug: SAR3419|Drug: rituximab","Investigational Site Number 040002, Graz, Austria|Investigational Site Number 250004, Creteil Cedex, France|Investigational Site Number 250009, Dijon, France|Investigational Site Number 250006, Lille Cedex, France|Investigational Site Number 250011, Marseille Cedex 9, France|Investigational Site Number 250010, Montpellier, France|Investigational Site Number 250008, Nantes Cedex 01, France|Investigational Site Number 250007, Paris Cedex 10, France|Investigational Site Number 250001, Pierre Benite Cedex, France|Investigational Site Number 250005, Rennes, France|Investigational Site Number 250003, Rouen Cedex, France|Investigational Site Number 250002, Villejuif Cedex, France|Investigational Site Number 578001, Oslo, Norway","https://ClinicalTrials.gov/show/NCT01470456"
524,"Safety and Pharmacokinetics of SAR245408 Daily Oral in Patients With Solid Tumors","Completed","No Results Available","Neoplasm Malignant","Drug: SAR245408","Investigational Site Number 392002, Kobe-Shi, Japan|Investigational Site Number 392001, Nagoya-Shi, Japan","https://ClinicalTrials.gov/show/NCT01392924"
525,"Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine","Completed","Has Results","Type 1 Diabetes Mellitus","Drug: SAR342434|Drug: Humalog|Drug: Insulin glargine HOE901","Investigational Site Number 840049, Tucson, Arizona, United States|Investigational Site Number 840016, Bell Gardens, California, United States|Investigational Site Number 840048, Chula Vista, California, United States|Investigational Site Number 840046, Concord, California, United States|Investigational Site Number 840039, Fresno, California, United States|Investigational Site Number 840028, La Jolla, California, United States|Investigational Site Number 840022, Ventura, California, United States|Investigational Site Number 840003, Denver, Colorado, United States|Investigational Site Number 840037, Denver, Colorado, United States|Investigational Site Number 840005, Bradenton, Florida, United States|Investigational Site Number 840061, Miami Lakes, Florida, United States|Investigational Site Number 840057, Miami Lakes, Florida, United States|Investigational Site Number 840050, Miami, Florida, United States|Investigational Site Number 840042, Miami, Florida, United States|Investigational Site Number 840006, New Port Richey, Florida, United States|Investigational Site Number 840013, North Miami Beach, Florida, United States|Investigational Site Number 840031, Port Charlotte, Florida, United States|Investigational Site Number 840036, Atlanta, Georgia, United States|Investigational Site Number 840045, Roswell, Georgia, United States|Investigational Site Number 840020, Idaho Falls, Idaho, United States|Investigational Site Number 840019, Chicago, Illinois, United States|Investigational Site Number 840033, Chicago, Illinois, United States|Investigational Site Number 840012, McHenry, Illinois, United States|Investigational Site Number 840004, Des Moines, Iowa, United States|Investigational Site Number 840043, Marrero, Louisiana, United States|Investigational Site Number 840021, Metairie, Louisiana, United States|Investigational Site Number 840038, Baltimore, Maryland, United States|Investigational Site Number 840014, Rockville, Maryland, United States|Investigational Site Number 840060, Great Falls, Montana, United States|Investigational Site Number 840026, Omaha, Nebraska, United States|Investigational Site Number 840040, Omaha, Nebraska, United States|Investigational Site Number 840015, Albuquerque, New Mexico, United States|Investigational Site Number 840054, Albuquerque, New Mexico, United States|Investigational Site Number 840059, Mineola, New York, United States|Investigational Site Number 840030, Burlington, North Carolina, United States|Investigational Site Number 840051, Greenville, North Carolina, United States|Investigational Site Number 840062, Wilmington, North Carolina, United States|Investigational Site Number 840018, Gallipolis, Ohio, United States|Investigational Site Number 840007, Dakota Dunes, South Dakota, United States|Investigational Site Number 840027, Rapid City, South Dakota, United States|Investigational Site Number 840041, Dallas, Texas, United States|Investigational Site Number 840029, Dallas, Texas, United States|Investigational Site Number 840034, Dallas, Texas, United States|Investigational Site Number 840002, Houston, Texas, United States|Investigational Site Number 840011, Chesapeake, Virginia, United States|Investigational Site Number 840023, Tacoma, Washington, United States|Investigational Site Number 840009, Milwaukee, Wisconsin, United States|Investigational Site Number 250002, Corbeil Essonnes, France|Investigational Site Number 250005, Mantes La Jolie, France|Investigational Site Number 250003, Montpellier Cedex 5, France|Investigational Site Number 250001, Vandoeuvre Les Nancy, France|Investigational Site Number 276001, Berlin, Germany|Investigational Site Number 276004, Dortmund, Germany|Investigational Site Number 276006, Hannover, Germany|Investigational Site Number 276002, Heidelberg, Germany|Investigational Site Number 276003, Neumünster, Germany|Investigational Site Number 276008, Pirna, Germany|Investigational Site Number 276007, Potsdam, Germany|Investigational Site Number 276005, Sulzbach-Rosenberg, Germany|Investigational Site Number 348002, Budapest, Hungary|Investigational Site Number 348005, Budapest, Hungary|Investigational Site Number 348003, Budapest, Hungary|Investigational Site Number 348011, Budapest, Hungary|Investigational Site Number 348010, Budapest, Hungary|Investigational Site Number 348001, Budapest, Hungary|Investigational Site Number 348007, Debrecen, Hungary|Investigational Site Number 392006, Chuo-Ku, Japan|Investigational Site Number 392003, Higashiosaka-Shi, Japan|Investigational Site Number 392004, Izumisano-Shi, Japan|Investigational Site Number 392005, Kamakura-Shi, Japan|Investigational Site Number 392001, Shinjuku-Ku, Japan|Investigational Site Number 392002, Yamato-Shi, Japan|Investigational Site Number 616005, Krakow, Poland|Investigational Site Number 616001, Poznan, Poland|Investigational Site Number 616003, Szczecin, Poland|Investigational Site Number 616002, Warszawa, Poland|Investigational Site Number 616004, Zabrze, Poland|Investigational Site Number 643003, Moscow, Russian Federation|Investigational Site Number 643006, Samara, Russian Federation|Investigational Site Number 643002, Saratov, Russian Federation|Investigational Site Number 643004, St-Petersburg, Russian Federation|Investigational Site Number 643001, St-Petersburg, Russian Federation|Investigational Site Number 643005, St-Petersburg, Russian Federation|Investigational Site Number 643007, Tomsk, Russian Federation|Investigational Site Number 724002, A Coruña, Spain|Investigational Site Number 724001, Cáceres, Spain|Investigational Site Number 724004, Lérida, Spain|Investigational Site Number 724005, Málaga, Spain|Investigational Site Number 724003, Sabadell, Spain","https://ClinicalTrials.gov/show/NCT02273180"
526,"Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia","Completed","No Results Available","Hematopoietic Neoplasm","Drug: SAR302503","Investigational Site Number 840008, Scottsdale, Arizona, United States|Investigational Site Number 840004, La Jolla, California, United States|Investigational Site Number 840005, Los Angeles, California, United States|Investigational Site Number 840011, Palo Alto, California, United States|Investigational Site Number 840010, Ann Arbor, Michigan, United States|Investigational Site Number 840007, Rochester, Minnesota, United States|Investigational Site Number 840003, St Louis, Missouri, United States|Investigational Site Number 840001, Houston, Texas, United States|Investigational Site Number 036001, Clayton, Australia|Investigational Site Number 036002, Kingswood, Australia|Investigational Site Number 036004, Kogarah, Australia|Investigational Site Number 036003, Randwick, Australia|Investigational Site Number 124002, Montreal, Canada|Investigational Site Number 124003, Toronto, Canada|Investigational Site Number 124001, Vancouver, Canada|Investigational Site Number 250004, Brest, France|Investigational Site Number 250003, Marseille, France|Investigational Site Number 250001, Paris Cedex 10, France|Investigational Site Number 276004, Frankfurt Am Main, Germany|Investigational Site Number 276003, Mannheim, Germany|Investigational Site Number 380003, Bologna, Italy|Investigational Site Number 380001, Firenze, Italy|Investigational Site Number 380004, Orbassano, Italy|Investigational Site Number 410001, Seongnam, Korea, Republic of|Investigational Site Number 410003, Seoul, Korea, Republic of|Investigational Site Number 410004, Seoul, Korea, Republic of|Investigational Site Number 410002, Seoul, Korea, Republic of|Investigational Site Number 724004, Badalona, Spain|Investigational Site Number 724001, Barcelona, Spain|Investigational Site Number 724003, Madrid, Spain|Investigational Site Number 724002, Valencia, Spain|Investigational Site Number 826001, Belfast, United Kingdom|Investigational Site Number 826006, Birmingham, United Kingdom|Investigational Site Number 826003, London, United Kingdom|Investigational Site Number 826004, London, United Kingdom","https://ClinicalTrials.gov/show/NCT01420783"
527,"Phase I, Dose Escalation of SAR125844 in Asian Solid Tumor Patients","Completed","No Results Available","Neoplasm Malignant","Drug: SAR125844","Investigational Site Number 392001, Kashiwa-Shi, Japan|Investigational Site Number 392004, Suita-Shi, Japan|Investigational Site Number 392002, Sunto-Gun, Japan|Investigational Site Number 392003, Takatsuki-Shi, Japan|Investigational Site Number 410001, Seoul, Korea, Republic of|Investigational Site Number 410004, Seoul, Korea, Republic of|Investigational Site Number 410003, Seoul, Korea, Republic of|Investigational Site Number 410002, Seoul, Korea, Republic of","https://ClinicalTrials.gov/show/NCT01657214"
528,"Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial","Recruiting","No Results Available","Coronavirus|Severe Acute Respiratory Syndrome","Drug: Azithromycin|Drug: Hydoxychloroquine or Chloroquine|Drug: Interferon-Beta","Hamilton Health Sciences, Hamilton, Ontario, Canada","https://ClinicalTrials.gov/show/NCT04324463"
529,"Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies","Recruiting","No Results Available","Neoplasm","Drug: Isatuximab SAR650984|Drug: Atezolizumab","Investigational Site Number 8400003, Los Angeles, California, United States|Investigational Site Number 8400004, Santa Monica, California, United States|Investigational Site Number 8400207, Boston, Massachusetts, United States|Investigational Site Number 8400007, Boston, Massachusetts, United States|Investigational Site Number 8400107, Boston, Massachusetts, United States|Investigational Site Number 8400001, Hackensack, New Jersey, United States|Investigational Site Number 8400006, Philadelphia, Pennsylvania, United States|Investigational Site Number 8400002, Houston, Texas, United States|Investigational Site Number 8400005, Seattle, Washington, United States|Investigational Site Number 0560001, Bruxelles, Belgium|Investigational Site Number 0560002, Gent, Belgium|Investigational Site Number 1240002, Edmonton, Canada|Investigational Site Number 1240001, Toronto, Canada|Investigational Site Number 2030001, Brno, Czechia|Investigational Site Number 2030003, Olomouc, Czechia|Investigational Site Number 2030002, Praha 2, Czechia|Investigational Site Number 2030004, Praha 8, Czechia|Investigational Site Number 2500003, Bordeaux Cedex, France|Investigational Site Number 2500005, Rennes Cedex, France|Investigational Site Number 2500001, Villejuif Cedex, France|Investigational Site Number 3000002, Patra, Greece|Investigational Site Number 3800007, Meldola, Italy|Investigational Site Number 3800009, Milano, Italy|Investigational Site Number 3800006, Napoli, Italy|Investigational Site Number 3800004, Padova, Italy|Investigational Site Number 3800002, Pavia, Italy|Investigational Site Number 3800005, Roma, Italy|Investigational Site Number 3800003, Rozzano, Italy|Investigational Site Number 5280001, Rotterdam, Netherlands|Investigational Site Number 7240001, Barcelona, Spain|Investigational Site Number 7240002, Barcelona, Spain|Investigational Site Number 7240006, Hospitalet De Llobregat, Spain|Investigational Site Number 7240009, Madrid, Spain|Investigational Site Number 7240003, Madrid, Spain|Investigational Site Number 7240007, Madrid, Spain|Investigational Site Number 7240004, Madrid, Spain|Investigational Site Number 7240008, Pamplona, Spain|Investigational Site Number 1580005, Kaohsiung, Taiwan|Investigational Site Number 1580002, Tainan, Taiwan|Investigational Site Number 1580001, Taipei 100, Taiwan|Investigational Site Number 1580003, Taipei, Taiwan|Investigational Site Number 1580006, Taipei, Taiwan|Investigational Site Number 1580004, Taipei, Taiwan","https://ClinicalTrials.gov/show/NCT03637764"
530,"Efficacy and Safety of SAR339658 in Patients With Moderate to Severe Ulcerative Colitis","Terminated","No Results Available","Ulcerative Colitis","Drug: SAR339658|Other: Placebo","Investigational Site Number 840065, Sun City, Arizona, United States|Investigational Site Number 840059, Mission Hills, California, United States|Investigational Site Number 840074, San Diego, California, United States|Investigational Site Number 840061, Littleton, Colorado, United States|Investigational Site Number 840003, Miami, Florida, United States|Investigational Site Number 840008, Miramar,, Florida, United States|Investigational Site Number 840048, Winter Park,, Florida, United States|Investigational Site Number 840053, Savannah,, Georgia, United States|Investigational Site Number 840001, Chicago, Illinois, United States|Investigational Site Number 840005, Oak Lawn, Illinois, United States|Investigational Site Number 840078, Hammond, Louisiana, United States|Investigational Site Number 840070, Rochester Hills, Michigan, United States|Investigational Site Number 840060, Ocean Springs, Mississippi, United States|Investigational Site Number 840024, Mexico, Missouri, United States|Investigational Site Number 840051, Great Neck, New York, United States|Investigational Site Number 840071, Rochester, New York, United States|Investigational Site Number 840089, Winston Salem, North Carolina, United States|Investigational Site Number 840046, Cincinnati, Ohio, United States|Investigational Site Number 840045, Phoenixville, Pennsylvania, United States|Investigational Site Number 840019, Pasadena,, Texas, United States|Investigational Site Number 840088, San Antonio, Texas, United States|Investigational Site Number 840038, Sugar Land, Texas, United States|Investigational Site Number 840068, Charlottesville,, Virginia, United States|Investigational Site Number 840034, Seattle, Washington, United States|Investigational Site Number 840064, Wauwatosa, Wisconsin, United States|Investigational Site Number 040003, Innsbruck, Austria|Investigational Site Number 124002, Vancouver, Canada|Investigational Site Number 250003, Grenoble, France|Investigational Site Number 250006, Vandoeuvre Les Nancy, France|Investigational Site Number 276001, Berlin, Germany|Investigational Site Number 276007, Hamburg, Germany|Investigational Site Number 276005, Hamburg, Germany|Investigational Site Number 380003, Firenze, Italy|Investigational Site Number 380006, San Giovanni Rotondo, Italy|Investigational Site Number 616001, Gdynia, Poland|Investigational Site Number 616004, Lodz, Poland|Investigational Site Number 616005, Lodz, Poland|Investigational Site Number 616002, Lodz, Poland|Investigational Site Number 616007, Poznan, Poland|Investigational Site Number 616006, Sroda Wielkopolska, Poland|Investigational Site Number 616008, Warszawa, Poland","https://ClinicalTrials.gov/show/NCT01659138"
531,"Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration","Active, not recruiting","No Results Available","Stargardt's Disease","Drug: Long term follow up in all patients who received SAR422459 in previous study TDU13583","Investigational Site Number 840001, Portland, Oregon, United States|Investigational Site Number 250001, Paris, France","https://ClinicalTrials.gov/show/NCT01736592"
532,"Proof of Biological Activity of SAR100842 in Systemic Sclerosis","Completed","No Results Available","Systemic Sclerosis","Drug: SAR100842|Drug: Placebo (for SAR100842)","Investigational Site Number 840006, Scottsdale, Arizona, United States|Investigational Site Number 840003, Washington, District of Columbia, United States|Investigational Site Number 840004, Baltimore, Maryland, United States|Investigational Site Number 840001, Boston, Massachusetts, United States|Investigational Site Number 840002, Ann Arbor, Michigan, United States|Investigational Site Number 840007, New Brunswick, New Jersey, United States|Investigational Site Number 840008, Pittsburgh, Pennsylvania, United States|Investigational Site Number 250003, Lille, France|Investigational Site Number 250001, Paris Cedex 14, France|Investigational Site Number 380001, Milano, Italy|Investigational Site Number 756001, Zürich, Switzerland|Investigational Site Number 826001, London, United Kingdom|Investigational Site Number 826002, Salford, United Kingdom","https://ClinicalTrials.gov/show/NCT01651143"
533,"SAR3419 Administered Weekly in Patients With Relapsed/Refractory CD19-positive B-cell Non-Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma|Non-Hodgkin","Drug: SAR3419","Sanofi-Aventis Investigational Site Number 250004, Creteil Cedex, France|Sanofi-Aventis Investigational Site Number 250006, Lille Cedex, France|Sanofi-Aventis Investigational Site Number 250001, Pierre Benite Cedex, France|Sanofi-Aventis Investigational Site Number 250005, Rennes, France|Sanofi-Aventis Investigational Site Number 250003, Rouen Cedex, France|Sanofi-Aventis Investigational Site Number 250002, Villejuif Cedex, France","https://ClinicalTrials.gov/show/NCT00796731"
534,"Open Label Pharmacokinetic Study of SAR302503 in Subjects With Renal Impairment","Completed","No Results Available","Renal Impairment","Drug: SAR302503","Investigational Site Number 840002, Orlando, Florida, United States|Investigational Site Number 840003, St. Paul, Minnesota, United States|Investigational Site Number 840001, Knoxville, Tennessee, United States","https://ClinicalTrials.gov/show/NCT01763190"
535,"Phase I/IIA Study of SAR422459 in Participants With Stargardt's Macular Degeneration","Terminated","Has Results","Stargardt's Disease","Drug: SAR422459","Investigational Site Number 840002, Miami, Florida, United States|Investigational Site Number 840005, Iowa City, Iowa, United States|Investigational Site Number 840001, Portland, Oregon, United States|Investigational Site Number 840004, Houston, Texas, United States|Investigational Site Number 250001, Paris, France","https://ClinicalTrials.gov/show/NCT01367444"
536,"Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial)","Recruiting","No Results Available","COVID-19|Severe Acute Respiratory Syndrome","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Instituto Nacional de Enfermedades Respiratorias, ""Ismael Cosío Villegas"", Mexico, City, Mexico","https://ClinicalTrials.gov/show/NCT04318015"
537,"Clinical Benefit of SAR650984, Bortezomib, Lenalidomide and Dexamethasone Combination in NDMM Patients Not Eligible for Transplant","Active, not recruiting","No Results Available","Plasma Cell Myeloma","Drug: Isatuximab SAR650984|Drug: Bortezomib|Drug: Lenalidomide|Drug: Dexamethasone|Drug: Acetaminophen (paracetamol) or equivalent|Drug: Ranitidine or equivalent|Drug: Diphenhydramine or equivalent","Investigational Site Number 8400006, Fort Myers, Florida, United States|Investigational Site Number 8400004, Saint Petersburg, Florida, United States|Investigational Site Number 8400007, Kansas City, Missouri, United States|Investigational Site Number 8400005, Nashville, Tennessee, United States|Investigational Site Number 8400001, Houston, Texas, United States|Investigational Site Number 8400009, Tyler, Texas, United States|Investigational Site Number 0360005, Clayton, Australia|Investigational Site Number 0360004, Heidelberg West, Australia|Investigational Site Number 0360003, Liverpool, Australia|Investigational Site Number 0360006, Nedlands, Australia|Investigational Site Number 0360007, South Brisbane, Australia|Investigational Site Number 0360001, Waratah, Australia|Investigational Site Number 0360008, West Perth, Australia|Investigational Site Number 0360002, Wollongong, Australia|Investigational Site Number 0560001, Liège, Belgium|Investigational Site Number 1560002, Beijing, China|Investigational Site Number 1560003, Beijing, China|Investigational Site Number 1560008, Changchun, China|Investigational Site Number 1560007, Fuzhou, China|Investigational Site Number 1560009, Guangzhou, China|Investigational Site Number 1560006, Guangzhou, China|Investigational Site Number 1560005, Hangzhou, China|Investigational Site Number 1560014, Hangzhou, China|Investigational Site Number 1560004, Nanjing, China|Investigational Site Number 1560013, Shanghai, China|Investigational Site Number 1560011, Shenyang, China|Investigational Site Number 1560001, Tianjin, China|Investigational Site Number 1560012, Wuhan, China|Investigational Site Number 2030002, Brno, Czechia|Investigational Site Number 2030007, Hradec Kralove, Czechia|Investigational Site Number 2030004, Olomouc, Czechia|Investigational Site Number 2030003, Ostrava - Poruba, Czechia|Investigational Site Number 2030006, Plzen, Czechia|Investigational Site Number 2030001, Praha 2, Czechia|Investigational Site Number 2080002, Aalborg, Denmark|Investigational Site Number 2080003, Aarhus N, Denmark|Investigational Site Number 2080004, Odense C, Denmark|Investigational Site Number 2500011, Bayonne, France|Investigational Site Number 2500007, Caen Cedex 9, France|Investigational Site Number 2500009, Dijon, France|Investigational Site Number 2500008, La Roche Sur Yon, France|Investigational Site Number 2500001, Lille, France|Investigational Site Number 2500003, Nantes, France|Investigational Site Number 2500012, Paris, France|Investigational Site Number 2500002, Pessac, France|Investigational Site Number 2500006, Pierre Benite Cedex, France|Investigational Site Number 2500005, Poitiers Cedex, France|Investigational Site Number 2500004, Toulouse Cedex 9, France|Investigational Site Number 2500010, Vandoeuvre-Les-Nancy Cedex, France|Investigational Site Number 2760003, Berlin, Germany|Investigational Site Number 2760004, Frankfurt Am Main, Germany|Investigational Site Number 2760001, Heidelberg, Germany|Investigational Site Number 2760005, Tübingen, Germany|Investigational Site Number 3000003, Athens, Greece|Investigational Site Number 3000001, Athens, Greece|Investigational Site Number 3000002, Thessaloniki, Greece|Investigational Site Number 3800005, Ancona, Italy|Investigational Site Number 3800003, Bergamo, Italy|Investigational Site Number 3800001, Bologna, Italy|Investigational Site Number 3800004, Brescia, Italy|Investigational Site Number 3800002, Torino, Italy|Investigational Site Number 3920004, Higashiibaraki-Gun, Japan|Investigational Site Number 3920008, Konan-Ku, Yokohama-Shi, Japan|Investigational Site Number 3920003, Kumamoto-Shi, Japan|Investigational Site Number 3920007, Nagoya-Shi, Japan|Investigational Site Number 3920005, Okayama-Shi, Japan|Investigational Site Number 3920009, Sendai-Shi, Japan|Investigational Site Number 3920001, Shibuya-Ku, Japan|Investigational Site Number 3920002, Shinjuku-Ku, Japan|Investigational Site Number 3920006, Sunto-Gun, Japan|Investigational Site Number 3920010, Yamagata-Shi, Japan|Investigational Site Number 4400002, Klaipeda, Lithuania|Investigational Site Number 4400001, Vilnius, Lithuania|Investigational Site Number 4840001, Monterrey, Mexico|Investigational Site Number 5540001, Auckland, New Zealand|Investigational Site Number 5540003, Hamilton, New Zealand|Investigational Site Number 5540002, Takapuna, New Zealand|Investigational Site Number 6160002, Gdansk, Poland|Investigational Site Number 6160003, Lodz, Poland|Investigational Site Number 6160004, Poznan, Poland|Investigational Site Number 6160001, Warszawa, Poland|Investigational Site Number 6200002, Braga, Portugal|Investigational Site Number 6200006, Coimbra, Portugal|Investigational Site Number 6200001, Lisboa, Portugal|Investigational Site Number 6200005, Porto, Portugal|Investigational Site Number 6200003, Porto, Portugal|Investigational Site Number 6430001, Moscow, Russian Federation|Investigational Site Number 6430002, Moscow, Russian Federation|Investigational Site Number 7240005, Barcelona, Spain|Investigational Site Number 7240004, Barcelona, Spain|Investigational Site Number 7240003, Madrid, Spain|Investigational Site Number 7240001, Murcia, Spain|Investigational Site Number 7520002, Lund, Sweden|Investigational Site Number 7520001, Stockholm, Sweden|Investigational Site Number 1580003, Changhua, Taiwan|Investigational Site Number 1580002, Taichung, Taiwan|Investigational Site Number 1580001, Taipei, Taiwan|Investigational Site Number 7920006, Adana, Turkey|Investigational Site Number 7920007, Ankara, Turkey|Investigational Site Number 7920001, Ankara, Turkey|Investigational Site Number 7920002, Istanbul, Turkey|Investigational Site Number 7920004, Izmir, Turkey|Investigational Site Number 7920003, Izmir, Turkey|Investigational Site Number 7920005, Kayseri, Turkey|Investigational Site Number 7920008, Samsun, Turkey","https://ClinicalTrials.gov/show/NCT03319667"
538,"Open Label Pharmacokinetic Study of SAR302503 in Subjects With Hepatic Impairment","Completed","No Results Available","Hepatic Impairment","Drug: SAR302503","Investigational Site Number 840003, Miami, Florida, United States|Investigational Site Number 840002, Orlando, Florida, United States|Investigational Site Number 840001, Knoxville, Tennessee, United States","https://ClinicalTrials.gov/show/NCT01762462"
539,"Phase 2 Study of SAR302503 in Patients With Myelofibrosis","Completed","No Results Available","Hematopoietic Neoplasm","Drug: SAR302503","Investigational Site Number 840001, San Francisco, California, United States|Investigational Site Number 840003, Ann Arbor, Michigan, United States|Investigational Site Number 840006, Rochester, Minnesota, United States|Investigational Site Number 840007, Canton, Ohio, United States","https://ClinicalTrials.gov/show/NCT01420770"
540,"A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia","Completed","No Results Available","Lymphoma","Drug: SAR245409","Investigational Site Number 840012, Los Angeles, California, United States|Investigational Site Number 840104, Fort Meyers, Florida, United States|Investigational Site Number 840006, Augusta, Georgia, United States|Investigational Site Number 840011, Maywood, Illinois, United States|Investigational Site Number 840010, Kansas City, Kansas, United States|Investigational Site Number 840013, Lexington, Kentucky, United States|Investigational Site Number 840007, Paducah, Kentucky, United States|Investigational Site Number 840004, Boston, Massachusetts, United States|Investigational Site Number 840015, St Louis, Missouri, United States|Investigational Site Number 840014, Canton, Ohio, United States|Investigational Site Number 840001, Philadelphia, Pennsylvania, United States|Investigational Site Number 840002, Morgantown, West Virginia, United States|Investigational Site Number 036002, Clayton, Australia|Investigational Site Number 036001, Hobart, Australia|Investigational Site Number 036005, Kingswood, Australia|Investigational Site Number 036003, Perth, Australia|Investigational Site Number 056003, Bruxelles, Belgium|Investigational Site Number 056002, Gent, Belgium|Investigational Site Number 056001, Leuven, Belgium|Investigational Site Number 250002, Montpellier, France|Investigational Site Number 250001, Pierre Benite Cedex, France|Investigational Site Number 250004, Rennes, France|Investigational Site Number 250005, Rouen Cedex, France|Investigational Site Number 250003, Villejuif Cedex, France|Investigational Site Number 276003, Frankfurt Am Main, Germany|Investigational Site Number 276002, Jena, Germany|Investigational Site Number 276001, Ulm, Germany|Investigational Site Number 528001, Amsterdam, Netherlands|Investigational Site Number 528003, Groningen, Netherlands|Investigational Site Number 528002, Rotterdam, Netherlands","https://ClinicalTrials.gov/show/NCT01403636"
541,"A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of SAR421869 in Patients With Usher Syndrome Type 1B","Active, not recruiting","No Results Available","Usher's Syndrome","Drug: Blood draw for the laboratory assessment","Investigational Site Number 840001, Portland, Oregon, United States|Investigational Site Number 250001, Paris, France","https://ClinicalTrials.gov/show/NCT02065011"
542,"Prevalence and Incidence of COVID-19 Infection in Patients With Chronic Plaque Psoriasis on Immunosuppressant Therapy","Not yet recruiting","No Results Available","Coronavirus Infection","Diagnostic Test: Nasopharyngeal swab",,"https://ClinicalTrials.gov/show/NCT04324866"
543,"A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification","Completed","No Results Available","Neoplasm Malignant","Drug: SAR125844","Investigational Site Number 056001, Edegem, Belgium","https://ClinicalTrials.gov/show/NCT02435121"
544,"Safety and Pharmacokinetics of SAR240550 (BSI-201) Twice Weekly in Patients With Advanced Solid Tumors","Completed","No Results Available","Advance Solid Tumors","Drug: Iniparib (SAR240550 - BSI-201)|Drug: Gemcitabine|Drug: Carboplatin","Sanofi-Aventis Investigational Site Number 392001, Kobe-Shi, Japan|Sanofi-Aventis Investigational Site Number 392002, Matsuyama-Shi, Japan","https://ClinicalTrials.gov/show/NCT01213381"
545,"A Study of the Safety and Pharmacokinetics of SAR245408 Tablets in Patients With Solid Tumors or Lymphoma","Completed","No Results Available","Neoplasm Malignant","Drug: SAR245408","Investigational Site Number 056001, Leuven, Belgium","https://ClinicalTrials.gov/show/NCT01943838"
546,"A Study of Investigational SAR256212 in Combination With SAR245408 in Patients With Solid Tumor Cancers","Completed","No Results Available","Solid Tumor Cancers","Drug: MM-121 (SAR256212)|Drug: SAR245408","Investigational Site Number 840001, Boston, Massachusetts, United States|Investigational Site Number 840101, Brookline, Massachusetts, United States|Investigational Site Number 840002, Nashville, Tennessee, United States","https://ClinicalTrials.gov/show/NCT01436565"
547,"Study of SAR97276A in the Treatment of Uncomplicated and Severe Malaria in Adults and Children.","Terminated","No Results Available","Malaria","Drug: SAR97276A","Sanofi-Aventis Administrative Office, Porto Novo, Benin|Sanofi-Aventis Administrative Office, Ouagadougou, Burkina Faso|Sanofi-Aventis Administrative Office, Libreville, Gabon|Sanofi-Aventis Administrative Office, Dodoma, Tanzania","https://ClinicalTrials.gov/show/NCT00739206"
548,"Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin Infusion","Completed","No Results Available","Type 1 Diabetes Mellitus","Drug: SAR342434|Drug: insulin lispro","Investigational Site Number 840002, Little Rock, Arkansas, United States|Investigational Site Number 840001, Denver, Colorado, United States","https://ClinicalTrials.gov/show/NCT02603510"
549,"Pharmacokinetic of Alirocumab SAR236553 (REGN727) Administered Subcutaneously at 3 Different Injection Sites in Healthy Subjects","Completed","No Results Available","Hypercholesterolemia","Drug: alirocumab SAR236553 (REGN727)","Investigational Site Number 826001, London, United Kingdom","https://ClinicalTrials.gov/show/NCT01785329"
550,"Drug Interaction Study of SAR302503 in Patients With Solid Tumor","Completed","No Results Available","Solid Tumor","Drug: SAR302503|Drug: omeprazol|Drug: metoprolol|Drug: midazolam","Investigational Site Number 840004, Augusta, Georgia, United States|Investigational Site Number 840001, Detroit, Michigan, United States|Investigational Site Number 840002, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT01585623"
551,"Safety and Tolerability Study of REGN846 (SAR302352) in Healthy Volunteers","Completed","No Results Available","Healthy","Biological: REGN846","Nucleus Network, Melbourne, Australia","https://ClinicalTrials.gov/show/NCT01209793"
552,"First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic Syndrome","Recruiting","No Results Available","Leukaemia","Drug: SAR440234","Investigational Site Number 8400001, Houston, Texas, United States|Investigational Site Number 2500004, Marseille, France|Investigational Site Number 2500001, Paris Cedex 10, France|Investigational Site Number 2500003, Villejuif Cedex, France","https://ClinicalTrials.gov/show/NCT03594955"
553,"Induction of Cytokines in Human Monocytes by SARS-CoV in Adults and Children","Unknown status","No Results Available","Healthy",,"National Taiwan University Hospital, Taipei, Taiwan","https://ClinicalTrials.gov/show/NCT00173563"
554,"A Study to Assess Primarily the Tolerability and Safety of SAR439794 After Repeated Sublingual Daily Administration in Peanut Allergic Adult and Adolescent Patients","Completed","No Results Available","Food Allergy","Drug: Glucopyranosyl Lipid A (GLA)|Drug: Sublingual Immuno Therapy (SLIT) Peanut Extract (PE)|Drug: Placebo for GLA|Drug: Placebo for SLIT PE","Investigational Site Number 8400004, Little Rock, Arkansas, United States|Investigational Site Number 8400019, Mission Viejo, California, United States|Investigational Site Number 8400008, San Diego, California, United States|Investigational Site Number 8400020, San Jose, California, United States|Investigational Site Number 8400006, Stanford, California, United States|Investigational Site Number 8400013, Denver, Colorado, United States|Investigational Site Number 8400014, Louisville, Kentucky, United States|Investigational Site Number 8400002, Baltimore, Maryland, United States|Investigational Site Number 8400001, Boston, Massachusetts, United States|Investigational Site Number 8400009, Minneapolis, Minnesota, United States|Investigational Site Number 8400016, Minneapolis, Minnesota, United States|Investigational Site Number 8400010, Charleston, North Carolina, United States|Investigational Site Number 8400011, Cincinnati, Ohio, United States|Investigational Site Number 8400012, Medford, Oregon, United States|Investigational Site Number 8400003, Seattle, Washington, United States|Investigational Site Number 8400017, Madison, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT03463135"
555,"A Study to Compare Pharmacokinetics (PK) and Pharmacodynamics (PD) of SAR341402 to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus","Completed","No Results Available","Type 1 Diabetes","Drug: SAR341402|Drug: Insulin Aspart","Investigational Site 276001, Neuss, Germany","https://ClinicalTrials.gov/show/NCT03202875"
556,"A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma","Completed","No Results Available","Neoplasm Malignant","Drug: SAR245409","Investigational Site Number 840001, Detroit, Michigan, United States|Investigational Site Number 840002, New Brunswick, New Jersey, United States|Investigational Site Number 840003, Dallas, Texas, United States","https://ClinicalTrials.gov/show/NCT01596270"
557,"Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors","Completed","No Results Available","Malignant Solid Tumors","Drug: SAR125844","Investigational Site Number 840001, Boston, Massachusetts, United States|Investigational Site Number 250002, Dijon, France|Investigational Site Number 250001, Villejuif, France|Investigational Site Number 380004, Bologna, Italy|Investigational Site Number 380002, Milano, Italy|Investigational Site Number 380001, Milano, Italy|Investigational Site Number 724001, Barcelona, Spain|Investigational Site Number 724003, Madrid, Spain","https://ClinicalTrials.gov/show/NCT01391533"
558,"Bepotastine Besilate Nasal Sprays in the Treatment of Seasonal Allergic Rhinitis (SAR)","Completed","No Results Available","Seasonal Allergic Rhinitis","Drug: Bepotastine besilate|Drug: Placebo","Bausch & Lomb Incorporated, Irvine, California, United States","https://ClinicalTrials.gov/show/NCT01753739"
559,"Inhaled Sedation in COVID-19-related Acute Respiratory Distress Syndrome (ISCA): an International Research Data Study in the Recent Context of Widespread Disease Resulting From the 2019 (SARS-CoV2) Coronavirus Pandemics (COVID-19)","Not yet recruiting","No Results Available","Critically Illness|Sedation|Invasive Mechanical Ventilation|Acute Respiratory Distress Syndrome","Drug: Intravenous sedation|Drug: Inhaled sedation","CHU, Clermont-Ferrand, France|Centre Hospitalier, Dunkerque, France|Pitié-Salpêtrière Hospital - APHP, Paris, France|CH Privé de la Loire, Saint-Étienne, France|University Medical Center Schleswig-Holstein, Kiel, Germany|Hospital Clínico Universitario de Valencia, Valencia, Spain","https://ClinicalTrials.gov/show/NCT04383730"
560,"Comparison of Exposure and Activity of SAR341402 Mix 70/30 to NovoLog Mix 70/30, NovoMix 30 and SAR341402 Rapid-acting Solution in Patients With Type 1 Diabetes Mellitus","Completed","No Results Available","Type 1 Diabetes","Drug: SAR341402|Drug: Insulin Aspart","Investigational Site Number 2760001, Neuss, Germany","https://ClinicalTrials.gov/show/NCT03916601"
561,"Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)","Completed","No Results Available","Chronic Obstructive Pulmonary Disease","Drug: Any Inhaled Corticosteroids as prescribed by treating physician as standard of care|Drug: Any Long Acting Beta Agonist as prescribed by treating physician as standard of care|Drug: Any Long Acting Muscarinic Agonist as prescribed by treating physician as standard of care|Drug: Any short-acting β agonist as prescribed by treating physician as standard of care","Investigational Site Number 8400002, Los Angeles, California, United States|Investigational Site Number 8400003, Riverside, California, United States|Investigational Site Number 8400006, Rolling Hills Estates, California, United States|Investigational Site Number 8400015, Westminster, California, United States|Investigational Site Number 8400013, Jacksonville, Florida, United States|Investigational Site Number 8400012, Columbia, Maryland, United States|Investigational Site Number 8400016, North Dartmouth, Massachusetts, United States|Investigational Site Number 8400020, South Dartmouth, Massachusetts, United States|Investigational Site Number 8400011, Minneapolis, Minnesota, United States|Investigational Site Number 8400005, Jamaica, New York, United States|Investigational Site Number 8400019, Chapel Hill, North Carolina, United States|Investigational Site Number 8400004, Raleigh, North Carolina, United States|Investigational Site Number 8400001, Medford, Oregon, United States|Investigational Site Number 8400009, Philadelphia, Pennsylvania, United States|Investigational Site Number 8400007, Plano, Texas, United States|Investigational Site Number 8400008, Greenfield, Wisconsin, United States|Investigational Site Number 0320001, Buenos Aires, Argentina|Investigational Site Number 0320005, Caba, Argentina|Investigational Site Number 0320002, Caba, Argentina|Investigational Site Number 0320004, Caba, Argentina|Investigational Site Number 0320006, Quilmes, Argentina|Investigational Site Number 0320003, Rosario, Argentina|Investigational Site Number 0360005, Bedford Park, Australia|Investigational Site Number 0360002, Chermside, Australia|Investigational Site Number 0360004, Clayton, Australia|Investigational Site Number 0360003, Frankston, Australia|Investigational Site Number 0360006, Kent Town, Australia|Investigational Site Number 0360001, Murdoch, Australia|Investigational Site Number 1240002, Burlington, Canada|Investigational Site Number 1240009, Hamilton, Canada|Investigational Site Number 1240003, Montreal, Canada|Investigational Site Number 1240001, Montreal, Canada|Investigational Site Number 1240005, Quebec, Canada|Investigational Site Number 1240006, St-Charles Borrommee, Canada|Investigational Site Number 1240008, Trois-Rivieres, Canada|Investigational Site Number 1240007, Vancouver, Canada|Investigational Site Number 1240004, Victoriaville, Canada|Investigational Site Number 1520002, Quillota, Chile|Investigational Site Number 1520001, Santiago, Chile|Investigational Site Number 1520007, Santiago, Chile|Investigational Site Number 1520004, Santiago, Chile|Investigational Site Number 1520003, Talcahuano, Chile|Investigational Site Number 1520005, Talca, Chile|Investigational Site Number 2760006, Berlin, Germany|Investigational Site Number 2760001, Großhansdorf, Germany|Investigational Site Number 2760002, Hamburg, Germany|Investigational Site Number 2760007, Koblenz, Germany|Investigational Site Number 2760004, München, Germany|Investigational Site Number 2760005, Rüdersdorf Bei Berlin, Germany|Investigational Site Number 6160001, Bialystok, Poland|Investigational Site Number 6160008, Bialystok, Poland|Investigational Site Number 6160005, Bydgoszcz, Poland|Investigational Site Number 6160009, Grudziadz, Poland|Investigational Site Number 6160007, Krakow, Poland|Investigational Site Number 6160002, Poznan, Poland|Investigational Site Number 6160006, Poznan, Poland|Investigational Site Number 6160010, Rzeszow, Poland|Investigational Site Number 6160003, Znin, Poland|Investigational Site Number 6430003, Moscow, Russian Federation|Investigational Site Number 6430001, Moscow, Russian Federation|Investigational Site Number 6430005, Moscow, Russian Federation|Investigational Site Number 6430002, Moscow, Russian Federation|Investigational Site Number 6430010, Saint-Petersburg, Russian Federation|Investigational Site Number 6430006, Saint-Petersburg, Russian Federation|Investigational Site Number 6430007, St-Petersburg, Russian Federation|Investigational Site Number 6430009, Stavropol, Russian Federation|Investigational Site Number 6430004, Ulyanovsk, Russian Federation|Investigational Site Number 7920004, Ankara, Turkey|Investigational Site Number 7920001, Istanbul, Turkey|Investigational Site Number 7920006, Izmir, Turkey|Investigational Site Number 7920007, Izmir, Turkey|Investigational Site Number 7920008, Kirikkale, Turkey|Investigational Site Number 7920002, Mersin, Turkey|Investigational Site Number 8040008, Chernivtsi, Ukraine|Investigational Site Number 8040012, Ivano-Frankivsk, Ukraine|Investigational Site Number 8040004, Ivano-Frankivsk, Ukraine|Investigational Site Number 8040002, Kharkiv, Ukraine|Investigational Site Number 8040011, Kharkiv, Ukraine|Investigational Site Number 8040007, Kyiv, Ukraine|Investigational Site Number 8040001, Kyiv, Ukraine|Investigational Site Number 8040006, Odesa, Ukraine|Investigational Site Number 8040003, Ternopil, Ukraine|Investigational Site Number 8040005, Vinnytsya, Ukraine","https://ClinicalTrials.gov/show/NCT03546907"
562,"Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia","Completed","Has Results","Hypercholesterolemia","Drug: Alirocumab|Drug: Ezetimibe|Drug: Placebo (for Alirocumab)|Drug: Placebo (for Ezetimibe)","Investigational Site Number 840603, Overland Park, Kansas, United States|Investigational Site Number 840601, Cincinnati, Ohio, United States|Investigational Site Number 840602, Richmond, Virginia, United States|Investigational Site Number 056601, Antwerpen, Belgium|Investigational Site Number 246601, Helsinki, Finland|Investigational Site Number 528602, Groningen, Netherlands|Investigational Site Number 528601, Rotterdam, Netherlands|Investigational Site Number 528603, Velp, Netherlands","https://ClinicalTrials.gov/show/NCT01644474"
563,"Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and / or JAK Inhibitors in the Prevention of SARS-CoV-2 Infection","Not yet recruiting","No Results Available","COVID 19|Immunomediated Inflammatory Disease in Treatment With Biological Agents and / or Jak Inhibitors","Drug: Hidroxicloroquina|Drug: Control group",,"https://ClinicalTrials.gov/show/NCT04330495"
564,"A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI","Terminated","Has Results","Microvascular Coronary Artery Disease","Drug: SAR407899|Drug: Placebo|Drug: Adenosine|Drug: Regadenoson|Drug: 13N-ammonia|Drug: 82Rubidium","Investigational Site Number 8400003, Los Angeles, California, United States|Investigational Site Number 8400001, Jacksonville, Florida, United States|Investigational Site Number 8400013, Wellington, Florida, United States|Investigational Site Number 8400008, Baltimore, Maryland, United States|Investigational Site Number 8400006, Boston, Massachusetts, United States|Investigational Site Number 8400010, Philadelphia, Pennsylvania, United States|Investigational Site Number 2080001, København Nv, Denmark|Investigational Site Number 4100002, Seoul, Korea, Republic of|Investigational Site Number 5280001, Nijmegen, Netherlands|Investigational Site Number 7520001, Lund, Sweden","https://ClinicalTrials.gov/show/NCT03236311"
565,"Single Injection of REGN475/SAR164877 in the Treatment of Chronic Pancreatitis Pain","Terminated","No Results Available","Abdominal Pain Upper","Drug: REGN475/SAR164877|Drug: Placebo (for REGN475/SAR164877)","Sanofi-Aventis Investigational Site Number 840024, Arcadia, California, United States|Sanofi-Aventis Investigational Site Number 840011, Bell Gardens, California, United States|Sanofi-Aventis Investigational Site Number 840003, Monterey, California, United States|Sanofi-Aventis Investigational Site Number 840048, San Diego, California, United States|Sanofi-Aventis Investigational Site Number 840034, Stanford, California, United States|Sanofi-Aventis Investigational Site Number 840031, Miami, Florida, United States|Sanofi-Aventis Investigational Site Number 840029, St. Petersburg, Florida, United States|Sanofi-Aventis Investigational Site Number 840017, Marietta, Georgia, United States|Sanofi-Aventis Investigational Site Number 840013, Worcester, Massachusetts, United States|Sanofi-Aventis Investigational Site Number 840030, Lebanon, New Hampshire, United States|Sanofi-Aventis Investigational Site Number 840023, New York, New York, United States|Sanofi-Aventis Investigational Site Number 840052, Winston Salem, North Carolina, United States|Sanofi-Aventis Investigational Site Number 840005, Cleveland, Ohio, United States|Sanofi-Aventis Investigational Site Number 840043, Dallas, Texas, United States|Sanofi-Aventis Investigational Site Number 840053, Desoto, Texas, United States|Sanofi-Aventis Investigational Site Number 840050, Southlake, Texas, United States|Sanofi-Aventis Investigational Site Number 840040, East Sandy, Utah, United States","https://ClinicalTrials.gov/show/NCT01001923"
566,"Safety Study of XL147 (SAR245408) in Combination With Erlotinib in Adults With Solid Tumors","Completed","No Results Available","Cancer|Non-small Cell Lung Cancer","Drug: XL147 (SAR245408)|Drug: Erlotinib","Investigational Site Number 1214, Nashville, Tennessee, United States","https://ClinicalTrials.gov/show/NCT00692640"
567,"A Phase III, Double-blind, Randomized, Placebo-controlled Multicentre Clinical Trial to Assess the Efficacy and Safety of VPM1002 in Reducing Healthcare Professionals' Absenteeism in the SARS-CoV-2 Pandemic by Modulating the Immune System","Not yet recruiting","No Results Available","Infection, Respiratory Tract","Biological: VPM1002|Biological: Placebo",,"https://ClinicalTrials.gov/show/NCT04387409"
568,"Multiple Ascending Dose Study To Assess The Safety Profile Of SAR113244 Versus Placebo In Lupus Male And Female Patients","Completed","No Results Available","Systemic Lupus Erythematosus","Drug: SAR113244|Drug: placebo","Investigational Site Number 276001, Berlin, Germany","https://ClinicalTrials.gov/show/NCT02321709"
569,"Evaluation of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-Naïve Adult Male Patients With Fabry Disease","Completed","Has Results","Fabry Disease","Drug: GZ/SAR402671","Investigational Site Number 840002, Atlanta, Georgia, United States|Investigational Site Number 840003, Cincinnati, Ohio, United States|Investigational Site Number 840001, Fairfax, Virginia, United States|Investigational Site Number 250001, Garches, France|Investigational Site Number 616001, Warszawa, Poland|Investigational Site Number 643002, Moscow, Russian Federation|Investigational Site Number 826002, Cambridge, United Kingdom","https://ClinicalTrials.gov/show/NCT02489344"
570,"A Phase 2 Study of the C3 Inhibitor AMY-101 in Patients With ARDS Due to COVID-19 (SAVE)","Not yet recruiting","No Results Available","Acute Respiratory Distress Syndrome Due to SARS-CoV-2 Infection (Severe COVID19)","Drug: AMY-101|Other: WFI 5% glucose",,"https://ClinicalTrials.gov/show/NCT04395456"
571,"A Phase Ib Study of SAR650984 in Combination With Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma","Suspended","No Results Available","Multiple Myeloma","Biological: Isatuximab|Drug: Carfilzomib|Drug: Dexamethasone|Drug: Lenalidomide","University of California, San Francisco, San Francisco, California, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States","https://ClinicalTrials.gov/show/NCT02332850"
572,"Behavior, Environment And Treatments for Covid-19","Recruiting","No Results Available","Coronavirus","Other: Observation of patients with known, suspected, or at risk for COVID-19 infection","BEAT19.org, San Francisco, California, United States","https://ClinicalTrials.gov/show/NCT04321811"
573,"Pharmacodynamics Assessment Study After Single Subcutaneous Dose Of SAR113244 Versus Placebo In Lupus Male And Female Patients","Withdrawn","No Results Available","Systemic Lupus Erythematosus","Drug: SAR113244|Drug: placebo",,"https://ClinicalTrials.gov/show/NCT02331810"
574,"A Study to Compare Pharmacokinetics and Pharmacodynamics of SAR342434 to Insulin Lispro in Subjects With Type 1 Diabetes","Completed","No Results Available","Type 1 Diabetes","Drug: SAR342434|Drug: Insulin Lispro","Sanofi Administrative Office, Frankfurt, Germany","https://ClinicalTrials.gov/show/NCT02273258"
575,"Single Injection of REGN475/SAR164877 in Treatment of Vertebral Fracture Pain","Terminated","No Results Available","Back Pain","Drug: REGN475/SAR164877|Drug: Placebo (for REGN475/SAR164877)","Sanofi-Aventis Investigational Site Number 840005, Beverly Hills, California, United States|Sanofi-Aventis Investigational Site Number 840001, Fresno, California, United States|Sanofi-Aventis Investigational Site Number 840017, Sacramento, California, United States|Sanofi-Aventis Investigational Site Number 840028, San Diego, California, United States|Sanofi-Aventis Investigational Site Number 840008, Stockton, California, United States|Sanofi-Aventis Investigational Site Number 840013, Boynton Beach, Florida, United States|Sanofi-Aventis Investigational Site Number 840047, Clearwater, Florida, United States|Sanofi-Aventis Investigational Site Number 840034, Atlanta, Georgia, United States|Sanofi-Aventis Investigational Site Number 840026, New York, New York, United States|Sanofi-Aventis Investigational Site Number 840044, Fort Worth, Texas, United States|Sanofi-Aventis Investigational Site Number 840023, Southlake, Texas, United States","https://ClinicalTrials.gov/show/NCT01001715"
576,"Extension Study for Long Term Evaluation of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis","Terminated","Has Results","Ankylosing Spondylitis","Drug: Sarilumab","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States|Sanofi-Aventis Administrative Office, Macquarie Park, New South Wales, Australia|Sanofi-Aventis Administrative Office, Wien, Austria|Sanofi-Aventis Administrative Office, Diegem, Belgium|Sanofi-Aventis Administrative Office, Laval, Canada|Sanofi-Aventis Administrative Office, Praha, Czechia|Sanofi-Aventis Administrative Office, Paris, France|Sanofi-Aventis Administrative Office, Budapest, Hungary|Sanofi-Aventis Administrative Office, Vilnius, Lithuania|Sanofi-Aventis Administrative Office, Gouda, Netherlands|Sanofi-Aventis Administrative Office, Warszawa, Poland|Sanofi-Aventis Administrative Office, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT01118728"
577,"Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-α Blockers","Terminated","Has Results","Rheumatoid Arthritis","Drug: Sarilumab|Drug: Placebo|Drug: Golimumab|Drug: methotrexate (MTX)|Drug: Folic/folinic acid","Investigational Site Number 840026, Freehold, New Jersey, United States|Investigational Site Number 840043, New York, New York, United States|Investigational Site Number 840025, Jackson, Tennessee, United States|Investigational Site Number 840038, Austin, Texas, United States|Investigational Site Number 170004, Barranquilla, Colombia|Investigational Site Number 170005, Barranquilla, Colombia|Investigational Site Number 170007, Bucaramanga, Colombia|Investigational Site Number 203002, Uherske Hradiste, Czechia|Investigational Site Number 380002, Firenze, Italy|Investigational Site Number 380005, Genova, Italy|Investigational Site Number 484008, Durango, Mexico|Investigational Site Number 484002, Guadalajara, Mexico|Investigational Site Number 724004, Oviedo, Spain|Investigational Site Number 724002, Valencia, Spain","https://ClinicalTrials.gov/show/NCT01217814"
578,"A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors","Recruiting","No Results Available","Metastatic Neoplasm","Drug: SAR441000|Drug: Cemiplimab REGN2810","Investigational Site Number 8400002, Houston, Texas, United States|Investigational Site Number 0560001, Bruxelles, Belgium|Investigational Site Number 0560002, Leuven, Belgium|Investigational Site Number 2500001, Villejuif Cedex, France|Investigational Site Number 2760002, Frankfurt Am Main, Germany|Investigational Site Number 2760001, Mainz, Germany|Investigational Site Number 2760003, Mannheim, Germany","https://ClinicalTrials.gov/show/NCT03871348"
579,"Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis","Completed","No Results Available","Hematopoietic Neoplasm","Drug: SAR302503|Drug: Placebo","Investigational Site Number 840014, Scottsdale, Arizona, United States|Investigational Site Number 840001, La Jolla, California, United States|Investigational Site Number 840012, La Jolla, California, United States|Investigational Site Number 840006, Los Angeles, California, United States|Investigational Site Number 840013, Baton Rouge, Louisiana, United States|Investigational Site Number 840008, Rochester, Minnesota, United States|Investigational Site Number 840009, Newark, New Jersey, United States|Investigational Site Number 840002, Canton, Ohio, United States|Investigational Site Number 840004, Houston, Texas, United States|Investigational Site Number 036001, Box Hill, Australia|Investigational Site Number 036005, Herston, Australia|Investigational Site Number 036003, Randwick, Australia|Investigational Site Number 036004, Tweed Heads, Australia|Investigational Site Number 036002, Wodonga, Australia|Investigational Site Number 040001, Wien, Austria|Investigational Site Number 056003, Antwerpen, Belgium|Investigational Site Number 056001, Leuven, Belgium|Investigational Site Number 076002, Jau, Brazil|Investigational Site Number 076004, Porto Alegre, Brazil|Investigational Site Number 076001, Rio De Janeiro, Brazil|Investigational Site Number 124001, Montreal, Canada|Investigational Site Number 124003, Montreal, Canada|Investigational Site Number 124002, Saint John, Canada|Investigational Site Number 250006, Marseille, France|Investigational Site Number 250005, Nantes Cedex 01, France|Investigational Site Number 250004, Nimes, France|Investigational Site Number 250002, Pierre Benite Cedex, France|Investigational Site Number 250007, Poitiers, France|Investigational Site Number 250003, Toulouse, France|Investigational Site Number 250001, Villejuif Cedex, France|Investigational Site Number 276006, Aachen, Germany|Investigational Site Number 276007, Bonn, Germany|Investigational Site Number 276008, Dresden, Germany|Investigational Site Number 276001, Mannheim, Germany|Investigational Site Number 348002, Budapest, Hungary|Investigational Site Number 348001, Debrecen, Hungary|Investigational Site Number 348007, Györ, Hungary|Investigational Site Number 348006, Kecskemét, Hungary|Investigational Site Number 348003, Miskolc, Hungary|Investigational Site Number 372002, Dublin, Ireland|Investigational Site Number 372001, Galway, Ireland|Investigational Site Number 376003, Haifa, Israel|Investigational Site Number 376002, Tel Hashomer, Israel|Investigational Site Number 380002, Bergamo, Italy|Investigational Site Number 380007, Bologna, Italy|Investigational Site Number 380004, Firenze, Italy|Investigational Site Number 380001, Pavia, Italy|Investigational Site Number 380006, Pavia, Italy|Investigational Site Number 380003, Varese, Italy|Investigational Site Number 410002, Bundang-Gu, Korea, Republic of|Investigational Site Number 410004, Seoul, Korea, Republic of|Investigational Site Number 410003, Seoul, Korea, Republic of|Investigational Site Number 410001, Seoul, Korea, Republic of|Investigational Site Number 410005, Seoul, Korea, Republic of|Investigational Site Number 410006, Seoul, Korea, Republic of|Investigational Site Number 410007, Seoul, Korea, Republic of|Investigational Site Number 440001, Kaunas, Lithuania|Investigational Site Number 440002, Klaipeda, Lithuania|Investigational Site Number 484001, Queretaro, Mexico|Investigational Site Number 616005, Brzozow, Poland|Investigational Site Number 616002, Gdansk, Poland|Investigational Site Number 616006, Lodz, Poland|Investigational Site Number 616010, Warszawa, Poland|Investigational Site Number 616003, Wroclaw, Poland|Investigational Site Number 620005, Coimbra, Portugal|Investigational Site Number 620004, Lisboa, Portugal|Investigational Site Number 620001, Lisboa, Portugal|Investigational Site Number 620003, Porto, Portugal|Investigational Site Number 642003, Brasov, Romania|Investigational Site Number 642004, Bucharest, Romania|Investigational Site Number 642002, Bucuresti, Romania|Investigational Site Number 642006, Bucuresti, Romania|Investigational Site Number 642001, Timisoara, Romania|Investigational Site Number 643009, Moscow, Russian Federation|Investigational Site Number 643001, Moscow, Russian Federation|Investigational Site Number 643010, Nizhny Novgorod, Russian Federation|Investigational Site Number 643008, Petrozavodsk, Russian Federation|Investigational Site Number 643004, St-Petersburg, Russian Federation|Investigational Site Number 643005, St.-Petersburg, Russian Federation|Investigational Site Number 643007, Volgograd, Russian Federation|Investigational Site Number 702002, Singapore, Singapore|Investigational Site Number 702001, Singapore, Singapore|Investigational Site Number 710003, Johannesburg, South Africa|Investigational Site Number 710002, Parktown, South Africa|Investigational Site Number 724001, Barcelona, Spain|Investigational Site Number 724002, Madrid, Spain|Investigational Site Number 752001, Stockholm, Sweden|Investigational Site Number 752002, Uddevalla, Sweden|Investigational Site Number 158002, Changhua, Taiwan|Investigational Site Number 158003, Kaohsiung, Taiwan|Investigational Site Number 158001, Taipei, Taiwan|Investigational Site Number 826006, Belfast, United Kingdom|Investigational Site Number 826003, Birmingham, United Kingdom|Investigational Site Number 826002, Glasgow, United Kingdom|Investigational Site Number 826004, Leeds, United Kingdom|Investigational Site Number 826001, London, United Kingdom|Investigational Site Number 826005, London, United Kingdom|Investigational Site Number 826007, Manchester, United Kingdom|Investigational Site Number 826008, Newcastle Upon Tyne, United Kingdom|Investigational Site Number 826009, Oxford, United Kingdom|Investigational Site Number 826010, Southampton, United Kingdom","https://ClinicalTrials.gov/show/NCT01437787"
580,"Phase 1 / 2 Study of SAR439859 Single Agent and in Combination With Palbociclib in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer (AMEERA-1)","Recruiting","No Results Available","Breast Cancer","Drug: SAR439859|Drug: palbociclib|Drug: midazolam","Investigational Site Number 8400005, Denver, Colorado, United States|Investigational Site Number 8400002, Boston, Massachusetts, United States|Investigational Site Number 8400102, Boston, Massachusetts, United States|Investigational Site Number 8400003, New York, New York, United States|Investigational Site Number 8400008, Pittsburgh, Pennsylvania, United States|Investigational Site Number 8400009, Charleston, South Carolina, United States|Investigational Site Number 8400004, Dallas, Texas, United States|Investigational Site Number 8400007, Round Rock, Texas, United States|Investigational Site Number 8400001, Seattle, Washington, United States|Investigational Site Number 0560001, Leuven, Belgium|Investigational Site Number 0560002, Wilrijk, Belgium|Investigational Site Number 1240004, Edmonton, Canada|Investigational Site Number 1240005, Montreal, Canada|Investigational Site Number 1240002, Toronto, Canada|Investigational Site Number 1240003, Vancouver, Canada|Investigational Site Number 2030002, Brno, Czechia|Investigational Site Number 2030004, Hradec Kralove, Czechia|Investigational Site Number 2030001, Praha 2, Czechia|Investigational Site Number 2030003, Praha 4, Czechia|Investigational Site Number 2500002, Bordeaux Cedex, France|Investigational Site Number 2500005, Lille, France|Investigational Site Number 2500003, Lyon, France|Investigational Site Number 2500001, Saint-Herblain, France|Investigational Site Number 2500004, Villejuif Cedex, France|Investigational Site Number 3800001, Milano, Italy|Investigational Site Number 3800003, Milano, Italy|Investigational Site Number 3800004, Napoli, Italy|Investigational Site Number 3800002, Negrar, Italy|Investigational Site Number 6160004, Gdynia, Poland|Investigational Site Number 6160003, Szczecin, Poland|Investigational Site Number 6160001, Warsaw, Poland|Investigational Site Number 6200001, Lisboa, Portugal|Investigational Site Number 6200002, Lisboa, Portugal|Investigational Site Number 6200003, Porto, Portugal|Investigational Site Number 7240007, Madrid, Spain|Investigational Site Number 7240001, Madrid, Spain|Investigational Site Number 7240002, Madrid, Spain|Investigational Site Number 8260002, Cardiff, United Kingdom|Investigational Site Number 8260001, Glasgow, United Kingdom|Investigational Site Number 8260003, Oxford, United Kingdom","https://ClinicalTrials.gov/show/NCT03284957"
581,"Myocardial Involvement of Severe Acute Respiratory Syndrome-Cov-2 (Covid19) Infected Patients","Recruiting","No Results Available","Cardiomyopathies","Diagnostic Test: Global Longitudinal Strain","UHToulouse, Toulouse, France","https://ClinicalTrials.gov/show/NCT04358952"
582,"Safety, Tolerability and Pharmacokinetics of SAR231893 (REGN668) in Healthy Japanese Adult Male Subjects","Completed","No Results Available","Healthy","Drug: SAR231893 (REGN668)|Drug: placebo","Investigational Site Number 392001, Toshima-Ku, Japan","https://ClinicalTrials.gov/show/NCT01537653"
583,"Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain","Completed","No Results Available","Neuropathic Pain","Drug: SAR292833|Drug: placebo","Investigational Site Number 840014, Tucson, Arizona, United States|Investigational Site Number 840007, Garden Grove, California, United States|Investigational Site Number 840020, Newport Beach, California, United States|Investigational Site Number 840038, Santa Ana, California, United States|Investigational Site Number 840002, Tustin, California, United States|Investigational Site Number 840046, Coral Gables, Florida, United States|Investigational Site Number 840013, Ocala, Florida, United States|Investigational Site Number 840034, Palm Beach Gardens, Florida, United States|Investigational Site Number 840019, Evansville, Indiana, United States|Investigational Site Number 840012, Indianapolis, Indiana, United States|Investigational Site Number 840042, Framingham, Massachusetts, United States|Investigational Site Number 840004, Springfield, Massachusetts, United States|Investigational Site Number 840035, St. Louis, Missouri, United States|Investigational Site Number 840010, Las Vegas, Nevada, United States|Investigational Site Number 840037, Albuquerque, New Mexico, United States|Investigational Site Number 840040, Hartsdale, New York, United States|Investigational Site Number 840001, New York, New York, United States|Investigational Site Number 840033, Rochester, New York, United States|Investigational Site Number 840015, Raleigh, North Carolina, United States|Investigational Site Number 840022, Winston Salem, North Carolina, United States|Investigational Site Number 840017, Toledo, Ohio, United States|Investigational Site Number 840044, Altoona, Pennsylvania, United States|Investigational Site Number 840018, Johnstown, Pennsylvania, United States|Investigational Site Number 840045, Tullahoma, Tennessee, United States|Investigational Site Number 840006, Austin, Texas, United States|Investigational Site Number 840043, Dallas, Texas, United States|Investigational Site Number 840032, Dallas, Texas, United States|Investigational Site Number 840016, Seattle, Washington, United States|Investigational Site Number 203002, Olomouc, Czech Republic|Investigational Site Number 203005, Praha 10, Czech Republic|Investigational Site Number 203006, Praha 10, Czech Republic|Investigational Site Number 348001, Budapest, Hungary|Investigational Site Number 348005, Budapest, Hungary|Investigational Site Number 348007, Budapest, Hungary|Investigational Site Number 348002, Budapest, Hungary|Investigational Site Number 348006, Debrecen, Hungary|Investigational Site Number 348003, Zalaegerszeg, Hungary|Investigational Site Number 616001, Bydgoszcz, Poland|Investigational Site Number 616002, Lublin, Poland|Investigational Site Number 616007, Sandomierz, Poland|Investigational Site Number 616004, Wloclawek, Poland|Investigational Site Number 643006, Kazan, Russian Federation|Investigational Site Number 643007, Kazan, Russian Federation|Investigational Site Number 643008, Moscow, Russian Federation|Investigational Site Number 643010, Moscow, Russian Federation|Investigational Site Number 643009, Moscow, Russian Federation|Investigational Site Number 643001, Moscow, Russian Federation|Investigational Site Number 643011, Moscow, Russian Federation|Investigational Site Number 643004, Nizhny Novgorod, Russian Federation|Investigational Site Number 643012, Novosibirsk, Russian Federation|Investigational Site Number 643013, St-Petersburg, Russian Federation|Investigational Site Number 643003, St-Petersburg, Russian Federation|Investigational Site Number 643014, St-Petersburg, Russian Federation|Investigational Site Number 643005, Yaroslavl, Russian Federation|Investigational Site Number 703004, Banska Bystrica, Slovakia|Investigational Site Number 703001, Dubnica Nad Vahom, Slovakia|Investigational Site Number 703003, Krompachy, Slovakia|Investigational Site Number 804002, Kiev, Ukraine|Investigational Site Number 804005, Kiev, Ukraine|Investigational Site Number 804004, Kyiv, Ukraine|Investigational Site Number 804003, Kyiv, Ukraine","https://ClinicalTrials.gov/show/NCT01463397"
584,"Stopping ACE-inhibitors in COVID-19","Recruiting","No Results Available","SARS-CoV-2|COVID-19","Drug: ACE inhibitor, angiotensin receptor blocker","Medical University Innsbruck, University Hospital of Internal Medicine III, Innsbruck, Tyrol, Austria|Landeskrankenhaus Hall, Hall In Tirol, Austria|Medical University Innsbruck, Intensive Care and Emergency Medicine Department, Innsbruck, Austria|Medical University Innsbruck, University Hospital of Internal Medicine II, Innsbruck, Austria|Medical University Innsbruck, University Hospital of Internal Medicine IV, Innsbruck, Austria|Medical University Innsbruck, University Hospital of Internal Medicine I, Innsbruck, Austria|Medical University Innsbruck, University Hospital of Internal Medicine V, Innsbruck, Austria|Klinikum Klagenfurt, Klagenfurt, Austria|Bezirkskrankenhaus Kufstein, Kufstein, Austria|Bezirkskrankenhaus St. Johann, Sankt Johann In Tirol, Austria|Bezirkskrankenhaus Schwaz, Schwaz, Austria|Krankenhaus St. Vinzenz Zams, Zams, Austria|LMU Klinikum, Medizinische Klinik I, Munich, Bavaria, Germany|Asklepios Stadtklinik Bad Tölz, Bad Tölz, Germany|Klinikum Landkreis Erding, Erding, Germany|Klinikum Memmingen, Memmingen, Germany|Deutsches Herzzentrum München, Munich, Germany|Klinikum rechts der Isar, Medizinische Klinik und Poliklinik I, Munich, Germany|LMU Klinikum, Medizinische Klinik III, Munich, Germany|LMU Klinikum, Medizinische Klinik II, Munich, Germany|LMU Klinikum, Medizinische Klinik IV, Munich, Germany|München Klinik Bogenhausen und Schwabing, Munich, Germany|Universitätsklinik der Paracelsus Medizinischen Privatuniversität, Nürnberg, Germany|Klinikum Starnberg, Starnberg, Germany|Klinik für Innere Medizin Weilheim, Weilheim, Germany","https://ClinicalTrials.gov/show/NCT04353596"
585,"Efficacy and Safety of Ciclesonide Nasal Spray in Participants With Seasonal Allergic Rhinitis (SAR) in Russia","Completed","Has Results","Seasonal Allergic Rhinitis","Drug: Ciclesonide|Drug: Ciclesonide Placebo","Kazan, Russian Federation|Krasnodar, Russian Federation|Moscow, Russian Federation|Saratov, Russian Federation|Stavropol, Russian Federation","https://ClinicalTrials.gov/show/NCT02155881"
586,"A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of GZ/SAR402671 in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation","Active, not recruiting","No Results Available","Parkinson's Disease","Drug: GZ/SAR402671|Drug: Placebo","Investigational Site Number 8400017, Scottsdale, Arizona, United States|Investigational Site Number 8400011, Scottsdale, Arizona, United States|Investigational Site Number 8400004, La Jolla, California, United States|Investigational Site Number 8400019, Palo Alto, California, United States|Investigational Site Number 8400013, Sunnyvale, California, United States|Investigational Site Number 8400015, New Haven, Connecticut, United States|Investigational Site Number 8400008, Boca Raton, Florida, United States|Investigational Site Number 8400016, Chicago, Illinois, United States|Investigational Site Number 8400005, Chicago, Illinois, United States|Investigational Site Number 8400014, Boston, Massachusetts, United States|Investigational Site Number 8400018, New York, New York, United States|Investigational Site Number 8400010, New York, New York, United States|Investigational Site Number 8400001, New York, New York, United States|Investigational Site Number 8400021, Portland, Oregon, United States|Investigational Site Number 8400020, Portland, Oregon, United States|Investigational Site Number 8400009, Portland, Oregon, United States|Investigational Site Number 8400002, Philadelphia, Pennsylvania, United States|Investigational Site Number 8400006, Fairfax, Virginia, United States|Investigational Site Number 8400012, Kirkland, Washington, United States|Investigational Site Number 0400001, Innsbruck, Austria|Investigational Site Number 1240001, Montreal, Canada|Investigational Site Number 1240002, Ottawa, Canada|Investigational Site Number 1240003, Vancouver, Canada|Investigational Site Number 2500001, Paris, France|Investigational Site Number 2760002, Kiel, Germany|Investigational Site Number 2760001, Tübingen, Germany|Investigational Site Number 3000004, Athens, Greece|Investigational Site Number 3000002, Larissa, Greece|Investigational Site Number 3760002, Haifa, Israel|Investigational Site Number 3760003, Petah-Tikva, Israel|Investigational Site Number 3760001, Tel Aviv, Israel|Investigational Site Number 3760004, Tel Hashomer, Israel|Investigational Site Number 3800001, Catanzaro, Italy|Investigational Site Number 3800004, Milano, Italy|Investigational Site Number 3800003, Pavia, Italy|Investigational Site Number 3800006, Rozzano, Italy|Investigational Site Number 3800002, Salerno, Italy|Investigational Site Number 3920001, Bunkyo-Ku, Japan|Investigational Site Number 3920003, Kodaira-Shi, Japan|Investigational Site Number 3920002, Kyoto-Shi, Japan|Investigational Site Number 3920005, Nagoya-Shi, Japan|Investigational Site Number 3920004, Osaka-Shi, Japan|Investigational Site Number 5780001, Trondheim, Norway|Investigational Site Number 6200002, Coimbra, Portugal|Investigational Site Number 6200003, Torres Vedras, Portugal|Investigational Site Number 7020001, Singapore, Singapore|Investigational Site Number 7020002, Singapore, Singapore|Investigational Site Number 7240002, Barcelona, Spain|Investigational Site Number 7240001, Sevilla, Spain|Investigational Site Number 7520001, Stockholm, Sweden|Investigational Site Number 1580001, Taoyuan County, Taiwan|Investigational Site Number 8260001, London, United Kingdom|Investigational Site Number 8260002, Oxford, United Kingdom","https://ClinicalTrials.gov/show/NCT02906020"
587,"QuadraMune(TM) for Prevention of COVID-19","Recruiting","No Results Available","Covid19|Coronavirus|SARS-CoV 2","Dietary Supplement: QuadraMune(TM)","Therapeutic Solutions International, Oceanside, California, United States","https://ClinicalTrials.gov/show/NCT04421391"
588,"Passive Immunity Trial of Nashville II for COVID-19","Recruiting","No Results Available","COVID-19|Coronavirus|SARS-CoV-2","Biological: pathogen reduced SARS-CoV-2 convalescent plasma|Biological: Placebo","Vanderbilt University Medical Center, Nashville, Tennessee, United States","https://ClinicalTrials.gov/show/NCT04362176"
589,"Comparison of the Pharmacokinetics and Safety of Two SAR231893 (REGN668) Drug Products in Healthy Subjects","Completed","No Results Available","Healthy","Biological: SAR231893 (REGN668) DP1|Biological: SAR231893 (REGN668) DP2","Investigational Site Number 840001, Daytona Beach, Florida, United States","https://ClinicalTrials.gov/show/NCT01537640"
590,"Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR)","Completed","Has Results","Seasonal Allergic Rhinitis","Drug: GSP 301 NS|Drug: Olopatadine HCl NS|Drug: Mometasone furoate NS|Drug: GSP 301 Placebo NS","Investigational Site 20, Mission Viejo, California, United States|Investigational Site 31, San Diego, California, United States|Investigational Site 29, San Jose, California, United States|Investigational Site 25, Centennial, Colorado, United States|Investigational Site 22, Colorado Springs, Colorado, United States|Investigational Site 10, Jupiter, Florida, United States|Investigational Site 30, Miami, Florida, United States|Investigational Site 37, Marietta, Georgia, United States|Investigational Site 15, Stockbridge, Georgia, United States|Investigational Site 23, Stockbridge, Georgia, United States|Investigational Site 11, Louisville, Kentucky, United States|Investigational Site 14, Baltimore, Maryland, United States|Investigational Site 33, Wheaton, Maryland, United States|Investigational Site 26, Ypsilanti, Michigan, United States|Investigational Site 19, Minneapolis, Minnesota, United States|Investigational Site 21, Saint Louis, Missouri, United States|Investigational Site 16, Bellevue, Nebraska, United States|Investigational Site 12, Skillman, New Jersey, United States|Investigational Site 36, Rochester, New York, United States|Investigational Site 18, Raleigh, North Carolina, United States|Investigational Site 27, Cincinnati, Ohio, United States|Investigational Site 34, Middleburg Heights, Ohio, United States|Investigational Site 32, Medford, Oregon, United States|Investigational Site 35, Portland, Oregon, United States|Investigational Site 13, Orangeburg, South Carolina, United States|Investigational Site 17, Spartanburg, South Carolina, United States|Investigational Site 3, Austin, Texas, United States|Investigational Site 5, Austin, Texas, United States|Investigational Site 8, Austin, Texas, United States|Investigational Site 1, Kerrville, Texas, United States|Investigational Site 7, New Braunfels, Texas, United States|Investigational Site 2, San Antonio, Texas, United States|Investigational Site 4, San Antonio, Texas, United States|Investigational Site 6, San Antonio, Texas, United States|Investigational Site 9, San Antonio, Texas, United States|Investigational Site 28, Waco, Texas, United States|Investigational Site 24, Draper, Utah, United States","https://ClinicalTrials.gov/show/NCT02631551"
591,"A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis","Completed","No Results Available","Myelofibrosis","Drug: SAR302503 (TG101348)","Investigational Site Number 840103, La Jolla, California, United States|Investigational Site Number 840102, Stanford, California, United States|Investigational Site Number 840105, Boston, Massachusetts, United States|Investigational Site Number 840106, Ann Arbor, Michigan, United States|Investigational Site Number 840104, Rochester, Minnesota, United States|Investigational Site Number 840101, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT00724334"
592,"Pharmacokinetic and Tolerability of Alirocumab SAR236553 (REGN727) in Patients With Hepatic Impairment and in Healthy Subjects","Completed","No Results Available","Hypercholesterolemia","Drug: alirocumab SAR236553 (REGN727)","Investigational Site Number 250001, Rennes, France|Investigational Site Number 498001, Chisinau, Moldova, Republic of","https://ClinicalTrials.gov/show/NCT01670734"
593,"Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)","Completed","Has Results","Seasonal Allergic Rhinitis|Hay Fever","Drug: Beclomethasone dipropionate|Drug: Placebo Nasal Aerosol","Teva Clinical Trial Site, Austin, Texas, United States|Teva Clinical Trial Site, New Braunfels, Texas, United States|Teva Clinical Trial Site, San Antonio, Texas, United States|Teva Clinical Trial Site, Waco, Texas, United States","https://ClinicalTrials.gov/show/NCT01024608"
594,"First in Man Study of SAR566658 Administered in Patients With CA6-Positive and Refractory Solid Tumor","Completed","No Results Available","Neoplasm Malignant","Drug: SAR566658","Investigational Site Number 840002, Cincinnati, Ohio, United States|Investigational Site Number 840001, San Antonio, Texas, United States|Investigational Site Number 250001, Toulouse Cedex, France|Investigational Site Number 724002, Madrid, Spain|Investigational Site Number 724001, Madrid, Spain","https://ClinicalTrials.gov/show/NCT01156870"
595,"COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111","Recruiting","No Results Available","Respiratory Distress Syndrome, Adult","Drug: Veru-111","HonorHealth, Scottsdale, Arizona, United States|Methodist Hospital, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|WC-CRCN at North Vista Hospital, Las Vegas, Nevada, United States|Inspira Medical Center, Vineland, New Jersey, United States","https://ClinicalTrials.gov/show/NCT04388826"
596,"To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF)","Completed","No Results Available","Idiopathic Pulmonary Fibrosis","Drug: SAR156597|Drug: Placebo (for SAR156597)","Investigational Site Number 840008, Sacramento, California, United States|Investigational Site Number 840009, Jacksonville, Florida, United States|Investigational Site Number 840011, Jacksonville, Florida, United States|Investigational Site Number 840006, Chicago, Illinois, United States|Investigational Site Number 840004, Joliet, Illinois, United States|Investigational Site Number 840005, Maywood, Illinois, United States|Investigational Site Number 840002, Wichita, Kansas, United States|Investigational Site Number 840003, Minneapolis, Minnesota, United States|Investigational Site Number 840013, New York, New York, United States|Investigational Site Number 840014, Cincinnati, Ohio, United States|Investigational Site Number 840010, Charleston, South Carolina, United States|Investigational Site Number 124003, Edmonton, Canada|Investigational Site Number 124001, Hamilton, Canada|Investigational Site Number 124002, Vancouver, Canada|Investigational Site Number 152003, Santiago, Chile|Investigational Site Number 152001, Santiago, Chile|Investigational Site Number 152002, Santiago, Chile|Investigational Site Number 484003, Mexico City, Mexico|Investigational Site Number 484002, Monterrey, Mexico|Investigational Site Number 724001, Barcelona, Spain|Investigational Site Number 724002, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT01529853"
597,"Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-naïve Adult Male Patients With Fabry Disease","Completed","Has Results","Fabry Disease","Drug: GZ/SAR402671","Investigational Site Number 840002, Atlanta, Georgia, United States|Investigational Site Number 840003, Cincinnati, Ohio, United States|Investigational Site Number 840001, Fairfax, Virginia, United States|Investigational Site Number 250001, Garches, France|Investigational Site Number 616001, Warszawa, Poland|Investigational Site Number 643002, Moscow, Russian Federation|Investigational Site Number 826003, Birmingham, United Kingdom|Investigational Site Number 826002, Cambridge, United Kingdom","https://ClinicalTrials.gov/show/NCT02228460"
598,"Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen","Completed","Has Results","Neoplasm Malignant","Drug: SAR245408|Drug: SAR245409","Investigational Site Number 840010, Birmingham, Alabama, United States|Investigational Site Number 840009, Los Angeles, California, United States|Investigational Site Number 840008, Los Angeles, California, United States|Investigational Site Number 840022, Denver, Colorado, United States|Investigational Site Number 840104, Fort Myers, Florida, United States|Investigational Site Number 840006, Augusta, Georgia, United States|Investigational Site Number 840004, Boston, Massachusetts, United States|Investigational Site Number 840021, Saint Louis, Missouri, United States|Investigational Site Number 840002, New Brunswick, New Jersey, United States|Investigational Site Number 840020, Canton, Ohio, United States|Investigational Site Number 840015, Columbus, Ohio, United States|Investigational Site Number 840017, Philadelphia, Pennsylvania, United States|Investigational Site Number 840007, Nashville, Tennessee, United States|Investigational Site Number 840003, Dallas, Texas, United States|Investigational Site Number 840005, San Antonio, Texas, United States|Investigational Site Number 840018, Morgantown, West Virginia, United States|Investigational Site Number 056001, Leuven, Belgium|Investigational Site Number 250004, Montpellier, France|Investigational Site Number 250003, Pierre Benite Cedex, France|Investigational Site Number 250005, Rouen Cedex, France|Investigational Site Number 724001, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT01587040"
599,"Safety, Tolerability and Pharmacokinetics of SAR113945 in Japanese Patients With Knee Osteoarthritis","Completed","No Results Available","Knee Osteoarthritis","Drug: placebo|Drug: SAR113945","Investigational Site Number 392001, Osaka-Shi, Japan","https://ClinicalTrials.gov/show/NCT01511549"
600,"Effect of Alirocumab (SAR236553/REGN727) Administered on Top of Ezetimibe or Fenofibrate on Lipid Profiles in Healthy Subjects","Completed","No Results Available","Hypercholesterolemia","Drug: Alirocumab|Drug: Ezetimibe|Drug: Ezetimibe Placebo|Drug: Fenofibrate","Investigational Site Number 250001, Rennes, France|Investigational Site Number 250002, Rueil Malmaison, France","https://ClinicalTrials.gov/show/NCT01723735"
601,"Identifying Critically-ill Patients With COVID-19 Who Will Benefit Most From Nutrition Support Therapy: Validation of the NUTRIC Nutritional Risk Assessment Tool","Active, not recruiting","No Results Available","Critically Ill|Coronavirus Infections","Other: Nutrition support","Peking University Third Hospital, Beijing, China","https://ClinicalTrials.gov/show/NCT04274322"
602,"Anti-parasitic Activity and Safety Assessment of SAR97276A in Children With Uncomplicated Malaria","Terminated","No Results Available","Malaria","Drug: SAR97276A|Drug: arthemeter + lumefantrine (ACTs)","Investigational Site Number 204001, Cotonou, Benin|Investigational Site Number 854001, Ouagadougou, Burkina Faso|Investigational Site Number 266001, Libreville, Gabon|Investigational Site Number 404001, Kisumu, Kenya","https://ClinicalTrials.gov/show/NCT01445938"
603,"Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OPUS-1)","Completed","Has Results","Keratoconjunctivitis Sicca|Dry Eye Disease","Drug: Lifitegrast|Drug: Placebo","OPUS-1 Investigational Site, Waterbury, Connecticut, United States|OPUS-1 Investigational Site, Louisville, Kentucky, United States|OPUS-1 Investigational Site, Augusta, Maine, United States|OPUS-1 Investigational Site, Lewiston, Maine, United States|OPUS-1 Investigational Site, Andover, Massachusetts, United States|OPUS-1 Investigational Site, Lancaster, Massachusetts, United States|OPUS-1 Investigational Site, Quincy, Massachusetts, United States|OPUS-1 Investigational Site, Wakefield, Massachusetts, United States|OPUS-1 Investigational Site, Winchester, Massachusetts, United States|OPUS-1 Investigational Site, Derry, New Hampshire, United States|OPUS-1 Investigational Site, Manchester, New Hampshire, United States|OPUS-1 Investigational Site, Memphis, Tennessee, United States|OPUS-1 Investigational Site, Norfolk, Virginia, United States","https://ClinicalTrials.gov/show/NCT01421498"
604,"Dose Ranging Study to Evaluate the Efficacy and Safety of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis","Completed","Has Results","Ankylosing Spondylitis","Drug: Sarilumab|Drug: Placebo","Investigational Site Number 840006, Birmingham, Alabama, United States|Investigational Site Number 840033, Anaheim, California, United States|Investigational Site Number 840027, Los Angeles, California, United States|Investigational Site Number 840007, San Diego, California, United States|Investigational Site Number 840013, San Francisco, California, United States|Investigational Site Number 840017, Upland, California, United States|Investigational Site Number 840009, Boca Raton, Florida, United States|Investigational Site Number 840001, Naples, Florida, United States|Investigational Site Number 840032, Orlando, Florida, United States|Investigational Site Number 840015, Boise, Idaho, United States|Investigational Site Number 840021, Rock Island, Illinois, United States|Investigational Site Number 840018, Kansas City, Kansas, United States|Investigational Site Number 840003, Wheaton, Maryland, United States|Investigational Site Number 840029, Worcester, Massachusetts, United States|Investigational Site Number 840008, Lansing, Michigan, United States|Investigational Site Number 840002, Saint Louis, Missouri, United States|Investigational Site Number 840028, Freehold, New Jersey, United States|Investigational Site Number 840016, Albany, New York, United States|Investigational Site Number 840036, Syracuse, New York, United States|Investigational Site Number 840010, Toledo, Ohio, United States|Investigational Site Number 840005, Oklahoma City, Oklahoma, United States|Investigational Site Number 840023, Bethlehem, Pennsylvania, United States|Investigational Site Number 840014, Duncansville, Pennsylvania, United States|Investigational Site Number 840004, Dallas, Texas, United States|Investigational Site Number 840030, Houston, Texas, United States|Investigational Site Number 840034, Chesapeake, Virginia, United States|Investigational Site Number 036001, East Malvern, Australia|Investigational Site Number 036003, Hobart, Australia|Investigational Site Number 036004, Shenton Park, Australia|Investigational Site Number 036002, Woolloongabba, Australia|Investigational Site Number 040001, Graz, Austria|Investigational Site Number 040002, Wien, Austria|Investigational Site Number 056003, Brussels, Belgium|Investigational Site Number 056005, Genk, Belgium|Investigational Site Number 056001, Gent, Belgium|Investigational Site Number 056002, Leuven, Belgium|Investigational Site Number 056004, Liège, Belgium|Investigational Site Number 124007, London, Canada|Investigational Site Number 124004, Montreal, Canada|Investigational Site Number 124008, Newmarket, Canada|Investigational Site Number 124003, Pointe-Claire, Canada|Investigational Site Number 124001, Quebec, Canada|Investigational Site Number 124006, Saskatoon, Canada|Investigational Site Number 124005, Toronto, Canada|Investigational Site Number 124009, Trois-Rivières, Canada|Investigational Site Number 124002, Vancouver, Canada|Investigational Site Number 124010, Vancouver, Canada|Investigational Site Number 203003, Brno, Czechia|Investigational Site Number 203005, Hlucin, Czechia|Investigational Site Number 203002, Hradec Kralove, Czechia|Investigational Site Number 203001, Praha 2, Czechia|Investigational Site Number 203004, Uherske Hradiste, Czechia|Investigational Site Number 250001, Besancon, France|Investigational Site Number 250005, Bordeaux, France|Investigational Site Number 250002, Creteil Cedex, France|Investigational Site Number 250003, Paris, France|Investigational Site Number 276002, Berlin, Germany|Investigational Site Number 276004, Erlangen, Germany|Investigational Site Number 276003, Frankfurt Am Main, Germany|Investigational Site Number 276005, Hamburg, Germany|Investigational Site Number 276001, Herne, Germany|Investigational Site Number 348001, Budapest, Hungary|Investigational Site Number 348003, Debrecen, Hungary|Investigational Site Number 348005, Sátoraljaújhely, Hungary|Investigational Site Number 348004, Veszprém, Hungary|Investigational Site Number 440001, Kaunas, Lithuania|Investigational Site Number 440002, Vilnius, Lithuania|Investigational Site Number 528001, Amsterdam, Netherlands|Investigational Site Number 528002, Nijmegen, Netherlands|Investigational Site Number 616002, Bialystok, Poland|Investigational Site Number 616001, Krakow, Poland|Investigational Site Number 616004, Lublin, Poland|Investigational Site Number 616005, Torun, Poland|Investigational Site Number 616003, Warszawa, Poland|Investigational Site Number 724005, Barcelona, Spain|Investigational Site Number 724004, La Coruña, Spain|Investigational Site Number 724002, Madrid, Spain|Investigational Site Number 724001, Sevilla, Spain|Investigational Site Number 792002, Ankara, Turkey|Investigational Site Number 792001, Izmir, Turkey","https://ClinicalTrials.gov/show/NCT01061723"
605,"Ascending Dose Study of the Safety and Tolerability of Alirocumab (SAR236553/REGN727) in Japanese Healthy Volunteers","Completed","No Results Available","Hypercholesterolemia","Drug: Alirocumab (Solution)|Drug: Alirocumab (Lyophilized formulation)|Drug: Placebo (Solution)|Drug: Placebo (Lyophilized formulation)","Sanofi-Aventis Administrative Office, Tokyo, Japan","https://ClinicalTrials.gov/show/NCT01448317"
606,"A Study on Safety and Tolerability of SAR425899 in Overweight to Obese Subjects and Type 2 Diabetes Mellitus Patients Not Requiring Anti-Diabetic Pharmacotherapy With an Optional 6-month Safety Extension Period","Completed","No Results Available","Type 2 Diabetes Mellitus","Drug: SAR425899","Investigational Site Number 8400002, Saint Paul, Minnesota, United States|Investigational Site Number 8400003, Knoxville, Tennessee, United States|Investigational Site Number 8400001, Austin, Texas, United States","https://ClinicalTrials.gov/show/NCT03414736"
607,"Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19)","Active, not recruiting","No Results Available","COVID-19","Biological: SARS-CoV-2 convalescent plasma","Danderyd Hospital, Danderyd, Sweden","https://ClinicalTrials.gov/show/NCT04390178"
608,"28-Day Repeated Topical Study to Evaluate the Safety and Activity of 5 Escalating Dose Levels of SAR366234 and One Dose of Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension","Completed","No Results Available","Open Angle Glaucoma -Ocular Hypertension","Drug: Latanoprost|Drug: SAR366234","Investigational Site Number 840001, Inglewood, California, United States|Investigational Site Number 840003, Cape Coral, Florida, United States|Investigational Site Number 840005, Roswell, Georgia, United States|Investigational Site Number 840004, St Joseph, Michigan, United States|Investigational Site Number 840002, Memphis, Tennessee, United States","https://ClinicalTrials.gov/show/NCT02531152"
609,"A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors","Recruiting","No Results Available","Malignant Solid Tumor","Biological: SAR439459|Drug: Cemiplimab REGN2810","Investigational Site Number 8400007, Duarte, California, United States|Investigational Site Number 8400004, Fairway, Kansas, United States|Investigational Site Number 8400001, Boston, Massachusetts, United States|Investigational Site Number 8400101, Boston, Massachusetts, United States|Investigational Site Number 8400008, Durham, North Carolina, United States|Investigational Site Number 8400006, Nashville, Tennessee, United States|Investigational Site Number 8400003, Dallas, Texas, United States|Investigational Site Number 0360002, Heidelberg West, Australia|Investigational Site Number 0360001, Melbourne, Australia|Investigational Site Number 0560001, Leuven, Belgium|Investigational Site Number 1240003, Calgary, Canada|Investigational Site Number 1240002, Montreal, Canada|Investigational Site Number 1240001, Toronto, Canada|Investigational Site Number 2330001, Tallinn, Estonia|Investigational Site Number 2500002, Marseille Cedex 5, France|Investigational Site Number 2500003, Nantes, France|Investigational Site Number 2500004, Paris Cedex 10, France|Investigational Site Number 2500001, Villejuif Cedex, France|Investigational Site Number 5280001, Rotterdam, Netherlands|Investigational Site Number 5280002, Utrecht, Netherlands|Investigational Site Number 7240002, Barcelona, Spain|Investigational Site Number 7240001, Barcelona, Spain|Investigational Site Number 7240003, Madrid, Spain|Investigational Site Number 7240004, Madrid, Spain|Investigational Site Number 8260002, Cardiff, United Kingdom","https://ClinicalTrials.gov/show/NCT03192345"
610,"Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer","Completed","No Results Available","Breast Cancer, Metastatic","Drug: Iniparib|Drug: Gemcitabine|Drug: Carboplatin","Sanofi-Aventis Investigational Site Number 036002, Parkville, Australia|Sanofi-Aventis Investigational Site Number 036001, Perth, Australia|Sanofi-Aventis Investigational Site Number 036003, Westmead, Australia|Sanofi-Aventis Investigational Site Number 056001, Bruxelles, Belgium|Sanofi-Aventis Investigational Site Number 056002, Leuven, Belgium|Sanofi-Aventis Investigational Site Number 250005, Besancon Cedex, France|Sanofi-Aventis Investigational Site Number 250003, Bordeaux, France|Sanofi-Aventis Investigational Site Number 250002, Dijon, France|Sanofi-Aventis Investigational Site Number 250006, Paris Cedex 05, France|Sanofi-Aventis Investigational Site Number 250004, Paris, France|Sanofi-Aventis Investigational Site Number 250001, Toulouse, France|Sanofi-Aventis Investigational Site Number 380004, Genova, Italy|Sanofi-Aventis Investigational Site Number 380001, Milano, Italy|Sanofi-Aventis Investigational Site Number 380002, Modena, Italy|Sanofi-Aventis Investigational Site Number 380003, Udine, Italy|Sanofi-Aventis Investigational Site Number 528001, Rotterdam, Netherlands|Sanofi-Aventis Investigational Site Number 724002, Barcelona, Spain|Sanofi-Aventis Investigational Site Number 724004, Madrid, Spain|Sanofi-Aventis Investigational Site Number 724001, Málaga, Spain|Sanofi-Aventis Investigational Site Number 724003, Valencia, Spain","https://ClinicalTrials.gov/show/NCT01045304"
611,"Colchicine Counteracting Inflammation in COVID-19 Pneumonia","Recruiting","No Results Available","Coronavirus Infections|Pneumonia, Viral","Drug: Colchicine","Azienda Ospedaliero Universitaria di Parma, Parma, PR, Italy","https://ClinicalTrials.gov/show/NCT04322565"
612,"Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors","Completed","No Results Available","Cancer|Non-Small Cell Lung Cancer|Endometrial Carcinoma|Ovarian Carcinoma","Drug: XL147 (SAR245408),|Drug: paclitaxel|Drug: carboplatin","Investigational Site Number, St. Louis, Missouri, United States|Investigational Site Number, Oklahoma City, Oklahoma, United States|Investigational Site Number, Houston, Texas, United States|Investigational Site Number, Madison, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT00756847"
613,"Pharmacokinetics, Pharmacodynamics and Safety Evaluation of SAR279356 in Intensive Care Unit Mechanically Ventilated Patients","Terminated","No Results Available","Infection Prophylaxis","Drug: SAR279356|Drug: placebo","Investigational Site Number 840010, Los Angeles, California, United States|Investigational Site Number 840020, Stanford, California, United States|Investigational Site Number 840006, Jacksonville, Florida, United States|Investigational Site Number 840001, Pikeville, Kentucky, United States|Investigational Site Number 840009, Butte, Montana, United States|Investigational Site Number 840003, Camden, New Jersey, United States","https://ClinicalTrials.gov/show/NCT01389700"
614,"Beaumont Health Large-scale Automated Serologic Testing for COVID-19","Recruiting","No Results Available","COVID-19|Coronavirus Infection|Severe Acute Respiratory Syndrome Coronavirus 2","Diagnostic Test: EUROIMMUN assay","Beaumont Health System, Royal Oak, Michigan, United States|Beaumont Health, Royal Oak, Michigan, United States","https://ClinicalTrials.gov/show/NCT04349202"
615,"A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses of SAR438544 in Comparison to Placebo and Glucagon in Healthy Subjects and Type 1 Diabetes Mellitus Patients","Completed","No Results Available","Type 1 Diabetes Mellitus","Drug: SAR438544|Drug: placebo|Drug: r-glucagon","Investigational Site Number 840001, Chula Vista, California, United States","https://ClinicalTrials.gov/show/NCT02625636"
616,"Study of How Single Rising Doses of SAR161271 Are Absorbed and Act in Patients With Type 1 Diabetes Mellitus (T1DM)","Completed","No Results Available","Type 1 Diabetes Mellitus","Drug: SAR161271|Drug: Insulin glargine HOE901","Sanofi-Aventis Administrative Office, Berlin, Germany","https://ClinicalTrials.gov/show/NCT01053728"
617,"Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer","Completed","No Results Available","Breast Cancer","Drug: XL147 (SAR245408)|Drug: XL765 (SAR245409)|Drug: letrozole (Femara)","Investigational Site Number 1537, Los Angeles, California, United States|Investigational Site Number 1601, Denver, Colorado, United States|Investigational Site Number 1238, Fort Meyers, Florida, United States|Investigational Site Number 1441, Chicago, Illinois, United States|Investigational Site Number 1138, Boston, Massachusetts, United States|Investigational Site Number 1331, Ann Arbor, Michigan, United States|Investigational Site Number 1330, Detroit, Michigan, United States|Investigational Site Number 5201, Columbia, Missouri, United States|Investigational Site Number 1252, Durham, North Carolina, United States|Investigational Site Number 1214, Nashville, Tennessee, United States|Investigational Site Number 5246, El Paso, Texas, United States|Investigational Site Number 3321, Nantes Saint Herblain, France|Investigational Site Number 3324, Paris Cedex 05, France|Investigational Site Number 3415, Barcelona, Spain|Investigational Site Number 3419, Barcelona, Spain|Investigational Site Number 3413, Madrid, Spain|Investigational Site Number 3420, Madrid, Spain","https://ClinicalTrials.gov/show/NCT01082068"
618,"Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib","Completed","No Results Available","Hematopoietic Neoplasm","Drug: SAR302503","Investigational Site Number 840007, Phoenix, Arizona, United States|Investigational Site Number 840003, San Francisco, California, United States|Investigational Site Number 840004, San Francisco, California, United States|Investigational Site Number 840005, Atlanta, Georgia, United States|Investigational Site Number 840014, Chicago, Illinois, United States|Investigational Site Number 840001, Kansas City, Kansas, United States|Investigational Site Number 840017, Baltimore, Maryland, United States|Investigational Site Number 840013, Baltimore, Maryland, United States|Investigational Site Number 840010, Ann Arbor, Michigan, United States|Investigational Site Number 840009, New York, New York, United States|Investigational Site Number 840018, New York, New York, United States|Investigational Site Number 840022, Cleveland, Ohio, United States|Investigational Site Number 840019, Middletown, Ohio, United States|Investigational Site Number 840024, Charleston, South Carolina, United States|Investigational Site Number 840002, Houston, Texas, United States|Investigational Site Number 840015, Salt Lake City, Utah, United States|Investigational Site Number 040002, Salzburg, Austria|Investigational Site Number 040001, Wien, Austria|Investigational Site Number 056002, Antwerpen, Belgium|Investigational Site Number 056003, Leuven, Belgium|Investigational Site Number 124001, Toronto, Canada|Investigational Site Number 250001, Marseille, France|Investigational Site Number 250003, Nimes Cedex 9, France|Investigational Site Number 250002, Paris Cedex 10, France|Investigational Site Number 250006, Paris Cedex 12, France|Investigational Site Number 250004, Toulouse, France|Investigational Site Number 276003, Frankfurt Am Main, Germany|Investigational Site Number 276007, Leipzig, Germany|Investigational Site Number 276006, Magdeburg, Germany|Investigational Site Number 276001, Mannheim, Germany|Investigational Site Number 276005, Ulm, Germany|Investigational Site Number 380004, Firenze, Italy|Investigational Site Number 380001, Milano, Italy|Investigational Site Number 380002, Roma, Italy|Investigational Site Number 380003, Varese, Italy|Investigational Site Number 528002, Amsterdam, Netherlands|Investigational Site Number 528003, Maastricht, Netherlands|Investigational Site Number 528001, Nijmegen, Netherlands|Investigational Site Number 724001, Barcelona, Spain|Investigational Site Number 724003, Majadahonda, Spain|Investigational Site Number 724002, Salamanca, Spain|Investigational Site Number 826001, London, United Kingdom","https://ClinicalTrials.gov/show/NCT01523171"
619,"A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer","Completed","No Results Available","Neoplasm Malignant","Drug: SAR260301|Drug: Vemurafenib","Investigational Site Number 840001, Boston, Massachusetts, United States|Investigational Site Number 840101, Boston, Massachusetts, United States|Investigational Site Number 840002, Houston, Texas, United States|Investigational Site Number 124001, Toronto, Canada","https://ClinicalTrials.gov/show/NCT01673737"
620,"A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas","Completed","No Results Available","Mixed Gliomas|Malignant Gliomas|Glioblastoma Multiforme","Drug: XL765 (SAR245409)|Drug: Temozolomide","Investigational Site Number, Birmingham, Alabama, United States|Investigational Site Number, Los Angeles, California, United States|Investigational Site Number, Boston, Massachusetts, United States|Investigational Site Number, New York, New York, United States|Investigational Site Number, Rochester, New York, United States|Investigational Site Number, Cleveland, Ohio, United States","https://ClinicalTrials.gov/show/NCT00704080"
621,"Injection Site Tolerability, Safety, Pharmacokinetics, Pharmacodynamics in Different Single-Dose Treatments of Alirocumab SAR236553 (REGN727) in Healthy Subjects","Completed","No Results Available","Hypercholesterolemia","Drug: alirocumab SAR236553 (REGN727)","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States","https://ClinicalTrials.gov/show/NCT01443650"
622,"Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients","Completed","Has Results","Rheumatoid Arthritis","Drug: Sarilumab|Drug: Placebo (for sarilumab)|Drug: Methotrexate|Drug: Folic Acid","Investigational Site Number 840070, Anniston, Alabama, United States|Investigational Site Number 840004, Birmingham, Alabama, United States|Investigational Site Number 840072, Gilbert, Arizona, United States|Investigational Site Number 840029, Beverly Hills, California, United States|Investigational Site Number 840007, Palm Desert, California, United States|Investigational Site Number 840008, San Francisco, California, United States|Investigational Site Number 840021, Santa Maria, California, United States|Investigational Site Number 840049, Upland, California, United States|Investigational Site Number 840050, Dunedin, Florida, United States|Investigational Site Number 840041, Jacksonville, Florida, United States|Investigational Site Number 840067, Jupiter, Florida, United States|Investigational Site Number 840048, Miami, Florida, United States|Investigational Site Number 840006, Orlando, Florida, United States|Investigational Site Number 840063, Palm Harbor, Florida, United States|Investigational Site Number 840060, Sarasota, Florida, United States|Investigational Site Number 840003, Atlanta, Georgia, United States|Investigational Site Number 840028, Decatur, Georgia, United States|Investigational Site Number 840027, Marietta, Georgia, United States|Investigational Site Number 840018, Idaho Falls, Idaho, United States|Investigational Site Number 840046, Chicago, Illinois, United States|Investigational Site Number 840015, Lexington, Kentucky, United States|Investigational Site Number 840073, Cumberland, Maryland, United States|Investigational Site Number 840055, Frederick, Maryland, United States|Investigational Site Number 840013, Wheaton, Maryland, United States|Investigational Site Number 840066, Saint Louis, Missouri, United States|Investigational Site Number 840071, Omaha, Nebraska, United States|Investigational Site Number 840056, New York, New York, United States|Investigational Site Number 840068, Hickory, North Carolina, United States|Investigational Site Number 840044, Toledo, Ohio, United States|Investigational Site Number 840002, Oklahoma City, Oklahoma, United States|Investigational Site Number 840011, Tulsa, Oklahoma, United States|Investigational Site Number 840065, Tulsa, Oklahoma, United States|Investigational Site Number 840010, Bethlehem, Pennsylvania, United States|Investigational Site Number 840009, Duncansville, Pennsylvania, United States|Investigational Site Number 840062, Reading, Pennsylvania, United States|Investigational Site Number 840058, Columbia, South Carolina, United States|Investigational Site Number 840016, North Charleston, South Carolina, United States|Investigational Site Number 840025, Jackson, Tennessee, United States|Investigational Site Number 840001, Dallas, Texas, United States|Investigational Site Number 840022, Dallas, Texas, United States|Investigational Site Number 840012, Dallas, Texas, United States|Investigational Site Number 840020, Houston, Texas, United States|Investigational Site Number 840069, Lubbock, Texas, United States|Investigational Site Number 840074, Mesquite, Texas, United States|Investigational Site Number 840061, Tacoma, Washington, United States|Investigational Site Number 032005, Buenos Aires, Argentina|Investigational Site Number 032007, Buenos Aires, Argentina|Investigational Site Number 032008, Buenos Aires, Argentina|Investigational Site Number 032006, Caba, Argentina|Investigational Site Number 032002, Cordoba, Argentina|Investigational Site Number 032003, Córdoba, Argentina|Investigational Site Number 032012, Mar Del Plata, Argentina|Investigational Site Number 032011, Quilmes, Argentina|Investigational Site Number 032010, Ramos Mejia, Argentina|Investigational Site Number 032001, Rosario, Argentina|Investigational Site Number 032004, Tucuman, Argentina|Investigational Site Number 032009, Zarate, Argentina|Investigational Site Number 036003, Camperdown, Australia|Investigational Site Number 036005, Clayton, Australia|Investigational Site Number 036002, East Malvern, Australia|Investigational Site Number 036012, Fitzroy, Australia|Investigational Site Number 036010, Garran, Australia|Investigational Site Number 036004, Heidelberg West, Australia|Investigational Site Number 036009, Herston, Australia|Investigational Site Number 036001, Maroochydore, Australia|Investigational Site Number 036006, St Leonards, Australia|Investigational Site Number 036011, Sydney, Australia|Investigational Site Number 036014, Victoria Park, Australia|Investigational Site Number 036007, Woodville, Australia|Investigational Site Number 040001, Graz, Austria|Investigational Site Number 040002, Wien, Austria|Investigational Site Number 112002, Minsk, Belarus|Investigational Site Number 112001, Minsk, Belarus|Investigational Site Number 056003, Genk, Belgium|Investigational Site Number 056001, Liège, Belgium|Investigational Site Number 076008, Campinas, Brazil|Investigational Site Number 076012, Campinas, Brazil|Investigational Site Number 076001, Curitiba, Brazil|Investigational Site Number 076006, Goiania, Brazil|Investigational Site Number 076010, Juiz De Fora, Brazil|Investigational Site Number 076004, Porto Alegre, Brazil|Investigational Site Number 076005, Rio De Janeiro, Brazil|Investigational Site Number 076011, Salvador, Brazil|Investigational Site Number 076002, Sao Paulo, Brazil|Investigational Site Number 076003, Sao Paulo, Brazil|Investigational Site Number 076013, Vitoria, Brazil|Investigational Site Number 124004, Burlington, Canada|Investigational Site Number 124003, Mississauga, Canada|Investigational Site Number 124008, Newmarket, Canada|Investigational Site Number 124002, St. Catharines, Canada|Investigational Site Number 124005, Toronto, Canada|Investigational Site Number 124001, Toronto, Canada|Investigational Site Number 124012, Winnipeg, Canada|Investigational Site Number 152005, Osorno, Chile|Investigational Site Number 152010, Puerto Montt, Chile|Investigational Site Number 152012, Santiago, Chile|Investigational Site Number 152001, Santiago, Chile|Investigational Site Number 152002, Santiago, Chile|Investigational Site Number 152008, Santiago, Chile|Investigational Site Number 152009, Santiago, Chile|Investigational Site Number 152011, Santiago, Chile|Investigational Site Number 152013, Santiago, Chile|Investigational Site Number 152014, Talca, Chile|Investigational Site Number 152004, Valdivia, Chile|Investigational Site Number 152006, Vina Del Mar, Chile|Investigational Site Number 152007, Viña Del Mar, Chile|Investigational Site Number 170004, Barranquilla, Colombia|Investigational Site Number 170001, Bogota, Colombia|Investigational Site Number 170008, Bogota, Colombia|Investigational Site Number 170003, Bogotá, Colombia|Investigational Site Number 170006, Bogotá, Colombia|Investigational Site Number 170007, Bucaramanga, Colombia|Investigational Site Number 170009, Bucaramanga, Colombia|Investigational Site Number 170002, Medellin, Colombia|Investigational Site Number 203005, Brno, Czechia|Investigational Site Number 203004, Hlucin, Czechia|Investigational Site Number 203001, Praha 2, Czechia|Investigational Site Number 203002, Uherske Hradiste, Czechia|Investigational Site Number 818001, Cairo, Egypt|Investigational Site Number 818002, Cairo, Egypt|Investigational Site Number 233001, Tallinn, Estonia|Investigational Site Number 233002, Tallinn, Estonia|Investigational Site Number 246001, Helsinki, Finland|Investigational Site Number 246002, Hyvinkää, Finland|Investigational Site Number 246003, Pori, Finland|Investigational Site Number 276007, Berlin, Germany|Investigational Site Number 276008, Berlin, Germany|Investigational Site Number 276004, Erlangen, Germany|Investigational Site Number 276003, Frankfurt Am Main, Germany|Investigational Site Number 276015, Halle/Saale, Germany|Investigational Site Number 276005, Hamburg, Germany|Investigational Site Number 276013, Hamburg, Germany|Investigational Site Number 276012, Heidelberg, Germany|Investigational Site Number 276001, Herne, Germany|Investigational Site Number 276006, Hildesheim, Germany|Investigational Site Number 300001, Athens, Greece|Investigational Site Number 300002, Heraklion, Greece|Investigational Site Number 300003, Thessaloniki, Greece|Investigational Site Number 348006, Budapest, Hungary|Investigational Site Number 348014, Budapest, Hungary|Investigational Site Number 348003, Debrecen, Hungary|Investigational Site Number 348010, Debrecen, Hungary|Investigational Site Number 348011, Eger, Hungary|Investigational Site Number 348013, Gy?r, Hungary|Investigational Site Number 348015, Szombathely, Hungary|Investigational Site Number 348005, Sátoraljaújhely, Hungary|Investigational Site Number 348004, Veszprém, Hungary|Investigational Site Number 356015, Ahmedabad, India|Investigational Site Number 356007, Bangalore, India|Investigational Site Number 356003, Chennai, India|Investigational Site Number 356012, Hyderabad, India|Investigational Site Number 356005, Hyderabad, India|Investigational Site Number 356011, Lucknow, India|Investigational Site Number 356013, Lucknow, India|Investigational Site Number 356001, Maharashtra, India|Investigational Site Number 356010, Mumbai, India|Investigational Site Number 356004, Mumbai, India|Investigational Site Number 356002, New Delhi, India|Investigational Site Number 356008, New Delhi, India|Investigational Site Number 410014, Anyang, Korea, Republic of|Investigational Site Number 410006, Busan, Korea, Republic of|Investigational Site Number 410004, Daegu, Korea, Republic of|Investigational Site Number 410013, Daegu, Korea, Republic of|Investigational Site Number 410005, Daejeon, Korea, Republic of|Investigational Site Number 410010, Gwangju, Korea, Republic of|Investigational Site Number 410009, Incheon, Korea, Republic of|Investigational Site Number 410001, Incheon, Korea, Republic of|Investigational Site Number 410011, Jeonju, Korea, Republic of|Investigational Site Number 410007, Seoul, Korea, Republic of|Investigational Site Number 410012, Seoul, Korea, Republic of|Investigational Site Number 410003, Seoul, Korea, Republic of|Investigational Site Number 410002, Seoul, Korea, Republic of|Investigational Site Number 410008, Suwon, Korea, Republic of|Investigational Site Number 440001, Kaunas, Lithuania|Investigational Site Number 440002, Vilnius, Lithuania|Investigational Site Number 458001, Ipoh, Malaysia|Investigational Site Number 458002, Kuching, Malaysia|Investigational Site Number 458003, Putrajaya, Malaysia|Investigational Site Number 484008, Durango, Mexico|Investigational Site Number 484002, Guadalajara, Mexico|Investigational Site Number 484004, Merida, Mexico|Investigational Site Number 484009, Merida, Mexico|Investigational Site Number 484007, Metepec, Mexico|Investigational Site Number 484003, Mexico City, Mexico|Investigational Site Number 484001, Mexico, D.F., Mexico|Investigational Site Number 484005, Monterrey, Mexico|Investigational Site Number 528002, Heerlen, Netherlands|Investigational Site Number 554004, Christchurch, New Zealand|Investigational Site Number 554002, Rotorua, New Zealand|Investigational Site Number 554003, Tauranga, New Zealand|Investigational Site Number 554001, Timaru, New Zealand|Investigational Site Number 578004, Kristiansand, Norway|Investigational Site Number 578006, Tønsberg, Norway|Investigational Site Number 608003, Cebu City, Philippines|Investigational Site Number 608001, Manila, Philippines|Investigational Site Number 608002, Manila, Philippines|Investigational Site Number 616002, Bialystok, Poland|Investigational Site Number 616003, Bialystok, Poland|Investigational Site Number 616001, Krakow, Poland|Investigational Site Number 616005, Lublin, Poland|Investigational Site Number 616006, Torun, Poland|Investigational Site Number 616004, Warszawa, Poland|Investigational Site Number 616012, Wroclaw, Poland|Investigational Site Number 620003, Aveiro, Portugal|Investigational Site Number 620001, Lisboa, Portugal|Investigational Site Number 620002, Lisboa, Portugal|Investigational Site Number 642006, Braila, Romania|Investigational Site Number 642004, Bucharest, Romania|Investigational Site Number 642010, Bucharest, Romania|Investigational Site Number 642001, Bucuresti, Romania|Investigational Site Number 642002, Bucuresti, Romania|Investigational Site Number 642003, Bucuresti, Romania|Investigational Site Number 642005, Galati, Romania|Investigational Site Number 642008, Ploiesti, Romania|Investigational Site Number 643017, Kemerovo, Russian Federation|Investigational Site Number 643006, Kemerovo, Russian Federation|Investigational Site Number 643004, Moscow, Russian Federation|Investigational Site Number 643020, Moscow, Russian Federation|Investigational Site Number 643001, Moscow, Russian Federation|Investigational Site Number 643002, Moscow, Russian Federation|Investigational Site Number 643012, Moscow, Russian Federation|Investigational Site Number 643009, Novosibirsk, Russian Federation|Investigational Site Number 643016, Ryazan, Russian Federation|Investigational Site Number 643014, Saint-Petersburg, Russian Federation|Investigational Site Number 643010, Samara, Russian Federation|Investigational Site Number 643011, Saratov, Russian Federation|Investigational Site Number 643007, St-Petersburg, Russian Federation|Investigational Site Number 643008, St-Petersburg, Russian Federation|Investigational Site Number 643013, Ufa, Russian Federation|Investigational Site Number 710011, Cape Town, South Africa|Investigational Site Number 710007, Cape Town, South Africa|Investigational Site Number 710009, Cape Town, South Africa|Investigational Site Number 710003, Durban, South Africa|Investigational Site Number 710002, Durban, South Africa|Investigational Site Number 710001, Johannesburg, South Africa|Investigational Site Number 710004, Kempton Park, South Africa|Investigational Site Number 710005, Pretoria, South Africa|Investigational Site Number 710006, Pretoria, South Africa|Investigational Site Number 710008, Pretoria, South Africa|Investigational Site Number 710010, Stellenbosch, South Africa|Investigational Site Number 724010, Barcelona, Spain|Investigational Site Number 724009, La Coruña, Spain|Investigational Site Number 724011, Sabadell, Spain|Investigational Site Number 724012, Santiago De Compostela, Spain|Investigational Site Number 724007, Sevilla, Spain|Investigational Site Number 158002, Linkou, Taiwan|Investigational Site Number 158001, Taipei, Taiwan|Investigational Site Number 764001, Bangkok, Thailand|Investigational Site Number 764003, Bangkok, Thailand|Investigational Site Number 792003, Adana, Turkey|Investigational Site Number 792002, Ankara, Turkey|Investigational Site Number 792005, Ankara, Turkey|Investigational Site Number 792004, Antalya, Turkey|Investigational Site Number 792001, Izmir, Turkey|Investigational Site Number 804003, Dnipropetrovsk, Ukraine|Investigational Site Number 804002, Donetsk, Ukraine|Investigational Site Number 804010, Kharkov, Ukraine|Investigational Site Number 804008, Kyiv, Ukraine|Investigational Site Number 804004, Kyiv, Ukraine|Investigational Site Number 804005, Lviv, Ukraine|Investigational Site Number 804006, Simferopol, Ukraine|Investigational Site Number 804009, Zaporizhzhia, Ukraine","https://ClinicalTrials.gov/show/NCT01061736"
623,"Clinical Characterisation Protocol for COVID-19 in People Living With HIV","Not yet recruiting","No Results Available","Adult Patients Living With HIV (PLWHIV) With Confirmed Infection With SARS-CoV-2 Since 1st January 2020","Biological: Biological collection (patients co infected HIV Sras-CoV-2)|Other: Auto-questionnaires (patients co infected HIV Sras-CoV-2)|Other: Qualitative interviews (in 40 patients : 20 with COVID-19 and 20 without COVID-19)","Department of Internal Medicine and Clinical Immunology of Professor Cécile Goujard, Le Kremlin-Bicêtre, France","https://ClinicalTrials.gov/show/NCT04361604"
624,"Quality of Life and Patient-centered Outcomes After UCI Admission for COVID-19","Not yet recruiting","No Results Available","Quality of Life|Long-term Outcomes|Coronavirus Infection|Morality|Rehospitalization","Other: COVID-19 Pneumonia","Centro Hospitalar Universitário do Algarve, Faro, Algarve, Portugal|Hospital de São Francisco Xavier, Lisbon, Portugal|Centro Hospitalar Universitário de São João, Porto, Portugal|Centro Hospitalar Universitário do Porto - Hospital de Santo António, Porto, Portugal","https://ClinicalTrials.gov/show/NCT04416464"
625,"Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients","Completed","No Results Available","Breast Cancer Female","Drug: paclitaxel|Drug: Iniparib (SAR2405550 -BSI-201)","Investigational Site Number 250001, Besancon Cedex, France|Investigational Site Number 250004, Bordeaux, France|Investigational Site Number 250006, Bron Cedex, France|Investigational Site Number 250003, Paris Cedex 10, France|Investigational Site Number 250002, Toulouse, France|Investigational Site Number 250005, Villejuif, France|Investigational Site Number 276003, Erlangen, Germany|Investigational Site Number 276004, Hamburg, Germany|Investigational Site Number 276002, Köln, Germany|Investigational Site Number 276001, Mönchengladbach, Germany|Investigational Site Number 724001, Barcelona, Spain|Investigational Site Number 724009, Cáceres, Spain|Investigational Site Number 724013, Córdoba, Spain|Investigational Site Number 724006, Islas Baleares, Spain|Investigational Site Number 724012, Jaén, Spain|Investigational Site Number 724002, Lérida, Spain|Investigational Site Number 724005, Madrid, Spain|Investigational Site Number 724016, Madrid, Spain|Investigational Site Number 724007, Reus, Spain|Investigational Site Number 724018, Santiago De Compostela, Spain|Investigational Site Number 724017, Sevilla, Spain|Investigational Site Number 724010, Sevilla, Spain|Investigational Site Number 724003, Torrevieja, Spain|Investigational Site Number 724011, Valencia, Spain|Investigational Site Number 724015, Valencia, Spain","https://ClinicalTrials.gov/show/NCT01204125"
626,"Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia","Completed","No Results Available","Indolent Non-Hodgkin Lymphoma|Mantle Cell Lymphoma|Chronic Lymphocytic Leukemia","Drug: SAR245409","Investigational Site Number 840004, Aurora, Colorado, United States|Investigational Site Number 840006, Augusta, Georgia, United States|Investigational Site Number 840002, Charleston, South Carolina, United States","https://ClinicalTrials.gov/show/NCT01410513"
627,"Long-term Effects of Coronavirus Disease 2019 on the Cardiovascular System: CV COVID-19 Registry","Recruiting","No Results Available","Sars-CoV2|Covid19|Cardiovascular Diseases|Cardiovascular Risk Factor",,"Hospital Clínic of Barcelona, Barcelona, Catalonia, Spain","https://ClinicalTrials.gov/show/NCT04359927"
628,"Single and Repeated Dosing Study to Assess the Safety and the Concentration-time Profile of SAR228810 in Alzheimer's Patients","Completed","No Results Available","Alzheimer's Disease","Drug: SAR228810","Investigational Site Number 100001, Sofia, Bulgaria|Investigational Site Number 250001, Pierre Bénite, France|Investigational Site Number 250002, Toulouse Cedex 3, France|Investigational Site Number 528001, Leiden, Netherlands|Investigational Site Number 710001, Bloemfontein, South Africa|Investigational Site Number 752003, Malmö, Sweden|Investigational Site Number 752002, Mölndal, Sweden|Investigational Site Number 752001, Stockholm, Sweden","https://ClinicalTrials.gov/show/NCT01485302"
629,"Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P03280)","Completed","Has Results","Rhinitis, Allergic, Seasonal|Asthma","Drug: Mometasone|Drug: Placebo|Drug: Albuterol/Salbutamol",,"https://ClinicalTrials.gov/show/NCT00070707"
630,"Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)","Completed","Has Results","Hypercholesterolemia","Drug: Atorvastatin|Drug: Ezetimibe|Drug: Alirocumab|Drug: Placebo","Anaheim, California, United States|Beverly Hills, California, United States|Mission Viejo, California, United States|Newport Beach, California, United States|Northridge, California, United States|Thousand Oaks, California, United States|Hartford, Connecticut, United States|Boynton Beach, Florida, United States|Jacksonville, Florida, United States|Lakeland, Florida, United States|Pembroke Pines, Florida, United States|Sarasota, Florida, United States|Tampa, Florida, United States|Trinity, Florida, United States|Addison, Illinois, United States|Chicago, Illinois, United States|Indianapolis, Indiana, United States|Kansas City, Kansas, United States|Auburn, Maine, United States|Boston, Massachusetts, United States|Minneapolis, Minnesota, United States|Rochester, Minnesota, United States|Saint Louis, Missouri, United States|Clifton, New Jersey, United States|New York, New York, United States|Poughkeepsie, New York, United States|Durham, North Carolina, United States|Cincinnati, Ohio, United States|Marion, Ohio, United States|Danville, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Port Matilda, Pennsylvania, United States|Scranton, Pennsylvania, United States|Wilkes-Barre, Pennsylvania, United States|Summerville, South Carolina, United States|Kingsport, Tennessee, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|Fort Worth, Texas, United States|Salt Lake City, Utah, United States|Richmond, Virginia, United States|Feldkirch, Austria|Graz, Austria|Innsbruck, Austria|Chicoutimi, Quebec, Canada|Montreal (2 locations), Quebec, Canada|Sainte-Foy, Quebec, Canada|Bron, France|Dijon, France|Lille, France|Paris, France|Saint-Herblain, France|Venissieux, France|Holon, Israel|Jerusalem, Israel|Ofakim, Israel|Safed, Israel|Tel-Hashomer, Israel|Cinisello Balsamo, Italy|Napoli, Italy|Palermo, Italy|Roma, Italy|Oslo (2 locations), Norway|Burton-on-Trent, United Kingdom|Chesterfield, United Kingdom|Isle of White, United Kingdom|Londonderry/N. Ireland, United Kingdom|Peterborough, United Kingdom|Salford, United Kingdom|Stevenage, United Kingdom","https://ClinicalTrials.gov/show/NCT01709513"
631,"Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in Allergic Conjunctivitis","Completed","Has Results","Allergic Conjunctivitis","Drug: Lifitegrast|Other: Placebo","Ora, Andover, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT00882687"
632,"Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)","Completed","Has Results","Hypercholesterolemia","Drug: Alirocumab|Drug: Placebo (for alirocumab)|Drug: Ezetimibe|Drug: Placebo (for ezetimibe)|Drug: Lipid Modifying Therapy (LMT)","Investigational Site Number 840980, Birmingham, Alabama, United States|Investigational Site Number 840918, Phoenix, Arizona, United States|Investigational Site Number 840925, Tucson, Arizona, United States|Investigational Site Number 840959, Anaheim, California, United States|Investigational Site Number 840301, Beverly Hills, California, United States|Investigational Site Number 840933, Chino, California, United States|Investigational Site Number 840991, Lincoln, California, United States|Investigational Site Number 840979, Los Angeles, California, United States|Investigational Site Number 840952, Palm Springs, California, United States|Investigational Site Number 840930, Thousand Oaks, California, United States|Investigational Site Number 840921, Vista, California, United States|Investigational Site Number 840962, Boynton Beach, Florida, United States|Investigational Site Number 840987, Bradenton, Florida, United States|Investigational Site Number 840302, Clearwater, Florida, United States|Investigational Site Number 840935, Jacksonville, Florida, United States|Investigational Site Number 840903, Miami, Florida, United States|Investigational Site Number 840920, Miami, Florida, United States|Investigational Site Number 840943, Ocala, Florida, United States|Investigational Site Number 840981, Oveido, Florida, United States|Investigational Site Number 840961, Port Orange, Florida, United States|Investigational Site Number 840303, Sarasota, Florida, United States|Investigational Site Number 840986, St. Petersburg, Florida, United States|Investigational Site Number 840988, St. Petersburg, Florida, United States|Investigational Site Number 840995, Meridian, Idaho, United States|Investigational Site Number 840902, Evansville, Indiana, United States|Investigational Site Number 840960, Topeka, Kansas, United States|Investigational Site Number 840940, Oxon Hill, Maryland, United States|Investigational Site Number 840966, Fall River, Massachusetts, United States|Investigational Site Number 840917, Kansas City, Missouri, United States|Investigational Site Number 840998, St. Louis, Missouri, United States|Investigational Site Number 840946, Butte, Montana, United States|Investigational Site Number 840914, Lincoln, Nebraska, United States|Investigational Site Number 840949, Albuquerque, New Mexico, United States|Investigational Site Number 840974, New Windsor, New York, United States|Investigational Site Number 840955, Greenville, North Carolina, United States|Investigational Site Number 840938, Lexington, North Carolina, United States|Investigational Site Number 840976, Smithfield, North Carolina, United States|Investigational Site Number 840985, Winston-Salem, North Carolina, United States|Investigational Site Number 840963, Cincinnati, Ohio, United States|Investigational Site Number 840970, Lyndhust, Ohio, United States|Investigational Site Number 840906, Marion, Ohio, United States|Investigational Site Number 840997, Marion, Ohio, United States|Investigational Site Number 840964, Perrysburg, Ohio, United States|Investigational Site Number 840913, Charleston, South Carolina, United States|Investigational Site Number 840912, Greer, South Carolina, United States|Investigational Site Number 840992, Summerville, South Carolina, United States|Investigational Site Number 840932, Bristol, Tennessee, United States|Investigational Site Number 840944, Nashville, Tennessee, United States|Investigational Site Number 840994, Fort Worth, Texas, United States|Investigational Site Number 840973, Houston, Texas, United States|Investigational Site Number 840939, Houston, Texas, United States|Investigational Site Number 840945, Sugar Land, Texas, United States|Investigational Site Number 840971, Tomball, Texas, United States|Investigational Site Number 840982, Orem, Utah, United States|Investigational Site Number 840931, Norfolk, Virginia, United States|Investigational Site Number 840984, Richmond, Virginia, United States|Investigational Site Number 840928, Renton, Washington, United States|Investigational Site Number 840990, Spokane, Washington, United States|Investigational Site Number 124902, Brampton, Canada|Investigational Site Number 124914, Mirabel, Canada|Investigational Site Number 124903, Montreal, Canada|Investigational Site Number 124918, Toronto, Canada|Investigational Site Number 208913, Esbjerg, Denmark|Investigational Site Number 208914, Glostrup, Denmark|Investigational Site Number 208905, Hellerup, Denmark|Investigational Site Number 208911, Herlev, Denmark|Investigational Site Number 208907, Hvidovre, Denmark|Investigational Site Number 208901, København S, Denmark|Investigational Site Number 208906, Køge, Denmark|Investigational Site Number 208908, Roskilde, Denmark|Investigational Site Number 208903, Silkeborg, Denmark|Investigational Site Number 250906, Dijon, France|Investigational Site Number 250907, Montpellier Cedex 5, France|Investigational Site Number 250903, Nantes, France|Investigational Site Number 250905, Nimes, France|Investigational Site Number 348908, Budapest, Hungary|Investigational Site Number 348901, Budapest, Hungary|Investigational Site Number 348903, Budapest, Hungary|Investigational Site Number 348905, Debrecen, Hungary|Investigational Site Number 348906, Szekesfehervar, Hungary|Investigational Site Number 376908, Holon, Israel|Investigational Site Number 376903, Kfar Saba, Israel|Investigational Site Number 376906, Ofakim, Israel|Investigational Site Number 376902, Petach Tikva, Israel|Investigational Site Number 376904, Rehovot, Israel|Investigational Site Number 376907, Safed, Israel|Investigational Site Number 376901, Tel Aviv, Israel|Investigational Site Number 410908, Anyang-Si, Korea, Republic of|Investigational Site Number 410920, Busan, Korea, Republic of|Investigational Site Number 410926, Daegu, Korea, Republic of|Investigational Site Number 410923, Gwangju, Korea, Republic of|Investigational Site Number 410909, Seoul, Korea, Republic of|Investigational Site Number 410922, Seoul, Korea, Republic of|Investigational Site Number 410921, Seoul, Korea, Republic of|Investigational Site Number 410905, Seoul, Korea, Republic of|Investigational Site Number 410901, Seoul, Korea, Republic of|Investigational Site Number 410914, Seoul, Korea, Republic of|Investigational Site Number 410924, Seoul, Korea, Republic of|Investigational Site Number 410915, Suwon, Korea, Republic of|Investigational Site Number 410913, Uijeongbu, Korea, Republic of|Investigational Site Number 410927, Wonju, Korea, Republic of|Investigational Site Number 643906, Barnaul, Russian Federation|Investigational Site Number 643903, Kemerovo, Russian Federation|Investigational Site Number 643927, Moscow, Russian Federation|Investigational Site Number 643928, Moscow, Russian Federation|Investigational Site Number 643931, Moscow, Russian Federation|Investigational Site Number 643924, Moscow, Russian Federation|Investigational Site Number 643932, Moscow, Russian Federation|Investigational Site Number 643908, Moscow, Russian Federation|Investigational Site Number 643904, Moscow, Russian Federation|Investigational Site Number 643911, Orenburg, Russian Federation|Investigational Site Number 643921, Ryazan, Russian Federation|Investigational Site Number 643925, Saint-Petersburg, Russian Federation|Investigational Site Number 643922, Saint-Petersburg, Russian Federation|Investigational Site Number 643929, Saratov, Russian Federation|Investigational Site Number 643914, St-Petersburg, Russian Federation|Investigational Site Number 710917, Alberton, South Africa|Investigational Site Number 710909, Bloemfontein, South Africa|Investigational Site Number 710914, Bloemfontein, South Africa|Investigational Site Number 710905, Cape Town, South Africa|Investigational Site Number 710904, Cape Town, South Africa|Investigational Site Number 710918, Middelburg, South Africa|Investigational Site Number 710913, Pretoria, South Africa|Investigational Site Number 710915, Somerset West, South Africa|Investigational Site Number 804905, Kiev, Ukraine|Investigational Site Number 804902, Uzhhorod, Ukraine","https://ClinicalTrials.gov/show/NCT01644188"
633,"Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy in Japan","Completed","Has Results","Hypercholesterolemia","Drug: Alirocumab|Drug: Placebo (for alirocumab)|Drug: Atorvastatin","Investigational Site Number 392002, Koganei-Shi, Japan|Investigational Site Number 392001, Shinjuku-Ku, Japan|Investigational Site Number 392003, Suita-Shi, Japan|Investigational Site Number 392004, Suita-Shi, Japan","https://ClinicalTrials.gov/show/NCT01812707"
634,"Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR) (Study P04054)","Completed","No Results Available","Seasonal Allergic Rhinitis","Drug: desloratadine|Drug: fexofenadine|Drug: placebo",,"https://ClinicalTrials.gov/show/NCT00783146"
635,"Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Patients 12 Years and Older With SAR","Completed","Has Results","Seasonal Allergic Rhinitis|Hayfever","Drug: Beclomethasone dipropionate HFA Nasal Aerosol|Drug: Placebo","Teva Global Respiratory Research Study Site, Mission Viejo, California, United States|Teva Global Respiratory Research Study Site, San Diego, California, United States|Teva Global Respiratory Research Study Site, San Diego, California, United States|Teva Global Respiratory Research Study Site, Colorado Springs, Colorado, United States|Teva Global Respiratory Research Study Site, Denver, Colorado, United States|Teva Global Respiratory Research Study Site, Gainesville, Georgia, United States|Teva Global Respiratory Research Study Site, Savannah, Georgia, United States|Teva Global Respiratory Research Study Site, Indianapolis, Indiana, United States|Teva Global Respiratory Research Study Site, Overland Park, Kansas, United States|Teva Global Respiratory Research Study Site, Bethesda, Maryland, United States|Teva Global Respiratory Research Study Site, St. Louis, Missouri, United States|Teva Global Respiratory Research Study Site, Brick, New Jersey, United States|Teva Global Respiratory Research Study Site, Raleigh, North Carolina, United States|Teva Global Respiratory Research Study Site, Medford, Oregon, United States|Teva Global Respiratory Research Study Site, Portland, Oregon, United States|Teva Global Respiratory Research Study Site, Blue Bell, Pennsylvania, United States|Teva Global Respiratory Research Study Site, Pittsburgh, Pennsylvania, United States|Teva Global Respiratory Research Study Site, Upland, Pennsylvania, United States|Teva Global Respiratory Research Study Site, Charleston, South Carolina, United States|Teva Global Respiratory Research Study Site, Austin, Texas, United States|Teva Global Respiratory Research Study Site, Dallas, Texas, United States|Teva Global Respiratory Research Study Site, New Braunfels, Texas, United States|Teva Global Respiratory Research Study Site, San Antonio, Texas, United States|Teva Global Respiratory Research Study Site, Draper, Utah, United States|Teva Global Respiratory Research Study Site, Burke, Virginia, United States|Teva Global Respiratory Research Study Site, Richmond, Virginia, United States","https://ClinicalTrials.gov/show/NCT00854360"
636,"Safety, Tolerability and Pharmacokinetics of SAR113945 Following Intra-articular Administration in Patients With Knee Osteoarthritis","Completed","No Results Available","Osteoarthritis","Drug: placebo|Drug: SAR113945","Sanofi-Aventis Investigational Site Number 276001, Berlin, Germany","https://ClinicalTrials.gov/show/NCT01113333"
637,"Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil","Completed","No Results Available","Dementia Alzheimer's Type","Drug: SAR110894|Drug: placebo (for SAR110894)|Drug: Donepezil","Investigational Site Number 840041, Gilbert, Arizona, United States|Investigational Site Number 840032, Phoenix, Arizona, United States|Investigational Site Number 840024, Costa Mesa, California, United States|Investigational Site Number 840013, Fresno, California, United States|Investigational Site Number 840030, La Jolla, California, United States|Investigational Site Number 840001, Redlands, California, United States|Investigational Site Number 840002, Santa Ana, California, United States|Investigational Site Number 840026, Sherman Oaks, California, United States|Investigational Site Number 840034, Darien, Connecticut, United States|Investigational Site Number 840003, Delray Beach, Florida, United States|Investigational Site Number 840015, Hialeah, Florida, United States|Investigational Site Number 840004, Jacksonville, Florida, United States|Investigational Site Number 840006, Miami, Florida, United States|Investigational Site Number 840012, Orlando, Florida, United States|Investigational Site Number 840011, Tampa, Florida, United States|Investigational Site Number 840005, W Palm Beach, Florida, United States|Investigational Site Number 840008, Baton Rouge, Louisiana, United States|Investigational Site Number 840025, Quincy, Massachusetts, United States|Investigational Site Number 840009, Hattiesburg, Mississippi, United States|Investigational Site Number 840040, Eatontown, New Jersey, United States|Investigational Site Number 840018, Cedarhurst, New York, United States|Investigational Site Number 840039, Charlotte, North Carolina, United States|Investigational Site Number 840037, Tulsa, Oklahoma, United States|Investigational Site Number 840014, Franklin, Tennessee, United States|Investigational Site Number 840038, Austin, Texas, United States|Investigational Site Number 840021, Bennington, Vermont, United States|Investigational Site Number 840031, Williamsburg, Virginia, United States|Investigational Site Number 036002, Adelaide, Australia|Investigational Site Number 036007, Chermside, Australia|Investigational Site Number 036008, Heidelberg West, Australia|Investigational Site Number 036006, Herston, Australia|Investigational Site Number 036001, Nedlands, Australia|Investigational Site Number 036004, Randwick, Australia|Investigational Site Number 036009, Toowoomba, Australia|Investigational Site Number 036005, Waratah, Australia|Investigational Site Number 036003, Woodville, Australia|Investigational Site Number 124010, Calgary, Canada|Investigational Site Number 124015, Gatineau, Canada|Investigational Site Number 124009, Greenfield Park, Canada|Investigational Site Number 124014, Halifax, Canada|Investigational Site Number 124001, London, Canada|Investigational Site Number 124011, Montreal, Canada|Investigational Site Number 124008, Ottawa, Canada|Investigational Site Number 124013, Regina, Canada|Investigational Site Number 124003, Sherbrooke, Canada|Investigational Site Number 124006, St. John, Canada|Investigational Site Number 124002, Toronto, Canada|Investigational Site Number 124004, Toronto, Canada|Investigational Site Number 250004, Bordeaux, France|Investigational Site Number 250001, Lille Cedex, France|Investigational Site Number 250009, Limoges, France|Investigational Site Number 250007, Marseille, France|Investigational Site Number 250003, Nantes, France|Investigational Site Number 250005, Nice, France|Investigational Site Number 250006, Paris, France|Investigational Site Number 250008, Strasbourg Cedex, France|Investigational Site Number 250002, Toulouse Cedex 3, France|Investigational Site Number 276011, Berlin, Germany|Investigational Site Number 276012, Dresden, Germany|Investigational Site Number 276007, München, Germany|Investigational Site Number 276008, München, Germany|Investigational Site Number 276001, Schwerin, Germany|Investigational Site Number 276009, Würzburg, Germany|Investigational Site Number 380006, Ancona, Italy|Investigational Site Number 380004, Castellanza, Italy|Investigational Site Number 380005, Cefalù, Italy|Investigational Site Number 380002, Milano, Italy|Investigational Site Number 380001, Milano, Italy|Investigational Site Number 380003, Milano, Italy|Investigational Site Number 616004, Bydgoszcz, Poland|Investigational Site Number 616003, Gdansk, Poland|Investigational Site Number 616001, Gdynia, Poland|Investigational Site Number 616002, Poznan, Poland|Investigational Site Number 616006, Szczecin, Poland|Investigational Site Number 616005, Warszawa, Poland|Investigational Site Number 620002, Amadora, Portugal|Investigational Site Number 620001, Lisboa, Portugal|Investigational Site Number 724002, Algorta, Spain|Investigational Site Number 724001, Barcelona, Spain|Investigational Site Number 724008, Madrid, Spain|Investigational Site Number 724007, Sevilla, Spain|Investigational Site Number 724003, Terrassa, Spain","https://ClinicalTrials.gov/show/NCT01266525"
638,"Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy)","Completed","Has Results","Heterozygous Familial Hypercholesterolemia","Drug: LMT (atorvastatin, simvastatin, or rosuvastatin)|Drug: alirocumab|Drug: Placebo","Hradec Kralove, Czech Republic|Praha 2, Czech Republic|Praha 5, Czech Republic|Praha 8, Czech Republic|Trutnov, Czech Republic|Vyskov, Czech Republic|Alkmaar, Netherlands|Amsterdam, Netherlands|Apeldoorn, Netherlands|Enschede, Netherlands|Goes, Netherlands|Groningen, Netherlands|Hoogeveen, Netherlands|Hoorn, Netherlands|Rotterdam, Netherlands|Sittard- Geleen, Netherlands|Utrecht (2 locations), Netherlands|Venlo, Netherlands|Waalwijk, Netherlands|Oslo, Norway|Cardiff, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Middlesex, United Kingdom|Newcastle upon Tyne, United Kingdom|West Bromwich, United Kingdom","https://ClinicalTrials.gov/show/NCT01709500"
639,"Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR)(Study P04053)(COMPLETED)","Completed","No Results Available","Seasonal Allergic Rhinitis","Drug: desloratadine|Drug: fexofenadine|Drug: placebo",,"https://ClinicalTrials.gov/show/NCT00783211"
640,"Effect of Loratadine/Montelukast Combination on Congestion in SAR Patients Exposed to Pollen in an EEU (Study P04822)","Completed","No Results Available","Seasonal Allergic Rhinitis","Drug: Loratadine/montelukast combination",,"https://ClinicalTrials.gov/show/NCT00423995"
641,"Safety of Single Doses of SAR113945 and Efficacy and Safety of a New Formulation Given Into the Knee in Osteoarthritis Patients / Part II","Completed","No Results Available","Knee Osteoarthritis","Drug: SAR113945|Drug: placebo","Investigational Site Number 276001, Berlin, Germany|Investigational Site Number 276002, München, Germany","https://ClinicalTrials.gov/show/NCT01598415"
642,"Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)","Completed","Has Results","Hypercholesterolemia","Drug: Placebo (for alirocumab)|Drug: Alirocumab|Drug: Lipid-Modifying Therapy (LMT)","Investigational Site Number 840857, Birmingham, Alabama, United States|Investigational Site Number 840891, Mobile, Alabama, United States|Investigational Site Number 840876, Montgomery, Alabama, United States|Investigational Site Number 840865, Glendale, Arizona, United States|Investigational Site Number 840826, Jonesboro, Arkansas, United States|Investigational Site Number 840870, Burbank, California, United States|Investigational Site Number 840851, Los Angeles, California, United States|Investigational Site Number 840845, Los Gatos, California, United States|Investigational Site Number 840844, Sacramento, California, United States|Investigational Site Number 840801, San Jose, California, United States|Investigational Site Number 840886, Tarzana, California, United States|Investigational Site Number 840862, Torrance, California, United States|Investigational Site Number 840893, Vista, California, United States|Investigational Site Number 840867, Boca Raton, Florida, United States|Investigational Site Number 840884, Boynton Beach, Florida, United States|Investigational Site Number 840836, Clearwater, Florida, United States|Investigational Site Number 840866, Coral Gables, Florida, United States|Investigational Site Number 840895, Ft. Lauderdale, Florida, United States|Investigational Site Number 840820, Hialeah, Florida, United States|Investigational Site Number 840805, Miami, Florida, United States|Investigational Site Number 840811, Oviedo, Florida, United States|Investigational Site Number 840881, Port Orange, Florida, United States|Investigational Site Number 840816, West Palm Beach, Florida, United States|Investigational Site Number 840850, Columbus, Georgia, United States|Investigational Site Number 840840, Eagle, Idaho, United States|Investigational Site Number 840842, Chicago, Illinois, United States|Investigational Site Number 840898, Evanston, Illinois, United States|Investigational Site Number 840847, Morton, Illinois, United States|Investigational Site Number 840896, Indianapolis, Indiana, United States|Investigational Site Number 840894, Michigan City, Indiana, United States|Investigational Site Number 840838, Mishawaka, Indiana, United States|Investigational Site Number 840823, Paducah, Kentucky, United States|Investigational Site Number 840858, Eunice, Louisiana, United States|Investigational Site Number 840802, New Orleans, Louisiana, United States|Investigational Site Number 840855, Salisbury, Massachusetts, United States|Investigational Site Number 840890, Battle Creek, Michigan, United States|Investigational Site Number 840832, Southfield, Michigan, United States|Investigational Site Number 840839, Edina, Minnesota, United States|Investigational Site Number 840888, Minneapolis, Minnesota, United States|Investigational Site Number 840837, Port Gibson, Mississippi, United States|Investigational Site Number 840814, Jefferson City, Missouri, United States|Investigational Site Number 840833, Sparks, Nevada, United States|Investigational Site Number 840817, Newington, New Hampshire, United States|Investigational Site Number 840853, New Windsor, New York, United States|Investigational Site Number 840822, Rochester, New York, United States|Investigational Site Number 840824, Cary, North Carolina, United States|Investigational Site Number 840880, Smithfield, North Carolina, United States|Investigational Site Number 840502, Winston-Salem, North Carolina, United States|Investigational Site Number 840852, Winston-Salem, North Carolina, United States|Investigational Site Number 840846, Cincinnati, Ohio, United States|Investigational Site Number 840899, Cincinnati, Ohio, United States|Investigational Site Number 840831, Columbus, Ohio, United States|Investigational Site Number 840860, Kettering, Ohio, United States|Investigational Site Number 840809, Willoughby Hills, Ohio, United States|Investigational Site Number 840818, Norman, Oklahoma, United States|Investigational Site Number 840812, Eugene, Oregon, United States|Investigational Site Number 840803, Downington, Pennsylvania, United States|Investigational Site Number 840869, Philadelphia, Pennsylvania, United States|Investigational Site Number 840825, Pittsburgh, Pennsylvania, United States|Investigational Site Number 840872, Anderson, South Carolina, United States|Investigational Site Number 840885, Charleston, South Carolina, United States|Investigational Site Number 840813, Greer, South Carolina, United States|Investigational Site Number 840827, Mt. Pleasant, South Carolina, United States|Investigational Site Number 840868, Corpus Christi, Texas, United States|Investigational Site Number 840877, Houston, Texas, United States|Investigational Site Number 840841, Houston, Texas, United States|Investigational Site Number 840830, San Antonio, Texas, United States|Investigational Site Number 840854, San Antonio, Texas, United States|Investigational Site Number 840883, San Antonio, Texas, United States|Investigational Site Number 840889, Tomball, Texas, United States|Investigational Site Number 840878, Bountiful, Utah, United States|Investigational Site Number 840819, Orem, Utah, United States|Investigational Site Number 840863, Salt Lake City, Utah, United States|Investigational Site Number 840804, Manassas, Virginia, United States|Investigational Site Number 840882, Norfolk, Virginia, United States|Investigational Site Number 840810, Weber City, Virginia, United States","https://ClinicalTrials.gov/show/NCT01644175"
643,"Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)","Completed","Has Results","Hypercholesterolaemia","Drug: Alirocumab|Drug: Placebo (for alirocumab)|Drug: Lipid Modifying Therapy (LMT)","Investigational Site Number 840742, Bell Gardens, California, United States|Investigational Site Number 840703, Newport Beach, California, United States|Investigational Site Number 840712, Newport Beach, California, United States|Investigational Site Number 840743, Northridge, California, United States|Investigational Site Number 840734, Washington, District of Columbia, United States|Investigational Site Number 840738, Miami, Florida, United States|Investigational Site Number 840710, Ponte Vedra, Florida, United States|Investigational Site Number 840701, New York, New York, United States|Investigational Site Number 840702, Durham, North Carolina, United States|Investigational Site Number 840714, Cincinnati, Ohio, United States|Investigational Site Number 840705, Philadelphia, Pennsylvania, United States|Investigational Site Number 840709, Philadelphia, Pennsylvania, United States|Investigational Site Number 840713, Philadelphia, Pennsylvania, United States|Investigational Site Number 840736, Dallas, Texas, United States|Investigational Site Number 124704, Quebec, Canada|Investigational Site Number 124703, Sherbrooke, Canada|Investigational Site Number 528713, Amsterdam, Netherlands|Investigational Site Number 528701, Amsterdam, Netherlands|Investigational Site Number 528704, Groningen, Netherlands|Investigational Site Number 528716, Leiden, Netherlands|Investigational Site Number 528709, Utrecht, Netherlands|Investigational Site Number 643706, Arkhangelsk, Russian Federation|Investigational Site Number 643705, Kazan, Russian Federation|Investigational Site Number 643703, Moscow, Russian Federation|Investigational Site Number 643711, Moscow, Russian Federation|Investigational Site Number 643708, Moscow, Russian Federation|Investigational Site Number 643702, Saint Petersburg, Russian Federation|Investigational Site Number 643710, St-Petersburg, Russian Federation|Investigational Site Number 643709, St-Petersburg, Russian Federation|Investigational Site Number 643707, Yaroslavl, Russian Federation|Investigational Site Number 710701, Bloemfontein, South Africa|Investigational Site Number 710704, Bloemfontein, South Africa|Investigational Site Number 710706, Cap Town, South Africa|Investigational Site Number 710702, Parktown, South Africa|Investigational Site Number 710703, Somerset West, South Africa","https://ClinicalTrials.gov/show/NCT01617655"
644,"Will Hydroxychloroquine Impede or Prevent COVID-19","Recruiting","No Results Available","COVID-19|Coronavirus|Coronavirus Infections|SARS-CoV 2","Drug: Hydroxychloroquine - Daily Dosing|Drug: Hydroxychloroquine - Weekly Dosing|Other: Placebo oral tablet|Diagnostic Test: Monitoring Visit - Baseline|Diagnostic Test: Monitoring Visit - Week 4|Diagnostic Test: Monitoring Visit - Week 8|Other: Weekly Assessment","Henry Ford Hospital, Detroit, Michigan, United States|Detroit Department of Transportation (DDOT), Detroit, Michigan, United States|Detroit Fire Department & Detroit EMS, Detroit, Michigan, United States|Detroit Police Department, Detroit, Michigan, United States","https://ClinicalTrials.gov/show/NCT04341441"
645,"Safety of Single Doses of SAR113945 and Efficacy and Safety of a New Formulation Given Into the Knee in Osteoarthritis Patients / Part I","Completed","No Results Available","Knee Osteoarthritis","Drug: SAR113945|Drug: placebo","Investigational Site Number 276001, Berlin, Germany","https://ClinicalTrials.gov/show/NCT01463488"
646,"A Phase II Study Evaluating Intranasal GSK256066 and Fluticasone Propionate in Subjects With Seasonal Allergic Rhinitis (SAR)","Completed","No Results Available","Rhinitis, Allergic, Seasonal","Drug: GSK256066|Drug: fluticasone propionate","GSK Investigational Site, Vienna, Austria","https://ClinicalTrials.gov/show/NCT00612820"
647,"Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)","Completed","Has Results","Hypercholesterolemia","Drug: Placebo (for alirocumab)|Drug: Alirocumab|Drug: Lipid-Modifying Therapy (LMT)","Investigational Site Number 840159, Huntsville, Alabama, United States|Investigational Site Number 840028, Gilbert, Arizona, United States|Investigational Site Number 840035, Sierra Vista, Arizona, United States|Investigational Site Number 840052, Tempe, Arizona, United States|Investigational Site Number 840065, Tempe, Arizona, United States|Investigational Site Number 840079, Tempe, Arizona, United States|Investigational Site Number 840094, Tempe, Arizona, United States|Investigational Site Number 840103, Tucson, Arizona, United States|Investigational Site Number 840209, Beverly Hills, California, United States|Investigational Site Number 840194, Beverly Hills, California, United States|Investigational Site Number 840207, Fresno, California, United States|Investigational Site Number 840101, Lincoln, California, United States|Investigational Site Number 840076, Long Beach, California, United States|Investigational Site Number 840214, Pasadena, California, United States|Investigational Site Number 840045, Sacramento, California, United States|Investigational Site Number 840163, Santa Rosa, California, United States|Investigational Site Number 840086, Colorado Springs, Colorado, United States|Investigational Site Number 840077, Golden, Colorado, United States|Investigational Site Number 840224, Bridgeport, Connecticut, United States|Investigational Site Number 840134, Guilford, Connecticut, United States|Investigational Site Number 840246, Hartford, Connecticut, United States|Investigational Site Number 840055, Stamford, Connecticut, United States|Investigational Site Number 840091, Stamford, Connecticut, United States|Investigational Site Number 840150, Atlantis, Florida, United States|Investigational Site Number 840020, Bradenton, Florida, United States|Investigational Site Number 840041, Brandon, Florida, United States|Investigational Site Number 840184, Clearwater, Florida, United States|Investigational Site Number 840242, Clearwater, Florida, United States|Investigational Site Number 840039, Clearwater, Florida, United States|Investigational Site Number 840182, Crystal River, Florida, United States|Investigational Site Number 840002, Daytona Beach, Florida, United States|Investigational Site Number 840166, Daytona Beach, Florida, United States|Investigational Site Number 840167, Fleming Island, Florida, United States|Investigational Site Number 840018, Fort Lauderdale, Florida, United States|Investigational Site Number 840090, Ft. Lauderdale, Florida, United States|Investigational Site Number 840153, Jacksonville, Florida, United States|Investigational Site Number 840181, Jacksonville, Florida, United States|Investigational Site Number 840152, Jacksonville, Florida, United States|Investigational Site Number 840154, Lake Mary, Florida, United States|Investigational Site Number 840059, Largo, Florida, United States|Investigational Site Number 840221, Miami, Florida, United States|Investigational Site Number 840021, New Port Richey, Florida, United States|Investigational Site Number 840122, New Smyrna Beach, Florida, United States|Investigational Site Number 840151, Ocala, Florida, United States|Investigational Site Number 840108, Ormond Beach, Florida, United States|Investigational Site Number 840067, Palm Harbor, Florida, United States|Investigational Site Number 840006, Pembroke Pines, Florida, United States|Investigational Site Number 840168, Ponte Vedra, Florida, United States|Investigational Site Number 840164, Sarasota, Florida, United States|Investigational Site Number 840175, Sarasota, Florida, United States|Investigational Site Number 840001, St. Petersburg, Florida, United States|Investigational Site Number 840003, St. Petersburg, Florida, United States|Investigational Site Number 840036, West Palm Beach, Florida, United States|Investigational Site Number 840117, Cumming, Georgia, United States|Investigational Site Number 840110, Roswell, Georgia, United States|Investigational Site Number 840026, Savannah, Georgia, United States|Investigational Site Number 840075, Meridian, Idaho, United States|Investigational Site Number 840027, Evansville, Indiana, United States|Investigational Site Number 840093, Indianapolis, Indiana, United States|Investigational Site Number 840222, Iowa City, Iowa, United States|Investigational Site Number 840165, West Des Moines, Iowa, United States|Investigational Site Number 840200, Kansas City, Kansas, United States|Investigational Site Number 840040, Wichita, Kansas, United States|Investigational Site Number 840061, Wichita, Kansas, United States|Investigational Site Number 840032, Wichita, Kansas, United States|Investigational Site Number 840084, Wichita, Kansas, United States|Investigational Site Number 840244, Biddeford, Maine, United States|Investigational Site Number 840158, Framingham, Maine, United States|Investigational Site Number 840193, Novi, Michigan, United States|Investigational Site Number 840162, Saginaw, Michigan, United States|Investigational Site Number 840033, Saint Louis, Missouri, United States|Investigational Site Number 840113, St. Louis, Missouri, United States|Investigational Site Number 840095, Henderson, Nevada, United States|Investigational Site Number 840096, Henderson, Nevada, United States|Investigational Site Number 840022, Edison, New Jersey, United States|Investigational Site Number 840011, Hillsborough, New Jersey, United States|Investigational Site Number 840049, Trenton, New Jersey, United States|Investigational Site Number 840097, Bronxville, New York, United States|Investigational Site Number 840129, Brooklyn, New York, United States|Investigational Site Number 840160, Poughkeepsie, New York, United States|Investigational Site Number 840217, Asheville, North Carolina, United States|Investigational Site Number 840023, Charlotte, North Carolina, United States|Investigational Site Number 840083, Greensboro, North Carolina, United States|Investigational Site Number 840104, Raleigh, North Carolina, United States|Investigational Site Number 840068, Cincinnati, Ohio, United States|Investigational Site Number 840007, Dayton, Ohio, United States|Investigational Site Number 840013, Marion, Ohio, United States|Investigational Site Number 840161, Mentor, Ohio, United States|Investigational Site Number 840005, Tulsa, Oklahoma, United States|Investigational Site Number 840170, Beaver, Pennsylvania, United States|Investigational Site Number 840180, Camp Hill, Pennsylvania, United States|Investigational Site Number 840004, Duncansville, Pennsylvania, United States|Investigational Site Number 840046, Jersey Shore, Pennsylvania, United States|Investigational Site Number 840155, Phoenixville, Pennsylvania, United States|Investigational Site Number 840177, Scranton, Pennsylvania, United States|Investigational Site Number 840202, Wyomissing, Pennsylvania, United States|Investigational Site Number 840073, Charleston, South Carolina, United States|Investigational Site Number 840087, Greenville, South Carolina, United States|Investigational Site Number 840074, Simpsonville, South Carolina, United States|Investigational Site Number 840105, Varnville, South Carolina, United States|Investigational Site Number 840190, Knoxville, Tennessee, United States|Investigational Site Number 840092, Dallas, Texas, United States|Investigational Site Number 840212, Dallas, Texas, United States|Investigational Site Number 840058, Fort Worth, Texas, United States|Investigational Site Number 840149, Fort Worth, Texas, United States|Investigational Site Number 840070, Fort Worth, Texas, United States|Investigational Site Number 840038, Houston, Texas, United States|Investigational Site Number 840047, Houston, Texas, United States|Investigational Site Number 840053, Plano, Texas, United States|Investigational Site Number 840072, Sugar Land, Texas, United States|Investigational Site Number 840241, Tyler, Texas, United States|Investigational Site Number 840031, Salt Lake City, Utah, United States|Investigational Site Number 840204, Chesapeake, Virginia, United States|Investigational Site Number 840120, Spokane, Washington, United States|Investigational Site Number 840111, Milwaukee, Wisconsin, United States|Investigational Site Number 032006, Buenos Aires, Argentina|Investigational Site Number 032010, Caba, Argentina|Investigational Site Number 032008, Capital Federal, Argentina|Investigational Site Number 032001, Coronel Suarez, Argentina|Investigational Site Number 032004, Resistencia, Argentina|Investigational Site Number 032007, Zarate, Argentina|Investigational Site Number 056005, Antwerpen, Belgium|Investigational Site Number 056004, Genk, Belgium|Investigational Site Number 056001, Natoye, Belgium|Investigational Site Number 056002, Wetteren, Belgium|Investigational Site Number 100008, Pleven, Bulgaria|Investigational Site Number 100014, Plovdiv, Bulgaria|Investigational Site Number 100005, Sofia, Bulgaria|Investigational Site Number 100012, Sofia, Bulgaria|Investigational Site Number 100015, Sofia, Bulgaria|Investigational Site Number 100009, Sofia, Bulgaria|Investigational Site Number 100001, Sofia, Bulgaria|Investigational Site Number 100013, Stara Zagora, Bulgaria|Investigational Site Number 100007, Varna, Bulgaria|Investigational Site Number 124013, Cambridge, Canada|Investigational Site Number 124027, Coquitlam, Canada|Investigational Site Number 124001, Hawkesbury, Canada|Investigational Site Number 124002, London, Canada|Investigational Site Number 124009, Mirabel, Canada|Investigational Site Number 124018, Montreal, Canada|Investigational Site Number 124007, Ottawa, Canada|Investigational Site Number 124011, Quebec, Canada|Investigational Site Number 124005, Saint John'S, Canada|Investigational Site Number 124008, Sarnia, Canada|Investigational Site Number 124022, Terrebonne, Canada|Investigational Site Number 124003, Vancouver, Canada|Investigational Site Number 124006, Victoria, Canada|Investigational Site Number 124015, Woodstock, Canada|Investigational Site Number 152007, Osorno, Chile|Investigational Site Number 152008, Santiago, Chile|Investigational Site Number 152006, Santiago, Chile|Investigational Site Number 152004, Temuco, Chile|Investigational Site Number 170004, Barranquilla, Colombia|Investigational Site Number 170005, Barranquilla, Colombia|Investigational Site Number 170008, Barranquilla, Colombia|Investigational Site Number 170001, Manizales, Colombia|Investigational Site Number 170003, Medellin, Colombia|Investigational Site Number 203004, Praha 2, Czech Republic|Investigational Site Number 203007, Praha 5, Czech Republic|Investigational Site Number 203006, Praha 5, Czech Republic|Investigational Site Number 208005, Aarhus, Denmark|Investigational Site Number 208004, Hellerup, Denmark|Investigational Site Number 208003, Slagelse, Denmark|Investigational Site Number 208001, Svendborg, Denmark|Investigational Site Number 208002, Viborg, Denmark|Investigational Site Number 246002, Joensuu, Finland|Investigational Site Number 246001, Kokkola, Finland|Investigational Site Number 246003, Kuopio, Finland|Investigational Site Number 246004, Vantaa, Finland|Investigational Site Number 250007, Bandol, France|Investigational Site Number 250003, Broglie, France|Investigational Site Number 250014, Bron Cedex, France|Investigational Site Number 250004, Dijon, France|Investigational Site Number 250006, Lille Cedex, France|Investigational Site Number 250009, Nantes, France|Investigational Site Number 250001, Nantes, France|Investigational Site Number 250002, Paris Cedex 13, France|Investigational Site Number 250010, Pessac, France|Investigational Site Number 250012, Rennes, France|Investigational Site Number 250005, Vieux Conde, France|Investigational Site Number 250008, Vihiers, France|Investigational Site Number 276001, Bad Wörishofen, Germany|Investigational Site Number 276007, Berlin, Germany|Investigational Site Number 276005, Berlin, Germany|Investigational Site Number 276014, Berlin, Germany|Investigational Site Number 276008, Bochum, Germany|Investigational Site Number 276009, Dresden, Germany|Investigational Site Number 276004, Essen, Germany|Investigational Site Number 276010, Frankfurt A.M., Germany|Investigational Site Number 276011, Görlitz, Germany|Investigational Site Number 276019, Hannover, Germany|Investigational Site Number 276013, Leipzig, Germany|Investigational Site Number 276012, Magdeburg, Germany|Investigational Site Number 276003, Magdeburg, Germany|Investigational Site Number 276006, Schwerin, Germany|Investigational Site Number 276015, Witten, Germany|Investigational Site Number 348003, Baja, Hungary|Investigational Site Number 348007, Budapest, Hungary|Investigational Site Number 348009, Budapest, Hungary|Investigational Site Number 348008, Budapest, Hungary|Investigational Site Number 348013, Budapest, Hungary|Investigational Site Number 348004, Debrecen, Hungary|Investigational Site Number 348002, Nagykanizsa, Hungary|Investigational Site Number 348006, Nyiregyhaza, Hungary|Investigational Site Number 348001, Sopron, Hungary|Investigational Site Number 348011, Urhida, Hungary|Investigational Site Number 376002, Afula, Israel|Investigational Site Number 376003, Holon, Israel|Investigational Site Number 376005, Holon, Israel|Investigational Site Number 376004, Nazareth, Israel|Investigational Site Number 380006, Chieti, Italy|Investigational Site Number 380002, Cinisello Balsamo, Italy|Investigational Site Number 380009, Milano, Italy|Investigational Site Number 380007, Napoli, Italy|Investigational Site Number 380001, Palermo, Italy|Investigational Site Number 380005, Pozzilli, Italy|Investigational Site Number 380008, Vittorio Veneto, Italy|Investigational Site Number 380010, Zingonia-Osio Sotto, Italy|Investigational Site Number 484010, Df, Mexico|Investigational Site Number 484004, Mexico, Mexico|Investigational Site Number 484008, Not Provided, Mexico|Investigational Site Number 484001, San Luis Potosi, Mexico|Investigational Site Number 484002, Tijuana, Mexico|Investigational Site Number 484009, Torreon, Mexico|Investigational Site Number 484003, Xalapa, Mexico|Investigational Site Number 528013, Amsterdam, Netherlands|Investigational Site Number 528001, Amsterdam, Netherlands|Investigational Site Number 528004, Breda, Netherlands|Investigational Site Number 528005, Eindhoven, Netherlands|Investigational Site Number 528007, Groningen, Netherlands|Investigational Site Number 528011, Hoogeveen, Netherlands|Investigational Site Number 528002, Hoorn, Netherlands|Investigational Site Number 528008, Leiderdorp, Netherlands|Investigational Site Number 528009, Rotterdam, Netherlands|Investigational Site Number 528006, Velp, Netherlands|Investigational Site Number 528012, Venlo, Netherlands|Investigational Site Number 528010, Zoetermeer, Netherlands|Investigational Site Number 578005, Elverum, Norway|Investigational Site Number 578001, Hamar, Norway|Investigational Site Number 578002, Oslo, Norway|Investigational Site Number 578004, Skedsmokorset, Norway|Investigational Site Number 578003, Stavanger, Norway|Investigational Site Number 616008, Gdynia, Poland|Investigational Site Number 616003, Gdynia, Poland|Investigational Site Number 616001, Gniewkowo, Poland|Investigational Site Number 616010, Katowice, Poland|Investigational Site Number 616018, Krakow, Poland|Investigational Site Number 616004, Piotrkow Trybunalski, Poland|Investigational Site Number 616013, Pulawy, Poland|Investigational Site Number 616009, Warszawa, Poland|Investigational Site Number 616007, Wroclaw, Poland|Investigational Site Number 620006, Funchal / Madeira, Portugal|Investigational Site Number 620002, Lisboa, Portugal|Investigational Site Number 620001, Lisboa, Portugal|Investigational Site Number 620005, Porto, Portugal|Investigational Site Number 642005, Baia Mare, Romania|Investigational Site Number 642002, Brasov, Romania|Investigational Site Number 642004, Targu Mures, Romania|Investigational Site Number 642001, Timisoara, Romania|Investigational Site Number 643005, Barnaul, Russian Federation|Investigational Site Number 643012, Moscow, Russian Federation|Investigational Site Number 643008, Moscow, Russian Federation|Investigational Site Number 643014, Perm, Russian Federation|Investigational Site Number 643006, St Petersburg, Russian Federation|Investigational Site Number 643009, St.Petersburg, Russian Federation|Investigational Site Number 643004, Yaroslavl, Russian Federation|Investigational Site Number 710010, Centurion, South Africa|Investigational Site Number 710008, Meyerspark, South Africa|Investigational Site Number 710011, Middelburg, South Africa|Investigational Site Number 710006, Parktown, South Africa|Investigational Site Number 710004, Pretoria, South Africa|Investigational Site Number 710001, Pretoria, South Africa|Investigational Site Number 710002, Pretoria, South Africa|Investigational Site Number 710009, Roodepoort, South Africa|Investigational Site Number 710003, Somerset West, South Africa|Investigational Site Number 710005, Witbank, South Africa|Investigational Site Number 710007, Worcester, South Africa|Investigational Site Number 724006, Córdoba, Spain|Investigational Site Number 724003, Granada, Spain|Investigational Site Number 724002, Madrid, Spain|Investigational Site Number 724007, Málaga, Spain|Investigational Site Number 724008, Quart De Poblet, Spain|Investigational Site Number 724005, Reus, Spain|Investigational Site Number 724001, Sabadell, Spain|Investigational Site Number 724004, Sevilla, Spain|Investigational Site Number 752002, Rättvik, Sweden|Investigational Site Number 752006, Stockholm, Sweden|Investigational Site Number 752003, Stockholm, Sweden|Investigational Site Number 752004, Stockholm, Sweden|Investigational Site Number 752001, Örebro, Sweden|Investigational Site Number 804012, Chernivtsi, Ukraine|Investigational Site Number 804003, Dnipropetrovsk, Ukraine|Investigational Site Number 804002, Donetsk, Ukraine|Investigational Site Number 804014, Kharkiv, Ukraine|Investigational Site Number 804016, Kiev, Ukraine|Investigational Site Number 804011, Kyiv, Ukraine|Investigational Site Number 804010, Kyiv, Ukraine|Investigational Site Number 804001, Kyiv, Ukraine|Investigational Site Number 804008, Kyiv, Ukraine|Investigational Site Number 804013, Kyiv, Ukraine|Investigational Site Number 804005, Zhytomyr, Ukraine|Investigational Site Number 826004, Addlestone, United Kingdom|Investigational Site Number 826009, Birmingham, United Kingdom|Investigational Site Number 826016, Birmingham, United Kingdom|Investigational Site Number 826021, Blackpool, United Kingdom|Investigational Site Number 826023, Cambridge, United Kingdom|Investigational Site Number 826012, Cardiff, United Kingdom|Investigational Site Number 826024, Chichester, United Kingdom|Investigational Site Number 826006, Chorley, United Kingdom|Investigational Site Number 826010, Glasgow, United Kingdom|Investigational Site Number 826003, Irvine, United Kingdom|Investigational Site Number 826008, Liverpool, United Kingdom|Investigational Site Number 826005, Liverpool, United Kingdom|Investigational Site Number 826025, Manchester, United Kingdom|Investigational Site Number 826007, Manchester, United Kingdom|Investigational Site Number 826001, Middlesex, United Kingdom|Investigational Site Number 826019, Penzance, United Kingdom|Investigational Site Number 826011, Reading, United Kingdom|Investigational Site Number 826013, Romford, United Kingdom|Investigational Site Number 826014, Soham, United Kingdom","https://ClinicalTrials.gov/show/NCT01507831"
648,"Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)","Completed","No Results Available","Squamous Cell Lung Cancer","Drug: gemcitabine/carboplatin|Drug: gemcitabine/carboplatin plus Iniparib","Investigational Site Number 840306, Birmingham, Alabama, United States|Investigational Site Number 840207, Huntsville, Alabama, United States|Investigational Site Number 840351, Muscle Shoals, Alabama, United States|Investigational Site Number 840338, Anaheim, California, United States|Investigational Site Number 840353, Burbank, California, United States|Investigational Site Number 840341, Concord, California, United States|Investigational Site Number 840317, Duarte, California, United States|Investigational Site Number 840339, La Verne, California, United States|Investigational Site Number 840309, Loma Linda, California, United States|Investigational Site Number 840307, Los Angeles, California, United States|Investigational Site Number 840327, Maywood, California, United States|Investigational Site Number 840303, San Diego, California, United States|Investigational Site Number 840321, Santa Rosa, California, United States|Investigational Site Number 840326, Stockton, California, United States|Investigational Site Number 840310, Vallejo, California, United States|Investigational Site Number 840336, Denver, Colorado, United States|Investigational Site Number 840346, Norwich, Connecticut, United States|Investigational Site Number 840315, Newark, Delaware, United States|Investigational Site Number 840216, Ft. Lauderdale, Florida, United States|Investigational Site Number 840215, Jacksonville, Florida, United States|Investigational Site Number 840217, Lakeland, Florida, United States|Investigational Site Number 840205, Orlando, Florida, United States|Investigational Site Number 840104, Sarasota, Florida, United States|Investigational Site Number 840343, Athens, Georgia, United States|Investigational Site Number 840213, Augusta, Georgia, United States|Investigational Site Number 840347, Augusta, Georgia, United States|Investigational Site Number 840201, Gainesville, Georgia, United States|Investigational Site Number 840301, Lawrenceville, Georgia, United States|Investigational Site Number 840305, Marietta, Georgia, United States|Investigational Site Number 840314, Tucker, Georgia, United States|Investigational Site Number 840313, Chicago, Illinois, United States|Investigational Site Number 840218, Evansville, Indiana, United States|Investigational Site Number 840319, Indianapolis, Indiana, United States|Investigational Site Number 840329, South Bend, Indiana, United States|Investigational Site Number 840316, Wichita, Kansas, United States|Investigational Site Number 840320, Louisville, Kentucky, United States|Investigational Site Number 840308, Scarborough, Maine, United States|Investigational Site Number 840202, Bethesda, Maryland, United States|Investigational Site Number 840345, Salisbury, Maryland, United States|Investigational Site Number 840337, Royal Oak, Michigan, United States|Investigational Site Number 840328, St. Louis Park, Minnesota, United States|Investigational Site Number 840210, Bridgeton, Missouri, United States|Investigational Site Number 840212, Omaha, Nebraska, United States|Investigational Site Number 840318, Las Vegas, Nevada, United States|Investigational Site Number 840204, Morristown, New Jersey, United States|Investigational Site Number 840350, Chapel Hill, North Carolina, United States|Investigational Site Number 840330, Durham, North Carolina, United States|Investigational Site Number 840105, Cincinnati, Ohio, United States|Investigational Site Number 840302, Cleveland, Ohio, United States|Investigational Site Number 840348, Cleveland, Ohio, United States|Investigational Site Number 840335, Columbus, Ohio, United States|Investigational Site Number 840311, Bend, Oregon, United States|Investigational Site Number 840211, West Reading, Pennsylvania, United States|Investigational Site Number 840352, Charleston, South Carolina, United States|Investigational Site Number 840106, Columbia, South Carolina, United States|Investigational Site Number 840220, Spartanburg, South Carolina, United States|Investigational Site Number 840103, Chattanooga, Tennessee, United States|Investigational Site Number 840208, Chattanooga, Tennessee, United States|Investigational Site Number 840203, Collierville, Tennessee, United States|Investigational Site Number 840101, Nashville, Tennessee, United States|Investigational Site Number 840323, Fort Worth, Texas, United States|Investigational Site Number 840219, Newport News, Virginia, United States|Investigational Site Number 840102, Richmond, Virginia, United States|Investigational Site Number 840312, Seattle, Washington, United States|Investigational Site Number 840344, Tacoma, Washington, United States|Investigational Site Number 840322, Morgantown, West Virginia, United States|Investigational Site Number 840331, Wauwatosa, Wisconsin, United States|Investigational Site Number 056004, Brugge, Belgium|Investigational Site Number 056003, Brussel, Belgium|Investigational Site Number 056001, Liège, Belgium|Investigational Site Number 124003, Edmonton, Canada|Investigational Site Number 124006, Greenfield Park, Canada|Investigational Site Number 124005, London, Canada|Investigational Site Number 124007, Oshawa, Canada|Investigational Site Number 124004, Quebec, Canada|Investigational Site Number 124001, Toronto, Canada|Investigational Site Number 250007, Brest, France|Investigational Site Number 250002, Dijon, France|Investigational Site Number 250009, Limoges Cedex, France|Investigational Site Number 250003, Marseille, France|Investigational Site Number 250004, Paris Cedex 13, France|Investigational Site Number 250010, Pierre Benite Cedex, France|Investigational Site Number 250008, Poitiers, France|Investigational Site Number 250001, Saint-Herblain Cedex, France|Investigational Site Number 250006, Strasbourg, France|Investigational Site Number 250005, Tours Cedex 1, France|Investigational Site Number 276002, Amberg, Germany|Investigational Site Number 276004, Berlin, Germany|Investigational Site Number 276007, Frankfurt Am Main, Germany|Investigational Site Number 276008, Großhansdorf, Germany|Investigational Site Number 276010, Halle/Saale, Germany|Investigational Site Number 276012, Heidelberg, Germany|Investigational Site Number 276009, Immenhausen, Germany|Investigational Site Number 276001, Löwenstein, Germany|Investigational Site Number 276006, München, Germany|Investigational Site Number 276003, Oldenburg, Germany|Investigational Site Number 348005, Budapest, Hungary|Investigational Site Number 348003, Budapest, Hungary|Investigational Site Number 348001, Mátraháza, Hungary|Investigational Site Number 348004, Nyíregyháza, Hungary|Investigational Site Number 376002, Kfar Saba, Israel|Investigational Site Number 376005, Petah-Tikva, Israel|Investigational Site Number 376003, Tel Hashomer, Israel|Investigational Site Number 376001, Tzrifin, Israel|Investigational Site Number 380006, Genova, Italy|Investigational Site Number 380001, Novara, Italy|Investigational Site Number 380008, Orbassano, Italy|Investigational Site Number 380002, Perugia, Italy|Investigational Site Number 380003, Roma, Italy|Investigational Site Number 380007, Roma, Italy|Investigational Site Number 442001, Luxembourg, Luxembourg|Investigational Site Number 528005, Breda, Netherlands|Investigational Site Number 528004, Eindhoven, Netherlands|Investigational Site Number 528001, Groningen, Netherlands|Investigational Site Number 528006, Maastricht, Netherlands|Investigational Site Number 528003, Zwolle, Netherlands|Investigational Site Number 616006, Bialystok, Poland|Investigational Site Number 616001, Krakow, Poland|Investigational Site Number 616007, Lubin, Poland|Investigational Site Number 616004, Olsztyn, Poland|Investigational Site Number 616008, Torun, Poland|Investigational Site Number 616002, Warszawa, Poland|Investigational Site Number 616005, Wroclaw, Poland|Investigational Site Number 642002, Alba Iulia, Romania|Investigational Site Number 642006, Bucuresti, Romania|Investigational Site Number 642001, Cluj Napoca, Romania|Investigational Site Number 642004, Craiova, Romania|Investigational Site Number 642005, Hunedoara, Romania|Investigational Site Number 724009, Badalona, Spain|Investigational Site Number 724003, Barcelona, Spain|Investigational Site Number 724004, La Coruña, Spain|Investigational Site Number 724005, Madrid, Spain|Investigational Site Number 724006, Madrid, Spain|Investigational Site Number 724002, Málaga, Spain|Investigational Site Number 724001, Palma De Mallorca, Spain|Investigational Site Number 724008, Sevilla, Spain|Investigational Site Number 724010, Valencia, Spain|Investigational Site Number 724007, Zaragoza, Spain|Investigational Site Number 826002, Glasgow, United Kingdom|Investigational Site Number 826005, Leeds, United Kingdom|Investigational Site Number 826001, Manchester, United Kingdom|Investigational Site Number 826006, Wolverhampton, United Kingdom","https://ClinicalTrials.gov/show/NCT01082549"
649,"Safety and Efficacy of Ectoin Allergy Nasal Spray and Ectoin Allergy Eye Drops in the Treatment of Seasonal Allergic Rhinitis (SAR) in Children and Adolescents","Completed","No Results Available","Seasonal Allergic Rhinitis|Seasonal Allergic Conjunctivitis","Device: ect4allergy Nasal Spray (ANS01) and Eye Drops (AAT01)|Device: Placebo products","Kinderarzt Bleckmann, Baunatal-Großenritte, Germany|Dr. med. Martina Weh, Berlin, Germany|Experimentelle Pneumologie RUB, Bochum, Germany|Kinderarztpraxis Bramsche, Bramsche, Germany|Dr. med. Friedrich Kaiser, Hamburg, Germany|Dr. Marlies Bölich, Jena, Germany|Dr. Ralph Maier, Tuttlingen, Germany|Dr.med. Dieter Schlegel und Lilli Hegai, Welzheim, Germany","https://ClinicalTrials.gov/show/NCT01342601"
650,"Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy","Completed","Has Results","Hypercholesterolemia","Drug: Alirocumab|Drug: Placebo (for alirocumab)|Drug: Atorvastatin","Investigational Site Number 840525, Tempe, Arizona, United States|Investigational Site Number 840516, Los Angeles, California, United States|Investigational Site Number 840528, Mission Viejo, California, United States|Investigational Site Number 840509, Newport Beach, California, United States|Investigational Site Number 840523, Palm Springs, California, United States|Investigational Site Number 840534, Westlake Village, California, United States|Investigational Site Number 840530, Colorado Springs, Colorado, United States|Investigational Site Number 840504, Aventura, Florida, United States|Investigational Site Number 840519, Aventura, Florida, United States|Investigational Site Number 840514, Jacksonville, Florida, United States|Investigational Site Number 840539, Jupiter, Florida, United States|Investigational Site Number 840502, Miami, Florida, United States|Investigational Site Number 840520, Pembroke Pines, Florida, United States|Investigational Site Number 840524, Ponte Vedra, Florida, United States|Investigational Site Number 840536, Port Orange, Florida, United States|Investigational Site Number 840507, St. Petersburg, Florida, United States|Investigational Site Number 840527, Chicago, Illinois, United States|Investigational Site Number 840506, Evansville, Indiana, United States|Investigational Site Number 840529, Indianapolis, Indiana, United States|Investigational Site Number 840515, Wichita, Kansas, United States|Investigational Site Number 840532, Madisonville, Kentucky, United States|Investigational Site Number 840535, Auburn, Maine, United States|Investigational Site Number 840503, Brockton, Massachusetts, United States|Investigational Site Number 840512, Las Vegas, Nevada, United States|Investigational Site Number 840505, Edison, New Jersey, United States|Investigational Site Number 840538, Rochester, New York, United States|Investigational Site Number 840508, Raleigh, North Carolina, United States|Investigational Site Number 840522, Statesville, North Carolina, United States|Investigational Site Number 840511, Cincinnati, Ohio, United States|Investigational Site Number 840526, Cincinnati, Ohio, United States|Investigational Site Number 840510, Lyndhurst, Ohio, United States|Investigational Site Number 840533, Tulsa, Oklahoma, United States|Investigational Site Number 840537, Eugene, Oregon, United States|Investigational Site Number 840521, Bristol, Tennessee, United States|Investigational Site Number 840531, Bountiful, Utah, United States|Investigational Site Number 840517, Norfolk, Virginia, United States|Investigational Site Number 840518, Richmond, Virginia, United States|Investigational Site Number 840513, Olympia, Washington, United States","https://ClinicalTrials.gov/show/NCT01288443"
651,"Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic Syndromes","Completed","No Results Available","Acute Myelogenous Leukemia","Drug: SAR103168","Sanofi-Aventis Investigational Site Number 840003, Atlanta, Georgia, United States|Sanofi-Aventis Investigational Site Number 840002, New York, New York, United States|Sanofi-Aventis Investigational Site Number 840001, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT00981240"
652,"Data Analysis of the Cytokine Adsorption Treatment on COVID-19 Patients With Respiratory Failure","Not yet recruiting","No Results Available","SARS-CoV-2|COVID-19",,,"https://ClinicalTrials.gov/show/NCT04422626"
653,"Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy","Completed","Has Results","Hypercholesterolemia","Drug: Alirocumab|Drug: Placebo (for alirocumab)|Drug: Lipid Modifying Therapy (LMT)","Investigational Site Number 840417, Bell Gardens, California, United States|Investigational Site Number 840429, Long Beach, California, United States|Investigational Site Number 840419, Los Angeles, California, United States|Investigational Site Number 840421, Mission Viejo, California, United States|Investigational Site Number 840412, Newport Beach, California, United States|Investigational Site Number 840428, Newport Beach, California, United States|Investigational Site Number 840461, Northridge, California, United States|Investigational Site Number 840452, Washington, District of Columbia, United States|Investigational Site Number 840456, Miami, Florida, United States|Investigational Site Number 840418, Ponte Vedra, Florida, United States|Investigational Site Number 840455, Evanston, Illinois, United States|Investigational Site Number 840415, Kansas City, Kansas, United States|Investigational Site Number 840425, Auburn, Maine, United States|Investigational Site Number 840411, Boston, Massachusetts, United States|Investigational Site Number 840409, St Louis, Missouri, United States|Investigational Site Number 840407, Morristown, New Jersey, United States|Investigational Site Number 840408, New York, New York, United States|Investigational Site Number 840401, Charlotte, North Carolina, United States|Investigational Site Number 840410, Durham, North Carolina, United States|Investigational Site Number 840430, Cincinnati, Ohio, United States|Investigational Site Number 840424, Portland, Oregon, United States|Investigational Site Number 840404, Philadelphia, Pennsylvania, United States|Investigational Site Number 840426, Philadelphia, Pennsylvania, United States|Investigational Site Number 840406, Nashville, Tennessee, United States|Investigational Site Number 840460, Dallas, Texas, United States|Investigational Site Number 840422, Bountiful, Utah, United States|Investigational Site Number 040403, Graz, Austria|Investigational Site Number 040402, Wien, Austria|Investigational Site Number 040405, Wien, Austria|Investigational Site Number 124404, Chicoutimi, Canada|Investigational Site Number 124401, Montreal, Canada|Investigational Site Number 124403, Quebec, Canada|Investigational Site Number 124406, Sherbrooke, Canada|Investigational Site Number 124407, Toronto, Canada|Investigational Site Number 203401, Praha, Czech Republic|Investigational Site Number 203403, Praha, Czech Republic|Investigational Site Number 203405, Uherske Hradiste, Czech Republic|Investigational Site Number 203402, Zlin, Czech Republic|Investigational Site Number 208401, Copenhagen, Denmark|Investigational Site Number 208403, Esbjerg, Denmark|Investigational Site Number 250403, Dijon, France|Investigational Site Number 250401, Paris Cedex 13, France|Investigational Site Number 250402, Saint Herblain, France|Investigational Site Number 376402, Holon, Israel|Investigational Site Number 376405, Jerusalem, Israel|Investigational Site Number 376404, Safed, Israel|Investigational Site Number 376401, Tel Hashomer, Israel|Investigational Site Number 528406, Amsterdam, Netherlands|Investigational Site Number 528410, Amsterdam, Netherlands|Investigational Site Number 528408, Den Helder, Netherlands|Investigational Site Number 528402, Groningen, Netherlands|Investigational Site Number 528411, Leiden, Netherlands|Investigational Site Number 528416, Maastricht, Netherlands|Investigational Site Number 528409, Nieuwegein, Netherlands|Investigational Site Number 528412, Sliedrecht, Netherlands|Investigational Site Number 578401, Bodø, Norway|Investigational Site Number 643402, Arkhangelsk, Russian Federation|Investigational Site Number 643407, Kazan, Russian Federation|Investigational Site Number 643409, Moscow, Russian Federation|Investigational Site Number 643413, Moscow, Russian Federation|Investigational Site Number 643401, Moscow, Russian Federation|Investigational Site Number 643412, Novisibirsk, Russian Federation|Investigational Site Number 643408, St-Petersburg, Russian Federation|Investigational Site Number 643406, St-Petersburg, Russian Federation|Investigational Site Number 643404, St-Petersburg, Russian Federation|Investigational Site Number 643410, Yaroslavl, Russian Federation|Investigational Site Number 710401, Bloemfontein, South Africa|Investigational Site Number 710405, Bloemfontein, South Africa|Investigational Site Number 710406, Cap Town, South Africa|Investigational Site Number 710402, Cape Town, South Africa|Investigational Site Number 710407, Parktown, South Africa|Investigational Site Number 710403, Parow, South Africa|Investigational Site Number 710408, Pretoria, South Africa|Investigational Site Number 710404, Rondebosch, South Africa|Investigational Site Number 710409, Somerset West, South Africa|Investigational Site Number 724403, A Coruna, Spain|Investigational Site Number 724408, Barcelona, Spain|Investigational Site Number 724406, Córdoba, Spain|Investigational Site Number 724407, Hospitalet De Llobregat, Spain|Investigational Site Number 724409, Madrid, Spain|Investigational Site Number 724401, Madrid, Spain|Investigational Site Number 724405, Madrid, Spain|Investigational Site Number 724404, Reus, Spain|Investigational Site Number 724402, Zaragoza, Spain|Investigational Site Number 752404, Goteborg, Sweden|Investigational Site Number 752401, Stockholm, Sweden|Investigational Site Number 826402, London, United Kingdom|Investigational Site Number 826403, London, United Kingdom|Investigational Site Number 826408, London, United Kingdom|Investigational Site Number 826409, London, United Kingdom|Investigational Site Number 826405, Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT01623115"
654,"Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen","Completed","No Results Available","Breast Cancer|Breast Neoplasms","Drug: XL147 (SAR245408)|Biological: trastuzumab|Drug: paclitaxel","Investigational Site Number 1537, Los Angeles, California, United States|Investigational Site Number 1238, Fort Meyers, Florida, United States|Investigational Site Number 1138, Boston, Massachusetts, United States|Investigational Site Number 1330, Detroit, Michigan, United States|Investigational Site Number 1151, Bronx, New York, United States|Investigational Site Number 1150, New York, New York, United States|Investigational Site Number 1214, Nashville, Tennessee, United States|Investigational Site Number 1246, Nashville, Tennessee, United States|Investigational Site Number 3413, Madrid, Spain","https://ClinicalTrials.gov/show/NCT01042925"
655,"Multi-dose-escalation Safety and Pharmacokinetic Study of SAR3419 as Single Agent in Relapsed/Refractory B-cell Non Hodgkin's Lymphoma","Completed","No Results Available","Lymphoma|Non-Hodgkin","Drug: SAR3419","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States","https://ClinicalTrials.gov/show/NCT00549185"
656,"Assessment of N-95 Facemask for Use in COVID-19 Pandemic in Case of Shortage of Personal Protective Equipment","Not yet recruiting","No Results Available","Coronavirus Infection|Disease Prevention","Other: Assembled mask","Oklahoma City VA Health Care System, Oklahoma City, Oklahoma, United States","https://ClinicalTrials.gov/show/NCT04416919"
657,"TAF/FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study)","Not yet recruiting","No Results Available","Healthcare Workers|COVID-19|SARS-CoV 2","Drug: Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet|Drug: Placebo","Sociedad Argentina de Infectología, A. J. Carranza 974, Ciudad Autonoma de Buenos Aires, Capital Federal, Argentina","https://ClinicalTrials.gov/show/NCT04405271"
658,"A Study Evaluating the Efficacy of SAR 1118 (0.1%, 1.0%, 5.0%) Ophthalmic Solution in Subjects With Dry Eye Conducted in a Controlled Adverse Environment (CAE)","Completed","Has Results","Dry Eye","Drug: Lifitegrast|Drug: Placebo","The Eye Care Group, Waterbury, Connecticut, United States|Central Maine Eye Care, Lewiston, Maine, United States|Ora, Inc. (two locations), Andover, Massachusetts, United States|Mundorf Eye Center, Charlotte, North Carolina, United States|Total Eye Care, P.A., Memphis, Tennessee, United States","https://ClinicalTrials.gov/show/NCT00926185"
659,"Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary Hypercholesterolemia","Completed","Has Results","Hypercholesterolemia","Drug: Alirocumab|Drug: Placebo (for alirocumab)|Drug: Atorvastatin|Drug: Placebo (for atorvastatin)","Investigational Site Number 840616, Mesa, Arizona, United States|Investigational Site Number 840601, Tucson, Arizona, United States|Investigational Site Number 840610, Los Angeles, California, United States|Investigational Site Number 840608, Newport Beach, California, United States|Investigational Site Number 840603, Doral, Florida, United States|Investigational Site Number 840611, Jacksonville, Florida, United States|Investigational Site Number 840618, Jupiter, Florida, United States|Investigational Site Number 840612, Miami, Florida, United States|Investigational Site Number 840614, Miami, Florida, United States|Investigational Site Number 840607, St. Petersburg, Florida, United States|Investigational Site Number 840605, Chicago, Illinois, United States|Investigational Site Number 840619, Chicago, Illinois, United States|Investigational Site Number 840604, Edison, New Jersey, United States|Investigational Site Number 840606, Rochester, New York, United States|Investigational Site Number 840615, Cincinnati, Ohio, United States|Investigational Site Number 840617, Cincinnati, Ohio, United States|Investigational Site Number 840602, Eugene, Oregon, United States|Investigational Site Number 840621, Richmond, Virginia, United States|Investigational Site Number 840609, Olympia, Washington, United States|Investigational Site Number 840613, Oregon, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT01288469"
660,"Microbiota in COVID-19 Patients for Future Therapeutic and Preventive Approaches","Recruiting","No Results Available","Corona Virus Infection|ARDS|Coinfection","Diagnostic Test: Sampling (EDTA blood, pharyngeal and nose swabs, bronchoalveolar lavage ,urine)","University Hospital Zurich, Zürich, Zurich, Switzerland","https://ClinicalTrials.gov/show/NCT04410263"
661,"Cardiac Arrest Incidence and Outcome Among Patients With COVID-19 in French ICUs","Recruiting","No Results Available","Sars-CoV2|Covid-19","Other: Cardiopulmonary resuscitation|Other: Modified Rankin score","CHU Felix Guyon, Saint-Denis, La Reunion, France|CHU Amiens Picardie, Amiens, France|CH Angoulème, Angoulême, France|CH Argenteuil, Argenteuil, France|CH Bethune, Beuvry, France|CHU Ambroise Paré AP-HP, Boulogne-Billancourt, France|CH Brive, Brive-la-Gaillarde, France|CHU Caen, Caen, France|Hôpital Privé St Martin, Caen, France|CH Cahors, Cahors, France|CHU Antoine Béclère AP-HP, Clamart, France|CH Louis Mourier AP-HP, Colombes, France|CHU Henri Mondor AP-HP, Créteil, France|CHU Dijon, Dijon, France|CH de la Dracénie, Draguignan, France|CHI Frejus St Raphael, Fréjus, France|Grand Hôpital de l'Est Francilien, Jossigny, France|CH La Rochelle, La Rochelle, France|CHU Grenoble-Alpes, La Tronche, France|CH Versailles, Le Chesnay, France|CHU Kremlin Bicêtre, Le Kremlin-Bicêtre, France|CH Lens, Lens, France|CHRU Roger Salengro, Lille, France|CH Sambre Avesnois, Maubeuge, France|CHU Meaux, Meaux, France|Groupe Hospitalier Sud Ile de France, Melun, France|CHU Montpellier, Montpellier, France|CHR Orléans, Orléans, France|CHU Lariboisière AP-HP, Paris, France|CHU Saint Louis AP-HP, Paris, France|CHU St Antoine, Paris, France|Groupe Hospitalier Saint Joseph, Paris, France|CHU Necker Enfants Malades, Paris, France|Groupe Hospitalier Diaconesse Croix Saint-Simon, Paris, France|Hôpital Privé Claude Galien, Quincy-sous-Sénart, France|CHU Rouen, Rouen, France|Centre Hospitalier Intercommunal Toulon La Seyne sur Mer, Toulon, France|Hôpital Nord Franche Comté, Trévenans, France|Institut Gustave Roussy, Villejuif, France|CH Etampes, Étampes, France|CHU Martinique - Fort de France, Fort-de-France, Martinique","https://ClinicalTrials.gov/show/NCT04373759"
662,"The Effects of Phenylephrine Compared With Those of Placebo and Pseudoephedrine on Nasal Congestion in Subjects With Seasonal Allergic Rhinitis (SAR)(P04579)","Completed","Has Results","Rhinitis, Allergic, Seasonal","Drug: phenylephrine|Drug: pseudoephedrine|Drug: placebo",,"https://ClinicalTrials.gov/show/NCT00276016"
663,"COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses","Not yet recruiting","No Results Available","COVID19|Mouthwash|Saliva","Device: mouthrinse with bêta-cyclodextrin and citrox|Device: mouthrinse without bêta-cyclodextrin and citrox",,"https://ClinicalTrials.gov/show/NCT04352959"
664,"Tocilizumab in Coronavirus-19 Positive Patients","Not yet recruiting","No Results Available","Covid19|COVID-19|Severe Acute Respiratory Syndrome Coronavirus 2|Coronavirus|Inflammation","Biological: Tocilizumab",,"https://ClinicalTrials.gov/show/NCT04423042"
665,"Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and Older","Completed","Has Results","Seasonal Allergic Rhinitis","Drug: Ciclesonide HFA 160 μg|Drug: Ciclesonide HFA 80 μg|Drug: Placebo","Allergy and Asthma Associates, Austin, Texas, United States|Sinus Clinical Research LLC, Austin, Texas, United States|Central Texas Health Research Corporation, New Braunfels, Texas, United States|Biogenics Research Institute, San Antonio, Texas, United States|Southwest Allergy and Asthma Research Center, Pa, San Antonio, Texas, United States|Sylvana Research, San Antonio, Texas, United States|San Antonio, Texas, United States","https://ClinicalTrials.gov/show/NCT01010971"
666,"Compare the Efficacy of Levocetirizine and Montelukast to Placebo in Reducing Seasonal Allergic Rhinitis (SAR) Symptoms in Ragweed Sensitive Subjects","Completed","Has Results","Rhinitis, Allergic, Seasonal","Drug: Placebo|Drug: Montelukast|Drug: Levocetirizine","Kingston, Ontario, Canada","https://ClinicalTrials.gov/show/NCT00295022"
667,"Study of Sargramostim in Patients With COVID-19","Not yet recruiting","No Results Available","COVID-19|Sars-CoV2","Drug: Sargramostim|Drug: Standard of care",,"https://ClinicalTrials.gov/show/NCT04411680"
668,"Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial)","Recruiting","No Results Available","Coronavirus Infection|Pneumonia, Viral","Drug: Hydroxychloroquine + placebo|Drug: hydroxychloroquine + azithromycin","Montpellier University hospital, Montpellier, France","https://ClinicalTrials.gov/show/NCT04345861"
669,"A Study to Compare the Efficacy of Levocetirizine to Placebo in Reducing Symptoms of Seasonal Allergic Rhinitis (SAR) in Sensitive Subjects Exposed to Ragweed Pollen","Completed","Has Results","Rhinitis|Allergic|Seasonal","Drug: Placebo drops|Drug: Placebo tablets matching to levocetirizine|Drug: Placebo tablets matching to cetirizine|Drug: Levocetirizine drops|Drug: Levocetirizine tablets|Drug: Cetirizine drops|Drug: Cetirizine tablets","Kingston, Ontario, Canada","https://ClinicalTrials.gov/show/NCT00291642"
670,"Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers","Recruiting","No Results Available","COVID|SARS Pneumonia|Cytokine Release Syndrome","Drug: Tocilizumab","UNIFESP, São Paulo, Sao Paulo, Brazil|HCOR -Hospital do Coracao, Sao Paulo, SP, Brazil|HAOC - Hospital Alemao Oswaldo Cruz, Sao Paulo, Brazil|Beneficência Portuguesa de Sao Paulo, Sao Paulo, Brazil|HAOC - Hospital Alemao Oswaldo Cruz - unidade Vergueiro, Sao Paulo, Brazil|HIAE - Hospital Israelita Albert Einstein, Sao Paulo, Brazil|HSL - Hospital Sírio Libanês, Sao Paulo, Brazil","https://ClinicalTrials.gov/show/NCT04403685"
671,"Coronavirus Infection in Primary or Secondary Immunosuppressed Children and Adults.","Enrolling by invitation","No Results Available","Immune Suppression|Immune Deficiency|Infection|COVID|Children, Adult","Other: Questionnaire","University Hospital Southampton NHS FT, Southampton, Hampshire, United Kingdom","https://ClinicalTrials.gov/show/NCT04382508"
672,"Compare the Efficacy of Levocetirizine to Montelukast in Reducing Symptoms of SAR in Sensitive Subjects Exposed to Ragweed Pollen","Completed","No Results Available","Rhinitis, Allergic, Seasonal","Drug: Levocetirizine","Mississauga, Ontario, Canada","https://ClinicalTrials.gov/show/NCT00315523"
673,"Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies","Completed","Has Results","Seasonal Allergic Rhinitis|SAR","Drug: BDP HFA|Drug: Placebo nasal aerosol","Teva Clinical Study Site, Oxford, Alabama, United States|Teva Clinical Study Site, Bell, California, United States|Teva Clinical Study Site, Costa Mesa, California, United States|Teva Clinical Study Site, Mission Viejo, California, United States|Teva Clinical Study Site, Orange, California, United States|Teva Clinical Study Site, Paramount, California, United States|Teva Clinical Study Site, San Diego, California, United States|Teva Clinical Study Site, San Diego, California, United States|Teva Clinical Study Site, Stockton, California, United States|Teva Clinical Study Site, Centennial, Colorado, United States|Teva Clinical Study Site, Colorado Springs, Colorado, United States|Teva Clinical Study Site, Gainesville, Georgia, United States|Teva Clinical Study Site, Lawrenceville, Georgia, United States|Teva Clinical Study Site, Savannah, Georgia, United States|Teva Clinical Study Site, Stockbridge, Georgia, United States|Teva Clinical Study Site, Indianapolis, Indiana, United States|Teva Clinical Study Site, Bethesda, Maryland, United States|Teva Clinical Study Site, Minneapolis, Minnesota, United States|Teva Clinical Study Site, Plymouth, Minnesota, United States|Teva Clinical Study Site, Columbia, Missouri, United States|Teva Clinical Study Site, Rolla, Missouri, United States|Teva Clinical Study Site, Warrensburg, Missouri, United States|Teva Clinical Study Site, Bozeman, Montana, United States|Teva Clinical Study Site, Brick, New Jersey, United States|Teva Clinical Study Site, High Point, North Carolina, United States|Teva Clinical Study Site, Oklahoma City, Oklahoma, United States|Teva Clinical Study Site, Portland, Oregon, United States|Teva Clinical Study Site, Blue Bell, Pennsylvania, United States|Teva Clinical Study Site, Collegeville, Pennsylvania, United States|Teva Clinical Study Site, Philadelphia, Pennsylvania, United States|Teva Clinical Study Site, Pittsburgh, Pennsylvania, United States|Teva Clinical Study Site, Charleston, South Carolina, United States|Teva Clinical Study Site, Orangeburg, South Carolina, United States|Teva Clinical Study Site, Austin, Texas, United States|Teva Clinical Study Site, Dallas, Texas, United States|Teva Clinical Study Site, Dallas, Texas, United States|Teva Clinical Study Site, El Paso, Texas, United States|Teva Clinical Study Site, Ft. Worth, Texas, United States|Teva Clinical Study Site, Houston, Texas, United States|Teva Clinical Study Site, Kerrville, Texas, United States|Teva Clinical Study Site, New Braunfels, Texas, United States|Teva Clinical Study Site, San Antonio, Texas, United States|Teva Clinical Study Site, Waco, Texas, United States|Teva Clinical Study Site, Burke, Virginia, United States|Teva Clinical Study Site, Richmond, Virginia, United States","https://ClinicalTrials.gov/show/NCT01307319"
674,"Ruxolitinib for the Treatment of Acute Respiratory Distress Syndrome in Patients With COVID-19 Infection","Not yet recruiting","No Results Available","Severe Acute Respiratory Syndrome Coronavirus 2","Drug: Ruxolitinib Oral Tablet",,"https://ClinicalTrials.gov/show/NCT04361903"
675,"Prone Positioning in Spontaneously Breathing Nonintubated Covid-19 Patient: a Pilot Study","Recruiting","No Results Available","Coronavirus Infection|Oxygen Deficiency","Procedure: Prone positioning","CHI Aix-Pertuis, Aix-en-Provence, France","https://ClinicalTrials.gov/show/NCT04344106"
676,"Clinical Efficacy of Nafamostat Mesylate for COVID-19 Pneumonia","Not yet recruiting","No Results Available","Corona Virus Infection|COVID-19","Drug: Nafamostat Mesylate",,"https://ClinicalTrials.gov/show/NCT04418128"
677,"Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19","Not yet recruiting","No Results Available","Pulmonary Complications in Surgical Patients|COVID|Severe Acute Respiratory Syndrome","Drug: Lopinavir-Ritonavir|Drug: Hydroxychloroquine",,"https://ClinicalTrials.gov/show/NCT04386070"
678,"COVID-19 Specific T Cell Derived Exosomes (CSTC-Exo)","Active, not recruiting","No Results Available","Corona Virus Infection|Pneumonia","Biological: COVID-19 Specific T Cell derived exosomes (CSTC-Exo)","GENKOK, Kayseri, Melikgazi, Turkey","https://ClinicalTrials.gov/show/NCT04389385"
679,"This Study Contains an Active Drug Treatment Group With Mometasone Furoate Nasal Spray and a Placebo (Dummy) Treatment Group for Seasonal Allergic Rhinitis (SAR). (Study P05073)(COMPLETED)","Completed","Has Results","Seasonal Allergic Rhinitis","Drug: Mometasone Furoate Nasal Spray|Other: Placebo",,"https://ClinicalTrials.gov/show/NCT00491504"
680,"P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19","Not yet recruiting","No Results Available","COVID|Coronavirus Infection|SARS-CoV 2|COVID19","Drug: P2Et (Caesalpinia spinosa extract)|Other: Placebo",,"https://ClinicalTrials.gov/show/NCT04410510"
681,"Assessment of Exam Findings in Coronavirus Disease 2019 (COVID-19) With Point-of-Care Ultrasonography (POCUS)","Recruiting","No Results Available","Coronavirus Infection|COVID|Covid-19|SARS-CoV-2","Diagnostic Test: Point-of-Care Ultrasonography (POCUS)","University of Minnesota Medical Center (UMMC), Minneapolis, Minnesota, United States|M Health Fairview Bethesda Hospital, Saint Paul, Minnesota, United States","https://ClinicalTrials.gov/show/NCT04339998"
682,"LDCT in COVID-19 Pneumonia: a Prospective Moscow Study","Completed","No Results Available","Pneumonia|Coronavirus Infection","Diagnostic Test: Low-dose Chest CT","Victor Gombolevskiy, Moscow, Russian Federation","https://ClinicalTrials.gov/show/NCT04379531"
683,"Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Kidney Transplant Patients","Recruiting","No Results Available","Kidney Transplant; Complications|Coronavirus Infection","Other: blood sample","Lyon Univerity Hospital, Lyon, France|APHM, Marseille, France|Montpellier University Hospital, Montpellier, France|University Nice Hospital, Nice, France|APHP, Paris, France|Saint Etienne University Hospital, Saint-Étienne, France|Strasbourg Univeristy Hospital, Strasbourg, France","https://ClinicalTrials.gov/show/NCT04369456"
684,"Proflaxis Using Hydroxychloroquine Plus Vitamins-Zinc During COVID-19 Pandemia","Recruiting","No Results Available","Pneumonitis|Coronavirus Infection","Drug: Plaquenil 200Mg Tablet","Istinye University Medical School, Istanbul, Turkey","https://ClinicalTrials.gov/show/NCT04326725"
685,"A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19","Not yet recruiting","No Results Available","COVID-19|Coronavirus|Coronavirus Infection","Combination Product: INOpulse|Combination Product: Placebo","Houston Methodist, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT04421508"
686,"Extracellular Water in Covid 19 Pneumonia","Recruiting","No Results Available","Extracellular Fluid Alteration|Corona Virus Infection","Device: NİCaS","Gaziosmanpaşa TREH, Istanbul, Gaziosmanpaşa, Turkey","https://ClinicalTrials.gov/show/NCT04416009"
687,"St. Jude Tracking of Viral and Host Factors Associated With COVID-19","Recruiting","No Results Available","COVID-19|Coronavirus Infection|Coronavirus|SARS-CoV-2",,"St. Jude Children's Research Hospital, Memphis, Tennessee, United States","https://ClinicalTrials.gov/show/NCT04362995"
688,"Renal Outcome in Patients With COVID-19","Recruiting","No Results Available","Acute Kidney Injury|Corona Virus Infection",,"University Hospital Giessen and Marburg, Giessen, Giessen, Hessen, Germany","https://ClinicalTrials.gov/show/NCT04353583"
689,"Early Extubation for Patients With Acute Hypoxemic Respiratory Failure","Not yet recruiting","No Results Available","Mechanical Ventilation|Corona Virus Infection","Device: Helmet non-invasive ventilation (NIV)","University of Chicago Medical Center, Chicago, Illinois, United States","https://ClinicalTrials.gov/show/NCT04349332"
690,"Study to Evaluate the Effect of a Probiotic in COVID-19","Recruiting","No Results Available","COVID-19|Coronavirus Infection","Dietary Supplement: Probiotic","Hospital Universitario del Vinalopó, Elche, Alicante, Spain|Hospital Universitario de Torrevieja, Torrevieja, Alicante, Spain","https://ClinicalTrials.gov/show/NCT04390477"
691,"Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation","Enrolling by invitation","No Results Available","COVID|Corona Virus Infection","Dietary Supplement: Ascorbic Acid|Dietary Supplement: Zinc Gluconate|Dietary Supplement: Ascorbic Acid and Zinc Gluconate|Other: Standard of Care","Cleveland Clinic, Weston, Florida, United States|Cleveland Clinic, Cleveland, Ohio, United States","https://ClinicalTrials.gov/show/NCT04342728"
692,"HCQ for Primary Prophylaxis Against COVID19 in Health-care Workers","Not yet recruiting","No Results Available","Sars-CoV2|Infection Viral|Healthcare Worker|Prophylaxis","Drug: Hydroxychloroquine",,"https://ClinicalTrials.gov/show/NCT04336748"
693,"Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19","Recruiting","No Results Available","Sars-CoV2|COVID-19","Drug: Favipiravir (3200 mg + 1200 mg)|Drug: Favipiravir (3600 mg + 1600 mg)|Drug: Favipiravir (3200 mg + 1200 mg) combined with Hydroxychloroquine|Drug: Favipiravir (3200 mg + 1200 mg) combined with Azithromycin|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine combined with Azithromycin","Hacettepe University, School of Medicine, Ankara, Turkey","https://ClinicalTrials.gov/show/NCT04411433"
694,"Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients","Recruiting","No Results Available","Sars-CoV2|COVID","Drug: Enoxaparin|Drug: Prophylactic/Intermediate Dose Enoxaparin","Beth Israel Newark, Newark, New Jersey, United States|Southside Hospital, Bay Shore, New York, United States|Huntington Hospital, Huntington, New York, United States|Lenox Hill Hospital, New York, New York, United States|Long Island Jewish Medical Center, Queens, New York, United States|Staten Island University Hospital, Staten Island, New York, United States","https://ClinicalTrials.gov/show/NCT04401293"
695,"Mobile Health Study and Enhanced Symptom Monitoring in COVID-19 Cancer Patients","Not yet recruiting","No Results Available","Sars-CoV2|Covid-19","Other: mHealth Assessments","Stephenson Cancer Center, Oklahoma City, Oklahoma, United States","https://ClinicalTrials.gov/show/NCT04397614"
696,"A Study of Hydroxychloroquine and Zinc in the Prevention of COVID-19 Infection in Military Healthcare Workers","Not yet recruiting","No Results Available","Sars-CoV2|COVID19","Drug: Hydroxychloroquine|Drug: Hydroxychloroquine (placebo)|Drug: Zinc|Drug: Zinc (Placebo)","Military Hospital of Tunis, Tunis, Tunisia","https://ClinicalTrials.gov/show/NCT04377646"
697,"Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19","Recruiting","No Results Available","Sars-CoV2|Covid-19","Drug: Peginterferon Lambda-1A|Other: placebo","Toronto General Hospital, Toronto, Ontario, Canada","https://ClinicalTrials.gov/show/NCT04354259"
698,"Psychological Impact of Quarantine in Chronic Pain Patient During COVID-19 Outbreak","Completed","No Results Available","Sars-CoV2|Chronic Pain","Other: questionnaire assesment","Hopital Roger Salengro, CHU Lille, Lille, France","https://ClinicalTrials.gov/show/NCT04353011"
699,"Psychological Impact of Quarantine in Osteoporosis Patient During COVID-19 Outbreak","Completed","No Results Available","Sars-CoV2|Osteoporosis","Other: questionnaire assesment","Hopital Roger Salengro, CHU Lille, Lille, France","https://ClinicalTrials.gov/show/NCT04351633"
700,"Implementation of Physiotherapy on COVID-19 Patients in ICU","Recruiting","No Results Available","Sars-CoV2|COVID-19","Other: Phsyiotherapy","Uhmontpellier, Montpellier, France","https://ClinicalTrials.gov/show/NCT04347070"
701,"Clinical Characteristics and Outcomes of Pediatric COVID-19","Recruiting","No Results Available","COVID-19|SARS-CoV-2 Infection|Pediatric ALL|Pneumonia, Viral|Pandemic Response","Other: Exposure (not intervention) - SARS-CoV-2 infection","University of Calgary/Alberta Children's Hospital, Calgary, Alberta, Canada","https://ClinicalTrials.gov/show/NCT04330261"
702,"Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome","Recruiting","No Results Available","Covid-19","Biological: Cell therapy protocol 1|Biological: Cell therapy protocol 2","Royan Institute, Tehran, Iran, Islamic Republic of","https://ClinicalTrials.gov/show/NCT04366063"
703,"Protein Electrophoresis as a Tool for Complications Prediction in COVID-19 Hospitalised Patients","Not yet recruiting","No Results Available","SARS-CoV 2|Hospitalisation-Associated Infection",,"Clinique de l'Estrée, Stains, France","https://ClinicalTrials.gov/show/NCT04414059"
704,"Evaluation of Rapid Diagnostic Solutions, Serological and Molecular Tests for COVID-19","Not yet recruiting","No Results Available","SARS-CoV 2|COVID-19","Device: Taking blood samples (capillary and venous), saliva sampling and nasopharyngeal sampling.|Device: Capillary and salivary sampling",,"https://ClinicalTrials.gov/show/NCT04405492"
705,"Consequences of the QUARANTINE Relating to the COvid-19 Epidemic on the Mental Health of the Patients Followed in PSYchiatry","Not yet recruiting","No Results Available","SARS-CoV 2|Traumatic Stress Disorder",,,"https://ClinicalTrials.gov/show/NCT04405362"
706,"Characteristics of COVID-19 Infection Among PREGnant Women","Not yet recruiting","No Results Available","Corona Virus Infection|Pregnancy Related","Other: COVID-19 positive via testing",,"https://ClinicalTrials.gov/show/NCT04398264"
707,"Favipiravir vs Hydroxychloroquine in COVID -19","Not yet recruiting","No Results Available","SARS-CoV 2|COVID-19","Drug: Hydroxychloroquine|Drug: Favipiravir|Other: Routine care for COVID-19 patients","Royal College of Surgeons in Ireland - Bahrain, Manama, Bahrain","https://ClinicalTrials.gov/show/NCT04387760"
708,"Immune Changes in Severe COVID-19 Pulmonary Infections","Active, not recruiting","No Results Available","SARS-CoV-2|Immune System Disorder",,"Centre Hospitalier Universitaire NANCY, Vandoeuvre-les-Nancy, France","https://ClinicalTrials.gov/show/NCT04386395"
709,"Sirolimus in COVID-19 Phase 1","Recruiting","No Results Available","SARS-CoV-2|Covid-19","Drug: Sirolimus 1 MG/ML|Drug: Placebo","Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT04371640"
710,"VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL)","Active, not recruiting","No Results Available","SARS-CoV-2|COVID-19","Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Placebo oral tablet","San Francisco VA, San Francisco, California, United States","https://ClinicalTrials.gov/show/NCT04363203"
711,"Convalescent Plasma Trial in COVID -19 Patients","Recruiting","No Results Available","SARS-CoV 2|COVID-19","Other: plasma therapy using convalescent plasma with antibody against SARS-CoV-2|Other: Routine care for COVID-19 patients","Royal College of Surgeons in Ireland - Bahrain, Manama, Bahrain","https://ClinicalTrials.gov/show/NCT04356534"
712,"Immunological Profiling of Patients With COVID-19 in Respiratory Distress","Not yet recruiting","No Results Available","SARS-CoV-2|Covid-19","Other: Immunological profiling","CHU de Nimes, Nîmes, France","https://ClinicalTrials.gov/show/NCT04351711"
713,"Test and Treat COVID 65plus+","Recruiting","No Results Available","SARS-CoV 2|COVID-19","Drug: Hydroxychloroquine|Other: Placebo","Uniklinikum Tuebingen, Tuebingen, Germany|Uniklinikum Ulm, Ulm, Germany","https://ClinicalTrials.gov/show/NCT04351516"
714,"CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort","Recruiting","No Results Available","SARS-CoV-2|COVID19","Drug: Eculizumab","Saint Louis, Paris, Ile De France, France|Réanimation médicale, Paris, France|saint Louis, Paris, France","https://ClinicalTrials.gov/show/NCT04346797"
715,"National Survey of Symptoms of People Aged 70 and Overs Diagnosed With COVID-19","Completed","No Results Available","SARS-CoV-2|COVID-19","Other: observation","Angers University Hospital, Angers, France","https://ClinicalTrials.gov/show/NCT04343781"
716,"Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19","Recruiting","No Results Available","SARS-CoV-2|COVID-19","Combination Product: Hydroxychloroquine Sulfate + Azithromycin|Drug: Hydroxychloroquine Sulfate","Saint Barnabas Medical Center, Livingston, New Jersey, United States|Monmouth Medical Center, Long Branch, New Jersey, United States|Morristown Medical Center, Morristown, New Jersey, United States|Robert Wood Johnson University Hopsital, New Brunswick, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|The University Hospital, Newark, New Jersey, United States|Overlook Hospital, Summit, New Jersey, United States","https://ClinicalTrials.gov/show/NCT04336332"
717,"Prognostic Factors of Patients With COVID-19","Completed","No Results Available","SARS-CoV-2|Outcome, Fatal",,"The First Affiliated Hospital of Chongqing Medical University, Chongqing, China","https://ClinicalTrials.gov/show/NCT04292964"
718,"Lung Function, Exercise Capacity and Health-Related Quality of Life After Severe COVID-19","Recruiting","No Results Available","COVID-19|SARS-CoV-2 Infection","Diagnostic Test: Lung Function tests|Diagnostic Test: Exercise capacity|Diagnostic Test: Exercise physiology|Diagnostic Test: Health-related quality of life|Diagnostic Test: Respiratory symptoms, symptoms of anxiety and depression, and post-traumatic stress screening","Universidade de Passo Fundo, Passo Fundo, Rio Grande Do Sul, Brazil|Hospital Moinhos de Vento, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital de Clínicas de Porto Alegre/Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande Do Sul, Brazil|Univesidade de Ciências da Saúde de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Nossa Senhora da Conceição, Porto Alegre, Rio Grande Do Sul, Brazil","https://ClinicalTrials.gov/show/NCT04410107"
719,"Oropharyngeal Dysphagia in Patients With COVID-19","Recruiting","No Results Available","Oropharyngeal Dysphagia|COVID-19|Sars-CoV2|Nutrition","Diagnostic Test: Swallowing evaluation with the EAT-10 and the volume-viscosity swallowing test (V-VST)","Consorci Sanitari del Maresme (Hospital de Mataró), Mataró, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT04346212"
720,"The Impact of COVID-19 on Dialysis Users","Active, not recruiting","No Results Available","End Stage Renal Disease|Sars-CoV2",,"School of Sport Health and Exercise Science, Portsmouth, Outside The United States Or Canada, United Kingdom","https://ClinicalTrials.gov/show/NCT04422873"
721,"Echocardiography in Critically-ill Patients With COVID-19 Pneumonia","Enrolling by invitation","No Results Available","COVID|Sars-CoV2",,"University Hospital Ambroise Pare, Boulogne-Billancourt, Hauts De Seine, France","https://ClinicalTrials.gov/show/NCT04414410"
722,"COVID-19 and Cancer Patients","Recruiting","No Results Available","Cancer|Sars-CoV2",,"Imperial College Healthcare NHS Trust, London, United Kingdom","https://ClinicalTrials.gov/show/NCT04393974"
723,"Novel Agents for Treatment of High-risk COVID-19 Positive Patients","Recruiting","No Results Available","COVID|Sars-CoV2","Drug: Hydroxychloroquine|Drug: Hydroxychloroquine and Azithromycin|Drug: Hydroxychloroquine and Ivermectin|Drug: Camostat Mesilate","University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States","https://ClinicalTrials.gov/show/NCT04374019"
724,"Progesterone for the Treatment of COVID-19 in Hospitalized Men","Recruiting","No Results Available","COVID-19|Sars-CoV2","Drug: Progesterone 100 MG","Cedars Sinai Medical Center, Los Angeles, California, United States","https://ClinicalTrials.gov/show/NCT04365127"
725,"Preventing COVID-19 Complications With Low- and High-dose Anticoagulation","Recruiting","No Results Available","COVID|Sars-CoV2","Drug: Enoxaparin","Geneva University Hospitals, Geneva, Switzerland","https://ClinicalTrials.gov/show/NCT04345848"
726,"COVID19 Clinical Predictors and Outcome","Not yet recruiting","No Results Available","COVID|SARS-CoV 2","Other: SARS-CoV2 Infection",,"https://ClinicalTrials.gov/show/NCT04416347"
727,"Registry of Seraph®-100 Microbind® Affinity Blood Filter for COVID-19 Under EUA","Not yet recruiting","No Results Available","COVID-19|SARS-CoV 2","Device: Seraph®-100 Microbind® Affinity Blood Filter",,"https://ClinicalTrials.gov/show/NCT04413955"
728,"Slovenian National COVID-19 Prevalence Study","Recruiting","No Results Available","COVID-19|SARS-CoV-2","Diagnostic Test: NO intervention planned due to the observational study design - only a diagnostic testing","University of Ljubljana, Ljubljana, Slovenia","https://ClinicalTrials.gov/show/NCT04376996"
729,"A Study of Outcomes in Patients With Fractured Neck of Femur During the COVID-19 Pandemic","Completed","No Results Available","Femoral Neck Fractures|SARS-CoV 2","Other: Surgery: Dynamic Hip Screw, hemiarthroplasty, hip replacement, intramedullary nail","Barts Health NHS Trust, London, United Kingdom","https://ClinicalTrials.gov/show/NCT04375501"
730,"Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection","Active, not recruiting","No Results Available","COVID-19|SARS-CoV 2","Drug: Hydroxychloroquine|Dietary Supplement: Vitamin D","Sanford Health, Sioux Falls, South Dakota, United States","https://ClinicalTrials.gov/show/NCT04372017"
731,"COVID-19 Survival - The COVIVA Study","Recruiting","No Results Available","COVID-19|SARS-CoV 2",,"University Hospital Basel, Basel, Switzerland","https://ClinicalTrials.gov/show/NCT04366765"
732,"Canakinumab to Reduce Deterioration of Cardiac and Respiratory Function Due to COVID-19","Recruiting","No Results Available","COVID-19|SARS-CoV 2","Drug: Canakinumab Injection 600mg|Drug: Canakinumab Injection 300mg|Drug: Placebos","Cleveland Clinic, Cleveland, Ohio, United States","https://ClinicalTrials.gov/show/NCT04365153"
733,"EuRopean Study of MAjor Infectious Disease Syndromes Related to COVID-19","Not yet recruiting","No Results Available","COVID-19|SARS-CoV 2",,,"https://ClinicalTrials.gov/show/NCT04364711"
734,"Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19","Recruiting","No Results Available","COVID-19|SARS-CoV 2","Drug: Hydroxychloroquine (HCQ)|Drug: Azithromycin (Azithro)|Drug: Placebo for Hydroxychloroquine|Drug: Placebo for Azithromycin","Alabama CRS, Birmingham, Alabama, United States|UCLA CARE Center CRS, Los Angeles, California, United States|University of Southern California CRS, Los Angeles, California, United States|UCSD Antiviral Research Center CRS, San Diego, California, United States|Ucsf Hiv/Aids Crs, San Francisco, California, United States|Harbor-UCLA CRS, Torrance, California, United States|University of Colorado Hospital CRS, Aurora, Colorado, United States|Whitman-Walker Health CRS, Washington, District of Columbia, United States|The Ponce de Leon Center CRS, Atlanta, Georgia, United States|Northwestern University CRS, Chicago, Illinois, United States|Rush University CRS, Chicago, Illinois, United States|Massachusetts General Hospital CRS (MGH CRS), Boston, Massachusetts, United States|New Jersey Medical School Clinical Research Center CRS, Newark, New Jersey, United States|Weill Cornell Chelsea CRS, New York, New York, United States|Weill Cornell Uptown CRS, New York, New York, United States|University of Rochester Adult HIV Therapeutic Strategies Network CRS, Rochester, New York, United States|Chapel Hill CRS, Chapel Hill, North Carolina, United States|Greensboro CRS, Greensboro, North Carolina, United States|Cincinnati Clinical Research Site, Cincinnati, Ohio, United States|Case Clinical Research Site, Cleveland, Ohio, United States|Ohio State University CRS, Columbus, Ohio, United States|Penn Therapeutics, CRS, Philadelphia, Pennsylvania, United States|University of Pittsburgh CRS, Pittsburgh, Pennsylvania, United States|The Miriam Hospital Clinical Research Site (TMH CRS) CRS, Providence, Rhode Island, United States|Vanderbilt Therapeutics (VT) CRS, Nashville, Tennessee, United States|Trinity Health and Wellness Center CRS, Dallas, Texas, United States|University of Washington AIDS CRS, Seattle, Washington, United States|Puerto Rico AIDS Clinical Trials Unit CRS, San Juan, Puerto Rico","https://ClinicalTrials.gov/show/NCT04358068"
735,"Combination of Chest Scanography and Nasal Viral Detection Test to Detect COVID-19 Positive Patients Before Surgical Intervention in a University Hospital During Coronavirus Pandemia","Active, not recruiting","No Results Available","COVID 19|SARS-Cov-2",,"Uh Montpellier, Montpellier, France","https://ClinicalTrials.gov/show/NCT04355715"
736,"Azithromycin for COVID-19 Treatment in Outpatients Nationwide","Recruiting","No Results Available","COVID-19|SARS-CoV-2","Drug: Azithromycin|Drug: Placebos","University of California San Francisco, San Francisco, California, United States","https://ClinicalTrials.gov/show/NCT04332107"
737,"A Trial of Remdesivir in Adults With Mild and Moderate COVID-19","Suspended","No Results Available","COVID-19|SARS-CoV-2","Drug: Remdesivir|Drug: Remdesivir placebo","Jin Yin-tan hospital, Wuhan, Hubei, China","https://ClinicalTrials.gov/show/NCT04252664"
738,"hCT-MSCs for COVID19 ARDS","Not yet recruiting","No Results Available","COVID|Corona Virus Infection|COVID19","Biological: human cord tissue mesenchymal stromal cells",,"https://ClinicalTrials.gov/show/NCT04399889"
739,"Physical Activity Level, Stress Level, Sleep Quality in Pregnant Women During Covid-19 Quarantine","Not yet recruiting","No Results Available","Covid-19|Coronavirus Infection|Pregnancy Related","Other: Survey","Istanbul University - Cerrahpaşa, Istanbul, Turkey","https://ClinicalTrials.gov/show/NCT04336787"
740,"Cardiac COVID-19 Health Care Workers","Recruiting","No Results Available","SARS-CoV 2|COVID-19|Coronavirus|Cardiac Magnetic Resonance|Myocarditis|Cardiac Anomaly","Other: Passed infection of SARS-CoV-2","University Hospital of Salamanca, Salamanca, Spain","https://ClinicalTrials.gov/show/NCT04413071"
741,"Semi-automatic Response System(SARS)in Type 2 Diabetes","Completed","No Results Available","Diabetes Mellitus","Other: Internet","Seoul St. Mary's Hospital, Seoul, Korea, Republic of","https://ClinicalTrials.gov/show/NCT01058733"
742,"Hydroxychloroquine, Azithromycin in the Treatment of Covid-19","Not yet recruiting","No Results Available","SARS-CoV-2 Pneumonia|COVID-19","Drug: Hydroxychloroquine 200 Mg Oral Tablet|Drug: Azithromycin 250 MG",,"https://ClinicalTrials.gov/show/NCT04405921"
743,"Efficacy and Safety of Fixed Dose Combination (FDC) of Olopatadine Hydrochloride and Mometasone Furoate Nasal Spray (Molo; Also Referred as GSP 301) in the Treatment of Seasonal Allergic Rhinitis (SAR)","Completed","No Results Available","Seasonal Allergic Rhinitis","Drug: Molo 1 (also referred as GSP 301-2 NS)|Drug: Molo 2 (also referred as GSP 301-1 NS)|Drug: Placebo nasal spray|Drug: DYMISTA nasal spray|Drug: PATANASE nasal spray","Glenmark Investigational Site 1, Mississauga, Ontario, Canada","https://ClinicalTrials.gov/show/NCT03444506"
744,"Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Hydroxychloroquine for Treatment of COVID-19 : A Randomized Control Trial","Not yet recruiting","No Results Available","SARS-COV-2 Infections|COVID-19","Drug: Oral","Assistant Professor Subsai Kongsaengdao, Bangkok, Thailand","https://ClinicalTrials.gov/show/NCT04303299"
745,"Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO","Suspended","No Results Available","COVID19|SARS-CoV-2 Infection","Drug: Sarilumab|Drug: Azithromycin|Drug: Hydroxychloroquine","AP-HP Hôpital Avicenne, Bobigny, France|AP-HP Hôpital Ambroise Paré, Boulogne-Billancourt, France|AP-HP Hôpital Beaujon, Clichy, France|AP-HP Hôpital Pitié Salpétrière, Paris, France|AP-HP Hôpital Saint Antoine, Paris, France","https://ClinicalTrials.gov/show/NCT04341870"
746,"PREPARE-IBD: Physician Responses to Disease Flares and Patient Adaptation in Relation to Events in Inflammatory Bowel Disease During COVID-19 Pandemic","Active, not recruiting","No Results Available","Inflammatory Bowel Diseases|Coronavirus Infection",,"Gastroenterology, Hull Royal Infirmary, Hull University Teaaching Hospitals NHS Trust, Hull, United Kingdom","https://ClinicalTrials.gov/show/NCT04410484"
747,"Convalescent Plasma for Patients With COVID-19","Recruiting","No Results Available","Coronavirus Infection|Coronavirus|COVID","Biological: Convalescent plasma","Henry Ford Hospital, Detroit, Michigan, United States","https://ClinicalTrials.gov/show/NCT04385199"
748,"Convalescent Antibodies Infusion in COVID 19 Patients","Not yet recruiting","No Results Available","Pneumonia, Viral|Corona Virus Infection","Biological: Anti-coronavirus antibodies (immunoglobulins) obtained with DFPP form convalescent patients","ASST - Papa Giovanni XXIII - Unit of Nephrology, Bergamo, BG, Italy|Asst Hpg23 - Eas, Bergamo, BG, Italy|ASST HPG23 - Intensive Care Unit, Bergamo, BG, Italy|ASST HPG23 - Microbioly and Virology Unit, Bergamo, BG, Italy|Sst Hpg23 - S.I.M.T., Bergamo, BG, Italy|IRFMN - Clinical Research Center for Rare Diseases, Ranica, BG, Italy","https://ClinicalTrials.gov/show/NCT04418531"
749,"Convalescent Antibodies Infusion in Critically Ill COVID 19 Patients","Recruiting","No Results Available","Pneumonia, Ventilator-Associated|Coronavirus Infection","Biological: Anti-coronavirus antibodies (immunoglobulins)obtained with DFPP from convalescent patients","IRFMN - Clinical Research Center for Rare Diseases, Ranica, BG, Italy|ASST HPG23 - Unit of Nephrology, Bergamo, Italy|ASST Papa Giovanni XXIII - Microbiology and Virology Unit, Bergamo, Italy|Asst Pg23 - S.I.M.T, Bergamo, Italy|ASST-PG23 - Intensive Care Unit, Bergamo, Italy","https://ClinicalTrials.gov/show/NCT04346589"
750,"Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial","Not yet recruiting","No Results Available","Coronavirus|Respiratory Failure|Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere|SARS-CoV-2","Drug: Angiotensin 1-7|Drug: Placebos",,"https://ClinicalTrials.gov/show/NCT04332666"
751,"Epidemiology and Outcome of Ventilator-associated Pneumonia Among Critically Ill COVID-19 Patients","Recruiting","No Results Available","Ventilator Associated Pneumonia|Corona Virus Infection","Diagnostic Test: Assessment of ventilator-associated pneumonia criteria","Semmelweis University, Budapest, Hungary","https://ClinicalTrials.gov/show/NCT04372576"
752,"Quality of Life and Patient-centered Outcomes After Hospitalization for COVID-19","Not yet recruiting","No Results Available","Quality of Life|Long-term Outcomes|Coronavirus Infection","Other: COVID-19",,"https://ClinicalTrials.gov/show/NCT04376658"
753,"Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) Infections","Active, not recruiting","No Results Available","Respiratory Tract Infections|Corona Virus Infection","Drug: Nitric Oxide 0.5 % / Nitrogen 99.5 % Gas for Inhalation","Diamond Centre, Vancouver, British Columbia, Canada","https://ClinicalTrials.gov/show/NCT03331445"
754,"Quality of Life and Physical Performance After Novel Coronavirus Infection (COVID-19);","Recruiting","No Results Available","Covid-19 (New Coronavirus) Infection","Other: Physical exercise|Behavioral: Education sessions","Kantonsspital Winterthur, Winterthur, Zürich, Switzerland","https://ClinicalTrials.gov/show/NCT04375709"
755,"The Effects of Pulmonary Physiotherapy Treatments on Patients With COVID-19","Completed","No Results Available","Covid-19|Pneumonia|SARS Pneumonia","Other: Pulmonary Physiotherapy Techniques","Imam Khomeini Hospital Complex, Tehran, Iran, Islamic Republic of","https://ClinicalTrials.gov/show/NCT04357340"
756,"""COVID-19 and Diabetes Outcomes""","Recruiting","No Results Available","Coronavirus|Diabetes","Other: no interventional study","CHU Nantes, Nantes, France","https://ClinicalTrials.gov/show/NCT04324736"
757,"Acquiring Convalescent Specimens for COVID-19 Antibodies","Recruiting","No Results Available","COVID-19|Coronavirus Infection|Corona Virus Infection","Procedure: Blood draw","Columbia University Irving Medical Center/NYP, New York, New York, United States","https://ClinicalTrials.gov/show/NCT04342195"
758,"LIBERATE Trial in COVID-19","Recruiting","No Results Available","Coronavirus|Respiratory Distress Syndrome|SARS-CoV Infection","Drug: Ibuprofen","Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom","https://ClinicalTrials.gov/show/NCT04334629"
759,"Thrombosis Risk Assessment and Clinical Presentation of Covid-19 Pneumonia","Not yet recruiting","No Results Available","Corona Virus Infection|Thromboembolic Disease",,"Vital Hospital, Bahcelievler, Istanbul, Turkey","https://ClinicalTrials.gov/show/NCT04423315"
760,"Psychological Burden in ICU Survivors of Severe COVID-19 Pneumonia, Their Relatives and Their Healthcare Providers","Not yet recruiting","No Results Available","Corona Virus Infection|Post-traumatic Stress Disorder","Behavioral: PTSD|Behavioral: Burnout","Saint-Louis Hospital, Paris, Ile De France, France","https://ClinicalTrials.gov/show/NCT04341519"
761,"Genetic Basis of COVID-19 Infection","Recruiting","No Results Available","Genetic Basis of COVID-19 Infection","Diagnostic Test: Whole Exome Sequencing","Mansoura University, Mansoura, Dakahlyia, Egypt","https://ClinicalTrials.gov/show/NCT04384250"
762,"Biomarkers for Identification of COVID-19 Infection","Recruiting","No Results Available","Coronavirus","Diagnostic Test: Biomarkers expression","Luca Gallelli, Catanzaro, Italy","https://ClinicalTrials.gov/show/NCT04322513"
763,"NO Prevention of COVID-19 for Healthcare Providers","Not yet recruiting","No Results Available","Coronavirus Infections|Healthcare Associated Infection","Drug: Inhaled nitric oxide gas",,"https://ClinicalTrials.gov/show/NCT04312243"
764,"COVID-19 CHAMPS Study of Healthcare, First Responder and Service Workers","Recruiting","No Results Available","Occupational Exposure to SARS-CoV-2|COVID-19",,"Villanova University, Villanova, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT04370821"
765,"Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure","Recruiting","No Results Available","COVID-19|Acute Lung Injury|SARS-CoV-2","Drug: Dociparastat sodium|Drug: Placebo","Our Lady of the Lake, Baton Rouge, Louisiana, United States|University Medical Center, New Orleans, Louisiana, United States","https://ClinicalTrials.gov/show/NCT04389840"
766,"CORONA (COvid pRONe hypoxemiA): Prone Positioning for Hypoxemic COVID-19 Patients With Do-not-intubate Goals","Recruiting","No Results Available","Severe Acute Respiratory Syndrome Coronavirus 2|COVID-19|Acute Respiratory Distress Syndrome|ARDS|Hypoxemic Respiratory Failure","Procedure: Prone Positioning (PP)","Peter Lougheed Centre (PLC), Calgary, Alberta, Canada|Foothills Hospital Intensive Care Unit, Calgary, Alberta, Canada|Rockyview General Hospital, Calgary, Alberta, Canada|South Health Campus, Calgary, Alberta, Canada","https://ClinicalTrials.gov/show/NCT04402879"
767,"Prevalence and Impact of COVID-19 Infection in Pregnant Women, Fetuses and Newborns","Not yet recruiting","No Results Available","Pregnancy","Diagnostic Test: identify SARS-CoV-2 infection by serology|Biological: collection of biological samples",,"https://ClinicalTrials.gov/show/NCT04355234"
768,"COVID-19 Immune Repertoire Sequencing","Recruiting","No Results Available","COVID|SARS-CoV 2|Corona Virus Infection|RDT|B Cell",,"Universitairy hospital of Antwerp, Antwerp, Belgium","https://ClinicalTrials.gov/show/NCT04368143"
769,"Convalescent Plasma to Stem Coronavirus (CSSC-001)","Not yet recruiting","No Results Available","Coronavirus|Convalescence","Biological: Anti- SARS-CoV-2 Plasma|Biological: SARS-CoV-2 non-immune Plasma",,"https://ClinicalTrials.gov/show/NCT04323800"
770,"Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care","Suspended","No Results Available","COVID-19|Corona Virus Infection|SARS-CoV-2|2019-nCoV|2019 Novel Coronavirus","Drug: Hydroxychloroquine|Dietary Supplement: Vitamin C","Portland Providence Medical Center, Portland, Oregon, United States","https://ClinicalTrials.gov/show/NCT04334967"
771,"Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis","Completed","Has Results","Seasonal Allergic Rhinitis","Drug: 80 mcg Ciclesonide|Drug: 160 mcg Ciclesonide|Drug: Placebo","Austin, Texas, United States|Kerrville, Texas, United States|New Braunfels, Texas, United States|San Antonio, Texas, United States","https://ClinicalTrials.gov/show/NCT00790023"
772,"Pulsed Inhaled Nitric Oxide for the Treatment of Patients With Mild or Moderate COVID-19","Available","No Results Available","Coronavirus Infection|COVID-19|Pneumonia, Viral","Drug: iNO (inhaled nitric oxide) delivered via the INOpulse Delivery System",,"https://ClinicalTrials.gov/show/NCT04358588"
773,"ScreenNC, a Study to Determine the Number of Asymptomatic Individuals Who Have Antibodies to the Virus That Causes COVID-19","Enrolling by invitation","No Results Available","Asymptomatic Condition|Infection Viral|Coronavirus Infections|Severe Acute Respiratory Syndrome Coronavirus 2|Coronaviridae Infections|RNA Virus Infections|Virus Diseases|Communicable Disease","Diagnostic Test: To assess for development of IgG antibodies against SARS-CoV2","Center for Environmental Medicine, Asthma and Lung Biology, Chapel Hill, North Carolina, United States","https://ClinicalTrials.gov/show/NCT04367740"
774,"Outcomes in Hospitalized Older Patients With COVID-19","Completed","No Results Available","Coronavirus Infection|Sars-CoV2|Elderly Infection|Old Age; Debility",,"Department of Rehabilitation and Geriatrics, Geneva, Switzerland","https://ClinicalTrials.gov/show/NCT04385212"
775,"Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora","Recruiting","No Results Available","COVID|SARS-CoV 2|Pneumonia, Viral|Coronavirus Infection","Other: Oxygen-ozone therapy, probiotic supplementation and Standard of care|Dietary Supplement: SivoMixx (200 billion)|Drug: Azithromycin|Drug: hydroxychloroquine","Francesco Pugliese, Rome, RM, Italy","https://ClinicalTrials.gov/show/NCT04366089"
776,"Clinical Characteristics of Critically Ill Patients With COVID-19","Recruiting","No Results Available","Coronavirus Infection|Critical Illness|Characteristics Disease","Other: File Scanning","Konya Trainig and Research Hospital, Konya, Turkey","https://ClinicalTrials.gov/show/NCT04413435"
777,"Microvascular Flow and Reactivity in Patients Presenting in the Acute Phase of COVID-19.","Recruiting","No Results Available","Coronavirus Infection|Endothelial Dysfunction|Microvascular Rarefaction","Other: evaluation of skin microvascular flow and reactivity","National Institute of Cardiology, Rio de Janeiro, Brazil","https://ClinicalTrials.gov/show/NCT04406545"
778,"Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease","Recruiting","No Results Available","Coronavirus|Acute Respiratory Infection|SARS-CoV Infection","Drug: Hydroxychloroquine|Drug: Placebo","University of Arizona, Tucson, Arizona, United States|UCSF Fresno, Fresno, California, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|UC Davis Medical Center, Sacramento, California, United States|UCSF Medical Center, San Francisco, California, United States|Stanford University, Stanford, California, United States|Medical Center of Aurora, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|Denver Health Medical Center, Denver, Colorado, United States|St. Joseph Hospital, Denver, Colorado, United States|University of Florida, Gainesville, Florida, United States|University of Kentucky, Lexington, Kentucky, United States|University Medical Center, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|St. Vincent's Hospital, Worcester, Massachusetts, United States|University of Michigan Medical Center, Ann Arbor, Michigan, United States|Henry Ford Medical Center, Detroit, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Montefiore Medical Center-Weiler, Bronx, New York, United States|Montefiore Medical Center-Moses, Bronx, New York, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|UPMC Presbyterian/Mercy/Shadyside, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Health Science Center, Houston, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|University of Utah Hospital, Salt Lake City, Utah, United States|VCU Medical Center, Richmond, Virginia, United States|Harborview Medical Center, Seattle, Washington, United States|Swedish Hospital First Hill, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT04332991"
779,"A Study of Quintuple Therapy to Treat COVID-19 Infection","Not yet recruiting","No Results Available","COVID-19|Corona Virus Infection|Coronavirus-19|Sars-CoV2","Drug: Hydroxychloroquine|Drug: Azithromycin|Dietary Supplement: Vitamin C|Dietary Supplement: Vitamin D|Dietary Supplement: Zinc","ProgenaBiome, Ventura, California, United States","https://ClinicalTrials.gov/show/NCT04334512"
780,"Convalescent Plasma Therapy in Patients With COVID-19","Recruiting","No Results Available","Convalescence|Corona Virus Infection|Plaque","Biological: Convalescent plasma","Gatot Soebroto central army presidential hospital, Jakarta Pusat, Indonesia","https://ClinicalTrials.gov/show/NCT04407208"
781,"Streptokinase Versus Unfractionated Heparin Nebulization in Severe ARDS","Completed","No Results Available","Acute Respiratory Distress Syndrome|Severe Acute Respiratory Syndrome","Drug: Unfractionated heparin|Drug: Streptokinase",,"https://ClinicalTrials.gov/show/NCT03465085"
782,"Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Naso- Pharyngeal Viral Load in Patients With COVID-19","Not yet recruiting","No Results Available","COVID-19","Drug: Povidone-Iodine","University Hospital of Poitiers, Poitiers, France","https://ClinicalTrials.gov/show/NCT04371965"
783,"Clinical Trial of STAHIST in Seasonal Allergic Rhinitis (SAR) Subjects","Completed","No Results Available","Seasonal Allergic Rhinitis","Drug: Placebo|Drug: STAHIST","The South Bend Clinic, South Bend, Indiana, United States|Family Allergy & Asthma Research Institute, Louisville, Kentucky, United States","https://ClinicalTrials.gov/show/NCT01171664"
784,"Efficacy and Safety of IFN-α2β in the Treatment of Novel Coronavirus Patients","Not yet recruiting","No Results Available","COVID-19|Recombinant Human Interferon α1β","Drug: Recombinant human interferon α1β",,"https://ClinicalTrials.gov/show/NCT04293887"
785,"Protect: Study With Hydroxychloroquine for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19)","Recruiting","No Results Available","COVID19|Hydroxychloroquine|Prophylaxis|Treatment|SARS-CoV-2","Drug: Hydroxychloroquine","Irst Irccs, Meldola, FC, Italy","https://ClinicalTrials.gov/show/NCT04363827"
786,"Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)","Recruiting","No Results Available","COVID-19","Drug: Chloroquine or Hydroxychloroquine|Drug: Lopinavir/Ritonavir|Other: Best standard of care|Drug: Rivaroxaban|Drug: Thromboprophylaxis|Drug: Candesartan|Drug: non-RAS blocking antihypertensives|Drug: Clazakizumab|Drug: placebo for clazakizumab","Medical University of Innsbruck, Innsbruck, Tirol, Austria|Medical University of Vienna, Vienna, Austria|Wilhelminenspital, Vienna, Austria|SMZ Süd Kaiser Franz Josef Spital, Vienna, Austria|KH Hietzing, Vienna, Austria|SMZ Baumgartner Höhe Otto Wagner Spital, Vienna, Austria|SMZ Ost Donauspital, Vienna, Austria","https://ClinicalTrials.gov/show/NCT04351724"
787,"Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19","Recruiting","No Results Available","COVID|Corona Virus Infection|Covid-19|SARS-CoV-2 Infection","Drug: Dipyridamole 100 Milligram(mg)|Drug: Placebo oral tablet","University of Michigan, Ann Arbor, Michigan, United States","https://ClinicalTrials.gov/show/NCT04391179"
788,"Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection","Enrolling by invitation","No Results Available","Pulmonary Alveolar Proteinosis|COPD|Idiopathic Pulmonary Fibrosis|Viral Pneumonia|Coronavirus Infection|Interstitial Lung Disease","Procedure: Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF)|Device: Centricyte 1000|Procedure: IV Deployment Of cSVF In Sterile Normal Saline IV Solution|Drug: Liberase Enzyme (Roche)|Drug: Sterile Normal Saline for Intravenous Use","Robert W. Alexander, MD, FICS, LLC, Stevensville, Montana, United States","https://ClinicalTrials.gov/show/NCT04326036"
789,"Ruxolitinib in the Treatment of Covid-19","Not yet recruiting","No Results Available","COVID-19","Drug: INC424 / Ruxolitinib",,"https://ClinicalTrials.gov/show/NCT04414098"
790,"ALBERTA HOPE COVID-19 for the Prevention of Severe COVID19 Disease","Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine","University of Calgary/Foothills Medical Centre, Calgary, Alberta, Canada|University of Alberta, Edmonton, Alberta, Canada","https://ClinicalTrials.gov/show/NCT04329611"
791,"Prone Positioning and Regional Ventilation in Mechanically Ventilated COVID-19 Patients","Recruiting","No Results Available","Severe Acute Respiratory Syndrome Coronavirus 2|Electric Impedance|Prone Positioning","Other: Prone positioning","University Hospitals of Geneva, Geneva, Switzerland","https://ClinicalTrials.gov/show/NCT04359407"
792,"Assessing the Safety of Pregnancy In the CoRonavirus (COVID-19) pandEmic","Recruiting","No Results Available","Corona Virus Infection|COVID|Pregnancy Related|Early Pregnancy",,"University of California, San Francisco, San Francisco, California, United States","https://ClinicalTrials.gov/show/NCT04388605"
793,"Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP)","Recruiting","No Results Available","COVID-19|Corona Virus Infection|Wuhan Coronavirus|Prophylaxis|Healthcare Worker|Sars-CoV2|Hydroxychloroquine","Drug: Hydroxychloroquine|Drug: Placebo","Lafayette General Medical Center, Lafayette, Louisiana, United States|University Hospital and Clinics, Lafayette, Louisiana, United States","https://ClinicalTrials.gov/show/NCT04363450"
794,"Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19","Recruiting","No Results Available","COVID-19|Acute Respiratory Distress Syndrome|Severe Acute Respiratory Syndrome (SARS)|Coronavirus Infections","Drug: Naltrexone|Drug: Ketamine|Other: Placebo","William Beaumont Hospital, Royal Oak, Michigan, United States","https://ClinicalTrials.gov/show/NCT04365985"
795,"BCG Vaccination to Protect Healthcare Workers Against COVID-19","Recruiting","No Results Available","Coronavirus Disease 2019 (COVID-19)|Respiratory Illness|Corona Virus Infection|COVID-19","Drug: BCG Vaccine|Drug: 0.9%NaCl","St Vincent's Hospital, Sydney, Sydney, New South Wales, Australia|Prince of Wales Hospital, Sydney, New South Wales, Australia|Sydney Children's Hospital, Randwick, Sydney, New South Wales, Australia|The Children's Hospital at Westmead, Sydney, New South Wales, Australia|Westmead Hospital, Sydney, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia|Women's and Children's Hospital, North Adelaide, South Australia, Australia|Epworth Victoria Parade, Melbourne, Victoria, Australia|Royal Children's Hospital, Melbourne, Victoria, Australia|Epworth Richmond, Melbourne, Victoria, Australia|Epworth Eastern, Melbourne, Victoria, Australia|Monash Health- Monash Medical Centre, Melbourne, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|Perth Children's Hospital, Perth, Western Australia, Australia|Sir Charles Gairdner Hospital, Perth, Western Australia, Australia","https://ClinicalTrials.gov/show/NCT04327206"
796,"Respiratory Virus Hospitalization Study (FLU 003 Plus)","Recruiting","No Results Available","Influenza|Novel Respiratory Virus-1 Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV)|Novel Respiratory Virus-2 Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)",,"UCSD Antiviral Research Center, San Diego, California, United States|George Washington Medical Faculty Associates, Washington, District of Columbia, United States|Washington DC VA Medical Center, Washington, District of Columbia, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Baystate Infectious Diseases Clinical Research, Springfield, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Cooper University Hospital, Camden, New Jersey, United States|New Jersey Medical School Adult Clinical Research Center, Newark, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|Cornell CRS, New York, New York, United States|Duke University, Durham, North Carolina, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|University of Tennessee College of Medicine, Chattanooga, Tennessee, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Hospital Nacional Profesor Alejandro Posadas, El Palomar, Buenos Aires, Argentina|Instituto Medico Platense, La Plata, Buenos Aires, Argentina|Hospital Universitario Austral, Pilar, Buenos Aires, Argentina|Hospital Profesor Bernardo Houssay, Vicente Lopez, Buenos Aires, Argentina|Sanatorio Britanico, Rosario, Santa Fe, Argentina|CEMIC, Buenos Aires, Argentina|Hospital General de Agudos JM Ramos Mejia, Buenos Aires, Argentina|Hospital Interzonal General de Agudos Dr. Diego Paroissien, Buenos Aires, Argentina|Hospital Italiano de Buenos Aires, Buenos Aires, Argentina|Hospital Privado Centro Medico de Cordoba, Cordoba, Argentina|Hospital Rawson, Cordoba, Argentina|St. Vincent's Hospital, Darlinghurst, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Centre Hospitalier Universitaire St. Pierre (C.H.U. St. Pierre), Brussels, Belgium|Clinica Alemana, Santiago, Chile|Fundacion Arriaran, Santiago, Chile|Arhus Universitetshospital, Skejby, Aarhus, Denmark|CHIP, Copenhagen, Denmark|Hvidovre University Hospital, Department of Infectious Diseases, Hvidovre, Denmark|Odense University Hospital, Odense, Denmark|Medizinische Universitatsklinik - Bonn, Immunologische Ambulanz CRS, Bonn, Germany|Klinik I fur Innere Medizin der Universitat zu Koln, Studienburo fur Infektiologie u. HIV, Cologne, Germany|Johann Wolfgang Goethe - University Hospital, Infektionsambulanz CRS, Frankfurt, Germany|1st Dept of Critical Care Medicine and Pulmonary Services, Evangelismos Hospital, Athens, Greece|1st Respiratory Medicine Dept, Athens Hosp for Diseases of the Chest ""Sotiria Hospital"", Athens, Greece|Evangelismos General Hospital, Athens, Greece|Hippokration University General Hospital of Athens, Athens, Greece|Hospital Nacional Arzobispo Loayza, Lima, Peru|Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru|Hospital Clinico San Carlos, Madrid, Spain|Hospital La Paz, Madrid, Spain|Hospital Universitario Gregorio Mara�on, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Txagorritxu, Vitoria-Gasteiz, Spain|Chulalongkorn University Hospital, Bangkok, Thailand|Khon Kaen University, Srinagarind Hospital, Khon Kaen, Thailand|Bamrasnaradura Institute, Nonthaburi, Thailand|Heatherwood and Wexham Park Hospitals NHS Foundation Trust, Slough, Berkshire, United Kingdom|Brighton and Sussex University Hospitals NHS Trust, Brighton, East Sussex, United Kingdom|Churchill Hospital, Headington, Oxford, United Kingdom|Sheffield Teaching Hospital NHS Foundation Trust, Sheffield, South Yorkshire, United Kingdom|Bradford Teaching Hospitals NHS Foundation Trust, Bradford, West Yorkshire, United Kingdom|St James's University Hospital, Leeds, West Yorkshire, United Kingdom|Newcastle General Hospital, Newcastle upon Tyne, United Kingdom","https://ClinicalTrials.gov/show/NCT01056185"
797,"Personalized Health Education Against the Health Damage of Novel Coronavirus (COVID-19) Outbreak in Hungary","Recruiting","No Results Available","SARS-CoV-2|Coronavirus|COVID-19|2019-nCoV|2019nCoV","Behavioral: Personalized health education|Behavioral: General health education","Institute for Translational Medicine, University of Pécs, Pécs, Hungary","https://ClinicalTrials.gov/show/NCT04321928"
798,"Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM)","Not yet recruiting","No Results Available","Sars-CoV2|Coronavirus Infection|Prevention & Control|Nursing Home|Hydroxychloroquine","Drug: Hydroxychloroquine Only Product in Oral Dose Form",,"https://ClinicalTrials.gov/show/NCT04400019"
799,"Using GM-CSF as a Host Directed Therapeutic Against COVID-19","Not yet recruiting","No Results Available","COVID|Sars-CoV2|ARDS, Human","Drug: Sargramostim|Other: Normal Saline 0.9%",,"https://ClinicalTrials.gov/show/NCT04400929"
800,"Anxiety and Work Resilience Among Tertiary University Hospital Workers During the COVID-19 Outbreak: An Online Survey","Recruiting","No Results Available","Critical Illness|Sars-CoV2|SARS Pneumonia|Coronavirus Infection|Stress Disorders, Post-Traumatic",,"Intensive care unit CHU Nimes, Nîmes, France","https://ClinicalTrials.gov/show/NCT04358640"
801,"Imaging Feature of SARS-CoV2 Infection","Recruiting","No Results Available","Viral Pneumonia|COVID",,"Deaprtment of Radiology, IRCCS Ospedale San Raffaele, Milano, Italy","https://ClinicalTrials.gov/show/NCT04394026"
802,"Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection","Recruiting","No Results Available","Severe Acute Respiratory Syndrome|Respiratory Failure|Acute Respiratory Distress Syndrome","Drug: Alteplase 50 MG [Activase]|Drug: Alteplase 100 MG [Activase]","Denver Health Medical Center, Denver, Colorado, United States","https://ClinicalTrials.gov/show/NCT04357730"
803,"Yoga Pranayama Adjuvant to Treat Burden COVID -19","Not yet recruiting","No Results Available","Coronavirus Infection|Cytokine Storm|Mental Disorder","Behavioral: morning pranayama|Behavioral: pre_lunch pranayama|Behavioral: pre_dinner pranayama","Ambulatorio Telemedicina Giardino St Lucia, Massa Lombarda, Ravenna, Italy","https://ClinicalTrials.gov/show/NCT04413747"
804,"Outcomes of Patients With COVID-19 in the Intensive Care Unit","Active, not recruiting","No Results Available","Coronavirus Infections|COVID-19|Viral Pneumonia Human Coronavirus",,"Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico|All centres from Mexico willing to contribute are Welcome., Mexico, Mexico","https://ClinicalTrials.gov/show/NCT04336345"
805,"Characteristics and Outcomes of Patients With COVID-19 Admitted to the ICU","Recruiting","No Results Available","SARS-CoV 2|Respiratory Distress Syndrome, Adult|Corona Virus Infection|Critical Illness","Other: risk factors","Hospital das Clínicas -HCFMUSP, Sao Paulo, SP, Brazil","https://ClinicalTrials.gov/show/NCT04378582"
806,"University of Utah COVID-19 Hydrochloroquine Trial","Recruiting","No Results Available","Coronavirus Infection|Coronavirus|Infectious Disease","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","University of Utah, Salt Lake City, Utah, United States","https://ClinicalTrials.gov/show/NCT04342169"
807,"Safety in Convalescent Plasma Transfusion to COVID-19","Recruiting","No Results Available","COVID-19","Biological: Convalescent Plasma","Hospital San José, Monterrey, Nuevo Leon, Mexico","https://ClinicalTrials.gov/show/NCT04333355"
808,"Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia","Recruiting","No Results Available","COVID|Corona Virus Infection|Viral Pneumonia","Biological: Convalescent anti-SARS-CoV-2 plasma|Drug: Sarilumab|Drug: Baricitinib|Drug: Hydroxychloroquine|Other: Injective placebo|Other: Oral placebo","Aalborg University Hospital, Aalborg, Denmark|Aarhus University Hospital, Arhus, Denmark|Bispebjerg Hospital, Copenhagen, Denmark|Rigshospitalet, Copenhagen, Denmark|Herlev Gentofte Hospital, Herlev, Denmark|Herning Hospital, Herning, Denmark|Nordsjællands Hospital, Hillerød, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Kolding Hospital, Kolding, Denmark|Odense University Hospital, Odense, Denmark|Roskilde Hospital, Roskilde, Denmark|Vejle Hospital, Vejle, Denmark","https://ClinicalTrials.gov/show/NCT04345289"
809,"Study of the Spread of COVID-19 in Saint Petersburg, Russia","Recruiting","No Results Available","COVID19",,"Clinic ""Scandinavia"", Saint Petersburg, Russian Federation","https://ClinicalTrials.gov/show/NCT04406038"
810,"Safety and Efficacy of Convalescent Plasma Transfusion for Patients With COVID-19","Not yet recruiting","No Results Available","COVID-19","Biological: convalescent plasma",,"https://ClinicalTrials.gov/show/NCT04388410"
811,"Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia","Not yet recruiting","No Results Available","2019 Novel Coronavirus Pneumonia","Drug: Xiyanping injection|Drug: Lopinavir / ritonavir, alpha-interferon nebulization,Abidor Hydrochloride",,"https://ClinicalTrials.gov/show/NCT04275388"
812,"Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19","Recruiting","No Results Available","SARS (Severe Acute Respiratory Syndrome)|Cytokine Storm|ARDS, Human|COVID-19|Sars-CoV2|Acute Respiratory Failure","Drug: Hyperbaric oxygen","Bergmannsheil und Kinderklinik Buer GmbH, Gelsenkirchen, Germany|Krankenhaus St. Joesf, Regensburg, Germany|Blekingesjukhuset, Karlskrona, Blekinge, Sweden","https://ClinicalTrials.gov/show/NCT04327505"
813,"COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III","Recruiting","No Results Available","Coronavirus Infection|Pneumonia, Viral|Acute Respiratory Distress Syndrome","Drug: Dexamethasone","Hospital Ana Nery, Salvador, Bahia, Brazil|Instituto de Cardiologia do Distrito Federal, Brasília, Distrito Federal, Brazil|Fundação Social Rural de Colatina, Colatina, Esoírito Santo, Brazil|Hospital Vera Cruz AS, Belo Horizonte, Minas Gerais, Brazil|Hospital Maternidade E Pronto Socorro Santa Lucia Ltda, Poços De Caldas, Minas Gerais, Brazil|Universidade Estadual de Londrina, Londrina, Paraná, Brazil|Eurolatino Natal Pesquisas Médicas Ltda, Natal, Rio Grande Do Norte, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Maestri E Kormann Consultoria Medico-Cientifica, Blumenau, Santa Catarina, Brazil|Sociedade Literaria e Caritativa Santo Agostinho, Criciúma, Santa Catarina, Brazil|Fundação Pio XII, Barretos, São Paulo, Brazil|Santa Casa de Misericordia de Votuporanga, Votuporanga, São Paulo, Brazil|Associacao Beneficente Siria, São Paulo, Brazil|Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da USP - HCFMRP, São Paulo, Brazil|Hospital Israelita Albert Einstein, São Paulo, Brazil|Prevent Senior Private Operadora de Saude Ltda, São Paulo, Brazil|Real e Benemérita Associação Portuguesa de Beneficência/SP, São Paulo, Brazil|Santa Casa de Misericórdia, São Paulo, Brazil|Secretaria de Saúde do Estado de São Paulo, São Paulo, Brazil|Sociedade Beneficente de Senhoras Hospital Sírio-Libanês, São Paulo, Brazil|Universidade Federal de São Paulo, São Paulo, Brazil","https://ClinicalTrials.gov/show/NCT04327401"
814,"POPULAR (Preference Of Patient Using Levocetirizine in Allergic Rhinitis)","Completed","No Results Available","Seasonal Allergic Rhinitis","Drug: Levocetirizine",,"https://ClinicalTrials.gov/show/NCT00160537"
815,"Descriptive Study Regarding Ambulant Screening During COVID-19 Pandemia","Recruiting","No Results Available","COVID 19","Other: Questionnaire","Jessa hospital, Hasselt, Belgium","https://ClinicalTrials.gov/show/NCT04334252"
816,"SARS-CoV-2 and Surgery","Recruiting","No Results Available","Surgical Procedure, Unspecified","Other: No intervention (survey study for medical doctors).","2nd Department of General Surgery, Jagiellonian University Medical College, Cracovia, Małopolska, Poland","https://ClinicalTrials.gov/show/NCT04368026"
817,"Malaysian COVID-19 Anosmia Study (Phase 1) - A Nationwide Multicentre Cross-Sectional Study","Not yet recruiting","No Results Available","SARS-CoV Infection|COVID-19|Anosmia|Dysgeusia","Other: Patient-Reported Online Questionnaire on Olfactory & Taste Disturbances","Hospital Sultanah Aminah, Johor Bahru, Johor, Malaysia|Hospital Sultan Ismail, Johor Bahru, Johor, Malaysia|Hospital Permai, Johor Bahru, Johor, Malaysia|Hospital Enche' Besar Hajjah Khalsom, Kluang, Johor, Malaysia|Hospital Sultanah Bahiyah, Alor Setar, Kedah, Malaysia|Hospital Sultanah Maliha, Langkawi, Kedah, Malaysia|Hospital Raja Perempuan Zainab II, Kota Bharu, Kelantan, Malaysia|Hospital Tuanku Jaafar, Seremban, Negeri Sembilan, Malaysia|Hospital Tengku Ampuan Afzan, Kuantan, Pahang, Malaysia|Penang Hospital, George Town, Penang, Malaysia|Hospital Raja Permaisuri Bainun, Ipoh, Perak, Malaysia|Hospital Tuanku Fauziah, Kangar, Perlis, Malaysia|Hospital Queen Elizabeth, Kota Kinabalu, Sabah, Malaysia|Sarawak General Hospital, Kuching, Sarawak, Malaysia|Hospital Sungai Buloh, Sungai Buloh, Selangor, Malaysia|Hospital Sultanah Nur Zahirah, Kuala Terengganu, Terengganu, Malaysia|Kuala Lumpur General Hospital, Kuala Lumpur, Malaysia|Hospital Melaka, Melaka, Malaysia","https://ClinicalTrials.gov/show/NCT04390165"
818,"Malaysian COVID-19 Anosmia Study (Phase 2) - A Nationwide Multicentre Case-Control Study","Not yet recruiting","No Results Available","SARS-CoV Infection|COVID-19|Anosmia|Dysgeusia","Other: Patient-Reported Online Questionnaire on Olfactory & Taste Disturbances","Hospital Sultanah Aminah, Johor Bahru, Johor, Malaysia|Hospital Sultan Ismail, Johor Bahru, Johor, Malaysia|Hospital Permai, Johor Bahru, Johor, Malaysia|Hospital Enche' Besar Hajjah Khalsom, Kluang, Johor, Malaysia|Hospital Sultanah Bahiyah, Alor Setar, Kedah, Malaysia|Hospital Sultanah Maliha, Langkawi, Kedah, Malaysia|Hospital Raja Perempuan Zainab II, Kota Bharu, Kelantan, Malaysia|Hospital Tuanku Jaafar, Seremban, Negeri Sembilan, Malaysia|Hospital Tengku Ampuan Afzan, Kuantan, Pahang, Malaysia|Penang Hospital, George Town, Penang, Malaysia|Hospital Raja Permaisuri Bainun, Ipoh, Perak, Malaysia|Hospital Tuanku Fauziah, Kangar, Perlis, Malaysia|Hospital Queen Elizabeth, Kota Kinabalu, Sabah, Malaysia|Sarawak General Hospital, Kuching, Sarawak, Malaysia|Hospital Sungai Buloh, Sungai Buloh, Selangor, Malaysia|Hospital Sultanah Nur Zahirah, Kuala Terengganu, Terengganu, Malaysia|Kuala Lumpur General Hospital, Kuala Lumpur, Malaysia|Hospital Melaka, Melaka, Malaysia","https://ClinicalTrials.gov/show/NCT04384042"
819,"Th1/Th2/Th17/TREG and TLRs Activation/KIR for COVID 19 Prediction of Outcome","Recruiting","No Results Available","Disease, Viral|Cytokine Release Syndrome|TLRs","Diagnostic Test: Cytokines measurement|Diagnostic Test: Cellular response|Diagnostic Test: TLRs activation measurement|Diagnostic Test: KIR phenotype evaluation","Hospital Ramon y Cajal, Madrid, Spain","https://ClinicalTrials.gov/show/NCT04403061"
820,"Home Pulse Oximeter Use in Patients With COVID-19","Completed","No Results Available","Sars-CoV2|COVID-19|COVID","Device: Home Pulse Oximetry Monitoring","Swedish Hospital, Chicago, Illinois, United States","https://ClinicalTrials.gov/show/NCT04373161"
821,"Covid-19 in Patients With Chronic Inflammatory Rheumatism, Auto-immune or Auto-inflammatory Rare and Non-rare Diseases","Recruiting","No Results Available","Sars-CoV2|Chronic Inflammatory Rheumatism|Autoimmune Diseases",,"Hôpital Huriez, Lille, France","https://ClinicalTrials.gov/show/NCT04353609"
822,"Efficacy of Ivermectin in Adult Patients With Early Stages of COVID-19","Not yet recruiting","No Results Available","COVID-19","Drug: Ivermectin Oral Product|Drug: Placebo",,"https://ClinicalTrials.gov/show/NCT04405843"
823,"A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19","Recruiting","No Results Available","COVID-19|Corona Virus Infection|SARS-CoV 2|Coronavirus|Coronavirus Infection","Drug: ArtemiC|Drug: Placebo","Hillel Yaffe Medical Center, Hadera, Haifa, Israel|Nazareth Hospital EMMS, Nazareth, North, Israel|Rambam Health Care Campus, Haifa, Israel","https://ClinicalTrials.gov/show/NCT04382040"
824,"Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19","Recruiting","No Results Available","Solid Tumor|Sars-CoV2|Hematological Malignancy","Drug: BMS-986253","Columbia University Irving Medical Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT04347226"
825,"Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation","Recruiting","No Results Available","COVID 19|SARS-CoV 2|Pneumonia","Drug: Mavrilimumab|Drug: Placebos","Cleveland Clinic Health System, Cleveland, Ohio, United States","https://ClinicalTrials.gov/show/NCT04399980"
826,"Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients With Respiratory Distress Due to COVID-19","Recruiting","No Results Available","COVID-19|SARS-CoV 2|Adult Respiratory Distress Syndrome","Drug: XCEL-UMC-BETA|Other: Placebo","Hospital de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Mútua de Terrassa, Terrassa, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT04390139"
827,"Transpulmonary Driving Pressure in ARDS COVID19 Patients","Recruiting","No Results Available","Mechanical Ventilation|SARS-CoV-2|COVID-19",,"Uhmontpellier, Montpellier, France","https://ClinicalTrials.gov/show/NCT04381286"
828,"COVID-19 Search in Conjunctival Cells","Active, not recruiting","No Results Available","COVID 19|Pulmonary Disease","Diagnostic Test: conjunctival swab","Maria Cristina Savastano, Roma, Italy","https://ClinicalTrials.gov/show/NCT04364594"
829,"Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19","Recruiting","No Results Available","COVID-19 Pneumonia","Drug: Hidroxicloroquine|Drug: Lopinavir/ritonavir|Drug: Imatinib tablets|Drug: Baricitinib Oral Tablet","Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain","https://ClinicalTrials.gov/show/NCT04346147"
830,"Pilot Study on Cytokine Filtration in COVID-19 ARDS","Recruiting","No Results Available","Coronavirus Infection|Acute Respiratory Distress Syndrome|COVID","Device: Cytokine Adsorption","Hospital Clínic de Barcelona, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT04361526"
831,"Respiratory and Hemodynamic Changes Induced in Mechanically Ventilated Patients for COVID-19","Recruiting","No Results Available","COVID-19|ARDS|Sars-CoV2",,"Hopital Roger Salengro, CHU Lille, Lille, France","https://ClinicalTrials.gov/show/NCT04347928"
832,"Thrombosis and Covid-19","Recruiting","No Results Available","Thrombosis|Covid-19|SARS-CoV 2","Diagnostic Test: TEM-tPA","Hôpital Louis Pradel, Bron, France","https://ClinicalTrials.gov/show/NCT04366778"
833,"WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories","Not yet recruiting","No Results Available","COVID|COVID 19|SARS-CoV 2","Other: Equipment with smartwatch throughout hospital stay on the general ward","Emergency Department, University Hospital Bern, Inselspital, Bern, Switzerland","https://ClinicalTrials.gov/show/NCT04357834"
834,"A Trial of Remdesivir in Adults With Severe COVID-19","Terminated","No Results Available","COVID-19|Remdesivir|SARS-CoV-2","Drug: Remdesivir|Drug: Remdesivir placebo","Bin Cao, Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT04257656"
835,"Polyvalent Immunoglobulin in COVID-19 Related ARds","Recruiting","No Results Available","Acute Respiratory Distress Syndrome|COVID-19","Drug: Human immunoglobulin|Drug: Placebo","Centre Hospitalier Sainte-Anne, Paris, France","https://ClinicalTrials.gov/show/NCT04350580"
836,"Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)","Recruiting","No Results Available","COVID-19|COVID-19 Immunisation","Biological: mRNA-1273","Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|National Institutes of Health - Clinical Center - Vaccine Research Center Clinical Trials Program, Bethesda, Maryland, United States|Kaiser Permanente Washington Health Research Institute - Vaccines and Infectious Diseases, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT04283461"
837,"A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults","Recruiting","No Results Available","Infections, Respiratory|Virus Diseases|Infection Viral|Vaccine Adverse Reaction|RNA Virus Infections","Biological: BNT162a1|Biological: BNT162b1|Biological: BNT162b2|Biological: BNT162c2","Contract Research Organization, Berlin, Germany","https://ClinicalTrials.gov/show/NCT04380701"
838,"PK/PD and Steady State Efficacy Study of Bilastine Compared With Placebo Given Orally in the Treatment of the Symptoms of SAR in an EEC Model (5-arm)","Completed","No Results Available","Seasonal Allergic Rhinitis|Hay Fever|Rhinoconjunctivitis","Drug: Bilastine|Drug: Placebo","Allied Research International - Cetero Research, Mississauga, Ontario, Canada","https://ClinicalTrials.gov/show/NCT00574210"
839,"Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19","Recruiting","No Results Available","CoVID-19","Drug: HCQ|Other: Standard therapy","Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India|Post Graduate Institute of Medical Education and Research, Chandigarh, India","https://ClinicalTrials.gov/show/NCT04408456"
840,"COVID-19 Biological Samples Collection","Recruiting","No Results Available","Infection Viral","Other: biological samples collection","Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France","https://ClinicalTrials.gov/show/NCT04332016"
841,"A Study to Assess the Virus RNA, and miRNA Levels Related to Viral Infection, and Inflammatory Response in Tears of Patients Affected by COVID-19 Disease","Not yet recruiting","No Results Available","COVID|Conjunctivitis","Diagnostic Test: Schirmer Test I","Ophtalmology Clinic, G.d'Annunzio University, Chieti, Italy","https://ClinicalTrials.gov/show/NCT04346160"
842,"SAR231893-LPS15497- ""Dupilumab Effect on Sleep in AD Patients""","Recruiting","No Results Available","Atopic Dermatitis","Drug: DUPILUMAB|Drug: PLACEBO","Investigational Site Number 8400012, North Little Rock, Arkansas, United States|Investigational Site Number 8400002, Redwood City, California, United States|Investigational Site Number 8400001, Rolling Hills Estates, California, United States|Investigational Site Number 8400005, Denver, Colorado, United States|Investigational Site Number 8400003, Sarasota, Florida, United States|Investigational Site Number 8400007, Medford, Oregon, United States|Investigational Site Number 8400008, Charleston, South Carolina, United States|Investigational Site Number 0360003, Carlton, Australia|Investigational Site Number 0360001, Kogarah, Australia|Investigational Site Number 0360007, Woolloongabba, Australia|Investigational Site Number 2760001, Göttingen, Germany|Investigational Site Number 3760005, Afula, Israel|Investigational Site Number 3760003, Jerusalem, Israel|Investigational Site Number 3760001, Rehovot, Israel|Investigational Site Number 7560001, Bern, Switzerland|Investigational Site Number 7840002, Abu Dhabi, United Arab Emirates","https://ClinicalTrials.gov/show/NCT04033367"
843,"Study of the Immunity of Patients With Lung Cancer and COVID-19 Infection","Recruiting","No Results Available","Lung Cancer|COVID|Corona Virus Infection","Diagnostic Test: IgG test","Hospital General Universitario de Elche, Elche, Alicante, Spain|ICO Hospitalet, Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Insular de Gran canaria, Las Palmas De Gran Canaria, Gran Canaria, Spain|Hospital Universitario de Torrejón, Torrejón, Madrid, Spain|Hospital Universitario Son Llàtzer, Palma De Mallorca, Mallorca, Spain|Complexo Hospitalario Universitario de Vigo, Vigo, Pontevedra, Spain|Complejo Hospitalario de A Coruña, A Coruña, Spain|Hospital La Esperanza, A Coruña, Spain|Hospital Universitario de Ferrol, A Coruña, Spain|Hospital Virgen de los Lirios, Alicante, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitari Dexeus, Barcelona, Spain|Hospital Universitario Cruces, Bilbao, Spain|Hospital Universitario de Burgos, Burgos, Spain|Hospital Universitario Puerto Real, Cadiz, Spain|Hospital General La Mancha Centro, Ciudad Real, Spain|Hospital Universitario San Pedro de Alcántara, Cáceres, Spain|Hospital Universitario Puerta del Mar, Cádiz, Spain|Hospital Universitario Reina Sofía, Córdoba, Spain|Hospital Universitario de Vinalopó, Elche, Spain|Hospital Dr. Josep Trueta, Girona, Spain|Hospital Universitario de Guadalajara, Guadalajara, Spain|Complejo Hospitalario de Jaén, Jaén, Spain|Complejo Asistencial Universitario de León, León, Spain|Hospital universitari Arnau de Vilanova, Lleida, Spain|Hospital San Pedro, Logroño, Spain|Hospital Universitario Lucus Augusti, Lugo, Spain|Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Puerta de Hierro, Madrid, Spain|Clínica Universidad de Navarra, Madrid, Spain|Hospital de Sanchinarro, Madrid, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Severo Ochoa, Madrid, Spain|Hospital Universitario de Móstoles, Madrid, Spain|Hospital Universitario del Henares, Madrid, Spain|Hospital Universitario Fundación Alcorcón, Madrid, Spain|Hospital Universitario Infanta Cristina, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitario Infanta Sofía, Madrid, Spain|Hospital Universitario Príncipe de Asturias, Madrid, Spain|Hospital General Universitario de Málaga, Málaga, Spain|Hospital Costa del Sol, Málaga, Spain|Complejo Hospitalario Universitario de Ourense Santa María Nai, Ourense, Spain|Hospital Universitario Son Espases, Palma De Mallorca, Spain|Clínica Universidad de Navarra, Pamplona, Spain|Complejo Hospitalario de Navarra, Pamplona, Spain|Hospital Universitario Sant Joan de Reus, Reus, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario de Canarias, Santa Cruz De Tenerife, Spain|Hospital General de Segovia, Segovia, Spain|Hospital Virgen del Rocío, Sevilla, Spain|Hospital Sant Pau i Santa Tecla, Tarragona, Spain|Hospital Universitario Nuestra Señora de Candelaria, Tenerife, Spain|Hospital Universitari i Politécnic La Fe, Valencia, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital General de Valencia, Valencia, Spain|Hospital General de Valencia, Valencia, Spain|Hospital Arnau de Vilanova, Valencia, Spain|Hospital de Manises, Valencia, Spain|Hospital General Universitario de Valencia, Valencia, Spain|Hospital Lluís Alcanyís, Valencia, Spain|Hospital Universitario Dr. Peset, Valencia, Spain|Hospital Clínico Universitario de Valladolid, Valladolid, Spain|Hospital Universitario Río Ortega, Valladolid, Spain|Complejo Hospitalario Zamora, Zamora, Spain","https://ClinicalTrials.gov/show/NCT04407143"
844,"Proactive Prophylaxis With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19","Recruiting","No Results Available","Virus Diseases|Infection Viral|Corona Virus Infection","Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Aalborg Sygehus, Aalborg, Denmark|Bispebjerg Hospital, Copenhagen, Denmark|Herlev-Gentofte Hospital, Copenhagen, Denmark|Hvidovre Hospital, Copenhagen, Denmark|Nordsjællands Hospital, Hillerød, Denmark|Odense Universitetshospital, Odense, Denmark|Roskilde Sygehus, Roskilde, Denmark|Slagelse Sygehus, Slagelse, Denmark","https://ClinicalTrials.gov/show/NCT04322396"
845,"Aggrenox To Treat Acute Covid-19","Not yet recruiting","No Results Available","Covid19","Drug: Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally|Other: Standard of care",,"https://ClinicalTrials.gov/show/NCT04410328"
846,"Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy","Recruiting","No Results Available","COVID|Infectious Disease","Biological: High-Titer COVID-19 Convalescent Plasma (HT-CCP)|Biological: Standard Plasma (FFP)","Brigham and Women's Hospital, Boston, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT04361253"
847,"To Assess the Safety and Efficacy of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-401)","Completed","No Results Available","Rhinitis, Allergic, Seasonal|Hay Fever","Drug: Ciclesonide|Drug: Placebo","Altana/Nycomed, Austin, Texas, United States|Altana/Nycomed, Austin, Texas, United States|Altana/Nycomed, Kerrville, Texas, United States|Altana/Nycomed, New Braunfels, Texas, United States|Altana/Nycomed, San Antonio, Texas, United States|Altana/Nycomed, San Antonio, Texas, United States","https://ClinicalTrials.gov/show/NCT00659841"
848,"Study Using the Environmental Exposure Unit (EEU) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-407)","Completed","No Results Available","Rhinitis, Allergic, Seasonal|Hay Fever","Drug: Ciclesonide|Drug: Placebo","Altana/Nycomed, Kingston, Ontario, Canada","https://ClinicalTrials.gov/show/NCT00659503"
849,"Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in Treatment of Seasonal Allergic Rhinitis (BY9010/M1-406)","Completed","No Results Available","Rhinitis, Allergic, Seasonal|Hay Fever","Drug: Ciclesonide|Drug: Placebo","Altana/Nycomed, Mississauga, Ontario, Canada","https://ClinicalTrials.gov/show/NCT00659594"
850,"A Study of Ciclesonide Nasal Spray in Patients 18 Years and Older With Seasonal Allergic Rhinitis (BY9010/M1-413)","Completed","No Results Available","Rhinitis, Allergic, Seasonal|Hay Fever","Drug: Ciclesonide Nasal Spray","Altana Pharma/Nycomed, Ontario, Mississauga, Canada","https://ClinicalTrials.gov/show/NCT00384475"
851,"Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19","Recruiting","No Results Available","Coronavirus Infections|Pneumonia, Viral|Acute Respiratory Distress Syndrome","Drug: Nitric Oxide","Louisiana State University Health Shreveport, Shreveport, Louisiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT04305457"
852,"A Study for Efficacy and Safety of Live Biotherapeutic MRx4DP0004 to Treat COVID-19","Not yet recruiting","No Results Available","COVID-19","Drug: MRx-4DP0004|Drug: Placebo",,"https://ClinicalTrials.gov/show/NCT04363372"
853,"Lung Ultrasound for Assessment of Patients With Moderate to Severe Covid-19","Recruiting","No Results Available","Corona Virus Infection|Virus Diseases|Coronaviridae Infections",,"Falun Hospital, Falun, Sweden","https://ClinicalTrials.gov/show/NCT04412551"
854,"Genetics of COVID-19 Susceptibility and Manifestations","Recruiting","No Results Available","COVID-19|Coronavirus 2019",,"National Institutes of Health Clinical Center, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT04371432"
855,"Sequential Oxygen Therapy Strategy for Patients With COVID-19","Recruiting","No Results Available","Coronavirus Disease-2019","Other: oxygen treatment","Henan Provincial People's Hospital, Zhengzhou, Henan, China","https://ClinicalTrials.gov/show/NCT04312100"
856,"Detection of COVID-19 in Saliva Collection","Recruiting","No Results Available","Sars-CoV2|RT-PCR|Saliva Collection|Nasopharyngeal Sample",,"CHU Amiens, Amiens, France","https://ClinicalTrials.gov/show/NCT04386551"
857,"Compare the Effect of INS Alone and Added LTRA in Treatment of SAR","Completed","No Results Available","Allergic Rhinitis","Drug: budesonide","Beijing Tongren Hospital, Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT04077892"
858,"Study of Nesvacumab (REGN910/ SAR307746)","Completed","No Results Available","Solid Tumors","Drug: nesvacumab (REGN910/ SAR307746)","San Francisco, California, United States|San Antonio, Texas, United States|Toronto, Ontario, Canada","https://ClinicalTrials.gov/show/NCT01271972"
859,"Long-term Impact of Infection With Novel Coronavirus (COVID-19)","Recruiting","No Results Available","COVID",,"Zuckerberg San Francisco General Hospital (ZSFG), San Francisco, California, United States","https://ClinicalTrials.gov/show/NCT04362150"
860,"Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients","Recruiting","No Results Available","COVID-19","Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine sulfate|Drug: Baricitinib (janus kinase inhibitor)","Nova Scotia Health Authority, Halifax, Nova Scotia, Canada","https://ClinicalTrials.gov/show/NCT04321993"
861,"Efficacy and Safety of Tocilizumab in the Treatment of SARS-Cov-2 Related Pneumonia","Recruiting","No Results Available","COVID-19 Pneumonia",,"Ospedale San Salvatore, L'Aquila, Italy","https://ClinicalTrials.gov/show/NCT04332913"
862,"Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study)","Recruiting","No Results Available","COVID-19","Biological: Convalescent plasma","Erasmus Medical Center, Rotterdam, Zuid-Holland, Netherlands|NoordWest Ziekenhuisgroep, Alkmaar, Netherlands|Onze Lieve Vrouwen Gasthuis, Amsterdam, Netherlands|Rijnstate Ziekenhuis, Arnhem, Netherlands|Reinier de Graaf Gasthuis, Delft, Netherlands|Haaglanden Medisch Centrum, Den Haag, Netherlands|Catharina Ziekenhuis, Eindhoven, Netherlands|Medisch Spectrum Twente, Enschede, Netherlands|Groene Hart Ziekenhuis, Gouda, Netherlands|Martini Hospital, Groningen, Netherlands|Spaarna Gasthuis, Haarlem, Netherlands|Alrijne Ziekenhuis, Leiderdorp, Netherlands|Sint Antonius Ziekenhuis, Nieuwegein, Netherlands|Canisius-Wilhelmina Hospital, Nijmegen, Netherlands|Maasstad Ziekenhuis, Rotterdam, Netherlands|ZorgSaam Hospital, Terneuzen, Netherlands|Bernhoven Hospital, Uden, Netherlands|VieCuri, Venlo, Netherlands","https://ClinicalTrials.gov/show/NCT04342182"
863,"Investigating Anosmia and Ageusia in COVID-19 Adult Patients in Saudi Arabia","Not yet recruiting","No Results Available","Anosmia|Ageusia|Covid19|Corona Virus Infection","Other: NHANES smell and taste tests","Princess Nourah Bint Abdulrahman Univeristy, Riyadh, Central, Saudi Arabia","https://ClinicalTrials.gov/show/NCT04388618"
864,"Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia","Recruiting","No Results Available","COVID 19 Pneumonia, Impaired Respiratory Function","Drug: DFV890|Drug: Standard of Care (SoC)","Novartis Investigative Site, Copenhagen, Denmark|Novartis Investigative Site, Hvidovre, Denmark|Novartis Investigative Site, Heidelberg, Baden-Württemberg, Germany|Novartis Investigative Site, Regensburg, Bavaria, Germany|Novartis Investigative Site, Bonn, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Wuerzburg, Germany|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary","https://ClinicalTrials.gov/show/NCT04382053"
865,"Study to Assess the Safety and Bioeffect of REGN1033 (SAR391786)","Completed","No Results Available","Healthy Volunteers","Drug: REGN1033 (SAR391786)|Other: placebo","Gainesville, Florida, United States|Orlando, Florida, United States|Boston, Massachusetts, United States|St. Louis, Missouri, United States|Athens, Ohio, United States","https://ClinicalTrials.gov/show/NCT01910220"
866,"Closed-Loop Oxygen to Verify That Healthcare Workers Interventions Decrease During SARS-CoV-2 Pneumonia (COVID-19)","Recruiting","No Results Available","Coronavirus|Pneumonia|Oxygen Toxicity","Other: Standard administration of oxygen flow|Device: Automated oxygen administration - FreeO2","Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Quebec, Canada","https://ClinicalTrials.gov/show/NCT04320056"
867,"Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID19 Infection","Withdrawn","No Results Available","Coronavirus Infections|Pneumonia, Viral|Dyspnea","Drug: Nitric Oxide",,"https://ClinicalTrials.gov/show/NCT04290858"
868,"Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With Sarcopenia","Completed","No Results Available","Sarcopenia","Drug: REGN1033 (SAR391786)|Drug: placebo","Anniston, Alabama, United States|Phoenix, Arizona, United States|El Cajon, California, United States|Garden Grove, California, United States|Laguna Hills, California, United States|San Francisco, California, United States|Walnut Creek, California, United States|Aurora, Colorado, United States|Gainesville, Florida, United States|Jacksonville, Florida, United States|Jupiter, Florida, United States|Orlando, Florida, United States|South Miami, Florida, United States|Chicago, Illinois, United States|Baton Rouge, Louisiana, United States|College Park, Maryland, United States|Elkridge, Maryland, United States|Boston, Massachusetts, United States|Edina, Minnesota, United States|Omaha, Nebraska, United States|Albuquerque, New Mexico, United States|High Point, North Carolina, United States|Winston-Salem, North Carolina, United States|Athens, Ohio, United States|Columbus, Ohio, United States|Duncansville, Pennsylvania, United States|Spartanburg, South Carolina, United States|Dallas, Texas, United States|Plano, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|West Jordan, Utah, United States|Richmond, Virginia, United States|Limoges, France|Montpellier Cedex 5, France|Saint-Etienne Cedex 2, France|Toulouse, France|Amsterdam, Netherlands|Leeuwarden, Netherlands|Noord-Brabant, Netherlands|Albacete, Spain|L'Hospitalet de Llobregat, Spain|Madrid, Spain","https://ClinicalTrials.gov/show/NCT01963598"
869,"Study of the Safety and Tolerability of REGN2222(SAR438584) in Healthy Adult Volunteers","Completed","No Results Available","Healthy Volunteers","Drug: REGN2222(SAR438584)|Drug: placebo","Daytona Beach, Florida, United States|Evansville, Indiana, United States|Dallas, Texas, United States","https://ClinicalTrials.gov/show/NCT02121080"
870,"To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis","Completed","Has Results","RA","Drug: Sarilumab|Device: Auto-Injector Device (AID)|Device: Pre-filled Syringe (PFS)|Drug: Methotrexate|Drug: Sulfasalazine|Drug: Leflunomide|Drug: Hydroxychloroquine","Investigational Site Number 840152, Huntsville, Alabama, United States|Investigational Site Number 840221, Peoria, Arizona, United States|Investigational Site Number 840226, Roseville, California, United States|Investigational Site Number 840223, Boulder, Colorado, United States|Investigational Site Number 840229, Miami, Florida, United States|Investigational Site Number 840236, Orlando, Florida, United States|Investigational Site Number 840155, Palm Harbor, Florida, United States|Investigational Site Number 840220, South Miami, Florida, United States|Investigational Site Number 840202, Hagerstown, Maryland, United States|Investigational Site Number 840232, Flint, Michigan, United States|Investigational Site Number 840233, Kalamazoo, Michigan, United States|Investigational Site Number 840037, Tupelo, Mississippi, United States|Investigational Site Number 840112, Lincoln, Nebraska, United States|Investigational Site Number 840039, Albany, New York, United States|Investigational Site Number 840224, Cincinnati, Ohio, United States|Investigational Site Number 840002, Oklahoma City, Oklahoma, United States|Investigational Site Number 840065, Tulsa, Oklahoma, United States|Investigational Site Number 840009, Duncansville, Pennsylvania, United States|Investigational Site Number 840062, Reading, Pennsylvania, United States|Investigational Site Number 840016, North Charleston, South Carolina, United States|Investigational Site Number 840025, Jackson, Tennessee, United States|Investigational Site Number 840038, Austin, Texas, United States|Investigational Site Number 840230, Carrollton, Texas, United States|Investigational Site Number 840001, Dallas, Texas, United States|Investigational Site Number 840020, Houston, Texas, United States|Investigational Site Number 840239, Houston, Texas, United States|Investigational Site Number 840241, Houston, Texas, United States|Investigational Site Number 840242, Houston, Texas, United States|Investigational Site Number 840069, Lubbock, Texas, United States|Investigational Site Number 840074, Mesquite, Texas, United States|Investigational Site Number 840237, Plano, Texas, United States|Investigational Site Number 152005, Osorno, Chile|Investigational Site Number 152050, Santiago, Chile|Investigational Site Number 152014, Talca, Chile|Investigational Site Number 152007, Viña Del Mar, Chile|Investigational Site Number 484002, Guadalajara, Mexico|Investigational Site Number 484004, Merida, Mexico|Investigational Site Number 484005, Monterrey, Mexico|Investigational Site Number 616002, Bialystok, Poland|Investigational Site Number 616005, Lublin, Poland|Investigational Site Number 616004, Warszawa, Poland|Investigational Site Number 616017, Warszawa, Poland|Investigational Site Number 616012, Wroclaw, Poland|Investigational Site Number 643006, Kemerovo, Russian Federation|Investigational Site Number 643020, Moscow, Russian Federation|Investigational Site Number 643001, Moscow, Russian Federation|Investigational Site Number 643008, Saint-Petersburg, Russian Federation|Investigational Site Number 710050, Bellville, South Africa|Investigational Site Number 710011, Cape Town, South Africa|Investigational Site Number 710007, Cape Town, South Africa|Investigational Site Number 710003, Durban, South Africa|Investigational Site Number 710001, Johannesburg, South Africa|Investigational Site Number 710051, Port Elizabeth, South Africa","https://ClinicalTrials.gov/show/NCT02057250"
871,"Reducing COVID-19 Related Hospital Admission in Elderly by BCG Vaccination","Active, not recruiting","No Results Available","COVID-19","Biological: BCG vaccine|Biological: Placebo","Radboud University, Nijmegen, Gelderland, Netherlands|UMC Utrecht, Utrecht, Netherlands","https://ClinicalTrials.gov/show/NCT04417335"
872,"Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1033 (SAR391786)","Completed","No Results Available","Healthy Volunteers","Drug: REGN1033 (SAR391786)|Drug: Placebo","Daytona Beach, Florida, United States|Evansville, Indiana, United States","https://ClinicalTrials.gov/show/NCT01720576"
873,"A Study to Assess the Safety and Tolerability of Single Ascending Doses of REGN1033(SAR391786)","Completed","No Results Available","Healthy Volunteers","Drug: REGN1033(SAR391786)|Drug: Placebo","Honolulu, Hawaii, United States|Evansville, Indiana, United States","https://ClinicalTrials.gov/show/NCT01507402"
874,"Safety Study of a Single Dose of REGN88(SAR153191)in Patients With Rheumatoid Arthritis","Completed","No Results Available","Rheumatoid Arthritis","Biological: REGN88","Duncansville, Pennsylvania, United States|Dallas, Texas, United States","https://ClinicalTrials.gov/show/NCT01055899"
875,"Ascending Multi-dose Study of REGN727(SAR236553) With and Without Concomitant Atorvastatin","Completed","No Results Available","Hypercholesterolemia","Drug: REGN727(SAR236553)","Site 1, Cincinnati, Ohio, United States|Site 2, Knoxville, Tennessee, United States","https://ClinicalTrials.gov/show/NCT01161082"
876,"Safety and Efficacy Trial of Dymista Nasal Spray in Children Ages 4 to 11 With Seasonal Allergic Rhinitis (SAR)","Completed","Has Results","Seasonal Allergic Rhinitis","Drug: azelastine hydrochloride and fluticasone propionate|Drug: Dymista vehicle","Clinical Research Center of Alabama,LLC, Birmingham, Alabama, United States|Little Rock Allergy and Asthma Clinical research Center, Little Rock, Alaska, United States|Clinical Research Atlanta, Atlanta, Georgia, United States|Aeroallergy Research Laboratories of Savannah, Savannah, Georgia, United States|Atlanta Allergy and Asthma Clinic, Stockbridge, Georgia, United States|Sneeze, Wheeze and Itch Associates, Normal, Illinois, United States|Clinical Research Institute of Indiana, Indianapolis, Indiana, United States|Family Allergy and Asthma Reserach, Louisville, Kentucky, United States|Institute for Asthma and Allergy PC, Wheaton, Maryland, United States|Respiratory Medicine Research Institute of Michigan, Ypsilanti, Michigan, United States|Clinical Research Institute, Plymouth, Minnesota, United States|The Clinical Research Center, St. Louis, Missouri, United States|Clinical Research of the Ozarks,Inc, Warrensburg, Missouri, United States|Allergy and Asthma Research NJ inc, Mount Laurel, New Jersey, United States|Atlantic Research Center, Ocean, New Jersey, United States|Princeton Center for Clinical Research, Skillman, New Jersey, United States|North Carolina Clinical Research, Raleigh, North Carolina, United States|Bernstein Clinical Research Center, Cincinnati, Ohio, United States|Allergy, Asthma & Clinical Research Center, Oklahoma City, Oklahoma, United States|Oklahoma Institute of Allergy and Asthma, Oklahoma City, Oklahoma, United States|Allergy and Asthma Specialist PC, Blue Bell, Pennsylvania, United States|Asthma and Allergy Research Associate, Upland, Pennsylvania, United States|National Allergy, Asthma and Urticaria of Charleston, Charleston, South Carolina, United States|Allergy and Asthma Consultants, LLP, Charleston, South Carolina, United States|Isis Clinical Research, LLC, Ausitn, Texas, United States|Sirius Clinical Research, Austin, Texas, United States|Central Texas Health Research, New Braunfels, Texas, United States|Sylvana Research Associates, San Antonio, Texas, United States|Live Oak Allergy and Asthma Clinic, San Antonio, Texas, United States|Allergy Asthma Research Institute, Waco, Texas, United States|Immunology/allergy and asthma Care of Waco, Waco, Texas, United States","https://ClinicalTrials.gov/show/NCT01915823"
877,"Study of the Safety and Efficacy of REGN727/SAR236553 in Patients With HeFH Hypercholesterolemia","Completed","Has Results","Hypercholesterolemia","Drug: Alirocumab|Drug: Placebo","Huntsville, Alabama, United States|Mission Viejo, California, United States|Newport Beach, California, United States|Bridgeport, Connecticut, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Port Orange, Florida, United States|Chicago, Illinois, United States|Kansas City, Kansas, United States|Auburn, Maine, United States|Biddeford, Maine, United States|St. Louis, Missouri, United States|Concord, New Hampshire, United States|Durham, North Carolina, United States|Cincinnati, Ohio, United States|Nashville, Tennessee, United States|Houston, Texas, United States|Winnipeg, Manitoba, Canada|London, Ontario, Canada|Chicoutimi, Quebec, Canada|Montreal, Quebec, Canada|St. Foy, Quebec, Canada","https://ClinicalTrials.gov/show/NCT01266876"
878,"A Safety and Tolerability Study of REGN88(SAR153191) in Subjects With Rheumatoid Arthritis","Completed","No Results Available","Rheumatoid Arthritis","Drug: REGN88|Other: Placebo","Institute of Rheumatology under the Russian Academy of Medical Sciences, Moscow, Russian Federation","https://ClinicalTrials.gov/show/NCT01026519"
879,"Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis","Completed","Has Results","Dermatitis, Atopic","Drug: Dupilumab|Drug: Placebo (for Dupilumab)","Anniston, Alabama, United States|Birmingham, Alabama, United States|Phoenix, Arizona, United States|Bakersfield, California, United States|Costa Mesa, California, United States|Fremont, California, United States|Long Beach, California, United States|Los Angeles, California, United States|Orange, California, United States|Roseville, California, United States|Temecula, California, United States|Trumbull, Connecticut, United States|Miami, Florida, United States|Oviedo, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|Alpharetta, Georgia, United States|Atlanta, Georgia, United States|Columbus, Georgia, United States|Buffalo Grove, Illinois, United States|Plainfield, Indiana, United States|West Des Moines, Iowa, United States|Overland Park, Kansas, United States|Rockville, Maryland, United States|Washington Park, Maryland, United States|Boston, Massachusetts, United States|Farmington Hills, Michigan, United States|Minneapolis, Minnesota, United States|Plymouth, Minnesota, United States|Saint Joseph, Missouri, United States|Saint Louis, Missouri, United States|Billings, Montana, United States|Bozeman, Montana, United States|Las Vegas, Nevada, United States|Verona, New Jersey, United States|Forest Hills, New York, United States|New York, New York, United States|Smithtown, New York, United States|Chapel Hill, North Carolina, United States|Raleigh, North Carolina, United States|Wilmington, North Carolina, United States|Winston-Salem, North Carolina, United States|Tulsa, Oklahoma, United States|Portland, Oregon, United States|Jenkintown, Pennsylvania, United States|Greer, South Carolina, United States|Arlington, Texas, United States|Austin, Texas, United States|Bellaire, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Richmond, Virginia, United States|Seattle, Washington, United States|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|Surrey, British Columbia, Canada|St. John's, Newfoundland and Labrador, Canada|Ajax, Ontario, Canada|Mississauga, Ontario, Canada|Oakville, Ontario, Canada|Ottawa, Ontario, Canada|Peterborough, Ontario, Canada|Richmond Hill, Ontario, Canada|Montreal, Quebec, Canada|Lille Cedex, France|Marseille, France|Nantes, France|Berlin, Germany|Bochum, Germany|Darmstadt, Germany|Friedrichshafen, Germany|Hamburg, Germany|Kiel, Germany|Hong Kong, Hong Kong|Lucca, Italy|Pisa, Italy|Roma, Italy|Busan, Korea, Republic of|Gyeonggi-do, Korea, Republic of|Incheon, Korea, Republic of|Seoul, Korea, Republic of|Kaunas, Lithuania|Klaipeda, Lithuania|Vilnius, Lithuania|Elblag, Poland|Gdansk, Poland|Katowice, Poland|Poznan, Poland|Torun, Poland|Warsaw, Poland|Stockholm, Sweden|London, United Kingdom|Plymouth, United Kingdom","https://ClinicalTrials.gov/show/NCT02277769"
880,"Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)","Completed","No Results Available","Atopic Dermatitis","Drug: Dupilumab|Drug: Midazolam|Drug: Omeprazole|Drug: Warfarin|Drug: Caffeine|Drug: Metoprolol","Regeneron Study Site, Little Rock, Arkansas, United States|Regeneron Study Site, Centennial, Colorado, United States|Regeneron Study Site, Minneapolis, Minnesota, United States|Regeneron Study Site, Berlin, New Jersey, United States|Regeneron Study Site, Raleigh, North Carolina, United States","https://ClinicalTrials.gov/show/NCT02647086"
881,"Study of the Tolerability, Safety, Pharmacokinetics and Pharmacodynamics of Alirocumab SAR236553 (REGN727)","Completed","No Results Available","Hypercholesterolemia","Drug: alirocumab SAR236553 (REGN727)","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States","https://ClinicalTrials.gov/show/NCT01448304"
882,"Ascending Dose Study of the Safety and Tolerability of REGN727 (SAR236553) in Healthy Volunteers","Completed","No Results Available","Healthy Volunteers","Drug: REGN727|Drug: Placebo","Overland Park, Kansas, United States","https://ClinicalTrials.gov/show/NCT01074372"
883,"Ascending Dose Study of the Safety and Tolerability of REGN727(SAR236553) in Healthy Volunteers","Completed","No Results Available","Healthy","Drug: REGN727|Drug: Placebo","Overland Park, Kansas, United States","https://ClinicalTrials.gov/show/NCT01026597"
884,"A Single-Dose Study of the Safety and Tolerability of REGN475(SAR164877) in Healthy Subjects","Completed","No Results Available","Healthy","Biological: REGN475 (SAR164877)","Altoona, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT00856310"
885,"A Study of Alirocumab (REGN727/SAR236553) in Patients With ADH and GOFm of the PCSK9 Gene or LOFm of the apoB Gene","Unknown status","No Results Available","Hypercholesterolemia","Drug: alirocumab|Drug: placebo","Salt Lake City, Utah, United States|Lille, Cedex, France|Nante, Cedex, France|Paris, France","https://ClinicalTrials.gov/show/NCT01604824"
886,"Safety Study of XL765 (SAR245409) in Combination With Erlotinib in Adults With Solid Tumors","Completed","No Results Available","Cancer|Non-Small Cell Lung Cancer","Drug: XL765 (SAR245409)|Drug: erlotinib","Investigational Site Number 168983, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT00777699"
887,"Nesvacumab (REGN910/ SAR307746) and Aflibercept (""Ziv-aflibercept"" in the U.S.) in Patients With Advanced Solid Malignancies","Completed","No Results Available","Solid Tumors","Drug: nesvacumab (REGN910/ SAR307746)|Drug: aflibercept (ziv-aflibercept)","Indianapolis, Indiana, United States|New York, New York, United States|Oklahoma City, Oklahoma, United States|Philadelphia, Pennsylvania, United States|San Antonio, Texas, United States|Toronto, Canada","https://ClinicalTrials.gov/show/NCT01688960"
888,"Ascending Dose Study of the Safety and Tolerability of REGN668(SAR231893) in Normal Healthy Volunteers","Completed","No Results Available","Healthy","Biological: REGN668","Baltimore, Maryland, United States","https://ClinicalTrials.gov/show/NCT01015027"
889,"A Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Osteoarthritis of the Knee","Completed","No Results Available","Osteoarthritis of the Knee","Drug: REGN475|Other: Placebo","Anaheim, California, United States|Tampa, Florida, United States|Salt Lake City, Utah, United States","https://ClinicalTrials.gov/show/NCT00944892"
890,"A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Seasonal Allergic Rhinitis (SAR)","Completed","Has Results","Seasonal Allergic Rhinitis","Drug: Ciclesonide nasal aerosol 37 mcg|Drug: ciclesonide nasal aerosol 74 mcg|Drug: Placebo","Arkansas Pediatric Clinic, Little Rock, Arkansas, United States|San Jose Multispecialty Medical Group, Inc, Baldwin Park, California, United States|WCCT Global, LLC, Costa Mesa, California, United States|Premier Health Research Center, Downey, California, United States|Allergy, Asthma, Brochitis and Immunology Assoc Medical Group, Fountain Valley, California, United States|Pediatric Care Medical Group, Inc., Huntington Beach, California, United States|Pediatric Care Medical Group, Huntington Beach, California, United States|Allergy and Asthma Associates of Southern California, Mission Viejo, California, United States|CHOC, PSF, AMC, Division of Allergy, Asthma, and Immunology, Orange, California, United States|Center for Clinical Trials, LLC, Paramount, California, United States|Peninsula Research Associates, Rolling Hills Estates, California, United States|Capital Allergy & Respiratory Disease Center, Sacramento, California, United States|Allergy Associates Medical Group, San Diego, California, United States|Allergy & Asthma Medical Group and Research Center, APC, San Diego, California, United States|Bensch Research Associates, Stockton, California, United States|Asthma & Allergy Associates, PC, Colorado Springs, Colorado, United States|Storms Clinical Research Institute, Colorado Springs, Colorado, United States|Colorado Allergy and Asthma Centers, PC, Denver, Colorado, United States|Northeast Georgia Research Center, Gainesville, Georgia, United States|DataQuest Medical Research, LLC, Lawerenceville, Georgia, United States|Atlanta Allergy & Astma Clinic, Marietta, Georgia, United States|Aeroallergy Research Laboratories of Savannah, Inc, Savannah, Georgia, United States|Clinical Research Atlanta, Stockbridge, Georgia, United States|Alzein Pediatrics, Evergreen Park, Illinois, United States|Sneeze, Weeze, & Itch Associates, Normal, Illinois, United States|Gordon D. Raphael, MD, Berthesda, Maryland, United States|Clinical Research Institute, Plymouth, Minnesota, United States|Creighton University Medical Center, Omaha, Nebraska, United States|Atlantic Research Center, LLC, Ocean, New Jersey, United States|North Carolina Clinical Research, Raleigh, North Carolina, United States|Catalyst Medical Center, Fargo, North Dakota, United States|Toledo Center for Clinical Research, Sylvania, Ohio, United States|Baker Allergy Asthma and Dermatology Research Center LLC, Lake Oswego, Oregon, United States|Clinical Research Institute of Southern Oregon, PC, Medford, Oregon, United States|Allergy Associates Research Center, Portland, Oregon, United States|Asthma and Allergy Research Associates, Upland, Pennsylvania, United States|Asthma, Nasal Disease & Allergy Research Center of New England, Providence, Rhode Island, United States|National Allergy, Asthma, and Uticaria Centers of Charleston, PA, Charleston, South Carolina, United States|Spartanburg Medical Research, Spartanburg, South Carolina, United States|DCT - Anchor, LLC dba Discovery Clinical Trials, Arlington, Texas, United States|Discovery Clinical Trials, Arlington, Texas, United States|Benchmark Research, Austin, Texas, United States|Isis Clinical Research, LLC, Austin, Texas, United States|Sirius Clinical Research LLC, Austin, Texas, United States|TTS Research Center, Boeme, Texas, United States|Research Across America, Carroliton, Texas, United States|Dallas Allergy Immunology Research, Dallas, Texas, United States|Pharmaceutical Research and Consulting, Dallas, Texas, United States|Western Sky Medical Research, El Paso, Texas, United States|Benchmark Research, Fort Worth, Texas, United States|Kerrville Research Associates, Kerrville, Texas, United States|Live Oak Allergy and Asthma Clinic, Live Oak, Texas, United States|Central Texas Health Research, New Braunfels, Texas, United States|ACRC Trials, Plano, Texas, United States|North Texas Family Medicine, Plano, Texas, United States|Benchmark Research, San Angelo, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|DCT - Barlite Dba Discovery Clinical Trials, San Antonio, Texas, United States|Allergy and Asthma Research Center, PA, San Antonio, Texas, United States|San Antonio Ear, Nose & Throat Research, San Antonio, Texas, United States|Sylvana Research Associates, San Antonio, Texas, United States|DCT-Westover Hills, Dba Discovery Clinical Trials, San Antonio, Texas, United States|Pediatric Healthcare of Northwest Houston, Tomball, Texas, United States|Allergy & Asthma Care of Waco, Waco, Texas, United States|Allergy Asthma Research Institute, Waco, Texas, United States|Ericksen Research and Development, Clinton, Utah, United States","https://ClinicalTrials.gov/show/NCT01458275"
891,"Study of Efficacy and Safety of MAS825 in Patients With COVID-19","Not yet recruiting","No Results Available","COVID-19 Pneumonia, Impaired Respiratory Function","Drug: MAS825|Drug: Matching placebo",,"https://ClinicalTrials.gov/show/NCT04382651"
892,"Study of the Safety and Pharmacokinetics of XL765 (SAR245409) in Adults With Solid Tumors","Completed","No Results Available","Cancer","Drug: XL765 (SAR245409)","Investigational Site Number 1302, Detroit, Michigan, United States|Investigational Site Number 1435, Omaha, Nebraska, United States|Investigational Site Number 1402, San Antonio, Texas, United States|Investigational Site Number 3411, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT00485719"
893,"Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Pain Resulting From Thermal Injury","Withdrawn","No Results Available","Thermal Injury Pain","Drug: R475|Drug: Placebo","Tampa, Florida, United States","https://ClinicalTrials.gov/show/NCT01053702"
894,"A Study to Determine the Safety and Tolerability of Dupilumab (REGN668/SAR231893) in Patients Aged ≥6 to <18 Years With Atopic Dermatitis (Eczema)","Completed","No Results Available","Atopic Dermatitis","Drug: Dupilumab","Markham, Ontario, Canada|Peterborough, Ontario, Canada|Waterloo, Ontario, Canada|Windsor, Ontario, Canada|Kutna Hora, Czech Republic|Prague, Czech Republic|Dresden, Germany|Frankfurt, Germany|Gera, Germany|Hamburg, Germany|Kiel, Germany|Luebeck, Germany|Muenster, Germany|Munich, Germany|Tuebingen, Germany|Kaposvar, Hungary|Miskolc, Hungary|Szeged, Hungary|Szolnok, Hungary|Katowice, Poland|Krakow, Poland|Lodz, Poland|Warszawa, Poland|Wroclaw, Poland|Manchester, United Kingdom|Sheffield, United Kingdom","https://ClinicalTrials.gov/show/NCT02407756"
895,"A Multiple-dose Study of the Safety and Tolerability of REGN88(SAR153191) in Rheumatoid Arthritis Subjects","Completed","No Results Available","Rheumatoid Arthritis","Biological: REGN88","Santa Maria, California, United States|Boca Raton, Florida, United States|Clearwater, Florida, United States|Daytona Beach, Florida, United States|Delray Beach, Florida, United States|Palm Harbor, Florida, United States|Idaho Falls, Idaho, United States|Worcester, Massachusetts, United States|Lansing, Michigan, United States|Flowood, Mississippi, United States|Kalamzaoo, Missouri, United States|St. Louis, Missouri, United States|Reno, Nevada, United States|Charlotte, North Carolina, United States|Cincinnati, Ohio, United States|Toledo, Ohio, United States|Oklahoma City, Oklahoma, United States|Duncansville, Pennsylvania, United States|Greenville, South Carolina, United States|Orangeburg, South Carolina, United States|Hixson, Tennessee, United States|Austin, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States","https://ClinicalTrials.gov/show/NCT01011959"
896,"Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis","Completed","Has Results","Atopic Dermatitis","Drug: Dupilumab|Drug: Placebo (for Dupilumab)|Other: Topical Corticosteroid (TCS)","Phoenix, Arizona, United States|Hot Springs, Arkansas, United States|Little Rock, Arkansas, United States|Encinitas, California, United States|Oceanside, California, United States|Palmdale, California, United States|San Diego, California, United States|New Haven, Connecticut, United States|Trumbull, Connecticut, United States|Edgewater, Florida, United States|Lake Worth, Florida, United States|Miami Lakes, Florida, United States|Orlando, Florida, United States|Tampa, Florida, United States|Alpharetta, Georgia, United States|Columbus, Georgia, United States|Savannah, Georgia, United States|West Dundee, Illinois, United States|Carmel, Indiana, United States|New Albany, Indiana, United States|Rockville, Maryland, United States|Ann Arbor, Michigan, United States|Bay City, Michigan, United States|Edina, Minnesota, United States|Fridley, Minnesota, United States|Saint Louis, Missouri, United States|Omaha, Nebraska, United States|Henderson, Nevada, United States|Verona, New Jersey, United States|Albuquerque, New Mexico, United States|Corning, New York, United States|New York, New York, United States|Smithtown, New York, United States|Stony Brook, New York, United States|Cincinnati, Ohio, United States|Norman, Oklahoma, United States|Oklahoma City, Oklahoma, United States|Lake Oswego, Oregon, United States|Portland, Oregon, United States|Exton, Pennsylvania, United States|Hazleton, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Austin, Texas, United States|Dallas, Texas, United States|West Jordan, Utah, United States|South Burlington, Vermont, United States|Henrico, Virginia, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Spokane, Washington, United States|Phillip, Australian Capital Territory, Australia|Kogarah, New South Wales, Australia|Benowa, Queensland, Australia|Dulwich, Queensland, Australia|Hectorville, South Australia, Australia|Carlton, Victoria, Australia|Surrey, British Columbia, Canada|Vancouver, British Columbia, Canada|Ajax, Ontario, Canada|Barrie, Ontario, Canada|Hamilton, Ontario, Canada|Markham, Ontario, Canada|North Bay, Ontario, Canada|Oakville, Ontario, Canada|Ottawa, Ontario, Canada|Peterborough, Ontario, Canada|Richmond Hill, Ontario, Canada|Toronto, Ontario, Canada|Waterloo, Ontario, Canada|Windsor, Ontario, Canada|Drummondville, Quebec, Canada|Quebec, Canada|Hradec Kralove, Czechia|Nachod, Czechia|Praha 10, Czechia|Praha 5, Czechia|Svitavy, Czechia|Usti nad Labem, Czechia|Oroshaza, Békés, Hungary|Szolnok, Jász-Nagykun-Szolnok, Hungary|Veszprem, Veszprém, Hungary|Budapest, Hungary|Ancona, Italy|Bologna, Italy|Brescia, Italy|Novara, Italy|Pavia, Italy|Perugia, Italy|Roma, Italy|Kitakyushu, Fukuoka, Japan|Amagasaki, Hyôgo, Japan|Yokohama, Kanagawa, Japan|Kamimashiki-gun, Kumamoto, Japan|Saitama-shi, Saitama, Japan|Yaizu, Shizuoka, Japan|Koto-ku, Tokyo, Japan|Setagaya-ku, Tokyo, Japan|Adachi-ku, Tôkyô, Japan|Chiyoda-ku, Tôkyô, Japan|Nakano-ku, Tôkyô, Japan|Nerima-ku, Tôkyô, Japan|Shibuya-ku, Tôkyô, Japan|Shinagawa-ku, Tôkyô, Japan|Shinjuku-ku, Tôkyô, Japan|Suginami-ku, Tôkyô, Japan|Fukuoka, Japan|Bucheon-si, Gyeonggido, Korea, Republic of|Suwon, Gyeonggido, Korea, Republic of|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Seodaemun-gu, Korea, Republic of|Uijeongbu-si, Korea, Republic of|Breda, Noord-Brabant, Netherlands|Amsterdam, Noord-Holland, Netherlands|Rotterdam, Zuid-Holland, Netherlands|Groningen, Netherlands|Utrecht, Netherlands|Dunedin, South Island, New Zealand|Auckland, New Zealand|Wroclaw, Dolnośląskie, Poland|Lublin, Lubelskie, Poland|Warszawa, Mazowieckie, Poland|Krakow, Małopolskie, Poland|Strzelce Opolskie, Opolskie, Poland|Iwonicz Zdroj, Podkarpackie, Poland|Bialystok, Podlaskie, Poland|Gdansk, Pomorskie, Poland|Poznan, Wielkopolskie, Poland|Szczecin, Zachodniopomorskie, Poland|Gdynia, Poland|Łódź, Łódzkie, Poland|Katowice, Śląskie, Poland|Skarzysko-Kamienna, Świętokrzyskie, Poland|Brasov, Braşov, Romania|Bucuresti, Bucureşti, Romania|Cluj-Napoca, Cluj, Romania|Craiova, Dolj, Romania|Targu Mures, Mureş, Romania|Barcelona, Cataluña, Spain|Alicante, Spain|Madrid, Spain|Dundee, Angus, United Kingdom|Edgbaston, Birmingham, United Kingdom|Glasgow, Glasgow City, United Kingdom|Sidcup, Kent, United Kingdom|Northwood, Middlesex, United Kingdom|Liverpool, United Kingdom|Manchester, United Kingdom|Reading, United Kingdom|Salford, United Kingdom","https://ClinicalTrials.gov/show/NCT02260986"
897,"Comparison of the Safety and Pharmacokinetics of Two SAR153191 (REGN88) Drug Products in Rheumatoid Arthritis Patients","Completed","No Results Available","Rheumatoid Arthritis","Drug: SAR153191 (REGN88)","Investigational Site Number 840003, Beverly Hills, California, United States|Investigational Site Number 840001, Ocala, Florida, United States|Investigational Site Number 840004, Duncansville, Pennsylvania, United States|Investigational Site Number 840002, Dallas, Texas, United States","https://ClinicalTrials.gov/show/NCT01328522"
898,"Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)","Completed","Has Results","Hypercholesterolemia","Drug: Alirocumab|Drug: Rosuvastatin|Drug: Ezetimibe|Drug: Placebo","Chandler, Arizona, United States|Tucson, Arizona, United States|Anaheim, California, United States|Beverly Hills, California, United States|Fair Oaks, California, United States|Newport Beach, California, United States|Northridge, California, United States|Sacramento, California, United States|Walnut Creek, California, United States|Milford, Connecticut, United States|Atlantis, Florida, United States|Bradenton, Florida, United States|Clearwater, Florida, United States|Fort Lauderdale, Florida, United States|Jacksonville, Florida, United States|Lakeland, Florida, United States|(2 Locations), Miami, Florida, United States|Oviedo, Florida, United States|Pinellas Park, Florida, United States|Port Orange, Florida, United States|Sarasota, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|Winter Park, Florida, United States|Boise, Idaho, United States|Morton, Illinois, United States|Evansville, Indiana, United States|Indianapolis, Indiana, United States|Newton, Kansas, United States|Overland Park, Kansas, United States|Wichita, Kansas, United States|Lexington, Kentucky, United States|Louisville, Kentucky, United States|Auburn, Maine, United States|Bethesda, Maryland, United States|Edina, Minnesota, United States|Rochester, Minnesota, United States|Olive Branch, Mississippi, United States|Port Gibson, Mississippi, United States|Saint Louis, Missouri, United States|Butte, Montana, United States|Williamsville, New York, United States|Cincinnati, Ohio, United States|Marion, Ohio, United States|Portland, Oregon, United States|Warwick, Rhode Island, United States|Greer, South Carolina, United States|Summerville, South Carolina, United States|Kingsport, Tennessee, United States|Dallas, Texas, United States|Fort Worth, Texas, United States|Houston, Texas, United States|Bountiful, Utah, United States|Salt Lake City, Utah, United States|Herston, Australia|New Lambton Heights, Australia|Perth, Australia|Sherwood, Australia|Woolloongabba, Australia|Brampton, Ontario, Canada|Burlington, Ontario, Canada|Etobicoke, Ontario, Canada|London, Ontario, Canada|Newmarket, Ontario, Canada|Thornhill, Ontario, Canada|Toronto, Ontario, Canada|Chicoutimi, Quebec, Canada|Dijon, France|Lille, France|Bad Oeynhausen, Germany|Berlin, Germany|Koeln, Germany|Regensburg, Germany|Ulm, Germany|Chieti, Italy|Genova, Italy|Napoli, Italy|Palermo, Italy|(2 Locations), Roma, Italy|Baja California, Mexico|Distrito Federal, Mexico|(3 Locations), Guadalajara, Mexico|Monterrey, Mexico|Zapopan Jalisco, Mexico|(2 Locations), Barcelona, Spain|Madrid, Spain|Santiago, Spain|Sevilla, Spain|West Bromwich, West Midlands, United Kingdom|Chester, United Kingdom|Peterborough, United Kingdom|Salford, United Kingdom|Stevenage, United Kingdom","https://ClinicalTrials.gov/show/NCT01730053"
899,"Study of the Safety and Pharmacokinetics of XL147 (SAR245408) in Adults With Solid Tumors or Lymphoma","Completed","No Results Available","Cancer|Lymphoma","Drug: XL147 (SAR245408)","Investigational Site Number 1241, Augusta, Georgia, United States|Investigational Site Number 1503, Boston, Massachusetts, United States|Investigational Site Number 1401, Dallas, Texas, United States|Investigational Site Number 3412, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT00486135"
900,"Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)","Completed","No Results Available","Rheumatoid Arthritis","Drug: Sarilumab|Drug: Tocilizumab","Birmingham, Alabama, United States|Orange, California, United States|Deland, Florida, United States|Edgewater, Florida, United States|Miami Lakes, Florida, United States|Miami, Florida, United States|Granger, Indiana, United States|Grand Blanc, Michigan, United States|Charlotte, North Carolina, United States|Cinicinnati, Ohio, United States|Memphis, Tennessee, United States|Austin, Texas, United States|Carrollton, Texas, United States|Channelview, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|Mesquite, Texas, United States|Plano, Texas, United States|San Antonio, Texas, United States","https://ClinicalTrials.gov/show/NCT02097524"
901,"Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis","Completed","No Results Available","Dermatitis","Biological: REGN668","Los Angeles, California, United States|Riverside, California, United States|Miami, Florida, United States|Chicago, Illinois, United States|Troy, Michigan, United States|New York, New York, United States|﻿Rochester, New York, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Dallas, Texas, United States","https://ClinicalTrials.gov/show/NCT01259323"
902,"Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)","Completed","Has Results","Hypercholesterolemia","Drug: Alirocumab|Drug: Atorvastatin|Drug: Ezetimibe|Drug: Rosuvastatin|Drug: Placebo","Mobile, Alabama, United States|Chandler, Arizona, United States|Tucson, Arizona, United States|Anaheim, California, United States|Beverly Hills, California, United States|Lakeland, California, United States|Newport Beach, California, United States|Northridge, California, United States|Sacramento, California, United States|Walnut Creek, California, United States|Milford, Connecticut, United States|Atlantis, Florida, United States|Boca Raton, Florida, United States|Clearwater, Florida, United States|Jacksonville, Florida, United States|Miami (2 locations), Florida, United States|Oviedo, Florida, United States|Pinellas Park, Florida, United States|Port Orange, Florida, United States|Sarasota, Florida, United States|Tampa, Florida, United States|West Palm Beach, Florida, United States|Boise, Idaho, United States|Meridian, Idaho, United States|Chicago, Illinois, United States|Morton, Illinois, United States|Indianapolis, Indiana, United States|Newton, Kansas, United States|Overland Park, Kansas, United States|Wichita, Kansas, United States|Lexington, Kentucky, United States|Louisville, Kentucky, United States|Auburn, Maine, United States|Bethesda, Maryland, United States|Edina, Minnesota, United States|Rochester, Minnesota, United States|Olive Branch, Mississippi, United States|Port Gibson, Mississippi, United States|St. Louis, Missouri, United States|Butte, Montana, United States|Las Vegas, Nevada, United States|Williamsville, New York, United States|Winston-Salem, North Carolina, United States|Cleveland, Ohio, United States|Oklahoma City, Oklahoma, United States|Warwick, Rhode Island, United States|Greer, South Carolina, United States|Summerville, South Carolina, United States|Kingsport, Tennessee, United States|Dallas (2 locations), Texas, United States|Fort Worth, Texas, United States|Houston, Texas, United States|Bountiful, Utah, United States|Marion, Utah, United States|Salt Lake City, Utah, United States|Renton, Washington, United States|Herston QLD, Australia|New Lambton Heights, Australia|Perth, Australia|Sherwood, Australia|Woolloongabba, Australia|Brampton, Ontario, Canada|Etobicoke, Ontario, Canada|London, Ontario, Canada|Newmarke, Ontario, Canada|Thornhill, Ontario, Canada|Toronto, Ontario, Canada|Chicoutimi, Quebec, Canada|Dijon, France|Lille, France|Venissieux, France|Bad Oeynhausen, Germany|Berlin, Germany|Koeln, Germany|Munich, Germany|Regensburg, Germany|Ulm, Germany|Chiete, Italy|Genova, Italy|Napoli, Italy|Palermo, Italy|Roma (2 locations), Italy|Distrito Federal, Mexico|Guadalajara, Jalisco, Mexico|Guadalajara, Mexico|Monterrey Nuevo Leon, Mexico|Tijuana Baja California, Mexico|Zapopan Jalisco, Mexico|Barcelona (3 locations), Spain|Madrid, Spain|Sant Joan Despi, Spain|Carmarthen, United Kingdom|Chester, United Kingdom|Peterborough, United Kingdom|Salford, United Kingdom|Stevenage, United Kingdom|West Bromwich, West Midlands, United Kingdom","https://ClinicalTrials.gov/show/NCT01730040"
903,"Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy","Completed","Has Results","Heterozygous Familial Hypercholesterolemia","Drug: Placebo|Drug: Alirocumab","Aurora, Colorado, United States|Hartford, Connecticut, United States|Kansas City, Kansas, United States|Scarborough, Maine, United States|Rochester, Minnesota, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Dresden, Sachsen, Germany|Berlin, Germany|Göttingen, Germany|Muenchen (2 locations), Germany|Passau, Germany|Rostock, Germany","https://ClinicalTrials.gov/show/NCT02326220"
904,"A Study to Evaluate the Safety and Efficacy of Subcutaneously Administered REGN475(SAR164877) in Patients With Sciatic Pain","Completed","No Results Available","Sciatica","Drug: REGN475|Drug: Placebo Injection","Regeneron Investigational Site, Birmingham, Alabama, United States|Regeneron Investigational Site, Mobile, Alabama, United States|Regeneron Investigational Site, Peoria, Arizona, United States|Regeneron Investigational Site, Anaheim, California, United States|Regeneron Investigational Site, Beverly Hills, California, United States|Regeneron Investigational Site, National City, California, United States|Regeneron Investigational Site, Santa Ana, California, United States|Regeneron Investigational Site, Milford, Connecticut, United States|Regeneron Investigational Site, Stamford, Connecticut, United States|Regeneron Investigational Site, Clearwater, Florida, United States|Regeneron Investigational Site, Hallandale Beach, Florida, United States|Regeneron Investigational Site, St. Petersburg, Florida, United States|Regeneron Investigational Site, Tampa, Florida, United States|Regeneron Investigational Site, West Palm Beach, Florida, United States|Regeneron Investigational Site, Atlanta, Georgia, United States|Regeneron Investigational Site, Sandy Springs, Georgia, United States|Regeneron Investigational Site, Overland Park, Kansas, United States|Regeneron Investigational Site, Rockville, Maryland, United States|Regeneron Investigational Site, Kansas City, Missouri, United States|Regeneron Investigational Site, Albuquerque, New Mexico, United States|Regeneron Investigational Site, Raleigh, North Carolina, United States|Regeneron Investigational Site, Cincinnati, Ohio, United States|Regeneron Investigational Site, Duncansville, Pennsylvania, United States|Regeneron Investigational Site, Tyrone, Pennsylvania, United States|Regeneron Investigational Site, Warwick, Rhode Island, United States|Regeneron Investigational Site, Greer, South Carolina, United States|Regeneron Investigational Site, Memphis, Tennessee, United States|Regeneron Investigational Site, El Paso, Texas, United States|Regeneron Investigational Site, San Antonio, Texas, United States|Regeneron Invesitgational Site, West Jordan, Utah, United States","https://ClinicalTrials.gov/show/NCT00991172"
905,"COVID-19: A POC Test Under Research & Evaluation","Recruiting","No Results Available","COVID-19","Diagnostic Test: Sample Collection/Performance Evaluation (A)|Diagnostic Test: Sample Collection/Performance Evaluation (B)","Barts Health NHS Trust, London, United Kingdom|Homerton University Hospital NHS Foundation Trust, London, United Kingdom|University College London Hospitals NHS Foundation Trust, London, United Kingdom","https://ClinicalTrials.gov/show/NCT04408066"
906,"Open-Label Extension of Study R727-CL-1003 to Evaluate the Long-Term Safety and Efficacy of REGN727 (SAR236553) in Patients With Hypercholesterolemia","Completed","No Results Available","Hypercholesterolemia","Drug: REGN727 (SAR236553)","Mission Viejo, California, United States|Newport Beach, California, United States|Thousand Oaks, California, United States|Miami, Florida, United States|Port Orange, Florida, United States|Kansas City, Kansas, United States|Auburn, Maine, United States|Saint Louis, Missouri, United States|Durham, North Carolina, United States|Cincinnati, Ohio, United States|Houston, Texas, United States|Chicoutimi, Quebec, Canada|Montreal, Quebec, Canada|Sainte-Foy, Quebec, Canada","https://ClinicalTrials.gov/show/NCT01576484"
907,"To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)","Completed","Has Results","Rheumatoid Arthritis","Drug: Sarilumab|Drug: placebo|Drug: hydroxychloroquine|Drug: methotrexate|Drug: sulfasalazine|Drug: leflunomide","Investigational Site Number 840070, Anniston, Alabama, United States|Investigational Site Number 840138, Birmingham, Alabama, United States|Investigational Site Number 840142, Phoenix, Arizona, United States|Investigational Site Number 840134, Fullerton, California, United States|Investigational Site Number 840141, Glendale, California, United States|Investigational Site Number 840111, La Jolla, California, United States|Investigational Site Number 840135, San Diego, California, United States|Investigational Site Number 840021, Santa Maria, California, United States|Investigational Site Number 840100, Stanford, California, United States|Investigational Site Number 840049, Upland, California, United States|Investigational Site Number 840131, Whittier, California, United States|Investigational Site Number 840201, Denver, Colorado, United States|Investigational Site Number 840130, Lewes, Delaware, United States|Investigational Site Number 840125, DeBary, Florida, United States|Investigational Site Number 840048, Miami, Florida, United States|Investigational Site Number 840024, Naples, Florida, United States|Investigational Site Number 840006, Orlando, Florida, United States|Investigational Site Number 840128, Ormond Beach, Florida, United States|Investigational Site Number 840063, Palm Harbor, Florida, United States|Investigational Site Number 840060, Sarasota, Florida, United States|Investigational Site Number 840140, Tampa, Florida, United States|Investigational Site Number 840126, Vero Beach, Florida, United States|Investigational Site Number 840018, Idaho Falls, Idaho, United States|Investigational Site Number 840110, Meridian, Idaho, United States|Investigational Site Number 840052, Kansas City, Kansas, United States|Investigational Site Number 840015, Lexington, Kentucky, United States|Investigational Site Number 840120, Baton Rouge, Louisiana, United States|Investigational Site Number 840109, Lake Charles, Louisiana, United States|Investigational Site Number 840055, Frederick, Maryland, United States|Investigational Site Number 840150, Lansing, Michigan, United States|Investigational Site Number 840137, Saint Clair Shores, Michigan, United States|Investigational Site Number 840037, Tupelo, Mississippi, United States|Investigational Site Number 840112, Lincoln, Nebraska, United States|Investigational Site Number 840106, Orchard Park, New York, United States|Investigational Site Number 840121, Rochester, New York, United States|Investigational Site Number 840115, Roslyn, New York, United States|Investigational Site Number 840118, Smithtown, New York, United States|Investigational Site Number 840139, Syracuse, New York, United States|Investigational Site Number 840123, Charlotte, North Carolina, United States|Investigational Site Number 840116, Wilmington, North Carolina, United States|Investigational Site Number 840127, Oklahoma City, Oklahoma, United States|Investigational Site Number 840011, Tulsa, Oklahoma, United States|Investigational Site Number 840009, Duncansville, Pennsylvania, United States|Investigational Site Number 840117, Pittsburgh, Pennsylvania, United States|Investigational Site Number 840062, Reading, Pennsylvania, United States|Investigational Site Number 840058, Columbia, South Carolina, United States|Investigational Site Number 840025, Jackson, Tennessee, United States|Investigational Site Number 840059, Memphis, Tennessee, United States|Investigational Site Number 840132, Austin, Texas, United States|Investigational Site Number 840022, Dallas, Texas, United States|Investigational Site Number 840114, El Paso, Texas, United States|Investigational Site Number 840133, Houston, Texas, United States|Investigational Site Number 840129, Houston, Texas, United States|Investigational Site Number 840074, Mesquite, Texas, United States|Investigational Site Number 840036, Spokane, Washington, United States|Investigational Site Number 840124, Clarksburg, West Virginia, United States|Investigational Site Number 032015, Buenos Aires, Argentina|Investigational Site Number 032008, Buenos Aires, Argentina|Investigational Site Number 032019, Caba, Argentina|Investigational Site Number 032006, Caba, Argentina|Investigational Site Number 032016, Capital Federal, Argentina|Investigational Site Number 032020, Cordoba, Argentina|Investigational Site Number 032017, La Plata, Argentina|Investigational Site Number 032010, Ramos Mejia, Argentina|Investigational Site Number 032013, Rosario, Argentina|Investigational Site Number 032004, San Miguel De Tucuman, Argentina|Investigational Site Number 032009, Zarate, Argentina|Investigational Site Number 036014, Victoria Park, Australia|Investigational Site Number 040004, Stockerau, Austria|Investigational Site Number 040003, Wien, Austria|Investigational Site Number 076001, Curitiba, Brazil|Investigational Site Number 076016, Curitiba, Brazil|Investigational Site Number 076006, Goiania, Brazil|Investigational Site Number 076010, Juiz De Fora, Brazil|Investigational Site Number 076005, Rio De Janeiro, Brazil|Investigational Site Number 076015, Rio De Janeiro, Brazil|Investigational Site Number 124005, Toronto, Canada|Investigational Site Number 124009, Trois-Rivières, Canada|Investigational Site Number 124104, Victoria, Canada|Investigational Site Number 152015, Temuco, Chile|Investigational Site Number 170001, Bogota, Colombia|Investigational Site Number 170012, Bogota, Colombia|Investigational Site Number 170006, Bogotá, Colombia|Investigational Site Number 170007, Bucaramanga, Colombia|Investigational Site Number 170009, Bucaramanga, Colombia|Investigational Site Number 170014, Chia, Colombia|Investigational Site Number 170019, Medellin, Colombia|Investigational Site Number 203008, Hostivice, Czechia|Investigational Site Number 203004, Ostrava, Czechia|Investigational Site Number 203007, Praha 2, Czechia|Investigational Site Number 203002, Uherske Hradiste, Czechia|Investigational Site Number 203006, Zlin, Czechia|Investigational Site Number 218003, Cuenca, Ecuador|Investigational Site Number 218001, Guayaquil, Ecuador|Investigational Site Number 218002, Quito, Ecuador|Investigational Site Number 276011, Bad Nauheim, Germany|Investigational Site Number 276010, Berlin, Germany|Investigational Site Number 276001, Berlin, Germany|Investigational Site Number 276014, Berlin, Germany|Investigational Site Number 276018, Deggingen, Germany|Investigational Site Number 276004, Erlangen, Germany|Investigational Site Number 276015, Halle/Saale, Germany|Investigational Site Number 276013, Hamburg, Germany|Investigational Site Number 276016, Leipzig, Germany|Investigational Site Number 276017, München, Germany|Investigational Site Number 276021, Osnabrück, Germany|Investigational Site Number 276020, Tübingen, Germany|Investigational Site Number 276019, Zerbst, Germany|Investigational Site Number 300002, Heraklion, Greece|Investigational Site Number 300005, Thessaloniki, Greece|Investigational Site Number 320002, Guatemala City, Guatemala|Investigational Site Number 320003, Guatemala City, Guatemala|Investigational Site Number 320001, Guatemala City, Guatemala|Investigational Site Number 348022, Budapest, Hungary|Investigational Site Number 348003, Debrecen, Hungary|Investigational Site Number 348004, Veszprém, Hungary|Investigational Site Number 348017, Veszprém, Hungary|Investigational Site Number 376001, Haifa, Israel|Investigational Site Number 376003, Petach Tikva, Israel|Investigational Site Number 376002, Tel Hashomer, Israel|Investigational Site Number 380011, Catania, Italy|Investigational Site Number 380002, Firenze, Italy|Investigational Site Number 380005, Genova, Italy|Investigational Site Number 380014, Milano, Italy|Investigational Site Number 380013, Udine, Italy|Investigational Site Number 410017, Daejeon, Korea, Republic of|Investigational Site Number 410016, Seoul, Korea, Republic of|Investigational Site Number 440005, Kaunas, Lithuania|Investigational Site Number 440006, Klaipeda, Lithuania|Investigational Site Number 440007, Vilnius, Lithuania|Investigational Site Number 484023, Chihuahua, Mexico|Investigational Site Number 484018, Guadalajara, Mexico|Investigational Site Number 484002, Guadalajara, Mexico|Investigational Site Number 484024, Guadalajara, Mexico|Investigational Site Number 484010, Mexicali, Mexico|Investigational Site Number 484019, Monterrey, Mexico|Investigational Site Number 484020, Monterrey, Mexico|Investigational Site Number 484005, Monterrey, Mexico|Investigational Site Number 484017, México, Mexico|Investigational Site Number 484021, Queretaro, Mexico|Investigational Site Number 554005, Hamilton, New Zealand|Investigational Site Number 554011, Nelson, New Zealand|Investigational Site Number 554007, Otahuhu, New Zealand|Investigational Site Number 554001, Timaru, New Zealand|Investigational Site Number 554006, Wellington, New Zealand|Investigational Site Number 604010, Lima, Peru|Investigational Site Number 604009, Lima, Peru|Investigational Site Number 604006, Lima, Peru|Investigational Site Number 604012, Lima, Peru|Investigational Site Number 604013, Lima, Peru|Investigational Site Number 604001, Lima, Peru|Investigational Site Number 604008, Lima, Peru|Investigational Site Number 604007, Lima, Peru|Investigational Site Number 604005, Lima, Peru|Investigational Site Number 604014, Lima, Peru|Investigational Site Number 616014, Bialystok, Poland|Investigational Site Number 616019, Bydgoszcz, Poland|Investigational Site Number 616015, Elblag, Poland|Investigational Site Number 616018, Poznan, Poland|Investigational Site Number 616016, Szczecin, Poland|Investigational Site Number 616004, Warszawa, Poland|Investigational Site Number 616017, Warszawa, Poland|Investigational Site Number 616020, Wroclaw, Poland|Investigational Site Number 620002, Lisboa, Portugal|Investigational Site Number 620004, Lisboa, Portugal|Investigational Site Number 620007, Ponte De Lima, Portugal|Investigational Site Number 642001, Bucuresti, Romania|Investigational Site Number 642012, Bucuresti, Romania|Investigational Site Number 642002, Bucuresti, Romania|Investigational Site Number 642014, Iasi, Romania|Investigational Site Number 643001, Moscow, Russian Federation|Investigational Site Number 643021, Moscow, Russian Federation|Investigational Site Number 643022, Novosibirsk, Russian Federation|Investigational Site Number 643008, Saint-Petersburg, Russian Federation|Investigational Site Number 643010, Samara, Russian Federation|Investigational Site Number 703001, Kosice, Slovakia|Investigational Site Number 724016, Barakaldo, Spain|Investigational Site Number 724015, Barcelona, Spain|Investigational Site Number 724014, Cadiz, Spain|Investigational Site Number 724009, La Coruña, Spain|Investigational Site Number 724001, Málaga, Spain|Investigational Site Number 724011, Sabadell, Spain|Investigational Site Number 724017, Santiago De Compostela, Spain|Investigational Site Number 724013, Santiago De Compostela, Spain|Investigational Site Number 724007, Sevilla, Spain|Investigational Site Number 158005, Kaohsiung, Taiwan|Investigational Site Number 158006, Taipei, Taiwan|Investigational Site Number 158002, Taoyuan County, Taiwan|Investigational Site Number 792007, Edirne, Turkey|Investigational Site Number 792008, Gaziantep, Turkey|Investigational Site Number 792009, Samsun, Turkey|Investigational Site Number 804013, Kharkiv, Ukraine|Investigational Site Number 804014, Kyiv, Ukraine|Investigational Site Number 804027, Kyiv, Ukraine|Investigational Site Number 804011, Vinnytsia, Ukraine|Investigational Site Number 804009, Zaporizhzhya, Ukraine","https://ClinicalTrials.gov/show/NCT01709578"
908,"Exploratory Study of XL765 (SAR245409) or XL147 (SAR245408) in Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection","Completed","No Results Available","Glioblastoma|Astrocytoma, Grade IV","Drug: XL765 (SAR245409)|Drug: XL147 (SAR245408)","Investigational Site Number 840001, Los Angeles, California, United States|Investigational Site Number 840003, San Francisco, California, United States|Investigational Site Number 840004, Boston, Massachusetts, United States|Investigational Site Number 840002, New York, New York, United States","https://ClinicalTrials.gov/show/NCT01240460"
909,"Once-Daily Investigational Nasal Spray In Adults And Adolescents With Seasonal Allergic Rhinitis (SAR)","Completed","No Results Available","Rhinitis, Allergic, Seasonal","Drug: GW685698X Aqueous Nasal Spray","GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Lafayette, Indiana, United States|GSK Investigational Site, Louisville, Kentucky, United States|GSK Investigational Site, Novi, Michigan, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Columbia, Missouri, United States|GSK Investigational Site, Rolla, Missouri, United States|GSK Investigational Site, St. Louis, Missouri, United States|GSK Investigational Site, Lincoln, Nebraska, United States|GSK Investigational Site, Papillion, Nebraska, United States|GSK Investigational Site, Canton, Ohio, United States|GSK Investigational Site, Sylvania, Ohio, United States|GSK Investigational Site, Spartanburg, South Carolina, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Greenfield, Wisconsin, United States|GSK Investigational Site, West Allis, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT00197262"
910,"A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies","Completed","No Results Available","Advanced Solid Malignancies","Drug: REGN421(SAR153192)","Aurora, Colorado, United States|Indianapolis, Indiana, United States|Boston, Massachusetts, United States|Detroit, Michigan, United States|St. Louis, Missouri, United States|New York, New York, United States|Columbus, Ohio, United States|Oklahoma City, Oklahoma, United States","https://ClinicalTrials.gov/show/NCT00871559"
911,"Long Term Outcomes of Patients With COVID-19","Recruiting","No Results Available","Critical Illness|Corona Virus Infection|Respiratory Failure|Covid-19","Other: Quality of Life|Other: Impact Event Score|Other: Hospital anxiety and depression scale","University of Chicago Medical Center, Chicago, Illinois, United States","https://ClinicalTrials.gov/show/NCT04360538"
912,"Efficacy and Safety of Levocetirizine 8 Weeks Prior and After the Onset of the Grass Pollen Season in Subjects With SAR","Completed","No Results Available","Rhinitis, Allergic, Seasonal","Drug: Levocetirizine dihydrochloride",,"https://ClinicalTrials.gov/show/NCT00521040"
913,"Prazosin to Prevent COVID-19 (PREVENT-COVID Trial)","Recruiting","No Results Available","COVID-19","Drug: Prazosin|Other: Standard of care","Johns Hopkins Hospital, Baltimore, Maryland, United States","https://ClinicalTrials.gov/show/NCT04365257"
914,"Injection Site Tolerability, Safety, Pharmacokinetics and Pharmacodynamics Study After a Single Dose Subcutaneous Treatment of Alirocumab SAR236553 (REGN727)","Completed","No Results Available","Hypercholesterolemia","Drug: alirocumab SAR236553 (REGN727)","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States","https://ClinicalTrials.gov/show/NCT01448239"
915,"Risk Factors, Clinical Characteristics and Outcomes of Acute Infection With Coronavirus 2019 (COVID-19) In Children","Recruiting","No Results Available","Corona Virus Infection|Pediatric Cancer|Adult Children|Cancer",,"St. Jude Children's Research Hospital, Memphis, Tennessee, United States","https://ClinicalTrials.gov/show/NCT04371315"
916,"Clinical Study for Efficacy of Anti-Corona VS2 Immunoglobulins Prepared From COVID19 Convalescent Plasma Prepared by VIPS Mini-Pool IVIG Medical Devices in Prevention of SARS-CoV-2 Infection in High Risk Groups as Well as Treatment of Early Cases of COVID19 Patients","Not yet recruiting","No Results Available","COVID19","Other: hyper immunoglobulins containing anti-Corona VS2 immunoglobulin",,"https://ClinicalTrials.gov/show/NCT04383548"
917,"Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)","Completed","Has Results","Hypercholesterolemia","Drug: Placebo (for alirocumab)|Drug: Alirocumab|Drug: Statin","Chandler, Arizona, United States|Goodyear, Arizona, United States|Carmichael, California, United States|Fresno, California, United States|West Hills, California, United States|Wildomar, California, United States|Colorado Springs, Colorado, United States|Golden, Colorado, United States|Boynton Beach, Florida, United States|Jacksonville, Florida, United States|Safety Harbor, Florida, United States|Atlanta, Georgia, United States|Boise, Idaho, United States|Meridian, Idaho, United States|Chicago, Illinois, United States|Gurnee, Illinois, United States|Evansville, Indiana, United States|Indianapolis, Indiana, United States|Iowa City, Iowa, United States|Kansas City, Kansas, United States|Louisville, Kentucky, United States|Monroe, Louisiana, United States|Auburn, Maine, United States|Methuen, Massachusetts, United States|Minneapolis, Minnesota, United States|St. Louis, Missouri, United States|Rochester, New York, United States|Farmville, North Carolina, United States|Greensboro, North Carolina, United States|Greenville, North Carolina, United States|Raleigh, North Carolina, United States|Wilson, North Carolina, United States|Cincinnati, Ohio, United States|Marion, Ohio, United States|Tulsa, Oklahoma, United States|Philadelphia, Pennsylvania, United States|Wyomissing, Pennsylvania, United States|Knoxville, Tennessee, United States|Dallas, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Orem, Utah, United States|Salt Lake City, Utah, United States|South Jordan, Utah, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Spokane, Washington, United States|Tacoma, Washington, United States|Kenosha, Wisconsin, United States|Sofia, Bulgaria|Varna, Bulgaria|Victoria, British Columbia, Canada|Oshawa, Ontario, Canada|Toronto, Ontario, Canada|Woodstock, Ontario, Canada|Montreal, Quebec, Canada|Trois-Rivieres, Quebec, Canada|Quebec, Canada|Budapest, Becsi ut, Hungary|Debrecen, HBM, Hungary|Nyiregyhaza, Sz-sz-b_m, Hungary|Ajka, VeszprÃ©m, Hungary|Nagykanizsa, Zala, Hungary|Zalaegerszeg, Zala, Hungary|Tel Hashomer, IL, Israel|Safed, ISR, Israel|Ofakim, South, Israel|Holon, Israel|Tel Hashomer, Israel|Skedsmokorset, Akershus, Norway|Oslo, Norway|Svidnik, Presov, Slovakia|Bratislava, SK, Slovakia|Bratislava, SR, Slovakia|Lucenec, Slovakia|PovaÅ¾skÃ¡ Bystrica, Slovakia|Worton Grange, Reading, Berkshire, United Kingdom|Edgbaston, Birmingham, United Kingdom|Llanishen, Cardiff, United Kingdom|Choley, Lancashire, United Kingdom|Waterloo, Liverpool, United Kingdom|Lloyd Street North, Manchester, United Kingdom|Glasgow, Scotland, United Kingdom","https://ClinicalTrials.gov/show/NCT01926782"
918,"Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomatic Treatment of SAR","Completed","No Results Available","Seasonal Allergic Rhinitis|Hay Fever|Allergic Conjunctivitis|Hypersensitivity","Drug: Bilastine|Drug: Placebo","Oklahoma Allergy and Asthma Clinic, Oklahoma City, Oklahoma, United States|MetaClin Research Inc., Austin, Texas, United States|Austin Clinical Research, Austin, Texas, United States|Lovelace Scientific Resources, Austin, Texas, United States|Kerrville Research Associates, Kerrville, Texas, United States|Biogenics Research Institute, San Antonio, Texas, United States|DGD Research, San Antonio, Texas, United States|Diagnostics Research Group, San Antonio, Texas, United States|Southwest Allergy and Asthma Centre, San Antonio, Texas, United States|Sylvana Research Associates, San Antonio, Texas, United States|Live Oak Allergy and Asthma, San Antonio, Texas, United States|Allergy & Asthma Care of Waco, Waco, Texas, United States|Allergy Asthma Research Institute, Waco, Texas, United States","https://ClinicalTrials.gov/show/NCT00574379"
919,"To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)","Completed","Has Results","Rheumatoid Arthritis","Drug: sarilumab SAR153191 (REGN88)|Drug: tocilizumab|Drug: hydroxychloroquine|Drug: methotrexate|Drug: sulfasalazine|Drug: leflunomide|Drug: subcutaneous placebo|Drug: intravenous placebo","Investigational Site Number 840152, Huntsville, Alabama, United States|Investigational Site Number 840151, Colorado Springs, Colorado, United States|Investigational Site Number 840153, Aventura, Florida, United States|Investigational Site Number 840033, Fort Lauderdale, Florida, United States|Investigational Site Number 840048, Miami, Florida, United States|Investigational Site Number 840155, Palm Harbor, Florida, United States|Investigational Site Number 840013, Wheaton, Maryland, United States|Investigational Site Number 840154, Boston, Massachusetts, United States|Investigational Site Number 840150, Lansing, Michigan, United States|Investigational Site Number 840062, Reading, Pennsylvania, United States|Investigational Site Number 840038, Austin, Texas, United States|Investigational Site Number 840022, Dallas, Texas, United States|Investigational Site Number 840156, Dallas, Texas, United States|Investigational Site Number 840074, Mesquite, Texas, United States|Investigational Site Number 032006, Caba, Argentina|Investigational Site Number 032010, Ramos Mejia, Argentina|Investigational Site Number 032013, Rosario, Argentina|Investigational Site Number 032015, San Fernando, Argentina|Investigational Site Number 032004, San Miguel De Tucuman, Argentina|Investigational Site Number 032005, Tucuman, Argentina|Investigational Site Number 056010, Leuven, Belgium|Investigational Site Number 076001, Curitiba, Brazil|Investigational Site Number 076030, Sao Jose Do Rio Preto, Brazil|Investigational Site Number 203009, Liberec, Czechia|Investigational Site Number 203011, Praha 2, Czechia|Investigational Site Number 203010, Praha 4, Czechia|Investigational Site Number 233010, Tallinn, Estonia|Investigational Site Number 233002, Tallinn, Estonia|Investigational Site Number 246001, Helsinki, Finland|Investigational Site Number 246010, Riihimäki, Finland|Investigational Site Number 348014, Budapest, Hungary|Investigational Site Number 348022, Budapest, Hungary|Investigational Site Number 348021, Esztergom, Hungary|Investigational Site Number 348016, Kistarcsa, Hungary|Investigational Site Number 348009, Szolnok, Hungary|Investigational Site Number 348015, Szombathely, Hungary|Investigational Site Number 376010, Haifa, Israel|Investigational Site Number 376011, Tel Aviv, Israel|Investigational Site Number 380002, Firenze, Italy|Investigational Site Number 380005, Genova, Italy|Investigational Site Number 484008, Durango, Mexico|Investigational Site Number 484035, Leon, Mexico|Investigational Site Number 484009, Merida, Mexico|Investigational Site Number 484001, México, D.F., Mexico|Investigational Site Number 484036, Zapopan, Mexico|Investigational Site Number 528010, Amsterdam, Netherlands|Investigational Site Number 528001, Leiden, Netherlands|Investigational Site Number 578010, Kristiansand, Norway|Investigational Site Number 578006, Tønsberg, Norway|Investigational Site Number 616019, Bydgoszcz, Poland|Investigational Site Number 616054, Bytom, Poland|Investigational Site Number 616030, Lublin, Poland|Investigational Site Number 616031, Warszawa, Poland|Investigational Site Number 616017, Warszawa, Poland|Investigational Site Number 642006, Braila, Romania|Investigational Site Number 642020, Bucharest, Romania|Investigational Site Number 642010, Bucharest, Romania|Investigational Site Number 642021, Bucuresti, Romania|Investigational Site Number 642001, Bucuresti, Romania|Investigational Site Number 642022, Targoviste, Romania|Investigational Site Number 643017, Kemerovo, Russian Federation|Investigational Site Number 643020, Moscow, Russian Federation|Investigational Site Number 643001, Moscow, Russian Federation|Investigational Site Number 643002, Moscow, Russian Federation|Investigational Site Number 643031, Moscow, Russian Federation|Investigational Site Number 643030, Moscow, Russian Federation|Investigational Site Number 643032, St-Petersburg, Russian Federation|Investigational Site Number 724020, Barcelona, Spain|Investigational Site Number 724021, Santander, Spain|Investigational Site Number 724022, Sevilla, Spain|Investigational Site Number 752004, Malmö, Sweden|Investigational Site Number 752002, Uppsala, Sweden|Investigational Site Number 826004, Doncaster, United Kingdom|Investigational Site Number 826006, Edinburgh, United Kingdom|Investigational Site Number 826001, Leeds, United Kingdom|Investigational Site Number 826002, London, United Kingdom|Investigational Site Number 826005, Southampton, United Kingdom|Investigational Site Number 826025, Wigan, United Kingdom","https://ClinicalTrials.gov/show/NCT01768572"
920,"Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD)","Completed","Has Results","Atopic Dermatitis","Drug: Dupilumab|Drug: Placebo (for Dupilumab)|Other: Topical Corticosteroid (TCS)","Berlin, Germany|Dresden, Germany|Duelmen, Germany|Frankfurt, Germany|Gera, Germany|Langenau, Germany|Munster, Germany|Szeged-Hungary, Hungary|Szolnok, Hungary|Gdansk, Poland|Lodz, Poland|Lublin, Poland|Warszawa, Poland","https://ClinicalTrials.gov/show/NCT01639040"
921,"Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR)","Completed","Has Results","Allergic Conjunctivitis","Drug: Olopatadine 0.1%|Drug: Tranilast 0.5%|Drug: Placebo (Olopatadine)|Drug: Placebo (Tranilast)",,"https://ClinicalTrials.gov/show/NCT00818805"
922,"A Safety and Bioequivalence of a Mometasone Nasal Spray, 50 Mcg/Actuation Compared With Nasonex® Nasal Spray 50 Mcg/Actuation in the Relief of the Symptoms of Seasonal Allergic Rhinitis (SAR)","Completed","No Results Available","Seasonal Allergic Rhinitis","Drug: Mometasone furoate|Drug: Nasonex Nasal Spray|Drug: Placebo nasal spray","San Antonio, Texas, United States","https://ClinicalTrials.gov/show/NCT01673659"
923,"COVID-19 Health Messaging Efficacy and Its Impact on Public Perception, Anxiety, and Behavior","Recruiting","No Results Available","Public Health|Demography|Pandemics|Corona Virus Infection|News|Global Health|Perception",,"Penn State College of Medicine, Hershey, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT04377581"
924,"COG-UK Project Hospital-Onset COVID-19 Infections Study","Not yet recruiting","No Results Available","Covid-19|Nosocomial Infection|Coronavirus|Coronavirus Infection|SARS-CoV 2","Other: Use of virus (Covid-19) genome sequence report to inform infection prevention control procedures",,"https://ClinicalTrials.gov/show/NCT04405934"
925,"Clinical Use of Stem Cells for the Treatment of Covid-19","Recruiting","No Results Available","Covid19|Pneumonia|Multiple Organ Failure|Corona Virus Infection","Biological: MSC Treatment|Biological: Saline Control","Istinye University, Istanbul, Turkey|SBÜ Dr. Sadi Konuk Eğitim ve Araştırma Hastanesi, Istanbul, Turkey","https://ClinicalTrials.gov/show/NCT04392778"
926,"Covid-19 and Diabetes in West of Algeria","Recruiting","No Results Available","Coronavirus Infections|Diabetes Mellitus|Prevalence|Risk Factors|Patient Outcome Assessment|Severe Acute Respiratory Syndrome","Drug: MANAGEMENT OF COVID-19","Department of Internal Medicine, Acedemic Hospital of Tlemcen, Tlemcen, Algeria","https://ClinicalTrials.gov/show/NCT04412746"
927,"USZ BioResource COVID","Recruiting","No Results Available","COVID19","Other: blood sampling for biobank","University Hospital Zurich, Clinical Trials Center, Zurich, Switzerland","https://ClinicalTrials.gov/show/NCT04414657"
928,"COVID-19 Pandemic and Female Sexual Behavior","Completed","No Results Available","Sexual Behavior|COVID","Behavioral: fsfi survey","Haseki Training and Research Hospital, Istanbul, Turkey","https://ClinicalTrials.gov/show/NCT04374422"
929,"Investigating a Vaccine Against COVID-19","Not yet recruiting","No Results Available","Coronavirus","Biological: ChAdOx1 nCoV-19|Biological: MenACWY vaccine|Biological: ChAdOx1 nCoV-19 + boost|Biological: MenACWY vaccine + boost|Biological: ChAdox1 n-CoV vaccine low dose","University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, United Kingdom|St Georges University Hospital NHS Foundation Trust, London, Tooting, United Kingdom|University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom|University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom|North Bristol NHS Trust, Bristol, United Kingdom|NIHR Cambridge Clinical Research Facility, Cambridge, United Kingdom|Public Health Wales, Cardiff, United Kingdom|Castle Hill Hospital, Cottingham, United Kingdom|NHS Lothian, Western General Hospital, Edinburgh, United Kingdom|Glasgow University and NHS Greater Glasgow & Clyde, New Lister Building, Glasgow Royal Infirmary & Queen Elizabeth University Hospital, Glasgow, United Kingdom|Liverpool School of Tropical Medicine (LSTM), Accelerator Research Clinic. Clinical Sciences Accelerator, LIverpool, United Kingdom|London North West University Healthcare Trust (LNWUH), Northwick Park Hospital, London, United Kingdom|University College London Hospitals NHS Foundation Trust, London, United Kingdom|Guy's and St Thomas' NHS Foundation Trust, Department of Infection, St Thomas Hospital, London, United Kingdom|Imperial College Healthcare NHS Trust, London, United Kingdom|The Newcastle upon Tyne Hospitals NHS Foundation Trust, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom|University of Nottingham Health Service, Cripps Health Centre, University Park, Nottingham, United Kingdom|CCVTM, University of Oxford, Churchill Hospital, Oxford, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom|Sheffield Teaching Hospitals, Royal Hallamshire Hospital, Sheffield, United Kingdom","https://ClinicalTrials.gov/show/NCT04400838"
930,"Expanded Access Remdesivir (RDV; GS-5734™)","Available","No Results Available","Coronavirus Disease 2019","Drug: Remdesivir",,"https://ClinicalTrials.gov/show/NCT04302766"
931,"Asymptomatic COVID-19 Infection Among Healthcare Workers","Recruiting","No Results Available","Immunologic Activity Alteration","Diagnostic Test: Serum SARs COV 2 IGg screening in health care workers","Cairo University Hospital, Cairo, Egypt","https://ClinicalTrials.gov/show/NCT04354792"
932,"Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation","Recruiting","No Results Available","Coronavirus|COVID-19|SARS-CoV Infection|Respiratory Failure|Cytokine Storm","Device: vv-ECMO + cytokine adsorption (Cytosorb adsorber)|Device: vv-ECMO only (no cytokine adsorption)","University Clinic Freiburg, Freiburg, Germany","https://ClinicalTrials.gov/show/NCT04324528"
933,"Viral Specific T-cells for Treatment of COVID-19","Not yet recruiting","No Results Available","Viral Infection","Biological: Viral Specific T-cells (VSTs)","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States","https://ClinicalTrials.gov/show/NCT04406064"
934,"Acute Encephalopathy in Critically Ill Patients With COVID-19","Recruiting","No Results Available","COVID-19|Encephalopathy|Critically Ill","Other: Follow up","Jackson Memorial Health System; University of Miami, Miller School of Medicine, Miami, Florida, United States|Universidade Federal de São Paulo, São Paulo, Brazil|Fundación Valle del Lili, University Hospital, Cali, Colombia|Centre Hospitalier d'Argenteuil, Argenteuil, France|Centre Hospitalier de Beauvais, Beauvais, France|Centre Hospitalier Universitaire Ambroise Paré, Boulogne, France|Centre Hospitalier de Bourg en Bresse, Bourg-en-Bresse, France|Centre Hospitalier Régional Universitaire de Brest, Brest, France|Centre Hospitalier de Brives, Brive-la-Gaillarde, France|Centre Hospitalier Universitaire Beaujon, Clichy, France|Centre Hospitalier Universitaire Louis Mourier, Colombes, France|Centre Hospitalier Universitaire Henri Mondor, Créteil, France|Centre hospitalier de Dieppe, Dieppe, France|Centre Hospitalier Universitaire de Dijon, Dijon, France|Centre Hospitalier d'Etampes, Etampes, France|Grand Hôpital de l'Est Francilien - Site de Marne-la-Vallée, Jossigny, France|Centre Hospitalier de la Roche-sur-Yon, La Roche-sur-Yon, France|Centre Hospitalier de La Rochelle, La Rochelle, France|Centre Hospitalier de Versailles, Le Chesnay, France|Centre Hospitalier Universitaire de Lille, Lille, France|Centre Hospitalier Universitaire Hôpital Edouard Herriot, Lyon, France|Hôpital privé Jacques Cartier, Massy, France|Groupe Hospitalier Sud Ile-de-France, Melun, France|Centre Hospitalier Universitaire de Nantes, Nantes, France|Centre Hospitalier Régional d'Orléans, Orléans, France|Centre Hospitalier Universitaire Cochin, Paris, France|Groupe hospitalier Paris Saint-Joseph, Paris, France|Hôpital Fondation Adolphe de Rothschild, Paris, France|Hopital Privé Claude Galien, Quincy-sous-Sénart, France|Centre Hospitalier Universitaire de Rennes, Rennes, France|Centre Hospitalier de Roanne, Roanne, France|Hopital Foch, Suresnes, France|Centre Hospitalier de Toulon, Toulon, France|Centre Hospitalier Universitaire de Toulouse, Toulouse, France|Centre Hospitalier Universitaire de Tours, Tours, France|Gustave-Roussy, Villejuif, France|Hospital Clinic Universitari, Valencia, Spain","https://ClinicalTrials.gov/show/NCT04320472"
935,"COVID-19 Surveillance of Patients and Healthcare Workers in a Hospital Department","Enrolling by invitation","No Results Available","COVID-19","Diagnostic Test: COVID-19 test, polymerase chain reaction for SARS-CoV-2","Rigshospitalet University Hospital of Copenhagen, Copenhagen, Denmark","https://ClinicalTrials.gov/show/NCT04356560"
936,"COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1","Not yet recruiting","No Results Available","COVID-19|SARS-CoV-2|2019-nCoV|Pneumonia, Viral","Drug: Nivolumab",,"https://ClinicalTrials.gov/show/NCT04356508"
937,"The Critical Care Response to the COVID-19 Pandemic in Madrid","Recruiting","No Results Available","COVID-19|ARDS, Human",,"Hospital Clinico San Carlos, Madrid, Spain","https://ClinicalTrials.gov/show/NCT04393324"
938,"Mechanisms of Multi-organ Failure in COVID-19","Not yet recruiting","No Results Available","COVID","Other: no intervention-mechanistic study","Imperial College NHS Trust, London, United Kingdom","https://ClinicalTrials.gov/show/NCT04399603"
939,"Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation","Not yet recruiting","No Results Available","Coronavirus Infection|COVID|SARS-CoV 2|Respiratory Failure|Cytokine Storm|Extracorporeal Membrane Oxygenation","Device: vv-ECMO + cytokine adsorption (Cytosorb adsorber)|Device: vv-ECMO only (no cytokine adsorption)","University Clinic Freiburg, Freiburg, Germany","https://ClinicalTrials.gov/show/NCT04385771"
940,"Prognosis of Coronavirus Disease 2019 (COVID-19) Patients Receiving Receiving Antihypertensives","Recruiting","No Results Available","COVID-19","Drug: Angiotensin-Converting Enzyme Inhibitors (ACE-I) and Angiotensin II Receptor Blockers (ARB)","King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia","https://ClinicalTrials.gov/show/NCT04357535"
941,"Role of Children in Transmission of COVID-19 to Immunocompromised Patients","Not yet recruiting","No Results Available","Immunosuppression",,,"https://ClinicalTrials.gov/show/NCT04407546"
942,"Mesenchymal Stem Cells (MSCs) in Inflammation-Resolution Programs of Coronavirus Disease 2019 (COVID-19) Induced Acute Respiratory Distress Syndrome (ARDS)","Not yet recruiting","No Results Available","ARDS|COVID-19","Biological: MSC","University Hospital Tuebingen, Tuebingen, Germany","https://ClinicalTrials.gov/show/NCT04377334"
943,"Testing the Accuracy of a Digital Test to Diagnose Covid-19","Not yet recruiting","No Results Available","Covid-19","Diagnostic Test: Covid-19 swab PCR test","King's College London, London, United Kingdom","https://ClinicalTrials.gov/show/NCT04407585"
944,"COVID-EC Study: Clinical Characteristics of Patients With COVID-19 in Guayaquil, Ecuador","Not yet recruiting","No Results Available","COVID",,"GastroMuñoz, Guayaquil, Guayas, Ecuador","https://ClinicalTrials.gov/show/NCT04362969"
945,"Validation of COVID-19 Tests","Active, not recruiting","No Results Available","COVID-19","Diagnostic Test: Covid-19 Rapid Test Kit (RAPG-COV-019)|Diagnostic Test: Quantitative IgG Test","Richmond Pharmacology Ltd. 1a Newcomen St, London Bridge, London, United Kingdom","https://ClinicalTrials.gov/show/NCT04404062"
946,"Tofacitinib for Treatment of Moderate COVID-19","Not yet recruiting","No Results Available","COVID-19","Drug: Tofacitinib 10 mg|Drug: Placebo",,"https://ClinicalTrials.gov/show/NCT04415151"
947,"Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to COVID-19","Not yet recruiting","No Results Available","COVID","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Facultad de Medicina - Universidad Nacional de Colombia, Bogota, Cundinamarca, Colombia|Universidad Nacional de Colombia, Bogota, Cundinamarca, Colombia","https://ClinicalTrials.gov/show/NCT04346329"
948,"Individual Patient Compassionate Use of Fedratinib","Available","No Results Available","Myelofibrosis","Drug: Oral Fedratinib","Celgene, Summit, New Jersey, United States","https://ClinicalTrials.gov/show/NCT03723148"
949,"S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis","Active, not recruiting","No Results Available","Amorphous, Eosinophilic, and Acellular Deposit|Constipation|Diarrhea|Early Satiety|Gastrointestinal Hemorrhage|Hepatomegaly|Lymphadenopathy|Macroglossia|Nausea|Primary Systemic Amyloidosis|Purpura|Recurrent Primary Amyloidosis|Refractory Primary Amyloidosis","Biological: Isatuximab|Other: Laboratory Biomarker Analysis","Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States|Anchorage Radiation Therapy Center, Anchorage, Alaska, United States|Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States|Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States|Alaska Women's Cancer Care, Anchorage, Alaska, United States|Anchorage Oncology Centre, Anchorage, Alaska, United States|Katmai Oncology Group, Anchorage, Alaska, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|CHI Saint Vincent Cancer Center Hot Springs, Hot Springs, Arkansas, United States|Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States|Fremont - Rideout Cancer Center, Marysville, California, United States|UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|Rocky Mountain Cancer Centers-Aurora, Aurora, Colorado, United States|The Medical Center of Aurora, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|Boulder Community Hospital, Boulder, Colorado, United States|Rocky Mountain Cancer Centers-Boulder, Boulder, Colorado, United States|Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States|Rocky Mountain Cancer Centers-Penrose, Colorado Springs, Colorado, United States|Denver Health Medical Center, Denver, Colorado, United States|National Jewish Health-Main Campus, Denver, Colorado, United States|The Women's Imaging Center, Denver, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States|Rocky Mountain Cancer Centers-Midtown, Denver, Colorado, United States|SCL Health Saint Joseph Hospital, Denver, Colorado, United States|Rocky Mountain Cancer Centers-Rose, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|Western Surgical Care, Denver, Colorado, United States|Mercy Medical Center, Durango, Colorado, United States|Southwest Oncology PC, Durango, Colorado, United States|Comprehensive Cancer Care and Research Institute of Colorado LLC, Englewood, Colorado, United States|Swedish Medical Center, Englewood, Colorado, United States|Poudre Valley Hospital, Fort Collins, Colorado, United States|Mountain Blue Cancer Care Center, Golden, Colorado, United States|National Jewish Health-Western Hematology Oncology, Golden, Colorado, United States|Saint Mary's Hospital and Regional Medical Center, Grand Junction, Colorado, United States|North Colorado Medical Center, Greeley, Colorado, United States|Good Samaritan Medical Center, Lafayette, Colorado, United States|Rocky Mountain Cancer Centers-Lakewood, Lakewood, Colorado, United States|Saint Anthony Hospital, Lakewood, Colorado, United States|Rocky Mountain Cancer Centers-Littleton, Littleton, Colorado, United States|Littleton Adventist Hospital, Littleton, Colorado, United States|Rocky Mountain Cancer Centers-Sky Ridge, Lone Tree, Colorado, United States|Sky Ridge Medical Center, Lone Tree, Colorado, United States|Longmont United Hospital, Longmont, Colorado, United States|Rocky Mountain Cancer Centers-Longmont, Longmont, Colorado, United States|McKee Medical Center, Loveland, Colorado, United States|Parker Adventist Hospital, Parker, Colorado, United States|Rocky Mountain Cancer Centers-Parker, Parker, Colorado, United States|Saint Mary Corwin Medical Center, Pueblo, Colorado, United States|Rocky Mountain Cancer Centers - Pueblo, Pueblo, Colorado, United States|National Jewish Health-Northern Hematology Oncology, Thornton, Colorado, United States|Rocky Mountain Cancer Centers-Thornton, Thornton, Colorado, United States|SCL Health Lutheran Medical Center, Wheat Ridge, Colorado, United States|Smilow Cancer Hospital-Derby Care Center, Derby, Connecticut, United States|Smilow Cancer Hospital Care Center-Fairfield, Fairfield, Connecticut, United States|Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States|Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Yale-New Haven Hospital North Haven Medical Center, North Haven, Connecticut, United States|Smilow Cancer Hospital-Orange Care Center, Orange, Connecticut, United States|Smilow Cancer Hospital-Torrington Care Center, Torrington, Connecticut, United States|Smilow Cancer Hospital Care Center-Trumbull, Trumbull, Connecticut, United States|Smilow Cancer Hospital-Waterbury Care Center, Waterbury, Connecticut, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Cleveland Clinic-Weston, Weston, Florida, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States|Saint Alphonsus Cancer Care Center-Caldwell, Caldwell, Idaho, United States|Kootenai Medical Center, Coeur d'Alene, Idaho, United States|Walter Knox Memorial Hospital, Emmett, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Fruitland, Fruitland, Idaho, United States|Idaho Urologic Institute-Meridian, Meridian, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Meridian, Meridian, Idaho, United States|Saint Alphonsus Medical Center-Nampa, Nampa, Idaho, United States|Saint Luke's Mountain States Tumor Institute - Nampa, Nampa, Idaho, United States|Kootenai Cancer Center, Post Falls, Idaho, United States|Kootenai Cancer Clinic, Sandpoint, Idaho, United States|Saint Luke's Mountain States Tumor Institute-Twin Falls, Twin Falls, Idaho, United States|Rush - Copley Medical Center, Aurora, Illinois, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Memorial Hospital of Carbondale, Carbondale, Illinois, United States|SIH Cancer Institute, Carterville, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Centralia Oncology Clinic, Centralia, Illinois, United States|Carle on Vermilion, Danville, Illinois, United States|Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Carle Physician Group-Effingham, Effingham, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|Illinois CancerCare-Galesburg, Galesburg, Illinois, United States|Western Illinois Cancer Treatment Center, Galesburg, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Marjorie Weinberg Cancer Center at Loyola-Gottlieb, Melrose Park, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Valley Radiation Oncology, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Cancer Care Specialists of Illinois-Swansea, Swansea, Illinois, United States|Southwest Illinois Health Services LLP, Swansea, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|The Carle Foundation Hospital, Urbana, Illinois, United States|Rush-Copley Healthcare Center, Yorkville, Illinois, United States|Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States|Mercy Cancer Center-West Lakes, Clive, Iowa, United States|Alegent Health Mercy Hospital, Council Bluffs, Iowa, United States|Greater Regional Medical Center, Creston, Iowa, United States|Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|Mercy Medical Center-West Lakes, West Des Moines, Iowa, United States|Central Care Cancer Center - Garden City, Garden City, Kansas, United States|Central Care Cancer Center - Great Bend, Great Bend, Kansas, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Kansas Institute of Medicine Cancer and Blood Center, Lenexa, Kansas, United States|Minimally Invasive Surgery Hospital, Lenexa, Kansas, United States|Menorah Medical Center, Overland Park, Kansas, United States|Saint Luke's South Hospital, Overland Park, Kansas, United States|Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, Kansas, United States|Cancer Center of Kansas - Wichita, Wichita, Kansas, United States|Flaget Memorial Hospital, Bardstown, Kentucky, United States|Commonwealth Cancer Center-Corbin, Corbin, Kentucky, United States|Saint Joseph Radiation Oncology Resource Center, Lexington, Kentucky, United States|Saint Joseph Hospital East, Lexington, Kentucky, United States|Saint Joseph London, London, Kentucky, United States|Jewish Hospital, Louisville, Kentucky, United States|Saints Mary and Elizabeth Hospital, Louisville, Kentucky, United States|Jewish Hospital Medical Center Northeast, Louisville, Kentucky, United States|Jewish Hospital Medical Center South, Shepherdsville, Kentucky, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|Harold Alfond Center for Cancer Care, Augusta, Maine, United States|Eastern Maine Medical Center, Bangor, Maine, United States|Waldo County General Hospital, Belfast, Maine, United States|MaineHealth/SMHC Cancer Care and Blood Disorders-Biddeford, Biddeford, Maine, United States|Lafayette Family Cancer Center-EMMC, Brewer, Maine, United States|Stephens Memorial Hospital, Norway, Maine, United States|MaineHealth/SMHC Cancer Care and Blood Disorders-Sanford, Sanford, Maine, United States|Boston Medical Center, Boston, Massachusetts, United States|Mercy Medical Center, Springfield, Massachusetts, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|IHA Hematology Oncology Consultants-Brighton, Brighton, Michigan, United States|Saint Joseph Mercy Brighton, Brighton, Michigan, United States|IHA Hematology Oncology Consultants-Canton, Canton, Michigan, United States|Saint Joseph Mercy Canton, Canton, Michigan, United States|Caro Cancer Center, Caro, Michigan, United States|IHA Hematology Oncology Consultants-Chelsea, Chelsea, Michigan, United States|Saint Joseph Mercy Chelsea, Chelsea, Michigan, United States|Hematology Oncology Consultants-Clarkston, Clarkston, Michigan, United States|Newland Medical Associates-Clarkston, Clarkston, Michigan, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States|Ascension Saint John Hospital, Detroit, Michigan, United States|Great Lakes Cancer Management Specialists-Doctors Park, East China Township, Michigan, United States|Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States|Genesee Cancer and Blood Disease Treatment Center, Flint, Michigan, United States|Genesee Hematology Oncology PC, Flint, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Academic Hematology Oncology Specialists, Grosse Pointe Woods, Michigan, United States|Great Lakes Cancer Management Specialists-Van Elslander Cancer Center, Grosse Pointe Woods, Michigan, United States|Michigan Breast Specialists-Grosse Pointe Woods, Grosse Pointe Woods, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|Hope Cancer Clinic, Livonia, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|Great Lakes Cancer Management Specialists-Macomb Medical Campus, Macomb, Michigan, United States|Michigan Breast Specialists-Macomb Township, Macomb, Michigan, United States|Saint Mary's Oncology/Hematology Associates of Marlette, Marlette, Michigan, United States|21st Century Oncology-Pontiac, Pontiac, Michigan, United States|Hope Cancer Center, Pontiac, Michigan, United States|Newland Medical Associates-Pontiac, Pontiac, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|Great Lakes Cancer Management Specialists-Rochester Hills, Rochester Hills, Michigan, United States|Ascension Saint Mary's Hospital, Saginaw, Michigan, United States|Oncology Hematology Associates of Saginaw Valley PC, Saginaw, Michigan, United States|Bhadresh Nayak MD PC-Sterling Heights, Sterling Heights, Michigan, United States|Ascension Saint Joseph Hospital, Tawas City, Michigan, United States|Advanced Breast Care Center PLLC, Warren, Michigan, United States|Great Lakes Cancer Management Specialists-Macomb Professional Building, Warren, Michigan, United States|Macomb Hematology Oncology PC, Warren, Michigan, United States|Michigan Breast Specialists-Warren, Warren, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Saint Mary's Oncology/Hematology Associates of West Branch, West Branch, Michigan, United States|Huron Gastroenterology PC, Ypsilanti, Michigan, United States|IHA Hematology Oncology Consultants-Ann Arbor, Ypsilanti, Michigan, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Cambridge Medical Center, Cambridge, Minnesota, United States|Mercy Hospital, Coon Rapids, Minnesota, United States|Fairview-Southdale Hospital, Edina, Minnesota, United States|Unity Hospital, Fridley, Minnesota, United States|Fairview Maple Grove Medical Center, Maple Grove, Minnesota, United States|Minnesota Oncology Hematology PA-Maplewood, Maplewood, Minnesota, United States|Saint John's Hospital - Healtheast, Maplewood, Minnesota, United States|Abbott-Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Health Partners Inc, Minneapolis, Minnesota, United States|Monticello Cancer Center, Monticello, Minnesota, United States|New Ulm Medical Center, New Ulm, Minnesota, United States|Fairview Northland Medical Center, Princeton, Minnesota, United States|North Memorial Medical Health Center, Robbinsdale, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Saint Francis Regional Medical Center, Shakopee, Minnesota, United States|Lakeview Hospital, Stillwater, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Rice Memorial Hospital, Willmar, Minnesota, United States|Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States|Fairview Lakes Medical Center, Wyoming, Minnesota, United States|Central Care Cancer Center - Bolivar, Bolivar, Missouri, United States|Parkland Health Center-Bonne Terre, Bonne Terre, Missouri, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Southeast Cancer Center, Cape Girardeau, Missouri, United States|Centerpoint Medical Center LLC, Independence, Missouri, United States|Capital Region Southwest Campus, Jefferson City, Missouri, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|Saint Luke's East - Lee's Summit, Lee's Summit, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Siteman Cancer Center-South County, Saint Louis, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri, United States|Missouri Baptist Sullivan Hospital, Sullivan, Missouri, United States|Missouri Baptist Outpatient Center-Sunset Hills, Sunset Hills, Missouri, United States|Community Hospital of Anaconda, Anaconda, Montana, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Saint Vincent Healthcare, Billings, Montana, United States|Saint Vincent Frontier Cancer Center, Billings, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Saint James Community Hospital and Cancer Treatment Center, Butte, Montana, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|Great Falls Clinic, Great Falls, Montana, United States|Saint Peter's Community Hospital, Helena, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Saint Patrick Hospital - Community Hospital, Missoula, Montana, United States|Community Medical Hospital, Missoula, Montana, United States|CHI Health Saint Francis, Grand Island, Nebraska, United States|Heartland Hematology and Oncology, Kearney, Nebraska, United States|CHI Health Good Samaritan, Kearney, Nebraska, United States|Saint Elizabeth Regional Medical Center, Lincoln, Nebraska, United States|Alegent Health Immanuel Medical Center, Omaha, Nebraska, United States|Hematology and Oncology Consultants PC, Omaha, Nebraska, United States|Alegent Health Bergan Mercy Medical Center, Omaha, Nebraska, United States|Alegent Health Lakeside Hospital, Omaha, Nebraska, United States|Creighton University Medical Center, Omaha, Nebraska, United States|Midlands Community Hospital, Papillion, Nebraska, United States|Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina, United States|Southeastern Medical Oncology Center-Clinton, Clinton, North Carolina, United States|Southeastern Medical Oncology Center-Goldsboro, Goldsboro, North Carolina, United States|Wayne Memorial Hospital, Goldsboro, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|Onslow Memorial Hospital, Jacksonville, North Carolina, United States|Southeastern Medical Oncology Center-Jacksonville, Jacksonville, North Carolina, United States|Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio, United States|Bethesda North Hospital, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Westside, Cincinnati, Ohio, United States|TriHealth Cancer Institute-Anderson, Cincinnati, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Saint Alphonsus Medical Center-Baker City, Baker City, Oregon, United States|Saint Charles Health System, Bend, Oregon, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Providence Oncology and Hematology Care Southeast, Clackamas, Oregon, United States|Bay Area Hospital, Coos Bay, Oregon, United States|Providence Newberg Medical Center, Newberg, Oregon, United States|Saint Alphonsus Medical Center-Ontario, Ontario, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|Kaiser Permanente Northwest, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Saint Charles Health System-Redmond, Redmond, Oregon, United States|Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania, United States|Lehigh Valley Hospital - Muhlenberg, Bethlehem, Pennsylvania, United States|Pocono Medical Center, East Stroudsburg, Pennsylvania, United States|Lehigh Valley Hospital-Hazleton, Hazleton, Pennsylvania, United States|Memorial Hospital, Chattanooga, Tennessee, United States|Pulmonary Medicine Center of Chattanooga-Hixson, Hixson, Tennessee, United States|Memorial GYN Plus, Ooltewah, Tennessee, United States|Saint Joseph Regional Cancer Center, Bryan, Texas, United States|Providence Regional Cancer System-Aberdeen, Aberdeen, Washington, United States|PeaceHealth Saint Joseph Medical Center, Bellingham, Washington, United States|Harrison HealthPartners Hematology and Oncology-Bremerton, Bremerton, Washington, United States|Harrison Medical Center, Bremerton, Washington, United States|Highline Medical Center-Main Campus, Burien, Washington, United States|Providence Regional Cancer System-Centralia, Centralia, Washington, United States|Swedish Cancer Institute-Edmonds, Edmonds, Washington, United States|Saint Elizabeth Hospital, Enumclaw, Washington, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Saint Francis Hospital, Federal Way, Washington, United States|Swedish Cancer Institute-Issaquah, Issaquah, Washington, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States|Providence Regional Cancer System-Lacey, Lacey, Washington, United States|Saint Clare Hospital, Lakewood, Washington, United States|PeaceHealth Saint John Medical Center, Longview, Washington, United States|Harrison HealthPartners Hematology and Oncology-Poulsbo, Poulsbo, Washington, United States|Pacific Gynecology Specialists, Seattle, Washington, United States|Swedish Medical Center-Ballard Campus, Seattle, Washington, United States|Kaiser Permanente Washington, Seattle, Washington, United States|Swedish Medical Center-First Hill, Seattle, Washington, United States|Swedish Medical Center-Cherry Hill, Seattle, Washington, United States|PeaceHealth United General Medical Center, Sedro-Woolley, Washington, United States|Providence Regional Cancer System-Shelton, Shelton, Washington, United States|Franciscan Research Center-Northwest Medical Plaza, Tacoma, Washington, United States|Northwest Medical Specialties PLLC, Tacoma, Washington, United States|PeaceHealth Southwest Medical Center, Vancouver, Washington, United States|Providence Saint Mary Regional Cancer Center, Walla Walla, Washington, United States|Providence Regional Cancer System-Yelm, Yelm, Washington, United States|United Hospital Center, Bridgeport, West Virginia, United States|WVUH-Berkely Medical Center, Martinsburg, West Virginia, United States|West Virginia University Healthcare, Morgantown, West Virginia, United States|Camden Clark Medical Center, Parkersburg, West Virginia, United States|Marshfield Medical Center-EC Cancer Center, Eau Claire, Wisconsin, United States|Marshfield Medical Center-Marshfield, Marshfield, Wisconsin, United States|Marshfield Clinic-Minocqua Center, Minocqua, Wisconsin, United States|Cancer Center of Western Wisconsin, New Richmond, Wisconsin, United States|Marshfield Medical Center-Rice Lake, Rice Lake, Wisconsin, United States|Marshfield Clinic Stevens Point Center, Stevens Point, Wisconsin, United States|Marshfield Clinic - Weston Center, Weston, Wisconsin, United States|Cheyenne Regional Medical Center-West, Cheyenne, Wyoming, United States|Billings Clinic-Cody, Cody, Wyoming, United States|Welch Cancer Center, Sheridan, Wyoming, United States","https://ClinicalTrials.gov/show/NCT03499808"
950,"Epidemiological Characteristics of COVID-19 in Patients With MS or NMO","Recruiting","No Results Available","Multiple Sclerosis|NMO Spectrum Disorder|COVID-19","Other: Evaluation of the epidemiological characteristics of coronavirus infection (SARS-CoV-2)","Hôpital Pitié Salpétrière, Paris, France","https://ClinicalTrials.gov/show/NCT04355611"
951,"International Lung UltraSound Analysis (ILUSA) Study","Recruiting","No Results Available","COVID|Pregnancy Complications, Infectious|Pregnancy Related|Pregnancy, High Risk|Pregnancy Disease|Pneumonia|Pneumonia, Viral|Diagnoses Disease","Diagnostic Test: standardized Lung Ultrasound (LUS) examination","University Hospitals Leuven, Leuven, Belgium|University of Brescia, Brescia, Italy|University of Foggia, Foggia, Italy|University of Milan, Milan, Italy|University of Parma, Parma, Italy|Fondazione Policlinico Universitario A. Gemelli, Roma, Italy|Queen Charlotte's & Chelsea Hospital, London, United Kingdom","https://ClinicalTrials.gov/show/NCT04353141"
952,"COVID-19 Pneumonitis Low Dose Lung Radiotherapy (COLOR-19)","Recruiting","No Results Available","COVID-19","Radiation: Single fraction whole lung radiotherapy","Radiation Oncology Department, ASST SpedaliCivili, Brescia, Brescia, Italy","https://ClinicalTrials.gov/show/NCT04377477"
953,"Comparison of the ID NOW and Accula Point-of-Care Assays for Detection of COVID-19","Recruiting","No Results Available","Covid-19","Diagnostic Test: ID NOW vs. Accula","Ascension St. John Hospital, Detroit, Michigan, United States","https://ClinicalTrials.gov/show/NCT04403035"
954,"The GCO-002 CACOVID-19 Cohort: a French Nationwide Multicenter Study of COVID-19 Infected Cancer Patients","Recruiting","No Results Available","Cancer|COVID|Solid Tumor|Social Inequality|French National Cohort|Chemotherapy|Immunotherapy|Surgery|Radiotherapy",,"Ch D'Abbeville, Abbeville, France|CHU - Hôtel Dieu, Angers, France|CH Victor Dupouy, Argenteuil, France|AP - HP - Pitié Salpêtrière, Paris, France|Bichat, Paris, France|Centre Hospitalier Universitaire, Reims, France","https://ClinicalTrials.gov/show/NCT04397575"
955,"Isatuximab in Treating Patients With High Risk Smoldering Plasma Cell Myeloma","Active, not recruiting","No Results Available","Smoldering Plasma Cell Myeloma","Biological: Isatuximab|Other: Laboratory Biomarker Analysis","Mount Sinai Hospital, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|M D Anderson Cancer Center, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT02960555"
956,"The Role of a Private Hospital in Hong Kong Amid COVID-19 Pandemic","Active, not recruiting","No Results Available","COVID","Diagnostic Test: COVID 19 Diagnostic Test","Hong Kong Sanatorium & Hospital, Hong Kong, Hong Kong","https://ClinicalTrials.gov/show/NCT04416061"
957,"Tocilizumab for Patients With Cancer and COVID-19 Disease","Recruiting","No Results Available","Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm|Pneumonia|Pneumonitis|Severe Acute Respiratory Distress Syndrome|Symptomatic COVID-19 Infection Laboratory-Confirmed","Biological: Tocilizumab","National Cancer Institute, Rockville, Maryland, United States","https://ClinicalTrials.gov/show/NCT04370834"
958,"Hydroxychloroquine and Lopinavir/ Ritonavir to Improve the Health of People With COVID-19: ""The Hope Coalition - 1""","Recruiting","No Results Available","COVID-19|Coronavirus Infection|Virus Disease|Acute Respiratory Infection|SARS-CoV Infection","Drug: Hydroxychloroquine Sulfate Tablets|Drug: Lopinavir/ Ritonavir Oral Tablet|Drug: Hydroxychloroquine Sulfate Tablets plus Lopinavir/ Ritonavir Oral Tablets|Drug: Placebo","CARDRESEARCH - Cardiologia Assistencial e de Pesquisa, Belo Horizonte, Minas Gerais, Brazil|Pontificia Universidade Catolica de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil|Fundo Municipal de Saúde de Betim, Betim, Minas Gerais, Brazil|Universidade Federal de Ouro Preto, Ouro Preto, Minas Gerais, Brazil","https://ClinicalTrials.gov/show/NCT04403100"
959,"Colchicine Twice Daily During 10 Days as an Option for the Treatment of Symptoms Induced by Inflammation in Patients With Mild and Severe Coronavirus Disease","Recruiting","No Results Available","COVID","Drug: Colchicine|Drug: Placebo oral tablet","Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico","https://ClinicalTrials.gov/show/NCT04367168"
960,"MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer","Active, not recruiting","No Results Available","Recurrent Non-Small Cell Lung Carcinoma|Stage IV Non-Small Cell Lung Cancer","Drug: Anti-PD-L1 Monoclonal Antibody MPDL3280A|Radiation: Stereotactic Body Radiation Therapy","University of California Davis, Sacramento, California, United States","https://ClinicalTrials.gov/show/NCT02400814"
961,"Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers","Active, not recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine","Baylor University Medical Center, Dallas, Texas, United States","https://ClinicalTrials.gov/show/NCT04333225"
962,"Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in COVID-19 Patients With a Systemic Inflammatory Response Syndrome","Recruiting","No Results Available","COVID-19","Diagnostic Test: Cytokines dosage|Diagnostic Test: Complement dosage","CHU Brugmann, Brussels, Belgium","https://ClinicalTrials.gov/show/NCT04346017"
963,"Safety, Pharmacokinetics, and Preliminary Efficacy of Isatuximab in Patients Awaiting Kidney Transplantation","Recruiting","No Results Available","Immune System Disorder","Drug: Isatuximab SAR650984|Drug: Acetaminophen (paracetamol) or equivalent|Drug: Ranitidine or equivalent|Drug: Diphenhydramine or equivalent|Drug: Methylprednisolone or equivalent|Drug: Montelukast or equivalent","Investigational Site Number 8400004, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT04294459"
964,"ACCESS A Master Digital Surveillance Protocol for COVID-19","Recruiting","No Results Available","Coronavirus|COVID|COVID-19|COVID19|Corona Virus Infection|Coronavirus Infection",,"Medable Inc., Palo Alto, California, United States","https://ClinicalTrials.gov/show/NCT04363268"
965,"COVID-19, bLOod Coagulation and Thrombosis","Recruiting","No Results Available","COVID|Embolism and Thrombosis|Pneumonia, Viral","Diagnostic Test: Echo-Doppler","Hôpital Ambroise Paré, Boulogne-Billancourt, IDF, France|Hôpital Privé Jacques Cartier, Massy, IDF, France|Centre Cardiologique du Nord, Saint-Denis, IDF, France","https://ClinicalTrials.gov/show/NCT04388657"
966,"Morbidity and Mortality Due to Deferral of Aortic Valve Replacement in Patients With Severe Aortic Stenosis","Active, not recruiting","No Results Available","Aortic Valve Stenosis","Device: TAVR or SAVR","Department of Cardiology, Bern University Hospital, Bern, Switzerland","https://ClinicalTrials.gov/show/NCT04333875"
967,"Observational Study of COVID-19 Treatment Efficacy","Enrolling by invitation","No Results Available","Coronavirus|Coronavirus Infection|Corona Virus Infection|COVID|Sars-CoV2|Coronavirus as the Cause of Diseases Classified Elsewhere|SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere|COVID-19|Coronavirus Disease|Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere","Other: No intervention","OSF HealthCare St Francis Medical Center, Peoria, Illinois, United States","https://ClinicalTrials.gov/show/NCT04369989"
968,"Study of Late Fetal Loss in Poitou-Charentes. GYNE-COVID","Recruiting","No Results Available","Identification of the Mother or Fetus Contamination by SARS Cov-2|Research the Presence of Viruses at Different Sites of the Mother and the Fetus or Father|The Survey Builds on a Network Work Already Organized Around the CPDPN of Poitou-Charentes|Analysis Laboratories of the Poitiers CHU","Diagnostic Test: Identification by PCR of the SARS-COV-2 virus in samples taken from the fetus","CHU de Poitiers, Poitiers, France","https://ClinicalTrials.gov/show/NCT04387253"
969,"Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19","Recruiting","No Results Available","COVID-19","Drug: Tocilizumab|Drug: Hydroxychloroquine|Drug: Azithromycin","Hospital de la Santa Creu i Sant Pau, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT04332094"
970,"TOFAcitinib Plus Hydroxycloroquine vs Hydroxycloroquine in Patients With COVID-19 Interstitial Pneumonia","Not yet recruiting","No Results Available","Pneumonitis, Interstitial|COVID-19","Drug: Tofacitinib|Drug: Hydroxychloroquine",,"https://ClinicalTrials.gov/show/NCT04390061"
971,"Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure","Recruiting","No Results Available","Corona Virus Disease","Drug: RoActemra iv|Drug: RoActemra sc|Drug: Kevzara sc|Other: Standard medical care","Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark|Hillerød Hospital, Hillerød, Denmark","https://ClinicalTrials.gov/show/NCT04322773"
972,"COVID-19 Convalescent Plasma for Mechanically Ventilated Population","Recruiting","No Results Available","Covid-19","Biological: COVID-19 Convalescent Plasma","Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT04388527"
973,"Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19","Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Indomethacin|Drug: Zithromax Oral Product","Perseverance Research Center, Scottsdale, Arizona, United States|Covidcraz 19, Llc, New Orleans, Louisiana, United States","https://ClinicalTrials.gov/show/NCT04344457"
974,"Impact of Angiotensin II Receptor Blockers Treatment in Patients With COVID 19 (COVID-ARA2)","Recruiting","No Results Available","COVID|Acute Respiratory Distress Syndrome","Biological: blood sampling","University Hospital Angers, Angers, France","https://ClinicalTrials.gov/show/NCT04337190"
975,"Dexmedetomidine to Improve Outcomes of ARDS in Critical Care COVID-19 Patients","Not yet recruiting","No Results Available","Acute Respiratory Distress Syndrome|Inflammation|Dexmedetomidine|Cytokine Storm|Delirium, Emergence","Drug: Dexmedetomidine Injectable Product",,"https://ClinicalTrials.gov/show/NCT04358627"
976,"suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 (SAVE)","Recruiting","No Results Available","COVID-19|Virus Diseases|Corona Virus Infection|Lower Respiratory Tract Infection Viral","Drug: Anakinra|Drug: trimethoprim/sulfamethoxazole","COVID-19 Department, General Hospital of Attica SISMANOGLEIO-AMALIA FLEMING, Marousi, Athens, Greece|2nd Department of Internal Medicine, University General Hospital of Alexandroupolis, Alexandroupolis, Greece|Department of Internal Medicine, I PAMMAKARISTOS Hospital, Athens, Greece|1st Department of Internal Medicine, General Hospital of Athens G. GENNIMATAS, Athens, Greece|1st University Department of Internal Medicine, General Hospital of Athens LAIKO, Athens, Greece|2nd University Department of Internal Medicine, IPPOKRATEION General Hospital of Athens, Athens, Greece|3rd University Department of Internal Medicine, General Hospital of Chest Diseases of Athens I SOTIRIA, Athens, Greece|Department of Internal Medicine, General Hospital of Chest Diseases of Athens I SOTIRIA, Athens, Greece|Department of Clinical Therapeutics, ALEXANDRA General Hospital of Athens, Athens, Greece|Department of Infectious Diseases, General Hospital of Kerkira, Corfu, Greece|1st Department of Internal Medicine, General University Hospital of Ioannina, Ioánnina, Greece|Department of Internal Medicine, University General Hospital of Larissa, Larissa, Greece|Department of Internal Medicine, University General Hospital of Patras PANAGIA I VOITHIA, Patra, Greece|1st Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki, Thessaloníki, Greece","https://ClinicalTrials.gov/show/NCT04357366"
977,"A Study of ResCure™ to Treat COVID-19 Infection","Not yet recruiting","No Results Available","COVID|Covid-19|Corona Virus Infection|Sars-CoV2|Coronavirus-19|SARS Pneumonia|SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere","Biological: ResCure™","ProgenaBiome, Ventura, California, United States","https://ClinicalTrials.gov/show/NCT04395716"
978,"Efficacy of Convalescent Plasma to Treat COVID-19 Patients, a Nested Trial in the CORIMUNO-19 Cohort","Recruiting","No Results Available","Covid19","Drug: Transfusion of COVID-19 convalescent plasma","SMIT, Saint Antoine hospital, Paris, France","https://ClinicalTrials.gov/show/NCT04345991"
979,"Convalescent Plasma vs. Placebo in Emergency Room Patients With COVID-19","Not yet recruiting","No Results Available","COVID-19","Biological: Convalescent Plasma|Biological: Standard Plasma","Stanford University, Stanford, California, United States","https://ClinicalTrials.gov/show/NCT04355767"
980,"Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Hospitalized Patients With Moderate to Severe COVID-19","Suspended","No Results Available","COVID-19","Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin Tablets","Prevent Senior Private Operadora de Saúde LTDA., São Paulo, Brazil","https://ClinicalTrials.gov/show/NCT04329572"
981,"Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma","Not yet recruiting","No Results Available","Plasma Cell Myeloma","Drug: Isatuximab SAR650984|Drug: Lenalidomide|Drug: Dexamethasone",,"https://ClinicalTrials.gov/show/NCT04270409"
982,"SCB-2019 as COVID-19 Vaccine","Not yet recruiting","No Results Available","COVID-19","Biological: SCB-2019|Biological: SCB-2019 with AS03 adjuvant|Biological: SCB-2019 with CpG 1018 adjuvant plus Alum adjuvant",,"https://ClinicalTrials.gov/show/NCT04405908"
983,"Seasonal Allergic Rhinitis Study","Completed","No Results Available","Seasonal Affective Rhinitis|Asthma|Grass Allergy","Dietary Supplement: Lactobacillus casei Shirota (LcS)|Dietary Supplement: Placebo","Institute of Food Research, Norwich, Norfolk, United Kingdom|Norfolk and Norwich University Hospital, Norwich, Norfolk, United Kingdom|CRTU University of East Anglia, Norwich, Norfolk, United Kingdom|University of East Anglia, Norwich, Norfolk, United Kingdom","https://ClinicalTrials.gov/show/NCT01123252"
984,"Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19","Suspended","No Results Available","Covid-19","Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin Tablets","Prevent Senior Private Operadora de Saúde LTDA., São Paulo, Brazil","https://ClinicalTrials.gov/show/NCT04348474"
985,"Phase Ib-II Trial of Dendritic Cell Vaccine to Prevent COVID-19 in Frontline Healthcare Workers and First Responders","Not yet recruiting","No Results Available","COVID-19","Biological: AV-COVID-19",,"https://ClinicalTrials.gov/show/NCT04386252"
986,"Convalescent Plasma vs. Standard Plasma for COVID-19","Enrolling by invitation","No Results Available","COVID","Biological: Convalescent Plasma|Biological: Standard Donor Plasma","Stony Brook University Hospital, Stony Brook, New York, United States","https://ClinicalTrials.gov/show/NCT04344535"
987,"Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies","Active, not recruiting","No Results Available","Prostate Cancer|Non-small Cell Lung Cancer","Drug: Isatuximab SAR650984|Drug: Cemiplimab REGN2810","Investigational Site Number 8400003, Birmingham, Alabama, United States|Investigational Site Number 8400007, Atlanta, Georgia, United States|Investigational Site Number 8400002, Hackensack, New Jersey, United States|Investigational Site Number 8400005, Nashville, Tennessee, United States|Investigational Site Number 8400004, Houston, Texas, United States|Investigational Site Number 2500002, Bordeaux Cedex, France|Investigational Site Number 2500001, Villejuif Cedex, France|Investigational Site Number 3800006, Napoli, Italy|Investigational Site Number 3800001, Orbassano, Italy|Investigational Site Number 3800004, Padova, Italy|Investigational Site Number 3800002, Pavia, Italy|Investigational Site Number 3800003, Rozzano, Italy|Investigational Site Number 3800005, Verona, Italy|Investigational Site Number 1580002, Tainan, Taiwan|Investigational Site Number 1580001, Taipei 100, Taiwan|Investigational Site Number 8260002, Newcastle Upon Tyne, United Kingdom|Investigational Site Number 8260001, Sutton, United Kingdom","https://ClinicalTrials.gov/show/NCT03367819"
988,"A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma","Active, not recruiting","No Results Available","Plasma Cell Myeloma","Drug: Isatuximab","Investigational Site Number 840003, Scottsdale, Arizona, United States|Investigational Site Number 840004, San Francisco, California, United States|Investigational Site Number 840011, Detroit, Michigan, United States|Investigational Site Number 840015, Saint Louis, Missouri, United States|Investigational Site Number 840005, Hackensack, New Jersey, United States|Investigational Site Number 840010, Durham, North Carolina, United States|Investigational Site Number 840013, Canton, Ohio, United States|Investigational Site Number 840001, Nashville, Tennessee, United States|Investigational Site Number 840002, Salt Lake City, Utah, United States|Investigational Site Number 840006, Milwaukee, Wisconsin, United States|Investigational Site Number 203002, Brno, Czechia|Investigational Site Number 203001, Praha 2, Czechia|Investigational Site Number 250008, Creteil Cedex, France|Investigational Site Number 250005, Montpellier Cedex 5, France|Investigational Site Number 250002, Nantes Cedex 01, France|Investigational Site Number 250004, Pessac, France|Investigational Site Number 250001, Poitiers, France|Investigational Site Number 250006, Vandoeuvre-Les-Nancy Cedex, France","https://ClinicalTrials.gov/show/NCT02514668"
989,"Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND)","Active, not recruiting","No Results Available","Rheumatoid Arthritis","Drug: SAR153191 (REGN88)","Investigational Site Number 840070, Anniston, Alabama, United States|Investigational Site Number 840138, Birmingham, Alabama, United States|Investigational Site Number 840152, Huntsville, Alabama, United States|Investigational Site Number 840072, Gilbert, Arizona, United States|Investigational Site Number 840141, Glendale, Arizona, United States|Investigational Site Number 840134, Fullerton, California, United States|Investigational Site Number 840008, La Jolla, California, United States|Investigational Site Number 840135, San Diego, California, United States|Investigational Site Number 840021, Santa Maria, California, United States|Investigational Site Number 840100, Stanford, California, United States|Investigational Site Number 840049, Upland, California, United States|Investigational Site Number 840151, Colorado Springs, Colorado, United States|Investigational Site Number 840130, Lewes, Delaware, United States|Investigational Site Number 840153, Aventura, Florida, United States|Investigational Site Number 840050, Clearwater, Florida, United States|Investigational Site Number 840033, Fort Lauderdale, Florida, United States|Investigational Site Number 840041, Gainesville, Florida, United States|Investigational Site Number 840067, Jupiter, Florida, United States|Investigational Site Number 840048, Miami, Florida, United States|Investigational Site Number 840024, Naples, Florida, United States|Investigational Site Number 840006, Orlando, Florida, United States|Investigational Site Number 840128, Ormond Beach, Florida, United States|Investigational Site Number 840063, Palm Harbor, Florida, United States|Investigational Site Number 840155, Palm Harbor, Florida, United States|Investigational Site Number 840060, Sarasota, Florida, United States|Investigational Site Number 840140, Tampa, Florida, United States|Investigational Site Number 840126, Vero Beach, Florida, United States|Investigational Site Number 840003, Atlanta, Georgia, United States|Investigational Site Number 840028, Decatur, Georgia, United States|Investigational Site Number 840027, Marietta, Georgia, United States|Investigational Site Number 840018, Idaho Falls, Idaho, United States|Investigational Site Number 840046, Chicago, Illinois, United States|Investigational Site Number 840052, Kansas City, Kansas, United States|Investigational Site Number 840230, Elizabethtown, Kentucky, United States|Investigational Site Number 840015, Lexington, Kentucky, United States|Investigational Site Number 840120, Baton Rouge, Louisiana, United States|Investigational Site Number 840109, Lake Charles, Louisiana, United States|Investigational Site Number 840055, Frederick, Maryland, United States|Investigational Site Number 840013, Wheaton, Maryland, United States|Investigational Site Number 840154, Boston, Massachusetts, United States|Investigational Site Number 840150, Lansing, Michigan, United States|Investigational Site Number 840137, Saint Clair Shores, Michigan, United States|Investigational Site Number 840112, Lincoln, Nebraska, United States|Investigational Site Number 840026, Freehold, New Jersey, United States|Investigational Site Number 840115, Lake Success, New York, United States|Investigational Site Number 840056, New York, New York, United States|Investigational Site Number 840043, New York, New York, United States|Investigational Site Number 840106, Orchard Park, New York, United States|Investigational Site Number 840118, Smithtown, New York, United States|Investigational Site Number 840116, Wilmington, North Carolina, United States|Investigational Site Number 840233, Minot, North Dakota, United States|Investigational Site Number 840002, Oklahoma City, Oklahoma, United States|Investigational Site Number 840127, Oklahoma City, Oklahoma, United States|Investigational Site Number 840011, Tulsa, Oklahoma, United States|Investigational Site Number 840065, Tulsa, Oklahoma, United States|Investigational Site Number 840010, Bethlehem, Pennsylvania, United States|Investigational Site Number 840009, Duncansville, Pennsylvania, United States|Investigational Site Number 840062, Reading, Pennsylvania, United States|Investigational Site Number 840058, Columbia, South Carolina, United States|Investigational Site Number 840016, North Charleston, South Carolina, United States|Investigational Site Number 840025, Jackson, Tennessee, United States|Investigational Site Number 840059, Memphis, Tennessee, United States|Investigational Site Number 840032, Amarillo, Texas, United States|Investigational Site Number 840038, Austin, Texas, United States|Investigational Site Number 840001, Dallas, Texas, United States|Investigational Site Number 840022, Dallas, Texas, United States|Investigational Site Number 840012, Dallas, Texas, United States|Investigational Site Number 840129, Houston, Texas, United States|Investigational Site Number 840069, Lubbock, Texas, United States|Investigational Site Number 840074, Mesquite, Texas, United States|Investigational Site Number 840020, Nassau Bay, Texas, United States|Investigational Site Number 840103, San Antonio, Texas, United States|Investigational Site Number 840036, Spokane, Washington, United States|Investigational Site Number 840061, Tacoma, Washington, United States|Investigational Site Number 840124, Clarksburg, West Virginia, United States|Investigational Site Number 032006, Caba, Argentina|Investigational Site Number 032007, Caba, Argentina|Investigational Site Number 032008, Caba, Argentina|Investigational Site Number 032019, Capital Federal, Argentina|Investigational Site Number 032016, Capital Federal, Argentina|Investigational Site Number 032002, Cordoba, Argentina|Investigational Site Number 032020, Cordoba, Argentina|Investigational Site Number 032003, Córdoba, Argentina|Investigational Site Number 032017, La Plata, Argentina|Investigational Site Number 032012, Mar Del Plata, Argentina|Investigational Site Number 032011, Quilmes, Argentina|Investigational Site Number 032010, Ramos Mejia, Argentina|Investigational Site Number 032001, Rosario, Argentina|Investigational Site Number 032013, Rosario, Argentina|Investigational Site Number 032015, San Fernando, Argentina|Investigational Site Number 032005, San Miguel De Tucuman, Argentina|Investigational Site Number 032004, San Miguel De Tucuman, Argentina|Investigational Site Number 032009, Zarate, Argentina|Investigational Site Number 036003, Camperdown, Australia|Investigational Site Number 036012, Fitzroy, Australia|Investigational Site Number 036010, Garran, Australia|Investigational Site Number 036004, Heidelberg West, Australia|Investigational Site Number 036001, Maroochydore, Australia|Investigational Site Number 036014, Victoria Park, Australia|Investigational Site Number 036007, Woodville, Australia|Investigational Site Number 040001, Graz, Austria|Investigational Site Number 112002, Minsk, Belarus|Investigational Site Number 112001, Minsk, Belarus|Investigational Site Number 056010, Leuven, Belgium|Investigational Site Number 076001, Curitiba, Brazil|Investigational Site Number 076006, Goiania, Brazil|Investigational Site Number 076010, Juiz De Fora, Brazil|Investigational Site Number 076004, Porto Alegre, Brazil|Investigational Site Number 076005, Rio De Janeiro, Brazil|Investigational Site Number 076015, Rio De Janeiro, Brazil|Investigational Site Number 076011, Salvador, Brazil|Investigational Site Number 076002, Sao Paulo, Brazil|Investigational Site Number 076003, Sao Paulo, Brazil|Investigational Site Number 076013, Vitoria, Brazil|Investigational Site Number 124003, Mississauga, Canada|Investigational Site Number 124002, St. Catharines, Canada|Investigational Site Number 124005, Toronto, Canada|Investigational Site Number 124009, Trois-Rivières, Canada|Investigational Site Number 124104, Victoria, Canada|Investigational Site Number 124012, Winnipeg, Canada|Investigational Site Number 152005, Osorno, Chile|Investigational Site Number 152012, Santiago, Chile|Investigational Site Number 152002, Santiago, Chile|Investigational Site Number 152011, Santiago, Chile|Investigational Site Number 152009, Santiago, Chile|Investigational Site Number 152001, Santiago, Chile|Investigational Site Number 152013, Santiago, Chile|Investigational Site Number 152008, Santiago, Chile|Investigational Site Number 152014, Talca, Chile|Investigational Site Number 152015, Temuco IX Region, Chile|Investigational Site Number 152004, Valdivia, Chile|Investigational Site Number 152006, Vina Del Mar, Chile|Investigational Site Number 152007, Viña Del Mar, Chile|Investigational Site Number 170005, Barranquilla, Colombia|Investigational Site Number 170004, Barranquilla, Colombia|Investigational Site Number 170001, Bogota, Colombia|Investigational Site Number 170008, Bogota, Colombia|Investigational Site Number 170006, Bogotá, Colombia|Investigational Site Number 170003, Bogotá, Colombia|Investigational Site Number 170007, Bucaramanga, Colombia|Investigational Site Number 170009, Bucaramanga, Colombia|Investigational Site Number 203009, Liberec, Czechia|Investigational Site Number 203004, Ostrava, Czechia|Investigational Site Number 203034, Pardubice, Czechia|Investigational Site Number 203001, Praha 2, Czechia|Investigational Site Number 203007, Praha 2, Czechia|Investigational Site Number 203011, Praha 2, Czechia|Investigational Site Number 203010, Praha 4, Czechia|Investigational Site Number 203002, Uherske Hradiste, Czechia|Investigational Site Number 203006, Zlin, Czechia|Investigational Site Number 218003, Cuenca, Ecuador|Investigational Site Number 218001, Guayaquil, Ecuador|Investigational Site Number 218002, Quito, Ecuador|Investigational Site Number 233001, Tallinn, Estonia|Investigational Site Number 233010, Tallinn, Estonia|Investigational Site Number 233002, Tallinn, Estonia|Investigational Site Number 246001, Helsinki, Finland|Investigational Site Number 246002, Hyvinkää, Finland|Investigational Site Number 246003, Pori, Finland|Investigational Site Number 246010, Riihimäki, Finland|Investigational Site Number 276011, Bad Nauheim, Germany|Investigational Site Number 276010, Berlin, Germany|Investigational Site Number 276007, Berlin, Germany|Investigational Site Number 276008, Berlin, Germany|Investigational Site Number 276014, Berlin, Germany|Investigational Site Number 276018, Deggingen, Germany|Investigational Site Number 276015, Halle/Saale, Germany|Investigational Site Number 276005, Hamburg, Germany|Investigational Site Number 276013, Hamburg, Germany|Investigational Site Number 276001, Herne, Germany|Investigational Site Number 276016, Leipzig, Germany|Investigational Site Number 276017, München, Germany|Investigational Site Number 276021, Osnabrück, Germany|Investigational Site Number 276020, Tübingen, Germany|Investigational Site Number 276019, Zerbst, Germany|Investigational Site Number 300002, Heraklion, Greece|Investigational Site Number 300003, Thessaloniki, Greece|Investigational Site Number 300005, Thessaloniki, Greece|Investigational Site Number 320002, Guatemala City, Guatemala|Investigational Site Number 320003, Guatemala City, Guatemala|Investigational Site Number 320001, Guatemala, Guatemala|Investigational Site Number 348006, Budapest, Hungary|Investigational Site Number 348014, Budapest, Hungary|Investigational Site Number 348025, Budapest, Hungary|Investigational Site Number 348022, Budapest, Hungary|Investigational Site Number 348010, Debrecen, Hungary|Investigational Site Number 348003, Debrecen, Hungary|Investigational Site Number 348021, Esztergom, Hungary|Investigational Site Number 348013, Györ, Hungary|Investigational Site Number 348009, Szolnok, Hungary|Investigational Site Number 348015, Szombathely, Hungary|Investigational Site Number 348004, Székesfehérvár, Hungary|Investigational Site Number 348005, Sátoraljaújhely, Hungary|Investigational Site Number 376001, Haifa, Israel|Investigational Site Number 376010, Haifa, Israel|Investigational Site Number 376011, Tel Aviv, Israel|Investigational Site Number 376002, Tel Hashomer, Israel|Investigational Site Number 380005, Genova, Italy|Investigational Site Number 410014, Anyang-Si, Korea, Republic of|Investigational Site Number 410006, Busan, Korea, Republic of|Investigational Site Number 410004, Daegu, Korea, Republic of|Investigational Site Number 410017, Daejeon, Korea, Republic of|Investigational Site Number 410005, Daejeon, Korea, Republic of|Investigational Site Number 410010, Gwangju, Korea, Republic of|Investigational Site Number 410001, Incheon, Korea, Republic of|Investigational Site Number 410009, Incheon, Korea, Republic of|Investigational Site Number 410011, Jeonju, Korea, Republic of|Investigational Site Number 410007, Seoul, Korea, Republic of|Investigational Site Number 410012, Seoul, Korea, Republic of|Investigational Site Number 410016, Seoul, Korea, Republic of|Investigational Site Number 410003, Seoul, Korea, Republic of|Investigational Site Number 410008, Suwon, Korea, Republic of|Investigational Site Number 440001, Kaunas, Lithuania|Investigational Site Number 440006, Klaipeda, Lithuania|Investigational Site Number 440002, Vilnius, Lithuania|Investigational Site Number 440007, Vilnius, Lithuania|Investigational Site Number 458001, Ipoh, Malaysia|Investigational Site Number 458002, Kuching, Malaysia|Investigational Site Number 484023, Chihuahua, Mexico|Investigational Site Number 484008, Durango, Mexico|Investigational Site Number 484018, Guadalajara, Mexico|Investigational Site Number 484002, Guadalajara, Mexico|Investigational Site Number 484035, Leon, Mexico|Investigational Site Number 484009, Merida, Mexico|Investigational Site Number 484007, Metepec, Mexico|Investigational Site Number 484010, Mexicali, Mexico|Investigational Site Number 484003, Mexico City, Mexico|Investigational Site Number 484019, Monterrey, Mexico|Investigational Site Number 484020, Monterrey, Mexico|Investigational Site Number 484005, Monterrey, Mexico|Investigational Site Number 484004, Mérida, Mexico|Investigational Site Number 484001, México, D.F., Mexico|Investigational Site Number 484017, México, Mexico|Investigational Site Number 484021, Queretaro, Mexico|Investigational Site Number 528010, Amsterdam, Netherlands|Investigational Site Number 554004, Christchurch, New Zealand|Investigational Site Number 554011, Nelson, New Zealand|Investigational Site Number 554007, Otahuhu, New Zealand|Investigational Site Number 554002, Rotorua, New Zealand|Investigational Site Number 554001, Timaru, New Zealand|Investigational Site Number 604001, Lima, Peru|Investigational Site Number 604010, Lima, Peru|Investigational Site Number 604008, Lima, Peru|Investigational Site Number 604009, Lima, Peru|Investigational Site Number 604006, Lima, Peru|Investigational Site Number 604012, Lima, Peru|Investigational Site Number 604013, Lima, Peru|Investigational Site Number 604007, Lima, Peru|Investigational Site Number 604005, Lima, Peru|Investigational Site Number 608003, Cebu City, Philippines|Investigational Site Number 608001, Manila, Philippines|Investigational Site Number 616014, Bialystok, Poland|Investigational Site Number 616002, Bialystok, Poland|Investigational Site Number 616003, Bialystok, Poland|Investigational Site Number 616019, Bydgoszcz, Poland|Investigational Site Number 616054, Bytom, Poland|Investigational Site Number 616015, Elblag, Poland|Investigational Site Number 616001, Krakow, Poland|Investigational Site Number 616005, Lublin, Poland|Investigational Site Number 616030, Lublin, Poland|Investigational Site Number 616018, Poznan, Poland|Investigational Site Number 616016, Szczecin, Poland|Investigational Site Number 616006, Torun, Poland|Investigational Site Number 616031, Warszawa, Poland|Investigational Site Number 616004, Warszawa, Poland|Investigational Site Number 616017, Warszawa, Poland|Investigational Site Number 616020, Wroclaw, Poland|Investigational Site Number 616012, Wroclaw, Poland|Investigational Site Number 620002, Lisboa, Portugal|Investigational Site Number 642006, Braila, Romania|Investigational Site Number 642010, Bucharest, Romania|Investigational Site Number 642021, Bucuresti, Romania|Investigational Site Number 642001, Bucuresti, Romania|Investigational Site Number 642020, Bucuresti, Romania|Investigational Site Number 642002, Bucuresti, Romania|Investigational Site Number 642005, Galati, Romania|Investigational Site Number 643006, Kemerovo, Russian Federation|Investigational Site Number 643017, Kemerovo, Russian Federation|Investigational Site Number 643020, Moscow, Russian Federation|Investigational Site Number 643001, Moscow, Russian Federation|Investigational Site Number 643002, Moscow, Russian Federation|Investigational Site Number 643021, Moscow, Russian Federation|Investigational Site Number 643004, Moscow, Russian Federation|Investigational Site Number 643012, Moscow, Russian Federation|Investigational Site Number 643031, Moscow, Russian Federation|Investigational Site Number 643030, Moscow, Russian Federation|Investigational Site Number 643009, Novosibirsk, Russian Federation|Investigational Site Number 643016, Ryazan, Russian Federation|Investigational Site Number 643008, Saint-Petersburg, Russian Federation|Investigational Site Number 643010, Samara, Russian Federation|Investigational Site Number 643011, Saratov, Russian Federation|Investigational Site Number 643007, St-Petersburg, Russian Federation|Investigational Site Number 643032, St-Petersburg, Russian Federation|Investigational Site Number 643014, St-Petersburg, Russian Federation|Investigational Site Number 643013, Ufa, Russian Federation|Investigational Site Number 710011, Cape Town, South Africa|Investigational Site Number 710007, Cape Town, South Africa|Investigational Site Number 710009, Cape Town, South Africa|Investigational Site Number 710003, Durban, South Africa|Investigational Site Number 710002, Durban, South Africa|Investigational Site Number 710001, Johannesburg, South Africa|Investigational Site Number 710004, Kempton Park, South Africa|Investigational Site Number 710005, Pretoria, South Africa|Investigational Site Number 710006, Pretoria, South Africa|Investigational Site Number 710010, Stellenbosch, South Africa|Investigational Site Number 724016, Barakaldo, Spain|Investigational Site Number 724015, Barcelona, Spain|Investigational Site Number 724014, Cádiz, Spain|Investigational Site Number 724009, La Coruña, Spain|Investigational Site Number 724001, Málaga, Spain|Investigational Site Number 724011, Sabadell, Spain|Investigational Site Number 724012, Santiago De Compostela, Spain|Investigational Site Number 724013, Santiago De Compostela, Spain|Investigational Site Number 724022, Sevilla, Spain|Investigational Site Number 724007, Sevilla, Spain|Investigational Site Number 752002, Uppsala, Sweden|Investigational Site Number 158006, Taichung, Taiwan|Investigational Site Number 158002, Taoyuan County, Taiwan|Investigational Site Number 764001, Bangkok, Thailand|Investigational Site Number 764003, Bangkok, Thailand|Investigational Site Number 792008, Gaziantep, Turkey|Investigational Site Number 804003, Dnipro, Ukraine|Investigational Site Number 804010, Kharkiv, Ukraine|Investigational Site Number 804013, Kharkiv, Ukraine|Investigational Site Number 804014, Kyiv, Ukraine|Investigational Site Number 804004, Kyiv, Ukraine|Investigational Site Number 804027, Kyiv, Ukraine|Investigational Site Number 804005, Lviv, Ukraine|Investigational Site Number 804006, Simferopol, Ukraine|Investigational Site Number 804011, Vinnytsya, Ukraine|Investigational Site Number 804009, Zaporizhzhya, Ukraine|Investigational Site Number 826004, Doncaster, United Kingdom|Investigational Site Number 826006, Edinburgh, United Kingdom|Investigational Site Number 826002, Leytonstone, United Kingdom|Investigational Site Number 826005, Southampton, United Kingdom","https://ClinicalTrials.gov/show/NCT01146652"
990,"COVID-19 PrEP HCW HCQ Study","Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine (HCQ)","NYU Langone Health, New York, New York, United States","https://ClinicalTrials.gov/show/NCT04354870"
991,"The Geneva Covid-19 CVD Study","Active, not recruiting","No Results Available","COVID|CVD","Other: Covid-19 + patients","Geneva University Hospital (HUG), Geneva, Switzerland","https://ClinicalTrials.gov/show/NCT04384029"
992,"StahistRx Phase 2, Five-arm, Parallel Group, Active vs Active, Double-blind Study","Unknown status","No Results Available","Rhinitis, Seasonal, Allergic","Drug: PSE 120 mg, CM 8 mg, Atr 0.36 mg|Drug: PSE 120 mg, CM 8 mg, Atr 0.24 mg|Drug: PSE 120 mg, CM 8 mg, Atr 0.12 mg|Drug: PSE 120 mg, CM 8 mg|Drug: Atropine 0.24 mg","Clinical Research Atlanta, Stockbridge, Georgia, United States|Family Allergy and Asthma Institute, Louisville, Kentucky, United States|National Allergy, Asthma & Urticaria Centers of Charleston, PA, Charleston, South Carolina, United States|Central Texas Health Research, New Braunfels, Texas, United States","https://ClinicalTrials.gov/show/NCT02082054"
993,"Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)","Recruiting","No Results Available","Multiple Myeloma","Drug: isatuximab SAR650984|Drug: pomalidomide|Drug: dexamethasone","Investigational Site Number 8400002, Duarte, California, United States|Investigational Site Number 8400001, Canton, Ohio, United States|Investigational Site Number 0360002, Blacktown, Australia|Investigational Site Number 0360004, Fitzroy, Australia|Investigational Site Number 0360003, Richmond, Australia|Investigational Site Number 0360001, Wollongong, Australia|Investigational Site Number 0560001, Leuven, Belgium|Investigational Site Number 2500001, Nantes, France|Investigational Site Number 2500002, Toulouse Cedex 9, France|Investigational Site Number 7240001, Badalona, Spain|Investigational Site Number 7240003, Salamanca, Spain|Investigational Site Number 7240002, Santander, Spain","https://ClinicalTrials.gov/show/NCT04045795"
994,"Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors","Completed","Has Results","Locally Advanced Solid Tumor|Metastatic Solid Tumor|Breast Cancer|Non Small Cell Lung Cancer|Melanoma|Colorectal Cancer","Drug: MSC1936369B (pimasertib)|Drug: SAR245409 (PI3K and mTOR inhibitor)","Pinnacle Oncology Hematology, Scottsdale, Arizona, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Cancer Therapy and Research Center, San Antonio, Texas, United States|Merck Serono Research Site, Milan, Italy|Merck Serono Research Site, Madrid, Spain","https://ClinicalTrials.gov/show/NCT01390818"
995,"A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors","Completed","No Results Available","Neoplasm Malignant","Drug: Iniparib (SAR240550-BSI-201)|Drug: Gemcitabine|Drug: Carboplatin|Drug: Placlitaxel|Drug: Pegylated liposomal doxorubicin","Investigational Site Number 840002, Scottsdale, Arizona, United States|Investigational Site Number 840004, Los Angeles, California, United States|Investigational Site Number 840010, Augusta, Georgia, United States|Investigational Site Number 840007, St Louis, Missouri, United States|Investigational Site Number 840001, Cincinnati, Ohio, United States|Investigational Site Number 840006, San Antonio, Texas, United States","https://ClinicalTrials.gov/show/NCT01455532"
996,"Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone","Recruiting","No Results Available","Multiple Myeloma","Drug: Isatuximab|Drug: Carfilzomib|Drug: Lenalidomide|Drug: Dexamethasone","Vivantes Am Urban, Berlin, Germany|Campus Benjamin Franklin Charite Berlin, Berlin, Germany|Vivantes Klinikum Neukölln, Berlin, Germany|Städt. Kliniken Bielefeld Klinikum Mitte, Bielefeld, Germany|University Hospital Bochum, Bochum, Germany|Johanniter-Krankenhaus Bonn, Bonn, Germany|Uniklinikum Chemnitz, Chemnitz, Germany|St. Antonius Hospital, Eschweiler, Germany|Universitätsklinikum Essen, Essen, Germany|Asklepios Altona, Hamburg, Germany|University Hospital Hamburg Eppendorf, Hamburg, Germany|University Hospital Heidelberg, Heidelberg, Germany|Uniklinik Köln, Koln, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany|Philipps-Universität Marburg, Marburg, Germany|Klinik für Hämatologie, Onkologie und GastroenterologieKliniken Maria Hilf GmbH, Mönchengladbach, Germany|University Hospital Münster, Münster, Germany|Zentrum für Tumordiagnostik und -therapieHämatologie/Int. Onkologie, Osnabruck, Germany|Universitätsklinikum Tuebingen, Tuebingen, Germany","https://ClinicalTrials.gov/show/NCT03104842"
997,"A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients","Recruiting","No Results Available","Polycystic Kidney, Autosomal Dominant","Drug: Venglustat GZ402671|Drug: Placebo","Investigational Site Number 8400002, Birmingham, Alabama, United States|Investigational Site Number 8400017, Los Angeles, California, United States|Investigational Site Number 8400001, San Francisco, California, United States|Investigational Site Number 8400008, Aurora, Colorado, United States|Investigational Site Number 8400010, New Haven, Connecticut, United States|Investigational Site Number 8400004, Atlanta, Georgia, United States|Investigational Site Number 8400007, Chicago, Illinois, United States|Investigational Site Number 8400014, Iowa City, Iowa, United States|Investigational Site Number 8400003, Kansas City, Kansas, United States|Investigational Site Number 8400021, Baltimore, Maryland, United States|Investigational Site Number 8400016, Boston, Massachusetts, United States|Investigational Site Number 8400020, Rochester, Minnesota, United States|Investigational Site Number 8400011, Philadelphia, Pennsylvania, United States|Investigational Site Number 8400015, San Antonio, Texas, United States|Investigational Site Number 8400019, Morgantown, West Virginia, United States|Investigational Site Number 8400005, Madison, Wisconsin, United States|Investigational Site Number 8400006, Milwaukee, Wisconsin, United States|Investigational Site Number 0360002, Herston, Australia|Investigational Site Number 0360001, Westmead, Australia|Investigational Site Number 0400001, Graz, Austria|Investigational Site Number 0400004, Wien, Austria|Investigational Site Number 0560001, Bruxelles, Belgium|Investigational Site Number 0560002, Leuven, Belgium|Investigational Site Number 1240002, Edmonton, Canada|Investigational Site Number 1240003, Montreal, Canada|Investigational Site Number 1240001, Toronto, Canada|Investigational Site Number 1560005, Beijing, China|Investigational Site Number 1560004, Chengdu, China|Investigational Site Number 1560006, Hangzhou, China|Investigational Site Number 1560002, Hefei, China|Investigational Site Number 1560007, Nanjing, China|Investigational Site Number 1560001, Shanghai, China|Investigational Site Number 1560003, Shenyang, China|Investigational Site Number 2030001, Praha 2, Czechia|Investigational Site Number 2030002, Praha 4, Czechia|Investigational Site Number 2080001, København Ø, Denmark|Investigational Site Number 2080002, Roskilde, Denmark|Investigational Site Number 2500004, Bordeaux, France|Investigational Site Number 2500003, Brest, France|Investigational Site Number 2500002, Paris, France|Investigational Site Number 2500001, Toulouse, France|Investigational Site Number 2760001, Berlin, Germany|Investigational Site Number 2760002, Dresden, Germany|Investigational Site Number 2760010, Dresden, Germany|Investigational Site Number 2760007, Düsseldorf, Germany|Investigational Site Number 2760009, Essen, Germany|Investigational Site Number 2760005, Hannover, Germany|Investigational Site Number 2760003, Köln, Germany|Investigational Site Number 2760011, Leipzig, Germany|Investigational Site Number 2760004, München, Germany|Investigational Site Number 3800002, Milano, Italy|Investigational Site Number 3800001, Montichiari, Italy|Investigational Site Number 3800003, Napoli, Italy|Investigational Site Number 3920002, Bunkyo-Ku, Japan|Investigational Site Number 3920005, Kamakura-Shi, Japan|Investigational Site Number 3920006, Kawasaki-Shi, Japan|Investigational Site Number 3920010, Kyoto-Shi, Japan|Investigational Site Number 3920009, Nagoya-Shi, Japan|Investigational Site Number 3920003, Niigata-Shi, Japan|Investigational Site Number 3920007, Osaka-Shi, Japan|Investigational Site Number 3920001, Sapporo-Shi, Japan|Investigational Site Number 3920004, Shinjuku-Ku, Japan|Investigational Site Number 3920008, Toyoake-Shi, Japan|Investigational Site Number 4100001, Seoul, Korea, Republic of|Investigational Site Number 4100002, Seoul, Korea, Republic of|Investigational Site Number 5280001, Groningen, Netherlands|Investigational Site Number 5280002, Nijmegen, Netherlands|Investigational Site Number 6200004, Almada, Portugal|Investigational Site Number 6200001, Loures, Portugal|Investigational Site Number 6420002, Bucuresti, Romania|Investigational Site Number 6420001, Timisoara, Romania|Investigational Site Number 7240003, Barcelona, Spain|Investigational Site Number 7240001, Barcelona, Spain|Investigational Site Number 7240002, Madrid, Spain|Investigational Site Number 1580001, Taichung, Taiwan|Investigational Site Number 1580002, Taipei, Taiwan|Investigational Site Number 8260001, Sheffield, United Kingdom","https://ClinicalTrials.gov/show/NCT03523728"
998,"Vienna Challenge Chamber Study Using RV658 in Subjects With Allergic Rhinitis","Completed","No Results Available","Seasonal Allergic Rhinitis","Drug: RV568|Drug: Placebo","Institute for Allergy Research, Vienna Challenge Chamber, Vienna, Austria","https://ClinicalTrials.gov/show/NCT01230619"
999,"Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS","Recruiting","No Results Available","Prone Positioning|High Flow Nasal Cannula|Acute Respiratory Distress Syndrome|Corona Virus Infection","Device: high flow nasal cannula (HFNC)|Procedure: Prone positioning (PP)","Rush University Medical Center, Chicago, Illinois, United States","https://ClinicalTrials.gov/show/NCT04325906"
1000,"Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients","Active, not recruiting","Has Results","Plasma Cell Myeloma","Drug: Isatuximab|Drug: Pomalidomide|Drug: Dexamethasone","Investigational Site Number 8400002, Plantation, Florida, United States|Investigational Site Number 8400006, Boston, Massachusetts, United States|Investigational Site Number 0360005, Melbourne, Australia|Investigational Site Number 0360002, Prahran, Australia|Investigational Site Number 0360006, Richmond, Australia|Investigational Site Number 0360004, St Leonards, Australia|Investigational Site Number 0360001, Waratah, Australia|Investigational Site Number 0560003, Antwerpen, Belgium|Investigational Site Number 0560002, Brussel, Belgium|Investigational Site Number 0560004, Gent, Belgium|Investigational Site Number 0560001, Leuven, Belgium|Investigational Site Number 1240001, Montreal, Canada|Investigational Site Number 1240004, Montreal, Canada|Investigational Site Number 1240005, Sherbrooke, Canada|Investigational Site Number 2030005, Brno, Czechia|Investigational Site Number 2030004, Hradec Kralove, Czechia|Investigational Site Number 2030001, Olomouc, Czechia|Investigational Site Number 2030002, Ostrava - Poruba, Czechia|Investigational Site Number 2030003, Praha 2, Czechia|Investigational Site Number 2080002, Ålborg, Denmark|Investigational Site Number 2500021, Bayonne, France|Investigational Site Number 2500008, Caen, France|Investigational Site Number 2500009, Dijon, France|Investigational Site Number 2500017, Grenoble, France|Investigational Site Number 2500013, La Roche Sur Yon, France|Investigational Site Number 2500003, Lille, France|Investigational Site Number 2500023, Limoges, France|Investigational Site Number 2500019, Montpellier Cedex, France|Investigational Site Number 2500002, Nantes, France|Investigational Site Number 2500015, Paris, France|Investigational Site Number 2500016, Paris, France|Investigational Site Number 2500005, Pessac, France|Investigational Site Number 2500004, Pierre Benite Cedex, France|Investigational Site Number 2500007, Poitiers Cedex, France|Investigational Site Number 2500025, Reims, France|Investigational Site Number 2500014, Rennes, France|Investigational Site Number 2500001, Toulouse Cedex 9, France|Investigational Site Number 2500012, Tours, France|Investigational Site Number 2500018, Vandoeuvre-Les-Nancy Cedex, France|Investigational Site Number 2760001, Leipzig, Germany|Investigational Site Number 3000002, Athens, Greece|Investigational Site Number 3000005, Athens, Greece|Investigational Site Number 3000001, Athens, Greece|Investigational Site Number 3000004, Patra, Greece|Investigational Site Number 3000003, Thessaloniki, Greece|Investigational Site Number 3480001, Budapest, Hungary|Investigational Site Number 3480003, Budapest, Hungary|Investigational Site Number 3480002, Debrecen, Hungary|Investigational Site Number 3800001, Bologna, Italy|Investigational Site Number 3800010, Catania, Italy|Investigational Site Number 3800009, Firenze, Italy|Investigational Site Number 3800008, Genova, Italy|Investigational Site Number 3800007, Milano, Italy|Investigational Site Number 3800002, Milano, Italy|Investigational Site Number 3800006, Padova, Italy|Investigational Site Number 3800004, Terni, Italy|Investigational Site Number 3800003, Torino, Italy|Investigational Site Number 3920006, Kyoto-Shi, Japan|Investigational Site Number 3920001, Nagoya-Shi, Japan|Investigational Site Number 3920003, Okayama-Shi, Japan|Investigational Site Number 3920004, Sapporo-Shi, Japan|Investigational Site Number 3920005, Shibukawa-Shi, Japan|Investigational Site Number 3920002, Shibuya-Ku, Japan|Investigational Site Number 3920007, Sunto-Gun, Japan|Investigational Site Number 3920008, Suwa-Shi, Japan|Investigational Site Number 4100007, Hwasun-Gun, Korea, Republic of|Investigational Site Number 4100006, Incheon, Korea, Republic of|Investigational Site Number 4100001, Seoul, Korea, Republic of|Investigational Site Number 4100002, Seoul, Korea, Republic of|Investigational Site Number 4100005, Seoul, Korea, Republic of|Investigational Site Number 5540002, Auckland, New Zealand|Investigational Site Number 5540004, Dunedin, New Zealand|Investigational Site Number 5540003, Hamilton, New Zealand|Investigational Site Number 5540001, Takapuna, New Zealand|Investigational Site Number 5780001, Oslo, Norway|Investigational Site Number 6160002, Chorzow, Poland|Investigational Site Number 6160005, Krakow, Poland|Investigational Site Number 6160003, Lublin, Poland|Investigational Site Number 6160001, Warszawa, Poland|Investigational Site Number 6200004, Coimbra, Portugal|Investigational Site Number 6200002, Lisboa, Portugal|Investigational Site Number 6200001, Porto, Portugal|Investigational Site Number 6430004, Moscow, Russian Federation|Investigational Site Number 6430001, Moscow, Russian Federation|Investigational Site Number 6430002, Moscow, Russian Federation|Investigational Site Number 7030001, Bratislava, Slovakia|Investigational Site Number 7240001, Barcelona, Spain|Investigational Site Number 7240003, Madrid, Spain|Investigational Site Number 7240002, Pamplona, Spain|Investigational Site Number 7240004, Salamanca, Spain|Investigational Site Number 7240006, Santander, Spain|Investigational Site Number 7240005, Santiago De Compostela, Spain|Investigational Site Number 7520004, Luleå, Sweden|Investigational Site Number 7520005, Uddevalla, Sweden|Investigational Site Number 1580004, Kaohsiung, Taiwan|Investigational Site Number 1580002, Taichung, Taiwan|Investigational Site Number 1580001, Taipei, Taiwan|Investigational Site Number 1580003, Taoyuan, Taiwan|Investigational Site Number 7920001, Ankara, Turkey|Investigational Site Number 7920002, Antalya, Turkey|Investigational Site Number 7920005, Istanbul, Turkey|Investigational Site Number 7920003, Istanbul, Turkey|Investigational Site Number 7920004, Istanbul, Turkey|Investigational Site Number 7920006, İstanbul, Turkey|Investigational Site Number 7920008, Izmir, Turkey|Investigational Site Number 7920010, Izmir, Turkey|Investigational Site Number 7920009, Kayseri, Turkey|Investigational Site Number 7920007, Kocaeli, Turkey|Investigational Site Number 8260002, London, United Kingdom|Investigational Site Number 8260003, London, United Kingdom|Investigational Site Number 8260001, London, United Kingdom","https://ClinicalTrials.gov/show/NCT02990338"
1001,"Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05528)(COMPLETED)","Completed","Has Results","Allergic Rhinitis","Drug: Mometasone furoate nasal spray (MFNS)|Drug: Matching placebo nasal spray",,"https://ClinicalTrials.gov/show/NCT00733005"
1002,"Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05529)","Completed","Has Results","Allergic Rhinitis","Drug: Mometasone furoate nasal spray (MFNS)|Drug: Matching placebo nasal spray",,"https://ClinicalTrials.gov/show/NCT00732381"
1003,"Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05583)","Completed","Has Results","Allergic Rhinitis","Drug: Mometasone furoate nasal spray (MFNS)|Drug: Matching placebo nasal spray",,"https://ClinicalTrials.gov/show/NCT00728416"
1004,"ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19","Recruiting","No Results Available","COVID-19","Drug: ABX464|Drug: Placebo","Centre Hospitalier Universitaire de Nice, Nice, France","https://ClinicalTrials.gov/show/NCT04393038"
1005,"Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia","Completed","Has Results","Hypercholesterolemia","Drug: Alirocumab|Drug: Placebo for alirocumab|Drug: ezetimibe|Drug: placebo for ezetimibe|Drug: atorvastatin|Drug: rosuvastatin|Drug: simvastatin","Investigational Site Number 1560027, Beijing, China|Investigational Site Number 1560043, Beijing, China|Investigational Site Number 1560039, Beijing, China|Investigational Site Number 1560012, Beijing, China|Investigational Site Number 1560018, Beijing, China|Investigational Site Number 1560006, Changchun, China|Investigational Site Number 1560020, Changchun, China|Investigational Site Number 1560023, Changsha, China|Investigational Site Number 1560030, Fuzhou, China|Investigational Site Number 1560005, Guangzhou, China|Investigational Site Number 1560040, Guangzhou, China|Investigational Site Number 1560025, Guangzhou, China|Investigational Site Number 1560048, Hangzhou, China|Investigational Site Number 1560037, Hangzhou, China|Investigational Site Number 1560008, Hangzhou, China|Investigational Site Number 1560014, Hohhot, China|Investigational Site Number 1560016, Jinan, China|Investigational Site Number 1560044, Lanzhou, China|Investigational Site Number 1560028, Nanchang, China|Investigational Site Number 1560045, Nanjing, China|Investigational Site Number 1560017, Nanjing, China|Investigational Site Number 1560031, Nanjing, China|Investigational Site Number 1560035, Nanning, China|Investigational Site Number 1560029, Shanghai, China|Investigational Site Number 1560041, Shanghai, China|Investigational Site Number 1560053, Shanghai, China|Investigational Site Number 1560009, Shenyang, China|Investigational Site Number 1560001, Shenyang, China|Investigational Site Number 1560042, Shenyang, China|Investigational Site Number 1560036, Shenzhen, China|Investigational Site Number 1560056, Siping, China|Investigational Site Number 1560021, Taiyuan, China|Investigational Site Number 1560002, Tianjin, China|Investigational Site Number 1560022, Tianjin, China|Investigational Site Number 1560052, Tianjin, China|Investigational Site Number 1560055, Wenzhou, China|Investigational Site Number 1560003, Wuhan, China|Investigational Site Number 1560004, Xi'An, China|Investigational Site Number 1560019, Xuzhou, China|Investigational Site Number 1560054, Yinchuan, China|Investigational Site Number 1560057, Zhanjiang, China|Investigational Site Number 3560017, Belgaum, India|Investigational Site Number 3560001, Gurgaon, India|Investigational Site Number 3560003, Hubli, India|Investigational Site Number 3560010, Kolkata, India|Investigational Site Number 3560019, Kolkata, India|Investigational Site Number 3560020, Mangalore, India|Investigational Site Number 3560006, Mumbai, India|Investigational Site Number 3560007, Nagpur, India|Investigational Site Number 3560004, Nagpur, India|Investigational Site Number 3560008, Nagpur, India|Investigational Site Number 3560016, Nagpur, India|Investigational Site Number 3560014, New Delhi, India|Investigational Site Number 3560005, Pune, India|Investigational Site Number 3560011, Pune, India|Investigational Site Number 3560013, Surat, India|Investigational Site Number 3560015, Vijayawada, India|Investigational Site Number 3560012, Vijaywada, India|Investigational Site Number 7640003, Bangkok-Noi, Thailand|Investigational Site Number 7640004, Bangkok, Thailand|Investigational Site Number 7640001, Muang, Thailand|Investigational Site Number 7640002, Pratumwan, Thailand","https://ClinicalTrials.gov/show/NCT02715726"
1006,"A 5-way Treatment Period Trial of Single Doses of Intranasal GSK256066 in Patients With Rhinitis","Completed","Has Results","Rhinitis, Allergic, Seasonal","Drug: GSK256066","GSK Investigational Site, Berlin, Germany","https://ClinicalTrials.gov/show/NCT00464568"
1007,"Study of Nasal Symptom Relief and Side Effects in Hayfever Patients Treated With Aerius (Desloratadine)(P03442)","Completed","No Results Available","Rhinitis, Allergic, Seasonal","Drug: desloratadine",,"https://ClinicalTrials.gov/show/NCT00805584"
1008,"Multiple Ascending Dose Study in Healthy Male Subjects and Overweight to Obese Male and Female Type 2 Diabetes Mellitus (T2DM) Patients","Completed","No Results Available","Type 2 Diabetes Mellitus","Drug: SAR425899|Drug: placebo|Drug: metformin","Investigational Site Number 276001, Berlin, Germany","https://ClinicalTrials.gov/show/NCT02411825"
1009,"A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection","Not yet recruiting","No Results Available","COVID-19|Coronavirus Infection|Sars-CoV2|Corona Virus Infection|COVID|Coronavirus|Coronavirus-19|Coronavirus 19","Drug: Hydroxychloroquine|Dietary Supplement: Vitamin C|Dietary Supplement: Vitamin D|Dietary Supplement: Zinc","ProgenaBiome, Ventura, California, United States","https://ClinicalTrials.gov/show/NCT04335084"
1010,"ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab","Completed","Has Results","Atherosclerotic Cardiovascular Disease","Drug: Alirocumab|Drug: Placebo|Drug: LMT","Investigational Site Number 840163, Birmingham, Alabama, United States|Investigational Site Number 840060, Birmingham, Alabama, United States|Investigational Site Number 840117, Huntsville, Alabama, United States|Investigational Site Number 840192, Huntsville, Alabama, United States|Investigational Site Number 840121, Mobile, Alabama, United States|Investigational Site Number 840319, Mobile, Alabama, United States|Investigational Site Number 840332, Atlantis, Arizona, United States|Investigational Site Number 840320, Newport Beach, Arizona, United States|Investigational Site Number 840103, Tucson, Arizona, United States|Investigational Site Number 840084, Tucson, Arizona, United States|Investigational Site Number 840139, Banning, California, United States|Investigational Site Number 840286, Beverly Hills, California, United States|Investigational Site Number 840246, Beverly Hills, California, United States|Investigational Site Number 840353, Beverly Hills, California, United States|Investigational Site Number 840341, Carmichael, California, United States|Investigational Site Number 840299, Chula Vista, California, United States|Investigational Site Number 840164, Fresno, California, United States|Investigational Site Number 840076, Fullerton, California, United States|Investigational Site Number 840073, Huntington Beach, California, United States|Investigational Site Number 840092, La Jolla, California, United States|Investigational Site Number 840208, Long Beach, California, United States|Investigational Site Number 840068, Long Beach, California, United States|Investigational Site Number 840269, Los Alamitos, California, United States|Investigational Site Number 840009, Los Angeles, California, United States|Investigational Site Number 840282, Los Angeles, California, United States|Investigational Site Number 840019, Mission Viejo, California, United States|Investigational Site Number 840336, Moreno Valley, California, United States|Investigational Site Number 840124, Northridge, California, United States|Investigational Site Number 840251, Pasadena, California, United States|Investigational Site Number 840289, Pasadena, California, United States|Investigational Site Number 840312, Port Hueneme, California, United States|Investigational Site Number 840261, San Diego, California, United States|Investigational Site Number 840310, San Diego, California, United States|Investigational Site Number 840024, San Diego, California, United States|Investigational Site Number 840071, Santa Ana, California, United States|Investigational Site Number 840236, Santa Rosa, California, United States|Investigational Site Number 840012, Torrance, California, United States|Investigational Site Number 840096, Aurora, Colorado, United States|Investigational Site Number 840037, Colorado Springs, Colorado, United States|Investigational Site Number 840189, Denver, Colorado, United States|Investigational Site Number 840122, Bridgeport, Connecticut, United States|Investigational Site Number 840219, Guilford, Connecticut, United States|Investigational Site Number 840347, Altamonte Springs, Florida, United States|Investigational Site Number 840066, Clearwater, Florida, United States|Investigational Site Number 840079, Daytona Beach, Florida, United States|Investigational Site Number 840051, Daytona Beach, Florida, United States|Investigational Site Number 840368, Delray Beach, Florida, United States|Investigational Site Number 840242, Fort Lauderdale, Florida, United States|Investigational Site Number 840134, Gainesville, Florida, United States|Investigational Site Number 840327, Hollywood, Florida, United States|Investigational Site Number 840153, Hudson, Florida, United States|Investigational Site Number 840105, Hudson, Florida, United States|Investigational Site Number 840253, Jacksonville, Florida, United States|Investigational Site Number 840141, Jacksonville, Florida, United States|Investigational Site Number 840042, Jacksonville, Florida, United States|Investigational Site Number 840206, Jacksonville, Florida, United States|Investigational Site Number 840063, Jacksonville, Florida, United States|Investigational Site Number 840002, Jupiter, Florida, United States|Investigational Site Number 840119, Largo, Florida, United States|Investigational Site Number 840241, Miami Beach, Florida, United States|Investigational Site Number 840210, Mount Clemens, Florida, United States|Investigational Site Number 840366, New Port Richey, Florida, United States|Investigational Site Number 840311, Palm Beach Gardens, Florida, United States|Investigational Site Number 840280, Palm Harbor, Florida, United States|Investigational Site Number 840054, Panama City, Florida, United States|Investigational Site Number 840239, Pembroke Pines, Florida, United States|Investigational Site Number 840044, Pensacola, Florida, United States|Investigational Site Number 840367, Plantation, Florida, United States|Investigational Site Number 840132, Safety Harbor, Florida, United States|Investigational Site Number 840061, Safety Harbor, Florida, United States|Investigational Site Number 840247, Sarasota, Florida, United States|Investigational Site Number 840264, Tampa, Florida, United States|Investigational Site Number 840082, Tampa, Florida, United States|Investigational Site Number 840213, Trinity, Florida, United States|Investigational Site Number 840165, Wellington, Florida, United States|Investigational Site Number 840323, West Palm Beach, Florida, United States|Investigational Site Number 840075, Atlanta, Georgia, United States|Investigational Site Number 840176, Augusta, Georgia, United States|Investigational Site Number 840048, Covington, Georgia, United States|Investigational Site Number 840065, Cumming, Georgia, United States|Investigational Site Number 840356, Thomasville, Georgia, United States|Investigational Site Number 840114, Tucker, Georgia, United States|Investigational Site Number 840211, Idaho Falls, Idaho, United States|Investigational Site Number 840237, Arlington Heights, Illinois, United States|Investigational Site Number 840292, Chicago, Illinois, United States|Investigational Site Number 840146, Harvey, Illinois, United States|Investigational Site Number 840340, Joliet, Illinois, United States|Investigational Site Number 840196, Peoria, Illinois, United States|Investigational Site Number 840081, Rock Island, Illinois, United States|Investigational Site Number 840090, Rock Island, Illinois, United States|Investigational Site Number 840358, Elkhart, Indiana, United States|Investigational Site Number 840036, Hammond, Indiana, United States|Investigational Site Number 840026, Indianapolis, Indiana, United States|Investigational Site Number 840102, Muncie, Indiana, United States|Investigational Site Number 840145, South Bend, Indiana, United States|Investigational Site Number 840154, Ames, Iowa, United States|Investigational Site Number 840345, Iowa City, Iowa, United States|Investigational Site Number 840283, West Des Moines, Iowa, United States|Investigational Site Number 840335, Kansas City, Kansas, United States|Investigational Site Number 840089, Kansas City, Kansas, United States|Investigational Site Number 840218, Kansas City, Kansas, United States|Investigational Site Number 840140, Overland Park, Kansas, United States|Investigational Site Number 840030, Lexington, Kentucky, United States|Investigational Site Number 840023, Louisville, Kentucky, United States|Investigational Site Number 840007, Louisville, Kentucky, United States|Investigational Site Number 840279, Owensboro, Kentucky, United States|Investigational Site Number 840308, Pikeville, Kentucky, United States|Investigational Site Number 840181, Saint Paul, Kentucky, United States|Investigational Site Number 840254, Alexandria, Louisiana, United States|Investigational Site Number 840344, Lafayette, Louisiana, United States|Investigational Site Number 840187, Lake Charles, Louisiana, United States|Investigational Site Number 840291, Minden, Louisiana, United States|Investigational Site Number 840278, New Orleans, Louisiana, United States|Investigational Site Number 840290, Shreveport, Louisiana, United States|Investigational Site Number 840142, Auburn, Maine, United States|Investigational Site Number 840148, Auburn, Maine, United States|Investigational Site Number 840097, Bangor, Maine, United States|Investigational Site Number 840234, Framingham, Maine, United States|Investigational Site Number 840276, Scarborough, Maine, United States|Investigational Site Number 840351, Annapolis, Maryland, United States|Investigational Site Number 840072, Beltsville, Maryland, United States|Investigational Site Number 840193, Bethesda, Maryland, United States|Investigational Site Number 840200, Columbia, Maryland, United States|Investigational Site Number 840349, Rockville, Maryland, United States|Investigational Site Number 840111, Winfield, Maryland, United States|Investigational Site Number 840056, Boston, Massachusetts, United States|Investigational Site Number 840144, Flint, Michigan, United States|Investigational Site Number 840365, Grandville, Michigan, United States|Investigational Site Number 840093, Kalamazoo, Michigan, United States|Investigational Site Number 840198, Lansing, Michigan, United States|Investigational Site Number 840087, Rochester Hills, Michigan, United States|Investigational Site Number 840004, Springfield, Michigan, United States|Investigational Site Number 840267, Springfield, Michigan, United States|Investigational Site Number 840035, Ypsilanti, Michigan, United States|Investigational Site Number 840199, Duluth, Minnesota, United States|Investigational Site Number 840116, Edina, Minnesota, United States|Investigational Site Number 840281, Minneapolis, Minnesota, United States|Investigational Site Number 840094, Saint Cloud, Minnesota, United States|Investigational Site Number 840324, Saint Paul, Minnesota, United States|Investigational Site Number 840046, Columbia, Missouri, United States|Investigational Site Number 840180, Independence, Missouri, United States|Investigational Site Number 840274, Little Rock, Missouri, United States|Investigational Site Number 840013, Marquette, Missouri, United States|Investigational Site Number 840179, Overland, Missouri, United States|Investigational Site Number 840228, Saint Louis, Missouri, United States|Investigational Site Number 840233, Saint Louis, Missouri, United States|Investigational Site Number 840235, Saint Louis, Missouri, United States|Investigational Site Number 840175, Saint Louis, Missouri, United States|Investigational Site Number 840125, Saint Louis, Missouri, United States|Investigational Site Number 840168, Saint Louis, Missouri, United States|Investigational Site Number 840032, Kalispell, Montana, United States|Investigational Site Number 840033, Grand Island, Nebraska, United States|Investigational Site Number 840015, Omaha, Nebraska, United States|Investigational Site Number 840021, Omaha, Nebraska, United States|Investigational Site Number 840001, Omaha, Nebraska, United States|Investigational Site Number 840221, Las Vegas, Nevada, United States|Investigational Site Number 840062, Nashua, New Hampshire, United States|Investigational Site Number 840077, Bridgewater, New Jersey, United States|Investigational Site Number 840173, Bridgewater, New Jersey, United States|Investigational Site Number 840127, Flemington, New Jersey, United States|Investigational Site Number 840359, Hackensack, New Jersey, United States|Investigational Site Number 840348, Moorestown, New Jersey, United States|Investigational Site Number 840128, New Brunswick, New Jersey, United States|Investigational Site Number 840167, Pomona, New Jersey, United States|Investigational Site Number 840067, Ridgewood, New Jersey, United States|Investigational Site Number 840250, Somerset, New Jersey, United States|Investigational Site Number 840277, Voorhees, New Jersey, United States|Investigational Site Number 840083, Westwood, New Jersey, United States|Investigational Site Number 840222, Bronx, New York, United States|Investigational Site Number 840322, Buffalo, New York, United States|Investigational Site Number 840248, New York, New York, United States|Investigational Site Number 840371, New York, New York, United States|Investigational Site Number 840333, Newburgh, New York, United States|Investigational Site Number 840017, Poughkeepsie, New York, United States|Investigational Site Number 840166, Valhalla, New York, United States|Investigational Site Number 840354, Williamsville, New York, United States|Investigational Site Number 840070, Elizabeth City, North Carolina, United States|Investigational Site Number 840303, Greenville, North Carolina, United States|Investigational Site Number 840182, Greenville, North Carolina, United States|Investigational Site Number 840243, Raleigh, North Carolina, United States|Investigational Site Number 840342, Raleigh, North Carolina, United States|Investigational Site Number 840293, Rocky Mount, North Carolina, United States|Investigational Site Number 840088, Statesville, North Carolina, United States|Investigational Site Number 840052, Wilmington, North Carolina, United States|Investigational Site Number 840306, Baltimore, North Dakota, United States|Investigational Site Number 840214, Fargo, North Dakota, United States|Investigational Site Number 840095, Minot, North Dakota, United States|Investigational Site Number 840257, Mountain Lakes, North Dakota, United States|Investigational Site Number 840364, Akron, Ohio, United States|Investigational Site Number 840131, Cincinnati, Ohio, United States|Investigational Site Number 840045, Columbus, Ohio, United States|Investigational Site Number 840265, Columbus, Ohio, United States|Investigational Site Number 840113, Lorain, Ohio, United States|Investigational Site Number 840115, Lorain, Ohio, United States|Investigational Site Number 840309, Maumee, Ohio, United States|Investigational Site Number 840297, Springfield, Ohio, United States|Investigational Site Number 840172, Toledo, Ohio, United States|Investigational Site Number 840263, Youngstown, Ohio, United States|Investigational Site Number 840334, Oklahoma City, Oklahoma, United States|Investigational Site Number 840337, Oklahoma City, Oklahoma, United States|Investigational Site Number 840018, Tulsa, Oklahoma, United States|Investigational Site Number 840184, Portland, Oregon, United States|Investigational Site Number 840133, Allentown, Pennsylvania, United States|Investigational Site Number 840104, Beaver, Pennsylvania, United States|Investigational Site Number 840170, Camp Hill, Pennsylvania, United States|Investigational Site Number 840020, Doylestown, Pennsylvania, United States|Investigational Site Number 840016, Erie, Pennsylvania, United States|Investigational Site Number 840329, Goodyear, Pennsylvania, United States|Investigational Site Number 840126, Knoxville, Pennsylvania, United States|Investigational Site Number 840249, Lancaster, Pennsylvania, United States|Investigational Site Number 840150, Lancaster, Pennsylvania, United States|Investigational Site Number 840231, Philadelphia, Pennsylvania, United States|Investigational Site Number 840339, Philadelphia, Pennsylvania, United States|Investigational Site Number 840230, Pittsburgh, Pennsylvania, United States|Investigational Site Number 840028, Sayre, Pennsylvania, United States|Investigational Site Number 840069, Scranton, Pennsylvania, United States|Investigational Site Number 840316, Scranton, Pennsylvania, United States|Investigational Site Number 840273, Seven Fields, Pennsylvania, United States|Investigational Site Number 840227, Washington, Pennsylvania, United States|Investigational Site Number 840129, Pawtucket, Rhode Island, United States|Investigational Site Number 840118, Anderson, South Carolina, United States|Investigational Site Number 840190, Greenwood, South Carolina, United States|Investigational Site Number 840360, Lancaster, South Carolina, United States|Investigational Site Number 840314, Myrtle Beach, South Carolina, United States|Investigational Site Number 840008, Rapid City, South Dakota, United States|Investigational Site Number 840285, Chattanooga, Tennessee, United States|Investigational Site Number 840287, Jackson, Tennessee, United States|Investigational Site Number 840040, Johnson City, Tennessee, United States|Investigational Site Number 840238, Knoxville, Tennessee, United States|Investigational Site Number 840195, Oak Ridge, Tennessee, United States|Investigational Site Number 840205, Amarillo, Texas, United States|Investigational Site Number 840352, Amarillo, Texas, United States|Investigational Site Number 840135, Austin, Texas, United States|Investigational Site Number 840301, Dallas, Texas, United States|Investigational Site Number 840152, Dallas, Texas, United States|Investigational Site Number 840157, Dallas, Texas, United States|Investigational Site Number 840229, Fort Worth, Texas, United States|Investigational Site Number 840120, Fort Worth, Texas, United States|Investigational Site Number 840258, Fort Worth, Texas, United States|Investigational Site Number 840136, Kingwood, Texas, United States|Investigational Site Number 840027, Lubbock, Texas, United States|Investigational Site Number 840202, Lufkin, Texas, United States|Investigational Site Number 840270, Odessa, Texas, United States|Investigational Site Number 840162, San Antonio, Texas, United States|Investigational Site Number 840232, San Antonio, Texas, United States|Investigational Site Number 840328, Schertz, Texas, United States|Investigational Site Number 840158, Tyler, Texas, United States|Investigational Site Number 840318, Victoria, Texas, United States|Investigational Site Number 840245, Wichita Falls, Texas, United States|Investigational Site Number 840256, Orem, Utah, United States|Investigational Site Number 840296, Salt Lake City, Utah, United States|Investigational Site Number 840053, Burlington, Vermont, United States|Investigational Site Number 840049, Charlottesville, Virginia, United States|Investigational Site Number 840260, Charlottesville, Virginia, United States|Investigational Site Number 840350, Harrisonburg, Virginia, United States|Investigational Site Number 840215, Leesburg, Virginia, United States|Investigational Site Number 840010, Lynchburg, Virginia, United States|Investigational Site Number 840225, Manassas, Virginia, United States|Investigational Site Number 840022, Richmond, Virginia, United States|Investigational Site Number 840078, Richmond, Virginia, United States|Investigational Site Number 840110, Richmond, Virginia, United States|Investigational Site Number 840149, Roanoke, Virginia, United States|Investigational Site Number 840223, Winchester, Virginia, United States|Investigational Site Number 840025, Bellevue, Washington, United States|Investigational Site Number 840321, Everett, Washington, United States|Investigational Site Number 840326, Spokane, Washington, United States|Investigational Site Number 840086, Tacoma, Washington, United States|Investigational Site Number 840295, Walla Walla, Washington, United States|Investigational Site Number 840262, Burlington, Wisconsin, United States|Investigational Site Number 840298, Green Bay, Wisconsin, United States|Investigational Site Number 840059, Green Bay, Wisconsin, United States|Investigational Site Number 840177, La Crosse, Wisconsin, United States|Investigational Site Number 840300, Manitowoc, Wisconsin, United States|Investigational Site Number 032012, Adrogue, Argentina|Investigational Site Number 032018, Bahia Blanca, Argentina|Investigational Site Number 032050, Caba, Argentina|Investigational Site Number 032048, Caba, Argentina|Investigational Site Number 032023, Caba, Argentina|Investigational Site Number 032020, Caba, Argentina|Investigational Site Number 032041, Caba, Argentina|Investigational Site Number 032011, Caba, Argentina|Investigational Site Number 032045, Caba, Argentina|Investigational Site Number 032010, Ciudad De Buenos Aires, Argentina|Investigational Site Number 032046, Ciudadela, Argentina|Investigational Site Number 032032, Cordoba, Argentina|Investigational Site Number 032019, Cordoba, Argentina|Investigational Site Number 032021, Cordoba, Argentina|Investigational Site Number 032008, Cordoba, Argentina|Investigational Site Number 032042, Cordoba, Argentina|Investigational Site Number 032038, Cordoba, Argentina|Investigational Site Number 032031, Cordoba, Argentina|Investigational Site Number 032017, Coronel Suarez, Argentina|Investigational Site Number 032009, Corrientes, Argentina|Investigational Site Number 032026, Córdoba, Argentina|Investigational Site Number 032049, Córdoba, Argentina|Investigational Site Number 032005, Junin, Argentina|Investigational Site Number 032001, La Plata, Argentina|Investigational Site Number 032040, La Plata, Argentina|Investigational Site Number 032033, Mar Del Plata, Argentina|Investigational Site Number 032014, Mar Del Plata, Argentina|Investigational Site Number 032016, Mendoza, Argentina|Investigational Site Number 032030, Merlo, Argentina|Investigational Site Number 032036, Moron, Argentina|Investigational Site Number 032007, Olivos, Argentina|Investigational Site Number 032044, Olivos, Argentina|Investigational Site Number 032004, Quilmes, Argentina|Investigational Site Number 032025, Rafaela, Argentina|Investigational Site Number 032035, Ramos Mejia, Argentina|Investigational Site Number 032039, Resistencia, Argentina|Investigational Site Number 032028, Rosario, Argentina|Investigational Site Number 032024, Rosario, Argentina|Investigational Site Number 032053, Salta, Argentina|Investigational Site Number 032037, San Isidro, Argentina|Investigational Site Number 032052, San Martin, Argentina|Investigational Site Number 032013, San Martin, Argentina|Investigational Site Number 032002, San Miguel De Tucuman, Argentina|Investigational Site Number 032034, San Miguel De Tucuman, Argentina|Investigational Site Number 032006, San Nicolas, Argentina|Investigational Site Number 032043, Santa Fe, Argentina|Investigational Site Number 032003, Santa Fe, Argentina|Investigational Site Number 032051, Santa Rosa, Argentina|Investigational Site Number 032047, Santiago Del Estero, Argentina|Investigational Site Number 032029, Venado Tuerto, Argentina|Investigational Site Number 032022, Villa Maria, Argentina|Investigational Site Number 032015, Zarate, Argentina|Investigational Site Number 036002, Ashford, Australia|Investigational Site Number 036023, Auchenflower, Australia|Investigational Site Number 036024, Ballarat, Australia|Investigational Site Number 036020, Bedford Park, Australia|Investigational Site Number 036015, Bruce, Australia|Investigational Site Number 036026, Cairns, Australia|Investigational Site Number 036005, Chermside, Australia|Investigational Site Number 036008, Chermside, Australia|Investigational Site Number 036011, Coffs Harbour, Australia|Investigational Site Number 036003, Concord, Australia|Investigational Site Number 036017, Elizabeth Vale, Australia|Investigational Site Number 036006, Fullarton, Australia|Investigational Site Number 036004, Gosford, Australia|Investigational Site Number 036019, Heidelberg West, Australia|Investigational Site Number 036027, Hobart, Australia|Investigational Site Number 036009, Kogarah, Australia|Investigational Site Number 036012, Mildura, Australia|Investigational Site Number 036028, Nambour, Australia|Investigational Site Number 036013, New Lambton, Australia|Investigational Site Number 036010, Perth, Australia|Investigational Site Number 036014, Prahran, Australia|Investigational Site Number 036018, Redcliffe, Australia|Investigational Site Number 036022, Richmond, Australia|Investigational Site Number 036025, Woodville South, Australia|Investigational Site Number 036021, Woolloongabba, Australia|Investigational Site Number 040004, Feldkirch, Austria|Investigational Site Number 040007, Graz, Austria|Investigational Site Number 040001, Salzburg, Austria|Investigational Site Number 040006, Wien, Austria|Investigational Site Number 040003, Wien, Austria|Investigational Site Number 040002, Wien, Austria|Investigational Site Number 056016, Aalst, Belgium|Investigational Site Number 056003, Antwerpen, Belgium|Investigational Site Number 056002, Antwerpen, Belgium|Investigational Site Number 056008, Bonheiden, Belgium|Investigational Site Number 056014, Brasschaat, Belgium|Investigational Site Number 056021, Brussels, Belgium|Investigational Site Number 056005, Bruxelles, Belgium|Investigational Site Number 056004, Bruxelles, Belgium|Investigational Site Number 056017, Edegem, Belgium|Investigational Site Number 056024, Genk, Belgium|Investigational Site Number 056007, Gent, Belgium|Investigational Site Number 056018, Gent, Belgium|Investigational Site Number 056020, La Louviere, Belgium|Investigational Site Number 056009, Leuven, Belgium|Investigational Site Number 056015, Liège, Belgium|Investigational Site Number 056010, Mechelen, Belgium|Investigational Site Number 056013, Mol, Belgium|Investigational Site Number 056001, Ottignies, Belgium|Investigational Site Number 056012, Overpelt, Belgium|Investigational Site Number 056006, Roeselare, Belgium|Investigational Site Number 056019, Tienen, Belgium|Investigational Site Number 070001, Banja Luka, Bosnia and Herzegovina|Investigational Site Number 070002, Banja Luka, Bosnia and Herzegovina|Investigational Site Number 070011, Bihac, Bosnia and Herzegovina|Investigational Site Number 070003, Mostar, Bosnia and Herzegovina|Investigational Site Number 070004, Mostar, Bosnia and Herzegovina|Investigational Site Number 070005, Sarajevo, Bosnia and Herzegovina|Investigational Site Number 070007, Sarajevo, Bosnia and Herzegovina|Investigational Site Number 070010, Sarajevo, Bosnia and Herzegovina|Investigational Site Number 070008, Tuzla, Bosnia and Herzegovina|Investigational Site Number 070009, Tuzla, Bosnia and Herzegovina|Investigational Site Number 070006, Zenica, Bosnia and Herzegovina|Investigational Site Number 076029, Aparecida De Goiania, Brazil|Investigational Site Number 076032, Belem, Brazil|Investigational Site Number 076017, Belo Horizonte, Brazil|Investigational Site Number 076004, Belo Horizonte, Brazil|Investigational Site Number 076022, Belo Horizonte, Brazil|Investigational Site Number 076038, Belo Horizonte, Brazil|Investigational Site Number 076002, Blumenau, Brazil|Investigational Site Number 076011, Brasilia, Brazil|Investigational Site Number 076007, Brasilia, Brazil|Investigational Site Number 076003, Campina Grande Do Sul, Brazil|Investigational Site Number 076006, Campinas, Brazil|Investigational Site Number 076040, Canoas, Brazil|Investigational Site Number 076033, Curitiba, Brazil|Investigational Site Number 076005, Curitiba, Brazil|Investigational Site Number 076009, Fortaleza, Brazil|Investigational Site Number 076008, Fortaleza, Brazil|Investigational Site Number 076012, Goiania, Brazil|Investigational Site Number 076021, Goiania, Brazil|Investigational Site Number 076019, Passo Fundo, Brazil|Investigational Site Number 076018, Pelotas, Brazil|Investigational Site Number 076024, Porto Alegre, Brazil|Investigational Site Number 076026, Porto Alegre, Brazil|Investigational Site Number 076014, Porto Alegre, Brazil|Investigational Site Number 076001, Porto Alegre, Brazil|Investigational Site Number 076027, Porto Alegre, Brazil|Investigational Site Number 076035, Riberao Preto, Brazil|Investigational Site Number 076010, Rio De Janeiro, Brazil|Investigational Site Number 076015, Salvador, Brazil|Investigational Site Number 076041, Salvador, Brazil|Investigational Site Number 076036, Santo Andre, Brazil|Investigational Site Number 076031, Sao Bernardo Do Campo, Brazil|Investigational Site Number 076030, Sao Jose Do Rio Preto, Brazil|Investigational Site Number 076020, Sao Jose Do Rio Preto, Brazil|Investigational Site Number 076025, Sao Paulo, Brazil|Investigational Site Number 076042, Sao Paulo, Brazil|Investigational Site Number 076039, Sao Paulo, Brazil|Investigational Site Number 076013, Sao Paulo, Brazil|Investigational Site Number 076023, Sao Paulo, Brazil|Investigational Site Number 076028, Sao Paulo, Brazil|Investigational Site Number 076016, Tatuí, Brazil|Investigational Site Number 076034, Uberlandia, Brazil|Investigational Site Number 100020, Blagoevgrad, Bulgaria|Investigational Site Number 100012, Burgas, Bulgaria|Investigational Site Number 100011, Pazardzhik, Bulgaria|Investigational Site Number 100013, Pleven, Bulgaria|Investigational Site Number 100018, Pleven, Bulgaria|Investigational Site Number 100005, Plovdiv, Bulgaria|Investigational Site Number 100015, Sandanski, Bulgaria|Investigational Site Number 100023, Smoljan, Bulgaria|Investigational Site Number 100017, Sofia, Bulgaria|Investigational Site Number 100007, Sofia, Bulgaria|Investigational Site Number 100001, Sofia, Bulgaria|Investigational Site Number 100004, Sofia, Bulgaria|Investigational Site Number 100010, Sofia, Bulgaria|Investigational Site Number 100019, Sofia, Bulgaria|Investigational Site Number 100016, Sofia, Bulgaria|Investigational Site Number 100003, Sofia, Bulgaria|Investigational Site Number 100022, Varna, Bulgaria|Investigational Site Number 100014, Veliko Tarnovo, Bulgaria|Investigational Site Number 124033, Calgary, Canada|Investigational Site Number 124017, Cambridge, Canada|Investigational Site Number 124013, Cambridge, Canada|Investigational Site Number 124026, Edmonton, Canada|Investigational Site Number 124019, Edmonton, Canada|Investigational Site Number 124016, Edmonton, Canada|Investigational Site Number 124027, Granby, Canada|Investigational Site Number 124002, Halifax, Canada|Investigational Site Number 124051, Hamilton, Canada|Investigational Site Number 124043, Joliette, Canada|Investigational Site Number 124045, Kitchener, Canada|Investigational Site Number 124053, Levis, Canada|Investigational Site Number 124015, Longueuil, Canada|Investigational Site Number 124004, Moncton, Canada|Investigational Site Number 124040, Montreal, Canada|Investigational Site Number 124032, Montreal, Canada|Investigational Site Number 124036, Montreal, Canada|Investigational Site Number 124042, Montreal, Canada|Investigational Site Number 124028, New Westminster, Canada|Investigational Site Number 124008, Newmarket, Canada|Investigational Site Number 124005, Oshawa, Canada|Investigational Site Number 124007, Ottawa, Canada|Investigational Site Number 124006, Penticton, Canada|Investigational Site Number 124012, Red Deer, Canada|Investigational Site Number 124054, Saint-Jerome, Canada|Investigational Site Number 124024, Sainte-Foy, Canada|Investigational Site Number 124035, Scarborough, Canada|Investigational Site Number 124047, Sherbrooke, Canada|Investigational Site Number 124025, St-Georges, Canada|Investigational Site Number 124044, St. Catherines, Canada|Investigational Site Number 124034, St. John'S, Canada|Investigational Site Number 124021, St. John, Canada|Investigational Site Number 124009, Surrey, Canada|Investigational Site Number 124022, Sydney, Canada|Investigational Site Number 124048, Thetford Mines, Canada|Investigational Site Number 124037, Thunder Bay, Canada|Investigational Site Number 124001, Toronto, Canada|Investigational Site Number 124049, Trois-Rivieres, Canada|Investigational Site Number 124039, Vancouver, Canada|Investigational Site Number 124023, Victoria, Canada|Investigational Site Number 124041, Victoria, Canada|Investigational Site Number 124038, Winnipeg, Canada|Investigational Site Number 152013, Concepcion, Chile|Investigational Site Number 152003, Osorno, Chile|Investigational Site Number 152017, Punta Arenas, Chile|Investigational Site Number 152004, Santiago, Chile|Investigational Site Number 152014, Santiago, Chile|Investigational Site Number 152001, Santiago, Chile|Investigational Site Number 152019, Santiago, Chile|Investigational Site Number 152007, Santiago, Chile|Investigational Site Number 152012, Santiago, Chile|Investigational Site Number 152011, Santiago, Chile|Investigational Site Number 152006, Santiago, Chile|Investigational Site Number 152016, Santiago, Chile|Investigational Site Number 152015, Santiago, Chile|Investigational Site Number 152009, Talca, Chile|Investigational Site Number 152002, Temuco, Chile|Investigational Site Number 152008, Valdivia, Chile|Investigational Site Number 152010, Viña Del Mar, Chile|Investigational Site Number 152018, Viña Del Mar, Chile|Investigational Site Number 156022, Baotou, China|Investigational Site Number 156004, Beijing, China|Investigational Site Number 156005, Beijing, China|Investigational Site Number 156006, Beijing, China|Investigational Site Number 156001, Beijing, China|Investigational Site Number 156082, Beijing, China|Investigational Site Number 156009, Beijing, China|Investigational Site Number 156003, Beijing, China|Investigational Site Number 156002, Beijing, China|Investigational Site Number 156013, Changchun, China|Investigational Site Number 156064, Changchun, China|Investigational Site Number 156052, Changsha, China|Investigational Site Number 156053, Changsha, China|Investigational Site Number 156088, Changsha, China|Investigational Site Number 156057, Chongqing, China|Investigational Site Number 156070, Fuzhou, China|Investigational Site Number 156079, Fuzhou, China|Investigational Site Number 156059, Guangzhou, China|Investigational Site Number 156060, Guangzhou, China|Investigational Site Number 156071, Guangzhou, China|Investigational Site Number 156061, Guangzhou, China|Investigational Site Number 156072, Guiyang, China|Investigational Site Number 156047, Hangzhou, China|Investigational Site Number 156077, Hangzhou, China|Investigational Site Number 156048, Hangzhou, China|Investigational Site Number 156068, Hangzhou, China|Investigational Site Number 156078, Hangzhou, China|Investigational Site Number 156046, Hangzhou, China|Investigational Site Number 156020, Hohhot, China|Investigational Site Number 156032, Jinan, China|Investigational Site Number 156031, Jinan, China|Investigational Site Number 156027, Lanzhou, China|Investigational Site Number 156074, Lanzhou, China|Investigational Site Number 156081, Luzhou, China|Investigational Site Number 156054, Nanchang, China|Investigational Site Number 156055, Nanchang, China|Investigational Site Number 156034, Nanjing, China|Investigational Site Number 156035, Nanjing, China|Investigational Site Number 156039, Shanghai, China|Investigational Site Number 156076, Shanghai, China|Investigational Site Number 156044, Shanghai, China|Investigational Site Number 156043, Shanghai, China|Investigational Site Number 156038, Shanghai, China|Investigational Site Number 156040, Shanghai, China|Investigational Site Number 156016, Shenyang, China|Investigational Site Number 156017, Shenyang, China|Investigational Site Number 156073, Shenzhen, China|Investigational Site Number 156084, Shenzhen, China|Investigational Site Number 156063, Siping, China|Investigational Site Number 156037, Suzhou, China|Investigational Site Number 156066, Tianjin, China|Investigational Site Number 156067, Tianjin, China|Investigational Site Number 156083, Tianjin, China|Investigational Site Number 156025, Tianjin, China|Investigational Site Number 156065, Wenzhou, China|Investigational Site Number 156051, Wuhan, China|Investigational Site Number 156087, Wuhan, China|Investigational Site Number 156029, Xi'An, China|Investigational Site Number 156086, Xi'An, China|Investigational Site Number 156062, Xuzhou, China|Investigational Site Number 156014, Yanji, China|Investigational Site Number 156075, Yueyang, China|Investigational Site Number 156080, Zhanjiang, China|Investigational Site Number 170006, Armenia, Colombia|Investigational Site Number 170003, Barranquilla, Colombia|Investigational Site Number 170011, Barranquilla, Colombia|Investigational Site Number 170013, Barranquilla, Colombia|Investigational Site Number 170022, Bogota D.C., Colombia|Investigational Site Number 170018, Bogota, Colombia|Investigational Site Number 170016, Bogota, Colombia|Investigational Site Number 170010, Cali, Colombia|Investigational Site Number 170001, Cali, Colombia|Investigational Site Number 170017, Cartagena, Colombia|Investigational Site Number 170004, Cartagena, Colombia|Investigational Site Number 170008, Espinal - Tolima, Colombia|Investigational Site Number 170005, Floridablanca, Colombia|Investigational Site Number 170002, Manizales, Colombia|Investigational Site Number 170007, Medellin, Colombia|Investigational Site Number 170009, Medellin, Colombia|Investigational Site Number 170021, Medellin, Colombia|Investigational Site Number 191013, Dubrovnik, Croatia|Investigational Site Number 191017, Krapinske Toplice, Croatia|Investigational Site Number 191009, Opatija, Croatia|Investigational Site Number 191006, Rijeka, Croatia|Investigational Site Number 191012, Slavonski Brod, Croatia|Investigational Site Number 191003, Varazdin, Croatia|Investigational Site Number 191001, Zagreb, Croatia|Investigational Site Number 191002, Zagreb, Croatia|Investigational Site Number 191005, Zagreb, Croatia|Investigational Site Number 191007, Zagreb, Croatia|Investigational Site Number 191008, Zagreb, Croatia|Investigational Site Number 191010, Zagreb, Croatia|Investigational Site Number 191011, Zagreb, Croatia|Investigational Site Number 191015, Zagreb, Croatia|Investigational Site Number 191016, Zagreb, Croatia|Investigational Site Number 191018, Zagreb, Croatia|Investigational Site Number 203003, Brno, Czechia|Investigational Site Number 203020, Ceska Lipa, Czechia|Investigational Site Number 203025, Cesky Krumlov, Czechia|Investigational Site Number 203023, Hodonin, Czechia|Investigational Site Number 203006, Hradec Kralove, Czechia|Investigational Site Number 203019, Kladno, Czechia|Investigational Site Number 203005, Kladno, Czechia|Investigational Site Number 203008, Kromeriz, Czechia|Investigational Site Number 203015, Liberec, Czechia|Investigational Site Number 203024, Marianske Lazne, Czechia|Investigational Site Number 203013, Olomouc, Czechia|Investigational Site Number 203016, Ostrava, Czechia|Investigational Site Number 203014, Pardubice, Czechia|Investigational Site Number 203018, Plzen, Czechia|Investigational Site Number 203011, Praha 10, Czechia|Investigational Site Number 203017, Praha 2, Czechia|Investigational Site Number 203004, Praha 4, Czechia|Investigational Site Number 203021, Praha 4, Czechia|Investigational Site Number 203007, Praha 5 - Motol, Czechia|Investigational Site Number 203012, Praha 5, Czechia|Investigational Site Number 203009, Rakovnik, Czechia|Investigational Site Number 203010, Zlin, Czechia|Investigational Site Number 208016, Aabenraa, Denmark|Investigational Site Number 208012, Aalborg, Denmark|Investigational Site Number 208011, Aarhus N, Denmark|Investigational Site Number 208002, Copenhagen, Denmark|Investigational Site Number 208003, Glostrup, Denmark|Investigational Site Number 208007, Hellerup, Denmark|Investigational Site Number 208006, Herning, Denmark|Investigational Site Number 208018, Hillerød, Denmark|Investigational Site Number 208014, Holbaek, Denmark|Investigational Site Number 208013, Hvidovre, Denmark|Investigational Site Number 208004, Køge, Denmark|Investigational Site Number 208017, Næstved, Denmark|Investigational Site Number 208009, Odense C, Denmark|Investigational Site Number 208015, Silkeborg, Denmark|Investigational Site Number 208008, Slagelse, Denmark|Investigational Site Number 208001, Vejle, Denmark|Investigational Site Number 208010, Viborg, Denmark|Investigational Site Number 233007, Pärnu, Estonia|Investigational Site Number 233004, Tallinn, Estonia|Investigational Site Number 233002, Tallinn, Estonia|Investigational Site Number 233001, Tallinn, Estonia|Investigational Site Number 233005, Tallinn, Estonia|Investigational Site Number 233003, Tartu, Estonia|Investigational Site Number 233006, Viljandimaa, Estonia|Investigational Site Number 246004, Helsinki, Finland|Investigational Site Number 246001, Oulu, Finland|Investigational Site Number 246003, Tampere, Finland|Investigational Site Number 246002, Turku, Finland|Investigational Site Number 250003, Besancon, France|Investigational Site Number 250007, Brest Cedex, France|Investigational Site Number 250010, Cambrai Cedex, France|Investigational Site Number 250018, Clermont-Ferrand Cedex 1, France|Investigational Site Number 250021, Compiegne, France|Investigational Site Number 250002, Dijon, France|Investigational Site Number 250001, Grenoble, France|Investigational Site Number 250009, Limoges Cedex 1, France|Investigational Site Number 250019, Marseille, France|Investigational Site Number 250008, Massy, France|Investigational Site Number 250005, Montfermeil, France|Investigational Site Number 250023, Montpellier Cedex 5, France|Investigational Site Number 250025, Nantes, France|Investigational Site Number 250017, Nice Cedex 01, France|Investigational Site Number 250015, Paris Cedex 12, France|Investigational Site Number 250020, Paris, France|Investigational Site Number 250012, Paris, France|Investigational Site Number 250004, Paris, France|Investigational Site Number 250011, Pau, France|Investigational Site Number 250016, Pessac, France|Investigational Site Number 250026, Rouen, France|Investigational Site Number 250022, Strasbourg Cedex, France|Investigational Site Number 268004, Batumi, Georgia|Investigational Site Number 268001, Kutaisi, Georgia|Investigational Site Number 268005, Tbilisi, Georgia|Investigational Site Number 268002, Tbilisi, Georgia|Investigational Site Number 268003, Tbilisi, Georgia|Investigational Site Number 268008, Tbilisi, Georgia|Investigational Site Number 268009, Tbilisi, Georgia|Investigational Site Number 276013, Aachen, Germany|Investigational Site Number 276019, Bad Krozingen, Germany|Investigational Site Number 276008, Berlin, Germany|Investigational Site Number 276040, Berlin, Germany|Investigational Site Number 276051, Berlin, Germany|Investigational Site Number 276039, Berlin, Germany|Investigational Site Number 276025, Berlin, Germany|Investigational Site Number 276054, Bernau, Germany|Investigational Site Number 276037, Bielefeld, Germany|Investigational Site Number 276016, Bonn, Germany|Investigational Site Number 276009, Bonn, Germany|Investigational Site Number 276001, Dortmund, Germany|Investigational Site Number 276006, Dortmund, Germany|Investigational Site Number 276031, Dortmund, Germany|Investigational Site Number 276050, Dresden, Germany|Investigational Site Number 276024, Eschweiler, Germany|Investigational Site Number 276028, Essen, Germany|Investigational Site Number 276036, Frankfurt Am Main, Germany|Investigational Site Number 276012, Freiburg, Germany|Investigational Site Number 276030, Halle/Saale, Germany|Investigational Site Number 276032, Hamburg, Germany|Investigational Site Number 276017, Hamburg, Germany|Investigational Site Number 276027, Hamburg, Germany|Investigational Site Number 276029, Hamm, Germany|Investigational Site Number 276052, Haßloch, Germany|Investigational Site Number 276014, Heidelberg, Germany|Investigational Site Number 276023, Homburg/Saar, Germany|Investigational Site Number 276035, Kassel, Germany|Investigational Site Number 276046, Leipzig, Germany|Investigational Site Number 276020, Limburg, Germany|Investigational Site Number 276026, Lippstadt, Germany|Investigational Site Number 276044, Lübeck, Germany|Investigational Site Number 276021, Magdeburg, Germany|Investigational Site Number 276015, Mainz, Germany|Investigational Site Number 276010, Marburg, Germany|Investigational Site Number 276018, Münster, Germany|Investigational Site Number 276042, Nürnberg, Germany|Investigational Site Number 276048, Peine, Germany|Investigational Site Number 276053, Rotenburg An Der Fulda, Germany|Investigational Site Number 276045, Rüdersdorf Bei Berlin, Germany|Investigational Site Number 276002, Stuttgart, Germany|Investigational Site Number 276033, Warendorf, Germany|Investigational Site Number 300001, Athens, Greece|Investigational Site Number 300002, Athens, Greece|Investigational Site Number 300007, Athens, Greece|Investigational Site Number 300008, Chios, Greece|Investigational Site Number 300013, Haidari, Greece|Investigational Site Number 300010, Heraklion, Greece|Investigational Site Number 300005, Ioannina, Greece|Investigational Site Number 300003, Marousi, Greece|Investigational Site Number 300006, N. Ionia, Greece|Investigational Site Number 300004, Patra, Greece|Investigational Site Number 300011, Thessaloniki, Greece|Investigational Site Number 300009, Thessaloniki, Greece|Investigational Site Number 320003, Guatemala, Guatemala|Investigational Site Number 320001, Guatemala, Guatemala|Investigational Site Number 320002, Guatemala, Guatemala|Investigational Site Number 320004, Guatemala, Guatemala|Investigational Site Number 344003, Hong Kong, Hong Kong|Investigational Site Number 344001, Shatin, Nt, Hong Kong|Investigational Site Number 348013, Balatonfüred, Hungary|Investigational Site Number 348002, Budapest, Hungary|Investigational Site Number 348012, Budapest, Hungary|Investigational Site Number 348005, Budapest, Hungary|Investigational Site Number 348006, Budapest, Hungary|Investigational Site Number 348008, Debrecen, Hungary|Investigational Site Number 348004, Eger, Hungary|Investigational Site Number 348003, Gyula, Hungary|Investigational Site Number 348010, Pécs, Hungary|Investigational Site Number 348009, Szeged, Hungary|Investigational Site Number 348007, Szekesfehervar, Hungary|Investigational Site Number 348011, Szombathely, Hungary|Investigational Site Number 348001, Zalaegerszeg, Hungary|Investigational Site Number 356060, Ahmedabad, India|Investigational Site Number 356056, Aurangabad, India|Investigational Site Number 356025, Bangalore, India|Investigational Site Number 356028, Bangalore, India|Investigational Site Number 356083, Bangalore, India|Investigational Site Number 356018, Bangalore, India|Investigational Site Number 356026, Bangalore, India|Investigational Site Number 356084, Bangalore, India|Investigational Site Number 356103, Belgaum, India|Investigational Site Number 356019, Bikaner, India|Investigational Site Number 356013, Chennai, India|Investigational Site Number 356012, Chennai, India|Investigational Site Number 356081, Chennai, India|Investigational Site Number 356093, Delhi, India|Investigational Site Number 356038, Delhi, India|Investigational Site Number 356101, Gurgaon, India|Investigational Site Number 356100, Gurgaon, India|Investigational Site Number 356035, Hyderabad, India|Investigational Site Number 356082, Hyderabad, India|Investigational Site Number 356015, Jaipur, India|Investigational Site Number 356053, Karad, India|Investigational Site Number 356102, Karamsad, India|Investigational Site Number 356022, Kochi, India|Investigational Site Number 356106, Kolhapur, India|Investigational Site Number 356067, Kolkata, India|Investigational Site Number 356079, Kolkata, India|Investigational Site Number 356069, Kolkata, India|Investigational Site Number 356089, Ludhiana, India|Investigational Site Number 356095, Mangalore, India|Investigational Site Number 356071, Mumbai, India|Investigational Site Number 356057, Mumbai, India|Investigational Site Number 356007, Mysore, India|Investigational Site Number 356087, Nagpur, India|Investigational Site Number 356098, Nagpur, India|Investigational Site Number 356097, Nagpur, India|Investigational Site Number 356096, Nashik, India|Investigational Site Number 356055, New Delhi, India|Investigational Site Number 356031, New Delhi, India|Investigational Site Number 356041, Panaji, India|Investigational Site Number 356077, Pune, India|Investigational Site Number 356099, Pune, India|Investigational Site Number 356048, Pune, India|Investigational Site Number 356049, Pune, India|Investigational Site Number 356050, Pune, India|Investigational Site Number 356045, Pune, India|Investigational Site Number 356046, Pune, India|Investigational Site Number 356094, Pune, India|Investigational Site Number 356042, Secunderabad, Hyderabad, India|Investigational Site Number 356009, Secunderabad, India|Investigational Site Number 356032, Secunderabad, India|Investigational Site Number 356091, Surat, India|Investigational Site Number 356002, Vijayawada, India|Investigational Site Number 356105, Vijaywada, India|Investigational Site Number 356033, Visakhapatnam, India|Investigational Site Number 356039, Vishkhapattanam, India|Investigational Site Number 356104, Wardha, India|Investigational Site Number 376006, Afula, Israel|Investigational Site Number 376024, Afula, Israel|Investigational Site Number 376009, Ashkelon, Israel|Investigational Site Number 376012, Beer Sheva, Israel|Investigational Site Number 376011, Haifa, Israel|Investigational Site Number 376017, Haifa, Israel|Investigational Site Number 376025, Haifa, Israel|Investigational Site Number 376018, Haifa, Israel|Investigational Site Number 376007, Holon, Israel|Investigational Site Number 376021, Holon, Israel|Investigational Site Number 376016, Jerusalem, Israel|Investigational Site Number 376005, Jerusalem, Israel|Investigational Site Number 376027, Jerusalem, Israel|Investigational Site Number 376002, Kfar Saba, Israel|Investigational Site Number 376013, Kfar Saba, Israel|Investigational Site Number 376004, Nahariya, Israel|Investigational Site Number 376015, Nazareth, Israel|Investigational Site Number 376001, Petah-Tikva, Israel|Investigational Site Number 376019, Petah-Tikva, Israel|Investigational Site Number 376020, Rehovot, Israel|Investigational Site Number 376003, Safed, Israel|Investigational Site Number 376008, Safed, Israel|Investigational Site Number 376010, Tel Aviv, Israel|Investigational Site Number 376014, Tel Aviv, Israel|Investigational Site Number 376022, Tel Hashomer, Israel|Investigational Site Number 376023, Tiberias, Israel|Investigational Site Number 376026, Tzrifin, Israel|Investigational Site Number 380019, Augusta, Italy|Investigational Site Number 380017, Bergamo, Italy|Investigational Site Number 380026, Brescia, Italy|Investigational Site Number 380008, Brescia, Italy|Investigational Site Number 380012, Ferrara, Italy|Investigational Site Number 380027, Forlì, Italy|Investigational Site Number 380015, Livorno, Italy|Investigational Site Number 380033, Massa, Italy|Investigational Site Number 380030, Milano, Italy|Investigational Site Number 380005, Milano, Italy|Investigational Site Number 380003, Milano, Italy|Investigational Site Number 380025, Monza, Italy|Investigational Site Number 380001, Napoli, Italy|Investigational Site Number 380002, Napoli, Italy|Investigational Site Number 380021, Novara, Italy|Investigational Site Number 380009, Osio Sotto, Italy|Investigational Site Number 380007, Palermo, Italy|Investigational Site Number 380013, Perugia, Italy|Investigational Site Number 380031, Rho, Italy|Investigational Site Number 380014, Rimini, Italy|Investigational Site Number 380024, Roma, Italy|Investigational Site Number 380028, Seriate, Italy|Investigational Site Number 380032, Treviso, Italy|Investigational Site Number 380020, Vittorio Veneto, Italy|Investigational Site Number 392013, Amagasaki-Shi, Japan|Investigational Site Number 392041, Amagasaki-Shi, Japan|Investigational Site Number 392029, Fukuoka-Shi, Japan|Investigational Site Number 392019, Hachioji-Shi, Japan|Investigational Site Number 392026, Higashihiroshima-Shi, Japan|Investigational Site Number 392024, Higashiibaraki-Gun, Japan|Investigational Site Number 392003, Hiroshima-Shi, Japan|Investigational Site Number 392002, Itabashi-Ku, Japan|Investigational Site Number 392014, Itabashi-Ku, Japan|Investigational Site Number 392033, Izumisano-Shi, Japan|Investigational Site Number 392020, Kanazawa-Shi, Japan|Investigational Site Number 392015, Kitakyushu-Shi, Japan|Investigational Site Number 392017, Kobe-Shi, Japan|Investigational Site Number 392028, Kobe-Shi, Japan|Investigational Site Number 392037, Kobe-Shi, Japan|Investigational Site Number 392025, Koga-Shi, Japan|Investigational Site Number 392010, Komatsu-Shi, Japan|Investigational Site Number 392035, Komatsushima-Shi, Japan|Investigational Site Number 392023, Kumamoto-Shi, Japan|Investigational Site Number 392031, Kumamoto-Shi, Japan|Investigational Site Number 392039, Kure-Shi, Japan|Investigational Site Number 392012, Kurume-Shi, Japan|Investigational Site Number 392032, Kusatsu-Shi, Japan|Investigational Site Number 392001, Kyoto City, Japan|Investigational Site Number 392027, Minato-Ku, Japan|Investigational Site Number 392016, Morioka-Shi, Japan|Investigational Site Number 392005, Nagoya-Shi, Japan|Investigational Site Number 392022, Nerima-Ku, Japan|Investigational Site Number 392009, Osaka-Shi, Japan|Investigational Site Number 392011, Osaka-Shi, Japan|Investigational Site Number 392040, Osaka-Shi, Japan|Investigational Site Number 392004, Sagamihara-Shi, Japan|Investigational Site Number 392036, Sapporo-Shi, Japan|Investigational Site Number 392034, Shinagawa-Ku, Japan|Investigational Site Number 392018, Suita-Shi, Japan|Investigational Site Number 392030, Tokushima-Shi, Japan|Investigational Site Number 392008, Urasoe-Shi, Japan|Investigational Site Number 392006, Yokohama-Shi, Japan|Investigational Site Number 392021, Yokohama-Shi, Japan|Investigational Site Number 410013, Busan, Korea, Republic of|Investigational Site Number 410003, Busan, Korea, Republic of|Investigational Site Number 410002, Daegu, Korea, Republic of|Investigational Site Number 410012, Goyang-Si, Korea, Republic of|Investigational Site Number 410001, Gwangju, Korea, Republic of|Investigational Site Number 410008, Seongnam, Korea, Republic of|Investigational Site Number 410004, Seoul, Korea, Republic of|Investigational Site Number 410007, Seoul, Korea, Republic of|Investigational Site Number 410010, Seoul, Korea, Republic of|Investigational Site Number 410011, Seoul, Korea, Republic of|Investigational Site Number 410006, Seoul, Korea, Republic of|Investigational Site Number 410009, Suwon, Korea, Republic of|Investigational Site Number 410005, Wonju, Korea, Republic of|Investigational Site Number 428004, Daugavpils, Latvia|Investigational Site Number 428002, Liepaja, Latvia|Investigational Site Number 428006, Riga, Latvia|Investigational Site Number 428001, Riga, Latvia|Investigational Site Number 428005, Riga, Latvia|Investigational Site Number 428003, Ventspils, Latvia|Investigational Site Number 440004, Kaunas, Lithuania|Investigational Site Number 440005, Kaunas, Lithuania|Investigational Site Number 440009, Kaunas, Lithuania|Investigational Site Number 440008, Kaunas, Lithuania|Investigational Site Number 440001, Klaipeda, Lithuania|Investigational Site Number 440006, Klaipeda, Lithuania|Investigational Site Number 440002, Vilnius, Lithuania|Investigational Site Number 440007, Vilnius, Lithuania|Investigational Site Number 440003, Vilnius, Lithuania|Investigational Site Number 807005, Bitola, Macedonia, The Former Yugoslav Republic of|Investigational Site Number 807004, Shtip, Macedonia, The Former Yugoslav Republic of|Investigational Site Number 807002, Skopje, Macedonia, The Former Yugoslav Republic of|Investigational Site Number 807001, Skopje, Macedonia, The Former Yugoslav Republic of|Investigational Site Number 807003, Tetovo, Macedonia, The Former Yugoslav Republic of|Investigational Site Number 458004, Batu Caves, Malaysia|Investigational Site Number 458007, Kota Bharu, Malaysia|Investigational Site Number 458006, Kota Kinabalu, Malaysia|Investigational Site Number 458002, Kuala Lumpur, Malaysia|Investigational Site Number 458005, Kuala Lumpur, Malaysia|Investigational Site Number 458003, Kuching, Malaysia|Investigational Site Number 458001, Sungai Buloh, Malaysia|Investigational Site Number 484005, Aguascalientes, Mexico|Investigational Site Number 484015, Aguascalientes, Mexico|Investigational Site Number 484004, Culiacan, Mexico|Investigational Site Number 484003, Durango, Mexico|Investigational Site Number 484010, Guadalajara, Mexico|Investigational Site Number 484006, Guadalajara, Mexico|Investigational Site Number 484008, Jalapa, Mexico|Investigational Site Number 484019, Mexico D.F., Mexico|Investigational Site Number 484023, Mexico Df, Mexico|Investigational Site Number 484027, Mexico, Mexico|Investigational Site Number 484013, Monterrey, Mexico|Investigational Site Number 484018, Monterrey, Mexico|Investigational Site Number 484011, Monterrey, Mexico|Investigational Site Number 484007, Monterrey, Mexico|Investigational Site Number 484017, Morelia, Mexico|Investigational Site Number 484012, Oaxaca, Mexico|Investigational Site Number 484014, Querétaro, Mexico|Investigational Site Number 484009, San Luis Potosi, Mexico|Investigational Site Number 484002, Tijuana, Mexico|Investigational Site Number 484020, Toluca, Mexico|Investigational Site Number 528006, Alkmaar, Netherlands|Investigational Site Number 528022, Amsterdam, Netherlands|Investigational Site Number 528026, Amsterdam, Netherlands|Investigational Site Number 528021, Apeldoorn, Netherlands|Investigational Site Number 528029, Arnhem, Netherlands|Investigational Site Number 528004, Breda, Netherlands|Investigational Site Number 528002, Delft, Netherlands|Investigational Site Number 528007, Eindhoven, Netherlands|Investigational Site Number 528032, Goes, Netherlands|Investigational Site Number 528012, Gouda, Netherlands|Investigational Site Number 528001, Groningen, Netherlands|Investigational Site Number 528025, Haarlem, Netherlands|Investigational Site Number 528023, Hardenberg, Netherlands|Investigational Site Number 528024, Heerenveen, Netherlands|Investigational Site Number 528016, Hoorn, Netherlands|Investigational Site Number 528019, Leeuwarden, Netherlands|Investigational Site Number 528008, Leiden, Netherlands|Investigational Site Number 528017, Meppel, Netherlands|Investigational Site Number 528030, Nieuwegein, Netherlands|Investigational Site Number 528011, Nijmegen, Netherlands|Investigational Site Number 528015, Purmerend, Netherlands|Investigational Site Number 528018, Roosendaal, Netherlands|Investigational Site Number 528014, Rotterdam, Netherlands|Investigational Site Number 528027, Rotterdam, Netherlands|Investigational Site Number 528005, Sneek, Netherlands|Investigational Site Number 528034, Tiel, Netherlands|Investigational Site Number 528013, Tilburg, Netherlands|Investigational Site Number 528028, Uden, Netherlands|Investigational Site Number 528009, Venlo, Netherlands|Investigational Site Number 528033, Zaandam, Netherlands|Investigational Site Number 528031, Zutphen, Netherlands|Investigational Site Number 528020, Zwolle, Netherlands|Investigational Site Number 554010, Auckland, New Zealand|Investigational Site Number 554001, Christchurch, New Zealand|Investigational Site Number 554006, Dunedin, New Zealand|Investigational Site Number 554004, Hamilton, New Zealand|Investigational Site Number 554011, Lower Hutt, New Zealand|Investigational Site Number 554005, Nelson, New Zealand|Investigational Site Number 554007, New Plymouth, New Zealand|Investigational Site Number 554002, Otahuhu, New Zealand|Investigational Site Number 554008, Palmerston North, New Zealand|Investigational Site Number 554012, Rotorua, New Zealand|Investigational Site Number 554009, Takapuna, New Zealand|Investigational Site Number 554003, Wellington, New Zealand|Investigational Site Number 578004, Arendal, Norway|Investigational Site Number 578013, Bergen, Norway|Investigational Site Number 578009, Hamar, Norway|Investigational Site Number 578006, Kongsvinger, Norway|Investigational Site Number 578003, Oslo, Norway|Investigational Site Number 578005, Oslo, Norway|Investigational Site Number 578012, Stavanger, Norway|Investigational Site Number 578002, Svelvik, Norway|Investigational Site Number 578011, Tynset, Norway|Investigational Site Number 604018, Arequipa, Peru|Investigational Site Number 604004, Callao, Peru|Investigational Site Number 604025, Callao, Peru|Investigational Site Number 604022, Cuzco, Peru|Investigational Site Number 604013, Ica, Peru|Investigational Site Number 604010, Lima, Peru|Investigational Site Number 604008, Lima, Peru|Investigational Site Number 604001, Lima, Peru|Investigational Site Number 604007, Lima, Peru|Investigational Site Number 604005, Lima, Peru|Investigational Site Number 604006, Lima, Peru|Investigational Site Number 604015, Lima, Peru|Investigational Site Number 604016, Lima, Peru|Investigational Site Number 604017, Lima, Peru|Investigational Site Number 604019, Lima, Peru|Investigational Site Number 604003, Lima, Peru|Investigational Site Number 604024, Lima, Peru|Investigational Site Number 604012, Lima, Peru|Investigational Site Number 604020, Piura, Peru|Investigational Site Number 604023, Trujillo, Peru|Investigational Site Number 608012, Cavite, Philippines|Investigational Site Number 608003, Cebu City, Philippines|Investigational Site Number 608013, Cebu City, Philippines|Investigational Site Number 608011, Davao City, Philippines|Investigational Site Number 608010, Davao, Philippines|Investigational Site Number 608006, Iloilo City, Philippines|Investigational Site Number 608002, Makati City, Philippines|Investigational Site Number 608004, Manila, Philippines|Investigational Site Number 608014, Manila, Philippines|Investigational Site Number 608001, Quezon City, Philippines|Investigational Site Number 608009, Quezon City, Philippines|Investigational Site Number 608005, Quezon, Philippines|Investigational Site Number 608008, San Juan, Philippines|Investigational Site Number 616026, Bydgoszcz, Poland|Investigational Site Number 616029, Bydgoszcz, Poland|Investigational Site Number 616010, Chrzanow, Poland|Investigational Site Number 616036, Czeladz, Poland|Investigational Site Number 616034, Gdansk, Poland|Investigational Site Number 616015, Gdansk, Poland|Investigational Site Number 616035, Gdynia, Poland|Investigational Site Number 616005, Gdynia, Poland|Investigational Site Number 616033, Gdynia, Poland|Investigational Site Number 616037, Grodzisk Mazowiecki, Poland|Investigational Site Number 616030, Jelenia Gora, Poland|Investigational Site Number 616031, Krakow, Poland|Investigational Site Number 616002, Krakow, Poland|Investigational Site Number 616012, Leczna, Poland|Investigational Site Number 616017, Legnica, Poland|Investigational Site Number 616019, Lodz, Poland|Investigational Site Number 616016, Lubin, Poland|Investigational Site Number 616021, Olawa, Poland|Investigational Site Number 616039, Olsztyn, Poland|Investigational Site Number 616003, Plock, Poland|Investigational Site Number 616011, Poznan, Poland|Investigational Site Number 616018, Pulawy, Poland|Investigational Site Number 616006, Skierniewice, Poland|Investigational Site Number 616027, Sobotka, Poland|Investigational Site Number 616007, Sokolka, Poland|Investigational Site Number 616022, Swidnik, Poland|Investigational Site Number 616024, Szczecin, Poland|Investigational Site Number 616004, Torun, Poland|Investigational Site Number 616013, Torun, Poland|Investigational Site Number 616025, Torun, Poland|Investigational Site Number 616032, W?Grów, Poland|Investigational Site Number 616040, Warszawa, Poland|Investigational Site Number 616020, Warszawa, Poland|Investigational Site Number 616038, Warszawa, Poland|Investigational Site Number 616008, Warszawa, Poland|Investigational Site Number 616041, Wroclaw, Poland|Investigational Site Number 620004, Almada, Portugal|Investigational Site Number 620005, Aveiro, Portugal|Investigational Site Number 620011, Coimbra, Portugal|Investigational Site Number 620008, Coimbra, Portugal|Investigational Site Number 620001, Leiria, Portugal|Investigational Site Number 620003, Ponta Delgada, Portugal|Investigational Site Number 620002, Setubal, Portugal|Investigational Site Number 620010, Vila Franca De Xira, Portugal|Investigational Site Number 620006, Vila Nova Gaia, Portugal|Investigational Site Number 642001, Braila, Romania|Investigational Site Number 642003, Bucharest, Romania|Investigational Site Number 642012, Bucuresti, Romania|Investigational Site Number 642021, Bucuresti, Romania|Investigational Site Number 642007, Bucuresti, Romania|Investigational Site Number 642008, Bucuresti, Romania|Investigational Site Number 642005, Buzau, Romania|Investigational Site Number 642013, Codlea, Romania|Investigational Site Number 642004, Constanta, Romania|Investigational Site Number 642002, Craiova, Romania|Investigational Site Number 642016, Craiova, Romania|Investigational Site Number 642010, Focsani, Romania|Investigational Site Number 642017, Iasi, Romania|Investigational Site Number 642006, Targoviste, Romania|Investigational Site Number 642019, Targu Mures, Romania|Investigational Site Number 642015, Targu Mures, Romania|Investigational Site Number 642018, Timisoara, Romania|Investigational Site Number 643027, Barnaul, Russian Federation|Investigational Site Number 643037, Kazan, Russian Federation|Investigational Site Number 643013, Kemerovo, Russian Federation|Investigational Site Number 643020, Krasnodar, Russian Federation|Investigational Site Number 643053, Krasnodar, Russian Federation|Investigational Site Number 643033, Moscow, Russian Federation|Investigational Site Number 643002, Moscow, Russian Federation|Investigational Site Number 643011, Moscow, Russian Federation|Investigational Site Number 643029, Moscow, Russian Federation|Investigational Site Number 643028, Moscow, Russian Federation|Investigational Site Number 643004, Moscow, Russian Federation|Investigational Site Number 643016, Moscow, Russian Federation|Investigational Site Number 643023, Moscow, Russian Federation|Investigational Site Number 643044, Moscow, Russian Federation|Investigational Site Number 643022, Moscow, Russian Federation|Investigational Site Number 643031, Moscow, Russian Federation|Investigational Site Number 643043, Nizhny Novgorod, Russian Federation|Investigational Site Number 643034, Novosibirsk, Russian Federation|Investigational Site Number 643052, Novosibirsk, Russian Federation|Investigational Site Number 643050, Novosibirsk, Russian Federation|Investigational Site Number 643035, Omsk, Russian Federation|Investigational Site Number 643039, Perm, Russian Federation|Investigational Site Number 643008, Rostov-Na-Donu, Russian Federation|Investigational Site Number 643017, Ryazan, Russian Federation|Investigational Site Number 643006, Saint - Petersburg, Russian Federation|Investigational Site Number 643015, Saint - Petersburg, Russian Federation|Investigational Site Number 643001, Saint Petersburg, Russian Federation|Investigational Site Number 643007, Saint Petersburg, Russian Federation|Investigational Site Number 643051, Saint-Petersburg, Russian Federation|Investigational Site Number 643042, Saint-Petersburg, Russian Federation|Investigational Site Number 643040, Saint-Petersburg, Russian Federation|Investigational Site Number 643012, Saratov, Russian Federation|Investigational Site Number 643021, Saratov, Russian Federation|Investigational Site Number 643003, Saratov, Russian Federation|Investigational Site Number 643014, Saratov, Russian Federation|Investigational Site Number 643030, St-Petersburg, Russian Federation|Investigational Site Number 643010, St-Petersburg, Russian Federation|Investigational Site Number 643054, St-Petersburg, Russian Federation|Investigational Site Number 643049, Tomsk, Russian Federation|Investigational Site Number 643019, Tyumen, Russian Federation|Investigational Site Number 643025, Tyumen, Russian Federation|Investigational Site Number 643045, Voronezh, Russian Federation|Investigational Site Number 643009, Yaroslavl, Russian Federation|Investigational Site Number 688003, Belgrade, Serbia|Investigational Site Number 688005, Belgrade, Serbia|Investigational Site Number 688006, Belgrade, Serbia|Investigational Site Number 688007, Belgrade, Serbia|Investigational Site Number 688008, Belgrade, Serbia|Investigational Site Number 688010, Belgrade, Serbia|Investigational Site Number 688011, Belgrade, Serbia|Investigational Site Number 688013, Belgrade, Serbia|Investigational Site Number 688015, Belgrade, Serbia|Investigational Site Number 688002, Belgrade, Serbia|Investigational Site Number 688012, Kragujevac, Serbia|Investigational Site Number 688016, Leskovac, Serbia|Investigational Site Number 688001, Niska Banja, Serbia|Investigational Site Number 688004, Nis, Serbia|Investigational Site Number 688018, Pancevo, Serbia|Investigational Site Number 688009, Sremska Kamenica, Serbia|Investigational Site Number 688017, Sremska Mitrovica, Serbia|Investigational Site Number 688014, Valjevo, Serbia|Investigational Site Number 702002, Singapore, Singapore|Investigational Site Number 702003, Singapore, Singapore|Investigational Site Number 702001, Singapore, Singapore|Investigational Site Number 703001, Bardejov, Slovakia|Investigational Site Number 703008, Bratislava, Slovakia|Investigational Site Number 703020, Bratislava, Slovakia|Investigational Site Number 703014, Bratislava, Slovakia|Investigational Site Number 703013, Bratislava, Slovakia|Investigational Site Number 703023, Dolny Kubin, Slovakia|Investigational Site Number 703002, Kosice, Slovakia|Investigational Site Number 703009, Kosice, Slovakia|Investigational Site Number 703016, Kosice, Slovakia|Investigational Site Number 703019, Kosice, Slovakia|Investigational Site Number 703007, Kosice, Slovakia|Investigational Site Number 703012, Kralovsky Chlmec, Slovakia|Investigational Site Number 703006, Lucenec, Slovakia|Investigational Site Number 703010, Lucenec, Slovakia|Investigational Site Number 703003, Nitra, Slovakia|Investigational Site Number 703004, Presov, Slovakia|Investigational Site Number 703018, Svidnik, Slovakia|Investigational Site Number 703022, Trebisov, Slovakia|Investigational Site Number 703005, Zilina, Slovakia|Investigational Site Number 705001, Celje, Slovenia|Investigational Site Number 705004, Izola, Slovenia|Investigational Site Number 705002, Jesenice, Slovenia|Investigational Site Number 705005, Ljubljana, Slovenia|Investigational Site Number 705006, Ljubljana, Slovenia|Investigational Site Number 710017, Alberton, South Africa|Investigational Site Number 710007, Bellville, South Africa|Investigational Site Number 710015, Bloemfontein, South Africa|Investigational Site Number 710009, Cape Town, South Africa|Investigational Site Number 710010, Cape Town, South Africa|Investigational Site Number 710005, Chatsworth, South Africa|Investigational Site Number 710006, Durban, South Africa|Investigational Site Number 710004, Durban, South Africa|Investigational Site Number 710002, Durban, South Africa|Investigational Site Number 710012, Johannesburg, South Africa|Investigational Site Number 710014, Johannesburg, South Africa|Investigational Site Number 710019, Kempton Park, South Africa|Investigational Site Number 710011, Kimberley, South Africa|Investigational Site Number 710021, Kuils River, South Africa|Investigational Site Number 710018, Parow, South Africa|Investigational Site Number 710008, Pretoria, South Africa|Investigational Site Number 710016, Pretoria, South Africa|Investigational Site Number 710020, Stellenbosch, South Africa|Investigational Site Number 710013, Tongaat, South Africa|Investigational Site Number 710022, Western Cape, South Africa|Investigational Site Number 710003, Worcester, South Africa|Investigational Site Number 724010, Alcalá De Henares, Spain|Investigational Site Number 724007, Almería, Spain|Investigational Site Number 724037, Barcelona, Spain|Investigational Site Number 724041, Barcelona, Spain|Investigational Site Number 724038, Barcelona, Spain|Investigational Site Number 724008, Barcelona, Spain|Investigational Site Number 724039, Cáceres, Spain|Investigational Site Number 724042, Córdoba, Spain|Investigational Site Number 724027, Fuenlabrada, Spain|Investigational Site Number 724002, Girona, Spain|Investigational Site Number 724013, Granada, Spain|Investigational Site Number 724032, Guadalajara, Spain|Investigational Site Number 724025, Hospitalet De Llobregat, Spain|Investigational Site Number 724003, Huelva, Spain|Investigational Site Number 724021, León, Spain|Investigational Site Number 724026, Lleida, Spain|Investigational Site Number 724006, Lugo, Spain|Investigational Site Number 724030, Madrid, Spain|Investigational Site Number 724020, Madrid, Spain|Investigational Site Number 724015, Madrid, Spain|Investigational Site Number 724031, Madrid, Spain|Investigational Site Number 724033, Madrid, Spain|Investigational Site Number 724017, Madrid, Spain|Investigational Site Number 724035, Majadahonda, Spain|Investigational Site Number 724036, Murcia, Spain|Investigational Site Number 724016, Málaga, Spain|Investigational Site Number 724043, Málaga, Spain|Investigational Site Number 724001, Oviedo, Spain|Investigational Site Number 724022, Sabadell, Spain|Investigational Site Number 724029, San Sebastian De Los Reyes, Spain|Investigational Site Number 724028, Santander, Spain|Investigational Site Number 724034, Santiago De Compostela, Spain|Investigational Site Number 724014, Sevilla, Spain|Investigational Site Number 724024, Tarragona, Spain|Investigational Site Number 724019, Valencia, Spain|Investigational Site Number 724009, Valencia, Spain|Investigational Site Number 724011, Valencia, Spain|Investigational Site Number 724023, Valladolid, Spain|Investigational Site Number 724005, Vigo, Spain|Investigational Site Number 724040, Zaragoza, Spain|Investigational Site Number 144002, Colombo 7, Sri Lanka|Investigational Site Number 144004, Colombo 8, Sri Lanka|Investigational Site Number 144003, Colombo, Sri Lanka|Investigational Site Number 144010, Colombo, Sri Lanka|Investigational Site Number 144005, Colombo, Sri Lanka|Investigational Site Number 144006, Colombo, Sri Lanka|Investigational Site Number 144001, Colombo, Sri Lanka|Investigational Site Number 144008, Kandy, Sri Lanka|Investigational Site Number 144009, Kurunegala, Sri Lanka|Investigational Site Number 144007, Ragama, Sri Lanka|Investigational Site Number 752001, Falun, Sweden|Investigational Site Number 752016, Göteborg, Sweden|Investigational Site Number 752011, Halmstad, Sweden|Investigational Site Number 752006, Karlshamn, Sweden|Investigational Site Number 752008, Karlskrona, Sweden|Investigational Site Number 752004, Kristianstad, Sweden|Investigational Site Number 752013, Köping, Sweden|Investigational Site Number 752015, Malmö, Sweden|Investigational Site Number 752012, Mölndal, Sweden|Investigational Site Number 752009, Stockholm, Sweden|Investigational Site Number 752002, Stockholm, Sweden|Investigational Site Number 752014, Sundsvall, Sweden|Investigational Site Number 752007, Uppsala, Sweden|Investigational Site Number 756005, Basel, Switzerland|Investigational Site Number 756003, Geneve, Switzerland|Investigational Site Number 756004, Lugano, Switzerland|Investigational Site Number 756002, Zürich, Switzerland|Investigational Site Number 158003, Changhua, Taiwan|Investigational Site Number 158008, Division Of Cardiology, Taiwan|Investigational Site Number 158014, Hsinchu, Taiwan|Investigational Site Number 158013, Kaohsiung, Taiwan|Investigational Site Number 158004, Taichung, Taiwan|Investigational Site Number 158009, Tainan, Taiwan|Investigational Site Number 158011, Tainan, Taiwan|Investigational Site Number 158005, Taipei, Taiwan|Investigational Site Number 158001, Taipei, Taiwan|Investigational Site Number 158010, Taipei, Taiwan|Investigational Site Number 158007, Taipei, Taiwan|Investigational Site Number 158012, Taoyuan Hsien, Taiwan|Investigational Site Number 158002, Yunlin, Taiwan|Investigational Site Number 764009, Bangkok-Noi, Thailand|Investigational Site Number 764001, Bangkok, Thailand|Investigational Site Number 764011, Bangkok, Thailand|Investigational Site Number 764007, Bangkok, Thailand|Investigational Site Number 764012, Bangkok, Thailand|Investigational Site Number 764005, Hat Yai, Thailand|Investigational Site Number 764008, Klong Luang, Thailand|Investigational Site Number 764002, Moung, Thailand|Investigational Site Number 764003, Muang, Thailand|Investigational Site Number 764010, Nonthaburi, Thailand|Investigational Site Number 764006, Pratumwan, Thailand|Investigational Site Number 792007, Adana, Turkey|Investigational Site Number 792009, Ankara, Turkey|Investigational Site Number 792006, Bursa, Turkey|Investigational Site Number 792016, Eskisehir, Turkey|Investigational Site Number 792014, Istanbul, Turkey|Investigational Site Number 792005, Istanbul, Turkey|Investigational Site Number 792011, Istanbul, Turkey|Investigational Site Number 792013, Istanbul, Turkey|Investigational Site Number 792004, Izmir, Turkey|Investigational Site Number 792003, Izmir, Turkey|Investigational Site Number 792015, Kocaeli, Turkey|Investigational Site Number 792010, Mersin, Turkey|Investigational Site Number 804015, Chernivtsi, Ukraine|Investigational Site Number 804018, Dnipropetrovsk, Ukraine|Investigational Site Number 804027, Donetsk, Ukraine|Investigational Site Number 804012, Donetsk, Ukraine|Investigational Site Number 804010, Ivano-Frankivsk, Ukraine|Investigational Site Number 804006, Kharkiv, Ukraine|Investigational Site Number 804003, Kharkiv, Ukraine|Investigational Site Number 804009, Kharkiv, Ukraine|Investigational Site Number 804020, Khmelnytskyi, Ukraine|Investigational Site Number 804001, Kiev, Ukraine|Investigational Site Number 804002, Kiev, Ukraine|Investigational Site Number 804011, Kyiv, Ukraine|Investigational Site Number 804014, Kyiv, Ukraine|Investigational Site Number 804025, Kyiv, Ukraine|Investigational Site Number 804034, Kyiv, Ukraine|Investigational Site Number 804036, Kyiv, Ukraine|Investigational Site Number 804016, Kyiv, Ukraine|Investigational Site Number 804030, Kyiv, Ukraine|Investigational Site Number 804028, Lutsk, Ukraine|Investigational Site Number 804033, Lviv, Ukraine|Investigational Site Number 804031, Lviv, Ukraine|Investigational Site Number 804029, Mykolaiv, Ukraine|Investigational Site Number 804013, Odesa, Ukraine|Investigational Site Number 804004, Odessa, Ukraine|Investigational Site Number 804017, Simferopol, Ukraine|Investigational Site Number 804035, Sumy, Ukraine|Investigational Site Number 804007, Uzhgorod, Ukraine|Investigational Site Number 804005, Vinnitsya, Ukraine|Investigational Site Number 804008, Vinnytsia, Ukraine|Investigational Site Number 804026, Zaporizhia, Ukraine|Investigational Site Number 804024, Zhytomyr, Ukraine|Investigational Site Number 804032, Zhytomyr, Ukraine|Investigational Site Number 826018, Basildon, United Kingdom|Investigational Site Number 826015, Birmingham, United Kingdom|Investigational Site Number 826030, Birmingham, United Kingdom|Investigational Site Number 826038, Bournemouth, United Kingdom|Investigational Site Number 826025, Bradford, United Kingdom|Investigational Site Number 826027, Burton On Trent, United Kingdom|Investigational Site Number 826017, Cardiff, United Kingdom|Investigational Site Number 826010, Chertsey, United Kingdom|Investigational Site Number 826012, Chesterfield, United Kingdom|Investigational Site Number 826039, Chichester, United Kingdom|Investigational Site Number 826024, Cumbria, United Kingdom|Investigational Site Number 826041, Dudley, United Kingdom|Investigational Site Number 826021, Harrow, United Kingdom|Investigational Site Number 826026, High Wycombe, United Kingdom|Investigational Site Number 826028, Hull, United Kingdom|Investigational Site Number 826034, London, United Kingdom|Investigational Site Number 826004, Manchester, United Kingdom|Investigational Site Number 826011, Newcastle Upon Tyne, United Kingdom|Investigational Site Number 826036, Northampton, United Kingdom|Investigational Site Number 826019, Peterborough, United Kingdom|Investigational Site Number 826020, Plymouth, United Kingdom|Investigational Site Number 826040, Portadown, United Kingdom|Investigational Site Number 826016, Portsmouth, United Kingdom|Investigational Site Number 826014, Redhill, United Kingdom|Investigational Site Number 826007, Rhyl, United Kingdom|Investigational Site Number 826001, Romford, United Kingdom|Investigational Site Number 826009, Rotherham, United Kingdom|Investigational Site Number 826002, Sheffield, United Kingdom|Investigational Site Number 826032, South Shields, United Kingdom|Investigational Site Number 826013, St Leonards, United Kingdom|Investigational Site Number 826005, Stoke-On-Trent, United Kingdom|Investigational Site Number 826031, Sunderland, United Kingdom|Investigational Site Number 826022, Truro, United Kingdom|Investigational Site Number 826035, Wigan, United Kingdom|Investigational Site Number 826003, Worcester, United Kingdom","https://ClinicalTrials.gov/show/NCT01663402"
1011,"A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis","Completed","Has Results","Rhinitis, Allergic, Perennial and Seasonal","Drug: FPNS|Drug: FPNS Placebo|Drug: Cetirizine|Drug: Cetirizine Placebo","GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Aventura, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Lenexa, Kansas, United States|GSK Investigational Site, Overland Park, Kansas, United States|GSK Investigational Site, Owensboro, Kentucky, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Bethesda, Maryland, United States|GSK Investigational Site, North Dartmouth, Massachusetts, United States|GSK Investigational Site, Ypsilanti, Michigan, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Columbia, Missouri, United States|GSK Investigational Site, Rolla, Missouri, United States|GSK Investigational Site, Saint Louis, Missouri, United States|GSK Investigational Site, Bellevue, Nebraska, United States|GSK Investigational Site, Canton, Ohio, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, Orangeburg, South Carolina, United States|GSK Investigational Site, Spartanburg, South Carolina, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Kerrville, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Waco, Texas, United States|GSK Investigational Site, South Burlington, Vermont, United States|GSK Investigational Site, Greenfield, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT01916226"
1012,"To Evaluate the Efficacy and Safety of Levocetirizine Versus Loratadine for Treatment of Seasonal Allergic Rhinitis","Completed","No Results Available","Rhinitis|Allergic|Seasonal","Drug: Levocetirizine dihydrochloride",,"https://ClinicalTrials.gov/show/NCT00525278"
1013,"Comparison of the Effects of Desloratadine and Placebo in the Relief of Nasal Symptom Scores in Subjects With Seasonal Allergic Rhinitis to Cypress Pollen (Study P02836)","Completed","No Results Available","Seasonal Allergic Rhinitis","Drug: Placebo|Drug: Desloratadine",,"https://ClinicalTrials.gov/show/NCT00867191"
1014,"Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies","Active, not recruiting","Has Results","Hematological Malignancy","Drug: Isatuximab SAR650984|Drug: Dexamethasone","Investigational Site Number 840003, Scottsdale, Arizona, United States|Investigational Site Number 840005, San Francisco, California, United States|Investigational Site Number 840009, Atlanta, Georgia, United States|Investigational Site Number 840010, Chicago, Illinois, United States|Investigational Site Number 840022, Ann Arbor, Michigan, United States|Investigational Site Number 840027, Detroit, Michigan, United States|Investigational Site Number 840018, Rochester, Minnesota, United States|Investigational Site Number 840013, Saint Louis, Missouri, United States|Investigational Site Number 840011, Hackensack, New Jersey, United States|Investigational Site Number 840014, New York, New York, United States|Investigational Site Number 840016, Durham, North Carolina, United States|Investigational Site Number 840004, Cincinnati, Ohio, United States|Investigational Site Number 840001, Nashville, Tennessee, United States|Investigational Site Number 840002, Salt Lake City, Utah, United States|Investigational Site Number 840012, Seattle, Washington, United States|Investigational Site Number 840017, Milwaukee, Wisconsin, United States|Investigational Site Number 032002, Caba, Argentina|Investigational Site Number 032003, Capital Federal, Argentina|Investigational Site Number 032001, Ciudad De Buenos Aires, Argentina|Investigational Site Number 056001, Antwerpen, Belgium|Investigational Site Number 076001, Barretos, Brazil|Investigational Site Number 076003, Porto Alegre, Brazil|Investigational Site Number 076004, Rio De Janeiro, Brazil|Investigational Site Number 076002, Sao Paulo, Brazil|Investigational Site Number 152001, Temuco, Chile|Investigational Site Number 246001, Helsinki, Finland|Investigational Site Number 246002, Turku, Finland|Investigational Site Number 250003, Nantes Cedex 01, France|Investigational Site Number 250004, Pierre Benite, France|Investigational Site Number 250001, Toulouse Cedex 9, France|Investigational Site Number 300001, Athens, Greece|Investigational Site Number 376004, Jerusalem, Israel|Investigational Site Number 376002, Tel Hashomer, Israel|Investigational Site Number 380001, Bologna, Italy|Investigational Site Number 380002, Torino, Italy|Investigational Site Number 484001, Monterrey, Mexico|Investigational Site Number 484003, San Luis Potosi, Mexico|Investigational Site Number 604001, Arequipa, Peru|Investigational Site Number 604002, Lima, Peru|Investigational Site Number 643002, Moscow, Russian Federation|Investigational Site Number 643003, Novosibirsk, Russian Federation|Investigational Site Number 643001, Petrozavodsk, Russian Federation|Investigational Site Number 643004, Saint-Petersburg, Russian Federation|Investigational Site Number 724007, Badalona, Spain|Investigational Site Number 724005, Barcelona, Spain|Investigational Site Number 724004, Madrid, Spain|Investigational Site Number 724002, Pamplona, Spain|Investigational Site Number 724001, Salamanca, Spain|Investigational Site Number 724008, Sevilla, Spain|Investigational Site Number 724006, Valencia, Spain|Investigational Site Number 792002, Ankara, Turkey|Investigational Site Number 792005, Ankara, Turkey|Investigational Site Number 792001, İstanbul, Turkey|Investigational Site Number 792004, Samsun, Turkey|Investigational Site Number 804001, Kyiv, Ukraine|Investigational Site Number 804004, Vinnitsya, Ukraine|Investigational Site Number 804002, Zaporizhzhya, Ukraine|Investigational Site Number 826001, Nottingham, United Kingdom|Investigational Site Number 826002, Southampton, United Kingdom","https://ClinicalTrials.gov/show/NCT01084252"
1015,"Study of the Effect of SCH 900538 on Congestion in Subjects With Seasonal Allergic Rhinitis (Study P05031)(COMPLETED)","Completed","No Results Available","Seasonal Allergic Rhinitis","Drug: SCH 900538|Drug: Pseudoephedrine|Drug: Placebo Capsules",,"https://ClinicalTrials.gov/show/NCT00673062"
1016,"Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation","Active, not recruiting","No Results Available","Plasma Cell Myeloma","Drug: lenalidomide|Drug: bortezomib|Drug: cyclophosphamide|Drug: dexamethasone|Drug: isatuximab SAR650984","Investigational Site Number 250002, Nantes Cedex 01, France|Investigational Site Number 250003, Pierre Benite, France|Investigational Site Number 250001, Toulouse Cedex 9, France|Investigational Site Number 276003, Berlin, Germany|Investigational Site Number 276002, Leipzig, Germany|Investigational Site Number 380003, Milano, Italy|Investigational Site Number 380002, Roma, Italy|Investigational Site Number 380001, Torino, Italy|Investigational Site Number 724003, Madrid, Spain|Investigational Site Number 724001, Pamplona, Spain|Investigational Site Number 724002, Salamanca, Spain|Investigational Site Number 724004, Santander, Spain","https://ClinicalTrials.gov/show/NCT02513186"
1017,"Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly","Completed","No Results Available","Myelofibrosis","Drug: SAR302503","Investigational Site Number 392010, Akita-Shi, Japan|Investigational Site Number 392002, Bunkyo-Ku, Japan|Investigational Site Number 392006, Bunkyo-Ku, Japan|Investigational Site Number 392004, Sendai-Shi, Japan|Investigational Site Number 392008, Shinjuku-Ku, Japan|Investigational Site Number 392009, Shinjuku-Ku, Japan|Investigational Site Number 392003, Suita-Shi, Japan","https://ClinicalTrials.gov/show/NCT01692366"
1018,"A Phase II Study Evaluating Intranasal GSK256066 and Azelastine Hydrochloride in Subjects With Seasonal Allergic Rhinitis","Completed","No Results Available","Allergic Rhinitis|Rhinitis, Allergic, Seasonal","Drug: GSK256066|Drug: azelastine hydrochloride","GSK Investigational Site, Vienna, Austria","https://ClinicalTrials.gov/show/NCT00612118"
1019,"Repeated Dosing Study to Assess Safety and Tolerability in CKD-3 Patients on Stable ACE-I Treatment","Completed","No Results Available","Chronic Kidney Disease","Drug: SAR407899A","Investigational Site Number 498002, Chisinau, Moldova, Republic of|Investigational Site Number 642001, Bucuresti, Romania","https://ClinicalTrials.gov/show/NCT01485900"
1020,"Trial With Allergic Rhinitis Patients Taking GSK256066 Versus Placebo In A Pollen Challenge Chamber","Completed","No Results Available","Rhinitis, Allergic, Seasonal|Seasonal Allergic Rhinitis","Drug: GSK256066","GSK Investigational Site, Vienna, Austria","https://ClinicalTrials.gov/show/NCT00430157"
1021,"COVIDNOCHE Trial (HFNO Versus CPAP Helmet) in COVID-19 Pneumonia","Not yet recruiting","No Results Available","Severe Acute Respiratory Syndrome Coronavirus 2|Hypoxemic Respiratory Failure|Pneumonia, Viral|COVID","Device: Helmet Continuous Positive Airway Pressure (CPAP)|Device: High Flow Nasal Oxygen (HFNO)",,"https://ClinicalTrials.gov/show/NCT04381923"
1022,"To Study GSP 301 in Patients With Seasonal Allergic Rhinitis","Completed","Has Results","Seasonal Allergic Rhinitis","Drug: GSP 301-1 NS (QD)|Drug: GSP 301-2 NS (BID)|Drug: GSP 301 Placebo NS|Drug: Olopatadine HCl-1 NS (QD)|Drug: Olopatadine HCl-2 NS (BID)|Drug: Mometasone Furoate-1 NS (QD)|Drug: Mometasone Furoate-2 NS (BID)","Glenmark Investigational Site 10, Austin, Texas, United States|Glenmark Investigational Site 5, Austin, Texas, United States|Glenmark Investigational Site 6, Austin, Texas, United States|Glenmark Investigational Site 2, Kerrville, Texas, United States|Glenmark Investigational Site 7, New Braunfels, Texas, United States|Glenmark Investigational Site 3, San Antonio, Texas, United States|Glenmark Investigational Site 4, San Antonio, Texas, United States|Glenmark Investigational Site 8, San Antonio, Texas, United States|Glenmark Investigational Site 9, San Antonio, Texas, United States|Glenmark Investigational Site 1, Waco, Texas, United States","https://ClinicalTrials.gov/show/NCT02318303"
1023,"Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer","Active, not recruiting","Has Results","Differentiated Thyroid Cancer","Drug: Vandetanib (SAR390530)|Drug: Placebo","Research Site, Little Rock, Arkansas, United States|Research Site, Torrance, California, United States|Research Site, Lexington, Kentucky, United States|Research Site, Boston, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Washington University, Saint Louis, Missouri, United States|Research Site, Omaha, Nebraska, United States|Research Site, New York, New York, United States|Research Site, Portland, Oregon, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Porto Alegre, Brazil|Research Site, Ribeirão Preto, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, São José do Rio Preto, Brazil|Research Site, São Paulo, Brazil|Research Site, Beijing, China|Research Site, Changchun, China|Research Site, Chengdu, China|Research Site, Huangzhou, China|Research Site, Shanghai, China|Research Site, Tianjin, China|Research Site, Wuhan, China|Research Site, Olomouc, Czechia|Research Site, Praha, Czechia|Research Site, Odense, Denmark|Research Site, Angers Cedex 01, France|Research Site, Bordeaux Cedex, France|Research Site, Caen Cedex 5, France|Research Site, Paris Cedex 13, France|Research Site, Villejuif Cedex, France|Research Site, Catania, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Pisa, Italy|Research Site, Roma, Italy|Research Site, Siena, Italy|Research Site, Bunkyo-ku, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Fukushima-shi, Japan|Research Site, Kashiwa-shi, Japan|Research Site, Kobe-shi, Japan|Research Site, Koto-ku, Japan|Research Site, Matsumoto-shi, Japan|Research Site, Nagasaki-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Niigata-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Yokohama-shi, Japan|Research Site, Gliwice, Poland|Research Site, Kielce, Poland|Research Site, Warszawa, Poland|Research Site, Zgierz, Poland|Research Site, Barnaul, Russian Federation|Research Site, Obninsk, Russian Federation|Research Site, Barcelona, Spain|Research Site, Gerona, Spain|Research Site, Hospitalet de Llobregat(Barcel, Spain|Research Site, Madrid, Spain|Research Site, Lund, Sweden|Research Site, Stockholm, Sweden","https://ClinicalTrials.gov/show/NCT01876784"
1024,"Trial With Rhinitic Patients Taking GSK256066 Versus Placebo In A Pollen Challenge Chamber","Completed","No Results Available","Rhinitis, Allergic, Seasonal|Seasonal Allergic Rhinitis","Drug: GSK256066","GSK Investigational Site, Vienna, Austria","https://ClinicalTrials.gov/show/NCT00377728"
1025,"Clinical Assessment of Oral Lactoferrin as a Safe Antiviral and Immunoregulatory in Treating COVID-19 Disease","Not yet recruiting","No Results Available","Corona Virus Infection|Middle East Respiratory Syndrome (MERS)|Acute Respiratory Distress Syndrome|Coronavirus Infection|COVID-19|SARS-CoV 2","Dietary Supplement: Lactoferrin (Apolactoferrin)|Drug: Placebo of excipient(s) will be administered","National Research Center, Egypt (Clinical and Molecular Pharmacology), Cairo, Giza, Egypt|Clinmax CRO (Clinical Research Organization), Cairo, Egypt|Clinical Trial Unit National Research Center, Cairo, Egypt|Egyptian Military Medical Services (Hospitals), Cairo, Egypt","https://ClinicalTrials.gov/show/NCT04412395"
1026,"New Nasal Applicator / New Formulation - User Study","Completed","No Results Available","Seasonal Allergic Rhinitis","Drug: budesonide|Device: Budesonide|Drug: Placebo",,"https://ClinicalTrials.gov/show/NCT00641979"
1027,"Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma","Completed","Has Results","Asthma","Drug: Dupilumab|Drug: Placebo (for Dupilumab)|Drug: Fluticasone/Salmeterol combination therapy|Drug: Fluticasone monotherapy|Drug: Albuterol|Drug: Levalbuterol","Investigational Site Number 840047, Anaheim, California, United States|Investigational Site Number 840046, Long Beach, California, United States|Investigational Site Number 840032, Los Angeles, California, United States|Investigational Site Number 840036, Los Angeles, California, United States|Investigational Site Number 840005, Mission Viejo, California, United States|Investigational Site Number 840007, Orange, California, United States|Investigational Site Number 840048, Riverside, California, United States|Investigational Site Number 840035, Rolling Hills Estates, California, United States|Investigational Site Number 840041, San Francisco, California, United States|Investigational Site Number 840042, San Francisco, California, United States|Investigational Site Number 840039, San Jose, California, United States|Investigational Site Number 840024, Santa Rosa, California, United States|Investigational Site Number 840002, Stockton, California, United States|Investigational Site Number 840031, Colorado Springs, Colorado, United States|Investigational Site Number 840011, Denver, Colorado, United States|Investigational Site Number 840017, Denver, Colorado, United States|Investigational Site Number 840026, New Haven, Connecticut, United States|Investigational Site Number 840044, Tallahassee, Florida, United States|Investigational Site Number 840029, Tampa, Florida, United States|Investigational Site Number 840028, Indianapolis, Indiana, United States|Investigational Site Number 840038, Iowa City, Iowa, United States|Investigational Site Number 840021, Overland Park, Kansas, United States|Investigational Site Number 840053, Owensboro, Kentucky, United States|Investigational Site Number 840014, Baltimore, Maryland, United States|Investigational Site Number 840015, North Dartmouth, Massachusetts, United States|Investigational Site Number 840003, Minneapolis, Minnesota, United States|Investigational Site Number 840010, Minneapolis, Minnesota, United States|Investigational Site Number 840006, Saint Louis, Missouri, United States|Investigational Site Number 840013, Saint Louis, Missouri, United States|Investigational Site Number 840022, Bozeman, Montana, United States|Investigational Site Number 840025, Omaha, Nebraska, United States|Investigational Site Number 840008, Papillion, Nebraska, United States|Investigational Site Number 840018, Princeton, New Jersey, United States|Investigational Site Number 840004, Winston-Salem, North Carolina, United States|Investigational Site Number 840023, Sylvania, Ohio, United States|Investigational Site Number 840045, Oklahoma City, Oklahoma, United States|Investigational Site Number 840001, Lake Oswego, Oregon, United States|Investigational Site Number 840012, Medford, Oregon, United States|Investigational Site Number 840016, Portland, Oregon, United States|Investigational Site Number 840040, Hershey, Pennsylvania, United States|Investigational Site Number 840037, Pittsburgh, Pennsylvania, United States|Investigational Site Number 840009, Upland, Pennsylvania, United States|Investigational Site Number 840027, Charleston, South Carolina, United States|Investigational Site Number 840030, El Paso, Texas, United States|Investigational Site Number 840050, San Antonio, Texas, United States|Investigational Site Number 840052, South Burlington, Vermont, United States|Investigational Site Number 840049, Richmond, Virginia, United States|Investigational Site Number 840020, Seattle, Washington, United States|Investigational Site Number 840019, Tacoma, Washington, United States|Investigational Site Number 840034, Madison, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT01312961"
1028,"Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)","Completed","No Results Available","Hay Fever|Seasonal Allergic Rhinitis","Drug: Ciclesonide nasal spray","Altana Pharma/Nycomed, Birmingham, Alabama, United States|Altana Pharma/Nycomed, Hot Springs, Arkansas, United States|Altana Pharma/Nycomed, Costa Mesa, California, United States|Altana Pharma/Nycomed, Huntington Beach, California, United States|Altana Pharma/Nycomed, Long Beach, California, United States|Altana Pharma/Nycomed, Los Alamitos, California, United States|Altana Pharma/Nycomed, Mission Viejo, California, United States|Altana Pharma/Nycomed, Orange, California, United States|Altana Pharma/Nycomed, Roseville, California, United States|Altana Pharma/Nycomed, San Diego, California, United States|Altana Pharma/Nycomed, San Diego, California, United States|Altana Pharma/Nycomed, San Jose, California, United States|Altana Pharma/Nycomed, Stockton, California, United States|Altana Pharma/Nycomed, Colorado Springs, Colorado, United States|Altana Pharma/Nycomed, Denver, Colorado, United States|Altana Pharma/Nycomed, Englewood, Colorado, United States|Altana Pharma/Nycomed, Lakewood, CO, Colorado, United States|Altana Pharma/Nycomed, Atlanta, Georgia, United States|Altana Pharma/Nycomed, Gainesville, Georgia, United States|Altana Pharma/Nycomed, Savannah, Georgia, United States|Altana Pharma/Nycomed, Woodstock, GA, Georgia, United States|Altana Pharma/Nycomed, Normal, Illinois, United States|Altana Pharma/Nycomed, Indianapolis, Indiana, United States|Altana Pharma/Nycomed, Overland Park, Kansas, United States|Altana Pharma/Nycomed, Louisville, KY, Kentucky, United States|Altana Pharma/Nycomed, Metairie, Louisiana, United States|Altana Pharma/Nycomed, Shreveport, Louisiana, United States|Altana Pharma/Nycomed, Bethesda, Maryland, United States|Altana Pharma/Nycomed, North Dartmouth, Massachusetts, United States|Altana Pharma/Nycomed, Minneapolis, Minnesota, United States|Altana Pharma/Nycomed, Jefferson City, Missouri, United States|Altana Pharma/Nycomed, Rolla, Missouri, United States|Altana Pharma/Nycomed, St. Louis, Missouri, United States|Altana Pharma/Nycomed, Lincoln, NE, Nebraska, United States|Altana Pharma/Nycomed, Papillion, Nebraska, United States|Altana Pharma/Nycomed, Brick, New Jersey, United States|Altana Pharma/Nycomed, Forked River, New Jersey, United States|Altana Pharma/Nycomed, Red Bank, New Jersey, United States|Altana Pharma/Nycomed, Skillman, New Jersey, United States|Altana Pharma/Nycomed, Warren, New Jersey, United States|Altana Pharma/Nycomed, Rochester, NY, New York, United States|Altana Pharma/Nycomed, Rockville Centre, New York, United States|Altana Pharma/Nycomed, Raleigh, North Carolina, United States|Altana Pharma/Nycomed, Cincinnati, OH, Ohio, United States|Altana Pharma/Nycomed, Cincinnati, Ohio, United States|Altana Pharma/Nycomed, Ashland, Oregon, United States|Altana Pharma/Nycomed, Lake Oswego, Oregon, United States|Altana Pharma/Nycomed, Medford, OR, Oregon, United States|Altana Pharma/Nycomed, Portland, Oregon, United States|Altana Pharma/Nycomed, Blue Bell, Pennsylvania, United States|Altana Pharma/Nycomed, Eerie, Pennsylvania, United States|Altana Pharma/Nycomed, Pittsburgh, Pennsylvania, United States|Altana Pharma/Nycomed, Pittsburgh, Pennsylvania, United States|Altana Pharma/Nycomed, Upland, Pennsylvania, United States|Altana Pharma/Nycomed, Charleston, SC, South Carolina, United States|Altana Pharma/Nycomed, Charleston, South Carolina, United States|Altana Pharma/Nycomed, Germantown, Tennessee, United States|Altana Pharma/Nycomed, Jackson, Tennessee, United States|Altana Pharma/Nycomed, Austin, Texas, United States|Altana Pharma/Nycomed, Austin, Texas, United States|Altana Pharma/Nycomed, Dallas, Texas, United States|Altana Pharma/Nycomed, El Paso, Texas, United States|Altana Pharma/Nycomed, Kerrville, Texas, United States|Altana Pharma/Nycomed, New Braunfels, Texas, United States|Altana Pharma/Nycomed, San Antonio, Texas, United States|Altana Pharma/Nycomed, Salt Lake City, Utah, United States|Altana Pharma/Nycomed, South Burlington, Vermont, United States|Altana Pharma/Nycomed, Burke, Virginia, United States|Altana Pharma/Nycomed, Charlottesville, Virginia, United States|Altana Pharma/Nycomed, Richmond, Virginia, United States|Altana Pharma/Nycomed, Milwaukee, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT00305487"
1029,"Bacillus Calmette-guérin Vaccination to Prevent COVID-19","Recruiting","No Results Available","COVID-19|Virus Diseases|Corona Virus Infection|Coronary Heart Disease|Chronic Obstructive Pulmonary Disease","Biological: BCG vaccine|Biological: Placebo","General Hospital of Argolida - Nafplion Unit, Náfplio, Argos, Greece|2nd Department of Internal Medicine, University General Hospital of Alexandroupolis, Alexandroupolis, Greece|1st Department of Internal Medicine, General Hospital of Athens G. GENNIMATAS, Athens, Greece|2nd University Department of Internal Medicine, IPPOKRATEION General Hospital of Athens, Athens, Greece|3rd University Department of Internal Medicine, General Hospital of Chest Diseases of Athens I SOTIRIA, Athens, Greece|4th Department of Internal Medicine, ""Attikon"" University Hospital, National and Kapodistrian University of Athens, Medical School, Athens, Greece|1st Department of Internal Medicine, General University Hospital of Ioannina, Ioánnina, Greece|General Hospital of Korinthos, Kórinthos, Greece|Department of Internal Medicine, Patras University Hospital, Patras, Greece|General Hospital of Ptolemaida MPODOSAKEIO, Ptolemaḯda, Greece|1st Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki, Thessaloníki, Greece|General Hospital of Imathia - Veria Unit, Véria, Greece","https://ClinicalTrials.gov/show/NCT04414267"
1030,"Seasonal Allergic Rhinitis In Pediatric Subjects","Completed","No Results Available","Rhinitis, Allergic, Perennial","Drug: GW685698X","GSK Investigational Site, Scottsdale, Arizona, United States|GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Costa Mesa, California, United States|GSK Investigational Site, Cudahy, California, United States|GSK Investigational Site, Huntington Beach, California, United States|GSK Investigational Site, Long Beach, California, United States|GSK Investigational Site, Long Beach, California, United States|GSK Investigational Site, Mission Viejo, California, United States|GSK Investigational Site, Orange, California, United States|GSK Investigational Site, Riverside, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, Walnut Creek, California, United States|GSK Investigational Site, Centennial, Colorado, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Englewood, Colorado, United States|GSK Investigational Site, Fort Collins, Colorado, United States|GSK Investigational Site, Lakewood, Colorado, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Tampa, Florida, United States|GSK Investigational Site, Gainesville, Georgia, United States|GSK Investigational Site, Lawrenceville, Georgia, United States|GSK Investigational Site, Lilburn, Georgia, United States|GSK Investigational Site, Stockbridge, Georgia, United States|GSK Investigational Site, Woodstock, Georgia, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Topeka, Kansas, United States|GSK Investigational Site, Metairie, Louisiana, United States|GSK Investigational Site, Shreveport, Louisiana, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Bethesda, Maryland, United States|GSK Investigational Site, Brockton, Massachusetts, United States|GSK Investigational Site, North Andover, Massachusetts, United States|GSK Investigational Site, North Dartmouth, Massachusetts, United States|GSK Investigational Site, Springfield, Massachusetts, United States|GSK Investigational Site, Richland, Michigan, United States|GSK Investigational Site, Ypsilanti, Michigan, United States|GSK Investigational Site, Jackson, Mississippi, United States|GSK Investigational Site, Kansas City, Missouri, United States|GSK Investigational Site, Rolla, Missouri, United States|GSK Investigational Site, Warrensburg, Missouri, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Hackensack, New Jersey, United States|GSK Investigational Site, Ocean, New Jersey, United States|GSK Investigational Site, Ithaca, New York, United States|GSK Investigational Site, Mineola, New York, United States|GSK Investigational Site, Utica, New York, United States|GSK Investigational Site, Durham, North Carolina, United States|GSK Investigational Site, Raleigh, North Carolina, United States|GSK Investigational Site, Canton, Ohio, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Lake Oswego, Oregon, United States|GSK Investigational Site, Altoona, Pennsylvania, United States|GSK Investigational Site, Cranberry Township, Pennsylvania, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Knoxville, Tennessee, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, El Paso, Texas, United States|GSK Investigational Site, El Paso, Texas, United States|GSK Investigational Site, Greenfield, Wisconsin, United States|GSK Investigational Site, Madison, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT00107757"
1031,"Psychological Impact of Quarantine in Rheumatoid Arthritis Patient During COVID-19 Outbreak","Completed","No Results Available","Sars-CoV2|Rheumatic Diseases|Rheumatoid Arthritis|Chronic Pain","Other: questionnaire assesment","Hopital Roger Salengro, CHU Lille, Lille, France","https://ClinicalTrials.gov/show/NCT04351399"
1032,"Study Testing Convalescent Plasma vs Best Supportive Care","Not yet recruiting","No Results Available","Pneumonia, Interstitial","Biological: high-titer anti-Sars-CoV-2 plasma|Other: oxygen therapy",,"https://ClinicalTrials.gov/show/NCT04333251"
1033,"Timing of Tracheotomy in Covid-19 Patients","Recruiting","No Results Available","Covid-19|ARDS|Tracheostomy Complication|Respiratory Insufficiency|Corona Virus Infection","Procedure: Tracheotomy","Sahlgrenska University Hospital, Gothenburg, Sweden","https://ClinicalTrials.gov/show/NCT04412356"
1034,"Clinical Scores for Outcome Prediction in Patients With Severe COVID-19 Pneumonia Requiring ECMO","Recruiting","No Results Available","COVID-19|SARS-CoV 2|Extracorporeal Membrane Oxygenation|ARDS","Device: vv-ECMO","University Clinic Freiburg, Freiburg, Germany","https://ClinicalTrials.gov/show/NCT04405973"
1035,"Ultraprotective Ventilation Without Extracorporeal Circulation During COVID 19 Pneumonia","Not yet recruiting","No Results Available","Acute Respiratory Distress Syndrome|COVID19|Sars-CoV2|Pneumonia","Other: PROTECTIVE VENTILATION|Other: ULTRAPROTECTIVE VENTILATION","Service de Médecine Intensive Réanimation CHU Gabriel Montpied, Clermont-Ferrand, France|Service de Médecine Intensive Réanimation Hôpital Michallon - CHU Grenoble Alpes, La Tronche, France|Service de Médecine Intensive Réanimation Hôpital Edouard Herriot Hospices Civils de Lyon, Lyon, France|Service de Réanimation Chirurgicale Hôpital Edouard Herriot Hospices Civils de Lyon, Lyon, France|Service de Médecine Intensive Réanimation Hôpital de la Croix Rousse Hospices Civils de Lyon, Lyon, France|Service de Réanimation Chirurgicale Hôpital de la Croix Rousse Hospices Civils de Lyon, Lyon, France|Service de réanimation Polyvalente Centre Hospitalier Saint Joseph-Saint Luc, Lyon, France|Service de Réanimation Clinique de la Sauvegarde, Lyon, France|Service de Réanimation Polyvalente Centre Hospitalier Lyon Sud Hospices Civils de Lyon, Pierre-Bénite, France|Service de Réanimation Centre hospitalier Annecy Genevois, Pringy, France|Service de Médecine Intensive Réanimation Hôpital Nord - CHU Saint-Etienne, Saint-Priest-en-Jarez, France","https://ClinicalTrials.gov/show/NCT04349618"
1036,"Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity","Recruiting","No Results Available","Budesonide|Olfaction Disorders|SARS-CoV-2|Anosmia","Drug: Budesonide Nasal|Other: Physiological serum","Amélie YAvchitz, Paris, France","https://ClinicalTrials.gov/show/NCT04361474"
1037,"Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19","Completed","No Results Available","Pneumonia, Viral|Corona Virus Infection|Respiratory Failure|Embolism and Thrombosis","Drug: Tirofiban Injection|Drug: Clopidogrel|Drug: Acetylsalicylic acid|Drug: Fondaparinux","L. Sacco Hospital, Milano, Lombardia, Italy","https://ClinicalTrials.gov/show/NCT04368377"
1038,"Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia","Recruiting","No Results Available","Coronavirus Disease 2019 (COVID-19) Pneumonia","Biological: Lenzilumab|Drug: Standard of Care","Mayo Clinic, Phoenix, Arizona, United States|Stanford University, Redwood City, California, United States|Mayo Clinic, Jacksonville, Florida, United States|AdventHealth Orlando, Orlando, Florida, United States|Emory University, Atlanta, Georgia, United States|Mayo Clinic, Rochester, Minnesota, United States|Dartmouth-Hitchcock, Lebanon, New Hampshire, United States|Atrium Health, Charlotte, North Carolina, United States|Texas Health, Dallas, Texas, United States","https://ClinicalTrials.gov/show/NCT04351152"
1039,"Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19","Recruiting","No Results Available","Covid-19|SARS|Cytokine Storm|Cytokine Release Syndrome|Tocilizumab","Drug: Tocilizumab|Other: Standard of care|Procedure: Continuous renal replacement therapy","Tongji Hospital, Wuhan, Hubei, China","https://ClinicalTrials.gov/show/NCT04306705"
1040,"Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure","Recruiting","No Results Available","Critical COVID-19 With Respiratory Failure|Acute Respiratory Distress Syndrome (ARDS)|Corona Virus Infection|Acute Lung Injury","Drug: Aviptadil by intravenous infusion + standard of care|Drug: Normal Saline Infusion + standard of care","University of California - Irvine, Irvine, California, United States|Miller School of Medicine / University of Miami Medical Center, Miami, Florida, United States|Robert I Grossman School of Medicine / NYU Langone Medical Center, New York, New York, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Rambam Health Care Campus, Haifa, Israel","https://ClinicalTrials.gov/show/NCT04311697"
1041,"Negative-PCR for Covid- 19 Pneumonia (NPC-19)","Recruiting","No Results Available","Pneumonia, Viral|Pneumonia, Bacterial|Coronavirus Infection|Obstructive Lung Disease","Diagnostic Test: Serology for Covid-19","Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy","https://ClinicalTrials.gov/show/NCT04387799"
1042,"Chloroquine as Antiviral Treatment in Coronavirus Infection 2020","Recruiting","No Results Available","COVID-19","Drug: Chloroquine phosphate|Other: Telemedicine","Uniwersytecki Szpital Kliniczny, Wrocław, Ul. Borowska 213, Poland|Wielospecjalistyczny Szpital Miejski, Poznań, Ul. Szwajcarska 3, Poland","https://ClinicalTrials.gov/show/NCT04331600"
1043,"Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms","Recruiting","No Results Available","COVID|Corona Virus Infection|Respiratory Failure|Respiratory Distress Syndrome, Adult|ARDS, Human|SARS (Severe Acute Respiratory Syndrome)","Device: gammaCore® Sapphire (non-invasive vagus nerve stimulator)|Other: Standard of care therapies","AHN Allegheny General Hospital, Pittsburgh, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT04382391"
1044,"Convalescent Plasma Collection and Treatment in Pediatrics and Adults","Recruiting","No Results Available","COVID19|Coronavirus Infection|Coronavirus|Virus Diseases|RNA Virus Infections","Biological: Convalescent Plasma 1 Unit|Biological: Convalescent Plasma 2 Units|Other: Standard of Care","WVU Medicine, Morgantown, West Virginia, United States","https://ClinicalTrials.gov/show/NCT04376034"
1045,"Increased Risk of Severe Coronavirus Disease 2019 in Patients With Vitamin D Deficiency","Recruiting","No Results Available","Coronavirus Disease 2019 (COVID-19)",,"Hospital Clínico San Carlos, Madrid, Spain","https://ClinicalTrials.gov/show/NCT04403932"
1046,"Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19)","Not yet recruiting","No Results Available","Covid-19|Pneumonia, Viral|ARDS|ARDS, Human|Sars-CoV2|Coronavirus Infection|Corona Virus Infection","Drug: Ciclesonide Inhalation Aerosol","Danderyd Hospital, Danderyd, Entrévägen 2, Sweden|Capio S:t Görans Hospital, Stockholm, Sankt Göransplan 1, Sweden|Västmanland County Hospital Västerås, Västerås, Sigtunagatan, Sweden|Karolinska University Hospital, Stockholm, Sweden","https://ClinicalTrials.gov/show/NCT04381364"
1047,"A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia","Not yet recruiting","No Results Available","Coronavirus","Biological: MSCs-derived exosomes",,"https://ClinicalTrials.gov/show/NCT04276987"
1048,"CONVALESCENT PLASMA FOR ILL PATIENTS BY COVID-19","Recruiting","No Results Available","COVID-19|SARS-CoV 2|Convalescence|Plasma|Doses","Biological: convalescent plasma","Hospital Del Issste Regional En Guadalajara Jalisco, Guadalajara, Jalisco, Mexico|Secretaria de Salud Del Estado de Sonora, Hospital General Del Estado, Hermosillo, Sonora, Mexico|Hospital Central Norte Pemex, Mexico City, Mexico","https://ClinicalTrials.gov/show/NCT04356482"
1049,"Identification of a Responsive Subpopulation to Hydroxychloroquine in COVID-19 Patients Using Machine Learning","Completed","No Results Available","COVID-19|Coronavirus|Mortality","Device: COViage","Dascena, Oakland, California, United States","https://ClinicalTrials.gov/show/NCT04423991"
1050,"Patient Preference Trial for COVID-19 (PPT-COVID)","Recruiting","No Results Available","Coronavirus",,"Centre Hospitalier Princesse Grace, Monaco, Monaco","https://ClinicalTrials.gov/show/NCT04418193"
1051,"COVID 19 : Seroprevalence Study of Anti SRAS-CoV-2 Antibodies in GHT Employees in Haute Bretagne (AntiCoV-HB)","Recruiting","No Results Available","Coronavirus","Diagnostic Test: NG test|Diagnostic Test: Blood test|Behavioral: Self-questionnary","Chu Rennes, Rennes, France","https://ClinicalTrials.gov/show/NCT04416308"
1052,"A Phase 2 Study to Evaluate Axatilimab for Hospitalized Patients With Respiratory Involvement Secondary to COVID-19","Recruiting","No Results Available","Coronavirus|COVID|ARDS|Cytokine Storm|Cytokine Release Syndrome","Drug: SNDX-6352|Drug: Placebo","HonorHealth, Scottsdale, Arizona, United States|Montefiore Medical Center, Bronx, New York, United States","https://ClinicalTrials.gov/show/NCT04415073"
1053,"Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients","Not yet recruiting","No Results Available","COVID, Coronavirus","Device: Hyperbaric Chamber",,"https://ClinicalTrials.gov/show/NCT04409886"
1054,"COVID 19 Viral Clearance Among the Infected Healthcare Workers In Assiut University Hospitals","Not yet recruiting","No Results Available","Infection, Coronavirus",,,"https://ClinicalTrials.gov/show/NCT04409574"
1055,"Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID‑19)","Not yet recruiting","No Results Available","Coronavirus Disease 2019 (COVID‑19)","Biological: Garadacimab, Factor XIIa Antagonist Monoclonal Antibody|Drug: Placebo",,"https://ClinicalTrials.gov/show/NCT04409509"
1056,"This Study Examines the Use of Disinfectants by Egyptian Women During the Coronavirus Lockdown and How They Seak Medical Advice for Adverse Reactions Related to the Use of Disinfectants.","Not yet recruiting","No Results Available","Adult Women Living in Egypt Using Disinfectants in Deep Household Cleaning","Other: use and exposure to disinfectants during the coronavirus pandemic",,"https://ClinicalTrials.gov/show/NCT04405284"
1057,"Extraordinary Measures for Egyptian Children With Hemato-Oncological Disorders During COVID-19 Pandemic","Recruiting","No Results Available","Coronavirus COVID-19",,"Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt","https://ClinicalTrials.gov/show/NCT04404244"
1058,"The Clinical Difference Between the Nonfatal Patients and the Fatal Patients With Severe COVID-19","Recruiting","No Results Available","Coronavirus Disease 2019|Character of the Severe Patients","Other: no intervention","The First Affiliated Hospital of Guangzhou Medical University, Guanzhou, Guangdong, China|Hankou Hospital, Wuhan, Hubei, China","https://ClinicalTrials.gov/show/NCT04403009"
1059,"COVID-19: Laser Interferometry for Rapid Single Coronavirus Detection","Not yet recruiting","No Results Available","Diagnoses Disease|Coronavirus","Diagnostic Test: Novel laser inferometry test for CORONA virus","Somerset NHS Foundation Trust, Taunton, Somerset, United Kingdom","https://ClinicalTrials.gov/show/NCT04401644"
1060,"1,3,7-Trimethylxanthine as a Treatment of COVID-19: Results of a Controlled Study","Not yet recruiting","No Results Available","Coronavirus Disease 2019","Other: Data collection",,"https://ClinicalTrials.gov/show/NCT04395742"
1061,"Convalescent Plasma Compared to Anti-COVID-19 Human Immunoglobulin and Standard Treatment (TE) in Hospitalized Patients","Not yet recruiting","No Results Available","Coronavirus Disease 2019 (COVID-19)","Biological: COVID-19 convalescent plasma|Biological: Anti-COVID-19 human immunoglobulin|Drug: Standard (specific) therapy for COVID-19","LifeFactors Zona Franca SAS, Medellín, Antioquia, Colombia","https://ClinicalTrials.gov/show/NCT04395170"
1062,"At-Home COVID-19 Antibody Test Usability Assessment & Behavior Change Study","Recruiting","No Results Available","COVID19|COVID-19|Coronavirus","Device: Premier Biotech COVID-19 IgG/IgM Rapid test Cassette","ProofPilot Online App (https://p.proofpilot.com), New York, New York, United States","https://ClinicalTrials.gov/show/NCT04393961"
1063,"COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers","Recruiting","No Results Available","Coronavirus","Drug: EIDD-2801|Drug: Placebo","Covance Daytona Beach Clinical Research Unit, Daytona Beach, Florida, United States|Covance Dallas Clinical Research Unit, Dallas, Texas, United States|Covance Madison Clinical Research Unit, Madison, Wisconsin, United States|Covance Leeds Clinical Research Unit, Leeds, United Kingdom","https://ClinicalTrials.gov/show/NCT04392219"
1064,"Resting Energy Expenditure of the COronaVirus (COVID19) Patient in Reanimation Context","Not yet recruiting","No Results Available","COVID-19|Obesity","Diagnostic Test: indirect calorimetry","Arras general hospital, Arras, France","https://ClinicalTrials.gov/show/NCT04391686"
1065,"Respiratory Decompensation and Model for the Triage of COVID-19 Patients","Active, not recruiting","No Results Available","COVID-19|Coronavirus|Mortality|Mechanical Ventilation","Device: COViage","Dascena, Oakland, California, United States","https://ClinicalTrials.gov/show/NCT04390516"
1066,"Early CPAP in COVID-19 Confirmed or Suspected Patients","Recruiting","No Results Available","COVID-19|COVID|Coronavirus","Device: Continuous Positive Airway Pressure","Icahn School of Medicine at Mount Sinai, New York, New York, United States","https://ClinicalTrials.gov/show/NCT04390191"
1067,"The Impact and Coping Strategy of COVID-19 Among Taiwan Society and Medical and Nursing Institutes","Not yet recruiting","No Results Available","The Psychological Impact of Coronavirus Disease 2019 (COVID-19)","Other: Standardized crisis management and coping protocol plan toward Coronavirus disease 2019 (COVID-19)",,"https://ClinicalTrials.gov/show/NCT04389476"
1068,"Neonatal Complications of Coronavirus Disease (COVID-19)","Recruiting","No Results Available","Neonatal COVID-19 Disease","Other: No intervention - exposure is to COVID-19","Imperial College, London, United Kingdom","https://ClinicalTrials.gov/show/NCT04386109"
1069,"Inactivated Convalescent Plasma as a Therapeutic Alternative in Patients CoViD-19","Not yet recruiting","No Results Available","Infections, Coronavirus","Drug: Inactivated convalescent plasma|Drug: Support treatment","Clínica Antioquía, Medellín, Antioquía, Colombia|Clínica Sagrado Corazón, Medellín, Antioquía, Colombia|IPS Universitaria, Medellín, Antioquía, Colombia|Universidad de Antioquía, Medellín, Antioquía, Colombia|National Blood Center Foundation, Hemolife/Fundación Banco Nacional de Sangre Hemolife, Bogotá, Cundinamarca, Colombia|Clínica Rosales, Pereira, Risaralda, Colombia|Clinica Nuestra, Cali, Valle, Colombia|Clínica Corpas, Bogotá, Colombia|E.S.E Hospital San Rafael Facatativa, Facatativa, Colombia|Clínica la Estancia, Popayán, Colombia","https://ClinicalTrials.gov/show/NCT04385186"
1070,"Outcomes of Elective Cancer Surgery During the COVID-19 Pandemic Crisis","Recruiting","No Results Available","COVID-19|Coronavirus|Cancer|Surgery","Procedure: Elective Cancer Surgery","Hospital del Henares, Madrid, Spain","https://ClinicalTrials.gov/show/NCT04384926"
1071,"Collection of Coronavirus COVID-19 Outbreak Samples in New South Wales","Recruiting","No Results Available","COVID","Other: Biological sample and clinical data collection","NSW Health Pathology, Randwick, New South Wales, Australia|Prince of Wales Hospital, Randwick, New South Wales, Australia|Sydney Children's Hospital, Randwick, New South Wales, Australia|Blacktown Hospital, Blacktown, Australia|Royal Prince Alfred Hospital, Camperdown, Australia|St Vincent's Hospital, Darlinghurst, Australia|Northern Beaches Hospital, Frenchs Forest, Australia|Royal North Shore Hospital, Saint Leonards, Australia|Westmead Hospital, Westmead, Australia","https://ClinicalTrials.gov/show/NCT04383652"
1072,"Egyptian Initial Experience About 2019 Novel Corona Virus: Study of 48 Patients in Alexandria-Egypt Using Chest CT","Completed","No Results Available","COVID",,"Faculty of Medicine, University of Alexandria, Alexandria, Egypt","https://ClinicalTrials.gov/show/NCT04382469"
1073,"Efficacy and Safety of Polyoxidonium® in Hospitalized Patients With Coronavirus Disease COVID-19","Recruiting","No Results Available","Infections, Coronavirus","Drug: azoximer bromide|Other: Placebo","Regional state budgetary institution of public health ""City hospital No. 5 of Barnaul"", Barnaul, Russian Federation|Central Research Institute of Epidemiology of Rospotrebnadzor, Moscow, Russian Federation|The state healthcare institution of the city of Moscow ""City Clinical Hospital No. 15 named after OM Filatov"" in ""Moscow City Department of Health"", Moscow, Russian Federation|Moscow State Budgetary Healthcare Institution ""Infectious Clinical Hospital No. 1 of the Moscow Department of Healthcare"", Moscow, Russian Federation|Moscow State Budgetary Healthcare Institution ""City Clinical Hospital No. 24 of the Moscow Department of Healthcare"", Moscow, Russian Federation|State budgetary institution ""Research Institute of Emergency Care named after N.V. Sklifosovsky in Department of Health of the city of Moscow"", Moscow, Russian Federation|Moscow State Budgetary Healthcare Institution ""City Clinical Hospital No. 40 of the Moscow Department of Healthcare"", Moscow, Russian Federation|State budgetary institution of health care of the Nizhny Novgorod region ""Infectious clinical hospital No. 2 of Nizhny Novgorod"", Nizhny Novgorod, Russian Federation|Federal State Budgetary Educational Institution of Higher Education ""Orenburg State Medical University"" of the Ministry of Health of the Russian Federation, Orenburg, Russian Federation|Federal State Budgetary Educational Institution of Higher Education ""First St. Petersburg State Medical University named after Academician I.P. Pavlov, Saint Petersburg, Russian Federation|State budgetary health institution of the Vladimir region ""Regional Clinical Hospital"", Vladimir, Russian Federation|Yaroslavl State Medical University of Ministry of Health of the Russian Federation, Yaroslavl, Russian Federation","https://ClinicalTrials.gov/show/NCT04381377"
1074,"A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19","Recruiting","No Results Available","Severe or Critical Confirmed Coronavirus Disease (COVID)-19","Drug: Sirukumab|Drug: Placebo|Other: Standard of Care (SOC)","Loyola University Medical Center, Maywood, Illinois, United States|Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States|Wayne State University/Detroit Medical Center, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Beaumont Health Systems, Royal Oak, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mercury Street Medical Group, PLLC, Butte, Montana, United States|Saint Michael's Medical Center- Infectious Disease, Newark, New Jersey, United States|Baylor Scott & White Research Institute, Dallas, Texas, United States","https://ClinicalTrials.gov/show/NCT04380961"
1075,"ROCO - Self-help for People With Psychological Distress Due to the Covid-19 Situation","Recruiting","No Results Available","Psychological Distress|Adjustment, Psychological|Coronavirus","Behavioral: Internet-based self-help|Behavioral: Internet-based self-help after 3 weeks","Universität Bern, Bern, Switzerland","https://ClinicalTrials.gov/show/NCT04380909"
1076,"A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)","Not yet recruiting","No Results Available","COVID-19","Drug: IMU-838|Other: Placebo",,"https://ClinicalTrials.gov/show/NCT04379271"
1077,"Efficacy of Human Coronavirus-immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children","Not yet recruiting","No Results Available","Hospitalized Children|Covid-19 Infection","Biological: Convalescent plasma (CP)","Alberta Children's Hospital, Calgary, Alberta, Canada|Stollery Children's Hospital, Edmonton, Alberta, Canada|BC Children's Hospital, Vancouver, British Columbia, Canada|Winnipeg Children's Hospital, Winnipeg, Manitoba, Canada|IWK Health Centre, Halifax, Nova Scotia, Canada|McMaster Children's Hospital, Hamilton, Ontario, Canada|Kingston Health Sciences Centre, Kingston, Ontario, Canada|Children's Hospital, London, Ontario, Canada|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|The Hospital for Sick Children, Toronto, Ontario, Canada|CHU Sainte-Justine, Montréal, Quebec, Canada|Royal University Hospital, Saskatoon, Saskatchewan, Canada","https://ClinicalTrials.gov/show/NCT04377568"
1078,"Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial","Recruiting","No Results Available","Coronavirus","Biological: Plasma exchange|Drug: Standar medical treatmen","Hospital Clinic i Provincial de Barcelona, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT04374539"
1079,"Unplanned Shifting to Online Distance Learning: Nursing Students' Perception and Achievement","Enrolling by invitation","No Results Available","Distance Learning-Online Learning|Traditional Classroom-Based Learning|Coronavirus Disease Social Distancing Measures|Nursing Students' Perception and Achievement","Other: impliminting Online Distance Learning","Cairo University Hospital, Cairo, Egypt","https://ClinicalTrials.gov/show/NCT04372693"
1080,"COVID-19 Health Messaging to Underserved Communities","Recruiting","No Results Available","Coronavirus","Behavioral: Messaging","JPAL North America, Cambridge, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT04371419"
1081,"International Registry of Coronavirus (COVID-19) Exposure in Pregnancy","Not yet recruiting","No Results Available","Covid-19","Other: Tested for SARS-CoV-2 (regardless of the result)|Other: Clinical diagnosis of COVID-19 by a health care professional","Pregistry, Los Angeles, California, United States","https://ClinicalTrials.gov/show/NCT04366986"
1082,"Atrium COVID-19 Syndromic and Serologic Surveillance","Enrolling by invitation","No Results Available","Coronavirus|COVID","Other: daily syndromic surveillance|Diagnostic Test: monthly serologic IgM/G test","Atrium Health, Charlotte, North Carolina, United States","https://ClinicalTrials.gov/show/NCT04361123"
1083,"Evaluation of Antibody Tests for COVID-19","Recruiting","No Results Available","COVID|Coronavirus","Diagnostic Test: Diagnostic test","Washington University School of Medicine, Saint Louis, Missouri, United States","https://ClinicalTrials.gov/show/NCT04360954"
1084,"Levamisole and Isoprinosine in Immune-prophylaxis of Egyptian Healthcare Workers Facing COVID-19","Not yet recruiting","No Results Available","Coronavirus Disease (COVID-19)","Drug: Levamisole|Drug: Isoprinosine|Drug: Levamisole and Isoprinosine","Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt","https://ClinicalTrials.gov/show/NCT04360122"
1085,"A Human Clinical Study to Collect Calibration and Performance Data for the RBA-2 Device","Not yet recruiting","No Results Available","Coronavirus|COVID","Diagnostic Test: RBA-2","Tampa General Hospital, Tampa, Florida, United States|University of South Florida, Tampa, Florida, United States|AdventHealth Tampa, Tampa, Florida, United States","https://ClinicalTrials.gov/show/NCT04357977"
1086,"Comparison of New Coronavirus (COVID-19) Awareness in Individuals of Different Age Groups: Analysis of Turkey","Not yet recruiting","No Results Available","Healthy",,"Istanbul University-Cerrahpasa, Istanbul, Turkey","https://ClinicalTrials.gov/show/NCT04357886"
1087,"CORonavirus (COVID-19) Diagnostic Lung UltraSound Study","Not yet recruiting","No Results Available","COVID-19","Diagnostic Test: Lung ultrasound",,"https://ClinicalTrials.gov/show/NCT04351802"
1088,"Application of BCG Vaccine for Immune-prophylaxis Among Egyptian Healthcare Workers During the Pandemic of COVID-19","Not yet recruiting","No Results Available","Coronavirus Disease (COVID-19)","Biological: intradermal injection of BCG Vaccine|Other: placebo","Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt","https://ClinicalTrials.gov/show/NCT04350931"
1089,"Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore","Withdrawn","No Results Available","COVID|Coronavirus|COVID-19","Drug: Hydroxychloroquine","Montefiore Medical Center, Bronx, New York, United States","https://ClinicalTrials.gov/show/NCT04350450"
1090,"Efficacy and Safety of Favipiravir in Management of COVID-19","Not yet recruiting","No Results Available","Coronavirus Disease (COVID-19)","Drug: favipiravir|Drug: Standard of care therapy","Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt","https://ClinicalTrials.gov/show/NCT04349241"
1091,"Plasma Rich Antibodies From Recovered Patients From COVID19","Not yet recruiting","No Results Available","Coronavirus Disease (COVID-19)","Other: Antibody-Rich Plasma from COVID-19 recovered patients","Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt","https://ClinicalTrials.gov/show/NCT04348877"
1092,"Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)","Recruiting","No Results Available","Coronavirus Disease 2019","Drug: Placebos|Drug: Leronlimab (700mg)","UCLA, Los Angeles, California, United States|Eisenhower Health, Rancho Mirage, California, United States|Yale, New Haven, Connecticut, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|St. Barnabas, Livingston, New Jersey, United States|Atlantic Health System Hospital, Morristown, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|Novant Health, Winston-Salem, North Carolina, United States|Ohio Health, Columbus, Ohio, United States|Oregon Health and Sciences University, Portland, Oregon, United States|Baylor Scott & White research Institute, Dallas, Texas, United States|University of Texas, Houston, Texas, United States","https://ClinicalTrials.gov/show/NCT04347239"
1093,"Video-Based Exercise for Individuals With Social Isolation Due to Coronavirus (COVID-19)","Not yet recruiting","No Results Available","Healthy Lifestyle","Behavioral: Video based exercise",,"https://ClinicalTrials.gov/show/NCT04346953"
1094,"Telerehabilitation for Patients Diagnosed With Coronavirus","Not yet recruiting","No Results Available","Telerehabilitation|Coronavirus","Other: Telerehabilitation|Other: exercise brochure",,"https://ClinicalTrials.gov/show/NCT04346927"
1095,"Bone Marrow-Derived Mesenchymal Stem Cell Treatment for Severe Patients With Coronavirus Disease 2019 (COVID-19)","Not yet recruiting","No Results Available","Coronavirus Disease 2019 (COVID-19)","Biological: BM-MSCs|Biological: Placebo","Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China","https://ClinicalTrials.gov/show/NCT04346368"
1096,"Retrospective Study on Severe Respiratory Illness to Access the Presence of COVID-19","Recruiting","No Results Available","Coronavirus Disease (COVID-19)|COVID-19",,"Faculty of Medicine Ain Shams University, Cairo, Non-US, Egypt|Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt","https://ClinicalTrials.gov/show/NCT04346056"
1097,"To Access the Egyptian COVID-19 Whole Genome by NGS and Compare to the International Worldwide Database","Not yet recruiting","No Results Available","Coronavirus Disease (COVID-19)",,"Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt","https://ClinicalTrials.gov/show/NCT04346043"
1098,"COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial)","Recruiting","No Results Available","Coronavirus","Drug: cholecalciferol 200,000 IU|Drug: cholecalciferol 50,000 IU","CHU Angers, Angers, France|CHU Bordeaux, Bordeaux, France|CH Le Mans, Le Mans, France|CHU Lille, Lille, France|CHU Limoges, Limoges, France|CHU Nantes, Nantes, France|CHU Nice, Nice, France|CHU Saint Etienne, Saint Etienne, France|CH Saumur, Saumur, France|CHU Tours, Tours, France","https://ClinicalTrials.gov/show/NCT04344041"
1099,"Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19","Recruiting","No Results Available","Coronavirus Disease 2019","Drug: Placebos|Drug: Leronlimab (700mg)","University of California, Los Angeles, Los Angeles, California, United States|Palmtree Clinical Research, Inc., Palm Springs, California, United States|Eisenhower Health, Rancho Mirage, California, United States|Yale, New Haven, Connecticut, United States|Center for Advanced Research & Education (CARE), Gainesville, Georgia, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Atlantic Health System Hospital, Morristown, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|White Plains Hospital, White Plains, New York, United States|Novant Health, Charlotte, North Carolina, United States|Ohio Health, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States","https://ClinicalTrials.gov/show/NCT04343651"
1100,"COVID-19 Community Research Partnership","Active, not recruiting","No Results Available","Coronavirus|COVID",,"Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States","https://ClinicalTrials.gov/show/NCT04342884"
1101,"Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)","Recruiting","No Results Available","Coronavirus Disease 2019 COVID-19","Drug: TJ003234|Drug: Placebo","The GW Medical Faculty Associates, Washington, District of Columbia, United States|OSF Healthcare Saint Francis Medical Center, Peoria, Illinois, United States|Indiana University Health, Indianapolis, Indiana, United States|Medpharmics, LLC, Metairie, Louisiana, United States|Ochsner Medical Center, New Orleans, Louisiana, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Oregon Health and Science University, Portland, Oregon, United States|Temple Univeristy Hospital, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT04341116"
1102,"COVID-19 Convalescent Plasma","Active, not recruiting","No Results Available","Coronavirus","Biological: anti-SARS-CoV-2 convalescent plasma","University of Chicago Medicine, Chicago, Illinois, United States","https://ClinicalTrials.gov/show/NCT04340050"
1103,"Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019","Enrolling by invitation","No Results Available","COVID-19","Other: Discontinuation of ARB/ACEI|Other: Continuation of ARB/ACEI","University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT04338009"
1104,"Clinical and Radiomic Model of COVID-19","Completed","No Results Available","Coronavirus|Machine Learning","Diagnostic Test: Machine learning model","The central hospital of Wuhan, Wuhan, Hubei, China","https://ClinicalTrials.gov/show/NCT04337502"
1105,"Remote Monitoring Use In Cases Of Suspected COVID-19 (Coronavirus)","Not yet recruiting","No Results Available","Coronavirus","Device: SensiumVitals wearable sensor",,"https://ClinicalTrials.gov/show/NCT04337489"
1106,"Renin Angiotensin System - CoronaVirus","Recruiting","No Results Available","COVID 19","Other: blood draw","ASSISTANCE PUBLIQUE HÖPITAUX de MARSEILLE, Marseille, France","https://ClinicalTrials.gov/show/NCT04337008"
1107,"Telerehabilitation in Individuals Over 65 Years of Age Having Social Isolation Due to Coronavirus (Covid-19)","Not yet recruiting","No Results Available","Telerehabilitation","Other: Telerehabilitation","Istanbul university Cerrahpasa, Istanbul, Turkey","https://ClinicalTrials.gov/show/NCT04334434"
1108,"Telephony Or Videophony for Isolated elDerly in Maine-Et-Loire 49 During COVID-19","Recruiting","No Results Available","Coronavirus",,"Angers University Hospital, Angers, France","https://ClinicalTrials.gov/show/NCT04333849"
1109,"An Observational Study of Patients With Coronavirus Disease 2019","Recruiting","No Results Available","COVID-19|Coronavirus",,"University of Washington, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT04331886"
1110,"Impact of the Coronavirus (COVID-19) on Patients With Cancer","Not yet recruiting","No Results Available","Cancer|COVID-19",,,"https://ClinicalTrials.gov/show/NCT04330521"
1111,"Clinical Characteristics and Prognostic Factors of Patients With COVID-19","Recruiting","No Results Available","Coronavirus","Other: retrospective analysis","Shanghai 10th People's Hospital, Shanghai, Shanghai, China","https://ClinicalTrials.gov/show/NCT04328454"
1112,"Hydroxychloroquine Versus Placebo in COVID-19 Patients at Risk for Severe Disease","Recruiting","No Results Available","Coronavirus","Drug: Hydroxychloroquine|Drug: Placebo","CH Agen, Agen, France|CHU Amiens, Amiens, France|CHU Angers, Angers, France|CH Auxerre, Auxerre, France|APHP Avicenne, Bobigny, France|CHU Brest, Brest, France|CHU Caen, Caen, France|CH Chalon Sur Saône, Chalon Sur Saône, France|CH Cherbroug, Cherbourg, France|CH Cholet, Cholet, France|CH Colmar, Colmar, France|CH Compiègne, Compiègne, France|APHP Henri Mondor, Créteil, France|CH Intercommunal Créteil, Créteil, France|CHU Dijon, Dijon, France|APHP Joffre Dupuytren, Draveil, France|CHD Vendée, La Roche-sur-Yon, France|CH Laval, Laval, France|CH Le Mans, Le Mans, France|CH Emile Roux, Le Puy-en-Velay, France|APHP Emile ROUX, Limeil-Brevannes, France|CHU Limoges, Limoges, France|CH Lorient, Lorient, France|Hôpital Européen - Marseille, Marseille, France|Hôpital Saint-Joseph, Marseille, France|CH Melun, Melun, France|CHU Nantes, Nantes, France|Hôpital Privé du Confluent, Nantes, France|CH Niort, Niort, France|CHR Orléans, Orléans, France|APHP Saint-Antoine, Paris, France|GH Croix Saint Simon, Paris, France|La Pitié-Salpétrière, Paris, France|CHU Poitiers, Poitiers, France|CH Pointoise, Pontoise, France|CH Quimper, Quimper, France|CH Saint-Brieuc, Saint-Brieuc, France|CH Saint-Nazaire, Saint-Nazaire, France|CHU Saint-Etienne, Saint-Étienne, France|CHU Toulouse, Toulouse, France|CH Tourcoing, Tourcoing, France|CHU Tours, Tours, France|CH Valenciennes, Valenciennes, France|Clinique Tessier Valenciennes, Valenciennes, France|CH Vannes, Vannes, France|CH Versailles, Versailles, France|CH Princesse Grace, Monaco, Monaco","https://ClinicalTrials.gov/show/NCT04325893"
1113,"A Study of a Candidate COVID-19 Vaccine (COV001)","Active, not recruiting","No Results Available","Coronavirus","Biological: ChAdOx1 nCoV-19|Biological: MenACWY|Biological: ChAdOx1 nCoV-19 boost|Drug: Paracetamol","University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, United Kingdom|University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom|St Georges University Hospital NHS Foundation Trust, London, United Kingdom|Imperial College Healthcare NHS Trust, London, United Kingdom|CCVTM, University of Oxford, Churchill Hospital, Oxford, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom","https://ClinicalTrials.gov/show/NCT04324606"
1114,"COVID-19 PRIORITY (Pregnancy CoRonavIrus Outcomes RegIsTrY)","Recruiting","No Results Available","Pregnancy|Coronavirus|COVID-19","Other: Pregnant women under investigation for Coronavirus or diagnosed with COVID-19|Other: Postpartum women under investigation for Coronavirus or diagnosed with COVID-19","University of California, San Francisco, San Francisco, California, United States","https://ClinicalTrials.gov/show/NCT04323839"
1115,"Outcomes of Surgery in COVID-19 Infection: International Cohort Study (CovidSurg)","Recruiting","No Results Available","COVID-19|Coronavirus|Surgery","Procedure: Surgery","Hospital del Henares, Madrid, Spain","https://ClinicalTrials.gov/show/NCT04323644"
1116,"Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus","Recruiting","No Results Available","COVID-19","Dietary Supplement: Natural Honey|Other: Standard Care","Mahmoud Tantawy, Cairo, Egypt","https://ClinicalTrials.gov/show/NCT04323345"
1117,"Risk Factors for Community- and Workplace Transmission of COVID-19","Recruiting","No Results Available","Coronavirus","Behavioral: Observation of behavior and COVID-19 infection will be conducted.","Oslo University Hospital, Oslo, Norway","https://ClinicalTrials.gov/show/NCT04320732"
1118,"Effects of Social Isolation From Coronavirus; on Physical Activity, Quality of Life and Stress","Not yet recruiting","No Results Available","Healthy People","Other: Determination of physical activity, quality of life, stress levels of isolated people at home with the danger of coronavirus.","Istanbul University Cerrahpasa, Istanbul, Turkey","https://ClinicalTrials.gov/show/NCT04319211"
1119,"Multicentric Study of Coronavirus Disease 2019 (COVID-2019) in Solid Organ Transplant Recipients","Not yet recruiting","No Results Available","Transplant Recipient|Infections, Coronavirus",,,"https://ClinicalTrials.gov/show/NCT04319172"
1120,"CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment","Recruiting","No Results Available","Severe Coronavirus Disease (COVID-19)","Drug: CD24Fc|Drug: Placebo","Baptist Health Research Institute, Jacksonville, Florida, United States|Martin Army Community Hospital, Fort Benning, Georgia, United States|Anne Anundel Medical Center, Annapolis, Maryland, United States|Institute of Human Virology, University of Maryland Baltimore, Baltimore, Maryland, United States|Shady Grove Medical Center, Rockville, Maryland, United States|White Oak Medical Center, Silver Spring, Maryland, United States|Henry Ford Health System, Detroit, Michigan, United States|Cooper University Hospital, Camden, New Jersey, United States|Atlantic Health System, Morristown, New Jersey, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|Thomas Jefferson University Medical Center, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT04317040"
1121,"Development and Verification of a New Coronavirus Multiplex Nucleic Acid Detection System","Not yet recruiting","No Results Available","COVID-19","Diagnostic Test: New QIAstat-Dx fully automatic multiple PCR detection platform","Huashan Hospital of Fudan University, Shanghai, Shanghai, China","https://ClinicalTrials.gov/show/NCT04311398"
1122,"Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)","Terminated","No Results Available","COVID-19","Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine sulfate","Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of","https://ClinicalTrials.gov/show/NCT04307693"
1123,"Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting","Recruiting","No Results Available","COVID19|Coronavirus|Acute Respiratory Illnesses","Drug: Chloroquine or Hydroxychloroquine|Drug: Placebo","Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand","https://ClinicalTrials.gov/show/NCT04303507"
1124,"Medical Masks vs N95 Respirators for COVID-19","Not yet recruiting","No Results Available","Coronavirus|N95|Medical Mask","Device: Medical Mask|Device: N95 respirator",,"https://ClinicalTrials.gov/show/NCT04296643"
1125,"Eculizumab (Soliris) in Covid-19 Infected Patients","Available","No Results Available","Coronavirus","Drug: Eculizumab",,"https://ClinicalTrials.gov/show/NCT04288713"
1126,"Humanistic Care in Healthcare Workers in Coronavirus Disease 2019","Withdrawn","No Results Available","Coronavirus Disease 2019","Behavioral: Humanistic Care",,"https://ClinicalTrials.gov/show/NCT04283838"
1127,"Humanistic Care in Patients With Coronavirus Disease 2019","Withdrawn","No Results Available","Coronavirus Disease 2019","Behavioral: Psychological and physical rehabilitation based humanistic care",,"https://ClinicalTrials.gov/show/NCT04283825"
1128,"Clinical Outcomes of Patients With COVID19","Withdrawn","No Results Available","Coronavirus Disease 2019","Other: retrospective analysis","HuiZhou Municipal Central Hospital, Huizhou, Guangdong, China","https://ClinicalTrials.gov/show/NCT04280913"
1129,"Fingolimod in COVID-19","Recruiting","No Results Available","Coronavirus Disease (COVID-19)","Drug: Fingolimod 0.5 mg","Wan-Jin Chen, Fuzhou, China","https://ClinicalTrials.gov/show/NCT04280588"
1130,"Detection of 2019 Novel Coronavirus in Multiple Organ System and Its Relationship With Clinical Manifestations","Recruiting","No Results Available","Coronavirus",,"The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China","https://ClinicalTrials.gov/show/NCT04279795"
1131,"Viral Excretion in Contact Subjects at High/Moderate Risk of Coronavirus 2019-nCoV Infection. COVID-19.","Recruiting","No Results Available","Coronavirus","Biological: 2019-nCoV PCR","Service de maladies infectieuses et tropicales Hôpital Jean Minjoz CHRU Besançon, Besançon, France|Service des Maladies infectieuses et tropicales, Pôle Spécialités médicales, CHU Pellegrin, Bordeaux, France|Service des maladies infectieuses Hôpital Gabriel Montpied CHU de Clermont Ferrand, Clermont-Ferrand, France|Centre d'investigation clinique 1432 Hôpital François Mitterrand CHU Bourgogne, Dijon, France|Centre d'investigation clinique 1406 CHU Grenoble, Grenoble, France|Centre d'Investigation Clinique 1403 -CHU Lille, Lille, France|Centre Investigation Clinique 1433 CHRU de NANCY, Nancy, France|Centre d'investigation clinique Infectiologie Hôtel-Dieu CHU Nantes, Nantes, France|Centre d'Investigation Clinique Hôpital Saint Louis, Paris, France|Centre d'investigation Clinique 1425, Hôpital Bichat Claude Bernard, Paris, France|Centre Investigation Clinique 1417 Hôpital Cochin Bâtiment Lavoisier, Paris, France|Centre d'investigation clinique 1414 Service de Pharmacologie clinique CHU Rennes Hôpital Pontchaillou, Rennes, France|Centre Hospitalier Félix Guyon Ile de la Réunion CHU nord, Saint Denis, France|Centre d'Investigation Clinique Ile de la Réunion CHU sud, Saint-Pierre, France|Département maladie infectieux CHU Saint Etienne, Saint-Étienne, France|Centre Investigation Clinique 1415 CHRU Tours - Hôpital Bretonneau, Tours, France|Service de Maladies infectieuses et tropicales Centre hospitalier, Cayenne, French Guiana","https://ClinicalTrials.gov/show/NCT04259892"
1132,"Development of a Simple, Fast and Portable Recombinase Aided Amplification Assay for 2019-nCoV","Recruiting","No Results Available","New Coronavirus","Diagnostic Test: Recombinase aided amplification (RAA) assay","Department of Hepatology Division 2, Beijing Ditan Hospital, Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT04245631"
1133,"Randomized, Double-blind, Placebo-controlled, Phase Ib Study to Assess the Safety and Immunogenicity of MVA-MERS-S_DF-1","Not yet recruiting","No Results Available","MERS (Middle East Respiratory Syndrome)","Biological: MVA-MERS-S_DF1 - Low Dose|Biological: MVA-MERS-S_DF1 - High Dose|Other: Placebo","CTC North, Hamburg, Germany|Erasmus Medical Centre, Rotterdam, Netherlands","https://ClinicalTrials.gov/show/NCT04119440"
1134,"Lessening Organ Dysfunction With VITamin C","Recruiting","No Results Available","Sepsis|Vitamin C|Intensive Care Unit|COVID-19|Pandemic|Coronavirus","Drug: Vitamin C|Other: Control","Research Center of the CHUS, Sherbrooke, Quebec, Canada","https://ClinicalTrials.gov/show/NCT03680274"
1135,"Safety, Tolerability and Immunogenicity of Vaccine Candidate MVA-MERS-S","Completed","No Results Available","MERS (Middle East Respiratory Syndrome)","Biological: vaccine candidate MVA-MERS-S","CTC North GmbH & Co. KG at the University Medical Center Hamburg-Eppendorf, Hamburg, Germany","https://ClinicalTrials.gov/show/NCT03615911"
1136,"MERS-CoV Infection tReated With A Combination of Lopinavir /Ritonavir and Interferon Beta-1b","Completed","No Results Available","Middle East Respiratory Syndrome Coronavirus (MERS-CoV)","Drug: Combination of Lopinavir /Ritonavir and Interferon beta-1b|Drug: Placebo","Intensive Care Unit, King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Saudi Arabia|King Abdullah International Medical Research Center, Riyadh, Saudi Arabia","https://ClinicalTrials.gov/show/NCT02845843"
1137,"Safety, Tolerability, and Pharmacokinetics of SAB-301 in Healthy Adults","Completed","Has Results","Middle East Respiratory Syndrome Coronavirus","Biological: SAB-301|Other: Normal (9%) Saline","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT02788188"
1138,"Assessment of the Psycho-social Impact of COVID-19 Outbreak","Recruiting","No Results Available","SARS-CoV 2|COVID-19|Quality of Life|Mental Health Wellness 1|Social Distance|SARS (Disease)|Psychological","Behavioral: COM-COVID anonimous survey","Fundació Institut Germans Trias i Pujol, Badalona, Catalonia, Spain|Fundació Lluita contra la Sida (FLS, Fight AIDS Foundation), Badalona, Catalonia, Spain|Anaxomics biotech, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT04378452"
1139,"COVID-19 and Pregnancy Outcomes","Recruiting","No Results Available","Coronavirus Infection|Pregnancy Complications|Vertical Transmission of Infectious Disease|Breastfeeding|Neonatal Infection","Diagnostic Test: RT PCR SARS-CoV-2","Nova Medical School - UNL, Lisbon, Portugal","https://ClinicalTrials.gov/show/NCT04416373"
1140,"A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19","Recruiting","No Results Available","COVID|Covid-19|Coronavirus|Coronavirus Infection|Severe Acute Respiratory Syndrome|Severe Acute Respiratory Syndrome Coronavirus 2|Sars-CoV2|Ards|Acute Respiratory Distress Syndrome","Drug: APL-9|Other: Vehicle Control","Westchester General Hospital, Miami, Florida, United States|Norton Women's and Children's Hospital, Louisville, Kentucky, United States|Audobon Hospital, Louisville, Kentucky, United States|University at Buffalo, Buffalo, New York, United States","https://ClinicalTrials.gov/show/NCT04402060"
1141,"COVid-19: Awake Proning and High-flow Nasal Cannula in respiratorY DistrEss","Recruiting","No Results Available","Coronavirus Infection|COVID|Severe Acute Respiratory Syndrome|Respiratory Failure|Respiratory Insufficiency|Respiratory Distress Syndrome|ARDS|Lung Diseases","Procedure: Awake Prone Positioning|Procedure: Standard care","Hôpital de Verdun, Montréal, Quebec, Canada","https://ClinicalTrials.gov/show/NCT04395144"
1142,"SARSCoV2 (COVID-19) Convalescent Plasma (CP) Expanded Access Protocol (EAP)","Available","No Results Available","COVID|SARSCoV2 Convalescent Plasma","Biological: SARSCoV2 Convalescent Plasma","AdventHealth Orlando, Orlando, Florida, United States","https://ClinicalTrials.gov/show/NCT04374370"
1143,"Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe COVID-19","Recruiting","No Results Available","Coronavirus Disease 2019 Infectious Disease (COVID-19 Infection)","Other: convalescent plasma application to SARS-CoV-2 infected patients","Blutspendezentrum SRK beider Basel, University Hospital Basel, Basel, Switzerland","https://ClinicalTrials.gov/show/NCT04389944"
1144,"Epidemiology of Acute Kidney Injury in COVID19 Disease in United Kingdom","Not yet recruiting","No Results Available","COVID|AKI","Other: acute kidney injury","Derby Hospital NHS Foundation Trust, Derby, Derbyshire, United Kingdom","https://ClinicalTrials.gov/show/NCT04407156"
1145,"Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells","Enrolling by invitation","No Results Available","COVID|Covid-19|Coronavirus|Pneumonia|Pneumonia, Viral|Pneumonia, Interstitial|Sars-CoV2","Biological: Allogenic pooled olfactory mucosa-derived mesenchymal stem cells|Other: Standard treatment according to the Clinical protocols","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus, Minsk, Belarus","https://ClinicalTrials.gov/show/NCT04382547"
1146,"Mavrilimumab in Severe COVID-19 Pneumonia and Hyper-inflammation (COMBAT-19)","Not yet recruiting","No Results Available","Covid-19|Acute Respiratory Failure|ARDS, Human|Sars-CoV2|Viral Pneumonia","Drug: Mavrilimumab|Drug: Placebo","IRCCS Policlinico San Donato, San Donato, MI, Italy|IRCCS Ospedale San Raffaele, Milano, Italy|IRCCS Istituto Ortopedico Galeazzi, Milano, Italy","https://ClinicalTrials.gov/show/NCT04397497"
1147,"COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement","Not yet recruiting","No Results Available","COVID-19|Therapeutic Vaccine|BCG|SARS-CoV 2|Transmission","Biological: BCG|Biological: Placebo","Hospital das Clínicas Unicamp, Campinas, SP, Brazil","https://ClinicalTrials.gov/show/NCT04369794"
1148,"Steroid Dosing by bioMARker Guided Titration in Critically Ill Patients With Pneumonia","Recruiting","No Results Available","Pneumonia","Drug: Methylprednisolone|Other: Usual Care","Mayo Clinic in Rochester, Rochester, Minnesota, United States","https://ClinicalTrials.gov/show/NCT03852537"
1149,"Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm","Recruiting","No Results Available","Covid-19","Drug: MethylPREDNISolone 80 Mg/mL Injectable Suspension","San Juan City Hospital / Puerto Rico Medical Center, San Juan, Puerto Rico|Hospital Auxilio Mutuo Cancer Center, San Juan, Puerto Rico","https://ClinicalTrials.gov/show/NCT04355247"
1150,"Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells","Recruiting","No Results Available","Use of Stem Cells for COVID-19 Treatment","Biological: WJ-MSCs","Stem Cells Arabia, Amman, Jordan","https://ClinicalTrials.gov/show/NCT04313322"
1151,"Use of UC-MSCs for COVID-19 Patients","Recruiting","No Results Available","Corona Virus Infection|ARDS|ARDS, Human|Acute Respiratory Distress Syndrome|COVID-19","Biological: Umbilical Cord Mesenchymal Stem Cells|Other: Standard of Care","Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, Florida, United States","https://ClinicalTrials.gov/show/NCT04355728"
1152,"Risk of Venous Thromboembolism in Critically Ill Patients With Severe COVID-19","Completed","No Results Available","COVID-19|Critical Illness|Venous Thromboembolism|Venous Thromboses|Venous Thromboses, Deep|Venous Thrombosis Pulmonary|Pulmonary Embolism|Pulmonary Embolism and Thrombosis|Sars-CoV2|SARS-CoV Infection","Diagnostic Test: Duplex ultrasound and Computed Tomography Angiography","Vall d´Hebron Research Institute VHIR, Barcelona, Catalunya, Spain|Hospital Germans Trias i Pujol. Universitat Autònoma de Barcelona, Badalona, Spain|Hospital Universitari Vall d'Hebron. Universitat Autonoma de Barcelona, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT04374617"
1153,"Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 (CYNK-001-COVID-19)","Recruiting","No Results Available","Coronavirus|Coronavirus Infection|Severe Acute Respiratory Syndrome Coronavirus 2|Pneumonia|Pneumonia, Viral|Lung Diseases|Respiratory Tract Disease|Respiratory Tract Infections|Coronaviridae Infections|Nidovirales Infections|RNA Virus Infections|Virus Disease|Immunologic Disease|ARDS|Immunologic Factors|Physiological Effects of Drugs|Antiviral Agents|Anti-infective Agents|Analgesics|Antimetabolites, Antineoplastic","Biological: CYNK-001","Hackensack University Medical Center, Hackensack, New Jersey, United States|Multicare Health System, Tacoma, Washington, United States","https://ClinicalTrials.gov/show/NCT04365101"
1154,"Prone Positioning and High-flow Nasal Cannula in COVID-19 Induced ARDS","Recruiting","No Results Available","COVID|ARDS|Acute Respiratory Distress Syndrome|Acute Respiratory Failure|Corona Virus Infection","Other: Prone position","Hospital Universitari Vall d'Hebron, Barcelona, Spain","https://ClinicalTrials.gov/show/NCT04391140"
1155,"Evaluating the Use of Polymyxin B Cartridge Hemoperfusion for Patients With Septic Shock and COVID 19","Available","No Results Available","Septic Shock|Endotoxemia|COVID|Corona Virus Infection|Sepsis, Severe","Device: Toraymyxin PMX-20R (PMX Cartridge)","George Washington University, Washington, District of Columbia, United States|Stony Brook University Hospital, Stony Brook, New York, United States","https://ClinicalTrials.gov/show/NCT04352985"
1156,"Compare CE-Budesonide Nasal Solution & Rhinocort Aqua in an EEC Study of AR","Completed","No Results Available","Seasonal Allergic Rhinitis","Drug: Budesonide|Drug: Placebo","Allied Research International - Cetero Research, Mississauga, Ontario, Canada","https://ClinicalTrials.gov/show/NCT00938613"
1157,"Telerehabilitation in Patients With COVID-19 After Hospitalization. The ATHLOS Study","Recruiting","No Results Available","COVID-19|Comorbidities and Coexisting Conditions","Device: Telerehabilitation","Clinical exercise Physiology and rehabilitation research laboratory, Lamia, Greece","https://ClinicalTrials.gov/show/NCT04368845"
1158,"Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19","Not yet recruiting","No Results Available","COVID 19|Coronavirus|Diabetes Mellitus, Type 2|Diabetes Mellitus|Glucose Metabolism Disorders|Metabolic Disease|Endocrine System Diseases|Dipeptidyl-Peptidase IV Inhibitors|Linagliptin|Severe Acute Respiratory Syndrome Coronavirus 2|Sars-CoV2|Hypoglycemic Agents|Respiratory Tract Diseases|Incretins|Hormones","Drug: Linagliptin 5 MG","Rabin Medical Center, Petah tikva, Israel","https://ClinicalTrials.gov/show/NCT04371978"
1159,"A Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry Eye","Completed","Has Results","Dry Eye Disease","Drug: Lifitegrast|Drug: Placebo","OPUS-2 Investigational Site, Artesia, California, United States|OPUS-2 Investigational Site, Hemet, California, United States|OPUS-2 Investigational Site, Lancaster, California, United States|OPUS-2 Investigational Site, Mission Hills, California, United States|OPUS-2 Investigational Site, Montebello, California, United States|OPUS-2 Investigational Site, Newport Beach, California, United States|OPUS-2 Investigational Site, Petaluma, California, United States|OPUS-2 Investigational SIte, Rancho Cordova, California, United States|OPUS-2 Investigational Site, Danbury, Connecticut, United States|OPUS-2 Investigational Site, Fort Myers, Florida, United States|OPUS-2 Investigational Site, Hoffman Estates, Illinois, United States|OPUS-2 Investigational Site, Indianapolis, Indiana, United States|OPUS-2 Investigational Site, New Albany, Indiana, United States|OPUS-2 Investigational Site, Lexington, Kentucky, United States|OPUS-2 Investigational Site, Saint Paul, Minnesota, United States|OPUS-2 Investigational Site, Chesterfield, Missouri, United States|OPUS-2 Investigational Site, Des Peres, Missouri, United States|OPUS-2 Investigational Site, Independence, Missouri, United States|OPUS-2 Investigational Site, Kansas City, Missouri, United States|OPUS-2 Investigational Site, Washington, Missouri, United States|OPUS-2 Investigational Site, New York, New York, United States|OPUS-2 Investigational Site, New York, New York, United States|OPUS-2 Investigational Site, Wantagh, New York, United States|OPUS-2 Investigational Site, Cleveland, Ohio, United States|OPUS-2 Investigational Site, Philadelphia, Pennsylvania, United States|OPUS-2 Investigational Site, Houston, Texas, United States|OPUS-2 Investigational Site, Houston, Texas, United States|OPUS-2 Investigational Site, League City, Texas, United States|OPUS-2 Investigational Site, San Antonio, Texas, United States|OPUS-2 Investigational Site, San Antonio, Texas, United States|OPUS-2 Investigational Site, Norfolk, Virginia, United States","https://ClinicalTrials.gov/show/NCT01743729"
1160,"FAvipiravir and HydroxyChloroquine Combination Therapy","Not yet recruiting","No Results Available","COVID19","Combination Product: Favipiravir and Hydroxychloroquine","King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Saudi Arabia","https://ClinicalTrials.gov/show/NCT04392973"
1161,"Association Between Long-term Hydroxychloroquine Treatment and Outcome of a History of Symptoms Suggestive of COVID-19 Infection During the Epidemic Period in France in Patients With Autoimmune Disease","Active, not recruiting","No Results Available","SARS-CoV-2|Systemic Lupus Erythematosus|Rheumatoid Arthritis|Sjogren's Syndrome|Psoriatic Arthritis","Other: Questionnaire by phone call","Fondation Adolphe de Rothschild, Paris, France","https://ClinicalTrials.gov/show/NCT04345159"
1162,"ICBT for Mental Health Problems Related to the Coronavirus Pandemic","Recruiting","No Results Available","Depression and Quality of Life Related to the Coronavirus Pandemic","Behavioral: Intervention group CoronaCope","Linköping University, Linköping, Östergötland, Sweden","https://ClinicalTrials.gov/show/NCT04424212"
1163,"Neurologic Manifestations of COVID-19","Not yet recruiting","No Results Available","Coronavirus Disease 2019",,,"https://ClinicalTrials.gov/show/NCT04386083"
1164,"Incidence of Covid-19 in School Children","Withdrawn","No Results Available","Infection; Viral, Coronavirus","Diagnostic Test: RT-PCR Covid-19","Hôpitaux Pédiatrique de Nice CHU Lenval, Nice, France","https://ClinicalTrials.gov/show/NCT04377737"
1165,"A Single-blinded, Randomized, Placebo Controlled Phase II Trial of Prophylactic Treatment With Oral Azithromycin Versus Placebo in Cancer Patients Undergoing Antineoplastic Treatment During the Corona Virus Disease 19 (COVID-19) Pandemic","Recruiting","No Results Available","COVID","Drug: Azithromycin 500 milligram (mg) oral Tablet|Drug: Placebo","AKH Vienna, Department for Internal Medicine I, Oncology, Vienna, Austria","https://ClinicalTrials.gov/show/NCT04369365"
1166,"Social Media and COVID-19","Recruiting","No Results Available","Coronavirus|Depression|Anxiety|Stress","Behavioral: Social media & news consumption","Yale-NUS College, Singapore, Singapore","https://ClinicalTrials.gov/show/NCT04367363"
1167,"Protective Effect of Aspirin on COVID-19 Patients","Enrolling by invitation","No Results Available","Novel Coronavirus Pneumonia|Aspirin|Treatment","Drug: Aspirin 100mg","Cai Yue, Xi'an, Shaanxi, China","https://ClinicalTrials.gov/show/NCT04365309"
1168,"The Ariel University Survey on Dietary Changes and Anxiety During the Coronavirus Pandemic","Recruiting","No Results Available","Dietary Habits|Anxiety",,"Ariel University, Ariel, Israel","https://ClinicalTrials.gov/show/NCT04353934"
1169,"Predictive Biomarkers of Secondary Aggravation in Covid-19 Suspect Patient","Not yet recruiting","No Results Available","Infection Viral|Coronavirus|COVID-19",,,"https://ClinicalTrials.gov/show/NCT04341792"
1170,"Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019","Recruiting","No Results Available","COVID-19","Drug: Anluohuaxian","The Second People's Hospital of Fuyang, Fuyang, Anhui, China|Ezhou Central Hospital, Wuhan, Hubei, China|Huoshenshan Hospital of Wuhan, Wuhan, Hubei, China|Jinyintan Hospital of Wuhan, Wuhan, Hubei, China|Tongji Hospital of Huazhong University of Science and Technology, Wuhan, Hubei, China|West Hospital Union Hospital Huazhong University of Science and Technology, Wuhan, Hubei, China|Wuhan Pulmonary Hospital, Wuhan, Hubei, China|Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China|Wenzhou Medical University Affiliated First Hospital, Wenzhou, Zhejiang, China","https://ClinicalTrials.gov/show/NCT04334265"
1171,"Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive","Recruiting","No Results Available","COVID-19","Drug: Favipiravir","The Second People's Hospital of Fuyang, Fuyang, Anhui, China|Ezhou Hospital of Traditional Chinese Medicine, Ezhou, Hubei, China|Ezhou Central Hospital, Wuhan, Hubei, China|Huoshenshan Hospital of Wuhan, Wuhan, Hubei, China|Jinyintan Hospital of Wuhan, Wuhan, Hubei, China|Wuhan Pulmonary Hospital, Wuhan, Hubei, China|Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China|Wenzhou Medical University Affiliated First Hospital, Wenzhou, Zhejiang, China","https://ClinicalTrials.gov/show/NCT04333589"
1172,"Coronavirus (COVID-19) ACEi/ARB Investigation","Recruiting","No Results Available","Hypertension|COVID-19","Drug: Thiazide or Thiazide-like diuretics|Drug: Calcium Channel Blockers|Drug: ACE inhibitor|Drug: Angiotensin receptor blocker","University Hospital Galway, Galway, Ireland","https://ClinicalTrials.gov/show/NCT04330300"
1173,"Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia","Recruiting","No Results Available","Novel Coronavirus Pnuemonia","Drug: favipiravir tablets+chloroquine phosphatetablets tablets|Drug: Favipiravir tablets|Drug: Placebo","Beijing Chaoyang hospital, Beijing, Beijing, China","https://ClinicalTrials.gov/show/NCT04319900"
1174,"Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy: The Italian Registry on Coronavirus in Pregnancy.","Recruiting","No Results Available","Infection Viral","Other: pregnant women with laboratory-confirmed 2019-n-CoV","University of Naples Federico II, Napoli, Italy","https://ClinicalTrials.gov/show/NCT04315870"
1175,"The Observational Study of Cardiac and Pulmonary Ultrasound and Evaluation of Treatment of Severe Patients With Novel Coronavirus Pneumonia","Recruiting","No Results Available","Novel Coronavirus Pneumonia",,"Xiangya Hospital, Central South University, Changsha, Hunan, China","https://ClinicalTrials.gov/show/NCT04314271"
1176,"Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019","Recruiting","No Results Available","COVID-19","Drug: Favipiravir Combined With Tocilizumab|Drug: Favipiravir|Drug: Tocilizumab","Guiqiang Wang, Beijing, Beijing, China|Peking University First Hospital, Beijing, Beijing, China|Ezhou Central Hospital, Wuhan, Hubei, China|Huoshenshan Hospital of Wuhan, Wuhan, Hubei, China|Jinyintan Hospital of Wuhan, Wuhan, Hubei, China|Wuhan Pulmonary Hospital, Wuhan, Hubei, China","https://ClinicalTrials.gov/show/NCT04310228"
1177,"Social Media Use During COVID-19","Recruiting","No Results Available","Coronavirus|Depression|Anxiety|Stress","Behavioral: Use of social media during COVID-19","Yale-NUS College, Singapore, Singapore","https://ClinicalTrials.gov/show/NCT04305574"
1178,"Clinical Progressive Characteristics and Treatment Effects of 2019-novel Coronavirus","Active, not recruiting","No Results Available","Pneumonia Caused by Human Coronavirus",,"Fujian Provincial Hospital, Fuzhou, Fujian, China","https://ClinicalTrials.gov/show/NCT04292327"
1179,"Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19)","Recruiting","No Results Available","Corona Virus Disease 2019(COVID-19)","Biological: MSCs|Biological: Saline containing 1% Human serum albumin（solution of MSC）","Maternal and Child Hospital of Hubei Province, Wuhan, Hubei, China|Wuhan Huoshenshan Hospital, Wuhan, Hubei, China","https://ClinicalTrials.gov/show/NCT04288102"
1180,"The Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With COVID-19","Not yet recruiting","No Results Available","Coronavirus Disease 2019|Novel Coronavirus Pneumonia","Drug: T89",,"https://ClinicalTrials.gov/show/NCT04285190"
1181,"Study for Novel Coronavirus Pneumonia (NCP)","Recruiting","No Results Available","Novel Coronavirus Pneumonia","Combination Product: systemic treatment","Union hospital, Wuhan, Hubei, China","https://ClinicalTrials.gov/show/NCT04283396"
1182,"NK Cells Treatment for COVID-19","Recruiting","No Results Available","Novel Coronavirus Pneumonia","Biological: NK Cells","The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China","https://ClinicalTrials.gov/show/NCT04280224"
1183,"Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)","Active, not recruiting","No Results Available","Novel Coronavirus Pneumonia|2019-nCoV","Drug: Bromhexine Hydrochloride Tablets|Drug: Arbidol Hydrochloride Granules|Drug: Recombinant Human Interferon α2b Spray","The Second AffIliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China","https://ClinicalTrials.gov/show/NCT04273763"
1184,"Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe COVID-19","Not yet recruiting","No Results Available","2019 Novel Coronavirus Pneumonia|COVID-19","Biological: UC-MSCs|Drug: Placebo","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China","https://ClinicalTrials.gov/show/NCT04273646"
1185,"A Clinical Trial to Determine the Safety and Immunogenicity of Healthy Candidate MERS-CoV Vaccine (MERS002)","Recruiting","No Results Available","Middle East Respiratory Syndrome Coronavirus","Biological: ChAdOx1 MERS","King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, Saudi Arabia","https://ClinicalTrials.gov/show/NCT04170829"
1186,"Study of Safety and Immunogenicity of BVRS-GamVac","Recruiting","No Results Available","MERS (Middle East Respiratory Syndrome)|MERS","Biological: BVRS-GamVac|Other: placebo","Research Institute of Influenza, Sankt-Peterburg, Russian Federation","https://ClinicalTrials.gov/show/NCT04130594"
1187,"Study of Safety and Immunogenicity of BVRS-GamVac-Combi","Recruiting","No Results Available","MERS (Middle East Respiratory Syndrome)|MERS","Drug: BVRS-GamVac-Combi|Other: placebo","ECO-Safety, Sankt-Peterburg, Russian Federation","https://ClinicalTrials.gov/show/NCT04128059"
1188,"Assessment of the Efficacy and Safety of (HCQ) as a Prophylaxis for COVID19 for Health Professionals","Recruiting","No Results Available","COVID19|Sars-CoV2|Hydroxychloroquine|Prophylaxis|Healthcare Worker","Drug: Hydroxychloroquine (HCQ)|Drug: Placebo oral tablet","Eshmoun Clinical Research Centre/ Hôpital Abderrahmane Mami-Ariana, Tunis, Tunisia","https://ClinicalTrials.gov/show/NCT04349228"
1189,"Safety and Immunogenicity of a Candidate MERS-CoV Vaccine (MERS001)","Recruiting","No Results Available","MERS (Middle East Respiratory Syndrome)","Biological: ChAdOx1 MERS","Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford, United Kingdom","https://ClinicalTrials.gov/show/NCT03399578"
1190,"A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection","Recruiting","No Results Available","Coronavirus|COVID-19|Convalescent Plasma","Drug: Convalescent Plasma","Good Samaritan Hospital, Cincinnati, Ohio, United States|Bethesda North Hospital, Cincinnati, Ohio, United States","https://ClinicalTrials.gov/show/NCT04392232"
1191,"Screening & Risk Assessment of Healthcare Workers & Infection Control in University & COVID-19 Quarantine Hospitals","Recruiting","No Results Available","Coronavirus Disease (COVID-19)",,"Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt","https://ClinicalTrials.gov/show/NCT04348214"
1192,"A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection","Recruiting","No Results Available","COVID 19|Coronavirus","Drug: Fluvoxamine|Drug: Placebo","BJC, Belleville, Illinois, United States|Washington University School of Medicine, Saint Louis, Missouri, United States","https://ClinicalTrials.gov/show/NCT04342663"
1193,"Prevalence and Severity of Venous Thromboembolism in a General Population During the COVID-19 Pandemic","Not yet recruiting","No Results Available","COVID-19|Venous Thromboembolism|Pulmonary Embolism|Deep Vein Thrombosis|SARS-CoV 2","Diagnostic Test: Diagnostic examination for venous thromboembolism","University Hospital Linköping, Linköping, Östergötland, Sweden","https://ClinicalTrials.gov/show/NCT04400877"
1194,"French Single Centre Experience of Critically Ill Patients With Covid 19","Not yet recruiting","No Results Available","Epidemiology|Sars-CoV2|COVID 19|Critical Care|Prognostic|Survival",,"CHU Amiens, Amiens, France","https://ClinicalTrials.gov/show/NCT04354558"
1195,"A Study to Explore the Role of Gut Flora in COVID-19 Infection","Recruiting","No Results Available","Gut Microbiome|Gastrointestinal Microbiome|COVID|COVID-19|Corona Virus Infection|Coronavirus|Coronaviridae Infections|Coronavirus 19|Coronavirus-19|COVID 19","Other: There is no intervention in this study","ProgenaBiome, Ventura, California, United States","https://ClinicalTrials.gov/show/NCT04359836"
1196,"Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.","Recruiting","No Results Available","COVID-19","Drug: Aspirin 75mg|Drug: Clopidogrel 75mg|Drug: Rivaroxaban 2.5 MG|Drug: Atorvastatin 40mg|Drug: Omeprazole 20mg","Charing Cross Hospital, London, United Kingdom","https://ClinicalTrials.gov/show/NCT04333407"
1197,"Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients","Completed","No Results Available","COVID","Drug: Convalescent Plasma Transfusion|Other: Supportive Care|Drug: Random Donor Plasma","Maulana Azad medical College, New Delhi, Delhi, India|Institute of Liver and Biliary Sciences, New Delhi, Delhi, India","https://ClinicalTrials.gov/show/NCT04346446"
1198,"Thrombomodulin-modified Thrombin Generation Assay (TGA-TM) in Patients With Critical Infections","Recruiting","No Results Available","Disseminated Intravascular Coagulation|Critical Illness|Sars-CoV2|Viral Infection|Coagulation Disorder, Blood|Covid19","Diagnostic Test: Thrombin Generation Assay (TGA)|Diagnostic Test: Thrombomodulin Modified Thrombin Generation Assay (TGA-TM)","Medical University Vienna, Vienna, Austria","https://ClinicalTrials.gov/show/NCT04356144"
1199,"Advanced Endoscopy During COVID-19","Recruiting","No Results Available","Cholangitis, Secondary Biliary|Cholangiocarcinoma|Obstructive Jaundice|Pancreas Cancer|COVID-19|SARS-CoV-2","Other: Endoscopic management according to standard of care","Kings County Hospital Center, Brooklyn, NY, USA, Albertson, New York, United States|Al-Azhar Univerisity, Cairo, Egypt|University Medicine Greifswald, Greifswald, Germany|2- Hospital Guillermo Kaelin De la Fuente - EsSalud, Lima, Peru|Singapore General Hospital, Singapore, Singapore","https://ClinicalTrials.gov/show/NCT04385147"
1200,"Safety and Efficacy Study of rEV131 in Allergic Rhinitis","Unknown status","No Results Available","Hay Fever","Drug: topical nasal rEV131","Diagnostics Research Group, San Antonio, Texas, United States|Sylvana Research Associates, San Antonio, Texas, United States","https://ClinicalTrials.gov/show/NCT00247520"
1201,"Trial of STAHIST in Seasonal Allergic Rhinitis","Completed","No Results Available","Seasonal Allergic Rhinitis","Drug: STAHIST|Drug: Placebo","Clinical Research Atlanta, Stockbridge, Georgia, United States|The South Bend Clinic, South Bend, Indiana, United States|Family Allergy and Asthma Institute, Louisville, Kentucky, United States|Family Allergy and Asthma, Somerset, Kentucky, United States|New Horizons Clinical Research, Cincinnati, Ohio, United States|National Allergy, Asthma & Urticaria Centers of Charleston, PA, Charleston, South Carolina, United States|Pharmaceutical Research and Consulting, Inc, Dallas, Texas, United States|Central Texas Health Research, New Braunfels, Texas, United States","https://ClinicalTrials.gov/show/NCT01293201"
1202,"Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies (HYACINTHE)","Not yet recruiting","No Results Available","COVID19|Hematologic Malignancy","Drug: Hydroxychloroquine Sulfate 200 MG [Plaquenil]|Drug: Azithromycin 250 MG Oral Capsule|Drug: Placebo oral tablet|Drug: Placebo oral capsule","Institut de Cancérologie Strasbourg Europe, Strasbourg, France","https://ClinicalTrials.gov/show/NCT04392128"
1203,"Saved From COVID-19","Recruiting","No Results Available","COVID","Drug: Chloroquine|Drug: Placebo oral tablet","Columbia University Irving Medical Center/NYP, New York, New York, United States","https://ClinicalTrials.gov/show/NCT04349371"
1204,"Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19","Withdrawn","No Results Available","COVID-19","Drug: Recombinant human angiotensin-converting enzyme 2 (rhACE2)","GCP Office of The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China","https://ClinicalTrials.gov/show/NCT04287686"
1205,"Qualitative and Quantitative Evaluation of Anosmia Over Time in Clinically Symptomatic Patients Tested for COVID-19 Infection","Recruiting","No Results Available","COVID-19","Other: olfactory and gustatory tests","CHU de Nimes, Nîmes, France","https://ClinicalTrials.gov/show/NCT04354857"
1206,"Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection","Not yet recruiting","No Results Available","COVID-19","Drug: Clazakizumab|Other: Placebo","Columbia University Medical Center / New York Presbyerian Hospital, New York, New York, United States","https://ClinicalTrials.gov/show/NCT04381052"
1207,"Audio Data Collection for Identification and Classification of Coughing","Recruiting","No Results Available","COVID-19|Coronavirus Infections|Hay Fever|Asthma|Chronic Obstructive Pulmonary Disease|Influenza|Common Cold|Respiratory Tract Infections|Healthy",,"Virtual Facility, Bronx, New York, United States","https://ClinicalTrials.gov/show/NCT04326309"
1208,"Implementation of Lung Protective Ventilation in Patients With Acute Respiratory Failure","Recruiting","No Results Available","Acute Respiratory Distress Syndrome|ARDS|Respiratory Distress Syndrome, Acute|Respiratory Insufficiency|Respiratory Distress Syndrome|Shock Lung|Severe Acute Respiratory Syndrome",,"Colin Grissom, Murray, Utah, United States","https://ClinicalTrials.gov/show/NCT03225807"
1209,"In-vitro Diagnostic Test to Predict COVID-19 Mortality and Disease Severity","Not yet recruiting","No Results Available","SARS-CoV 2|COVID|COVID-19|Androgenetic Alopecia|Androgen Receptor Abnormal|Androgen Deficiency","Diagnostic Test: CAG length <24|Diagnostic Test: CAG length >=24","Hospital Universitario Ramon y Cajal, Madrid, Spain","https://ClinicalTrials.gov/show/NCT04368897"
1210,"Inhaled Aviptadil for the Treatment of Non-Acute Lung Injury in COVID-19","Not yet recruiting","No Results Available","SARS-CoV 2|COVID|ARDS|ALI|Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)|Dyspnea","Drug: Aviptadil (VIP)|Drug: Placebo",,"https://ClinicalTrials.gov/show/NCT04360096"
1211,"Validity of at Home Visual Acuity Measurements for Telemedicine During Corona Virus (COVID-19) Pandemic","Recruiting","No Results Available","Visual Impairment","Other: Non invasive visual acuity testing","Vanderbilt Eye Institute, Nashville, Tennessee, United States","https://ClinicalTrials.gov/show/NCT04391166"
1212,"Evaluation of Novel Diagnostic Tests for COVID-19","Recruiting","No Results Available","Acute Disease|Coronavirus|Respiratory Viral Infection","Diagnostic Test: SAMBA II (Diagnostic for the Real World)|Diagnostic Test: Public Health England Gold Standard|Diagnostic Test: Cambridge Validated Viral Detection Method|Diagnostic Test: Radiological Detection","Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom","https://ClinicalTrials.gov/show/NCT04326387"
1213,"A Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019 (COVID-19)","Recruiting","No Results Available","Neoplasms|Lymphoma|Hematologic Neoplasms|Coronavirus Disease","Drug: TAK-981|Drug: Standard of care","University of California San Diego Moores Cancer Center, La Jolla, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|HealthPartners Cancer Care Center - Regions Hospital, Saint Paul, Minnesota, United States|University Hospitals Seidman Cancer Center, Cleveland, Ohio, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT03648372"
1214,"A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer","Not yet recruiting","No Results Available","COVID-19|Sars-CoV2|Cancer|Solid Tumor|Carcinoma|Blood Cancer","Drug: Part 1 - TL-895|Drug: Part 2 - TL-895|Drug: Part 2 - Placebo",,"https://ClinicalTrials.gov/show/NCT04419623"
1215,"Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)","Recruiting","No Results Available","Coronavirus Infection (COVID-19)|Pulmonary Arterial Hypertension|Urinary Tract Infections in Children|Hypertension|Pain|Hyperphosphatemia|Primary Hyperaldosteronism|Edema|Hypokalemia|Heart Failure|Hemophilia Prior to Tooth Extraction|Menorrhagia|Insomnia|Pneumonia|Skin Infection|Arrythmia|Asthma in Children|Bronchopulmonary Dysplasia|Adrenal Insufficiency|Hypertension, Resistant to Conventional Therapy|Fibrinolysis; Hemorrhage","Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:","Arkansas Children's Hospital Research Institute, Little Rock, Arkansas, United States|Colorado University Denver, Aurora, Colorado, United States|Alfred I. DuPont Hospital for Children, Wilmington, Delaware, United States|University of Florida Jacksonville Shands Medical Center, Jacksonville, Florida, United States|Kapiolani Womens and Childrens Medical Center, Honolulu, Hawaii, United States|Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States|Riley Hospital for Children at Indiana University, Indianapolis, Indiana, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Wesley Medical Center, Wichita, Kansas, United States|University of Louisville Norton Childrens Hospital, Louisville, Kentucky, United States|Tulane University Health Science Center, New Orleans, Louisiana, United States|Ochsner Baptist Clinical Trials Unit, New Orleans, Louisiana, United States|University of Minnesota, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Childrens Mercy Hospital, Kansas City, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|University of New Mexico Health Science Center, Albuquerque, New Mexico, United States|Kravis Children's Hospital at Mt. Sinai, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Health System, Durham, North Carolina, United States|Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States|Board of Regents of the University of Oklahoma, Oklahoma City, Oklahoma, United States|Oregon Health and Science University, Portland, Oregon, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina Children's Hospital, Charleston, South Carolina, United States|University of South Carolina, Columbia, South Carolina, United States|Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee, United States|Dell Children's Medical Center of Central Texas, Austin, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|University Wisconsin, Madison, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|The Hospital for Sick Children, Toronto, Ontario, Canada|CHU Sainte-Justine, Montréal, Quebec, Canada","https://ClinicalTrials.gov/show/NCT04278404"
1216,"COVID-19 Pandemic Response Network","Recruiting","No Results Available","COVID-19|SARS-CoV-2|Coronavirus|Influenza -Like Illness|Lower Resp Tract Infection|Upper Resp Tract Infection",,"Duke University Medical Center, Durham, North Carolina, United States","https://ClinicalTrials.gov/show/NCT04320862"
1217,"COVID-19 Antibody Self-testing Using Virtual Point-of-care","Recruiting","No Results Available","Communicable Disease|COVID-19|Sars-CoV2|Infectious Disease|Coronavirus|Virus Diseases","Diagnostic Test: COVID-19 IgM/IgG Rapid Testing, mobile device image capture and telemedicine support|Other: Telemedicine","Neuroganics, Northglenn, Colorado, United States","https://ClinicalTrials.gov/show/NCT04348864"
1218,"Contagiousness and Immunogenicity Status of COVID-19 in Asymptomatic Population (COVID-19 CONDITION)","Recruiting","No Results Available","COVID-19",,"Igenomix, Paterna, Valencia, Spain","https://ClinicalTrials.gov/show/NCT04389658"
1219,"The Clinical Study of Carrimycin on Treatment Patients With COVID-19","Not yet recruiting","No Results Available","Novel Coronavirus Infectious Disease (COVID-19)","Drug: Carrimycin|Drug: lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate|Drug: basic treatment",,"https://ClinicalTrials.gov/show/NCT04286503"
1220,"Non-invasive Ventilatory Support of Patients Affected by COVID-19","Active, not recruiting","No Results Available","Covid-19","Device: Non-invasive ventilatory support","Policlinico San Marco - Ospedale Zingonia, Zingonia, BG, Italy|ASST Papa Giovanni XXIII - Bergamo, Bergamo, Italy|Azienda Ospedaliera - Universitaria di Bologna, Policlinico S. Orsola Malpighi, Bologna, Italy|ASST Spedali Civili - Brescia, Brescia, Italy|ASST Valle Olona - Ospedale di Busto Arsizio, Busto Arsizio, Italy|ASST Lariana - Ospedale Sant'Anna, Como, Italy|ASST Crema - Ospedale Maggiore di Crema, Crema, Italy|ASST Cremona - Ospedale di Cremona, Cremona, Italy|Istituto Clinico Humanitas Gavazzeni, Cremona, Italy|ASST Garda - Presidio di Desenzano del Garda, Desenzano Del Garda, Italy|ASST Monza - Desio, Desio, Italy|ASST Spedali Civili -Ospedale di Gardone Val Trompia, Gardone Val Trompia, Italy|ASST Lecco - Ospedale ""A. Manzoni"", Lecco, Italy|ASST Ovest milanese - Ospedale di Legnano, Legnano, Italy|ASST Lodi - Ospedale Maggiore di Lodi, Lodi, Italy|ASST OVEST Milanese - Ospedale di Magenta, Magenta, Italy|ASST Garda - Ospedale di Manerbio, Manerbio, Italy|ASST Mantova - Ospedale Carlo Poma, Mantova, Italy|ASST Melegnano e della Martesana - Presidio di Melzo-Gorgonzola, Melzo, Italy|ASST Fatebenefratelli - Presidi Fatebenefratelli & M. Melloni, Milano, Italy|ASST Fatebenefratelli - Sacco, Milano, Italy|ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy|Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Italy|Ospedale San Giuseppe, Milano, Italy|ASST Spedali Civili -Presidio Ospedaliero di Montichiari, Montichiari, Italy|ASST Monza - Ospedale San Gerardo, Monza, Italy|Fondazione IRCCS Policlinico San Matteo - Pavia, Pavia, Italy|Policlinico San Pietro, Ponte San Pietro, Italy|Istituto Clinico Humanitas Rozzano, Rozzano, Italy|ASST Valle Olona - Ospedale di Saronno, Saronno, Italy|ASST Bergamo OVEST - Ospedale ""Treviglio-Caravaggio"" di Treviglio, Treviglio, Italy|Ospedale di Circolo e Fondazione Macchi - Varese, Varese, Italy|ASST Vimercate - Ospedale di Vimercate, Vimercate, Italy|ASST Melegnano e della Martesana - Ospedale di Vizzolo Predabissi, Vizzolo Predabissi, Italy","https://ClinicalTrials.gov/show/NCT04382235"
1221,"The Covid-19 HEalth caRe wOrkErS (HEROES) Study","Recruiting","No Results Available","Covid-19|Mental Health Disorder|Stress Disorder|Anxiety|Depression|SARS-CoV-2","Other: Exposure to the SARS-CoV-2 and its consequences","Columbia University, New York, New York, United States|Universidad del Chubut, Rawson, Chubut, Argentina|University of Sydney, Sidney, New South Wales, Australia|Salud Global, Sucre, Chuquisaca, Bolivia|University of Chile, Santiago, Chile|Universidad Nacional de Costa Rica, Heredia, Costa Rica|Society for Emergecy and Disaster Medicine CzMA JEP, Kladno, Bohemia, Czechia|Hochschule Emden/Leer, Emden, Niedersachsen, Germany|Centro de Investigaciones de las Ciencias de la Salud -CICS- Facultad de Ciencias Médicas Universidad de San Carlos de Guatemala -USAC-, Guatemala City, Guatemala|University of Cagliari, Cagliari, CA, Italy|University of Cagliari, Cagliari, Italy|The Institute for Development Research Advocacy and Applied Care (IDRAAC), Beirut, Lebanon|Logotipo del comercio Instituto Jalisciense De Salud Mental (SALME), Guadalajara, Jalisco, Mexico|Maastricht University, Maastricht, Limburg, Netherlands|University of Ibadan, Ibadan, Oyo State, Nigeria|Ponce Health Sciences University, Ponce, Puerto Rico|King Abdullah International medical research center, Riyadh, Central, Saudi Arabia|Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain|Razi Hospital La Manouba, Tunis, La Manouba, Tunisia|Koc University, Istanbul, Sariyer, Turkey|PNFA Salud Colectiva Instituto de Altos Estudios Dr Arnoldo Gabaldon, Maracay, Aragua, Venezuela","https://ClinicalTrials.gov/show/NCT04352634"
1222,"Kidney Injury Severity and COVID-19","Not yet recruiting","No Results Available","COVID-19|Kidney Injury","Diagnostic Test: mRNA in urine test","Sechenov University., Moscow, Russian Federation","https://ClinicalTrials.gov/show/NCT04386564"
1223,"European/Euro-ELSO Survey on Adult and Neonatal/ Pediatric COVID-19 Patients in ECMO","Recruiting","No Results Available","COVID|SARS-CoV-2|ARDS, Human|Refractory Hypoxemia|Cardiogenic Shock|Septic Shock|Extracorporeal Membrane Oxygenation",,"Universitätskliniken Innsbruck, Innsbruck, Austria|Landesklinikum Sankt Polten, St.Pölten, Austria|Medical University of Vienna, Vienna, Austria|Onze Lieve Vrouwziekenhuis Aalst, Aalst, Belgium|University Hospital, Antwerp, Antwerp, Belgium|Centre Hospitalier Universitaire Saint Pierre, Brussels, Belgium|Chirec, Brussels, Belgium|Erasme University Hospital, Brussel, Belgium|Universitair Ziekenhuis Brussel, Brussel, Belgium|Hôpital Civil Marie Curie de Charleroi, Charleroi, Belgium|University Hospital, Ghent, Ghent, Belgium|La Louvière Hopital, La Louvière, Belgium|Universitaire Ziekenhuizen Leuven, Leuven, Belgium|CHU de Liege, Liège, Belgium|Charles University, Czech Republic, Praha, Czechia|General University Hospital, Prague, Praha, Czechia|Copenhagen University Hospital at Herlev, Copenhagen, Denmark|University Hospital, Bordeaux, Bourdeaux, France|Hospices Civils de Lyon, Lyon, France|University Hospital, Montpellier, Montpellier, France|Henri Mondor University Hospital, Paris, France|Paris South University Hospitals, Paris, France|Pitié-Salpêtrière Hospital, Paris, France|Rennes University Hospital, Rennes, France|University Hospital, Aachen, Aachen, Germany|German Heart Center, Berlin, Germany|Universitätsklinikum Düsseldorf, Düsseldorf, Germany|Children's Medical Hospital, University of Essen, Essen, Germany, Essen, Germany|University Hospital, Essen, Essen, Germany|University Heart Center Freiburg - Bad Krozingen, Freiburg, Germany|Hannover Medical School, Hannover, Germany|Klinikum Kassel, Kassel, Germany|Universitätsklinikum Köln, Köln, Germany|Heart Center Leipzig - University Hospital, Leipzig, Germany|Klinikum Nürnberg, Nürnberg, Germany|University Hospital Regensburg, Regensburg, Germany|University Hospital Tuebingen, Tuebingen, Germany|University Hospital, Alexandroupolis, Alexandroupolis, Greece|Heim Pal Children's Hospital, Budapest, Hungary|ECMO Centers Israel, Jerusalem, Israel|San Giorgio Clinic, Alessandria, Italy|Ospedali Riuniti Ancona, Ancona, Italy|Papa Giovanni XXIII Hospital, Bergamo, Italy|St. Orsola Hospital, Bologna, Italy|Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy|Ospedale Maurizio Bufalini, Cesena, Italy|Gaslini Children's Hospital, Genua, Italy|G. Pasquinucci Heart Hospital, Massa, Massa, Italy|Policlinico Hospital Milan, Milano, Italy|Niguarda Hospital, Milan, Italy|Ospedale San Donato, Milan, Italy|San Raffaele University Hospital, Italy, Milan, Italy|San Gerardo Hospital, Monza, Italy|IRCCS Policlinico S. Matteo, Pavia, Italy|GVM Care & Research, Puglia, Italy|Bambino Gesù Hospital and Research Institute, Roma, Italy|San Camillo Hospital, Rome, Roma, Italy|A.O.U. Città della Salute e della Scienza - Molinette Hospital, Turin, Italy|Mauriziano Umberto I Hospital, Turin, Italy|Ospedale S. Giovanni Bosco, Turin, Italy|University Hospital, Udine, Italy, Udine, Italy|Ospedale dell'Angelo, Venezia-Mestre, Venice, Italy|Ospedale San Bortolo di Vicenza, Vicenza, Italy|Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania|University of Groningen, Groningen, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Maastricht University Medical Center, Maastricht, Netherlands|Erasmus Medical Center, Rotterdam, Netherlands|UMC Utrecht, Utrecht, Netherlands|Medical University of Warsaw, Warsaw, Poland|Hospital Sao Joao, Porto, Portugal|Chelyabinsk Regional Clinical Hospital, Chelyabinsk, Russian Federation|City Hospital No 41, Ekaterinburg, Russia, Ekaterinburg, Russian Federation|Kemerovo Regional Clinical Cardiological Center named after academician L.S. Barbarash, Kemerovo, Russian Federation|Krasnodar Regional Hospital no 1, Krasnodar, Russian Federation|City Clinical Hospital No. 67, Moscow, Russia, Moscow, Russian Federation|Novosibirsk City Hospital #2, Novosibirsk, Russian Federation|City Hospital No 40, Saint Petersburg, Russia, Saint Petersburg, Russian Federation|Hospital Sant Joan de Deu, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Miguel Servet, Zaragoza, Spain|Lund University Hospital, Lund, Sweden|Karolinska University Hospital, Stockholm, Sweden|University Hospital, Basel, Switzerland, Basel, Switzerland|University of Bern, Bern, Switzerland|University Hospital, Geneva, Geneva, Switzerland|University of Lausanne Hospitals, Lausanne, Switzerland|Cardiocentro Ticino, Lugano, Switzerland|Klinik Hirslanden, Zurich, Zürich, Switzerland|University of Zurich, Zürich, Switzerland|Royal Brompton & Harefield NHS Foundation Trust, Brompton, United Kingdom|Paediatric Intensive Care Glasgow, Glasgow, United Kingdom|Leicester Children's Hospital, Leicester, United Kingdom|Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom|Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom|Newcastle-upon-Tyne Hospitals NHS Trust, Newcastle Upon Tyne, United Kingdom","https://ClinicalTrials.gov/show/NCT04366921"
1224,"Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease","Recruiting","No Results Available","Pneumonia","Drug: HCQ|Drug: HCQ+AZT|Drug: Placebo","Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, Gainesville, Florida, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Baton Rouge, Louisiana, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Columbia, Missouri, United States|Novartis Investigative Site, Chapel Hill, North Carolina, United States|Novartis Investigative Site, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT04358081"
1225,"The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation","Recruiting","No Results Available","Covid19 Pneumonia","Drug: Tocilizumab","Hadassah Medical Orginisation, Jerusalem, Please Select:, Israel|Barzilai Medical Center, Ashkelon, Israel|Wolfson Medical Center, H̱olon, Israel|Sheba Medical Center, Ramat Gan, Israel","https://ClinicalTrials.gov/show/NCT04377750"
1226,"Efficacy of Convalescent Plasma Therapy in the Early Care of COVID-19 Patients.","Not yet recruiting","No Results Available","COVID-19","Drug: Transfusion of SARS-CoV-2 Convalescent Plasma.|Drug: Transfusion of standard Plasma.","HIA Percy, Clamart, France|HIA Laveran, Marseille, France|HIA Bégin, Saint-Mandé, France|HIA Sainte Anne, Toulon, France","https://ClinicalTrials.gov/show/NCT04372979"
1227,"Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection","Available","No Results Available","COVID-19","Drug: Ruxolitinib",,"https://ClinicalTrials.gov/show/NCT04355793"
1228,"Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19","Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Azithromycin","Intermountain Medical Center, Murray, Utah, United States|University of Utah, Salt Lake City, Utah, United States","https://ClinicalTrials.gov/show/NCT04329832"
1229,"MSCs in COVID-19 ARDS","Recruiting","No Results Available","Mesenchymal Stromal Cells|Remestemcel-L|Acute Respiratory Distress Syndrome|COVID","Biological: Remestemcel-L|Drug: Placebo","University of Southern California, Los Angeles, California, United States|Emory University, Atlanta, Georgia, United States|Lutheran Hospital, Fort Wayne, Indiana, United States|Ochsner Clinic, New Orleans, Louisiana, United States|University of Maryland, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Dartmouth-Hitchcock, Lebanon, New Hampshire, United States|Mount Sinai Health, New York, New York, United States|Northwell Health, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States|Baylor, Smith & White, Plano, Texas, United States|University of Virginia, Charlottesville, Virginia, United States","https://ClinicalTrials.gov/show/NCT04371393"
1230,"Characteristics and Outcomes of Hospitalized Patients With COVID-19 in Spain","Completed","No Results Available","Covid19",,"Comp. Hosp. Univ. A Coruña, A Coruña, Spain|H. Quiron A Coruña, A Coruña, Spain|H. de Alcaniz, Alcañiz, Spain|H. Gral Univ. de Alicante, Alicante, Spain|H. Univ. San Juan de Alicante, Alicante, Spain|H. Univ. de la Ribera, Alzira, Spain|H. Santos Reyes, Aranda De Duero, Spain|H. Dr. Jose Molina Orosa, Arrecife, Spain|Consorcio Sanitari Integral (CAIDM), Barcelona, Spain|H. Clinic, Barcelona, Spain|H. del Mar, Barcelona, Spain|H. Parc Sanitari Sant Joan de Deu, Barcelona, Spain|H. Santa Creu y Sant Pau, Barcelona, Spain|H. Univ. de Bellvitge, Barcelona, Spain|H. Vall d'Hebron, Barcelona, Spain|Hospital CIMA-Sanitas, Barcelona, Spain|SCIAS H. de Barcelona, Barcelona, Spain|H. Clinica de Benidorm, Benidorm, Spain|H. de Cruces, Bilbao, Spain|H. San Eloy_Barakaldo, Bilbao, Spain|H. Univ. de Basurto, Bilbao, Spain|H. Urduliz-Alfredo Espinosa, Bilbao, Spain|H. Gral de La Palma, Breña Alta, Spain|H. de Puerto Real, Cadiz, Spain|H. de Calahorra, Calahorra, Spain|H. Sant Jaume de Calella, Calella, Spain|H. Univ Santa Lucia, Cartagena, Spain|H. Univ de Henares, Coslada, Spain|Hospital Marina Salud de Dénia, Denia, Spain|Hospital Don Benito-Villanueva de la Serena, Don Benito, Spain|H. Gral Univ. de Elche, Elche, Spain|H. Univ. del Vinalopo, Elche, Spain|Comp. Hospt. Univ. de Ferrol, Ferrol, Spain|H. Francesc de Borja, Gandia, Spain|H. de Figueres, Gerona, Spain|H. Comarcal de Blanes, Girona, Spain|H. Josep Trueta, Girona, Spain|H. Clinico San Cecilio, Granada, Spain|Hospital HLA Inmaculada, Granada, Spain|H. de Guadalajara, Guadalajara, Spain|H. de Guadarrama, Guadarrama, Spain|H. Juan Ramón Jiménez, Huelva, Spain|H. Riotinto, Huelva, Spain|H. Can Misses, Ibiza, Spain|H. Universitario de Jaén, Jaén, Spain|H. Univ. de Jerez de la Frontera, Jerez De La Frontera, Spain|H. Univ Insular de Gran Canaria, Las Palmas De Gran Canaria, Spain|H. Universitario de Gran Canaria Dr. Negrin, Las Palmas De Gran Canaria, Spain|H. Univ. Severo Ochoa, Leganés, Spain|H. San Pedro, Logroño, Spain|H. Univ. Menez Rafael Mendez, Lorca, Spain|H. Lucus Augusti, Lugo, Spain|H. 12 de Octubre, Madrid, Spain|H. Clinica Univ. de Navarra_ Campus Madrid, Madrid, Spain|H. Clinico San Carlos, Madrid, Spain|H. Fundacion Jiménez Díaz, Madrid, Spain|H. Gral de la Defensa Gomez Ulla, Madrid, Spain|H. HLA Univ. Moncloa, Madrid, Spain|H. HM Sanchinarro, Madrid, Spain|H. Puerta de Hierro, Madrid, Spain|H. Univ HM Madrid, Madrid, Spain|H. Univ Principe de Asturias, Madrid, Spain|H. Univ. de Alcorcón, Madrid, Spain|H. Univ. de Getafe, Madrid, Spain|H. Univ. de Móstoles, Madrid, Spain|H. Univ. Gregorio Marañon, Madrid, Spain|H. Univ. HM Monteprincipe, Madrid, Spain|H. UNiv. HM Puerta del Sur, Madrid, Spain|H. Univ. Infanta Leonor, Madrid, Spain|H. Univ. La Paz, Madrid, Spain|H. Univ. La Princesa, Madrid, Spain|H. Univ. Ramón y Cajal, Madrid, Spain|H. Univ. Rey Juan Carlos, Madrid, Spain|H. Costa del Sol, Marbella, Spain|H. de Mataro, Mataró, Spain|H. de Melilla, Melilla, Spain|H. de Mendaro, Mendaro, Spain|Hospital Alto Deba, Mondragón, Spain|H. Virgen de la Arrixaca, Murcia, Spain|H. Marbella Internacional, Málaga, Spain|H. Virgen de la Victoria, Málaga, Spain|H. Vega Baja, Orihuela, Spain|H. Univ. Central de Asturias, Oviedo, Spain|H. de Palamos, Palamós, Spain|H. Son Espases, Palma De Mallorca, Spain|H. Son Llatzer, Palma De Mallorca, Spain|H. Clinica Univ. Navarra, Pamplona, Spain|H. Virgen del Puerto, Plasencia, Spain|H. El Bierzo, Ponferrada, Spain|H. Do Salnes, Pontevedra, Spain|H. UNiv. Los Arcos del Mar Menor, Pozo Aledo, Spain|H. Santa Barbara, Puertollano, Spain|H. Parc Tauli, Sabadell, Spain|Complejo Asist. Univ. de Salamanca, Salamanca, Spain|H. Infanta Sofia, San Sebastián De Los Reyes, Spain|H. de Donostia, San Sebastián, Spain|H. de l'Esperit Sant, Santa Coloma De Gramenet, Spain|H. Univ. Marques de Valdecilla, Santander, Spain|H. Clinico Univ. Santiago de Compostela, Santiago De Compostela, Spain|H. Univ de Valme, Sevilla, Spain|H. Univ. Virgen del Rocio, Sevilla, Spain|H. Univ. Virgen Macarena, Sevilla, Spain|H. Virgen Macarena, Sevilla, Spain|H. Univ Joan XXIII, Tarragona, Spain|H. U. de Canarias, Tenerife, Spain|H. Univ. Nuestra Sra. de la Candelaria, Tenerife, Spain|H. Mutua de Terrasa, Terrassa, Spain|Complejo Hospitalario Virgen de la Salud, Toledo, Spain|H. Univ. HM Torrelodones, Torrelodones, Spain|H. Quiron Salud Torrevieja, Torrevieja, Spain|H. Virgen de la Cinta, Tortosa, Spain|H. Reina Sofia de Tudela, Tudela, Spain|H. Arnau de Vilanova-Lliria, Valencia, Spain|H. Clinico Univ. de Valencia, Valencia, Spain|H. de Sagunto, Valencia, Spain|H. Univ. y Polit. La Fe, Valencia, Spain|H. Clin. Univ. de Valladolid, Valladolid, Spain|H. Rio Hortega, Valladolid, Spain|H. Alvaro Cunqueiro, Vigo, Spain|H. de Viladecans, Viladecans, Spain|H. de la Marina Baixa, Villajoyosa, Spain|Hospital de la Plana, Villareal, Spain|H. Univ de Alava, Vitoria, Spain|H. Virgen de la Concha, Zamora, Spain|H. Lozano Blesa, Zaragoza, Spain|H. Miguel Servet, Zaragoza, Spain|H. Ntra. Sra. de Gracia, Zaragoza, Spain|Complejo Asistencial de Avila, Ávila, Spain","https://ClinicalTrials.gov/show/NCT04355871"
1231,"Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19","Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Azithromycin","Intermountain Medical Center, Murray, Utah, United States|University of Utah, Salt Lake City, Utah, United States","https://ClinicalTrials.gov/show/NCT04334382"
1232,"COVID-19 Convalescent Plasma (CCP) Transfusion","Recruiting","No Results Available","COVID-19","Biological: COVID Convalescent Plasma","University of Mississippi Medical Center, Jackson, Mississippi, United States","https://ClinicalTrials.gov/show/NCT04412486"
1233,"Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19","Not yet recruiting","No Results Available","COVID-19","Drug: Merimepodib|Drug: Matching Placebo|Drug: Remdesivir","Mayo Clinic in Arizona, Phoenix, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Mayo Clinic, Rochester, Minnesota, United States","https://ClinicalTrials.gov/show/NCT04410354"
1234,"Ozone Auto-hemotherapy for COVID-19 Pneumonia","Not yet recruiting","No Results Available","COVID-19 Pneumonia","Biological: Ozone auto-hemotherapy","Hospital Universitari Dr Josep Trueta, Girona, Spain|Clinica Nuestra Señora del Rosario, Ibiza, Spain|Hospital Quirón Rey Juan Carlos I, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitario Príncipe de Asturias de Alcalá de Henares, Madrid, Spain|Fundació Althaia de Manresa, Manresa, Spain|Hospital Vithas Valencia Consuelo, Valencia, Spain|Hospital Clínico Universitario de Valladolid, Valladolid, Spain|Clinica Claro, Vigo, Spain","https://ClinicalTrials.gov/show/NCT04370223"
1235,"Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia","Recruiting","No Results Available","COVID-19","Drug: FT516","University of Minnesota, Minneapolis, Minnesota, United States","https://ClinicalTrials.gov/show/NCT04363346"
1236,"Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection","Recruiting","No Results Available","COVID-19",,"National Institutes of Health Clinical Center, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT04362865"
1237,"A Prospective ""Universal"" Observational Database for COVID-19","Recruiting","No Results Available","COVID-19",,"Hackensack Meridian Health - John Theurer Cancer Center, Hackensack, New Jersey, United States","https://ClinicalTrials.gov/show/NCT04347993"
1238,"Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection","Recruiting","No Results Available","COVID-19","Biological: Convalescent Plasma","Hackensack University Medical Center, Hackensack, New Jersey, United States","https://ClinicalTrials.gov/show/NCT04343755"
1239,"A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector)","Active, not recruiting","No Results Available","COVID-19","Biological: Recombinant novel coronavirus vaccine (Adenovirus type 5 vector)|Other: Placebo","Hubei Provincial Center for Disease Control and Prevention, Wuhan, Hubei, China","https://ClinicalTrials.gov/show/NCT04341389"
1240,"Renin-Angiotensin System Inhibitors and COVID-19","Recruiting","No Results Available","COVID-19|Hypertension|Cardiovascular Diseases",,"Spedali Civili di Brescia, Brescia, Italy","https://ClinicalTrials.gov/show/NCT04331574"
1241,"Psychological Impact of the Lockdown on Patients Giving Birth During the COVID-19 Epidemic Short Title : Isolement and Childbirth: Psychological Impact","Not yet recruiting","No Results Available","Post Partum Depression","Behavioral: psychological assessment","Service médecine foetale-Hôpital Trousseau, Paris, France","https://ClinicalTrials.gov/show/NCT04366817"
1242,"Adverse Events Related to Treatments Used Against Coronavirus Disease 2019","Recruiting","No Results Available","Coronavirus|Iatrogenic Disease|Acute Kidney Injury|ARDS, Human","Drug: Any drug used to treat Covid-19","AP-HP Assistance Publique Hopitaux de Paris, Paris, France","https://ClinicalTrials.gov/show/NCT04314817"
1243,"Frailty in Elderly Patients With COVID-19","Recruiting","No Results Available","Covid19","Other: Relation between frailty and clinical outcomes in elderly patients with COVID-19.","ASST Monza-Ospedale San Gerardo, Monza, Italy","https://ClinicalTrials.gov/show/NCT04412265"
1244,"UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients","Recruiting","No Results Available","Metastatic Non-small Cell Lung Cancer (NSCLC)","Drug: Avelumab|Radiation: Stereotactic ablative radiotherapy (SAR)","UC Davis, Sacramento, California, United States","https://ClinicalTrials.gov/show/NCT03158883"
1245,"Use of High Flow Nasal Cannula Oxygen and Covid-19 Acute Hypoxemic Respiratory Failure","Completed","No Results Available","Respiratory Syndrome, Acute, Severe|Hypoxic Respiratory Failure|Viral Pneumonia","Device: patients receiving nasal high flow","Hôpital Louis Mourier, Assistance Publique - Hôpitaux de Paris, Colombes, France","https://ClinicalTrials.gov/show/NCT04385823"
1246,"A Study of Baricitinib (LY3009104) in Participants With COVID-19","Not yet recruiting","No Results Available","COVID-19","Drug: Baricitinib|Drug: Placebo","Valleywise Health, Phoenix, Arizona, United States|Sharp Healthcare, San Diego, California, United States|San Francisco VA Medical Center, San Francisco, California, United States|Community Hospital South, Indianapolis, Indiana, United States|White Oak Medical Center, Adventist Healthcare, Silver Spring, Maryland, United States|Temple University School of Medicine, Philadelphia, Pennsylvania, United States|Multicare Health System, Tacoma, Washington, United States|Klinikum Chemnitz gGmbH, Chemnitz, Germany|Medica Sur, Mexico, DF, Mexico|Instituto Nacional de Cardiologia Ignacio Chavez, Mexico, DF, Mexico|Instituto Nacional de Cancerologia, Mexico City, FD, Mexico|ITESM Campus Monterrey, Monterrey, Nuevo Leon, Mexico|Hospital Universitario ""Dr. Jose Eleuterio Gonzalez"", Monterrey, Nuevo León, Mexico|Hospital Universitario Infanta Leonor-INTERNAL MED, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain","https://ClinicalTrials.gov/show/NCT04421027"
1247,"Study of ACT-129968 in Adult Patients With Seasonal Allergic Rhinitis","Completed","No Results Available","Seasonal Allergic Rhinitis","Drug: ACT-129968|Drug: Cetirizine|Drug: Placebo","Clinical Investigative Site 7905, Austin, Texas, United States|Clinical Investigative Site 7907, Kerrville, Texas, United States|Clinical Investigative Site 7903, New Braunfels, Texas, United States|Clinical Investigative Site 7901, San Antonio, Texas, United States|Clinical Investigative Site 7902, San Antonio, Texas, United States|Clinical Investigative Site 7904, San Antonio, Texas, United States|Clinical Investigative Site 7906, San Antonio, Texas, United States","https://ClinicalTrials.gov/show/NCT01241214"
1248,"A Study of LY3127804 in Participants With COVID-19","Recruiting","No Results Available","COVID-19|Pneumonia","Drug: LY3127804|Drug: Placebo","NorthShore University HealthSystem, Evanston, Illinois, United States|Franciscan St. Francis Health, Indianapolis, Indiana, United States","https://ClinicalTrials.gov/show/NCT04342897"
1249,"COVID-19 Associated Lymphopenia Pathogenesis Study in Blood (CALYPSO)","Recruiting","No Results Available","Corona Virus Disease 2019",,"MedStar Georgetown University Hospital, Washington, District of Columbia, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT04401436"
1250,"COVID-19 Infection: Exploration of Respiratory Control Center Abnormalities","Not yet recruiting","No Results Available","Covid19|Neurological Complication","Other: hypoxia : 14.3 and 12.7% FIO2, hypercapnia 7% CO2, inspiratory mechanical constraint",,"https://ClinicalTrials.gov/show/NCT04363749"
1251,"Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals","Enrolling by invitation","No Results Available","Hydroxychloroquine|Antimalarials|Enzyme Inhibitors|Antirheumatic Agents","Drug: Hydroxychloroquine Sulfate|Drug: Bromhexine 8 MG","National Institute of Rehabilitation, Mexico City, Cdmx, Mexico","https://ClinicalTrials.gov/show/NCT04340349"
1252,"A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study","Not yet recruiting","No Results Available","Covid-19","Drug: Anakinra Prefilled Syringe|Drug: Tocilizumab Prefilled Syringe|Drug: Standard-of-care treatment","Karolinska University Hospital, Huddinge, Stockholm, Sweden","https://ClinicalTrials.gov/show/NCT04412291"
1253,"COVID-19 Ozanimod Intervention Study","Not yet recruiting","No Results Available","COVID-19","Drug: Ozanimod|Other: Standard of care",,"https://ClinicalTrials.gov/show/NCT04405102"
1254,"Immunosupressive Treatment in COVID-19 Patients","Recruiting","No Results Available","COVID-19 Infection","Drug: NO-Immunosuppressive|Drug: Immunosuppressive|Drug: Immunoglubulins","Hospital Virgen Macarena, Sevilla, Spain","https://ClinicalTrials.gov/show/NCT04382781"
1255,"Safety and Efficacy of Ruxolitinib for COVID-19","Not yet recruiting","No Results Available","COVID-19","Drug: Ruxolitinib",,"https://ClinicalTrials.gov/show/NCT04348071"
1256,"The Safety of Chemotherapy for Patients With Gynecological Malignancy in High-risk Region of COVID-19","Not yet recruiting","No Results Available","Gynecological Cancer","Drug: Chemotherapy","Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China","https://ClinicalTrials.gov/show/NCT04341480"
1257,"Safety and Efficacy of Baricitinib for COVID-19","Not yet recruiting","No Results Available","COVID-19","Drug: Baricitinib","University of Colorado, Denver, Aurora, Colorado, United States","https://ClinicalTrials.gov/show/NCT04340232"
1258,"Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection","Not yet recruiting","No Results Available","COVID-19","Drug: 1: Naproxen|Drug: 2: Standard of care",,"https://ClinicalTrials.gov/show/NCT04325633"
1259,"DAS181 for Severe COVID-19: Compassionate Use","Completed","No Results Available","COVID-19","Drug: DAS181","Renmin Hospital of Wuhan University, Wuhan, Hubei, China","https://ClinicalTrials.gov/show/NCT04324489"
1260,"A Trial of CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness","Not yet recruiting","No Results Available","COVID-19","Biological: Convalescent plasma","Weill Cornell Medicine, New York, New York, United States","https://ClinicalTrials.gov/show/NCT04418518"
1261,"Safety and Efficacy of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia Who Are Receiving Standard of Care Therapy","Not yet recruiting","No Results Available","COVID-19","Drug: Tofacitinib|Other: Placebo","University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States","https://ClinicalTrials.gov/show/NCT04412252"
1262,"Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19","Recruiting","No Results Available","COVID-19","Drug: Plitidepsin 1.5 mg/day|Drug: Plitidepsin 2.0 mg/day|Drug: Plitidepsin 2.5 mg/day","Hospital Universitario Hm Montepríncipe, Boadilla Del Monte, Madrid, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Hospital Ciudad Real, Ciudad Real, Spain|Hospital La Princesa, Madrid, Spain|Hospital Ramón Y Cajal, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain","https://ClinicalTrials.gov/show/NCT04382066"
1263,"Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)","Recruiting","No Results Available","Cytokine Storm (Covid-19)","Drug: Ruxolitinib|Drug: Placebo","Novartis Investigative Site, Aurora, Colorado, United States|Novartis Investigative Site, Stamford, Connecticut, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Ann Arbor, Michigan, United States|Novartis Investigative Site, Newark, New Jersey, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Madison, Wisconsin, United States|Novartis Investigative Site, Aachen, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Nuernberg, Germany|Novartis Investigative Site, Firenze, FI, Italy|Novartis Investigative Site, Ryazan, Russian Federation|Novartis Investigative Site, Salamanca, Castilla Y Leon, Spain|Novartis Investigative Site, Barcelona, Cataluna, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Leeds, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT04362137"
1264,"CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1)","Recruiting","No Results Available","COVID-19","Biological: Convalescent plasma","Brooklyn Hospital, Brooklyn, New York, United States|Lower Manhattan Hospital, New York, New York, United States|Weill Cornell Medical Center, New York, New York, United States|Hamilton General Hospital, Hamilton, Ontario, Canada|Juravinski Hospital, Hamilton, Ontario, Canada|Grand River Hospital, Kitchener, Ontario, Canada|London Health Sciences Centre - University Hospital, London, Ontario, Canada|Trillium Health Partners, Mississauga, Ontario, Canada|Trillium Health Partners - Credit Valley, Mississauga, Ontario, Canada|Ottawa Hospital - General Campus, Ottawa, Ontario, Canada|Ottawa Hospital - Civic Campus, Ottawa, Ontario, Canada|Scarborough Health Network - Centenary Hospital, Scarborough, Ontario, Canada|Scarborough Health Network - General Hospital, Scarborough, Ontario, Canada|Scarborough Health Network - Birchmount Hospital, Scarborough, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Unity Health St. Michael's Hospital, Toronto, Ontario, Canada|Sinai Health System, Toronto, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|Windsor Regional Hospital - Metropolitan Campus, Windsor, Ontario, Canada|Windsor Regional Hospital - Ouellette Campus, Windsor, Ontario, Canada|Hôpital de la Cité-de-la-Santé, Laval, Quebec, Canada|Hotel Dieu Hospital of Lévis, Lévis, Quebec, Canada|Hôpital Maisonneuve-Rosemont, Montréal, Quebec, Canada|Centre hospitalier de l'Université de Montréal, Montréal, Quebec, Canada|Centre hospitalier universitaire Sainte-Justine, Montréal, Quebec, Canada|Jewish General Hospital, Montréal, Quebec, Canada|McGill University Health Centre, Montréal, Quebec, Canada|Hôpital du Sacré-Coeur de Montreal, Montréal, Quebec, Canada|Ciussse De L'Estrie CHUS, Sherbrooke, Quebec, Canada|Centre hospitalier affilié universitaire régional de Trois-Rivières, Trois-Rivières, Quebec, Canada","https://ClinicalTrials.gov/show/NCT04348656"
1265,"Reorganization of the Healthcare System During COVID-19 Pandemic: Impact on Management of Patients With Exocrine Pancreatic Cancer","Recruiting","No Results Available","Pancreatic Adenocarcinoma","Other: Data record","Damien JOLLY, Reims, France","https://ClinicalTrials.gov/show/NCT04406571"
1266,"Endovascular Thrombectomy in COVID-19 Infected Patients","Recruiting","No Results Available","Ischemic Stroke|Covid 19","Other: Mechanical Trombectomy","Uhmontpellier, Montpellier, France","https://ClinicalTrials.gov/show/NCT04406090"
1267,"Almitrine and COVID-19 Related Hypoxemia","Completed","No Results Available","COVID-19|Hypoxic Respiratory Failure",,"Centre Hospitalier Universitaire NANCY, Vandoeuvre-les-Nancy, France","https://ClinicalTrials.gov/show/NCT04380727"
1268,"COVID-19 Endoscopy Survey","Completed","No Results Available","COVID-19","Other: Practice details","Kings County Hospital Center, Brooklyn, NY, USA, Albertson, New York, United States|Faculty of Medicine, Zagazig University, Zagazig, Sharkia, Egypt|Al-Azhar Univerisity, Cairo, Egypt|Ahvaz Imam hospital, Ahvaz, Iran, Islamic Republic of","https://ClinicalTrials.gov/show/NCT04342637"
1269,"Study of Open Label Losartan in COVID-19","Recruiting","No Results Available","COVID-19","Drug: Losartan","University of Kansas Medical Center, Kansas City, Kansas, United States","https://ClinicalTrials.gov/show/NCT04335123"
1270,"Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID)","Recruiting","No Results Available","Covid-19","Drug: Sarilumab|Other: Standar of care","Hospital Universitario de la Princesa, Madrid, Spain","https://ClinicalTrials.gov/show/NCT04357808"
1271,"A Study To Investigate If MRI Scanning Is Effective At Seeing What Hayfever Drugs Do In Nasal Passage.","Completed","No Results Available","Seasonal Allergic Rhinitis|Sinusitis","Drug: pseudoephedrine hydrochloride|Drug: cetirizine hydrochloride","GSK Investigational Site, London, United Kingdom","https://ClinicalTrials.gov/show/NCT00517946"
1272,"Tableted COVID-19 Therapeutic Vaccine","Active, not recruiting","No Results Available","Covid19","Biological: V-SARS","Immunitor Inc, Vancouver, BC - British Columbia, Canada|Aldar Bourinbayar, Ulaanbaatar, BZD, 3-khoroo, Mongolia","https://ClinicalTrials.gov/show/NCT04380532"
1273,"Predictive Immune Biomarkers for COVID-19 Pathogenesis","Not yet recruiting","No Results Available","COVID-19","Biological: Blood collection on admission and longitudinally|Biological: Blood collection on their first consultation and 10 to 14 days later","Purpan University Hospital, Toulouse, France","https://ClinicalTrials.gov/show/NCT04385108"
1274,"Comparison of VieScope vs. Macintosh Laryngoscope for Intubation in Level Cpersonal Protective Equipment Conditions","Completed","No Results Available","Tracheal Intubation|Infection|Projection","Device: The standard Macintosh laryngoscope|Device: The Vie Scope laryngoscope","Lazarski Univeristy, Warsaw, Poland","https://ClinicalTrials.gov/show/NCT04363775"
1275,"PROLIFIC ChemoprophylaxisTrial (COVID-19)","Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine - Daily dosing|Drug: Hydroxychloroquine - Weekly Dosing|Other: Matched Placebo Hydroxychloroquine","Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom","https://ClinicalTrials.gov/show/NCT04352933"
1276,"CovidDB: The Covid-19 Inpatient Database","Recruiting","No Results Available","COVID-19",,"RoMed - Klinikum Bad Aibling, Bad Aibling, Germany|DONAUISAR Klinikum Deggendorf, Deggendorf, Germany|DONAUISAR Klinikum Dingolfing, Dingolfing, Germany|RoMed - Klinikum Prien am Chiemsee, Prien, Germany|RoMed - Klinikum Rosenheim, Rosenheim, Germany|Universitätsklinikum Ulm, Ulm, Germany|RoMed - Klinikum Wasserburg Am Inn, Wasserburg Am Inn, Germany|Klinikum Altmühlfranken, Weißenburg, Germany|Timiş County Emergency Clinical Hospital, Timisoara, Romania","https://ClinicalTrials.gov/show/NCT04344171"
1277,"A Trial of Ciclesonide in Adults With Mild COVID-19","Not yet recruiting","No Results Available","COVID-19","Drug: Ciclesonide Metered Dose Inhaler [Alvesco]|Drug: Hydroxychloroquine",,"https://ClinicalTrials.gov/show/NCT04330586"
1278,"Phase 2 Study in Adults Sensitized to Short Ragweed","Withdrawn","No Results Available","Allergic Rhinitis","Biological: Standardized Allergenic Extract, Short Ragweed (Ambrosia artemisiifolia)|Biological: Placebo",,"https://ClinicalTrials.gov/show/NCT00670384"
1279,"Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19","Not yet recruiting","No Results Available","COVID 19","Drug: 1: ILT101|Drug: 2: Placebo Comparator","Service Anesthésie Réanimation - Groupe Hospitalier Pitié-Salpêtrière, Paris, France","https://ClinicalTrials.gov/show/NCT04357444"
1280,"A Longitudinal Study of COVID-19 Sequelae and Immunity","Recruiting","No Results Available","COVID-19",,"National Institutes of Health Clinical Center, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT04411147"
1281,"Cardiopulmonary Inflammation and Multi-System Imaging During the Clinical Course of COVID-19 Infection in Asymptomatic and Symptomatic Persons","Enrolling by invitation","No Results Available","Acute and Long Term Effects of COVID-19:on Systemic Inflammation|Acute and Long Term Effects of COVID-19 on Lung Function|Acute and Long Term Effects of COVID-19 on Mrain Function|Acute and Long Term Effects of COVID-19 on Cardiac Function|Acute and Long Term Effects of COVID-19 on Kidney Function",,"National Institutes of Health Clinical Center, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT04401449"
1282,"Investigating the Role of Vitamin D in the Morbidity of COVID-19 Patients","Not yet recruiting","No Results Available","COVID-19|Vitamin D Deficiency",,"Tameside Hospital NHS Foundation Trust, Ashton-under-Lyne, Greater Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT04386044"
1283,"The University of the Philippines Hydroxychloroquine PEP Against COVID-19 Trial","Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine plus standard preventive measures|Drug: Placebo plus standard preventive measures",,"https://ClinicalTrials.gov/show/NCT04364815"
1284,"Clinical Features and Risk Factors Associated With Worse Outcome in Patients Hospitalized for Covid-19 Pneumonia","Recruiting","No Results Available","Covid-19",,"Service des Maladies Infectieuses et Tropicales, Strasbourg, France","https://ClinicalTrials.gov/show/NCT04362345"
1285,"Washed Microbiota Transplantation for Patients With 2019-nCoV Infection","Withdrawn","No Results Available","COVID-19 Complicated With Refractory Intestinal Infections","Other: washed microbiota transplantation|Other: placebo","Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China","https://ClinicalTrials.gov/show/NCT04251767"
1286,"Pathogenesis of BTK-mediated Hyper-Inflammatory Responses in COVID-19 (RESPOND)","Recruiting","No Results Available","COVID-19",,"Johns Hopkins Hospital, Baltimore, Maryland, United States|Walter Reed National Medical Center, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT04394884"
1287,"COVID-19 Pandemic Impact on Alcohol (PIA) - A Natural History Study","Recruiting","No Results Available","Alcohol Drinking|Alcohol-Related Disorders|Pandemic|Psychological Stress",,"NIAAA Section on Human Psychopharmacology, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT04391816"
1288,"Evaluation of Airway Pressure Release Ventilation in COVID-19 ARDS","Not yet recruiting","No Results Available","ARDS|COVID19","Other: Airway pressure release ventilation",,"https://ClinicalTrials.gov/show/NCT04386369"
1289,"Covid-19 Epidemic on Acute Stroke Management","Recruiting","No Results Available","Stroke, Acute",,"Service de Neuroradiologie Interventionnelle, Strasbourg, France","https://ClinicalTrials.gov/show/NCT04370197"
1290,"Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia","Recruiting","No Results Available","Covid-19","Drug: Canakinumab|Drug: Placebo","Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Brooklyn, New York, United States|Novartis Investigative Site, Chapel Hill, North Carolina, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Richmond, Virginia, United States|Novartis Investigative Site, Lubeck, Germany|Novartis Investigative Site, Mainz, Germany|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, San Sebastian de los Reyes, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Barnet, United Kingdom|Novartis Investigative Site, Leeds, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom","https://ClinicalTrials.gov/show/NCT04362813"
1291,"Prone Position in Patients on High-flow Nasal Oxygen Therapy for COVID-19 (HIGH-PRONE-COVID-19)","Recruiting","No Results Available","Acute Respiratory Distress Syndrome|COVID-19","Other: Prone decubitus","Intensive Care Unit, Hospital, Argenteuil, Argenteuil, France|Medical Intensive Care Unit, University Hospital, Brest, Brest, France|Intensive Care Unit, Louis Mourier-APHP, Colombes, France|Intensive Care Unit, Hospital, Le Mans, Le Mans, France|Intensive Care Unit, University Hospital, Lille, Lille, France|Medical Intensive Care Unit, University Hospital, Nantes, Nantes, France|Medical Intensive Care Unit, University Hospital, Nice, NIce, France|Medical Intensive Care Unit, Hospital, Orléans, Orléans, France|Medical Intensive Care Unit, Tenon-APHP, Paris, France|Medical Intensive Care Unit, University Hospital, Poitiers, Poitiers, France|Medical Intensive Care Unit, University Hospital, Tours, Tours, France|Surgical Intensive Care Unit, University Hospital, Tours, Tours, France|Intensive Care Unit, Hospital, Vannes, Vannes, France","https://ClinicalTrials.gov/show/NCT04358939"
1292,"Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection","Recruiting","No Results Available","Pulmonary Infection|Covid-19","Drug: T3 solution for injection|Drug: Placebo","Attikon University General Hospital, Haidari/Athens, Greece","https://ClinicalTrials.gov/show/NCT04348513"
1293,"Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study","Recruiting","No Results Available","COVID-19","Biological: SARS-CoV-2 convalescent plasma","Danderyd Hospital, Danderyd, Stockholm, Sweden|Karolinska University Hospital, Stockholm, Sweden","https://ClinicalTrials.gov/show/NCT04384497"
1294,"PROne Positioning in coVID-19 Oxygeno-dependent Patients in Spontaneous Ventilation (PROVID Study)","Not yet recruiting","No Results Available","COVID|ARDS","Behavioral: 1: Prone positioning|Behavioral: 2: No instruction regarding positioning","Département d'Anesthésie Réanimation - Kremlin Bicêtre, Le Kremlin-Bicêtre, France","https://ClinicalTrials.gov/show/NCT04366856"
1295,"Patient Outcome of Cardiac Surgery During the COVID-19 Pandemic","Recruiting","No Results Available","Patients Undergoing Cardiac or Thoracic Surgery","Other: No intervention","University Hospital, Nantes, France","https://ClinicalTrials.gov/show/NCT04389463"
1296,"Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study","Completed","No Results Available","Influenza|Severe Acute Respiratory Distress Syndrome|Smallpox|Ebola|Unknown Respiratory Viruses","Drug: Poly-ICLC","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT00646152"
1297,"Rehabilitation for People With COVID-19 in ICU","Not yet recruiting","No Results Available","Corona Virus Disease 19 (COVID-19)|COVID|Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)|Critical Illness","Other: Pulmonary and Motor Rehabilitation","Teaching Hospital, University of Padova, Padova, Italy|Teaching Hospital, University of Verona, Verona, Italy","https://ClinicalTrials.gov/show/NCT04381338"
1298,"Plasma Adsorption in Patients With Confirmed COVID-19","Recruiting","No Results Available","Respiratory Failure|ARDS","Device: Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol)","UNM Health Science Center, Albuquerque, New Mexico, United States|Providence Portland Medical Center, Portland, Oregon, United States|UT Southwestern/Clements Hospital, Dallas, Texas, United States|UTMB, Galveston, Texas, United States","https://ClinicalTrials.gov/show/NCT04358003"
1299,"COVID-19 Detection Test in Oncology","Recruiting","No Results Available","Oncology",,"Centre Francois Baclesse, Caen, France|Centre Jean Perrin, Clermont-Ferrand, France|Hopitaux Civils de Colmar, Colmar, France|Centre Leon Berard, Lyon, France|Institut Paoli Calmettes, Marseille, France|Institut Regional Du Cancer Montpellier Val D Aurelle, Montpellier, France|Centre Antoine Lacassagne, Nice, France|Hôpital Universitaire Pitié Salpêtrière, Paris, France|Institut Curie, Paris, France|Centre Henri Becquerel, Rouen, France|Institut Curie, Saint-Cloud, France","https://ClinicalTrials.gov/show/NCT04367870"
1300,"Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation (JAKINCOV)","Not yet recruiting","No Results Available","Covid-19","Drug: Anakinra alone (stages 2b/3)|Drug: Anakinra and Ruxolitinib (overcome stage 3)|Other: Standard of care","AP-HM, Hôpital de la Conception, Marseille, Bouches-du-Rhône, France|Hôpital Sainte-Musse, Toulon, VAR, France|Sainte Anne Teaching Military Hospital, Toulon, Var, France","https://ClinicalTrials.gov/show/NCT04366232"
1301,"NGS Diagnostic in COVID-19 Hosts - Genetic Cause Relating to the Course of Disease Progression","Not yet recruiting","No Results Available","COVID-19","Genetic: Whole Genome Analysis|Genetic: T-cell receptor (TCR) repertoire|Genetic: SARS-CoV-2 viral composition",,"https://ClinicalTrials.gov/show/NCT04364828"
1302,"Needle Stick Injuries in Emergency Medical Service Practice","Completed","No Results Available","Cardiac Arrest|Needle Stick|Injuries|Glowe","Procedure: double gloves","Lazarski Univeristy, Warsaw, Poland","https://ClinicalTrials.gov/show/NCT04363788"
1303,"Azithromycin in Hospitalized COVID-19 Patients","Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Azithromycin","Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of","https://ClinicalTrials.gov/show/NCT04359316"
1304,"Cholecalciferol to Improve the Outcomes of COVID-19 Patients","Not yet recruiting","No Results Available","COVID","Drug: Vitamin D|Drug: Placebo","Hospital de Alta Complejidad en Red El Cruce, Florencio Varela, Buenos Aires, Argentina","https://ClinicalTrials.gov/show/NCT04411446"
1305,"Clinical and Biological Predictors of COVID-19 Disease in Older Patients","Not yet recruiting","No Results Available","COVID-19",,"IRCCS INRCA Hospital, Ancona, Italy","https://ClinicalTrials.gov/show/NCT04348396"
1306,"Convalescent Plasma Therapy vs. SOC for the Treatment of COVID19 in Hospitalized Patients","Recruiting","No Results Available","COVID-19","Other: Blood and derivatives.|Drug: Standard of Care","Hospital Clínico Universitario Lozano Blesa, Zaragoza, Aragón, Spain|Hospital Universitario Severo Ochoa, Leganés, Madrid, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain|Hospital Universitario Príncipe de Asturias, Meco, Madrid, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain","https://ClinicalTrials.gov/show/NCT04345523"
1307,"Cohort of Patients With Inflammatory Bowel Disease During COVID-19 Pandemic","Recruiting","No Results Available","IBD|COVID",,"Chu Nantes, Nantes, France","https://ClinicalTrials.gov/show/NCT04344249"
1308,"Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)","Recruiting","No Results Available","COVID-19","Drug: Placebo|Drug: Ruxolitinib","Georgetown University Hospital, Washington, District of Columbia, United States|Tampa General Hospital, Tampa, Florida, United States|Indiana University Simon Cancer Center, Indianapolis, Indiana, United States|Boston Medical Center, Boston, Massachusetts, United States|Lahey Clinic Inc., Burlington, Massachusetts, United States|UMass MMC - University Campus, Worcester, Massachusetts, United States|Duke University Medical Center, Durham, North Carolina, United States|Jefferson Hospital, Philadelphia, Pennsylvania, United States|West Penn Hospital, Pittsburgh, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT04377620"
1309,"Colchicine in COVID-19: a Pilot Study","Recruiting","No Results Available","COVID-19","Drug: Colchicine 1 MG Oral Tablet","Associazione Italiana Pneumologi Ospedalieri, Milan, Italy|Società Italiana di Reumatologia, Milan, Italy","https://ClinicalTrials.gov/show/NCT04375202"
1310,"ACT-20 in Patients With Severe COVID-19 Pneumonia","Not yet recruiting","No Results Available","COVID-19 Pneumonia","Biological: ACT-20-MSC|Biological: ACT-20-CM|Biological: Placebo",,"https://ClinicalTrials.gov/show/NCT04398303"
1311,"Favipiravir in Hospitalized COVID-19 Patients","Not yet recruiting","No Results Available","COVID-19","Drug: Favipiravir|Drug: Hydroxychloroquine","Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of","https://ClinicalTrials.gov/show/NCT04359615"
1312,"Collection and Testing of Respiratory Samples","Completed","Has Results","QIAGEN ResPlex II Advanced Panel|Influenza A|Respiratory Syncytial Virus Infections|Infection Due to Human Parainfluenza Virus 1|Parainfluenza Type 2|Parainfluenza Type 3|Parainfluenza Type 4|Human Metapneumovirus A/B|Rhinovirus|Coxsackie Virus/Echovirus|Adenovirus Types B/C/E|Coronavirus Subtypes 229E|Coronavirus Subtype NL63|Coronavirus Subtype OC43|Coronavirus Subtype HKU1|Human Bocavirus|Artus Influenza A/B RT-PCR Test|Influenza B","Device: artus Influenza A/B RT-PCR Test","University of Arizona, Tuscon, Arizona, United States|Albany Medical College, Albany, New York, United States|Wadsworth Center, New York State Department of Health, Albany, New York, United States|The University of North Carolina, Chapel Hill, North Carolina, United States|Ohio State University, Columbus, Ohio, United States","https://ClinicalTrials.gov/show/NCT01302418"
1313,"Zilucoplan® in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure","Not yet recruiting","No Results Available","COVID-19","Drug: Zilucoplan®|Drug: Placebo","OLVZ Aalst, Aalst, Belgium|AZ Sint Jan Brugge, Brugge, Belgium|Erasmus University Hospital, Brussels, Belgium|AZ Sint-Lucas, Gent, Belgium|University Hospital Ghent, Gent, Belgium|Jan Yperman Ziekenhuis Ieper, Ieper, Belgium|University Hospital Liège, Liège, Belgium|AZ Delta, Roeselare, Belgium|AZ Vesalius, Tongeren, Belgium","https://ClinicalTrials.gov/show/NCT04382755"
1314,"Treatment of COVID-19 Patients With Anti-interleukin Drugs","Recruiting","No Results Available","COVID-19","Other: Usual Care|Drug: Anakinra|Drug: Siltuximab|Drug: Tocilizumab","AZ Sint-Jan Brugge, Brugge, Belgium|University Hospital Saint-Pierre, Brussels, Belgium|Erasmus University Hospital, Brussels, Belgium|University Hospital Saint-Luc, Brussels, Belgium|University Hospital Antwerp, Edegem, Belgium|Ziekenhuis Oost-Limurg, Genk, Belgium|AZ Sint-Lucas, Gent, Belgium|University Hospital Ghent, Gent, Belgium|Jessa ZH, Hasselt, Belgium|University Hospital Brussels, Jette, Belgium|CHU Tivoli, La Louvière, Belgium|CHR de la Citadelle, Liège, Belgium|University Hospital Liège, Liège, Belgium|Cliniques Saint-Pierre Ottignies, Ottignies-Louvain-la-Neuve, Belgium|AZ Delta, Roeselare, Belgium","https://ClinicalTrials.gov/show/NCT04330638"
1315,"Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC)","Recruiting","No Results Available","COVID-19","Drug: Sargramostim|Other: Control","AZ Sint Jan Brugge, Brugge, Belgium|University Hospital Ghent, Gent, Belgium|UZ Brussel, Jette, Belgium|AZ Delta Roeselare, Roeselare, Belgium","https://ClinicalTrials.gov/show/NCT04326920"
1316,"A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE).","Recruiting","No Results Available","Lung Injury or Acute Respiratory Distress Syndrome Due to COVID-19","Drug: Gimsilumab|Drug: Placebo","UCLA Ronald Reagan Medical Center, Los Angeles, California, United States|Piedmont Healthcare, Atlanta, Georgia, United States|Emory University School of Medicine, Atlanta, Georgia, United States|NorthShore University HealthSystem, Evanston, Illinois, United States|East Jefferson General Hospital, Metairie, Louisiana, United States|Beaumont Hospital - Royal Oak, Royal Oak, Michigan, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Mount Sinai Beth Israel, New York, New York, United States|Mount Sinai West, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Baylor University Medical Center, Dallas, Texas, United States|Baylor Scott & White Heart Hospital, Plano, Texas, United States|Baylor Scott & White Medical Center - Temple, Temple, Texas, United States","https://ClinicalTrials.gov/show/NCT04351243"
1317,"Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine","Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","University of Florida, Gainesville, Florida, United States|University of Florida Jacksonville, Jacksonville, Florida, United States|University of South Florida, Tampa, Florida, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University Medical Center New Orleans, New Orleans, Louisiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Johns Hopkins, Baltimore, Maryland, United States|Mayo Clinic Hospital Rochester, Rochester, Minnesota, United States|University of Missouri-Columbia, Columbia, Missouri, United States|Hospital for Special Surgery, New York, New York, United States|Weill Cornell Medicine, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Clinical Trials Center of Middle Tennessee, Franklin, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Baylor Scott & White Medical Center-Temple, Temple, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|Marshfield Clinic Health System, Marshfield, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT04334148"
1318,"Diagnostic Value of Patient - Reported and Clinically Verified Olfactory Disorders (COVID-19)","Completed","No Results Available","COVID-19","Biological: Reporting of anosmia, ageusia and other clinical symptoms","Uhmontpellier, Montpellier, France","https://ClinicalTrials.gov/show/NCT04407494"
1319,"A Multicentre Open-label Two-arm Randomised Superiority Clinical Trial of Azithromycin Versus Usual Care In Ambulatory COVID19 (ATOMIC2)","Recruiting","No Results Available","COVID-19","Drug: Azithromycin Capsule","Horton General Hospital, Banbury, Oxfordshire, United Kingdom|John Radcliffe Hospital, Oxford, Oxfordshire, United Kingdom|Ninewells Hospital, Dundee, Scotland, United Kingdom|Birmingham City Hospital, Birmingham, United Kingdom|Sandwell General Hospital, West Bromwich, United Kingdom","https://ClinicalTrials.gov/show/NCT04381962"
1320,"Early Care Program for the Management of Post-ICU Syndrome and Chronic Pain After COVID-19 Infection.","Not yet recruiting","No Results Available","Post ICU Syndrome|Chronic Pain|Covid-19","Behavioral: Intervention program",,"https://ClinicalTrials.gov/show/NCT04394169"
1321,"COVID-19 Virtual Care at Home","Not yet recruiting","No Results Available","Covid-19","Other: Virtual Care at Home","London Health Sciences Centre, London, Ontario, Canada","https://ClinicalTrials.gov/show/NCT04420182"
1322,"Vielight RX Plus for the Treatment of COVID-19 Respiratory Symptoms","Not yet recruiting","No Results Available","COVID-19","Device: Vielight RX Plus","Dr. Michael Zahavi, Oshawa, Ontario, Canada","https://ClinicalTrials.gov/show/NCT04418505"
1323,"Evaluation of the Evolution of Pregnancies in the First Trimester Following MAR Management During a COVD-19 Pandemic Period","Recruiting","No Results Available","Covid-19",,"Service Clinico biologique d'Assistance Médicale à La Procréation, Strasbourg, France","https://ClinicalTrials.gov/show/NCT04415359"
1324,"Randomized Proof-of-Concept Trial to Evaluate the Safety and Explore the Effectiveness of Resveratrol for COVID-19","Not yet recruiting","No Results Available","COVID-19","Drug: Resveratrol|Dietary Supplement: Vitamin D3",,"https://ClinicalTrials.gov/show/NCT04400890"
1325,"Silymarin in COVID-19 Pneumonia","Not yet recruiting","No Results Available","COVID-19|Viral Pneumonia Human Coronavirus","Drug: Silymarin|Drug: Placebo","Cairo University, Giza, Cairo, Egypt","https://ClinicalTrials.gov/show/NCT04394208"
1326,"Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal","Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + Azithromycin","Infectious and Tropical Diseases Department, Fann Hospital, Dakar, Senegal|Diamniadio Children Hospital, Diamniadio, Senegal|Dalal Jamm Hospital, Guédiawaye, Senegal","https://ClinicalTrials.gov/show/NCT04390594"
1327,"DIgital Online SuPport for COVID-19 StrEss","Recruiting","No Results Available","COVID-19|Psychosocial Stress|Mental Health","Behavioral: Guided online support program|Behavioral: WHO recommendations (waiting condition)","Selfapy GmbH, Berlin, Germany","https://ClinicalTrials.gov/show/NCT04324190"
1328,"Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19","Recruiting","No Results Available","COVID-19","Drug: Sarilumab|Drug: Placebo","Regeneron Study Site, Los Angeles, California, United States|Regeneron Study Site, Sacramento, California, United States|Regeneron Study Site, Santa Monica, California, United States|Regeneron Study Site, Aurora, Colorado, United States|Regeneron Study Site, Denver, Colorado, United States|Regeneron Study Site, New Haven, Connecticut, United States|Regeneron Study Site, Washington, District of Columbia, United States|Regeneron Study Site, Coral Gables, Florida, United States|Regeneron Study Site, Gainesville, Florida, United States|Regeneron Study Site, Orlando, Florida, United States|Regeneron Study Site, Tampa, Florida, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Decatur, Georgia, United States|Regeneron Study Site, Marietta, Georgia, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, New Orleans, Louisiana, United States|Regeneron Study Site, Baltimore, Maryland, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Ann Arbor, Michigan, United States|Regeneron Study Site, Rochester, Minnesota, United States|Regeneron Study Site, Edison, New Jersey, United States|Regeneron Study Site, Hackensack, New Jersey, United States|Regeneron Study Site, Livingston, New Jersey, United States|Regeneron Study Site, Morristown, New Jersey, United States|Regeneron Study Site, Neptune, New Jersey, United States|Regeneron Study Site, Newark, New Jersey, United States|Regeneron Study Site, Teaneck, New Jersey, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site 1, Bronx, New York, United States|Regeneron Study Site 2, Bronx, New York, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Brooklyn, New York, United States|Regeneron Study Site, Buffalo, New York, United States|Regeneron Study Site, Elmhurst, New York, United States|Regeneron Study Site 1, Manhasset, New York, United States|Regeneron Study Site 2, Manhasset, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site 1, New York, New York, United States|Regeneron Study Site 2, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Stony Brook, New York, United States|Regeneron Study Site, Valhalla, New York, United States|Regeneron Study Site, Tulsa, Oklahoma, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Danville, Pennsylvania, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Scranton, Pennsylvania, United States|Regeneron Study Site, Wilkes-Barre, Pennsylvania, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Murray, Utah, United States|Regeneron Study Site, Falls Church, Virginia, United States|Regeneron Study Site, Richmond, Virginia, United States|Regeneron Study Site, Everett, Washington, United States|Regeneron Study Site, Renton, Washington, United States","https://ClinicalTrials.gov/show/NCT04315298"
1329,"Viral Infections in Healthy and Immunocompromised Hosts","Recruiting","No Results Available","Herpes Viruses",,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","https://ClinicalTrials.gov/show/NCT01306084"
1330,"Hydroxychloroquine Azithromycin COVID-19 Pregnancy Trial","Not yet recruiting","No Results Available","COVID19","Drug: Hydroxychloroquine and azithromycin treatment|Other: conventional management of patients","Hopital Saint Joseph, Marseille, Paca, France","https://ClinicalTrials.gov/show/NCT04365231"
1331,"Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia","Not yet recruiting","No Results Available","COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome|Pneumonia, Viral","Biological: Ravulizumab|Other: Best Supportive Care",,"https://ClinicalTrials.gov/show/NCT04369469"
1332,"SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19","Available","No Results Available","COVID-19|Pneumonia, Viral|Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)","Biological: eculizumab","Hôpital Henri Mondor, Creteil, France|Hôpital Garches Raymond Poincaré, Garches, France|Hôpital de Bicêtre, Le Kremlin Bicêtre, France|Hôpital Saint Louis, Paris, France|Hôpital Paul Brousse, Villejuif, France","https://ClinicalTrials.gov/show/NCT04355494"
1333,"DAS181 for STOP COVID-19","Not yet recruiting","No Results Available","COVID-19","Drug: DAS181|Drug: Placebo","Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milano, Italy|A.O.U Policlinico Di Modena, Modena, Italy","https://ClinicalTrials.gov/show/NCT04354389"
1334,"Survey of the Anxiety Associated With the COVID-19 Pandemic","Recruiting","No Results Available","Anxiety Related to the COVID-19 Pandemic","Diagnostic Test: Online Questionnaire","Charité-Universitätsmedizin Berlin - Department of Psychiatry and Psychotherapy, Berlin, Germany","https://ClinicalTrials.gov/show/NCT04331106"
1335,"Safety and Efficacy Trial of Vazegepant Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen","Recruiting","No Results Available","COVID-19 Infection","Drug: Vazegepant (BHV-3500)|Drug: Placebo","Georgetown University Medical Center, Washington, District of Columbia, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT04346615"
1336,"Simple, Safe, Same: Lung Ultrasound for COVID-19","Recruiting","No Results Available","Coronavirus|Epidemic Disease|Pneumonia, Viral","Diagnostic Test: Lung ultrasound","Bresciamed, Brescia, Italy|Pulmonary Medicine Unit, Lodi General Hospital, Lodi, Italy|118 USL Nordovest Toscana, Lucca, Italy|Diagnostic and Interventional Ultrasound Unit, Valle del Serchio General Hospital, Lucca, Italy|Emergency Department, Fondazione IRCCS Policlinico San Matteo, and Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy|Department of woman and child health and public health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy|Pulmonary Medicine Unit, Dept. Medical and Surgical Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy|Department of Information Engineering and Computer Science, Ultrasound Laboratory Trento, University of Trento, Trento, Italy|Emergency Medicine Unit, General Hospital, Voghera, Italy","https://ClinicalTrials.gov/show/NCT04322487"
1337,"TD-0903 for ALI Associated With COVID-19","Not yet recruiting","No Results Available","Acute Lung Injury (ALI) Associated With COVID-19|Lung Inflammation Associated With COVID-19","Drug: TD-0903|Drug: Placebo","Theravance Biopharma Investigational Site, Manchester, United Kingdom","https://ClinicalTrials.gov/show/NCT04402866"
1338,"Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Canada","Not yet recruiting","No Results Available","COVID-19","Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)|Biological: Placebo","Canadian Center for Vaccinology, Halifax, Canada","https://ClinicalTrials.gov/show/NCT04398147"
1339,"Prehospital Intubation of COVID-19 Patient With Personal Protective Equipment","Recruiting","No Results Available","Intubation Complication|Intubation; Difficult or Failed|Cardiac Arrest|Influenza|Safety Issues","Procedure: Direct laryngoscopy|Procedure: Vie Scope laryngoscopy","Emergency Medical Service, Poznan, Poland|Emergency Medical Service, Warsaw, Poland","https://ClinicalTrials.gov/show/NCT04365608"
1340,"Interferon Beta 1a in Hospitalized COVID-19 Patients","Enrolling by invitation","No Results Available","COVID-19","Drug: Interferon Beta-1A|Drug: Lopinavir / Ritonavir|Drug: Single Dose of Hydroxychloroquine","Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of","https://ClinicalTrials.gov/show/NCT04350671"
1341,"Longitudinal Energy Expenditure and Metabolic Effects in Patients With COVID-19 (LEEP-COVID)","Recruiting","No Results Available","COVID-19","Device: Q-NRG Metobolic Cart Device|Device: MuscleSound Ultrasound|Device: Multifrequency Bioimpedance Spectroscopy","Duke University Medial Center, Durham, North Carolina, United States","https://ClinicalTrials.gov/show/NCT04350073"
1342,"Qatar Prospective RCT Of Therapy Eliminating Covid Transmission","Not yet recruiting","No Results Available","Covid19","Drug: Hydroxychloroquine + Azithromycin|Drug: Hydroxychloroquine + Placebo|Other: Placebo + Placebo",,"https://ClinicalTrials.gov/show/NCT04349592"
1343,"Respiratory Virus Outpatient Study (FLU 002 Plus)","Completed","No Results Available","Influenza and Other Novel Respiratory Viruses",,"UCSD Antiviral Research Center, San Diego, California, United States|Denver Public Health, Denver, Colorado, United States|George Washington Medical Faculty Associates, Washington, D.C., District of Columbia, United States|Washington DC VA Medical Center, Washington, D.C., District of Columbia, United States|Infectious Diseases Associates NW FL, PA, Pensacola, Florida, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Henry Ford Health System, Detroit, Michigan, United States|Newland Immunology Center of Excellence (NICE), Southfield, Michigan, United States|New Jersey Medical School Adult Clinical Research Center, Newark, New Jersey, United States|Cornell CRS, New York, New York, United States|Bronx-Lebanon Hospital Center, The Bronx, New York, United States|UNC AIDS Clinical Trials Unit, Chapel Hill, North Carolina, United States|Duke University, Durham, North Carolina, United States|University of Tennessee College of Medicine, Chattanooga, Tennessee, United States|University of North Texas Health Science Center, Fort Worth, Texas, United States|Houston AIDS Research Team, Houston, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Hospital Nacional Profesor Alejandro Posadas, El Palomar, Buenos Aires, Argentina|Hospital Interzonal General de Agudos Dr. Diego Paroissien, La Matanza, Buenos Aires, Argentina|Instituto Medico Platense, La Plata, Buenos Aires, Argentina|Hospital Profesor Bernardo Houssay, Vicente Lopez, Buenos Aires, Argentina|CAICI (Instituto Centralizado de Assistencia e Investigacion Clinica Integral), Rosario, Santa Fe, Argentina|Sanatorio Britanico, Rosario, Santa Fe, Argentina|CEMIC, Buenos Aires, Argentina|FUNCEI, Buenos Aires, Argentina|Hospital General de Agudos JM Ramos Mejia, Buenos Aires, Argentina|Hospital Italiano de Buenos Aires, Buenos Aires, Argentina|Hospital Privado Centro Medico de Cordoba, Cordoba, Argentina|Hospital Rawson, Cordoba, Argentina|Interchange General Practice, Canberra, Australian Capital Territory, Australia|Holdsworth House Medical Practice, Darlinghurst, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Prahran Market Clinic, Melbourne, Victoria, Australia|Northside Clinic, North Fitzroy, Victoria, Australia|Centre Hospitalier Universitaire St. Pierre (C.H.U. St. Pierre), Brussels, Belgium|Practimed Medisch Centrum Tessenderlo, Tessenderlo, Belgium|Clinica Alemana, Santiago, Chile|Fundacion Arriaran, Santiago, Chile|Pontificia Universidad Catolica de Chile, Santiago, Chile|Arhus Universitetshospital, Skejby, Aarhus, Denmark|CHIP, Copenhagen, Denmark|Rigshospitalet, Infektionsmedicinsk ambulatorium 8622, Copenhagen, Denmark|University Clinic of General Practice, Copenhagen, Denmark|West Tallinn Central Hospital Infectious Diseases, Tallinn, Estonia|Medizinische Universitatsklinik - Bonn, Immunologische Ambulanz CRS, Bonn, Germany|Klinik I fur Innere Medizin der Universitat zu Koln, Studienburo fur Infektiologie u. HIV, Cologne, Germany|Johann Wolfgang Goethe - University Hospital, Infektionsambulanz CRS, Frankfurt, Germany|Ifi - Studien und Projekte GmbH, Hamburg, Germany|1st Dept of Critical Care Medicine and Pulmonary Services, Evangelismos Hospital, Athens, Greece|1st Respiratory Medicine Dept, Athens Hosp for Diseases of the Chest ""Sotiria Hospital"", Athens, Greece|Evangelismos General Hospital, Athens, Greece|Hippokration University General Hospital of Athens, Athens, Greece|National Hospital Organization Nagoya Medical Center, Nagoya, Japan|Hospital Nacional Arzobispo Loayza, Lima, Peru|Asociacion Civil IMPACTA Salud y Educacion, Lima, Peru|Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru|Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru|Wojewodzki Szpital Zakazny, Warsaw, Poland|EMC Instytut Medyczny SA, Wroclaw, Poland|Hospital Universitario y Politécnico La Fe, Valencia, Spain|Hospital Txagorritxu, Vitoria-Gasteiz, Spain|Chulalongkorn University Hospital, Bangkok, Thailand|Khon Kaen University, Srinagarind Hospital, Khon Kaen, Thailand|Bamrasnaradura Institute, Nonthaburi, Thailand|Norfolk and Norwich University Hospital, Norwich, Norfolk, United Kingdom|Churchill Hospital, Headington, Oxford, United Kingdom|Bradford Teaching Hospitals NHS Foundation Trust, Bradford, West Yorkshire, United Kingdom|St James's University Hospital, Leeds, West Yorkshire, United Kingdom","https://ClinicalTrials.gov/show/NCT01056354"
1344,"Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study","Recruiting","No Results Available","Lower Respiratory Tract Infection|Parainfluenza|Immunocompromised|COVID-19","Drug: DAS181|Drug: Placebo|Drug: DAS181 COVID-19|Drug: DAS181 OL","City of Hope cancer Center, Duarte, California, United States|UCLA, Los Angeles, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|University of Kansas Medical Center, Fairway, Kansas, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Washington University, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Duke University, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center Health System, Pittsburgh, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Cook Children's, Fort Worth, Texas, United States|MD Anderson, Houston, Texas, United States|VCU Health System, Richmond, Virginia, United States|Seattle Children's Hospital, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Westmead Hospital, Sydney, New South Wales, Australia|The Wesley Hospital, Brisbane, Queensland, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|Seoul National University Bundang Hospital, Seongnam-si, Guenoggi-do, Korea, Republic of|Samsung Medical Center, Gangnam-gu, Seoul, Korea, Republic of|Seoul National University Hospital, Jongno-gu, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seocho-gu, Seoul, Korea, Republic of|Asan Medical Center, Songpa-gu, Seoul, Korea, Republic of|National Taiwan University Hospital, Zhongzheng Dist., Taipei City, Taiwan","https://ClinicalTrials.gov/show/NCT03808922"
1345,"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","Recruiting","No Results Available","Community-acquired Pneumonia, Influenza, COVID-19","Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra|Drug: Fixed-duration higher dose Hydrocortisone|Drug: Tocilizumab|Drug: Sarilumab","St Vincent's Hospital Sydney, Sydney, New South Wales, Australia|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|Royal North Shore Hospital, Sydney, New South Wales, Australia|Nepean Hospital, Sydney, New South Wales, Australia|Wollongong Hospital, Sydney, New South Wales, Australia|Royal Darwin Hospital,, Darwin, Northern Territory, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Logan Hospital, Brisbane, Queensland, Australia|Toowoomba Hospital, Toowoomba, Queensland, Australia|The Queen Elizabeth Hospital, Adelaide, South Australia, Australia|Bendigo Hospital, Bendigo, Victoria, Australia|University Hosptial Geelong, Geelong, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Sir Charles Gairdner Hospital, Perth, Western Australia, Australia|St John of God Hospital Midland, Perth, Western Australia, Australia|Fiona Stanley Hospital, Perth, Western Australia, Australia|St John of God Hospital Murdoch, Perth, Western Australia, Australia|AZ Sint-Jan, Brugge, Belgium|CHU de Charleroi - Hôpital Civil Marie Curie, Charleroi, Belgium|Universitair Ziekenhuis Antwerp, Edegem, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|St. Joseph's Healthcare Hamilton, Hamilton, Canada|Centre Hospitalier de l'Université de Sherbrooke, Sherbrooke, Canada|St. Michael's Hospital Unity Health Toronto, Toronto, Canada|General County Hospital Požega, Požega, Croatia|University Hospital Centre Zagreb, Zagreb, Croatia|University Hospital for Infectious Diseases, Zagreb, Croatia|Charité - Universitätsmedizin Berlin - Infektiologie und Pneumologie, Berlin, Germany|Charité - Universitätsmedizin Berlin - Nephrologie, Berlin, Germany|Vivantes Klinikum Neukölln, Berlin, Germany|Universitätsklinikum Köln, Cologne, Germany|Universitätsklinikum Frankfurt, Frankfurt, Germany|University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Jena, Jena, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|Universitäts Klinikum Tübingen, Tübingen, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|Jósa András County Hospital, Nyíregyháza, Hungary|Csolnoky Ferenc Kórház - Veszprem County Hospital, Veszprém, Hungary|Almási Balogh Pál Kórház, Ózd, Hungary|Beaumont Hospital, Dublin, Ireland|St. Vincent's University Hospital, Dublin, Ireland|University Hospital Galway, Galway, Ireland|Meander Medisch Centrum, Amersfoort, Netherlands|Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands|Martini Hospital Groningen, Groningen, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|North Shore Hospital, Auckland, New Zealand|CVICU, Auckland City Hospital, Auckland, New Zealand|DCCM, Auckland City Hospital, Auckland, New Zealand|Middlemore Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Waikato Hospital, Hamilton, New Zealand|Rotorua Hospital, Rotorua, New Zealand|Tauranga Hospital, Tauranga, New Zealand|Wellington Regional Hospital, Wellington, New Zealand|Whangarei Hospital, Whangarei, New Zealand|Centro Hospitalar do Medio Tejo, Abrantes, Portugal|Hospital Lusíadas Lisbon, Lisboa, Portugal|Clinical Hospital of Infectious and Tropical Diseases ""Dr. Victor Babes"", Bucharest, Romania|Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain|Hospital Universitario Reina Sofia, Córdoba, Spain|Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom|Southmead Hospital, Bristol, United Kingdom|University Hospital Coventry, Coventry, United Kingdom|Darlington Memorial Hospital, Darlington, United Kingdom|University Hospital of North Durham, Durham, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom|Maidstone Hospital - Maidstone and Tunbridge Wells NHS Trust, Maidstone, United Kingdom|The James Cook University Hospital, Middlesbrough, United Kingdom|Milton Keynes University Hospital, Milton Keynes, United Kingdom|Northampton General Hospital, Northampton, United Kingdom|Queen's Medical Centre - Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Poole Hospital NHS Foundation Trust, Poole, United Kingdom|Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust, Portsmouth, United Kingdom|Royal Berkshire Hospital, Reading, United Kingdom|University Hospital of North Tees, Stockton-on-Tees, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom|Tunbridge Wells Hospital - Maidstone and Tunbridge Wells NHS Trust, Tunbridge Wells, United Kingdom|York Hospital, York, United Kingdom","https://ClinicalTrials.gov/show/NCT02735707"
